Contents: flip page - EAU Annual Congress - Barcelona 2010
Contents: flip page - EAU Annual Congress - Barcelona 2010
Contents: flip page - EAU Annual Congress - Barcelona 2010
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Welcome to<br />
<strong>Barcelona</strong>!<br />
<strong>Contents</strong>: <strong>flip</strong> <strong>page</strong>
<strong>Contents</strong><br />
Welcome 3<br />
<strong>EAU</strong> Patrons & Contributors 4<br />
General<br />
Floorplan 6<br />
Synopsis & Programme 7<br />
General Information 20<br />
Speaker Guidelines 26<br />
About <strong>Barcelona</strong> 27<br />
Historical Overview 32<br />
<strong>Congress</strong> hotels 34<br />
<strong>EAU</strong> Programme Friday, 16 April 39<br />
<strong>EAU</strong> Programme Saturday, 17 April 55<br />
<strong>EAU</strong> Programme Sunday, 18 April 91<br />
<strong>EAU</strong> Programme Monday, 19 April 167<br />
<strong>EAU</strong> Programme Tuesday, 20 April 239<br />
ESU & Hands-on Training Sessions<br />
ESU Courses 241<br />
ESU/ESUT Hands-on Laparoscopy courses 297<br />
ESU Interactive virtual training courses 300<br />
<strong>EAU</strong> Section Meetings 303<br />
Sponsored Sessions 323<br />
European Society of Residents in Urology (ESRU) 359<br />
Programme 17 th meeting<br />
European Association of Urology Nurses (<strong>EAU</strong>N) 361<br />
Programme 11 th meeting<br />
About <strong>EAU</strong><br />
<strong>EAU</strong> Membership 381<br />
<strong>EAU</strong> Offices 382<br />
Accreditation 384<br />
EU-ACME Programme 385<br />
Exhibition Guide<br />
Exhibition Floorplan 388<br />
Alphabetical list of Exhibitors 390<br />
Company and Product Description 394<br />
Indices<br />
Digital Video Library 425<br />
Abstract Authors 478<br />
Abstracts sorted by Topic 511<br />
Sessions sorted by Topic 513<br />
List of Speakers (not abstracts) 514<br />
2 Programme Book
Welcome to <strong>Barcelona</strong><br />
by the <strong>EAU</strong> Secretary General<br />
Dear Friends and Colleagues,<br />
With the renowned warm hospitality and cosmopolitan ambience of <strong>Barcelona</strong>, it is with<br />
pleasure that we welcome you to our 25th Anniversary <strong>Congress</strong>. <strong>EAU</strong> <strong>Congress</strong>. Whilst Whilst celebrating celebrating a a<br />
milestone event in the European Association of Urology’s (<strong>EAU</strong>) history, this year’s congress<br />
also marks a crossroads in our speciality, a time when we are witnesses to fast-changing<br />
developments in medicine.<br />
This is our third congress in Spain and the second in <strong>Barcelona</strong> since 1998, and our return to<br />
this city provides us with the chance not only to look back to the achievements of European<br />
urology but also carefully assess the manifold and still unresolved issues that impact our daily<br />
clinical practice.<br />
Our Scientific <strong>Congress</strong> Office has prepared a scientific programme that aims to provide clarity<br />
and direction. With the results of major research studies still being awaited and technological<br />
advances prodding our treatment approaches into a state of renewal, we are in a period of<br />
transition. Keeping an eye to these challenges, we have invited frontline opinion leaders and<br />
experts from and outside Europe to lead and highlight discussions on topics that cover the<br />
breadth of urology.<br />
As in previous years, we attempt to bring depth and a comprehensive reach in the plenary<br />
sessions through the Section Meetings and the Urology Beyond Europe, amongst other<br />
meetings, with both programmes scheduled right on the opening and second days of the<br />
congress.<br />
With attendance figures reaching beyond 11,000 participants and record numbers of abstract<br />
submissions presentations and exhibitors, without doubt you will find the next few days not only a a unique<br />
learning experience but also a memorable one as you re-unite with friends and colleagues.<br />
On In behalf of the <strong>EAU</strong>, welcome to <strong>Barcelona</strong>, certainly a delightful Mediterranean destination<br />
and a most fitting venue for a signpost event in the <strong>EAU</strong>’s history.<br />
Bienvenidos a <strong>Barcelona</strong>!<br />
Per-Anders<br />
Abrahamsson<br />
<strong>EAU</strong> Secretary<br />
General<br />
Per-Anders<br />
Abrahamsson<br />
<strong>EAU</strong> Secretary<br />
General<br />
Per-Anders Abrahamsson<br />
<strong>EAU</strong> Secretary General<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
3
<strong>EAU</strong> Patrons & Contributors<br />
<strong>EAU</strong> Platinum Corporate Sponsors<br />
AMGEN<br />
ASTELLAS<br />
FERRING PHARMACEUTICALS<br />
GLAXOSMITHKLINE<br />
OLYMPUS<br />
PFIZER INC<br />
SANOFI-AVENTIS<br />
<strong>EAU</strong> Gold Corporate Sponsors<br />
AMERICAN MEDICAL SYSTEMS<br />
ASTRAZENECA<br />
INTUITIVE SURGICAL, INC<br />
IPSEN<br />
JANSSEN CILAG EMEA A DIVISION OF JANSSEN PHARMACEUTICA NV<br />
KARL STORZ GMBH & CO.KG<br />
LILLY USA, LLC<br />
NOVARTIS ONCOLOGY<br />
PIERRE FABRE MÉDICAMENT<br />
<strong>EAU</strong> <strong>Congress</strong> Contributors<br />
AB CERNELLE<br />
BAYER SCHERING PHARMA<br />
BECKMAN COULTER, INC.<br />
BERLIN-CHEMIE MENARINI<br />
BOSTON SCIENTIFIC<br />
COLOPLAST<br />
COOK MEDICAL<br />
EDAP TMS<br />
GALIL MEDICAL<br />
GE HEALTHCARE<br />
ORION PHARMA<br />
RECORDATI<br />
ROTTAPHARM | MADAUS<br />
SANOFI PASTEUR<br />
STEBA BIOTECH<br />
4 Programme Book
All sessions showing the webcast symbol will be<br />
available online at<br />
www.eaubarcelona<strong>2010</strong>.org<br />
Let op! Hier komt<br />
een tabblad
Floorplan<br />
6 Programme Book<br />
F.M.A.<br />
<strong>EAU</strong>RF
10.00<br />
11.00<br />
12.00<br />
13.00<br />
14.00<br />
15.00<br />
16.00<br />
17.00<br />
18.00<br />
19.00<br />
20.00<br />
20.30<br />
Programme Friday, 16 April<br />
eURO Auditorium<br />
16.00-17.40<br />
Urology beyond<br />
Europe<br />
Plenary Session<br />
<strong>page</strong> 50<br />
18.00-20.30<br />
<strong>EAU</strong> Opening<br />
Ceremony and<br />
Welcome<br />
Cocktail<br />
<strong>page</strong> 53<br />
Amsterdam Room <strong>Barcelona</strong> Room Paris Room Stockholm Room Vienna Room Athens Room Istanbul Room<br />
10.45-13.15<br />
Urology beyond<br />
Europe<br />
Joint Session<br />
of the<br />
European<br />
Association of<br />
Urology (<strong>EAU</strong>)<br />
and the Korean<br />
Society of Urology<br />
(KUA)<br />
<strong>page</strong> 39<br />
13.25-15.55<br />
Urology beyond<br />
Europe<br />
Joint Session<br />
of the<br />
European<br />
Association<br />
of Urology<br />
(<strong>EAU</strong>) and the<br />
Confederaçion<br />
Americana de<br />
Urologia (CAU)<br />
<strong>page</strong> 44<br />
10.45-13.15<br />
Urology beyond<br />
Europe<br />
Joint Session<br />
of the<br />
European<br />
Association<br />
of Urology<br />
(<strong>EAU</strong>) and the<br />
Indonesian<br />
Urological<br />
Association (IUAI)<br />
<strong>page</strong> 40<br />
13.25-15.55<br />
Urology beyond<br />
Europe<br />
Joint Session<br />
of the<br />
European<br />
Association of<br />
Urology (<strong>EAU</strong>)<br />
and the Arab<br />
Association<br />
of Urology (AAU)<br />
<strong>page</strong> 45<br />
10.45-13.15<br />
Urology beyond<br />
Europe<br />
Joint Session<br />
of the<br />
European<br />
Association of<br />
Urology (<strong>EAU</strong>)<br />
and the Chinese<br />
Urological<br />
Association (CUA)<br />
<strong>page</strong> 41<br />
13.25-15.55<br />
Urology beyond<br />
Europe<br />
Joint Session<br />
of the<br />
European<br />
Association of<br />
Urology (<strong>EAU</strong>)<br />
and the Japanese<br />
Urological<br />
Association (JUA)<br />
<strong>page</strong> 47<br />
10.45-13.15<br />
Urology beyond<br />
Europe<br />
Joint Session<br />
of the<br />
European<br />
Association of<br />
Urology (<strong>EAU</strong>)<br />
and the Iranian<br />
Urological<br />
Association (IUA)<br />
<strong>page</strong> 42<br />
13.25-15.55<br />
Urology beyond<br />
Europe<br />
<strong>EAU</strong>-<br />
International:<br />
Caucasus and<br />
Central Asia<br />
Session<br />
10.45-13.15<br />
Urology beyond<br />
Europe<br />
Joint Session<br />
of the<br />
European<br />
Association<br />
of Urology<br />
(<strong>EAU</strong>) and the<br />
Urological Society<br />
of India (USI)<br />
<strong>page</strong> 43<br />
11.00-16.00<br />
ICUD-<strong>EAU</strong><br />
International<br />
Consultation on<br />
Kidney Cancer<br />
<strong>2010</strong><br />
<strong>page</strong> 48 <strong>page</strong> 51<br />
14.00-17.00<br />
Guidelines<br />
Training Session<br />
Evidence-based<br />
guidelines:<br />
A workshop<br />
for guideline<br />
developers<br />
<strong>page</strong> 52<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
7
Programme Saturday, 17 April<br />
07.30<br />
08.00<br />
09.00<br />
10.00<br />
11.00<br />
12.00<br />
13.00<br />
14.00<br />
15.00<br />
16.00<br />
17.00<br />
18.00<br />
19.00<br />
eURO Auditorium Amsterdam Room <strong>Barcelona</strong> Room Paris Room Stockholm Room Milan Room Vienna Room<br />
08.30 –10.00<br />
PlEnAry SESSIOn 1<br />
Advances in the management of<br />
kidney cancer<br />
08.30 – 09.00<br />
Debate<br />
Medical therapy for advanced kidney cancer:<br />
The truth behind the figures<br />
09.00 – 09.15<br />
Urological Association of Asia (UAA) lecture<br />
Current status of minimally invasive ablative<br />
techniques in the treatment of unresectable<br />
or metastatic renal tumours<br />
09.15 – 09.45<br />
International Consultation on Kidney<br />
Cancer <strong>2010</strong><br />
Consensus highlights<br />
09.45-10.00<br />
late breaking news<br />
Partial vs radical nephrectomy in renal<br />
cancer: Results from the EORTC 30904 study<br />
<strong>page</strong> 56<br />
10.00-17.30<br />
Meeting of the <strong>EAU</strong> Section of<br />
Uro-Technology (ESUT)<br />
The future of MIS – the real facts<br />
in real-time<br />
ADVAnCED MEDICAL<br />
DIAGnOSTICS,<br />
B-K MEDICAL,<br />
FRESEnIUS KABI,<br />
GE HEALTHCARE,<br />
HITACHI MEDICAL SySTEMS,<br />
InTERnATIOnAL HIFU,<br />
InTUITIVE SURGICAL,<br />
KARL STORz GMBH & CO.KG,<br />
OLyMPUS,<br />
PERGEnTIUM LTD.<br />
17.45-19.15<br />
Symposium<br />
Multidisciplinarity in prostate<br />
cancer: A promising approach?<br />
ASTELLAS<br />
07.30-08.30<br />
<strong>EAU</strong> General<br />
Assembly<br />
10.00-14.00<br />
Meeting of the <strong>EAU</strong> Section of<br />
Female and Functional Urology<br />
(ESFFU)<br />
Functional urology: Transition<br />
from science to clinical practice<br />
14.15-15.45<br />
Video Session 1<br />
nOTES and LESS in renal surgery<br />
V1-V7<br />
16.00-17.30<br />
Video Session 2<br />
LESS and robotics in adrenal and<br />
prostatic surgery<br />
V8-V14<br />
<strong>page</strong> 306 <strong>page</strong> 72<br />
8 Programme Book<br />
<strong>page</strong> 55<br />
<strong>page</strong> 318<br />
<strong>page</strong> 59<br />
17.45-19.15<br />
Symposium<br />
The clinician as architect:<br />
Building a strong foundation for<br />
patient satisfaction<br />
PFIzER InC<br />
10.00-14.00<br />
Meeting of the <strong>EAU</strong> Section of<br />
Andrological Urology (ESAU)<br />
The role of the uro-andrologist<br />
in managing a couple’s sexuality<br />
<strong>page</strong> 304<br />
14.15-15.45<br />
Oral Session 1<br />
Percutaneous stone removal 1<br />
1-9<br />
<strong>page</strong> 60<br />
16.00-17.30<br />
Oral Session 3<br />
Botulinum toxin in nDO-IDO:<br />
Latest breaking news from<br />
basics and clinics<br />
85-93<br />
<strong>page</strong> 73<br />
17.45-19.15<br />
Symposium<br />
The impact of BPH on men’s<br />
lives: new evidence for disease<br />
management<br />
GLAXOSMITHKLInE<br />
10.00-14.00<br />
Joint meeting of the European<br />
Organisation for research and<br />
Treatment of Cancer Genito-<br />
Urinary Group (EOrTC-GU<br />
Group) in conjunction with<br />
the <strong>EAU</strong> Section for Urological<br />
research (ESUr) and the<br />
European Section of Oncological<br />
Urology (ESOU)<br />
new insights in uro-oncology<br />
<strong>page</strong> 308<br />
14.15-15.45<br />
Poster Session 1<br />
Pathology and predictive factors<br />
18-32<br />
<strong>page</strong> 62<br />
16.00-17.30<br />
Poster Session 6<br />
Evaluating indolent prostate<br />
cancer 1<br />
102-116<br />
<strong>page</strong> 77<br />
17.45-19.15<br />
Symposium<br />
Challenges in individualising<br />
management of patients with<br />
prostate cancer<br />
IPSEn<br />
10.00-17.30<br />
17th Meeting of the European<br />
Society of residents in Urology<br />
(ESrU)<br />
17.45-19.15<br />
Symposium<br />
BPH treatment - from laser<br />
to plasma<br />
OLyMPUS<br />
10.00-15.00<br />
Meeting of the <strong>EAU</strong> Section of<br />
Genito-Urinary reconstructive<br />
Surgeons (ESGUrS)<br />
Long term results in<br />
genitourinary reconstructive<br />
surgery<br />
<strong>page</strong> 310<br />
16.00-17.30<br />
Poster Session 7<br />
Bladder pharmacology 1<br />
117-131<br />
17.45-19.15<br />
Symposium<br />
Advances in the treatment of<br />
castration-resistant prostate<br />
cancer: Targeted therapies,<br />
better prognoses<br />
ASTRAzEnECA<br />
10.00-14.00<br />
Meeting of the <strong>EAU</strong> Section of<br />
Uropathology (ESUP)<br />
Precancerous lesions of the<br />
urogenital organs<br />
<strong>page</strong> 303<br />
14.15-15.45<br />
Poster Session 2<br />
Epidemiology and pathology of<br />
urothelial cancer<br />
33-43<br />
<strong>page</strong> 64<br />
16.00-17.30<br />
Poster Session 8<br />
Metastatic disease: First<br />
line therapy<br />
132-145<br />
<strong>page</strong> 359 <strong>page</strong> 79 <strong>page</strong> 81<br />
<strong>page</strong> 324 <strong>page</strong> 332 <strong>page</strong> 328 <strong>page</strong> 329 <strong>page</strong> 330 <strong>page</strong> 325
Athens Room Istanbul Room Padua Room Genoa Room Birmingham Room Monte Carlo Room Geneva Room Prague Room<br />
10.00-13.40<br />
Meeting of the <strong>EAU</strong> Section<br />
of Transplantation Urology<br />
(ESTU)<br />
Renal transplantation –<br />
what urologists must know<br />
in <strong>2010</strong><br />
<strong>page</strong> 312<br />
14.15-15.45<br />
Oral Session 2<br />
Bladder sparing treatment<br />
and chemotherapy<br />
10-17<br />
16.00-17.30<br />
Oral Session 4<br />
Renal tumours: Medical<br />
treatment<br />
94-101<br />
17.45-19.15<br />
Symposium<br />
night-time urology: Why<br />
daytime symptoms do not<br />
drive night-time diagnosis<br />
FERRInG<br />
PHARMACEUTICALS<br />
10.00-14.00<br />
Meeting of the <strong>EAU</strong> Section<br />
of Urological Imaging (ESUI)<br />
What do we need to know<br />
about prostate imaging<br />
in <strong>2010</strong>?<br />
17.45-19.15<br />
Symposium<br />
Managing metastatic renal<br />
cell carcinoma as a chronic<br />
disease: Weighing up the<br />
evidence<br />
BAyER SCHERInG PHARMA<br />
10.00-14.00<br />
Meeting of the eUrolithiasis<br />
Section (eUlIS)<br />
Advances in the<br />
management of stones<br />
17.45-19.15<br />
Symposium<br />
A novel approach to the<br />
needs of the BPH patient<br />
RECORDATI<br />
10.00-14.00<br />
Meeting of the <strong>EAU</strong> Section<br />
of Infections in Urology<br />
(ESIU)<br />
Improving practice - facing<br />
threats<br />
<strong>page</strong> 314 <strong>page</strong> 316 <strong>page</strong> 320<br />
14.15-15.45<br />
Poster Session 3<br />
Imaging, urinary markers<br />
and molecular biology of<br />
urothelial carcinoma<br />
44-55<br />
16.00-17.30<br />
Poster Session 9<br />
Imaging and new<br />
techniques<br />
146-159<br />
14.15-15.45<br />
Poster Session 4<br />
How to improve prostate<br />
cancer detection on<br />
biopsies<br />
56-70<br />
16.00-17.30<br />
Poster Session 10<br />
Pain control and infection<br />
during prostate needle<br />
biopsies<br />
160-172<br />
14.15-15.45<br />
Poster Session 5<br />
Sex, testosterone and the<br />
prostate<br />
71-84<br />
<strong>page</strong> 61 <strong>page</strong> 66 <strong>page</strong> 68 <strong>page</strong> 70<br />
16.00-17.30<br />
Poster Session 11<br />
Sexual dysfunction<br />
173-187<br />
<strong>page</strong> 75 <strong>page</strong> 83 <strong>page</strong> 85 <strong>page</strong> 87<br />
09.00-11.00<br />
<strong>EAU</strong>n Workshop<br />
Cryoablation for prostate<br />
and kidney cancer; an<br />
overview on background,<br />
procedure and nurses’<br />
responsibilities<br />
<strong>page</strong> 361<br />
11.15-12.15<br />
Symposium<br />
Building on the vital framework<br />
to improve outcomes<br />
with bisphosphonates<br />
nOVARTIS OnCOLOGy<br />
<strong>page</strong> 363<br />
14.00-15.00<br />
Special Session of the<br />
Spanish Association of<br />
Urology nurses<br />
15.15-15.30<br />
<strong>EAU</strong>n Opening<br />
<strong>page</strong> 364<br />
15.30-15.45<br />
Guideline introduction<br />
16.00-17.00<br />
Symposium<br />
“Ins and outs” of<br />
intermittent catheterisation<br />
HOLLISTER InCORPORATED<br />
17.45-19.15<br />
Symposium<br />
Advances in prostate cancer<br />
management: The first<br />
once-yearly LH-RH agonist<br />
ORIOn PHARMA<br />
<strong>page</strong> 327 <strong>page</strong> 326 <strong>page</strong> 333 <strong>page</strong> 331<br />
<strong>page</strong> 364<br />
<strong>page</strong> 364<br />
<strong>page</strong> 365<br />
12.00-13.00<br />
European Urology Session<br />
Surgery in motion<br />
<strong>page</strong> 58<br />
12.30-14.00<br />
Workshop<br />
Challenges in non-muscle<br />
invasive bladder cancer -<br />
interactive case discussions<br />
GE HEALTHCARE &<br />
PHOTOCURE ASA<br />
<strong>page</strong> 323<br />
15.00-16.30<br />
Workshop<br />
Challenges in non-muscle<br />
invasive bladder cancer -<br />
interactive case discussions<br />
GE HEALTHCARE &<br />
PHOTOCURE ASA<br />
<strong>page</strong> 323<br />
09.00-11.00<br />
<strong>EAU</strong>n Workshop<br />
Quality of life in urology<br />
stoma patients<br />
<strong>page</strong> 362<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
07.30<br />
08.00<br />
09.00<br />
10.00<br />
11.00<br />
12.00<br />
13.00<br />
14.00<br />
15.00<br />
16.00<br />
17.00<br />
18.00<br />
19.00<br />
9
Programme Sunday, 18 April, Morning<br />
07.30<br />
08.00<br />
09.00<br />
10.00<br />
11.00<br />
12.00<br />
eURO Auditorium Amsterdam Room<br />
07.30-11.00<br />
PlEnAry SESSIOn 2<br />
Prostate cancer: From<br />
prevention to risk<br />
calculator<br />
07.30 – 08.00<br />
Highlight Session 1<br />
08.00– 08.40<br />
Debate<br />
Screening<br />
08.40 – 09.20<br />
Debate<br />
Chemoprevention<br />
09.20 – 10.00<br />
Debate<br />
Risk classification<br />
10.00 – 10.20<br />
State-of-the-art lecture<br />
Population based<br />
service screening - Time<br />
for an active attitude?<br />
10.20-10.40<br />
State-of-the-art lecture<br />
The patients view<br />
10.40-11.00<br />
State-of-the-art lecture<br />
The <strong>EAU</strong> position<br />
<strong>page</strong> 91<br />
11.00-12.00<br />
Sub-Plenary Session 1<br />
Bladder cancer:<br />
Management of non muscle<br />
invasive disease<br />
11.00-11.20<br />
State-of-the-art lecture<br />
TURB staging: standard<br />
of quality and optimising<br />
techniques<br />
11.20-11.40<br />
State-of-the-art lecture<br />
Early single instillation<br />
chemotherapy<br />
11.40-12.00<br />
State-of-the-art lecture<br />
Management of high<br />
risk disease<br />
11.00-12.00<br />
Sub-plenary Session 2<br />
Andrology<br />
11.00-11.20<br />
State-of-the-art lecture<br />
Modern management of<br />
Peyronie’s disease<br />
11.20-11.40<br />
State-of-the-art lecture<br />
Male circumcision and its<br />
role in HIV prevention. The<br />
WHO programme<br />
11.40-12.00<br />
State-of-the-art lecture<br />
The role of micro-TESE in<br />
the management of nonobstructive<br />
azoospermia<br />
<strong>Barcelona</strong><br />
Room<br />
11.00-12.00<br />
Sub-plenary Session 3<br />
<strong>EAU</strong> Guidelines Office 1<br />
11.00-11.05<br />
Introduction<br />
11.05-11.35<br />
State-of-the-art lecture<br />
EBM technology assessment<br />
– Lasers<br />
11.35-12.00<br />
Guidelines and medico-legal<br />
aspects<br />
Paris<br />
Room<br />
11.00-12.00<br />
Sub-plenary Session 4<br />
Urological follow-up of the<br />
transplant patient<br />
11.00-11.15<br />
State-of-the-art lecture<br />
Upper tract dilatation<br />
11.15-11.30<br />
State-of-the-art lecture<br />
Bladder dysfunction<br />
11.30-11.45<br />
State-of-the-art lecture<br />
Erectile dysfunction<br />
11.45-12.00<br />
State-of-the-art lecture<br />
Urological neoplasms<br />
Stockholm<br />
Room<br />
09.15-10.45<br />
Poster Session 12<br />
Management of<br />
non muscle invasive<br />
urothelial tumours 1<br />
188-202<br />
11.00-12.00<br />
Sub-plenary Session 5<br />
Female urology<br />
11.00-11.20<br />
State-of-the-art lecture<br />
Mini-slings: Are they as good<br />
as they are marketed?<br />
11.20-11.40<br />
State-of-the-art lecture<br />
Pelvic organ prolapses: Can<br />
laparoscopy beat vaginal<br />
meshes?<br />
11.40-12.00<br />
State-of-the-art lecture<br />
Optimising therapy for<br />
overactive bladder: Current<br />
concepts and future<br />
directions<br />
<strong>page</strong> 105 <strong>page</strong> 106 <strong>page</strong> 108 <strong>page</strong> 109 <strong>page</strong> 111<br />
10 Programme Book<br />
Milan<br />
Room<br />
09.15-10.45<br />
Poster Session 13<br />
Adrenals and trauma<br />
203-217<br />
Vienna<br />
Room<br />
09.15-10.45<br />
Poster Session 14<br />
Medical therapy, ESWL<br />
and stents<br />
218-232<br />
Athens<br />
Room<br />
09.15-10.45<br />
Poster Session 15<br />
Male incontinence<br />
233-247<br />
Istanbul<br />
Room<br />
09.15-10.45<br />
Poster Session 16<br />
Tissue engineering,<br />
reconstructive<br />
urology and gender<br />
reassignment<br />
248-262<br />
Padua<br />
Room<br />
09.15-10.45<br />
Poster Session 17<br />
Bladder<br />
pharmacology 2<br />
263-277<br />
<strong>page</strong> 93 <strong>page</strong> 95 <strong>page</strong> 97 <strong>page</strong> 99 <strong>page</strong> 101 <strong>page</strong> 103
Genoa<br />
Room<br />
08.30-10.30<br />
ESU Course 39<br />
How to become the best<br />
reviewer for European<br />
Urology<br />
<strong>page</strong> 270<br />
Birmingham Room<br />
08.00-10.15<br />
<strong>EAU</strong>n-ESU<br />
Course<br />
Erectile Dysfunction<br />
<strong>page</strong> 366<br />
10.30-11.10<br />
State-of-the-art<br />
lecture<br />
new developments in<br />
urological cancer care<br />
including the nursing<br />
aspects<br />
<strong>page</strong> 367<br />
11.10-11.25<br />
<strong>EAU</strong>n Quiz<br />
<strong>page</strong> 367<br />
Monte Carlo<br />
Room<br />
08.30-11.30<br />
ESU Course 1<br />
Laparoscopic and robot<br />
assisted laparoscopic<br />
radical cystectomy<br />
London<br />
Room<br />
08.30-11.30<br />
ESU Course 2<br />
Evaluation and<br />
management of female<br />
pelvic floor disorders<br />
Geneva<br />
Room<br />
08.30-11.30<br />
ESU Course 3<br />
Update on stone<br />
disease<br />
Arnhem<br />
Room<br />
08.30-11.30<br />
ESU Course 4<br />
Retropubic radical<br />
prostatectomy - tips,<br />
tricks and pitfalls<br />
Budapest<br />
Room<br />
08.30-11.30<br />
ESU Course 5<br />
Robot surgery in<br />
urology - how to start<br />
<strong>page</strong> 241 <strong>page</strong> 243 <strong>page</strong> 245 <strong>page</strong> 246 <strong>page</strong> 247<br />
Madrid<br />
Room<br />
08.30-10.30<br />
ESU Course 7<br />
Safe outpatient<br />
operations:<br />
How and where?<br />
Prague<br />
Room<br />
09.00-11.00<br />
ESU<br />
Hands-on-training<br />
Brussels<br />
Room<br />
08.30-10.30<br />
ESU Course 6<br />
Surgical management<br />
of locally advanced<br />
& metastatic renal<br />
cancer<br />
<strong>page</strong> 251 <strong>page</strong> 249<br />
<strong>page</strong> 297<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
07.30<br />
08.00<br />
09.00<br />
10.00<br />
11.00<br />
12.00<br />
11
Programme Sunday, 18 April, Afternoon<br />
12.00<br />
13.00<br />
14.00<br />
15.00<br />
16.00<br />
17.00<br />
18.00<br />
19.00<br />
eURO Auditorium Amsterdam Room<br />
12.15-13.45<br />
Video Session 3<br />
How to handle<br />
complications<br />
V15-V21<br />
<strong>page</strong> 112<br />
14.00-15.30<br />
Video Session 4<br />
Endourology<br />
V22-V27<br />
<strong>page</strong> 130<br />
15.45-17.15<br />
Video Session 5<br />
Open oncological<br />
surgery<br />
V28-V33<br />
<strong>page</strong> 148<br />
17.30-19.00<br />
Symposium<br />
new perspectives and<br />
challenges in androgen<br />
deprivation therapies:<br />
Can we improve the<br />
treatments further?<br />
FERRInG<br />
PHARMACEUTICALS<br />
<strong>page</strong> 340<br />
12.15-13.45<br />
Oral Session 5<br />
Prostate cancer stem/<br />
initiating cells and the<br />
microenvironment<br />
278-285<br />
<strong>page</strong> 113<br />
14.00-15.30<br />
Oral Session 6<br />
Techniques and<br />
outcome of urinary<br />
diversion<br />
406-413<br />
<strong>page</strong> 131<br />
15.45-17.15<br />
Oral Session 8<br />
Penile surgery<br />
525-532<br />
<strong>page</strong> 149<br />
17.30-19.00<br />
Symposium<br />
OAB – the test of TIME<br />
ASTELLAS<br />
<strong>page</strong> 338<br />
12 Programme Book<br />
<strong>Barcelona</strong><br />
Room<br />
12.15-13.45<br />
Poster Session 18<br />
Renal tumours:<br />
Diagnosis and<br />
imaging 1<br />
286-300<br />
<strong>page</strong> 114<br />
14.00-15.30<br />
Oral Session 7<br />
Renal tumours:<br />
Diagnosis and<br />
imaging 2<br />
414-421<br />
<strong>page</strong> 132<br />
15.45-17.15<br />
Poster Session 33<br />
Renal tumours:<br />
Total and partial<br />
nephrectomy<br />
533-546<br />
<strong>page</strong> 150<br />
17.30-19.00<br />
Symposium<br />
Clinical experience in<br />
premature ejaculation:<br />
An expert roundtable<br />
debate<br />
JAnSSEn-CILAG<br />
<strong>page</strong> 341<br />
Paris<br />
Room<br />
12.15-13.45<br />
Poster Session 19<br />
Treatment of male<br />
sexual dysfunction<br />
301-315<br />
<strong>page</strong> 116<br />
14.00-15.30<br />
Poster Session 26<br />
Infertility<br />
422-436<br />
<strong>page</strong> 134<br />
15.45-17.15<br />
Poster Session 34<br />
Penis cancer<br />
547-561<br />
<strong>page</strong> 152<br />
17.30-19.00<br />
Symposium<br />
Strategies for<br />
optimising outcomes<br />
in patients with GU<br />
malignancies<br />
nOVARTIS OnCOLOGy<br />
<strong>page</strong> 342<br />
Stockholm<br />
Room<br />
12.15-13.45<br />
Poster Session 20<br />
Analysis of risk factors<br />
and outcome: Urothelial<br />
cancer<br />
316-329<br />
<strong>page</strong> 118<br />
14.00-15.30<br />
Poster Session 27<br />
Renal tumours:<br />
Innovation in surgical<br />
treatment<br />
437-451<br />
<strong>page</strong> 136<br />
15.45-17.15<br />
Poster Session 35<br />
Renal tumours: Basic<br />
research<br />
562-576<br />
<strong>page</strong> 154<br />
17.30-19.00<br />
Symposium<br />
Urgency: The problems<br />
and the solutions<br />
ROTTAPHARM |<br />
MADAUS<br />
<strong>page</strong> 345<br />
Milan<br />
Room<br />
12.15-13.45<br />
Poster Session 21<br />
Kidney transplantation:<br />
Clinical<br />
330-344<br />
<strong>page</strong> 120<br />
14.00-15.30<br />
Poster Session 28<br />
Kidney transplantation:<br />
From lab to clinic<br />
452-466<br />
<strong>page</strong> 138<br />
15.45-17.15<br />
Poster Session 36<br />
Evaluating indolent<br />
prostate cancer 2<br />
577-591<br />
<strong>page</strong> 156<br />
17.30-19.00<br />
Symposium<br />
The evolving role of<br />
the urologist in the<br />
management of RCC<br />
PFIzER InC<br />
<strong>page</strong> 343<br />
Vienna<br />
Room<br />
12.15-13.45<br />
Poster Session 22<br />
Percutaneous stone<br />
removal 2<br />
345-359<br />
<strong>page</strong> 122<br />
14.00-15.30<br />
Poster Session 29<br />
Basic research and<br />
epidemiology of urinary<br />
stones<br />
467-481<br />
<strong>page</strong> 140<br />
15.45-17.15<br />
Poster Session 37<br />
Ureterorenoscopic stone<br />
treatment<br />
592-606<br />
<strong>page</strong> 158<br />
Athens<br />
Room<br />
12.15-13.45<br />
Poster Session 23<br />
Prostatitis<br />
360-374<br />
<strong>page</strong> 124<br />
14.00-15.30<br />
Poster Session 30<br />
Urinary tract infection<br />
482-495<br />
<strong>page</strong> 142<br />
15.45-17.15<br />
Poster Session 38<br />
Active surveillance and<br />
brachy-/radiotherapy<br />
607-622<br />
<strong>page</strong> 160<br />
17.30-19.00<br />
Symposium<br />
Proven surgical<br />
solutions for today<br />
incontinent patients<br />
AMERICAn MEDICAL<br />
SySTEMS<br />
<strong>page</strong> 336<br />
Istanbul<br />
Room<br />
12.15-13.45<br />
Poster Session 24<br />
Urethral repair<br />
375-390<br />
<strong>page</strong> 126<br />
14.00-15.30<br />
Poster Session 31<br />
Epidemiology and<br />
evaluation of BPH<br />
496-510<br />
<strong>page</strong> 144<br />
15.45-17.15<br />
Poster Session 39<br />
Basic research of BPH<br />
623-636<br />
<strong>page</strong> 162<br />
17.30-19.00<br />
Symposium<br />
nEWS FLASH: RAnK<br />
Ligand inhibitor reduces<br />
the risk of fracture in<br />
men receiving ADT<br />
AMGEn<br />
<strong>page</strong> 337<br />
Padua<br />
Room<br />
12.15-13.45<br />
Poster Session 25<br />
Surgery for female<br />
stress incontinence<br />
391-405<br />
<strong>page</strong> 128<br />
14.00-15.30<br />
Poster Session 32<br />
neuromodulation and<br />
the urinary tract<br />
511-524<br />
<strong>page</strong> 146<br />
15.45-17.15<br />
Poster Session 40<br />
Painful bladder and<br />
beyond<br />
637-651<br />
<strong>page</strong> 164<br />
17.30-19.00<br />
Symposium<br />
Physical and<br />
psychological aspects of<br />
LUTS/BPH<br />
BERLIn CHEMIE<br />
MEnARInI<br />
<strong>page</strong> 339
Genoa<br />
Room<br />
12.15-13.45<br />
Workshop<br />
Advancing your skills in<br />
endourology<br />
BOSTOn SCIEnTIFIC<br />
<strong>page</strong> 334<br />
15.45-17.15<br />
Workshop<br />
Ureteral access:<br />
Situation and new<br />
perspectives<br />
COLOPLAST<br />
<strong>page</strong> 335<br />
Birmingham Room<br />
12.30-14.30<br />
<strong>EAU</strong>n Workshop<br />
nursing tools for<br />
patient instruction on<br />
prostate cancer<br />
Supported by<br />
unrestricted educational<br />
grant from<br />
AMGEn,<br />
FERRInG<br />
PHARMACEUTICALS<br />
AnD<br />
nOVARTIS OnCOLOGy<br />
<strong>page</strong> 368<br />
14.30-16.15<br />
Poster Abstract Session<br />
<strong>page</strong> 369<br />
16.15-17.15<br />
<strong>EAU</strong>n Workshop<br />
Ensuring continence in<br />
difficult cases<br />
<strong>page</strong> 370<br />
17.30-19.00<br />
Symposium<br />
Inflammation: A<br />
common target for BPH<br />
and PCA therapies?<br />
PIERRE FABRE<br />
MéDICAMEnT<br />
<strong>page</strong> 344<br />
Monte Carlo<br />
Room<br />
12.00-15.00<br />
ESU Course 8<br />
Prostate cancer -<br />
screening, diagnosis<br />
and staging<br />
<strong>page</strong> 253<br />
15.30-17.30<br />
ESU Course 15<br />
Laparoscopy for<br />
beginners<br />
London<br />
Room<br />
12.00-15.00<br />
ESU Course 11<br />
Office management<br />
of male sexual<br />
dysfunction<br />
15.30-17.30<br />
ESU Course 14<br />
Renal transplantation:<br />
Technical aspects,<br />
diagnosis and<br />
management of early<br />
and late urological<br />
complications<br />
Geneva<br />
Room<br />
12.00-15.00<br />
ESU Course 10<br />
Paediatric urology for<br />
the adult urologist:<br />
A practical update<br />
15.30-17.30<br />
ESU Course 16<br />
Management and<br />
outcome in invasive<br />
and locally advanced<br />
bladder cancer<br />
Arnhem<br />
Room<br />
12.00-15.00<br />
ESU Course 9<br />
Advanced management<br />
of urethral stricture<br />
disease<br />
15.30-17.30<br />
ESU Course 17<br />
Minimally invasive<br />
treatment for localised<br />
prostate cancer<br />
Budapest<br />
Room<br />
12.00-15.00<br />
ESU Course 12<br />
Lower urinary tract<br />
dysfunction and<br />
urodynamics<br />
15.30-17.30<br />
ESU Course 18<br />
Metastatic prostate<br />
cancer<br />
Madrid<br />
Room<br />
12.30-14.30<br />
ESU<br />
Interactive virtual<br />
training of laparoscopic<br />
radical prostatectomy<br />
<strong>page</strong> 300<br />
15.30-17.30<br />
ESU<br />
Interactive virtual<br />
training of laparoscopic<br />
radical prostatectomy<br />
<strong>page</strong> 263 <strong>page</strong> 262<br />
<strong>page</strong> 264 <strong>page</strong> 266 <strong>page</strong> 268 <strong>page</strong> 300<br />
Prague<br />
Room<br />
12.00-14.00<br />
ESU<br />
Hands-on-training<br />
<strong>page</strong> 297<br />
15.0-17.00<br />
ESU<br />
Hands-on-training<br />
<strong>page</strong> 297<br />
Brussels<br />
Room<br />
12.00-15.00<br />
ESU Course 13<br />
Chronic Pelvic Pain<br />
Syndromes (CPPS)<br />
with Special Focus on<br />
Chronic Prostatitis (CP)<br />
and Painful Bladder<br />
Syndrome/Interstitial<br />
Cystitis (PBS/IC)<br />
<strong>page</strong> 257 <strong>page</strong> 256 <strong>page</strong> 254 <strong>page</strong> 259 <strong>page</strong> 260<br />
15.30-17.30<br />
ESU Course 19<br />
Robot renal surgery<br />
<strong>page</strong> 269<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
12.00<br />
13.00<br />
14.00<br />
15.00<br />
16.00<br />
17.00<br />
18.00<br />
19.00<br />
13
Programme Monday, 19 April, Morning<br />
07.30<br />
08.00<br />
09.00<br />
10.00<br />
11.00<br />
12.00<br />
eURO Auditorium<br />
07.45-11.00<br />
PlEnAry SESSIOn 3<br />
07.45 - 08.15<br />
Highlight Session 2<br />
08.15 – 08.35<br />
Sociéte<br />
Internationale<br />
d’Urologie (SIU)<br />
lecture<br />
Review of urethral<br />
stricture disease:<br />
Hamilton Russell to<br />
present<br />
08.35 – 08.50<br />
State-of-the-art<br />
lecture<br />
Bladder sensation:<br />
Have we got it wrong<br />
all along?<br />
08.50 – 09.35<br />
Debate<br />
Open surgery,<br />
robotics and<br />
beyond<br />
09.35 – 09.55<br />
American Urological<br />
Association (AUA)<br />
lecture<br />
The AUA meeting the<br />
challenges of surgical<br />
education in the 21st<br />
century<br />
09.55 – 10.10<br />
State-of-the-art<br />
lecture<br />
Surgical education in<br />
Europe: The EBU<br />
10.10 – 10.50<br />
Debate<br />
Energy ablative<br />
surgery<br />
10.50 – 11.00<br />
Award Session 1<br />
<strong>page</strong> 167<br />
11.00-12.00<br />
Sub-plenary Session 6<br />
new developments in<br />
tissue engineering and<br />
reconstructive surgery<br />
11.00-11.15<br />
State-of-the-art lecture<br />
Adult stem cells in tissue<br />
engineering<br />
11.15-11.30<br />
State-of-the-art lecture<br />
Biomaterial development<br />
and clinical applications<br />
11.30-11.45<br />
State-of-the-art lecture<br />
Urological tissue<br />
engineering, biomaterials<br />
and cell interactions<br />
11.45-12.00<br />
State-of-the-art lecture<br />
Pediatric urological<br />
reconstructions and tissue<br />
engineering in the clinic<br />
Amsterdam Room<br />
11.00-12.00<br />
Sub-plenary Session 7<br />
Paediatric urology<br />
11.00-11.20<br />
State-of-the-art lecture<br />
Renal transplantation<br />
in children<br />
11.20-11.40<br />
State-of-the-art lecture<br />
Undescended testis: Is it<br />
worth doing surgery?<br />
11.40-12.00<br />
State-of-the-art lecture<br />
Vesicoureteral reflux: new<br />
diagnostic categories and a<br />
treatment shift?<br />
<strong>Barcelona</strong><br />
Room<br />
09.15-10.45<br />
Poster Session 41<br />
Experimental therapy<br />
and diagnostics in<br />
prostate cancer<br />
661-676<br />
11.00-12.00<br />
Sub-plenary Session 8<br />
nOTES and SILS<br />
11.00-11.15<br />
State-of-the-art lecture<br />
The concept of nOTES<br />
11.15-11.30<br />
State-of-the-art lecture<br />
nOTES nephrectomy and<br />
transvesical approach<br />
11.30-11.45<br />
State-of-the-art lecture<br />
The concept of SILS<br />
11.45-12.00<br />
State-of-the-art lecture<br />
SILS procedures in urology<br />
Paris<br />
Room<br />
09.15-10.45<br />
Poster Session 42<br />
Management of<br />
high risk prostate<br />
disease<br />
677-691<br />
11.00-12.00<br />
Sub-plenary Session 9<br />
European Society of<br />
Urogenital Radiology (ESUR)<br />
State-of-the-art in imaging<br />
11.00-11.20<br />
State-of-the-art lecture<br />
Haematuria<br />
11.20-11.40<br />
State-of-the-art lecture<br />
Recent advances in staging<br />
prostatic cancer<br />
11.40-12.00<br />
State-of-the-art lecture<br />
Scrotal masses<br />
Stockholm<br />
Room<br />
09.15-10.45<br />
Poster Session 43<br />
LUT testing and<br />
dysfunctions<br />
692-706<br />
11.00-12.00<br />
Sub-plenary Session 10<br />
Androgen suppression:<br />
Who and how<br />
11.00-11.20<br />
State-of-the-art lecture<br />
Immediate versus deferred<br />
hormonal therapy: When,<br />
why and how?<br />
11.20-11.40<br />
State-of-the-art lecture<br />
Managing complications of<br />
androgen suppression<br />
11.40-12.00<br />
State-of-the-art lecture<br />
new approaches to<br />
hormonal therapy<br />
Milan<br />
Room<br />
09.15-10.45<br />
Poster Session 44<br />
Imaging and new<br />
techniques<br />
707-719<br />
11.00-12.00<br />
Sub-plenary Session 11<br />
<strong>EAU</strong> Guidelines Office 2<br />
11.05-11.30<br />
Test yourself against the<br />
evidence<br />
11.30-11.40<br />
Paediatric urology<br />
11.40-11.50<br />
Prostate cancer<br />
11.50-12.00<br />
Urethral trauma<br />
<strong>page</strong> 181 <strong>page</strong> 183 <strong>page</strong> 184 <strong>page</strong> 186 <strong>page</strong> 188 <strong>page</strong> 189<br />
14 Programme Book<br />
Vienna<br />
Room<br />
09.15-10.45<br />
Oral Session 9<br />
neuropathic bladder<br />
dysfunction in<br />
children<br />
652-660<br />
Athens<br />
Room<br />
09.15-10.45<br />
Poster Session 45<br />
Testis cancer<br />
720-732<br />
<strong>page</strong> 171 <strong>page</strong> 173 <strong>page</strong> 175 <strong>page</strong> 177 <strong>page</strong> 170 <strong>page</strong> 179<br />
Istanbul<br />
Room<br />
Padua<br />
Room<br />
Genoa<br />
Room<br />
10.00-11.30<br />
Workshop<br />
Early stage localised<br />
prostate cancer:<br />
Local tumour<br />
ablation by Focal<br />
Vascular Occluding<br />
Agent [F(VOA)] -<br />
Tookad® Soluble<br />
STEBA BIOTECH<br />
<strong>page</strong> 346
Birmingham Room<br />
07.45-08.45<br />
Breakfast Symposium<br />
Optimising patient<br />
benefits in bladder<br />
cancer management<br />
GE HEALTHCARE &<br />
PHOTOCURE ASA<br />
<strong>page</strong> 371<br />
09.00-10.30<br />
<strong>EAU</strong>n nursing<br />
research<br />
Competition<br />
learning<br />
session<br />
10.45-11.45<br />
Symposium<br />
Urological management<br />
of Spina bifida<br />
during childhood and<br />
adolescence – what<br />
happens when entering<br />
adulthood?<br />
ASTRATECH AB<br />
Monte Carlo<br />
Room<br />
08.30-11.30<br />
ESU Course 21<br />
Vaginal surgery for<br />
urologists<br />
London<br />
Room<br />
08.30-11.30<br />
ESU Course 20<br />
How to write a<br />
manuscript and get it<br />
published in European<br />
Urology<br />
Copenhagen<br />
Room<br />
10.30-12.00<br />
live Surgery<br />
da Vinci Prostatectomy<br />
InTUITIVE SURGICAL<br />
Geneva<br />
Room<br />
08.30-11.30<br />
ESU Course 22<br />
Diagnosis and<br />
management of non-<br />
Muscle Invasive Bladder<br />
Cancer (nMIBC)<br />
08.30-11.30<br />
ESU Course 23<br />
Surgery or radiotherapy<br />
for localised and locally<br />
advanced prostate<br />
cancer<br />
08.30-11.30<br />
ESU Course 24<br />
The infertile couple -<br />
urological aspects<br />
08.30-10.30<br />
ESU<br />
Interactive virtual<br />
training of laparoscopic<br />
radical prostatectomy<br />
09.00-10.30<br />
ESU<br />
Hands-on-training<br />
<strong>page</strong> 373 <strong>page</strong> 299<br />
<strong>page</strong> 374<br />
Arnhem<br />
Room<br />
Budapest<br />
Room<br />
<strong>page</strong> 273 <strong>page</strong> 271 <strong>page</strong> 274 <strong>page</strong> 276 <strong>page</strong> 278<br />
<strong>page</strong> 347<br />
Madrid<br />
Room<br />
11.30-13.30<br />
ESU<br />
Interactive virtual<br />
training<br />
Prague<br />
Room<br />
11.00-12.30<br />
ESU<br />
Hands-on-training<br />
Brussels<br />
Room<br />
08.30-11.30<br />
ESU Course 25<br />
Management of small<br />
renal tumours<br />
<strong>page</strong> 279<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
07.30<br />
08.00<br />
09.00<br />
10.00<br />
11.00<br />
12.00<br />
15
Programme Monday, 19 April, Afternoon<br />
12.00<br />
13.00<br />
14.00<br />
15.00<br />
16.00<br />
17.00<br />
18.00<br />
19.00<br />
eURO Auditorium<br />
12.15-13.45<br />
Video Session 6<br />
Retroperitoneal and<br />
ureteral surgery<br />
V34-V39<br />
<strong>page</strong> 190<br />
14.00-15.30<br />
Video Session 7<br />
Reconstructive<br />
surgery and<br />
innovations<br />
V40-V46<br />
<strong>page</strong> 205<br />
15.45-16.55<br />
Video Session 8<br />
Award Session<br />
V47, V16, V1, V22<br />
<strong>page</strong> 221<br />
Amsterdam Room<br />
12.15-13.45<br />
Oral Session 10<br />
Diagnostics, VUR and<br />
enuresis in children<br />
733-740<br />
<strong>page</strong> 191<br />
14.00-15.30<br />
Oral Session 11<br />
History of Urology 1<br />
842-849<br />
<strong>page</strong> 206<br />
15.45-17.15<br />
Oral Session 12<br />
History of Urology 2<br />
951-958<br />
<strong>page</strong> 222<br />
17.30-19.00<br />
Symposium<br />
The new world of<br />
managing male<br />
LUTS: Focus on<br />
storage symptoms?<br />
ASTELLAS<br />
<strong>page</strong> 351<br />
16 Programme Book<br />
<strong>Barcelona</strong><br />
Room<br />
12.15-13.45<br />
Poster Session 46<br />
Molecular basis of<br />
prostate cancer<br />
741-755<br />
<strong>page</strong> 192<br />
14.00-15.30<br />
Poster Session 53<br />
Tumor cell biology<br />
and (molecular)<br />
endocrinology of<br />
prostate cancer<br />
850-864<br />
<strong>page</strong> 207<br />
15.45-17.15<br />
Poster Session 60<br />
Prevention and<br />
screening of prostate<br />
cancer<br />
959-974<br />
<strong>page</strong> 223<br />
17.30-19.00<br />
Symposium<br />
Time for change:<br />
Optimising metastatic<br />
Renal Cell Carcinoma<br />
(mRCC)<br />
GLAXOSMITHKLInE<br />
<strong>page</strong> 353<br />
Paris<br />
Room<br />
12.15-13.45<br />
Poster Session 47<br />
Renal tumours:<br />
Ablative techniques<br />
and single port<br />
surgery<br />
756-770<br />
<strong>page</strong> 194<br />
14.00-15.30<br />
Poster Session 54<br />
Prognostic<br />
biomarkers<br />
865-878<br />
<strong>page</strong> 209<br />
15.45-17.15<br />
Poster Session 61<br />
Diagnostic<br />
biomarkers<br />
975-989<br />
<strong>page</strong> 225<br />
Stockholm<br />
Room<br />
12.15-13.45<br />
Poster Session 48<br />
Overactive bladder<br />
771-785<br />
<strong>page</strong> 196<br />
14.00-15.30<br />
Poster Session 55<br />
Intervention therapy<br />
in BPH<br />
879-893<br />
<strong>page</strong> 211<br />
15.45-17.15<br />
Poster Session 62<br />
Medical therapy and<br />
injection for BPH<br />
treatment<br />
990-1002<br />
<strong>page</strong> 227<br />
17.30-19.00<br />
Symposium<br />
new trends in<br />
laparoscopy: Single<br />
portal and minilaparoscopy<br />
KARL STORz GMBH<br />
& CO. KG<br />
<strong>page</strong> 354<br />
Milan<br />
Room<br />
12.15-13.45<br />
Poster Session 49<br />
Surgical<br />
management of<br />
localised prostate<br />
cancer: Technical<br />
issues<br />
786-800<br />
<strong>page</strong> 198<br />
14.00-15.30<br />
Poster Session 56<br />
Hormone refractory<br />
prostate cancer<br />
894-905<br />
<strong>page</strong> 213<br />
15.45-17.15<br />
Poster Session 63<br />
Staging: From focal<br />
to advanced prostate<br />
cancer<br />
1003-1013<br />
<strong>page</strong> 229<br />
17.30-19.00<br />
Symposium<br />
The value of<br />
maintenance therapy<br />
in the management<br />
of nMIBC: What does<br />
the data tell us?<br />
SAnOFI PASTEUR<br />
<strong>page</strong> 356<br />
Vienna<br />
Room<br />
12.15-13.45<br />
Poster Session 50<br />
Hypospadias,<br />
testicular function in<br />
children<br />
801-811<br />
<strong>page</strong> 200<br />
14.00-15.30<br />
Poster Session 57<br />
Outcomes in the<br />
surgical management<br />
of prostate cancer<br />
906-920<br />
<strong>page</strong> 215<br />
15.45-17.15<br />
Poster Session 64<br />
Cystectomy and<br />
urinary diversion:<br />
Technical<br />
considerations<br />
1014-1028<br />
<strong>page</strong> 231<br />
17.30-19.00<br />
Symposium<br />
Prostate Health<br />
Index (phi) – A<br />
simple blood<br />
test significantly<br />
improves on PSA in<br />
the selection of men<br />
for biopsy and is a<br />
major advance in<br />
prostate cancer risk<br />
assessment<br />
BECKMAn<br />
COULTER InC<br />
<strong>page</strong> 352<br />
Athens<br />
Room<br />
12.15-13.45<br />
Poster Session 51<br />
Urothelial tumours:<br />
Basic research 1<br />
812-826<br />
<strong>page</strong> 201<br />
14.00-15.30<br />
Poster Session 58<br />
Urothelial tumours:<br />
Basic research 2<br />
921-935<br />
<strong>page</strong> 217<br />
15.45-17.15<br />
Poster Session 65<br />
Management of<br />
non muscle invasive<br />
urothelial tumours 2<br />
1029-1043<br />
<strong>page</strong> 233<br />
17.30-19.00<br />
Symposium<br />
Testosterone<br />
deficiency: Sharing<br />
our experience<br />
between countries<br />
and specialities<br />
PIERRE FABRE<br />
MéDICAMEnT<br />
<strong>page</strong> 355<br />
Istanbul<br />
Room<br />
14.00-17.00<br />
European Urological<br />
Scholarship<br />
Programme (EUSP)<br />
Session<br />
<strong>page</strong> 237<br />
17.30-19.00<br />
Symposium<br />
Expert analysis<br />
on new treatment<br />
options in advanced<br />
prostate cancer<br />
SAnOFI-AVEnTIS<br />
<strong>page</strong> 357<br />
Padua<br />
Room<br />
12.15-13.45<br />
Poster Session 52<br />
PLnD and oncological<br />
outcome in advanced<br />
disease<br />
827-841<br />
<strong>page</strong> 203<br />
14.00-15.30<br />
Poster Session 59<br />
Focal and systemic<br />
therapies<br />
936-950<br />
<strong>page</strong> 219<br />
15.45-17.15<br />
Poster Session 66<br />
Tissue engineering<br />
and beyond<br />
1044-1058<br />
<strong>page</strong> 235<br />
17.30-19.00<br />
Symposium<br />
new developments<br />
in the understanding<br />
and management of<br />
Chronic Prostatitis/<br />
Chronic Pelvic Pain<br />
Syndrome (CP/<br />
CPPS)<br />
AB CERnELLE<br />
<strong>page</strong> 350<br />
Genoa<br />
Room<br />
13.00-14.30<br />
Workshop<br />
Ablatherm® HIFU<br />
for PCa. From real<br />
clinical background<br />
to virtual training<br />
EDAP TMS<br />
<strong>page</strong> 348<br />
15.45-17.15<br />
Workshop<br />
Cryoablation: Setting<br />
the standard<br />
GALIL MEDICAL<br />
<strong>page</strong> 349
Birmingham Room<br />
12.00-12.30<br />
State-of-the-art lecture<br />
QoL after cystectomy<br />
<strong>page</strong> 375<br />
12.45-13.45<br />
lunch<br />
Symposium<br />
Vantas: A nurse’s<br />
perspective on the first<br />
once-yearly LH-RH<br />
agonist<br />
ORIOn PHARMA<br />
<strong>page</strong> 376<br />
13.45-14.15<br />
<strong>EAU</strong>n General<br />
Assembly<br />
<strong>page</strong> 377<br />
14.15-15.00<br />
State-of-the-art lecture<br />
Managing erectile<br />
dysfunction and Quality<br />
of Life<br />
<strong>page</strong> 377<br />
15.15-16.30<br />
Oral Abstract Session<br />
<strong>page</strong> 378<br />
16.45-17.15<br />
State-of-the-art lecture<br />
The importance of<br />
patient positioning and<br />
safety on a urology OR<br />
17.15-17.30<br />
Award session<br />
<strong>page</strong> 379<br />
<strong>page</strong> 379<br />
Monte Carlo<br />
Room<br />
12.00-15.00<br />
ESU Course 26<br />
Radical cystectomy<br />
and orthotopic bladder<br />
substitution - surgical<br />
tricks and management<br />
of complications<br />
<strong>page</strong> 280<br />
15.30-17.30<br />
ESU Course 32<br />
Advanced course on<br />
laparoscopic<br />
prostatectomy<br />
<strong>page</strong> 289<br />
London<br />
Room<br />
12.00-15.00<br />
ESU Course 27<br />
Advanced course on<br />
upper tract laparoscopy<br />
(UPJ, adrenal and<br />
stones)<br />
<strong>page</strong> 281<br />
15.30-17.30<br />
ESU Course 33<br />
Testicular cancer<br />
<strong>page</strong> 291<br />
Copenhagen<br />
Room<br />
15.30-17.00<br />
live Surgery<br />
da Vinci Prostatectomy<br />
InTUITIVE SURGICAL<br />
<strong>page</strong> 347<br />
Geneva<br />
Room<br />
12.00-15.00<br />
ESU Course 28<br />
Interventional therapies<br />
for BPH<br />
<strong>page</strong> 283<br />
15.30-17.30<br />
ESU Course 34<br />
Urinary tract and<br />
genital trauma<br />
<strong>page</strong> 292<br />
Arnhem<br />
Room<br />
12.00-15.00<br />
ESU Course 29<br />
Advanced course<br />
on laparoscopic<br />
nephrectomy<br />
<strong>page</strong> 284<br />
15.30-17.30<br />
ESU Course 35<br />
Ultrasound for the<br />
urologist - TRUS and<br />
TRUS guided biopsies<br />
<strong>page</strong> 293<br />
Budapest<br />
Room<br />
12.00-15.00<br />
ESU Course 30<br />
Robot assisted<br />
laparoscopic<br />
prostatectomy<br />
<strong>page</strong> 286<br />
15.30-17.30<br />
ESU Course 36<br />
Medical uro-oncology<br />
Madrid<br />
Room<br />
11.30-13.30<br />
ESU<br />
Interactive virtual<br />
training of laparoscopic<br />
radial prostatectomy<br />
15.30-17.30<br />
ESU Course 37<br />
Post surgical urinary<br />
incontinence in males<br />
<strong>page</strong> 294 <strong>page</strong> 295<br />
Prague<br />
Room<br />
11.00-12.30<br />
ESU<br />
Hands-on-training<br />
<strong>page</strong> 299<br />
14.30-16.00<br />
ESU<br />
Hands-on-training<br />
<strong>page</strong> 299<br />
Brussels<br />
Room<br />
12.00-14.00<br />
ESU Course 31<br />
Palliative treatment of<br />
advanced genito urinary<br />
cancer<br />
<strong>page</strong> 288<br />
15.30-17.30<br />
ESU Course 38<br />
General neuro-urology<br />
<strong>page</strong> 296<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
12.00<br />
13.00<br />
14.00<br />
15.00<br />
16.00<br />
17.00<br />
18.00<br />
19.00<br />
17
Programme Tuesday, 20 April<br />
07.30<br />
08.00<br />
09.00<br />
10.00<br />
11.00<br />
12.00<br />
13.00<br />
eURO Auditorium<br />
08.00-12.15<br />
Plenary Session 4<br />
Controversies<br />
08.00 – 10.00<br />
Souvenir Session by the <strong>EAU</strong> Scientific <strong>Congress</strong><br />
Office<br />
10.00 – 10.35<br />
State-of-the-art session<br />
Is botulinum toxin the new magic bullet?<br />
10.35 – 11.05<br />
Best <strong>EAU</strong> papers<br />
11.05 – 11.40<br />
Case discussion<br />
Postprostatectomy incontinence – treatment<br />
11.40 – 12.00<br />
Award Session 2<br />
12.00 – 12.15<br />
Closing remarks<br />
<strong>page</strong> 239<br />
18 Programme Book
General information<br />
Abstracts<br />
More than 1,000 abstracts have been accepted for presentation<br />
during poster, oral and video sessions at the<br />
25 th Anniversary <strong>EAU</strong> <strong>Congress</strong> in <strong>Barcelona</strong>. <strong>Congress</strong><br />
delegates can obtain a free copy of the abstract book<br />
at the special Abstract Book Desk in the main registration<br />
area on a first-come, first-served basis. At this<br />
desk it will also be possible to print certain <strong>page</strong>s of<br />
the abstract book. Due to <strong>EAU</strong>’s “green” measures a<br />
limited number of abstract books have been printed.<br />
Additional abstract books can be purchased at the<br />
Cashier Desk. The Abstract CD will be distributed to all<br />
congress delegates from the Ferring booth (booth E14).<br />
Abstract CDs are supported by an unrestricted educational<br />
grant from FERRING PHARMACEUTICALS<br />
Access to the Session Rooms<br />
Seating is regulated on a first-come, first-served basis.<br />
We recommend that you go to the session room well<br />
in advance of the session. Due to safety regulations,<br />
the organisers will close the access to the session<br />
room when all seats are taken. It is not allowed for<br />
delegates to stand in the aisles of the rooms.<br />
Address and Accessibility<br />
<strong>Congress</strong> Venue<br />
The Fira <strong>Barcelona</strong> is easily accessible by public transport.<br />
The public transport system is easy to use and a<br />
very efficient way to get around the city. All congress<br />
delegates will receive a complimentary transportation<br />
pass valid for 10 rides on all public transport within<br />
the City of <strong>Barcelona</strong> during the congress.<br />
Address:<br />
Fira <strong>Barcelona</strong> (Fira Gran Via)<br />
Access North (Entrada Norte) / Hall 8<br />
c/ Foc 47<br />
08038 <strong>Barcelona</strong>, Spain<br />
T +34 93 233 20 00<br />
F +34 93 233 20 16<br />
E info@firabcn.es<br />
W www.firabcn.es<br />
Metro / buses / car parking:<br />
The nearest metro station (FGC) is Europa–Fira. <strong>EAU</strong><br />
will provide shuttle buses between this metro station<br />
and Access North (Entrada Norte). The buses will<br />
depart from the square in front of the Access North.<br />
There will be buses every ten minutes.<br />
Car parking is available under the hall and open from<br />
07.00-20.00 hrs.<br />
20 Programme Book<br />
Please inform taxi drivers to go to the “Entrada Norte”,<br />
since Fira’s main entrance is the one on the south side<br />
and taxi drivers tend to drop off on that side!<br />
Badges<br />
The badge classification is as follows:<br />
Blue ID Card : <strong>Congress</strong> delegate <strong>EAU</strong><br />
member<br />
Grey ID Card : <strong>Congress</strong> delegate<br />
non-<strong>EAU</strong> member<br />
Orange ID Card : Nurse <strong>EAU</strong>N member<br />
Brown badge holder : Nurse non-<strong>EAU</strong>N<br />
member<br />
Green badge holder : Exhibitor<br />
Red badge holder : Press<br />
Purple badge holder : Accompanying person<br />
Pink badge holder : Special registration<br />
Yellow badge holder : Organising staff<br />
Bank, Exchange and Credit Cards<br />
The national currency in Spain is the Euro (EUR). An<br />
ATM machine is available in the main entrance hall.<br />
The nearest bank to the congress venue is:<br />
Banco Santander<br />
Centro Comercial Gran Via (in the shopping centre<br />
located behind the <strong>EAU</strong> congress halls)<br />
Vestibulo, 75<br />
T +34 93 259 19 09<br />
Banks are normally open Monday to Friday from<br />
08.30-14.15 hrs. and closed on Saturdays and Sundays.<br />
ATMs are widely available. All major credit cards<br />
are widely accepted in Spain and ATMs accept most<br />
international cards. Please be aware that smaller<br />
businesses may not accept credit card payments and<br />
you are advised to check prior to purchase. Service is<br />
included in the bill in bars and restaurants, but tips<br />
are welcome. Travellers’ cheques are best exchanged<br />
at an exchange office (“Cambio” or “Exchange”) as<br />
they are not accepted as payment in shops, restaurants<br />
and hotels.<br />
Certificate of Attendance<br />
A Certificate of Attendance for the 25 th Anniversary<br />
<strong>EAU</strong> <strong>Congress</strong> can be printed in the registration<br />
area during the last two days of the congress or<br />
afterwards online at www.eaubarcelona<strong>2010</strong>.org. You<br />
will need your registration number (under barcode<br />
on the badge) or <strong>EAU</strong> ID Card number to print the<br />
Certificate of Attendance. A list of CME accreditation
points granted by various national urological societies<br />
and the European Board of Urology is available in this<br />
programme book on <strong>page</strong> 384.<br />
Cloakroom / Luggage<br />
The cloakroom is located in the foyer on the first floor<br />
and open during congress hours. Please be sure to<br />
collect all personal belongings at the end of the day.<br />
CME Accreditation<br />
The 25 th Anniversary <strong>EAU</strong> <strong>Congress</strong> is accredited by the<br />
UEMS/EACCME through the European Board of Urology.<br />
More information on national credit systems and<br />
credits recognition is available in this programme book<br />
on <strong>page</strong> 384, 385.<br />
<strong>Congress</strong> Bag<br />
Each delegate can collect a congress bag, including a<br />
programme book, in the registration area.<br />
Sponsored by ASTELLAS<br />
<strong>Congress</strong> Hours<br />
Main entrance Registration Sessions Symposia Exhibition<br />
Wednesday, 14 April 09.00–18.15<br />
Thursday, 15 April 07.45–20.15<br />
Friday, 16 April 07.00-21.30 08.00-21.00 10.45-20.30<br />
Saturday, 17 April 06.45-20.15 07.00-20.00 07.30-19.15 17.45-19.15 09.00-18.00<br />
Sunday, 18 April 06.45-20.00 07.00-19.00 07.30-19.00 17.30-19.00 09.00-18.00<br />
Monday, 19 April 06.45-20.00 07.30-19.00 07.45-19.00 17.30-19.00 09.00-18.00<br />
Tuesday, 20 April 07.00-16.00 07.30-13.30 08.00-12.15<br />
Daily <strong>Congress</strong> Newsletter:<br />
European Urology Today Special<br />
Edition<br />
Special daily congress newsletters are available on<br />
Saturday 17, Sunday 18 and Monday 19 April. The newsletters<br />
cover on-site news, congress session<br />
information and background information on a variety<br />
of subjects. The newsletters will also be available online<br />
at www.eaubarcelona<strong>2010</strong>.org after the congress.<br />
Delegate Tracking System<br />
<strong>Congress</strong> delegates will receive an <strong>EAU</strong> ID Card which<br />
will act as an electronic business card, enabling visitors<br />
to leave their contact details with exhibitors in a<br />
quick and easy way. Paper badges do not have this<br />
function and should be exchanged for an <strong>EAU</strong> ID Card<br />
by Saturday, 17 April.<br />
<strong>EAU</strong> <strong>Congress</strong> History Wall<br />
As homage to the Anniversary <strong>Congress</strong>, the <strong>EAU</strong> has<br />
created the <strong>Congress</strong> History Wall, an audio-visual<br />
collage of photographs, texts and film footage that<br />
trace the early years of the annual congress and some<br />
highlights in the <strong>EAU</strong> <strong>Congress</strong> history. Consisting of<br />
26 wall panels, the <strong>Congress</strong> History Wall captures<br />
the changes and milestones in European urology.<br />
Visit the <strong>EAU</strong> <strong>Congress</strong> History Wall (located between<br />
the Paris and <strong>Barcelona</strong> Rooms) and reflect on the<br />
events, achievements, challenges and urological issues<br />
debated nearly three decades ago or gain insights<br />
into the visions and goals of pioneering leaders in<br />
European urology.<br />
<strong>EAU</strong> Central Research<br />
Office<br />
The <strong>EAU</strong> Central Research Office initiates and coordinates,<br />
as well as refines investigator initiated<br />
and other clinical research protocols. It also acts to<br />
facilitate all aspects of clinical research and expand<br />
the current network of active research centres and<br />
investigators - basic and clinical - both within the<br />
<strong>EAU</strong> member states and its international affiliates. The<br />
office coordinates clinical and translational research in<br />
close liaison with the Basic Research Committee of the<br />
<strong>EAU</strong> Research Foundation. The <strong>EAU</strong> Central Research<br />
Office can be visited at the <strong>EAU</strong> Square (booth B20) in<br />
the exhibition area.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
21
General information<br />
<strong>EAU</strong> <strong>Congress</strong> Office<br />
Managing Directors<br />
Jacqueline Roelofswaard<br />
j.roelofswaard@uroweb.org<br />
Maurice Schlief<br />
m.schlief@uroweb.org<br />
<strong>Congress</strong> Manager<br />
Patricia de Bont<br />
p.debont@congressconsultants.com<br />
Exhibition Manager<br />
Henriet Wieringa<br />
h.wieringa@congressconsultants.com<br />
<strong>Congress</strong> Consultants B.V.<br />
PO Box 30016<br />
6803 AA Arnhem<br />
The Netherlands<br />
T +31 (0)26 389 1751<br />
F +31 (0)26 389 1752<br />
E info@congressconsultants.com<br />
W www.eaubarcelona<strong>2010</strong>.org<br />
<strong>EAU</strong> Digital Video Library<br />
The <strong>EAU</strong> Digital Video Library (booth H30) will be<br />
operational during exhibition hours in the exhibition<br />
area. A wide choice of <strong>EAU</strong> videos, including all<br />
videos presented in <strong>Barcelona</strong> and at previous <strong>EAU</strong><br />
<strong>Congress</strong>es, can be viewed on request on individual<br />
monitors. All videos can be copied to DVD, a service<br />
that is provided free of charge to all congress<br />
delegates.<br />
Supported by an unrestricted educational grant from<br />
ASTELLAS<br />
<strong>EAU</strong> Education Office<br />
(European School of<br />
Urology)<br />
The European School of Urology (ESU), working with<br />
European faculties, aims to provide high quality<br />
international educational courses in urology. The ESU<br />
has a special booth in the session room hall with<br />
extensive information on its activities. Registration for<br />
the courses can be made at the ESU Registration Desks<br />
in the registration area. All congress delegates can<br />
collect an ESU Courses CD at the sanofi-aventis booth<br />
(booth J07)<br />
The ESU Courses CD <strong>2010</strong> is supported by an<br />
unrestricted educational grant from SANOFI-AVENTIS<br />
22 Programme Book<br />
Fees ESU Courses, ESUT Hands-on Training Courses,<br />
Interactive Virtual Training Courses (for congress registered<br />
delegates only)<br />
2 hrs. 3 hrs.<br />
<strong>EAU</strong> members € 32,10 € 48,15<br />
Non-<strong>EAU</strong> members, residents € 48,15 € 69,55<br />
Residents (members/non-members) € 21,40 € 21,40<br />
Prices are incl 7% VAT<br />
Special offer<br />
This year ESU offers a special discount on the ESU<br />
Course and Interactive Virtual Training fees for all<br />
residents (member and non-members of the <strong>EAU</strong>). The<br />
course fee is € 20,- for all ESU Courses (2 and 3 hour<br />
courses), and Interactive Virtual Trainings.<br />
Residents receive a maximum of one free ESU Course/<br />
Interactive Virtual Training per person. This is only<br />
applicable if you have already booked and paid for one<br />
or more ESU Courses/Interactive Virtual Trainings. This<br />
free ESU Course/Interactive Virtual Training can only be<br />
booked onsite and is subject to availability. There are<br />
only 10 free places per ESU Course/Interactive Virtual<br />
Training available. It is strongly recommended that you<br />
register online to ensure your place on your preferred<br />
ESU Course/Interactive Virtual Training.<br />
<strong>EAU</strong> Historical Exhibition<br />
The members of the <strong>EAU</strong> History Office have, once<br />
again, set up an historical exhibit located at the<br />
<strong>EAU</strong> Square (booth B20). The exhibit will present<br />
“Milestones and Controversies in European Urology”.<br />
<strong>EAU</strong> ID Card<br />
The <strong>EAU</strong> ID Card functions<br />
as an entrance badge for<br />
all <strong>EAU</strong> <strong>Congress</strong>es and<br />
Meetings and replaces the<br />
paper congress badge. The<br />
<strong>EAU</strong> ID Card enables: Quick<br />
Sweden<br />
P-A. Abrahamsson<br />
<strong>EAU</strong> Member ID 106985<br />
on-site registration, automatic registration of EU-ACME<br />
credit points and easy printing of certificates of attendance.<br />
Please do not forget to bring your <strong>EAU</strong> ID Card<br />
to the congress!<br />
Attendees are expected to wear their <strong>EAU</strong> ID Card<br />
visible at all times. A fixed price of e 15,- Euro will<br />
be charged for the replacement of a lost <strong>EAU</strong> ID Card.<br />
Paper badges should be replaced with an <strong>EAU</strong> ID Card<br />
by Saturday, 17 April.
<strong>EAU</strong> Internet Corners<br />
The <strong>EAU</strong> Internet Corners are at your disposal at different<br />
locations (booths A06 & J26) in the exhibition area.<br />
Supported by an unrestricted educational grant from<br />
ASTELLAS<br />
European Association of<br />
Urology Nurses (<strong>EAU</strong>N)<br />
The 11 th International Meeting of the European<br />
Association of Urology Nurses (<strong>EAU</strong>N) is a 3-day<br />
scientific meeting that will be held in conjunction with<br />
the 25 th Anniversary <strong>EAU</strong> <strong>Congress</strong> from 17-19 April in<br />
support of their goal to continually upgrade the nursing<br />
skills of urology nurses. Scheduled are for example<br />
abstract and learning sessions as well as hands-ontraining<br />
sessions and expert nurses and urologists will<br />
give lectures, workshops and courses. See <strong>page</strong> 361 for<br />
the extensive <strong>EAU</strong>N programme.<br />
<strong>EAU</strong> Square<br />
The <strong>EAU</strong> Square (booth B20) in the exhibition area<br />
consists of the <strong>EAU</strong> Membership Booth, EBU Corner,<br />
ESRU Corner, <strong>EAU</strong> Vienna 2011 Promotion Counter,<br />
Clinical Research Office, Uroweb work station and the<br />
<strong>EAU</strong> Historical Exhibition.<br />
There is also information on European Urology and<br />
other <strong>EAU</strong> publications. The <strong>EAU</strong> Membership Booth<br />
provides information on membership status and<br />
membership benefits. Non-members are welcome to<br />
visit the <strong>EAU</strong> Square for further information and to<br />
apply for <strong>EAU</strong> membership.<br />
European Board of<br />
Urology (EBU)<br />
The European Board of Urology (EBU) operates as an<br />
independent section of the UEMS (European Union of<br />
Medical Specialists) charged with regulatory matters.<br />
Visit the EBU Corner at the <strong>EAU</strong> Square (booth B20)<br />
in the exhibition area to obtain more information on<br />
EBU’s core activities:<br />
• European Board Examinations in Urology (FEBU)<br />
• In-Service Assessment<br />
• Accreditation of Continuing Medical Education &<br />
Professional Development (CME & CPD)<br />
• Certification of Sub-Specialty Centres and Residency<br />
Training Programmes in Urology<br />
EU-ACME Desk<br />
Information on the EU-ACME programme, CME/CPD<br />
credit points, membership status & benefits, accredited<br />
CME activities and national CME credits systems can<br />
be obtained at the EU-ACME Desk in the registration<br />
area. For more information see <strong>page</strong> 385.<br />
Electricity<br />
The electricity in Spain runs on 230 volts and the<br />
frequency is 50 Hz. Plugs have two round pins. A plug<br />
adaptor will be required if incompatible electronic<br />
devices are used.<br />
Emergency Phone Numbers<br />
In case of emergency call 112 for police, fire brigade<br />
and ambulance service. In case of an emergency in the<br />
congress venue contact a security guard immediately.<br />
European Urology<br />
European Urology, the official journal of the <strong>EAU</strong>, has<br />
been a respected urological forum for over 20 years<br />
and is currently read by more than 10,000 urologists<br />
across the globe. With an impact factor of 6,512 the<br />
Platinum Journal has become the leading scientific<br />
publication in the field of urology. To keep up with the<br />
rapidly evolving world of medicine, technology and<br />
surgical techniques, European Urology is constantly<br />
updating and innovating its features and layout in order<br />
to provide the best clinical guidance, research and<br />
education for urologists across Europe and the world.<br />
Come see European Urology for yourself - visit either<br />
the European Urology (booth K02) or the <strong>EAU</strong> Square<br />
(booth B20) in the exhibition area.<br />
Excursions and <strong>Barcelona</strong><br />
Information<br />
Information on <strong>Barcelona</strong> and excursions will be available<br />
at the Excursion and <strong>Barcelona</strong> Information Desk<br />
in the registration area.<br />
Exhibition<br />
An extensive technical exhibition will be held jointly<br />
with the congress. The exhibition is open to technical<br />
equipment manufacturers, pharmaceutical companies<br />
and scientific publishers. The official opening will take<br />
place on Saturday, 17 April at 09.00 hrs.<br />
Exhibition Hours<br />
Saturday, 17 April 09.00-18.00 hrs<br />
Sunday, 18 April 09.00-18.00 hrs<br />
Monday, 19 April 09.00-18.00 hrs<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
23
General information<br />
First Aid<br />
There is a medical unit present for first aid in the foyer<br />
of level 1. In case of emergency contact a security<br />
guard immediately.<br />
Future Meetings Promotion<br />
Posters and other information on future meetings can<br />
be displayed in the “Future Meetings Area” located<br />
in the foyer on level 1. It is strictly forbidden to put<br />
up promotional material at any other location in the<br />
building.<br />
Hotel Accommodation<br />
The <strong>EAU</strong> has contracted the company Viajes Iberia<br />
Congresos to deal with the housing for the congress<br />
participants. Their staff will be available at the Hotel<br />
Desk in the registration area.<br />
Hospitality Suites Companies<br />
ASTELLAS Level 1, exhibition hall; rooms HS-H<br />
and HS-J<br />
ASTRAZENECA Level 1, exhibition hall; room HS-A<br />
COOK MEDICAL Level 1, exhibition hall; room HS-G<br />
<strong>EAU</strong>RF Level 1, exhibition hall; room HS-C<br />
FERRING Level 1, exhibition hall; room HS-I<br />
Insurance<br />
The organisers do not accept responsibility for any personal<br />
damage. Participants are strongly recommended<br />
to arrange their own personal insurance.<br />
Language<br />
All presentations during the congress will be<br />
conducted in English, the official language of the <strong>EAU</strong>.<br />
There will be no translation provided.<br />
Lost and Found<br />
Found items should be returned to the Information<br />
Desk in the main entrance hall. If you lose something,<br />
please report to this desk for assistance.<br />
Mobile Phones<br />
Mobile phones must be switched off during all sessions.<br />
Media Policy<br />
Photography, filming and interviews during the congress<br />
(with the exception of the <strong>EAU</strong> Press Centre and<br />
<strong>EAU</strong> Press Conference Room) are prohibited without<br />
written permission from the <strong>EAU</strong> Communication<br />
Officer Ms. Lindy Brouwer (l.brouwer@uroweb.org).<br />
24 Programme Book<br />
Message & SMS Service<br />
A Message and SMS Service is available at the congress<br />
website: www.eaubarcelona<strong>2010</strong>.org.<br />
You can use the congress website to retrieve your<br />
messages and to send messages to other congress<br />
delegates.<br />
Poster Builder Service<br />
Poster presenters who created their posters for the<br />
25 th Anniversary <strong>EAU</strong> <strong>Congress</strong> through the <strong>EAU</strong> Online<br />
Poster Builder Service, can collect their posters at the<br />
Speaker Service Centre in the main entrance hall.<br />
Prayer Room<br />
A special room dedicated to prayer is located on level 1<br />
next to the Press Centre.<br />
Presentation Training Centre<br />
Mr. Casella (Iowa, USA) gives Individual Presentation<br />
Skills Training Sessions to help improve presentation<br />
and delivery skills. The one-on-one half hour sessions<br />
are free of charge and available to all speakers. Please<br />
go to the Speaker Service Centre to make an appointment<br />
for this very popular training session.<br />
Supported by an unrestricted educational grant from<br />
ASTRAZENECA<br />
Press Centre<br />
Journalists and medical/science writers can obtain free<br />
registration to the <strong>Congress</strong>. Journalists will receive<br />
a copy of the press pack, to be picked up at the <strong>EAU</strong><br />
Press Centre. All press are invited to report to the <strong>EAU</strong><br />
Press Centre, to obtain the assistance and information<br />
they require. Internet access, printer and photocopier<br />
are provided.
Restaurants<br />
Turisme de <strong>Barcelona</strong> is pleased to provide a restaurant<br />
booking service for individuals and groups,<br />
offering a wide variety of cuisines at more than 155<br />
restaurants. To place your restaurant booking visit:<br />
www.barcelonaturisme.com/restaurants or go to the<br />
<strong>Barcelona</strong> Information Desk in the registration area.<br />
In <strong>Barcelona</strong> you can eat at the open-air seafront terraces,<br />
in the sun, nearly all year round. And you can<br />
always sample some tapas: small portions which give<br />
you the chance to taste typical Spanish dishes. The<br />
Mediterranean diet originated here, by the sea, among<br />
the olives groves, vines and wheat fields. Olive oil,<br />
wine and bread, combined with vegetables, fish, meat<br />
and fruit, created a well-balanced, rich and healthy<br />
cuisine. A cuisine appreciated today throughout the<br />
world, which has been prepared here for thousands of<br />
years, and is renewed daily, with fresh ingredients and<br />
creative genius.<br />
Safety<br />
All bags may be subject to inspection. Security is<br />
present for your safety. Please take all personal effects<br />
with you when leaving a session room.<br />
Shuttle Buses<br />
Shuttle buses will run from the nearest Metro station:<br />
Europa-Fira to the main congress entrance during<br />
congress hours.<br />
Bus shuttle service<br />
Thursday, 15 April 07.45-20.15<br />
Friday, 16 April 07.00-20.15<br />
Saturday, 17 April 06.45-20.00<br />
Sunday, 18 April 06.45-20.00<br />
Monday, 19 April 06.45-20.00<br />
Tuesday, 20 April 07.00-16.00<br />
Smoking Policy<br />
Smoking is prohibited inside the congress centre and<br />
in the exhibition area.<br />
Taxi Service<br />
Taxis will be available in the taxi rank in front of Hall 8,<br />
North Access (Entrada Norte).<br />
Ask for fixed rates to Fira <strong>Barcelona</strong> (mention: Fira<br />
Gran Via). Rates from the airport to Fira are around<br />
20 Euro. Rates from the Fira to downtown are around<br />
10-15 Euro.<br />
To book a Taxi in <strong>Barcelona</strong> we recommend you to call<br />
one of the following companies that have reasonable<br />
and fixed rates.<br />
Taxi Class: +34 93 307 07 07<br />
Taxi Radio: +34 93 303 30 33<br />
Taxi Barna: +34 93 357 77 55<br />
Transportation Pass<br />
<strong>Congress</strong> delegates may collect a transportation pass<br />
in the registration area, which is valid on all public<br />
transport within the City of <strong>Barcelona</strong> during the<br />
congress days.<br />
Delegates are kindly requested to return unused<br />
passes to the special boxes which are located in the<br />
registration area. They will be donated to a local<br />
charity.<br />
Webcasts<br />
Many sessions will be webcasted via<br />
www.eaubarcelona<strong>2010</strong>.org. The webcasted sessions<br />
are indicated with the special logo in the synopsis and<br />
will be online within several hours after the session.<br />
The webcasts have not been edited and are exactly as<br />
presented. The statements and the opinions featured<br />
in the webcasts are solely those of the individual<br />
presenters and not of the European Association of<br />
Urology (<strong>EAU</strong>).<br />
WIFI<br />
Free wireless internet will be available within the indicated<br />
areas the Fira <strong>Barcelona</strong> during the congress.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
25
Speaker guidelines<br />
Speaker Service Centre<br />
Only digital presentations will be accepted during the<br />
congress and all presentations should be handed in at<br />
the Speaker Service Centre at least three hours prior to<br />
the start of the session. Failure to do so could result in<br />
presentations not being available for projection when<br />
required.<br />
Opening hours<br />
Thursday, 15 April 14.00-19.00 hrs<br />
Friday, 16 April 07.00-19.00 hrs<br />
Saturday, 17 April 07.00-19.00 hrs<br />
Sunday, 18 April 07.00-19.00 hrs<br />
Monday, 19 April 07.00-19.00 hrs<br />
Tuesday, 20 April 07.00-13.00 hrs<br />
Supported by an unrestricted educational grant from<br />
ELI LILLy AnD COMPAny<br />
If you are a chair person<br />
Locate your session room in time. Please be in your<br />
session room at least 15 minutes prior to the start of<br />
the session.<br />
We remind you that:<br />
• Speakers should strictly observe timing.<br />
• Discussants should not speak without permission<br />
and must first clearly state their name, institution<br />
and country of origin.<br />
If you are a speaker in an oral<br />
session<br />
Locate your session room in time. Facilities are<br />
provided for PowerPoint presentations only. Please<br />
be in your session room no later than 15 minutes<br />
prior to the start of the session. Do remember that<br />
time allotted to speakers in oral sessions is 9 minutes<br />
(including 2 minutes for discussion). A maximum of<br />
10 PowerPoint slides is allowed. Follow the chairs’<br />
instructions, in particular those regarding the timing<br />
of your presentation.<br />
If you are presenting a poster<br />
Posters must be put up in the room 15 minutes prior<br />
to the start of the session. The poster boards are<br />
numbered and your poster should be mounted on the<br />
board which corresponds with your abstract number.<br />
Pushpins are available in the session room. Please<br />
remove your poster immediately at the end of the<br />
session. A maximum of three PowerPoint slides is allowed<br />
during your poster presentation.<br />
26 Programme Book<br />
Disclose links to the industry<br />
The <strong>EAU</strong> Scientific Committee requests that you<br />
disclose to the audience any links you may have with<br />
the industry related to the topic of your lecture at<br />
the beginning of your session. A link can be: Being a<br />
member of an advisory board or having a consultancy<br />
agreement with a specific company.<br />
Presentation Training Centre<br />
Mr. Casella (Iowa, USA) gives Individual Presentation<br />
Skills Training Sessions to help improve presentation<br />
and delivery skills. The one-on-one half hour sessions<br />
are free of charge and available to all speakers. Please<br />
go to the Speaker Service Centre to make an appointment<br />
for this very popular training session.<br />
Supported by an unrestricted educational grant from<br />
ASTRAZENECA
About <strong>Barcelona</strong><br />
About <strong>Barcelona</strong><br />
<strong>Barcelona</strong> is known as the second capital of Spain<br />
after Madrid. But <strong>Barcelona</strong> is also the capital city of<br />
Catalunya, a region of Northern Spain that has its own<br />
traditions, cuisine and language which is very distinct<br />
from the rest of mainland Spain. The Catalan people<br />
are proud of their rich heritage and have successfully<br />
maintained it. This blending of cultures makes the city<br />
of <strong>Barcelona</strong> a truly fascinating city.<br />
<strong>Barcelona</strong>’s reputation as a world centre for art, architecture<br />
and design is growing yearly, with a plethora<br />
of cultural activities on offer. In 1999, the entire city<br />
was awarded a Royal Gold Medal for Architecture from<br />
the Royal Institute of British Architects. The seminal<br />
ghosts of such artistic luminaries as Antonio Gaudí,<br />
Pablo Picasso, Joan Miró and Antoni Tàpies permeate<br />
<strong>Barcelona</strong>’s cultural scene. <strong>Barcelona</strong> is also a<br />
showcase for homegrown Catalan traditions - dozens<br />
of festivals, religious holidays and special occasions<br />
are celebrated in the city each year.<br />
Some of the many key attractions<br />
Temple Expiatori de la Sagrada Familia (Expiatory<br />
Temple of the Holy Family)<br />
Gaudí’s unfinished masterpiece and the city’s most<br />
outlandish landmark, the Expiatory Temple of the Holy<br />
Family, towers crazily above the grid-like streets of the<br />
Eixample. Despite being very much a building site, the<br />
cathedral has a certain beauty that somehow emerges,<br />
despite the omnipresent scaffoldings.<br />
Museu Picasso (Picasso Museum)<br />
The Picasso Museum is one of the city’s main tourist<br />
attractions, housed in two 15th-century palaces close<br />
to the Parc de la Ciutadella. The impressive permanent<br />
collection is devoted to the artist’s early work,<br />
including a large number of childhood sketches,<br />
paintings from the Blue Period (1901-1904) and the<br />
Pink Period (1907-1920), exhibition posters, ceramics<br />
and cubist works.<br />
La Rambla<br />
La Rambla is not one street but rather a seamless<br />
series of pedestrian avenues stretching from the<br />
Monument of Colon on the waterfront to Plaça de<br />
Catalunya in the centre of the city. Lined with trees,<br />
cafes, restaurants, flower stalls, shops and newspaper<br />
stands, La Rambla is the perfect place in which<br />
to stroll and soak up the unique <strong>Barcelona</strong> atmosphere.<br />
Some of La Rambla’s most captivating attractions<br />
are its famous street entertainers who delight<br />
the crowds with their weird and wacky shows.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
27
About <strong>Barcelona</strong><br />
Attractions along the way include Gaudí’s first major<br />
architectural project, Palau Güell (Güell Palace), in<br />
Carrer Nou de la Rambla. Plaça Reial, also just off<br />
La Rambla, is one of the most attractive squares in<br />
the city - elegant 19th-century houses look down on<br />
palm trees, lampposts designed by Gaudí, and an<br />
eclectic mix of people enjoying the lively atmosphere<br />
at outdoor cafes. Other points of interest are the Gran<br />
Teatre del Liceu and the legendary Café de l’Opera opposite,<br />
as well as La Boqueria, <strong>Barcelona</strong>’s wonderful,<br />
bustling food market.<br />
Parc Güell (Güell Park)<br />
With Parc Güell, Gaudí created a fantasy land that<br />
seamlessly combines the natural and the man-made,<br />
as well as offering good views over the city. The park,<br />
originally conceived as a garden city, covers a hill to<br />
the north of the city centre. The gardens are enlivened<br />
by fantastic pavilions, stairways, columned halls and<br />
an organic plaza decorated with stunning broken-mosaic<br />
work (trencadís) by Gaudí’s assistant, Josep Maria<br />
Jujol. At the base of the hill is a house designed by<br />
Francesc Berenguer, which is now home to a collection<br />
of Gaudí’s furnishings and other memorabilia.<br />
Casa Milá<br />
Casa Milá, also known as La Pedrera (the stone quarry),<br />
is an undulating apartment block on the corner of<br />
Passeig de Gràcia. The building, inspired by the ocean,<br />
is an incredible testament to Gaudí’s ability to make<br />
stone malleable. Apartments (which are not open to<br />
the public) are arranged around elliptical patios with<br />
no square corners in sight. The roof terrace is watched<br />
over by sentry-like chimneys and offers an excellent<br />
view across the city to the spires of La Sagrada Familia.<br />
The loft space of Casa Milá houses a beautiful museum,<br />
Espai Gaudí, dedicated to the architect.<br />
Mançana de la Discòrdia (Block of Discord)<br />
A series of extraordinary houses by Montaner, Gaudí<br />
and Puig i Cadafalch make up the Mançana de la<br />
Discòrdia (Block of Discord). Gaudí’s Casa Batlló, at<br />
number 43, looks rather like an underwater grotto,<br />
with blue-green tiles on the facade, frog-faced balconies<br />
and a reptilian roof. Together they form part of<br />
the Ruta Modernista.<br />
28 Programme Book<br />
The Waterfront<br />
A stroll along the harbourside passeig and wooden<br />
walkway is an excellent way to see some of the results<br />
of <strong>Barcelona</strong>’s epic regeneration programme. The<br />
focus of interest and activity in <strong>Barcelona</strong> is shifting<br />
back towards the sea, with the continued development<br />
of Port Vell (Old Port). Barceloneta, the old fisherman’s<br />
quarter, which dates from 1755, still has some<br />
of the best fish restaurants in the city and is now also<br />
the gateway to <strong>Barcelona</strong>’s beaches. Further to the<br />
east, the Vila Olímpica at Poble Nou, created for the<br />
1992 Olympic Games, is one of the liveliest and most<br />
interesting areas of the city.<br />
Shopping<br />
<strong>Barcelona</strong> is a shopping paradise where modernity<br />
and tradition go hand in hand. The shopping possibilities<br />
are unlimited and include international and<br />
Spanish designers, traditional jewellers, small antique<br />
and art shops and not to mention the enormous shopping<br />
centres and department stores.<br />
<strong>Barcelona</strong> Shopping Line is the city’s vast shopping<br />
area. Its size is impressive: it starts at the old harbour<br />
and goes along las Ramblas, Barri Gotic, Portal de<br />
l’Angel, continues from Plaça de Catalunya along the<br />
stretch between Passeig de Gracia and Rambla de<br />
Catalunya with even more shops along Av. Diagonal.<br />
There is a special bus (Tombus) that runs along the<br />
shopping line from Plaça de Catalunya to the end of<br />
Avenida Diagonal.
<strong>Barcelona</strong> Markets<br />
The atmospheric Boqueria covered<br />
market on la Rambla, is not to be missed.<br />
The Boqueria is the most famous market<br />
in <strong>Barcelona</strong> and undoubtedly one of the<br />
best markets in the world. With its 6,000<br />
square metres of fruits, vegetables, meat,<br />
fish and other specialities, this market is<br />
a real pleasure to the senses!<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
29
Food<br />
<strong>Barcelona</strong> is the first non-French city to be nominated<br />
the “Gourmand” city of Europe by the prestigious<br />
Michelin Guide. The amount of restaurants is unlimited<br />
and you can choose from a traditional taberna or<br />
trendy restaurant. Just like in the rest of Spain, lunch is<br />
between 2 and 4 and dinner is never before 9.<br />
Catalan cuisine is based on seasonal foods: simple<br />
products from the land, herbs, fish and meat, with<br />
an abundant use of vegetables and olive oil. Another<br />
typical aspect is the ease with which the Catalans mix<br />
ingredients which are rarely found together, like fish<br />
and red meat.<br />
Popular gourmet dishes include botifarra amb mongetes<br />
(sausage with white beans), fricandò (pork stew),<br />
faves a la catalana (broad beans with smoked ham),<br />
Catalan spinach (with raisins and pine nuts), samfaina<br />
a puree of bell peppers and other vegetables served<br />
with meat or fish and fidéua (a paella made with<br />
pasta).<br />
Fish is very popular and easy available. Cod is found<br />
in many dishes, in particular esqueixada. Try zarzuela<br />
(fish stew) or romesco de pescado (a fish casserole<br />
cooked in romesco sauce) or one of the many suquets<br />
de peix, Catalan fish soup.<br />
The most typical desserts are miel i mato (soft cheese<br />
with honey) and of course crema catalana (crème<br />
brulee).<br />
Wine: Catalonia is one of the main wine growing<br />
regions of Spain; its most famous production is<br />
concentrated in the Penedés area between <strong>Barcelona</strong><br />
30 Programme Book<br />
and Tarragona. This area produces excellent white<br />
wines and the famous Cava, Spanish champagne<br />
which comes from the vineyards of Vilafranca and Sant<br />
Sadurnì d’Anoia. The best Catalan reds come from<br />
Priorat, an area south of Tarragona.<br />
Nightlife<br />
<strong>Barcelona</strong> is one of Europe’s coolest cities and offers<br />
nightlife as rich and varied as you would expect in any<br />
major city. When the sun goes down you will find all<br />
forms of entertainment from traditional fiestas and<br />
world-class opera which offer countless opportunities<br />
to have fun and enjoy yourself. To keep up to date on<br />
entertainment, the best source is the weekly magazine<br />
La Guia de Ocio.<br />
Getting around<br />
<strong>Barcelona</strong>’s public transport system is an easy-to-use<br />
and integrated service that makes travelling fairly<br />
manageable. As well as the regular public transport<br />
options, <strong>Barcelona</strong> has a cable car, tramway and uphill<br />
furnicular train for getting around. <strong>Barcelona</strong>’s bike<br />
paths make the city very adapted for cycling and you<br />
can easily hire bicycles to explore the city.<br />
<strong>Barcelona</strong>’s metro system is fairly simple to negotiate.<br />
Frequent trains and clearly indicated arrival times<br />
make travelling by underground a fast and simpler<br />
option.
http://esou.uroweb.org<br />
8 th Meeting of<br />
the <strong>EAU</strong> Section<br />
of Oncological<br />
Urology (ESOU)<br />
21-23 January 2011, London, England<br />
ESOU is a full member of the <strong>EAU</strong> Section Office<br />
European<br />
Association<br />
of Urology
Historical Overview <strong>EAU</strong> <strong>Congress</strong>es<br />
1974 12-14 September Padua, Italy<br />
1976 24-26 September Prague, Czech Republic<br />
1978 14-16 June Monte Carlo, Monaco<br />
1980 28-31 May Athens, Greece<br />
1982 12-15 May Vienna, Austria<br />
1984 23-26 May Copenhagen, Denmark<br />
1986 26-28 June Budapest, Hungary<br />
1988 18-21 May London, Great Britain<br />
1990 10-16 June Amsterdam, The Netherlands<br />
1992 22-25 July Genoa, Italy<br />
1994 13-16 July Berlin, Germany<br />
1996 1-4 September Paris, France<br />
1998 21-25 March <strong>Barcelona</strong>, Spain<br />
1999 7-10 April Stockholm, Sweden<br />
2000 12-15 April Brussels, Belgium<br />
2001 7-10 April Geneva, Switzerland<br />
2002 23-26 February Birmingham, Great Britain<br />
2003 12-15 March Madrid, Spain<br />
2004 24-27 March Vienna, Austria<br />
2005 16-19 March Istanbul, Turkey<br />
2006 5-8 April Paris, France<br />
2007 21-24 March Berlin, Germany<br />
2008 26-29 March Milan, Italy<br />
2009 17-21 March Stockholm, Sweden<br />
<strong>2010</strong> 16-20 April <strong>Barcelona</strong>, Spain<br />
32 Programme Book
<strong>EAU</strong> 25 th Anniversary <strong>Congress</strong><br />
From Padua to <strong>Barcelona</strong>: Transforming the face of European urology<br />
From the modest beginnings of a three-day conference first held from 12-14 September,<br />
1974 in Padua, Italy, the <strong>Annual</strong> <strong>EAU</strong> <strong>Congress</strong> has grown to what is now one of the<br />
biggest medical events in Europe, gathering more than 13,500 participants to witness not<br />
only the breadth of urology but also the challenges it faces in modern medicine.<br />
A homage<br />
As homage to the <strong>Annual</strong> <strong>Congress</strong> silver jubilee, this year’s congress will feature the<br />
<strong>EAU</strong> <strong>Congress</strong> History Wall, a collage of photographs, texts and audio-visual displays,<br />
tracing the early years of this annual congress and some of the highlights in the <strong>EAU</strong>’s<br />
history. This <strong>Congress</strong> Wall project, will attempt to capture the manifold changes that<br />
continue to transform not only the face of urology in Europe but also beyond. Visit the<br />
<strong>EAU</strong> <strong>Congress</strong> History Wall (located between the Paris and <strong>Barcelona</strong> Rooms) and reflect<br />
on the urological issues debated nearly three decades ago or gain insights into the<br />
visions and goals of pioneering leaders in urology.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
33
<strong>Congress</strong> hotels<br />
1898<br />
La Rambla 109<br />
08002 <strong>Barcelona</strong><br />
T +34 93 552 9552<br />
F +34 93 552 9550<br />
www.hotel1898.com<br />
Metro L3- Drassanes<br />
Transfer time to fair: 24 min<br />
Abba Sants<br />
Calle Numancia 32<br />
08029 <strong>Barcelona</strong><br />
T +34 936 003 100<br />
F +34 936 003 101<br />
www.abbasantshotelbarcelona.com<br />
Metro L3- Sants<br />
Transfer time to the venue: 21 min<br />
AC Irla<br />
Calvet 40-42<br />
08021 <strong>Barcelona</strong><br />
T +34 93 241 62 10<br />
F +34 93 241 62 11<br />
www.ac-hotels.com<br />
Metro L5- Hospital Cliníc<br />
Transfer time to the fair: 34 min<br />
AC Sants<br />
Passeig De Sant Antoni 36-40<br />
08014 <strong>Barcelona</strong><br />
T +34 934 324 512<br />
F +34 93 4324 504<br />
www.ac-hotels.com<br />
Metro L1-Plaza de Sants<br />
Transfer time to the fair: 23 min<br />
AC Som<br />
Carrer de l’Arquitectura 1<br />
08035 <strong>Barcelona</strong><br />
T +34 934 458 200<br />
F +34 934 458 201<br />
www.ac-hotels.com<br />
Metro L3- Montbau<br />
Transfer time to the fair: 33 min<br />
34 Programme Book<br />
AC Vilamari<br />
C/ Vilamarí, 34-36<br />
08015 <strong>Barcelona</strong><br />
T +34 93 289 09 09<br />
F +34 93 289 05 01<br />
www.ac-hotels.com<br />
Bus- N2<br />
Transfer time to the fair: 28 min<br />
Acevi Villaroel<br />
Villaroel 106<br />
08011 <strong>Barcelona</strong><br />
T +34 934 52 00 00<br />
F +34 933 23 97 51<br />
www.acevihotels.com<br />
Metro L1- Urgel<br />
Transfer time to the fair: 26 min<br />
Alexandra<br />
Mallorca 251<br />
08008 <strong>Barcelona</strong><br />
T +34 934 677 166<br />
F +34 934 880 258<br />
www.hotel-alexandra.com<br />
Metro L3- Passeig de Gracia<br />
Transfer time to the fair: 29 min<br />
Ayre Granvia<br />
Gran Via de Les Corts Catalanes,<br />
322 - 324<br />
08004 <strong>Barcelona</strong><br />
T +34 933 675 500<br />
F +34 933 675 501<br />
www.ayrehoteles.com<br />
Metro L1- Espanya<br />
Transfer time to the fair: 11 min<br />
Ayre Hotel Caspe<br />
Calle Caspe103<br />
08013 <strong>Barcelona</strong><br />
T +34 93 2467000<br />
F +34 93 2467001<br />
www.ayrehoteles.com<br />
Metro L1- Arc de triomf<br />
Transfer time to the fair: 41 min<br />
B–Hotel<br />
Gran Via de les Corts Catalanes<br />
389-391<br />
08015 <strong>Barcelona</strong><br />
T +34 935 529 500<br />
F +34 935 522 621<br />
www.b-hotel.com<br />
Metro L1- Espanya<br />
Transfer time to the fair: 10 min<br />
<strong>Barcelona</strong> Catedral<br />
Capellans 4<br />
08002 <strong>Barcelona</strong><br />
T +34 933 042 255<br />
F +34 933 042 366<br />
www.barcelonacatedral.com<br />
Metro L3- Liceu<br />
Transfer time to the fair: 28 min<br />
<strong>Barcelona</strong> Universal<br />
Avenida Paral.lel 76-80<br />
08001 <strong>Barcelona</strong><br />
T +34 935 677 447<br />
F +34 935 677 440<br />
www.hotelbarcelonauniversal.com<br />
Metro L2, L3- Paral-lel<br />
Transfer time to the fair: 18 min<br />
Barceló Raval<br />
Rambla del Raval 17-21<br />
08001 <strong>Barcelona</strong><br />
T +34 93 320 1490<br />
F +34 93 3201494<br />
www.barceloraval.com<br />
Metro L3- Liceu<br />
Transfer time to the fair: 21 min<br />
Barceló Sants<br />
Calle Pl.Paisos Catalans<br />
08014 <strong>Barcelona</strong><br />
T +34 935 035 301<br />
F +34 934 901 574<br />
www.barcelo.com<br />
Metro L3- Sants Estació<br />
Transfer time to the fair: 17 min
Catalonia Albeniz<br />
Carrer D’Aragó 591-593<br />
08026 <strong>Barcelona</strong><br />
T +34 93 265 26 26<br />
F +34 93 265 40 07<br />
www.Hoteles-Catalonia.com<br />
Metro L1- Clot<br />
Transfer time to the fair: 33 min<br />
Catalonia <strong>Barcelona</strong><br />
Plaza<br />
Plaça Espanya, 6-8<br />
08014 <strong>Barcelona</strong><br />
T +34 93 426 2600<br />
F +34 93 426 0400<br />
www.Hoteles-Catalonia.com<br />
Metro L1- Espanya<br />
Transfer time to the fair: 10 min<br />
Catalonia Berna<br />
Roger de Lluria 60<br />
08009 <strong>Barcelona</strong><br />
T +34 932 720 050<br />
F +34 932 720 058<br />
www.Hoteles-Catalonia.com<br />
Metro L3- Passeig de Gracias<br />
Transfer time to the fair: 40 min<br />
Catalonia Corcega<br />
Corcega 368<br />
08037 <strong>Barcelona</strong><br />
T +34 932081919<br />
F +34 932080857<br />
www.hoteles-catalonia.com<br />
Metro L3- Diagonal<br />
Transfer time to the fair: 25 min<br />
Catalonia Duques de<br />
Bergara<br />
C/ Bergara 11,<br />
08002 <strong>Barcelona</strong><br />
T +34 933 015 151<br />
F +34 932 360 026<br />
www.Hoteles-Catalonia.com<br />
Metro L3-Cataluña<br />
Transfer time to the fair: 25 min<br />
Catalonia Ramblas<br />
Pelai 28<br />
08001 <strong>Barcelona</strong><br />
T +34 933 168 400<br />
F +34 933 168 401<br />
www.hoteles-catalonia.com<br />
Metro L1, L3- Catalunya<br />
Transfer time to the fair: 22 min<br />
Catalonia Suite<br />
Muntaner 505<br />
08022 <strong>Barcelona</strong><br />
T +34 93 212 80 12<br />
F +34 93 211 23 17<br />
www.hoteles-catalonia.com<br />
Metro L1- Urgell<br />
Transfer time to the fair: 17 min<br />
City Park Nicaragua<br />
Calle Nicaragua 47<br />
08029 <strong>Barcelona</strong><br />
T +34 933 637 474<br />
F +34 934 197 163<br />
www.cityparkhoteles.com<br />
Metro L5- EntenÇa<br />
Transfer time to the fair: 26 min<br />
Colón<br />
Av. Catedral 7<br />
08002 <strong>Barcelona</strong><br />
T +34 933 01 14 04<br />
F +34 933 17 29 15<br />
www.hotelcolon.es<br />
Metro L3- Liceu<br />
Transfer time to the fair: 28 min<br />
Condes De <strong>Barcelona</strong><br />
Pg de Gracia 73-75<br />
08008 <strong>Barcelona</strong><br />
T +34 933 011 404<br />
F +34 933 172 915<br />
www.condesdebarcelona.com<br />
Metro L3- Diagonal<br />
Transfer time to the fair: 25 min<br />
Confortel Almirante<br />
Via Laietana 42<br />
08003 <strong>Barcelona</strong><br />
T +34 932 68 30 20<br />
F +34 932 68 31 92<br />
www.confortelhoteles.com<br />
Metro L1- Urquinaona<br />
Transfer time to the fair: 40 min<br />
Derby <strong>Barcelona</strong><br />
Loreto 21<br />
08029 <strong>Barcelona</strong><br />
T +34 933 22 32 15<br />
F +34 934 10 08 62<br />
www.derbyhotels.com<br />
Metro L5- Hospital Cliníc<br />
Transfer time to the fair: 34 min<br />
Eurostar Grand<br />
Marina<br />
Moll de <strong>Barcelona</strong>, s/n -<br />
Edificio Oeste<br />
08039 <strong>Barcelona</strong><br />
T +34 93 603 90 00<br />
F +34 93 603 90 90<br />
www.grandmarinahotel.com<br />
Metro L3- Drassanes<br />
Transfer time to the fair: 20 min<br />
Evenia Roselló<br />
Roselló 191<br />
08036 <strong>Barcelona</strong><br />
T +34 932 38 63 55<br />
F +34 932 38 63 05<br />
es.eveniahotels.com<br />
Metro L3- Diagonal<br />
Transfer time to the fair: 25 min<br />
Expo <strong>Barcelona</strong><br />
Mallorca 1-23<br />
08014 <strong>Barcelona</strong><br />
T +34 936 003 020<br />
F +34 932 927 960<br />
www.expohotelbarcelona.com<br />
Metro L3- Tarragona<br />
Transfer time to the fair: 17 min<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
35
<strong>Congress</strong> hotels<br />
Fira <strong>Congress</strong><br />
(ex Prestige <strong>Congress</strong>)<br />
C. de José Agustín Goytisolo, 9-11<br />
08909 L’Hospitalet de Llobregat<br />
T +34 932 671 800<br />
F +34 932 671 801<br />
www.firacongress.com<br />
Walking distance to the fair<br />
Fira Palace<br />
Av Ruis i Taulet 1-3<br />
08004 <strong>Barcelona</strong><br />
T +34 934 262 223<br />
F +34 934 255 047<br />
www.fira-palace.com<br />
Metro L1- Espanya<br />
Transfer time to the fair: 11 min<br />
Gran Catalonia<br />
Balmes 142-146<br />
08008 <strong>Barcelona</strong><br />
T +34 934 159 090<br />
F +34 932 360 026<br />
grancatalonia.barcelonahotels.it<br />
Metro L3- Diagonal<br />
Transfer time to the fair: 25 min<br />
Gran Hotel Central<br />
Via Laietana 30<br />
08003 <strong>Barcelona</strong><br />
T +34 932 957 900<br />
F +34 932 681 215<br />
www.grandhotelcentral.com<br />
Autobus- N 15<br />
Transfer time to the fair: 50 min<br />
H10 Itaca<br />
Avinguda Roma 22<br />
08015 <strong>Barcelona</strong><br />
T +34 932 26 55 94<br />
F +34 932 29 22 49<br />
www.itacahotel.com<br />
Metro L3- Tarragona<br />
Transfer time to the fair: 17 min<br />
36 Programme Book<br />
H10 Marina<br />
Av. Bogatell 64-68<br />
08005 <strong>Barcelona</strong><br />
T +34 933 09 79 17<br />
F +34 933 09 97 62<br />
www.h10hotels.com<br />
Metro L4- Bogatell<br />
Transfer time to the fair: 29 min<br />
Hesperia Presidente<br />
Av Diagonal 570<br />
08021 <strong>Barcelona</strong><br />
T +34 932 002 111<br />
F +34 932 095 106<br />
www.hesperia-presidente.es<br />
Metro L5- Hospital Cliníc<br />
Transfer time to the fair: 34 min<br />
Hesperia Tower<br />
Avinguda Gran Via 144<br />
08902 L’Hospitalet De Llobregat<br />
T +34 935 051 758<br />
F +34 932 373 473<br />
www.hesperia.es<br />
No metro nearby<br />
Transfer time to the fair: 20 min<br />
Husa Avenida Palace<br />
Gran Via de les Corts Catalanes 605<br />
08007 <strong>Barcelona</strong><br />
T +34 933 019 600<br />
F +34 934 189 967<br />
www.avenidapalace.com<br />
Metro L2, L3, L4- Passeig de Gracia<br />
Transfer time to the fair: 23 min<br />
Husa L’Illa<br />
Av. Diagonal 555<br />
08029 <strong>Barcelona</strong><br />
T +34 934 107 503<br />
F +34 934 189 967<br />
www.hotelhusalilla.com<br />
Metro L3- María Cristina<br />
Transfer time to the fair: 21 min<br />
Husa Mesón de<br />
Castilla<br />
Valldonzella 5<br />
08001 <strong>Barcelona</strong><br />
T +34 933 182 182<br />
F +34 934 124 020<br />
www.mesoncastilla.com<br />
Metro L1, L2- Universitat<br />
Transfer time to the fair: 18 min<br />
Husa Palace DL<br />
Gran Via de les Corts Catalanes 668<br />
08007 <strong>Barcelona</strong><br />
T +34 933 01 96 00<br />
F +34 934 189 967<br />
www.avenidapalace.com<br />
Metro L2, L3, L4- Passeig de Gracia<br />
Transfer time to the fair: 23 min<br />
Jazz<br />
Pelai 3<br />
08001 <strong>Barcelona</strong><br />
T +34 935 529 696<br />
F +34 935 529 697<br />
www.hoteljazz.com<br />
Metro L1, L2- Universitat<br />
Transfer time to the fair: 18 min<br />
Le Meridien <strong>Barcelona</strong><br />
La Rambla 111<br />
08002 <strong>Barcelona</strong><br />
T +34 93 318 62 00<br />
F +34 93 301 77 76<br />
www.starwoodhotels.com<br />
Metro L1, L3- Catalunya<br />
Transfer time to the fair: 22 min<br />
Meliá <strong>Barcelona</strong><br />
Av. Sarriá, 50<br />
08029 <strong>Barcelona</strong><br />
T +34 93 410 60 60<br />
F +34 93 410 77 44<br />
www.es.solmelia.com<br />
Metro L5- Hospital Cliníc<br />
Transfer time to the fair: 34 min
NH Calderón<br />
Rambla de Catalunya 26<br />
08007 <strong>Barcelona</strong><br />
T +34 933 010 000<br />
F +34 933 024 489<br />
www.nh-hotels.it<br />
Metro L1- Cataluña<br />
Transfer time to the fair: 28 min<br />
NH Constanza<br />
Deu I Mata 69-99<br />
08029 <strong>Barcelona</strong><br />
T +34 932 811 500<br />
F +34 934 100 335<br />
www.nh-hoteles.es<br />
Metro L3- Les Corts<br />
Transfer time to the fair: 20 min<br />
NH Numancia<br />
C/ Numancia 74<br />
08029 <strong>Barcelona</strong><br />
T +34 933 224 451<br />
F +34 934 107 642<br />
www.nh-hoteles.es<br />
Metro L3- Plaça del Centre<br />
Transfer time to the fair: 19 min<br />
Nh Podium<br />
Bailen 4<br />
08010 <strong>Barcelona</strong><br />
T +34 93 265 02 02<br />
F +34 93 265 05 06<br />
www.nh-hotels.it<br />
Metro L1- Arc del Triomf<br />
Transfer time to the fair: 22 min<br />
Onix Fira<br />
Gran Via 967<br />
08018 <strong>Barcelona</strong><br />
T +34 933 034 164<br />
F +34 933 034 153<br />
www.hotelonixfira.com<br />
Metro L1- Espanya<br />
Transfer time to the fair: 11 min<br />
Porta Fira<br />
Plaza de Europa 45<br />
T +34 933 620 290<br />
F +34 934 146 170<br />
www.h-santos.com<br />
Walking distance to the fair<br />
Princesa Sofía<br />
Pl. Pius XII 4<br />
08028 <strong>Barcelona</strong><br />
T +34 935 081 050<br />
F +34 934 112 106<br />
www.princesasofia.com<br />
Metro L3 – Palau Reial<br />
Transfer time to the fair: 22 min<br />
Pulitzer<br />
Bergara 8<br />
08002 <strong>Barcelona</strong><br />
T +34 934 816 767<br />
F +34 934 816 464<br />
www.hotelpulitzer.es<br />
Metro L1, L3- Catalunya<br />
Transfer time to the fair: 22 min<br />
Regina<br />
Bergara 4<br />
08002 <strong>Barcelona</strong><br />
T +34 93 301 32 32<br />
F +34 93 318 23 26<br />
www.reginahotel.com<br />
Metro L1, L3- Catalunya<br />
Transfer time to the fair: 22 min<br />
Rey Juan Carlos I<br />
Av. Diagonal 661-671<br />
08028 <strong>Barcelona</strong><br />
T +34 93 364 40 40<br />
F +34 93 364 40 82<br />
www.hrjuancarlos.com<br />
Metro L3- Zona Universitària<br />
Transfer time to the fair: 24 min<br />
Royal Ramblas<br />
Ramblas 117<br />
08002 <strong>Barcelona</strong><br />
T +34 933 019 400<br />
F +34 933 173 1979<br />
www.royalramblashotel.com<br />
Metro L1, L3- Catalunya<br />
Transfer time to the fair: 22 min<br />
Sant’Angelo<br />
Consell De Cent 74<br />
08015 <strong>Barcelona</strong><br />
T +34 93 423 46 47<br />
F +34 93 423 88 40<br />
www.apsishotels.com<br />
Metro L1- Rocafort<br />
Transfer time to the fair: 16 min<br />
Silken Gran Hotel<br />
Havana<br />
Gran Vía Corts Catalanes 647<br />
08010 <strong>Barcelona</strong><br />
T +34 933 47 10 00<br />
F +34 933 417 00 01<br />
www.hoteles-silken.com<br />
Metro L2- Tetuan<br />
Transfer time to the fair: 29 min<br />
Silken Ramblas<br />
Printor Fortuny 13<br />
08001 <strong>Barcelona</strong><br />
T +34 933 426 180<br />
F +34 933 027 977<br />
www.hoteles-silken.com<br />
Metro L1, L3- Catalunya<br />
Transfer time to the fair: 22 min<br />
Travelodge<br />
C/ Botánica 25<br />
08908 L’Hospitalet De Llobregat<br />
T +34 916 303 608<br />
F +34 916 301 750<br />
www.travelodgehoteles.net<br />
Walking distance<br />
Torre Catalunya<br />
Av. Roma 2-4<br />
08014 <strong>Barcelona</strong><br />
T +34 936 006 999<br />
F +34 936 006 977<br />
www.torrecatalunya.com<br />
Metro L3- Sants Estació<br />
Transfer time to the fair: 17 min<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
37
<strong>Congress</strong> hotels<br />
Tryp Apolo<br />
Av. Paral-el 76-80<br />
08001 <strong>Barcelona</strong><br />
T +34 933 433 002<br />
F +34 934 432 294<br />
www.tryp-apolo.com<br />
Metro L2, L3- Paral-lel<br />
Transfer time to the fair: 15 min<br />
U232<br />
Compte Urgel l 232<br />
08036 <strong>Barcelona</strong><br />
T +34 933 224 153<br />
F +34 934 190 106<br />
www.u232hotel.com<br />
Metro L5- Hospital Cliníc<br />
Transfer time to the fair: 34 min<br />
Vincci Arena<br />
C/ Consell de Cent 51-53<br />
08014 <strong>Barcelona</strong><br />
T +34 932 893 921<br />
F +34 934 254 525<br />
www.vinccihoteles.com<br />
Metro L3- Tarragona<br />
Transfer time to the fair: 17 min<br />
38 Programme Book
Friday, 16 April - <strong>EAU</strong> Programme<br />
10.45 - 13.15 Joint Session of the European Association of Urology (<strong>EAU</strong>) and the<br />
Korean Urological Association (KUA)<br />
Amsterdam Room<br />
Chairs: V. Mirone, Naples (IT)<br />
M.S. Choo, Seoul (KR)<br />
10.45 - 11.00 Welcome address from KUA President<br />
J.S. Paick, Seoul (KR)<br />
11.00 - 11.40 Session 1: Prostate cancer guidelines<br />
KUA - M.K. Chung, Busan (KR)<br />
<strong>EAU</strong> - A. Patel, London (GB)<br />
Discussion<br />
11.40 - 12.20 Session 2: Surgical treatment of female stress urinary incontinence<br />
KUA - K.S. Lee, Seoul (KR)<br />
<strong>EAU</strong> - P. Costa, Nimes (FR)<br />
Discussion<br />
12.20 - 13.00 Session 3: New insights into ED management<br />
KUA - K.S. Park, Kwangju (KR)<br />
<strong>EAU</strong> - H. Porst, Hamburg (DE)<br />
Discussion<br />
13.00 - 13.15 Closing remarks<br />
V. Mirone, Naples (IT)<br />
M.S Choo, Seoul (KR)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
39
Friday, 16 April - <strong>EAU</strong> Programme<br />
10.45 - 13.15 Joint Session of the European Association of Urology (<strong>EAU</strong>) and the<br />
Indonesian Urological Association (IAUI)<br />
40 Programme Book<br />
<strong>Barcelona</strong> Room<br />
Chairs: A. Patel, London (GB)<br />
S. Sugandi, Bandung (ID)<br />
10.45 - 10.50 Introduction<br />
A. Patel, London (GB)<br />
S. Sugandi, Bandung (ID)<br />
10.50 - 11.10 <strong>EAU</strong> - Role and extent of lymphadenectomy in kidney cancer<br />
H. Van Poppel, Leuven (BE)<br />
11.10 - 11.30 IAUI - Bone health in urological malignancy<br />
D.M. Soebadi, Surabaya (ID)<br />
11.30 - 11.50 <strong>EAU</strong> - Role and extent of lymphadenectomy in bladder cancer<br />
U.E. Studer, Berne (CH)<br />
11.50 - 12.10 IAUI - Continuous vs intermittent hormonal therapy in prostate cancer<br />
C.A. Mochtar, Jakarta (ID)<br />
12.10 - 12.30 IAUI - Chemotherapy by urologists<br />
R. Umbas, Jakarta (ID)<br />
12.30 - 12.50 <strong>EAU</strong> - Role and extent of lymphadenectomy in prostate cancer<br />
A. Heidenreich, Aachen (DE)<br />
12.50 - 13.10 Interactive audience discussion<br />
13.10 - 13.15 Closing remarks<br />
A. Patel, London (GB)<br />
S. Sugandi, Bandung (ID)
Friday, 16 April - <strong>EAU</strong> Programme<br />
10.45 - 13.15 Joint Session of the European Association of Urology (<strong>EAU</strong>) and the<br />
Chinese Urological Association (CUA)<br />
Paris Room<br />
10.45 - 10.50 Introduction<br />
Chairs: W. Artibani, Verona (IT)<br />
L.P. Xie, Hangzhou (CN)<br />
10.50 - 11.25 Hot topics in urology in Europe and China<br />
Covering epidemiology, screening, awareness, diagnosis and staging, and treatment<br />
case discussion<br />
W. Artibani, Verona (IT)<br />
L.P. Xie, Hangzhou (CN)<br />
11.25 - 12.00 Prostate cancer<br />
F.M.J. Debruyne, Arnhem (NL)<br />
M. Li, Beijing (CN)<br />
12.00 - 12.35 Urological training in Europe and China<br />
Covering training systems, manpower, unmet needs<br />
J.M. Nijman, Groningen (NL)<br />
J. Huang, Guangzhou (CN)<br />
12.35 - 13.10 Female urinary incontinence in Europe and China<br />
Covering epidemiology, diagnosis and treatment modalities<br />
case discussion<br />
13.10 - 13.15 Close<br />
D. Castro-Diaz, Santa Cruz de Tenerife (ES)<br />
J-Y. Wang, Beijing (CN)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
41
Friday, 16 April - <strong>EAU</strong> Programme<br />
10.45 - 13.15 Joint Session of the European Association of Urology (<strong>EAU</strong>) and the<br />
Iranian Urological Association (IUA)<br />
Stockholm Room<br />
Chairs: J. Hosseini, Tehran (IR)<br />
D. Jacqmin, Strasbourg (FR)<br />
10.45 - 11.20 Case discussion: Urethral stricture<br />
G. Barbagli, Arezzo (IT)<br />
J. Hosseini, Tehran (IR)<br />
11.20 - 12.10 Low risk prostatic carcinoma: Surgery or surveillance?<br />
Surgery: B. Djavan, New York (US)<br />
Surveillance: G.R. Pourmand, Tehran (IR)<br />
Brachytherapy: D. Jacqmin, Strasbourg (FR)<br />
12.10 - 12.45 Case discussion: Locally advanced prostate cancer - Surgery or hormonoradiotherapy<br />
Hormonoradiotherapy: M. Ayati, Tehran (IR)<br />
Surgery: H. Van Poppel, Leuven (BE)<br />
12.45 - 13.15 Case discussion: Management of azoospermia infertility<br />
D. Jacqmin, Strasbourg (FR)<br />
M.A. Sadighi, Tehran (IR)<br />
42 Programme Book
Friday, 16 April - <strong>EAU</strong> Programme<br />
10.45 - 13.15 Joint Session of the European Association of Urology (<strong>EAU</strong>) and the<br />
Urological Society of India (USI)<br />
10.45 - 11.05 Chyluria<br />
Vienna Room<br />
Chairs: C.R. Chapple, Sheffield (GB)<br />
K. Mammen, Ludhiana (IN)<br />
10.45 - 11.05 Recent advances in the management of chyluria<br />
P.B. Singh, Varanasi (IN)<br />
11.05 - 12.25 Penile cancer<br />
11.05 - 11.20 Prevention and pre-malignant lesions of penile cancer<br />
S. Minhas, London (GB)<br />
11.20 - 11.40 Diagnosis and staging of penile cancer<br />
J.N. Kulkarni, Mumbai (IN)<br />
11.40 - 11.55 New developments in the treatment of localised penile cancer<br />
E. Solsona, Valencia (ES)<br />
11.55 - 12.10 Management of advanced penile cancer<br />
V. Srinivas, Mumbai (IN)<br />
12.10 - 12.25 Prognostic factors in penile cancer<br />
V. Ficarra, Padua (IT)<br />
12.25 - 13.10 Stress urinary incontinence<br />
12.25 - 12.40 Appropriate evaluation of patients presenting with SUI<br />
A. Vaze, Mumbai (IN)<br />
12.40 - 12.55 The evidence base relating to the use of pubo-vaginal slings<br />
N. Rajamaheswari, Chennai (IN)<br />
12.55 - 13.10 The evidence base relating to the use of synthetic mid-urethral slings<br />
C.R. Chapple, Sheffield (GB)<br />
13.10 - 13.15 Close<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
43
Friday, 16 April - <strong>EAU</strong> Programme<br />
13.25 - 15.55 Joint Session of the European Association of Urology (<strong>EAU</strong>) and the<br />
Confederaçion Americana de Urologia (CAU)<br />
44 Programme Book<br />
Amsterdam Room<br />
Chairs: C.L.L. Llorente, Madrid (ES)<br />
O. Castillo, Santiago (CL)<br />
13.25 - 13.40 <strong>EAU</strong> - Management of the small renal mass<br />
A.R. Zlotta, Toronto (CA)<br />
13.40 - 13.55 CAU - Tissue engineering for urethral reconstruction in humans<br />
L. Ribeiro-Filho, Sao Paolo (BR)<br />
13.55 - 14.10 <strong>EAU</strong> - Testosterone and prostate cancer<br />
B. Tombal, Brussels (BE)<br />
14.10 - 14.25 CAU - Multidisciplinary treatment for invasive bladder cancer: Neoadjuvant chemotherapy<br />
R. Sanchez-Salas, Caracas (VE)<br />
14.25 - 14.40 <strong>EAU</strong> - New concepts in LUTS<br />
C.R. Chapple, Sheffield (GB)<br />
14.40 - 14.55 CAU - Mini slings: Less for less?<br />
P. Palma, Campinas (BR)<br />
14.55 - 15.10 <strong>EAU</strong> - Laparoscopic radical cystectomy. What for?<br />
L. Cecchini, <strong>Barcelona</strong> (ES)<br />
15.10 - 15.25 CAU - The role of radical surgery as a palliative treatment for metastatic prostate cancer<br />
A. Torres, Mexico City (MX)<br />
15.25 - 15.40 <strong>EAU</strong> - Management of upper urinary tract urothelial tumours<br />
C. Selli, Pisa (IT)<br />
15.40 - 15.55 CAU - Brachytherapy in prostate cancer: A treatment option to be considered by the urologist<br />
L.E. Cavelier, Bogota (CO)
Friday, 16 April - <strong>EAU</strong> Programme<br />
13.25 - 15.55 Joint Session of the European Association of Urology (<strong>EAU</strong>) and the<br />
Arab Association of Urology (AAU)<br />
<strong>Barcelona</strong> Room<br />
Chair: M. Marberger, Vienna (AT)<br />
R. Khauli, Beirut (LB)<br />
13.25 – 13.35 Welcome and introduction<br />
M. Marberger, Vienna (AT)<br />
R. Khauli, Beirut (LB)<br />
13.35 – 14.25 Session 1 – Prostate cancer<br />
Chairs: A. Al Dayel, Dammam (SA)<br />
M. Marberger, Vienna (AT)<br />
13.35 – 13.45 High PSA, negative biopsy – what now?<br />
F. Cruz, Porto (PT)<br />
13.45 – 13.55 Active surveillance: In whom, and how?<br />
J. Fitzpatrick, Dublin (IE)<br />
13.55 – 14.05 Focal therapy: Option or fantasy?<br />
M. Emberton, London (GB)<br />
14.05 – 14.15 The role of radical prostatectomy in T3 prostate cancer<br />
K. Khauli, Beirut (LB)<br />
14.15 – 14.25 Intermittent androgen withdrawal<br />
D. Rabah, Riyadh (SA)<br />
14.25 – 14.45 Panel discussion/debate<br />
Panelists: F. Cruz, Porto (PT)<br />
M. Emberton, London (GB)<br />
J. Fitzpatrick, Dublin (IE)<br />
K. Khauli, Beirut (LB)<br />
D. Rabah, Riyadh (SA)<br />
14.45 – 15.55 Session 2 – Renal cell cancer<br />
Chairs: K. Al Awadi, Rawda (KW)<br />
J. Fitzpatrick, Dublin (IE)<br />
14.45 – 14.55 Partial nephrectomy: Where are the limits?<br />
H. Van Poppel, Leuven (BE)<br />
14.55 – 15.05 Active surveillance of small renal masses<br />
W. Alkhudair, Riyadh (SA)<br />
15.05 – 15.15 Energy ablative therapy: Percutaneous or laparoscopic?<br />
M. Marberger, Vienna (AT)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
45
15.15 – 15.25 The role of biopsy of small renal masses<br />
K. Alothman, Riyadh (SA)<br />
15.25 – 15.55 Panel discussion/debate<br />
Panelists: W. Alkhudair, Riyadh (SA)<br />
H. Al Zahrani, Riyadh (SA)<br />
M. Marberger, Vienna (AT)<br />
H. Van Poppel, Leuven (BE)<br />
46 Programme Book
Friday, 16 April - <strong>EAU</strong> Programme<br />
13.25 - 15.55 Joint Session of the European Association of Urology (<strong>EAU</strong>) and the<br />
Japanese Urological Association (JUA)<br />
Paris Room<br />
Chairs: S. Egawa, Tokyo (JP)<br />
M. Wirth, Dresden (DE)<br />
Session 1<br />
Moderators: T. Kamoto, Miyazaki (JP)<br />
S. Takahashi, Tokyo (JP)<br />
13.25 - 13.55 Management of male LUTS: Which surgical management is the best?<br />
Panelists: N. Masumori, Sapporo (JP)<br />
F. Montorsi, Milan (IT)<br />
13.55 - 14.25 Overactive bladder: What treatment is the best?<br />
Panelists: N. Seki, Fukuoka (JP)<br />
C.R. Chapple, Sheffield (GB)<br />
14.25 - 14.45 Role of extended pelvic lymphadenectomy in urologic malignancy<br />
A. Heidenreich, Aachen (DE)<br />
Session 2<br />
Moderators: Y. Tomita, Yamagata (JP)<br />
H. Uemura, Osaka-Sayama (JP)<br />
14.45 - 15.00 Detection of prostate cancer, ideal method of biopsy<br />
S. Kawakami, Tokyo (JP)<br />
15.00 - 15.30 Renal cell carcinoma: What is the role of neoadjuvant/adjuvant therapy in the era of targeted therapy for<br />
locally advanced renal cell carcinoma?<br />
Panelists: M. Takahashi, Tokushima (JP)<br />
15.30 - 15.50 Case discussion: renal cell carcinoma<br />
Panelists: T. Kimura, Tokyo (JP)<br />
P.F.A. Mulders, Nijmegen (NL)<br />
N. Nonomura, Osaka (JP)<br />
M. Wirth, Dresden (DE)<br />
15.50 - 15.55 Closing remarks<br />
S. Naito, Fukuoka (JP)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
47
Friday, 16 April - <strong>EAU</strong> Programme<br />
13.25 - 15.55 <strong>EAU</strong>-International: Caucasus and Central Asia Session<br />
48 Programme Book<br />
Stockholm Room<br />
Chairs: P. Alken, Mannheim (DE)<br />
A. Kadioglu, Istanbul (TR)<br />
13.25 - 13.30 Introduction<br />
P. Alken, Mannheim (DE)<br />
13.30 - 13.35 A. Kadioglu, Istanbul (DE)<br />
13.35 - 13.45 Armenia<br />
G. Aghajanyan, Yerevan (AM)<br />
A. Muradyan, Yerevan (AM)<br />
13.45 - 13.55 Azerbaijan<br />
I. Figarov, Baku (AZ)<br />
B. Imamverdiyev, Baku (AZ)<br />
13.55 - 14.05 Georgia<br />
L. Managadze, Tbilisi (GE)<br />
Z. Tchanturaia, Tbilisi (GE)<br />
N. Turmanidze, Tbilisi (GE)<br />
14.05 - 14.15 Kazakhstan<br />
M.K. Alchinbayev, Almaty (KZ)<br />
M. Aref, Almaty (KZ)<br />
N. Kamal, Almaty (KZ)<br />
K. Timorlan, Almaty (KZ)<br />
14.15 - 14.25 Kyrgyzstan<br />
Z. Khakimhodzhaev, Bishkek (KG)<br />
N. Monolov, Bishkek (KG)<br />
A. Ch. Usupbaev, Bishkek (KG)<br />
14.25 - 14.35 Russia<br />
O. Apolikhin, Moscow (RU)<br />
D. Pushkar, Moscow (RU)<br />
14.35 - 14.45 Tajikistan<br />
K.M. Mahmadyor, Dushanbe (TJ)<br />
I. Nusratulloev, Dushanbe (TJ)<br />
14.45 - 14.55 Turkey<br />
B. Akduman, Zonguldak (TR)<br />
A. Kadioglu, Istanbul (TR)<br />
14.55 - 15.05 Turkmenistan<br />
B. Kadamov, Asgabat (TM)
15.05 - 15.15 Uzbekistan<br />
F. A. Akilov, Tashkent (UZ)<br />
B. Ayubov, Tashkent (UZ)<br />
A. Gaybullaev, Tashkent (UZ)<br />
S. T. Mukhtarov, Tashkent (UZ)<br />
15.15 - 15.55 Discussion<br />
<strong>EAU</strong> representatives:<br />
F. Gaboardi, Milan (IT)<br />
J.P.F.A. Heesakkers, Nijmegen (NL)<br />
M.S Michel, Mannheim (DE)<br />
R.M. Scarpa, Orbassano (IT)<br />
One representative from each of the Caucasus and Central Asian countries will give a presentation.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
49
Friday, 16 April - <strong>EAU</strong> Programme<br />
50 Programme Book<br />
Urology beyond Europe<br />
16.00 – 17.40 Plenary Session<br />
eURO Auditorium<br />
16.00 – 16.55 Case discussion: Clinical challenges in paediatric urology<br />
Moderator: G. Bogaert, Leuven (BE)<br />
Panel:<br />
JUA: H. Kakizaki, Asahikawa (JP)<br />
CAU: T.b.c.<br />
Caucasus & Central Asia: Z. Tchanturaia, Tbilisi (GE)<br />
IAUI: A. Rodjani, Jakarta (ID)<br />
IUA: H. Arshadi, Tehran (IR)<br />
16.55 – 17.40 Case discussion: Clinical challenges in transplantation<br />
Moderator: M. Giessing, Düsseldorf (DE)<br />
Panel:<br />
AAU: A. Shokeir, Mansoura (EG)<br />
USI: S.V. Kotwal, New Delhi (IN)<br />
KUA: T.b.c.<br />
CUA: D.L. Guan, Beijing (CN)
Friday, 16 April - <strong>EAU</strong> Programme<br />
Special Session<br />
11.00 - 16.00 ICUD-<strong>EAU</strong> International Consultation on Kidney Cancer <strong>2010</strong><br />
Athens Room<br />
Chairs: Z. Kirkali, Izmir (TR)<br />
P.F.A. Mulders, Nijmegen (NL)<br />
Etiology and epidemiology<br />
B. Ljungberg, Umeå (SE)<br />
Basic science<br />
E. Oosterwijk, Nijmegen (NL)<br />
Pathology<br />
F. Algaba, <strong>Barcelona</strong> (ES)<br />
Prognostic factors<br />
P. Karakiewicz, Montreal (CA)<br />
Treatment of localised disease<br />
H. Van Poppel, Leuven (BE)<br />
Treatment of locally advanced disease<br />
C.G. Wood, Houston (US)<br />
Treatment of metastatic disease<br />
J. Bellmunt, <strong>Barcelona</strong> (ES)<br />
J-J. Patard, Rennes (FR)<br />
Aims and objectives<br />
The ICUD (International Consultation on Urological Diseases) and the <strong>EAU</strong> are holding this first-time<br />
consensus meeting on one of the most hot topics in urology, Kidney Cancer. The committees which are<br />
composed of experts in the respective fields have been working on the final consensus document for nearly<br />
a year. The reports of each committee which is a state-of-the-art, evidence based knowledge together<br />
with recommendations will be presented by the committee chairs. Come and join the discussions by all<br />
participants and get the latest information hot off the press. At the end of this session, the attendees will be<br />
completely updated and able to learn the etiology and epidemiology, basic science, pathology, prognostic<br />
factors, treatment of localised, locally advanced and metastatic kidney cancer from a group of first-class<br />
international experts.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
51
Friday, 16 April - <strong>EAU</strong> Programme<br />
52 Programme Book<br />
Special Session<br />
14.00 - 17.00 Guidelines Training Session - Evidence-Based Guidelines: A workshop<br />
for guideline developers<br />
Istanbul Room<br />
14.00 – 14.15 Introduction, overview of guideline process & Claromentis<br />
K.F. Parsons, Liverpool (GB), Chairman <strong>EAU</strong> Guidelines Office<br />
J. N’Dow, Aberdeen (GB)<br />
14.15 – 15.00 Session 1<br />
J. N’Dow, Aberdeen (GB)<br />
14.15 – 14.30 Presentation on development and use of care pathways<br />
14.30 – 15. 00 Group exercise and discussion<br />
15:00 – 15:40 Session 2<br />
P. Dahm, Gainesville (US)<br />
15.00 – 15.15 Presentation on formulating a focused clinical question/rating outcomes<br />
15.15 – 15.40 Group exercise and discussion<br />
15.40 – 16.00 Break<br />
16.00 – 16.40 Session 3<br />
P. Dahm, Gainesville (US)<br />
16.00 – 16.15 Presentation on study limitations<br />
16.15 – 16.40 Group exercise and discussion<br />
16.40 – 17.00 Wrap-up, Q & A<br />
Aims and objectives<br />
Objectives<br />
• To familiarise panel members again with overall process and steps involved in developing evidence based<br />
clinical practice guidelines<br />
• Importance and development of care pathways<br />
• To provide hands on experience in:<br />
• Formulating focused clinical questions<br />
• Identifying and rating outcomes<br />
• Evaluating study limitations<br />
• Assessing studies for inconsistency, imprecision, indirectness and publication bias<br />
• To revisit with panel members a transparent group process for developing clinical recommendations<br />
based on judgments about:<br />
• Balance between desirable and undesirable effects<br />
• Quality of evidence<br />
• Values and preferences<br />
• Resource allocation (costs)<br />
Target audience<br />
• <strong>EAU</strong> Guideline Panel members involved in the development of evidence based clinical practice guidelines
Friday, 16 April - <strong>EAU</strong> Programme<br />
18.00 - 19.35 <strong>EAU</strong> Opening Ceremony<br />
eURO Auditorium<br />
Opening Show - Part I<br />
Opening address<br />
P-A. Abrahamsson, Malmö (SE), <strong>EAU</strong> Secretary General<br />
Announcement of the new <strong>EAU</strong> Honorary Members<br />
Citation by P-A. Abrahamsson, Malmö (SE)<br />
Honorary members: L. Denis, Antwerp (BE)<br />
D.H. Frohneberg, Karlsruhe (DE)<br />
U. Jonas, Hanover (DE)<br />
B. Lobel, Rennes (FR)<br />
I. Romics, Budapest (HU)<br />
Presentation Willy Gregoir Medal<br />
Citation by P-A. Abrahamsson, Malmö (SE)<br />
Presented to: F.M.J. Debruyne, Arnhem (NL)<br />
The <strong>EAU</strong> is proud to present the Willy Gregoir Medal to an important senior urologist who contributed in an<br />
extraordinary way to the development of urology in Europe<br />
Presentation Frans Debruyne Lifetime Achievement Award<br />
Citation by P-A. Abrahamsson, Malmö (SE)<br />
Presented to: R. Vela-Navarette, Madrid (ES)<br />
The <strong>EAU</strong> wishes both to honour and acknowledge the important and longstanding contribution by a<br />
distinguisted colleague to the activities and development of the association<br />
Presentation of the Crystal Matula Award<br />
Citation by P-A. Abrahamsson, Malmö (SE)<br />
Presented to: J. Catto, Sheffield (GB)<br />
This most prestigious prize is granted to a promising younger urological academician<br />
Supported by an unrestricted educational grant from LABORIE<br />
Presentation of the Hans Marberger Award<br />
Citation by P-A. Abrahamsson, Malmö (SE)<br />
Presented to:<br />
The Hans Marberger Award is awarded for the best European paper published on minimally invasive surgery<br />
in urology<br />
Supported by an unrestricted educational grant from KARL STORZ GMBH &CO.KG<br />
Opening Show - Part II<br />
19.35 - 20.30 Welcome Cocktail<br />
Foyer level 1<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
53
<strong>EAU</strong>’s Anniversary Gift<br />
Europe, the Cradle of Urology<br />
Dr. Johan J. Mattelaer and Prof. Dirk Schultheiss<br />
The 25 th Anniversary <strong>EAU</strong> <strong>Congress</strong> will see the presentation<br />
of a very special publication – Europe, the Cradle of Urology.<br />
Edited by Dr. Johan J. Mattelaer and Dr. Dirk Schultheiss, this<br />
book will feature a vast collection of articles on the history<br />
of urology in Europe, from its birth to some of the very latest<br />
developments.<br />
A collaborative effort of more than 40 enthusiasts - <strong>EAU</strong> History<br />
Office members and guest authors – this book will take its<br />
reader on the journey that urology as a medical subspecialty<br />
had to make to become what it is today. Richly illustrated, it<br />
is truly a collector’s item and will be of interest not only to<br />
urologists but to all medical professionals.<br />
All <strong>EAU</strong> members attending the 25 th Anniversary <strong>EAU</strong><br />
<strong>Congress</strong> in <strong>Barcelona</strong> can pick up a copy of Europe, the<br />
Cradle of Urology, free of charge at the <strong>EAU</strong> booth B20 in<br />
the exhibition area.
Saturday, 17 April - <strong>EAU</strong> Programme<br />
07.30 - 08.30 <strong>EAU</strong> General Assembly<br />
Amsterdam Room<br />
Welcome by the <strong>EAU</strong> Secretary General<br />
P-A. Abrahamsson, Malmö (SE)<br />
Approval minutes General Assembly of 21 March 2009, Stockholm, Sweden<br />
General report by the <strong>EAU</strong> Secretary General<br />
P-A. Abrahamsson, Malmö (SE)<br />
Report by the <strong>EAU</strong> Treasurer<br />
M. Wirth, Dresden (DE)<br />
Specific reports on the <strong>EAU</strong> Offices by the <strong>EAU</strong> Executive<br />
Report on the <strong>EAU</strong> Secretary General on the <strong>EAU</strong> Membership & Nomination Office<br />
• Approval new <strong>EAU</strong> members<br />
• Approval new Honorary members<br />
Other business<br />
Future <strong>Congress</strong>es<br />
Presentation of the 26 th <strong>Annual</strong> <strong>EAU</strong> <strong>Congress</strong> in Vienna, 18-22 March 2011<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
55
Saturday, 17 April - <strong>EAU</strong> Programme<br />
56 Programme Book<br />
Plenary Session 1<br />
08.30 - 10.00 Advances in kidney cancer management<br />
eURO Auditorium<br />
Chairs: G. Janetschek, Salzburg (AT)<br />
B. Tombal, Brussels (BE)<br />
08.30 - 09.00 Debate Medical therapy for advanced kidney cancer: The truth behind<br />
the figures<br />
Moderator: Z. Kirkali, Izmir (TR)<br />
Panel: J. Bellmunt, <strong>Barcelona</strong> (ES)<br />
A. Bex, Amsterdam (NL)<br />
J-J. Patard, Rennes (FR)<br />
Aims and objectives<br />
This debate on medical systemic therapy in advanced kidney cancer will address a couple of issues over<br />
some case discussions. The speakers will deal with the role of new targeted agents in neoadjuvant and<br />
adjuvant setting, metastasectomy and the timing and necessity of nephrectomy. Finally, the intelligent use of<br />
targeted agents in a patient with full-blown metastases will be discussed. Attendees to this lively session will<br />
learn the current status of the use of systemic therapy and its relation with surgery.<br />
09.00 - 09.15 Urological Association of Asia (UAA) lecture Current status of minimally<br />
invasive ablative techniques in the treatment of unresectable or metastatic<br />
renal tumours<br />
A. Chiu, Taipei (TW)<br />
09.15 - 09.45 International Consultation on Urological Diseases (ICUD) - European<br />
Association of Urology (<strong>EAU</strong>) International Consultation on Kidney Cancer<br />
<strong>2010</strong> Consensus highlights<br />
Z. Kirkali, Izmir (TR)<br />
P.F.A. Mulders, Nijmegen (NL)<br />
09.45 - 10.00 Late breaking news<br />
Partial versus radical nephrectomy in renal cancer: Results from EORTC 30904<br />
study<br />
H. Van Poppel, Leuven (BE)
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Section Meetings Overview<br />
10.00 - 14.00 Meeting of the <strong>EAU</strong> Section of Uropathology (ESUP) <strong>page</strong> 303<br />
Precancerous lesions of the urogenital organs<br />
Vienna Room<br />
10.00 - 14.00 Meeting of the <strong>EAU</strong> Section of Andrological Urology (ESAU) <strong>page</strong> 304<br />
The role of the uro-andrologist in managing a couple’s sexuality<br />
<strong>Barcelona</strong> Room<br />
10.00 - 17.30 Meeting of the <strong>EAU</strong> Section of Uro-Technology (ESUT) <strong>page</strong> 306<br />
The Future of MIS – the real facts in real-time<br />
eURO Auditorium<br />
10.00 - 14.00 Joint meeting of the European Organisation for Research and Treatment of Cancer <strong>page</strong> 308<br />
Genito-Urinary Group (EORTC-GU Group) in conjunction with the <strong>EAU</strong> Section for Urological<br />
Research (ESUR) and the European Section of Oncological Urology (ESOU)<br />
New insights in uro-oncology<br />
Paris Room<br />
10.00 - 15.00 Meeting of the <strong>EAU</strong> Section of Genito-Urinary Reconstructive Surgeons (ESGURS) <strong>page</strong> 310<br />
Long term results in genitourinary reconstructive surgery<br />
Milan Room<br />
10.00 - 13.40 Meeting of the <strong>EAU</strong> Section of Transplantation Urology (ESTU) <strong>page</strong> 312<br />
Renal transplantation – what urologists must know in <strong>2010</strong><br />
Athens Room<br />
10.00 - 14.00 Meeting of the <strong>EAU</strong> Section of Urological Imaging (ESUI) <strong>page</strong> 314<br />
What do we need to know about prostate imaging in <strong>2010</strong>?<br />
Istanbul Room<br />
10.00 - 14.00 Meeting of the eUrolithiasis Section (eULIS) <strong>page</strong> 316<br />
Advances in the management of stones<br />
Padua Room<br />
10.00 - 14.00 Meeting of the <strong>EAU</strong> Section of Female and Functional Urology (ESFFU) <strong>page</strong> 318<br />
Functional urology: Transition from science to clinical practice<br />
Amsterdam Room<br />
10.00 - 14.00 Meeting of the <strong>EAU</strong> Section of Infections in Urology (ESIU) <strong>page</strong> 320<br />
Improving practice - facing threats<br />
Genoa Room<br />
For detailed information see programmes Section Meetings from <strong>page</strong>s 303-321<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
57
Saturday, 17 April - <strong>EAU</strong> Programme<br />
European Urology Session<br />
12.00 - 13.00 Surgery in Motion<br />
58 Programme Book<br />
Monte Carlo Room<br />
Robot-assisted partial nephrectomy: An international experience<br />
Brian M Benway, Sam B Bhayani, Craig G Rogers, James R Porter, Nicolo M Buffi, Robert S Figenshau,<br />
Alexandre Mottrie.<br />
In this month’s Surgery in Motion article of European Urology, Mottrie et al describe the largest multicenter<br />
robot-assisted partial nephrectomy experience to date, demonstrating favourable operative parameters as<br />
well as excellent intermediate-term oncologic and functional outcomes.<br />
During this session, Dr. Mottrie will show the surgical video and discuss the technique used. Attendees are<br />
encouraged to ask questions at the end of the presentation.
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
14.15 - 15.45 NOTES and LESS in renal surgery<br />
Amsterdam Room<br />
Video Session 1<br />
Chairs: E. Barret, Paris (FR)<br />
M. Giessing, Düsseldorf (DE)<br />
All presentations have a maximum length of 10 minutes, followed by 4 minutes of discussion.<br />
V1 Gasless two port access total nephroureterectomy: MIES total nephroureterectomy<br />
K. Saito, K. Kihara, S. Kawakami, Y. Fujii, H. Masuda, F. Koga (Tokyo, Japan)<br />
V2 Hybrid NOTES transvaginal nephrectomy<br />
R. Sotelo, R. De Andrade, G. Fernandez, R. Garza, D. Ramirez, C. Giedelman, E. Di Grazia, O. Carmona,<br />
D. Canes, M. Aron, M. Desai, I. Gill (Caracas, Venezuela; Burlington, Los Angeles, United States of America)<br />
V3 Transvaginal NOTES-assisted laparoscopic living donor nephrectomy<br />
A. Alcaraz, L. Peri, M. Musquera, M. Piqueras, M.J. Ribal (<strong>Barcelona</strong>, Spain)<br />
V4 Gasless single port access ultrasound-guided clampless partial nephrectomy: MIES partial nephrectomy<br />
K. Kihara, T. Tsushima, S. Kawakami, Y. Fujii, H. Masuda, F. Koga, K. Saito (Tokyo, Okayama, Japan)<br />
V5 NOTES hybrid transvaginal upper pole heminephrectomy<br />
R. De Andrade, O. Carmona, D. Ramirez, C. Mejia, C. Giedelman, E. Herrera, D. Canes, M. Aron, M. Desai,<br />
I. Gill, R. Sotelo (Caracas, Venezuela; Burlington, Los Angeles, United States of America)<br />
V6 Left less partial nephrectomy without ischemia: First experience<br />
G.S. Gidaro, C.L. Cindolo, S.L. Schips (Chieti, Vasto, Italy)<br />
V7 Less transumbilical radical nephrectomy<br />
A. Alcaraz, L. Peri, M. Musquera, A. Molina, M.J. Ribal (<strong>Barcelona</strong>, Spain)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
59
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
14.15 - 15.45 Percutaneous stone removal 1<br />
60 Programme Book<br />
<strong>Barcelona</strong> Room<br />
Oral Session 1<br />
Chairs: M.R. Desai, Naidad (IN)<br />
F. Keeley, Bristol (GB)<br />
All presentations are 7 minutes in length, followed by 2 minutes of discussion.<br />
Introduction<br />
M.R. Desai, Naidad (IN)<br />
1 The global PCNL study: Indications and outcomes in 5000 cases<br />
J. De La Rosette, D.G. Assimos, M.R. Desai, J. Gutiérrez, J.E. Lingeman, R.M. Scarpa, A. Tefekli (Amsterdam,<br />
The Netherlands; Winston Salem, Indianapolis, United States of America; Nadiad, India; Zapopan, Mexico;<br />
Orbassano, Italy; Istanbul, Turkey)<br />
2 TachoSil-sealed tubeless percutaneous nephrolithotomy in supine antero-lateral position: A prospective<br />
study<br />
L. Cormio, A. Perrone, S. Pentimone, O. Selvaggio, F. Lorusso, G. Di Fino, P. Massenio, M. De Siati, P. Annese,<br />
R. Di Brina, G. Carrieri (Foggia, Italy)<br />
3 Choosing the nephrostomy size after percutaneous nephrolithotomy<br />
M. De Sio, F. Giugliano, D. Sorrentino, C. Manzi, M. Pizzuti, O. Simone, R. Autorino (Naples, Italy)<br />
4 Ultrasonography-guided percutaneous nephrolithotomy in flank position versus fluoroscopy-guided<br />
percutaneous nephrolithotomy in prone position: A comparative study<br />
H. Karami (Tehran, Iran)<br />
5 Supine position further minimizes invasiveness of Tubeless Percutaneous Nephrolithotomy (PCNL)<br />
G. Giusti, O. Maugeri, A. Benetti, S. Zandegiacomo, R. Peschechera, A. Piccinelli, G. Taverna, M. Seveso,<br />
P. Graziotti (Milan, Italy)<br />
6 Comparative study of hemodynamics electrolyte and metabolic changes during prone and complete supine<br />
percutaneous nephrolithotomy<br />
H. Khoshrang, S. Falahatkar, H. Naseh, M. Shakiba, S. Ilat (Rasht, Iran)<br />
7 Reporting of percutaneous nephrolithotomy complications using the modified clavien grading system: A<br />
prospective study<br />
V. Ambert, B. Braticevici, Y. Sallahedin, R.C. Petca, L. Hainagiu, C. Calin, D. Diaconescu (Bucharest,<br />
Romania)<br />
8 Assessing and developing percutaneous renal access skills of trainees using the state of the art PERC<br />
Mentor simulation trainer<br />
D. Patel, T. El Husseiny, K. Moraitis, T. Shaikh, N. Buchholz, J. Masood, I. Junaid (London, United Kingdom)<br />
9 Percutaneous Nephrolithotomy (PCNL): Comparison of Alken telescopic and one-shot metallic cone-tip<br />
dilator<br />
M.M. Hosseini, A.R. Aminsharifi, A.R. Tadayyon, S. Shakeri, D. Hosseini Niashiran (Shiraz, Iran)<br />
Summary<br />
F. Keeley, Bristol (GB)
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
14.15 - 15.45 Bladder sparing treatment and chemotherapy<br />
Athens Room<br />
Oral Session 2<br />
Chairs: J.E. Gschwend, Munich (DE)<br />
M.J. Ribal Caparros, <strong>Barcelona</strong> (ES)<br />
All presentations are 7 minutes in length, followed by 2 minutes of discussion.<br />
Introduction<br />
J.E. Gschwend, Munich (DE)<br />
10 Bladder preservation multimodality therapy as an alternative to radical cystectomy for treatment of muscle<br />
invasive bladder cancer<br />
A.M. Maarouf, S. Khalil, E. Salem, M. Eladl, N. Nawar (Zagazig, Egypt)<br />
11 Validation of clinical parameters on the 15-year long-term outcome of a trimodalitiy treatment and<br />
selective organ preservation for invasive bladder cancer<br />
F.S. Krause, O. Ott, L. Haeberle, B. Wullich (Erlangen, Germany)<br />
12 Partial cystectomy after induction chemoradiotherapy possibly improves oncological outcomes of selective<br />
bladder-sparing protocol against muscle-invasive bladder cancer<br />
F. Koga, K. Kihara, S. Yoshida, K. Saito, H. Masuda, Y. Fujii, S. Kawakami (Tokyo, Japan)<br />
13 Updated survival results of the phase III trial comparing Vinflunine (V) to Best Supportive Care (BSC) in<br />
advanced Transitional Cell Carcinoma of the Urothelium (TCCU) after failure of a prior platinum-containing<br />
regimen<br />
S. Culine, C. Lucas, Y. Salhi, J. Bellmunt (Creteil, Boulogne, France; <strong>Barcelona</strong>, Spain)<br />
14 Accelerated Methotrexate, Vinblastine, Doxorubicin, Cisplatin (MVAC) neoadjuvant chemotherapy in<br />
patients with transitional cell carcinoma of the bladder: A review of two UK centre experiences<br />
C. Blick, T. Pwint, P. Hall, J. Chester, J. Crew, A. Protheroe (Oxford, Leeds, United Kingdom)<br />
15 Feasibility of adoptive T-cell based immunotherapy in the first twelve patients with advanced urothelial<br />
urinary bladder cancer<br />
A.M. Sherif, M.N. Hasan, P. Marits, M. Karlsson, M. Thörn, O. Winqvist (Täby, Stockholm, Sundbyberg,<br />
Sweden; Dunedin, New Zealand)<br />
16 The impact of C-reactive protein kinetics on survival in patients with advanced urothelial carcinoma<br />
treated with gemcitabine, etoposide and cisplatin<br />
K. Saito, S. Urakami, Y. Komai, T. Kijima, G. Sukegawa, M. Ito, Y. Kubo, T. Suyama, S. Kitsukawa, Y. Okubo,<br />
S. Yamamoto, J. Yonese, I. Fukui (Tokyo, Japan)<br />
17 Disease progression while undergoing neo-adjuvant chemotherapy for TCC: Who’s at risk?<br />
M.S. Ahmad, J. Cresswell, N.K. Eronini, J.E. Whiteway, A.C. Thorpe (Middlesbrough, Newcastle Upon Tyne,<br />
United Kingdom)<br />
Summary<br />
M.J. Ribal Caparros, <strong>Barcelona</strong> (ES)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
61
Saturday, 17 April - <strong>EAU</strong> Programme<br />
62 Programme Book<br />
Abstract Session<br />
14.15 - 15.45 Pathology and predictive factors<br />
Paris Room<br />
Poster Session 1<br />
Chairs: A. Haese, Hamburg (DE)<br />
D.A.O. Waltregny, Liège (BE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
18 The effect of testosterone treatment on prostate histology and apoptosis in men with late-onset<br />
hypogonadism<br />
O. Efesoy, D. Apa, S. Cayan (Mersin, Turkey)<br />
19 Sixes cores prostate biopsy. For whom it is still justified as initial diagnostic tool for detection of prostate<br />
cancer?<br />
D. Milonas, A. Zabarskas, J. Masiliunas, M. Jievaltas (Kaunas, Lithuania)<br />
20 Smaller prostate volume is a risk factor of high grade prostate cancer detected by the three-dimensional<br />
26-core biopsy<br />
M. Yokoyama, S. Kawakami, N. Numao, Y. Fujii, F. Koga, K. Kazutaka, J. Yonese, Y. Yuichi, I. Fukui, K. Kihara<br />
(Tokyo, Japan)<br />
21 Is peri-neural invasion in prostate biopsy predictive of pathological outcomes and cancer recurrence postradical<br />
prostatectomy?<br />
S. Chopra, C. Pinnock, D. Tamblyn, T. Kopsaftis, P. Sutherland (Adelaide, Australia)<br />
22 End-diastolic velocity/resistive index at neurovascular bundle vessels might be a potential marker for<br />
prostate cancer detection and resistive index increased with higher Gleason score<br />
Y.S. Tsai, T.S. Tzai, C.Y. Wu (Tainan, Taiwan)<br />
23 A proposal for the ideal sampling scheme in prostate repeated biopsies: A recursive partitioning analysis<br />
based on 24-core systematic biopsy<br />
V. Scattoni, M. Raber, F. Abdollah, M. Roscigno, D. Angiolilli, L. Villa, M. Freschi, C. Maccagnano, L. Nava,<br />
P. Rigatti, F. Montorsi (Milan, Italy)<br />
24 Initial prostate biopsy: PCA3 outperforms established risk factors of prostate cancer and increases<br />
multivariate predictive accuracy<br />
M. Auprich, A. Haese, M. Graefen, A. De La Taille, T. De Reijke, P. Kil, A. Stenzl, H. Van Poppel, J. Irani,<br />
P. Gontero, M. Marberger, F. Chun (Graz, Vienna, Austria; Hamburg, Tübingen, Germany; Creteil, Poitiers,<br />
France; Amsterdam, Tilburg, The Netherlands; Leuven, Belgium; Turin, Italy)<br />
25 Risk assessment: Prostate cancer-specific mortality and bone metastasis for patients treated in the<br />
prostate cancer screening era<br />
P.J. Van Leeuwen, H.A. Van Vugt, R.C.N. Van Den Bergh, T. Wolters, F.H. Schröder, M.J. Roobol (Rotterdam,<br />
The Netherlands)<br />
26 Does the PCA3 score depend on tumor localization within the prostate? A morphometric computer<br />
animated analysis<br />
D. Schilling, J. Hennenlotter, C.H. Von Weyhern, U. Kuehs, T. Joerg, H. Buchner, A. Stenzl (Tübingen,<br />
Stuttgart, Germany)
27 Behaviour of PCA3 score in urine of patients with high grade prostatic intraepithelial neoplasia (HGPIN)<br />
J. Morote, M. Rigau, M. García, L. Castro, C. Mir, C. Ballesteros, J. Planas, C. Raventós, J. Placer, I. De Torres,<br />
J. Reventós, A. Doll (<strong>Barcelona</strong>, Spain)<br />
28 Bcl-2 as a predicting factor on biochemical recurrence after radical prostatectomy: A prospective study<br />
I.C. Cho, H.S. Chung, K.S. Cho, J.Y. Joung, H.K. Seo, J.S. Chung, W.S. Park, K.H. Lee (Goyang-Si, Gyeonggi-Do,<br />
South Korea)<br />
29 Margin status in radical prostatectomy: What about the vas deferens?<br />
M. Saar, R. Grobholz, S. Siemer, M. Stöckle, J. Kamradt (Homburg/Saar, Germany)<br />
30 Localisation of prostate cancer metastases within the lymph node: Sufficient histological evaluation<br />
demands analysis of more than one section<br />
D. Schilling, J. Hennenlotter, U. Kuehs, T. Maul, G. Gakis, K. Sotlar, A. Stenzl (Tübingen, Munich, Germany)<br />
31 Morphologic growth patterns of lymph node metastases predict extent of tumour expansion in prostate<br />
cancer<br />
D. Schilling, J. Hennenlotter, U. Kuehs, T. Maul, G. Gakis, K. Sotlar, A. Stenzl (Tübingen, Munich, Germany)<br />
32 Preoperative circulating estradiol, testosterone and sex hormone binding globulin are not predictors of<br />
positive surgical margins at open radical prostatectomy<br />
A. Salonia, A. Gallina, A. Briganti, N. Suardi, R. Bertini, V. Di Girolamo, L. Barbieri, M. Freschi, N. Buffi,<br />
G. Guazzoni, P. Rigatti, F. Montorsi (Milan, Italy)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
63
Saturday, 17 April - <strong>EAU</strong> Programme<br />
64 Programme Book<br />
Abstract Session<br />
14.15 - 15.45 Epidemiology and pathology of urothelial cancer<br />
Vienna Room<br />
Poster Session 2<br />
Chairs: G. Giannarini, Pisa (IT)<br />
M.O. Grimm, Dresden (DE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
33 Validation of the AJCC TNM substaging of pT2 bladder cancer: Deep muscle invasion is associated with<br />
significantly worse outcome<br />
D. Tilki, O. Reich, P.I. Karakiewicz, G. Novara, W. Kassouf, Y. Fradet, V. Ficarra, E. Skinner, R. Svatek, Y. Lotan,<br />
A.I. Sagalowsky, C.G. Stief, S.F. Shariat (Munich, Germany; Montreal, Quebec, Canada; Padua, Italy; Los<br />
Angeles, Dallas, United States of America)<br />
34 Lymph node positive urothelial cancer of the bladder: Extracapsular extension of lymph node metastases<br />
but not nodal tumour burden is an independent adverse risk factor<br />
R. Seiler, M. Von Gunten, A. Fleischmann, U.E. Studer, G.N. Thalmann (Berne, Switzerland)<br />
35 Concomitant carcinoma in situ is not associated with clinical outcomes after radical cystectomy<br />
P. Nuhn, P.J. Bastian, R.S. Svatek, P.I. Karakiewicz, E. Skinner, Y. Fradet, J.I. Izawa, W. Kassouf, G. Novara,<br />
F. Montorsi, H.M. Fritsche, D. Tilki, H. Isbarn, V. Ficarra, C.P. Dinney, S.F. Shariat (Munich, Regensburg,<br />
Germany; Houston, Los Angeles, Dallas, United States of America; Montreal, Québec, London, Canada;<br />
Padua, Milan, Italy)<br />
36 Outcome prediction in patients with bladder cancer after cystectomy using artificial neural networks<br />
A. Buchner, C. Bolenz, E. Herrmann, D. Tilki, A. Karl, T. Höfner, H. Fritsche, C. Wülfing, M. Burger, L. Trojan,<br />
A. Tiemann, A. Haferkamp, M. Michel, M. Hohenfellner, W. Wieland, S. Müller, C.G. Stief, P. Bastian<br />
(Munich, Mannheim, Münster, Heidelberg, Regensburg, Bonn, Germany)<br />
37 Validation of tumour architecture is an independent predictor of outcomes after radical<br />
nephroureterectomy<br />
H.M. Fritsche, G. Novara, A. Gupta, K. Matsumoto, W. Kassouf, T. Walton, M. Burger, S. Tritschler, S. Baba,<br />
P.J. Bastian, J. Carballido, C. Seitz, W. Otto, P.I. Karakiewicz, V. Ficarra, S.F. Shariat (Regensburg, Munich,<br />
Germany; Padua, Bolzano, Italy; Dallas, United States of America; Sagamihara, Japan; Montreal, Canada;<br />
Nottingham, United Kingdom; Madrid, Spain)<br />
38 Lymphovascular invasion is a pathologic feature of biologically aggressive disease in patients with<br />
urothelial carcinoma of the upper urinary tract: An international external validation study<br />
G. Novara, K. Matsumoto, W. Kassouf, J.T. Walton, H.M. Fritsche, J.P. Bastian, J.I. Martínez-Salamanca,<br />
C. Seitz, R.J. Lemberger, M. Burger, A. El-Hakim, S. Baba, G. Martignoni, A. Gupta, P.I. Karakiewicz,<br />
V. Ficarra, S.F. Shariat (Padua, Bolzano, Verona, Italy; Sagamihara, Japan; Montreal, Canada; Derby City,<br />
Nottingham, United Kingdom; Regensburg, Munich, Germany; Madrid, Spain; Dallas, United States of<br />
America)<br />
39 Prognostic factors of “high grade” Ta bladder cancers according to WHO 2004 classification: Are these<br />
equivalents to “high risk” non muscle invasive bladder cancer?<br />
P. Gontero, A. Gillo, C. Fiorito, M. Oderda, D. Pacchioni, G. Bussolati, G. Casetta, A. Tizzani, F. Ricceri (Turin,<br />
Italy)
40 The rates of metastatic bladder cancer are increasing over time: A population-based analysis<br />
D. Liberman, C. Jeldres, G. Lughezzani, L. Budaus, M. Sun, S.F. Shariat, P. Perrotte, M. Graefen, F. Montorsi,<br />
P.I. Karakiewicz (Montreal, Canada; Milan, Italy; Hamburg, Germany)<br />
41 Personalized management of upper urinary tract urothelial carcinoma: The effect of age on cancer-specific<br />
mortality<br />
D. Liberman, H. Isbarn, C. Jeldres, L. Budaus, G. Lughezzani, M. Sun, S.F. Shariat, P. Perrotte, F. Montorsi,<br />
M. Graefen, P.I. Karakiewicz (Montreal, Canada; Hamburg, Germany; Milan, Italy)<br />
42 The effects of urination frequency, water intake and smoking status on bladder cancer risk<br />
D. Garcia-Rojo, D. Silverman, A. Gelabert-Mas, J.M. Saladie, N. Rothman, F. Real, M. Garcia-Closas,<br />
N. Malats, C. Serra, K. Cantor, M. Kogevinas, A. Tardon, M. Dosemeci, A. Carrato, R. Garcia-Closas, O. Bielsa,<br />
M. Cespedes, J. Malet, F. Garcia-Lopez, J. Taño, J. Rodríguez De Vera, J.L. Guate, J.M. Fernandez, R. Abascal,<br />
M. Rivas, M. Diaz, A. Mateos, P. Muntañola, F. Huergo, J. Mosquera, J. Prats (Sabadell, <strong>Barcelona</strong>, Oviedo,<br />
Elche, La Laguna, Sant Boi de Llobregat, Manresa, Santa Cruz de Tenerife, Avilés, Gijón, Mieres, Coaña,<br />
Cangas, Spain; Bethesda, United States of America)<br />
43 Value of clinical and histopathological parameters for prognosis of pT1 urothelial bladder cancer: A singlecenter<br />
analysis of 309 patients<br />
W. Otto, H.M. Fritsche, S. Bertz, M. Burger, W. Rößler, W.F. Wieland, A. Hartmann, S. Denzinger<br />
(Regensburg, Erlangen, Germany)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
65
Saturday, 17 April - <strong>EAU</strong> Programme<br />
66 Programme Book<br />
Abstract Session<br />
14.15 - 15.45 Imaging, urinary markers and molecular biology of urothelial<br />
carcinoma<br />
Istanbul Room<br />
Poster Session 3<br />
Chairs: J. Kliment, Martin (SK)<br />
N. Longo, Naples (IT)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
44 MicroRNAs detection in urine samples from patients with urothelial carcinoma<br />
E. Hideki, T. Chiyomaru, I. Masahiko, S. Kojima, K. Nishiyama, S. Naohiko, N. Masayuki (Kagoshia, Chiba,<br />
Japan)<br />
45 Feasibility of diffusion-weighted magnetic resonance imaging in diagnosis of bladder cancer<br />
S. Kobayashi, S. Yoshida, F. Koga, C. Ishii, H. Tanaka, Y. Komai, K. Saito, H. Masuda, Y. Fujii, S. Kawakami,<br />
K. Kihara (Tokyo, Japan)<br />
46 Epigenomic silencing of microRNA expression in urothelial cell carcinoma<br />
H.M.Z. Choudhry, H. Own, J.W.F. Catto (Sheffield, United Kingdom)<br />
47 Diffusion-weighted magnetic resonance imaging in diagnosis of upper urinary tract cancer<br />
S. Yoshida, H. Masuda, C. Ishii, H. Tanaka, Y. Komai, N. Numao, K. Saito, F. Koga, Y. Fujii, S. Kawakami,<br />
K. Kihara (Tokyo, Japan)<br />
48 Evaluation of the diagnostic accuracy of Multidetector Computer Tomography Urography (MDCTU) for<br />
diagnosing bladder cancer in patients presenting with macroscopic haematuria over 40 years of age<br />
C.G.T. Blick, B.W. Turney, S. Nazir, J.P. Crew, N.C. Cowan (Oxford, United Kingdom)<br />
49 Positive NMP22 and absence of evident urological disease in patients followed for non-muscle invasive<br />
bladder cancer (NMI-BC). Long term outcome<br />
V. Serretta, F. Scuto, A. Ruggirello, D. Passalacqua, R. Allegro, D. Melloni (Tommaso Natale, Palermo, Italy)<br />
50 Association of hematuria on microscopic urinalysis and risk of urinary tract cancer development<br />
H. Jung, J. Gleason, R. Loo, H. Patel, J. Slezak, G. Chien, S. Jacobsen (Los Angeles, United States of America)<br />
51 Molecular markers show differences in biological potential per grade category for the WHO 1973 and 2004<br />
classification systems: A large multi-center study with central pathology review in non-muscle invasive<br />
bladder cancer<br />
B.W.G. Van Rhijn, M. Musquera, A.N. Vis, C.H. Bangma, E.C. Zwarthoff, L. Liu, B. Bapat, M.A.S. Jewett,<br />
A.R. Zlotta, T.H. Van Der Kwast (Toronto, Canada; Amsterdam, Rotterdam, The Netherlands)<br />
52 Comparison of molecular markers, sub-stage and the EORTC risk-score to predict clinical outcome of pT1<br />
bladder cancer<br />
B.W.G. Van Rhijn, T.H. Van Der Kwast, B. Bapat, P.J. Bostrom, N.E. Fleshner, M.N.M. Van Der Aa, L. Liu,<br />
C.H. Bangma, M.A.S. Jewett, E.C. Zwarthoff, A.R. Zlotta (Toronto, Canada; Rotterdam, The Netherlands)<br />
53 Impact of urinary sampling and urinary tract infection on the diagnostic value of urine tests (UroVysionR,<br />
uCyt+R) and cytology for transitional cell carcinoma – results from a cohort of 2077 patients<br />
C. Schwentner, J. Hennenlotter, U. Kuehs, V. Tews, D. Colleselli, S. Huber, D. Schilling, K.D. Sievert, A. Stenzl<br />
(Tübingen, Germany)
54 Is urine cytology a relevant investigation for urological malignancies?<br />
S.F. Mishriki, C.N. Molokwu, C. Sweeney, T. Lam, K.S. Janjua (Aberdeen, United Kingdom)<br />
55 Gene expression signature on urine samples for the noninvasive diagnosis and aggressiveness prediction<br />
of bladder urothelial carcinoma<br />
L. Mengual, M. Burset, M.J. Ribal, E. Ars, M. Marín-Aguilera, M. Fernández, M. Ingelmo-Torres,<br />
H. Villavicencio, A. Alcaraz (<strong>Barcelona</strong>, Spain)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
67
Saturday, 17 April - <strong>EAU</strong> Programme<br />
68 Programme Book<br />
Abstract Session<br />
14.15 - 15.45 How to improve prostate cancer detection on biopsies<br />
Padua Room<br />
Poster Session 4<br />
Chairs: P.C. Mozer, Paris (FR)<br />
P.J. Nyirády, Budapest (HU)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
56 Diagnostic performance of a three-dimensional 14-core systematic biopsy which can detect more than<br />
95% of the prostate cancers detected by the three-dimensional 26-core super-extended biopsy scheme<br />
S. Kawakami, H. Takeshita, M. Tatokoro, S. Yamamoto, T. Kijima, Y. Komai, K. Saito, N. Numao, F. Koga,<br />
Y. Fujii, I. Fukui, K. Kihara (Tokyo, Japan)<br />
57 Free hand 3D-TRUS prostate biopsies mapping<br />
P. Mozer, M. Baumann, V. Daanen, M. Bordenave, F. Thibault, P. Conort, M.O. Bitker, J. Troccaz (Paris,<br />
Grenoble, France)<br />
58 Transperineal template guided saturation biopsy: Outcome of a modified technique<br />
K.C. Ekwueme, H.D. Zakhour, N.J. Parr (Wirral, United Kingdom)<br />
59 Robotic-assisted transperineal prostate biopsy with novel device for future prostate interventions: 3–years<br />
clinical experience<br />
H.S.S. Ho, J.S.P. Yuen, P. Mohan, E. Lim, W.S. Ng, D.L. Li, C.W.S. Cheng (Singapore, Singapore)<br />
60 Are prostate biopsy and MRI predictive of the laterality of clinically localised prostate cancer?<br />
C.W. Jeong, M.C. Cho, Y.H. Park, S. Baik, S.B. Ha, H. Jeong, S.B. Lee, J.H. Ku, S.K. Hong, S.S. Byun, C. Kwak,<br />
J.K. Lee, H.H. Kim, S.E. Lee (Seoul, South Korea)<br />
61 The PCA3 Assay improves the prediction of initial biopsy outcome and may be indicative of prostate cancer<br />
aggressiveness<br />
A. De La Taille, M. Graefen, T. De Reijke, P. Kil, P. Gontero, A. Mottaz, J. Irani, A. Haese (Paris, Poitiers,<br />
France; Hamburg, Germany; Amsterdam, Tilburg, The Netherlands; Turin, Italy; Granges-Paccot,<br />
Switzerland)<br />
62 Saturation prostate biopsy is useful as initial procedure to detect prostate cancer in patients with total<br />
prostate specific antigen (tPSA) levels between 4 to 10 ng/ml<br />
A. Gavazzi, T. Cai, N. Mondaini, F. Melone, U. Farina, R. Bartoletti (Florence, Italy)<br />
63 The role of biopsy core number in selecting prostate cancer patients for active surveillance<br />
G. Ploussard, E. Xylinas, L. Salomon, Y. Allory, D. Vordos, A. Hoznek, C.C. Abbou, A. De La Taille (Creteil,<br />
France)<br />
64 High positive prostate saturation biopsy rates employing a brachytemplate transperineal ultrasoundguided<br />
method among men with previous at least two negative biopsies<br />
N. Mabjeesh, G. Lidawi, J. Chen, H. Matzkin (Tel Aviv, Israel)<br />
65 Positive core ratio between lobes in 12-core extended prostate biopsy independently predicts site-specific<br />
positive surgical margin and extracapsular extension in radical prostatectomy specimen<br />
K.S. Han, Y.H. Lee, H.S. Ryu, C.K. Oh, W.S. Ham, W.K. Han, K.H. Rha, Y.D. Choi, S.C. Yang, S.J. Hong (Seoul,<br />
South Korea)
66 Comparative analysis between 12 core and 18 core biopsy for detection of prostate cancer according to<br />
prostate specific antigen density level<br />
T.B. Kim, H.K. Park, K.Y. Lee, K.H. Kim, H. Jung, S.J. Yoon, M.S. Lee, J.C. Yun (Incheon, South Korea)<br />
67 How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer?<br />
E.C. Serefoglu, S. Altinova, N.S. Ugras, E. Akincioglu, E. Asil, M.D. Balbay (Ankara, Turkey)<br />
68 A comparative study of the diagnostic efficacy of six prostate biopsy cores versus twelve biopsy cores in<br />
prostate cancer screening trial<br />
T.L.J. Tammela, M. Laurila, A. Auvinen, P. Kujala (Tampere, Finland)<br />
69 Comparison between transperineal and transrectal biopsy for the detection of prostate cancer to guide<br />
focal therapy<br />
Y. Hu, N. Arumainayagam, H.U. Ahmed, A. Freeman, D. Hawkes, M. Emberton, D. Barratt (London, United<br />
Kingdom)<br />
70 Which is the biopsy scheme that best predicts tumour volume at radical prostatectomy?<br />
V. Scattoni, M. Raber, M. Roscigno, F. Dehò, D. Angiolilli, F. Abdollah, C. Doglioni, A. Saccà, C. Maccagnano,<br />
P. Rigatti, F. Montorsi (Milan, Bergamo, Italy)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
69
Saturday, 17 April - <strong>EAU</strong> Programme<br />
70 Programme Book<br />
Abstract Session<br />
14.15 - 15.45 Sex, testosterone and the prostate<br />
Genoa Room<br />
Poster Session 5<br />
Chairs: A. Martin-Morales, Malaga (ES)<br />
J.O.R. Sønksen, Herlev (DK)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
71 The role of intracellular kinases in ageing erectile dysfunction<br />
A. Castela, R. Soares, F. Rocha, P. Vendeira, C. Costa (Porto, Portugal)<br />
72 Testosterone deficiency and decrease of libido in obstructive sleep apnea syndrome (OSAS) patients<br />
B.S. Bercea, R.M. Bercea, E. Cojocaru, T. Mihaescu (Iasi, Romania)<br />
73 Withdrawn<br />
74 Effects of induced hypogonadism in human corpora cavernosa: An immunohistochemical and<br />
morphometric approach<br />
I. Tomada, N. Tomada, D. Neves (Porto, Portugal)<br />
75 Prostate safety of testosterone replacement therapy in male hypogonadism: Interim results from the largest<br />
international trial on injectable long-acting testosterone undecanoate involving 763 patients<br />
M. Zitzmann, J.U. Hanisch, A. Mattern, A. Jungwirth, M. Maggi (Münster, Leverkusen, Berlin, Germany; Bad<br />
Dürrnberg, Austria; Florence, Italy)<br />
76 Effect of lipid stem cell transplantation in penis and a combined medication of udenafil on the erectile<br />
function in a rat model with hypogonadism<br />
S.H. Yim, H.R. Lee, U.S. Ha, D.W. Sohn, S.D. Kim, S.W. Kim, D.B. Kim, Y.H. Cho, S.J. Kim, S.H. Hong (Seoul,<br />
South Korea)<br />
77 The associations among eNOS G894T gene polymorphism, erectile dysfunction and benign prostate<br />
hyperplasia-related lower urinary tract symptoms<br />
Y.C. Lee, W.J. Wu, C.C. Liu, C.J. Wang, W.M. Li, C.H. Huang, H.C. Yeh, H.L. Ke, S.P. Huang (Kaohsiung, Taiwan)<br />
78 Withdrawn<br />
79 Endothelial pre-conditioning - sildenafil prior to cavernous nerve injury in the rat model: Defining the<br />
optimal dosing and timing regimen for erectile function preservation<br />
A. Müller, J.F. Donohue, R. Tal, M. Mullerad, K.A. Kobylarz, D.A. Paduch, P.T. Scardino, J.P. Mulhall (Zürich,<br />
Switzerland; New York, United States of America)<br />
80 Activated RhoA/Rho-Kinase leads to impaired erectile function in a cavernous nerve injury rat model<br />
C.J. Gratzke, T.D. Strong, M.A. Gebska, H.C. Champion, C.G. Stief, A.L. Burnett, T.J. Bivalacqua (Munich,<br />
Germany; Baltimore, Iowa City, Pittsburgh, United States of America)<br />
81 Predicting factors for erectile function recovery following intrafascial bilateral nerve-sparing radical<br />
prostatectomy. A comparative study between the open and robotic approach<br />
N. Buffi, A. Gallina, G. Gadda, E. Scapaticci, M. Zanoni, A. Cestari, M. Lazzeri, N. Suardi, A. Briganti,<br />
P. Rigatti, F. Montorsi, G. Guazzoni (Milan, Italy)
82 If a pro-erectile pharmacological approach is considered after bilateral nerve sparing radical<br />
prostatectomy, this should be initiated soon after surgery<br />
A. Gallina, A. Briganti, A. Salonia, L. Barbieri, L. Rocchini, M. Tutolo, F. Castiglione, G. Gadda, A. Saccà,<br />
P. Rigatti, F. Montorsi (Milan, Italy)<br />
83 Identifying the best candidates for penile pharmacological rehabilitation after bilateral nerve sparing<br />
radical prostatectomy<br />
A. Briganti, A. Gallina, U. Capitanio, L. Barbieri, A. Salonia, M. Bianchi, L. Rocchini, A. Saccà, G. Guazzoni,<br />
P. Rigatti, F. Montorsi (Milan, Italy)<br />
84 Does orgasm associated incontinence (climacturia) impact on orgasmic function in men submitted to<br />
bilateral nerve sparing open radical prostatectomy?<br />
A. Salonia, U. Capitanio, M. Cava, A. Briganti, L. Rocchini, M. Ferrari, S. Saccà, R. Bertini, A. Cestari,<br />
L. Barbieri, P. Rigatti, F. Montorsi (Milan, Italy)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
71
Saturday, 17 April - <strong>EAU</strong> Programme<br />
72 Programme Book<br />
Abstract Session<br />
16.00 - 17.30 LESS and robotics in adrenal and prostatic surgery<br />
Amsterdam Room<br />
Video Session 2<br />
Chairs: H.P. Beerlage, ‘s-Hertogenbosch (NL)<br />
R.J.A. Van Moorselaar, Amsterdam (NL)<br />
All presentations have a maximum length of 10 minutes, followed by 4 minutes of discussion.<br />
V8 LESS adrenalectomy<br />
S. Gidaro, L. Cindolo, L. Schips, F. Neri (Chieti, Vasto, Italy)<br />
V9 Laparoscopic single port adrenalectomy<br />
W. Massoud, B. Iliescu, M. Fennouri, O. Dumonceau, M. Ceddaha, H. Baumert (Le Kremlin-Bicêtre, Paris,<br />
France)<br />
V10 Single incision single port transabdominal adrenalectomy: Our preliminary results<br />
I. Yavascaoglu, Y. Kordan (Bursa, Turkey)<br />
V11 “LESS” radical prostatectomy performed with a personal original technique<br />
F. Gaboardi, A. Salvaggio, A.M. Granata, A.L. Romanò, G.P. Incarbone, F. Scieri, F. Pietrantuono, A. Gregori<br />
(Milan, Italy)<br />
V12 Extraperitoneal laparo-endoscopic single site radical prostatectomy (LESS)<br />
R. Rabenalt, M. Giessing, C. Arsov, C. Winter, P. Albers (Düsseldorf, Germany)<br />
V13 Robotic simple prostatectomy<br />
V.D. Matei, M.G. Spinelli, A. Nordio, A. Brescia, N. Crisan, I. Coman (Milan, Italy; Cluj, Romania)<br />
V14 Robotic assisted laparoscopic radical prostatectomy: Lateral approach to the bladder neck preservation in<br />
case of median lobe<br />
F. Annino, A. Beato, C. De Carne, S. Micali, M.C. Sighinolfi, S. De Stefani, G. Bianchi (Modena, Italy)
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
16.00 - 17.30 Botulinum toxin in NDO-IDO: Latest breaking news from basics and<br />
clinics<br />
<strong>Barcelona</strong> Room<br />
Oral Session 3<br />
Chairs: A. Apostolidis, Thessaloniki (GR)<br />
P. Dinis Oliveira, Porto (PT)<br />
All presentations are 7 minutes in length, followed by 2 minutes of discussion.<br />
Introduction<br />
A. Apostolidis, Thessaloniki (GR)<br />
85 Botulinum toxin type A acts on bladder intramural parasympathetic ganglia. An experimental study in the<br />
guinea-pig<br />
A. Coelho, F. Cruz, C. Cruz, A. Avelino (Porto, Portugal)<br />
86 The effect of botulinum toxin injections into the detrusor muscle on bladder contractions evoked by<br />
efferent and afferent stimulation -observations in a chronic pig model<br />
S. Boy, R. Gelbke, K.P. Jünemann, G. Böhler, B. Klein, C. Seif (Kiel, Germany)<br />
87 Botulinum toxin decrease the expression of nerve growth factor and transient receptor potential V1 of rat<br />
urothelium in detrusor over activity induced by bladder outlet obstruction<br />
U.S. Ha, J.C. Kim, J.B. Choi, J. Tae Seo, C.H. Han, D.H. Lee, W.H. Park (Seoul, Suwon, Incheon, South Korea)<br />
88 Botulinum toxin-A does not appear to alter the gene expression of neurotrophic factors and their receptors<br />
or COX-1 & COX-2, PGE2 synthase, PGI2 synthase in the urothelium of patients with idiopathic detrusor<br />
overactivity at 4 or 12 weeks following intra<br />
C. Dowson, A. Sahai, M.S. Khan, P. Dasgupta, S. Mcmahon (London, United Kingdom)<br />
89 Cost-effectiveness and financial impact of botulinum toxin type A treatment for urinary incontinence due to<br />
neurogenic detrusor overactivity in multiple sclerosis patients within the French healthcare system<br />
J.D. Campbell, V.D. Patel, P. Denys, E. Chartier-Kastler, E. Hayward, S.D. Sullivan (Aurora, Irvine, Seattle,<br />
United States of America; Garches, Paris, France; Marlow, United Kingdom)<br />
90 10 year projection for actuarial costs for botulinum toxin injections and clam cystoplasty in patients with<br />
neurogenic and idiopathic overactive bladder<br />
B.W. Lamb, P. Patki, S. Wood, J. Green, J. Shah (Stevenage, London, United Kingdom)<br />
91 Botulinum A toxin intravesical injections in patients with overactive bladder syndrome and detrusor<br />
overactivity due to Parkinson’s disease and Multiple System Atrophy: Preliminary results<br />
A. Giannantoni, S. Proietti, S. Giovannozzi, M. Del Zingaro, E. Mearini, A. Berardelli (Perugia, Rome, Italy)<br />
92 Dose ranging Phase 2 study of BOTOX® (onabotulinumtoxinA) in idiopathic OAB: Benefit/risk assessment<br />
C.R. Chapple, R. Dmochowski, V. Nitti, M. Chancellor, K. Everaert, C.R. Thompson, G. Daniell, J. Zhou,<br />
C. Haag-Molkenteller (Sheffield, Marlow, United Kingdom; Nashville, New York, Pittsburgh, Irvine, United<br />
States of America; Ghent, Belgium)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
73
74 Programme Book<br />
93 The Zurich experiences including 8 year results of 240 Cases treated with botulinum-A toxin injections into<br />
the detrusor muscle for overactive bladder refractory to anticholinergics<br />
D.M. Schmid, S. Roy-Guggenbuehl, D. Eberli, B. Schuessler, D. Scheiner, D. Perucchini, T. Sulser, B. Schurch,<br />
D.M. Schmid (Zürich, Lucerne, Switzerland)<br />
Summary<br />
P. Dinis Oliveira, Porto (PT)
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
16.00 - 17.30 Renal tumours: Medical treatment<br />
Athens Room<br />
Oral Session 4<br />
Chairs: P.F.A. Mulders, Nijmegen (NL)<br />
J-J. Patard, Rennes (FR)<br />
All presentations are 7 minutes in length, followed by 2 minutes of discussion.<br />
Introduction<br />
P.F.A. Mulders, Nijmegen (NL)<br />
94 A real-life comparative effectiveness simulation of progression free survival comparing first-line sunitinib<br />
vs bevacizumab + interferon-alpha 2a in metastatic renal cell carcinoma – considering the effects of downdosing<br />
and patient compliance<br />
G.H. Mickisch, B. Schwander, B. Escudier, J. Bellmunt, J.P. Maroto, C. Porta, S. Walzer, M. Nuijten (Bremen,<br />
Lörrach, Germany; Villejuif, France; <strong>Barcelona</strong>, Spain; Pavia, Italy; Basel, Switzerland; Rotterdam, The<br />
Netherlands)<br />
95 Sequential use of temsirolimus (TEM) in patients with metastatic renal cell carcinoma (mRCC): Safety and<br />
efficacy following failure of receptor tyrosine kinase inhibitor (TKI) treatment<br />
S. Weikert, C. Kempkensteffen, K. Zimmermann, V. Grünwald, A. Floercken, J. Westermann, K. Miller,<br />
U. Keilholz, M. Johannsen (Berlin, Hanover, Germany)<br />
96 Evaluation of safety, tolerability and activity: A registry for temsirolimus-treated patients with advanced or<br />
metastatic renal cell carcinoma (aRCC) in the usual health care setting (STAR-TOR)<br />
H. Pelz, G. Krekeler, L. Bergmann, J. Roigas, T. Steiner, P.A. Loeschmann, M. Kosch (Münster, Frankfurt,<br />
Berlin, Jena, Germany)<br />
97 Everolimus (EVE) in RECORD-1 elderly patients (pts) with metastatic renal cell carcinoma (mRCC) and<br />
management of related adverse events (AEs)<br />
E. Calvo, C. Porta, B. Escudier, A. Ravaud, S. Oudard, S. Osanto, S. Bracarda, V. Grünwald, U. Vaishampayan,<br />
M.A. Climent , W.J. Berg, D. Lebwohl, R.J. Motzer (Madrid, Valencia, Spain; Pavia, Arezzo, Italy; Villejuif,<br />
Bordeaux, Paris, France; Leiden, The Netherlands; Hanover, Germany; Detroit, New York, United States of<br />
America)<br />
98 TKI therapy related proteomic patterns in serum from patients with metastastatic renal cell carcinoma<br />
M. Walter, N. Kröger, T. Steiner, F. Von Eggeling, H. Wunderlich, K. Junker (Jena, Germany)<br />
99 Pre-operative sorafenib in metastatic renal cell carcinoma undergoing cytoreductive nephrectomy<br />
A. Finelli, A. Horgan, K.L. Durrant, A.E. Evans, T.K. Kim, A. Zlotta, S. Sridhar, M.A.S. Jewett, N.E. Fleshner,<br />
J.J. Knox (Toronto, Canada)<br />
100 Retrospective database analysis of zoledronic acid treatment patterns in patients with renal cell carcinoma<br />
or bladder cancer and bone metastases<br />
S. Kaura, H.J. Henk (Florham Park, Eden Prairie, United States of America)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
75
101 Presurgical sunitinib in metastatic clear cell renal cancer (mRCC): Surgical safety and effect on the primary<br />
tumour<br />
T. Powles, J. Peters, S. Horenblas, W. Meinhardt, T. O’Brien, A. Sahdev, L. Lim, J. Green, S. Chowdhury,<br />
V. Nargund, J. Bycroft, J. Hannen, A. Bex (London, United Kingdom; Amsterdam, The Netherlands)<br />
76 Programme Book<br />
Summary<br />
J-J. Patard, Rennes (FR)
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
16.00 - 17.30 Evaluating indolent prostate cancer 1<br />
Paris Room<br />
Poster Session 6<br />
Chairs: J. Donovan, Bristol (GB)<br />
A. Hinev, Varna (BG)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
102 Food and prostate cancer (PCa): Can we find the smoking gun? Result of a Franco-Belgian survey<br />
S. Menard, J. Menard, A. Dillis, T. Ripert, F. Staerman, B. Tombal (Brussels, Belgium; Reims, France)<br />
103 Accuracy of computer-aided transrectal ultrasonography detection (histoScanning) of prostate cancer in<br />
the predicition of a negative margin in radical prostatectomy patients<br />
J. Spethmann, M. Graefen, A. Beckmann, C. Linse, T. Steuber, T. Schlomm, H. Heinzer, A. Haese, G. Salomon<br />
(Hamburg, Germany)<br />
104 Withdrawn<br />
105 PCA3: A multicenter experience from Southern Italy<br />
R. Autorino, R. Damiano, M. De Sio, M. Pizzuti, R. Muscariello, R. De Domenico, G. Quarto, G. Azzarito,<br />
L. Gallo, A. Gallo, M. D’Armiento, G. Di Lorenzo, S. Perdona (Naples, Catanzaro, Italy)<br />
106 Should we change number of sampling cores according to clinical variables at an initial prostate biopsy?<br />
N. Numao, S. Kawakami, Y. Kubo, S. Yamamoto, J. Yonese, K. Kihara, I. Fukui (Tokyo, Japan)<br />
107 Preoperative nomograms for predicting extracapsular extension in radical prostatectomy with localized<br />
prostate cancer: A multi-institutional clinicopathologic study<br />
Y.D. Choi, J.S. Chung, H.S. Yu, K.H. Choi, K.H. Kim, Y.S. Lee, W.J. Jeong, W.S. Ham, H.Y. Choi, H.R. Song,<br />
S.S. Byun, S.I. Seo, C. Song, J.S. Cho, S.E. Lee, H.J. Ahn, E.S. Lee, W.J. Kim, M.K. Chung, T.Y. Jung (Seoul,<br />
Seongnam, Chuncheon, Cheongju, Busan, South Korea)<br />
108 Template transperineal prostate mapping biopsies for prostate cancer risk stratification and cancer<br />
localization<br />
P.B. Singh, H.U. Ahmed, D. Stevens, P. Gurung, A. Freeman, M. Emberton (London, United Kingdom)<br />
109 Value of real-time elastography targeted and systematic transrectal ultrasound-guided biopsy for prostate<br />
cancer detection<br />
S. Voigt, M.O. Grimm, M.P. Wirth (Dresden, Germany)<br />
110 Tissue sampling is not adequate in the detection of prostate cancer in transition zone<br />
B. Dogan, E.C. Serefoglu, A.F. Atmaca, A.E. Canda, Z. Akbulut, M.D. Balbay (Ankara, Turkey)<br />
111 Fractal dimension as a novel measure of prostate cancer grading<br />
P. Waliszewski, R. Abu Eid, S. Kribus, W. Schafhauser, A. Stenzl (Straubing, Hof, Marktredwitz, Tübingen,<br />
Germany; Aberdeen, United Kingdom)<br />
112 Localization, volume and Gleason grade of prostate cancer index tumour in an unscreened population<br />
undergoing radical retropubic prostatectomy between 2000 and 2006<br />
M. Musch, M. Sahm, J.M. Pahnke, V. Klevecka, U. Roggenbuck, S. Stoerkel, M. Abbas, D. Kroepfl (Essen,<br />
Wuppertal, Germany)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
77
113 Prostate cancer tumour stages of patients with multiple negative systematic random biopsies<br />
T. Loch, B. Grabski, A.C. Loch, B. Wefer, L. Baeurle, C. Schroeder, U. Paul (Flensburg, Germany)<br />
114 Transperineal prostate biopsy: A study of sensitivity with comparison between 18 g and 14 g needle<br />
A. Lorusso, I. Intermite, G. Galeone, G. De Rienzo, G. Giocoli Nacci, A. Pagliarulo, V. Pagliarulo (Bari, Italy)<br />
115 The accuracy of the percentage of positive cores in predicting advanced prostate cancer does not change<br />
according to the extent of biopsy scheme<br />
F. Abdollah, A. Briganti, V. Scattoni, U. Capitanio, M. Raber, D. Di Trapani, G. Lughezzani, R. Bertini,<br />
R. Colombo, M. Freschi, A. Cestari, P. Rigatti, F. Montorsi (Milan, Italy; Montreal, Canada)<br />
116 Are clinically insignificant prostate cancers really insignificant in the Korean population?<br />
S.U. Park, S.H. Lee, K.K. Park, D.S. Kim, B.H. Chung (Seoul, South Korea)<br />
78 Programme Book
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
16.00 - 17.30 Bladder pharmacology 1<br />
Milan Room<br />
Poster Session 7<br />
Chairs: C.J. Fowler, London (GB)<br />
F. Van Der Aa, Leuven (BE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
117 Withdrawn<br />
118 NGF-induce detrusor overactivity is TRPV1 dependent<br />
F. Cruz, A. Charrua, B. Frias, A. Avelino, C.D. Cruz (Porto, Portugal)<br />
119 Sex difference in expression profiles of acid-sensing ion channels and transient receptor potential channel<br />
v1 in the mouse urinary bladder<br />
H. Kobayashi, M. Yoshiyama, I. Araki, S. Kira, H. Inuzuka, H. Nakagomi, T. Miyamoto, Y. Haneda, N. Sawada,<br />
M. Kamiyama, S. Kudou, H. Zakoji, T. Tsuchida, M. Fukasawa, M. Takeda (Tyuo-City, Japan)<br />
120 TRPV4 in the urothelium of the urogenital tract. A co-localization between TRPV4 and adherence junctions<br />
in human kidney, ureter & urinary bladder suggest involvement of TRPV4 in stretch sensation<br />
D.A.W. Janssen, J.P.F.A. Heesakkers, C.F.J. Jansen, J.A. Schalken (Nijmegen, The Netherlands)<br />
121 The expression of transient receptor potential (TRP) V4, A1, and V1 in the human bladder mucosa of<br />
normal and bladder outlet obstruction: A novel mechanism in the obstruction-induced bladder overactivity<br />
H. Nakagomi, S. Kira, T. Miyamoto, H. Inuzuka, S. Sawada, M. Kamiyama, H. Kobayashi, S. Kudo,<br />
T. Mochizuki, M Takeda (Chuo, Japan)<br />
122 Hyperosmolarity alters the proper micturition and bladder activity: The comparison of physiological and<br />
chemical model of overactive bladder<br />
K. Juszczak, M. Wyczółkowski, P.J. Thor (Cracow, Poland)<br />
123 Phasic contractions of the pig bladder: Functional heterogeneity between bladder regions and the role of<br />
the mucosa<br />
H. Nyamwaro, N.G. Mckay, K. Lawson, C.R. Chapple, D.J. Sellers (Sheffield, United Kingdom)<br />
124 PCREB immunohistochemical staining of dorsal root ganglia after acute and repeated urinary pathogenic<br />
E. coli infection into rat bladder<br />
J.H. Lee, D.K. Lee, S.J. Lee, J.I. Kim (Seoul, Uijeongbu, South Korea)<br />
125 ONO-8539, a novel EP1 receptor antagonist, suppresses bladder hyperactivity via excessive production of<br />
prostaglandin E2 (PGE2) induced by intravesical instillation of ATP in urodynamic evaluation of cynomolgus<br />
monkeys<br />
H. Okada, T. Konemura, T. Maruyama (Osaka, Japan)<br />
126 Attenuation of sensory afferent nerve firing by brefeldin-A in an ex vivo mouse bladder model<br />
V.M. Collins, C.R. Chapple, N.G. Mc Kay, D.J. Sellers, D. Grundy (Sheffield, United Kingdom)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
79
127 ATP release from bladders is decreased and may not be associated with spontaneous contractions in a rat<br />
model of bladder outlet obstruction<br />
H. Akino, I. Tanaka, K. Nagase, N. Watanabe, M. Maegawa, N. Oyama, Y. Miwa, O. Yokoyama (Fukui, Japan)<br />
128 Nitric oxide/cGMP signalling mediates an inhibitory action on sensory pathways of the micturition reflex<br />
in the rat<br />
R. Caremel, S. Oger, D. Behr-Roussel, P. Grise, F. Giuliano (Rouen, Orsay, Garches, France)<br />
129 Phosphodiesterase type 5 site of action in the Guinea pig bladder, a novel indirect visualisation technique<br />
M.S. Rahnama’i, G.A. Van Koeveringe, S.G.G. De Wachter, J. De Vente, P.E.V. Van Kerrebroeck, J.I. Gillespie<br />
(Maastricht, The Netherlands; Newcastle upon Tyne, United Kingdom)<br />
130 Vardenafil decreases bladder afferent nerve activity in unanesthetized decerebrate spinal cord-injured rats<br />
D. Behr-Roussel, S. Oger, S. Caisey, P. Sandner, J. Bernabé, F. Giuliano (Orsay, Garches, France; Wuppertal,<br />
Germany)<br />
131 Combined effect of a phosphodiesterase 5 inhibitor, udenafil, with an antimuscarinic, oxybutynin on<br />
human detrusor relaxation<br />
S. Oger, D. Behr-Roussel, D. Gorny, E. Chartier-Kastler, P. Validire, L. Alexandre, F. Giuliano (Orsay, Paris,<br />
Garches, France)<br />
80 Programme Book
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
16.00 - 17.30 Metastatic disease: First line therapy<br />
Vienna Room<br />
Poster Session 8<br />
Chairs: N.A. Mottet, Saint Etienne (FR)<br />
R. Zdrojowy, Wroclaw (PL)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
132 More evidence that local treatment matters: An updated survival analysis of radical prostatectomy and<br />
pelvic lymphadenectomy (PLND) (pT2-4) versus PLND alone (pTx) in men with lymph node positive disease<br />
T. Steuber, F. Beier, J. Walz, S. Ahyai, G. Sauter, F. Chun, H. Huland, M. Graefen (Hamburg, Germany;<br />
Marseille, France)<br />
133 Impact of adjuvant radiotherapy on cancer specific survival of patients with seminal vesicle invasion and<br />
node positive disease: Results of a matched-analysis<br />
A. Briganti, R. Karnes, C. Cozzarini, A. Gallina, N. Suardi, F. Da Pozzo, N. Di Muzio, P. Rigatti, F. Montorsi,<br />
M.L. Blute (Milan, Bergamo, Italy; Rochester, United States of America)<br />
134 Risk of thromboembolic diseases in men with prostate cancer: Results from PCBaSe Sweden<br />
M.J.J. Van Hemelrijck, J. Adolfsson, H. Garmo, A. Bill-Axelson, O. Bratt, E. Ingelsson, M. Lambe, P. Stattin,<br />
L. Holmberg (London, United Kingdom; Stockholm, Lund, Umea, Sweden)<br />
135 Early effects of androgen deprivation therapy on body composition, functional status and muscle fatigue in<br />
patients with prostate cancer<br />
J.E. Bestard Vallejo, J. Nistal Alonso, A. Prats Galino, J. Palou Redorta, J. Planas Morin, J. Morote Robles<br />
(Palma de Mallorca, <strong>Barcelona</strong>, Spain)<br />
136 Chlormadinone acetate is effective for hot flush in androgen deprivation therapy<br />
H. Koike, H. Matsui, Y. Shibata, K. Ito, K. Suzuki (Maeabshi, Gunma, Japan)<br />
137 Withdrawn<br />
138 Metabolic change after androgen deprivation therapy in Korean men with prostate cancer<br />
C.H. Park, S.J. Kim, C.M. Park, H.K. Kim, J.Y. Park (Gangneung, South Korea)<br />
139 Evaluation of the efficacy and safety of switching from treatment with leuprolide 1-month dosing regimen<br />
to degarelix 1-month dosing regimen in prostate cancer (PCa) patients<br />
J. De La Rosette, R.L. Davis III, B.E. Persson, T.K. Olesen (Amsterdam, The Netherlands; Greensboro, North<br />
Carolina, Parsippany, United States of America; Saint-Prex, Switzerland)<br />
140 Open-label, exploratory study of degarelix as second-line hormonal therapy in patients with prostate<br />
cancer (CS27)<br />
K. Miller, C. Rüssel, S. Goble, B.E. Persson (Berlin, Borken, Germany; Copenhagen, Denmark; Saint-Prex,<br />
Switzerland)<br />
141 Long-term efficacy and tolerability of once-yearly histrelin acetate implant in patients with advanced<br />
prostate cancer<br />
N.D. Shore, M. Gittelman, M.S. Cookson, M.D. Harnett, E. Löyttyniemi, A. Vuorela, P.N. Schlegel (Myrtle<br />
Beach, Aventura, Nashville, Lexington, New York, United States of America; Turku, Espoo, Finland)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
81
142 Phase III study of intermittent monotherapy versus continuous combined androgen deprivation<br />
F. Calais Da Silva Junior, F.E.C. Calais Da Silva, F.E.C. Gonçalves, A.R. Santos, J.K. Kliment, P. Whelan,<br />
T. Oliver, N. Antoniou, S. Pastidis, A.M. Queimadelos (Lisbon, Braga, Portugal; Bratislava, Martin, Slovakia;<br />
Leeds, London, United Kingdom; Melissa, Greece; Santiago de Compostela, Spain)<br />
143 Nadir PSA and time to PSA progression predict overall survival in patients with metastatic prostate cancer<br />
A. Tomioka, N. Tanaka, M. Miyake, T. Inoue, S. Anai, T. Ikeda, K. Fujimoto, Y. Hirao, N. Konishi (Kashihara,<br />
Japan)<br />
144 Prognostic impact of U-PAR in metastatic prostate cancer<br />
K. Brasso, C.E. Almasi, P. Iversen, H. Pappot, G.H. Høyer-Hansen, K. Danø, I.J. Christensen (Copenhagen,<br />
Denmark)<br />
145 Combined targeting the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway<br />
delays cell cycle progression and alters adhesion behaviour of prostate carcinoma cells<br />
S.A. Wedel, L. Hudak, J.M. Seibel, E. Juengel, D. Jonas, R.A. Blaheta (Frankfurt, Germany)<br />
82 Programme Book
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
16.00 - 17.30 Imaging and new techniques<br />
Istanbul Room<br />
Poster Session 9<br />
Chairs: T. Loch, Flensburg (DE)<br />
A. Villers, Lille (FR)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
146 Growth development of different orthotopic prostate tumours in nude mice using three-dimensional<br />
ultrasound micro imaging after standardised cell inoculation<br />
M. Saar, C. Körbel, V. Jung, R. Grobholz, M. Stöckle, M.D. Menger, G. Unteregger, J. Kamradt (Homburg/<br />
Saar, Germany)<br />
147 Can HistoScanning TM help in the assessment of patients with raised serum PSA level: A pilot study<br />
N. Nørgaard, P. Autier (Herlev, Denmark; Lyon, France)<br />
148 Analysis of urethral mobility after radical prostatectomy by perineal ultrasound<br />
A. Bouzouita, H. Belhiba, R. Caremel, J.N. Dacher, P. Grise (Rouen, France)<br />
149 Real-time elastography compared to 3.0 Tesla MRT findings in the localisation and diagnosis of prostate<br />
cancer: Preliminary results of a single centre study<br />
A.E. Pelzer, J. Heinzelbecker, M. Kirchner, J. Frühbauer, S. Schönberg, P. Stroebel, M.S. Michel, D.J. Dinter<br />
(Mannheim, Germany)<br />
150 Value of realtime elastography targeted prostate biopsy in patients with a PSA below 4 ng/ml<br />
M.J. Mitterberger, F. Aigner, L. Pallwein, G. Bartsch, W. Horninger, W. Werner, F. Frauscher (Innsbruck,<br />
Austria)<br />
151 Preoperative prostate cancer assessment: Comparison of the latest generation of transrectal<br />
sonoelastography and modern grayscale ultrasound with whole mount sections after radical<br />
prostatectomy<br />
M. Brock, J. Noldus, F. Sommerer, T. Eggert (Herne, Bochum, Germany)<br />
152 Is a pelvic MRI scan justified in men diagnosed with intermediate risk prostate cancer?<br />
J.B. Wild, N. Mayer, M.A. Khan (Leicester, United Kingdom)<br />
153 Evaluation of choline PET CT and diffusion weighted MRI for the nodal staging of prostate cancer with a<br />
high risk of lymph node metastases<br />
T. Budiharto, S. Joniau, L. Van Den Bergh, E. Lerut, K. Haustermans, F. Mottaghy, R. Oyen, F. Ameye,<br />
K. Bogaerts, H. Van Poppel (Leuven, Belgium)<br />
154 Early detection of recurrences following radical prostatectomy: The role of 18F Choline PET-CT<br />
G. Simone, R. Papalia, S. Guaglianone, R. Sciuto, C.L. Maini, E. Forastiere, M. Gallucci (Rome, Italy)<br />
155 [11C]choline PET/CT for restaging prostate cancer patients with biochemical failure after radical<br />
prostatectomy and no evidence of disease on conventional imaging<br />
A. Briganti, M. Picchio, V. Scattoni, G. Giovacchini, M. Tutolo, L. Gianolli, P. Rigatti, F. Montorsi, C. Messa<br />
(Milan, Italy)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
83
156 Multi-parametric magnetic resonance imaging in radio-recurrent prostate cancer<br />
N. Arumainayagam, H.U. Ahmed, C. Moore, A. Freeman, H. Payne, A. Kirkham, C. Allen, M. Emberton<br />
(London, United Kingdom)<br />
157 [11C]Choline PET/CT guided secondary lymph node dissection in recurrent prostate cancer after radical<br />
prostatectomy – salvage or desperation surgery?<br />
H. Kübler, M. Thalgott, T. Horn, A.J. Beer, B.J. Krause, J.E. Gschwend (Munich, Germany)<br />
158 The role of salvage lymph node dissection in patients with [11c]choline PET/CT scan detected nodal<br />
recurrence of prostate cancer after radical prostatectomy<br />
N. Suardi, A. Briganti, M. Tutolo, V. Scattoni, A. Gallina, U. Capitanio, R. Bertini, R. Colombo, L.F. Da Pozzo,<br />
P. Rigatti, F. Montorsi (Milan, Bergamo, Italy)<br />
159 Novel resources for bone metastasis diagnostics in prostate cancer with the “Rezoscan”<br />
O.I. Apolikhin, A.V. Koryakin, A.V. Sivkov, B.N. Oshepkov, E.Z. Rabinovitch, N.G. Keshishev (Moscow, Russia)<br />
84 Programme Book
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
16.00 - 17.30 Pain control and infection during prostate needle biopsies<br />
Padua Room<br />
Poster Session 10<br />
Chairs: S. Droupy, Le Kremlin Bicêtre (FR)<br />
E. Vjaters, Riga (LV)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
160 Antibiotic resistance changes in infections following transrectal ultrasound guided prostate biopsy –<br />
Review of 5-year period<br />
A. Cermák, N. Mareckova, K. Karmasova, D. Pacik (Brno, Czech Republic)<br />
161 Risk factors for acute bacterial prostatitis caused by transrectal biopsy of the prostate<br />
S.I. Kim, S.J. Kim, S.H. Lee, Y.Y. Won, J.B. Choi, H.S. Ahn, Y.S. Kim, S.J. Kim (Suwon, South Korea)<br />
162 Significance of combined anesthesia during TRUS prostate biopsy<br />
T. Karaolides, L. Fasoulis, S. Mpisias, A. Marketakis, A. Pappas, A. Thanos (Athens, Greece)<br />
163 Comparison between two local anaesthesiological procedures for transrectal ultrasound guided prostate<br />
biopsy: Our experience<br />
G. Anastasi, F. Greco, G. Mucciardi, A. Galì, A. Inferrera, G. Crea, G. Ricotta, P. Alongi, A. Militello, C. Magno<br />
(Messina, Italy)<br />
164 The combination of perianal-intrarectal ketorolac solution and lidocaine-prilocaine cream improves pain<br />
control during transrectal prostate biopsy<br />
L. Cormio, F. Lorusso, O. Selvaggio, G. Di Fino, P. Masenio, M. De Siati, T. Corvasce, V. Ariano, G. Carrieri<br />
(Foggia, Italy)<br />
165 A simple and effective local anesthetic method for three-dimensional extended prostate biopsy: A<br />
prospective confirmatory study with an expanded cohort<br />
Y. Kubo, S. Kawakami, N. Numao, S. Kitayama, R. Takazawa, M. Yokoyama, K. Saito, S. Uragami,<br />
S. Yamamoto, Y. Fujii, J. Yonese, T. Tsujii, I. Fukui, K. Kihara (Tokyo, Japan)<br />
166 Local anaesthesia for prostate biopsy by periprotatic infiltration: Lidocaine versus bupivacaine: A<br />
prospective, randomized, double blind placebo-controlled study<br />
M. Dridi, H. Larbi, J. Ghorbel, H. Khouni, S. Ghozzi, N. Ben Rais (Tunis, La Marsa, Tunisia)<br />
167 Transrectal prostate biopsy sepsis: Trends in its bacteriology and antibiotic prophylaxis in a single center<br />
over 8 years<br />
M.M. Uddin, H.S.S. Ho, L.G. Ng, C.W.S. Cheng (Singapore, Singapore)<br />
168 Evaluation of the risk factors for complications after prostate needle biopsy<br />
J.H. Yu, Y.I. Park, L.H. Sung, J.H. Han, J.Y. Chung, C.H. Noh (Seoul, South Korea)<br />
169 Transrectal versus transperineal 14-core prostate biopsy in detection of prostate cancer: A comparative<br />
evaluation at the same Institution<br />
M.A. Cerruto, G. Novella, F. Vianello, F. Zattoni (Verona, Italy)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
85
170 Higher cancer detection rate by the prostate biopsy protocol of 1st 8-core transrectal biopsy and 2nd more<br />
than 20 cores transperineal biopsy using original “Yamanashi”-template<br />
M. Kamiyama, M. Fukasawa, Y. Inuduka, S. Kira, Y. Haneda, T. Miyamoto, H. Nakagomi, N. Sawada,<br />
M. Takeda (Chuo, Japan)<br />
171 Changing antibiotic prophylaxis for transrectal ultrasound guided biopsies of the prostate: Are we putting<br />
our patients at risk?<br />
S. Hori, A. Sengupta, A. Joannides, B. Balogun-Ojuri, J. McLoughlin (Cambridge, Bury St. Edmunds, United<br />
Kingdom)<br />
172 Development and internal validation of a nomogram to assess the most accurate biopsy scheme to be<br />
performed in patients undergoing repeat biopsy. results derived from saturation biopsy data<br />
F. Abdollah, V. Scattoni, M. Raber, M. Roscigno, A. Briganti, A. Gallina, N. Suardi, A. Salonia, G. Lughezzani,<br />
M. Freschi, P.I. Karakiewicz, P. Rigatti, F. Montorsi (Milan, Italy; Montreal, Canada)<br />
86 Programme Book
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
16.00 - 17.30 Sexual dysfunction<br />
Genoa Room<br />
Poster Session 11<br />
Chairs: I. Gruenwald, Haifa (IL)<br />
A. Salonia, Milan (IT)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
173 Assessment of unmet needs in patients treated for a cancer justification for establishing an andrology and<br />
sexuality health clinic at a comprehensive cancer center<br />
E. Huyghe, D. Sui, E. Odensky, L. Schover (Toulouse, France; Houston, United States of America)<br />
174 Effects of smoking on plasma testosterone level and erectile function in male rats<br />
M.G. Park, K.W. Ko, M.M. Oh, D.K. Yoon, J.J. Kim, D.G. Moon (Seoul, South Korea)<br />
175 Systemic and penile endothelial function in ED and non ED patients: Do they correlate?<br />
R.V. Virag, J.F. Floresco, M.G. Galiano, C.C. Costa (Paris, France; Porto, Portugal)<br />
176 Relationship between coronary artery disease, vasculogenic erectile dysfunction and endogenous serum<br />
testosterone concentrations: An insight into the hormonal component of vascular dysfunction<br />
C. Fasoulakis, C. Vlachopoulos, P. Sakelariou, N. Ioakeimidis, J. Papazoglou, K. Rokkas, A. Rempelakos,<br />
C. Stefanadis (Athens, Greece)<br />
177 The association of metabolic syndrome and its components with the serum testosterone level: Results of a<br />
large volume, screened population cohort<br />
D. You, S.H. Cheon, S. Park, J.H. Hong, T.Y. Ahn (Seoul, Ulsan, South Korea)<br />
178 Change in cerebral activity in sexual arousal state by selective serotonin reuptake inhibitor administration<br />
to premature ejaculation patient: An analysis using LORETA (Low Resolution Brain Electromagnetic<br />
Tomography)<br />
J.S. Hyun, S.C. Gam, J.H. Jung, K.H. Moon (Jinju, Daegu, South Korea)<br />
179 Erectile dysfunction in epileptic men with antiepileptic drugs<br />
J. Hornberg, H. Schneider, E. Brähler, A. Wirbatz, W. Weidner (Giessen, Leipzig, Germany)<br />
180 Does cavernosal apoptotic cell density correlate to the clinical evaluation of erectile function?<br />
C. Costa, A. Castela, F. Rocha, P. Vendeira, R. Virag (Porto, Portugal; Paris, France)<br />
181 Effect of angiotensin II on corpus cavernosal smooth muscle contraction following partial bladder outlet<br />
obstruction in the rabbit<br />
H. Ertemi, D.H.W. Lau, F.H. Mumtaz, D.P. Mikhailidis , C.S. Thompson (London, United Kingdom)<br />
182 Nitric oxide-, cGMP- & PGK1-mediated relaxation of the mouse vagina is coupled to estrogen receptor<br />
subtype alpha<br />
F. Castiglione, A. Russo, K.E. Andersson, J.A. Gustafsson (Milan, Italy; Winston Salem, United States of<br />
America; Stockholm, Sweden)<br />
183 In vitro functional responses of isolated human vaginal tissue to vasoactive endogenous peptides and their<br />
interaction with cyclic nucleoside monophosphate pathway<br />
H.E. Rahardjo, S. Ückert, M. Meyer, W. Kauffels, F. Scheller, A. Taher, D. Rahardjo, U. Jonas, M.A. Kuczyk<br />
(Hanover, Hildesheim, Germany; Basel, Switzerland; Jakarta, Indonesia)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
87
184 Impact of pelvic floor dysfunctions on female sexual function: A cross-sectional controlled study<br />
E. Sacco, D. Tienforti, A. D’addessi, M. Racioppi, F. Pinto, G. Gulino, F. Marangi, P. Bassi (Rome, Italy)<br />
185 Sexual function in female patients suffering LUTS<br />
N.M. Sumerova, D.Y. Pushkar, G.K. Kasyan (Moscow, Russia)<br />
186 Transforming growth factor-β type I receptor kinase (ALK5) inhibitor alleviates fibrosis in fibroblasts<br />
derived from human Peyronie’s plaque<br />
S. Piao, M.J. Choi, M. Tumurbaatar, W.J. Kim, H.R. Jin, S.H. Shin, B. Tuvshintur, J.Y. Han, G.N. Yin,<br />
D.H. Seong, S.M. Yoon, J.K. Ryu, J.K. Suh (Incheon, South Korea)<br />
187 Withdrawn<br />
88 Programme Book
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Workshop Overview<br />
12.30 - 14.00 Challenges in non-muscle invasive blader cancer - interactive case discussions <strong>page</strong> 323<br />
Geneva Room Sponsored by GE HEALTHCARE AND PHOTOCURE ASA<br />
15.00 - 16.30 Challenges in non-muscle invasive blader cancer - interactive case discussions <strong>page</strong> 323<br />
Geneva Room Sponsored by GE HEALTHCARE AND PHOTOCURE ASA<br />
Symposia Overview<br />
17.45 - 19.15 Multidisciplinarity in prostate cancer: A promising approach? <strong>page</strong> 324<br />
eURO Auditorium Sponsored by ASTELLAS<br />
17.45 - 19.15 Advances in the treatment of castration-resistant prostate cancer: Targeted therapies,<br />
better prognoses <strong>page</strong> 325<br />
Milan Room Sponsored by ASTRAZENECA<br />
17.45 - 19.15 Managing metastatic renal cell carcinoma as a chronic disease: Weighing up the<br />
evidence <strong>page</strong> 326<br />
Istanbul Room Sponsored by BAYER SCHERING PHARMA<br />
17.45 - 19.15 Night-time urology: Why daytime symptoms do not drive night-time diagnosis <strong>page</strong> 327<br />
Athens Room Sponsored by FERRING PHARMACEUTICALS<br />
17.45 - 19.15 The impact of BPH on men’s lives: New evidence for disease management <strong>page</strong> 328<br />
<strong>Barcelona</strong> Room Sponsored by GLAXOSMITHKLINE<br />
17.45 - 19.15 Challenges in individualising management of patients with prostate cancer <strong>page</strong> 329<br />
Paris Room Sponsored by IPSEN<br />
17.45 - 19.15 BPH treatment - from laser to plasma <strong>page</strong> 330<br />
Stockholm Room Sponsored by OLYMPUS<br />
17.45 - 19.15 Advances in prostate cancer management: The first once-yearly LH-RH agonist <strong>page</strong> 331<br />
Birmingham Room Sponsored by ORION PHARMA<br />
17.45 - 19.15 The clinician as architect: Building a strong foundation for patient satisfaction <strong>page</strong> 332<br />
Amsterdam Room Sponsored by PFIZER INC<br />
17.45 - 19.15 A novel approach to the BPH patient needs <strong>page</strong> 333<br />
Padua Room Sponsored by RECORDATI<br />
For detailed information see programmes from <strong>page</strong>s 323-357<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
89
http://esusalzburg.uroweb.org<br />
ESU - Weill Cornell<br />
Masterclass in<br />
Urology<br />
4-10 July <strong>2010</strong>, Salzburg, Austria<br />
European<br />
Association<br />
of Urology
Sunday, 18 April - <strong>EAU</strong> Programme<br />
Plenary Session 2<br />
07.30 - 11.00 Prostate cancer: From prevention to risk calculator<br />
eURO Auditorium<br />
Chairs: F.C. Hamdy, Oxford (GB)<br />
G.N. Thalmann, Berne (CH)<br />
07.30 - 08.00 Highlight Session 1<br />
Female urology<br />
E. Costantini, Perugia (IT)<br />
Oncology<br />
M.J. Ribal Caparros, <strong>Barcelona</strong> (ES)<br />
Stone disease<br />
O. Traxer, Paris (FR)<br />
08.00 - 08.40 Debate Screening<br />
Moderator: L. Holmberg, London (GB)<br />
Panel: Pro: P.C. Albertsen, Farmington (US)<br />
Con: F.H. Schröder, Rotterdam (NL)<br />
Aims and objectives<br />
The debate will touch upon the following questions: Have we beyond doubt established that PSA screening<br />
confers a mortality reduction worthwhile to consider screening?<br />
Are the side-effects manageable with today’s techniques so that these side effects does not prohibit<br />
screening? Which are the most important and acute areas of research in PSA screening today? What do you<br />
see as a responsible official standpoint for a department of health or a regulatory public health institution<br />
to take? What are the key points of information for the lay public? What does the nearest future for PSA<br />
screening look like?<br />
08.40 - 09.20 Debate Chemoprevention<br />
Moderator: F.C. Hamdy, Oxford (GB)<br />
Panel: G. Andriole, St. Louis (US)<br />
N.W. Clarke, Manchester (GB)<br />
09.20 - 10.00 Debate Risk classification<br />
Moderator: D.E. Neal, Cambridge (GB)<br />
Panel: H. Gronberg, Stockholm (SE)<br />
A. Haese, Hamburg (DE)<br />
A.J. Vickers, New York (US)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
91
92 Programme Book<br />
Aims and objectives<br />
The decision as to whether to screen for prostate cancer and how to manage men who are diagnosed with<br />
screen detected prostate cancer remains a major uncertainty for urologists. This debate is geared at looking<br />
at whether the application of decision making tools such as nomograms can help in deciding who should<br />
be screened and how to manage different stages and grades of prostate cancer. There will be a discussion<br />
around whether these decision tools, many of which have been developed in the US can be applied to<br />
different countries in Europe which have very different screening policies and different penetrations of<br />
sporadic opportunistic PSA testing. We will also be covering some of the new genetic information looking<br />
at single nucleotide polymorphisms and whether they might help identify men who should be targeted for<br />
screening.<br />
10.00 - 10.20 State-of-the-art lecture Population based service screening - time for an<br />
active attitude?<br />
S. Törnberg, Stockholm (SE)<br />
Aims and objectives<br />
Prostate cancer is the most common cause of cancer death among men in many European countries and<br />
therefore a serious health problem. There is a need for the medical profession and the health care politicians<br />
to have an active attitude towards this problem. The medical society needs a strategy in the fight against<br />
prostate cancer deaths. The issue of population based screening differs from testing persons, by the fact<br />
that it involves organisational, ethical, and economical concerns beside the medical questions. The balance<br />
between interventions at an individual level or at a group level in terms of benefits, risks and costs, and<br />
the need of systems for quality control and evaluation of effects in population based screening will be<br />
discussed.<br />
10.20 - 10.40 State-of-the-art lecture The patients view<br />
L. Denis, Antwerp (BE)<br />
Aims and objectives<br />
The mortality decrease of prostate cancer (PC) by PSA screening is an important step forward in our clinical<br />
concepts on this tumour. As any evidenced trial answer it brings more questions: over- and undertreatment<br />
as in any other screening trial. We are prepared to deal with overtreatment by considering active surveillance<br />
as a treatment option if possible in prospective trials. We deal with undertreatment by using the five points of<br />
our Europa Uomo’s Proactive Prostates Call to Action endorsed by ten major professional organisations. Next<br />
to the key words awareness, sustainable research support, risk factors and partnerships one sentence counts<br />
here. Physicians to tailor treatment to the individual patient through appropriate use of PSA testing.<br />
Patients count on optimal medical treatment from the profession and share responsibility on holistic care.<br />
This includes programmes on exercise, nutrition and lifestyle enhancing quality of life after treatment.<br />
Treatment and care are verbs.<br />
10.40 - 11.00 State-of-the-art lecture The <strong>EAU</strong> position<br />
P-A. Abrahamsson, Malmö (SE)
Sunday, 18 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
09.15 - 10.45 Management of non muscle invasive urothelial tumours 1<br />
Stockholm Room<br />
Poster Session 12<br />
Chairs: G. Dalbagni, New York (US)<br />
D.J. Rosario, Sheffield (GB)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
188 Treatment of carcinoma in situ of the bladder associated or not associated to non-muscle invasive<br />
transitional carcinoma using two different BCG doses: The standard or one-third dose. A five year followup<br />
M. Montesino-Semper, R. Madero-Jarabo, E. Solsona-Narbón, J.M. Fernández-Gómez, J.M. Alonso-Dorrego,<br />
V. Chantada-Abal, J.A. Portillo-Martín, M. Unda-Urzaiz, A. Silimi-Moyano, E. González De Chaves, M. Blas<br />
Marín, P.L. Muntañola-Armora, M. Rabadan, A. Ojea-Calvo, J.A. Martinez-Piñeiro (Pamplona, Madrid,<br />
Valencia, Oviedo, La Coruña, Santander, Bilbao, Santa Cruz de Tenerife, Zaragoza, Mieres, Vigo, Spain)<br />
189 Sequential chemo-immunotherapy with mitomycin C (MMC) and bacillus Calmette-Guerin (BCG) versus<br />
BCG alone in patients with carcinoma in situ (CIS) of the urinary bladder. Results of EORTC GU Group<br />
randomized phase II study 30993<br />
W. Oosterlinck, Z. Kirkali, R.J. Sylvester, F. Calais Da Silva, C. Busch, F. Algaba, S. Collette, A.V. Bono (Ghent,<br />
Brussels, Belgium; Izmir, Turkey; Lisbon, Portugal; Uppsala, Sweden; <strong>Barcelona</strong>, Spain; Varese, Italy)<br />
190 Discontinuance of BCG instillation for nonmuscle invasive bladder cancer: prognostic impact on recurrence<br />
A. Picard, D. Champetier, P. Perrin, X. Martin, M. Devonec, M. Colombel (Lyon, France)<br />
191 Can single dose prulifloxacin improve patients’ compliance to bacillus Calmette-Guérin intravesical<br />
therapy?<br />
V. Serretta, A. Ruggirello, F. Scuto, R. Allegro, D. Melloni (Palermo, Italy)<br />
192 Is there a role for random biopsies of the bladder on the cystoscopy following intravesical BCG induction<br />
course<br />
M. Cohen, Y. Shahaf, A. Kaploun, A. Konstantinovsky, G. Fares, D. Goldin, B. Friedman, T. May, A. Stein,<br />
Y. Mecz, Y. Dekel (Haifa, Israel)<br />
193 Usefulness of Hexvix fluorescence cystoscopy after BCG induction treatment<br />
C. Pfister, J.L. Descotes, P. Conort, A. De La Taille, M. Colombel, D. Jacqmin (Rouen, Grenoble, Paris, Creteil,<br />
Lyon, Strasbourg, France)<br />
194 Outcome of T1 non-muscle invasive bladder cancer (NMIBC) treated with bacillus Calmette-Guerin (BCG):<br />
Differences between primary and non-primary tumours<br />
S.S. Alkhateeb, B.W. Van Rhijn, P.J. Bostrom, S. Hanna, R. Vajpeyi, A. Finelli, N.E. Fleshner, M.A.S. Jewett,<br />
A.R. Zlotta (Toronto, Canada)<br />
195 Impact of sub-stage on the clinical outcome of pT1 bladder cancer<br />
B.W.G. Van Rhijn, T.H. Van Der Kwast, D.M. Kakiashvili, N.E. Fleshner, M.N.M. Van Der Aa, S. Alkhateeb,<br />
C.H. Bangma, M.A.S. Jewett, A.R. Zlotta (Toronto, Canada; Rotterdam, The Netherlands)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
93
196 Single immediate preoperative intravesical instillation of electromotive mitomycin-C for primary nonmuscle<br />
invasive bladder cancer: A randomized prospective trial<br />
S.M. Di Stasi, C. Verri, G. Capelli, M. Brausi, G. Leprini, G. Zampa, R.L. Stephen (Rome, Cassino, Carpi,<br />
Medolla, Italy)<br />
197 Concentration-depth profiles of mitomycin–C in the human bladder wall after passive diffusion, thermochemotherapy<br />
and electromotive drug administration<br />
S.M. Di Stasi, R. Massoud, S. Dolci, P. Navarra, G. Fucci, C. Verri, G. Leprini, F. Torelli, R.L. Stephen (Rome,<br />
Medolla, Italy)<br />
198 Paclitaxel plus hyaluronic acid bioconiugated for intravesical therapy of BCG refractory carcinoma in situ of<br />
the bladder: Results of a phase I study<br />
B.P.F. Bassi, V.A. Volpe, D.D. D’Agostino, C.E. Cappa, S.E. Sacco, M.E. Miglioranza, P.G. Passaro,<br />
R.M. Racioppi (Rome, Italy)<br />
199 Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical<br />
cystectomy: An international study of 243 patients<br />
D. Tilki, O. Reich, R.S. Svatek, P.I. Karakiewicz, W. Kassouf, G. Novara, V. Ficarra, D.C. Chade, H.M. Fritsche,<br />
N. Gerwens, J.I. Izawa, S.P. Lerner, M. Schoenberg, E. Skinner, Y. Lotan, A.I. Sagalowsky, C.G. Stief,<br />
S.F. Shariat (Munich, Regensburg, Germany; Dallas, Houston, Baltimore, Los Angeles, United States of<br />
America; Montreal, London, Canada; Padua, Italy)<br />
200 Delay of radical cystectomy due to repeat TURB deteriorates cancer specific survival in “high-risk” nonmuscle<br />
invasive bladder cancer<br />
W. Jäger, C. Thomas, S. Haag, C. Hampel, A. Salzer, J.W. Thüroff, C. Wiesner (Mainz, Germany)<br />
201 Mode of clinical presentation of carcinoma in situ of the bladder does not predict progression or duration<br />
of bladder preservation<br />
R.P. Meijer, I.E.W. Van Onna, E.T. Kok, J.L.H.R. Bosch (Utrecht, Breda, The Netherlands)<br />
202 Natural history of high-grade papillary superficial carcinoma of the bladder may help to identify cases to<br />
be offered initial cystectomy<br />
J.C. Angulo, J.E. Hernandez, A. Garcia-Tello, J. Gonzalez, N. Rodriguez, I. Romero, C. Nuñez (Madrid,<br />
Burgos, Spain)<br />
94 Programme Book
Sunday, 18 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
09.15 - 10.45 Adrenals and trauma<br />
Milan Room<br />
Poster Session 13<br />
Chairs: L. Martínez-Piñeiro, Madrid (ES)<br />
G. Morgia, Catania (IT)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
203 The effect of phosphodiesterase type 5-A inhibitors chronic use on the adrenal glands<br />
D.G. Drenidis, I.I. Ioannis, D.C. Deliveliotis, R.A. Rebelakos, L.A. Leventis, F.C. Fasoulakis, C.M. Chrisofos,<br />
V.I. Varkarakis (Athens, Greece)<br />
204 Transperitoneal laparoscopic adrenalectomy: Lesson learned after 300 cases and 17-year experience<br />
A. Cestari, F. Fabbri, A. Centemero, T. Maga, N.M. Buffi, F. Montorsi, P. Rigatti, G. Guazzoni (Milan, Italy)<br />
205 Laparoscopic adrenalectomy for functioning and nonfunctioning adrenal disorders<br />
K. Novak, L. Safarik, M. Babjuk, P. Macek, J. Dvoracek, T. Hanus (Prague, Czech Republic)<br />
206 Retroperitoneoscopic adrenalectomy for adrenal tumors via a single large port versus conventional<br />
transperitoneal laparoscopic adrenalectomy<br />
D. Hirano, Y. Yamanaka, T. Igarashi, D. Ashikari, K. Satoh, J. Mochida, S. Takahashi (Tokyo, Japan)<br />
207 Stage I-II adrenocortical cancer: Open or laparoscopic adrenalectomy?<br />
F. Porpiglia, C. Fiori, R.M. Scarpa, F. Daffara, B. Zaggia, E. Bollito, A. Berruti, M. Terzolo (Orbassano, Italy)<br />
208 Is macroscopic hematuria a contraindication for performing a focused abdominal sonography for trauma<br />
(FAST) for blunt injuries in the emergency department (ED)?<br />
A. Ploumides, E. Serafetinides, P. Melides, G. Garaganis, K. Hatoupis, G. Papadopoulou, D. Delakas (Athens,<br />
Greece)<br />
209 Genitourinary trauma in serious polytraumatized patients. Incidence of missed injuries following an<br />
application of tertiary survey<br />
S. Montmany, S. Navarro, D. Garcia-Rojo, M. Barrio, N. Hannaoui, J. Prats (Sabadell, Spain)<br />
210 What is the value of routine delayed imaging after renal trauma?<br />
M.F. Bultitude, P.G. Davis, J. Koukounaras, P.L. Royce, N.M. Corcoran (Melbourne, Australia)<br />
211 Routine abdominal CT scan may result in unnecessary radiation exposure of children presenting with blunt<br />
abdominal trauma and microhematuria<br />
M. Haifler, O. Raz, E. Lang, H. Sipela, Y. Shilo, L. Copel, I. Abu-Kischk, G. Eshel, B. Klein, A. Lindner,<br />
A. Zisman (Beer Yaakov, Israel)<br />
212 Treatment of renal injury: Changing patterns of recent 10 years - multicenter trial in Korea<br />
J.B. Lee, J.Y. Chung, H.S. Ahn, K.H. Song, B. Hong, C.H. Han, H.S. Chang, H.J. Park, N.C. Park, S.H. Lee,<br />
S.C. Park (Seoul, Suwon, Daejeon, Daegu, Busan, Incheon, Iksan, South Korea)<br />
213 The York-Mason technique for recto-urinary fistulas: A single surgeon 18-year experience<br />
N. Suardi, A. Briganti, M. Roscigno, M. Bianchi, M. Tutolo, L. Villa, N. Passoni, R. Bertini, V. Di Girolamo,<br />
L. Da Pozzo, P. Rigatti, F. Montorsi (Milan, Bergamo, Italy)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
95
214 Early endoscopic realignment of post-traumatic complete posterior urethral rupture – evaluation of our<br />
preliminary results<br />
Y. Abdel-Salam, S. Safwat, O. Elganayny, A. Elhawary (Assiut, Egypt)<br />
215 Mid-term results with the new self-expanding, large caliber, Allium ureteral stent: Experience of 4 centers<br />
G. Carraffiello, M.R. Desai, B. Moskovitz, O. Nativ, E.M. Santos (Varese, Italy; Nadiad Gujarat, India; Haifa,<br />
Israel; Madrid, Spain)<br />
216 Endovascular management of uretero-arterial fistula due to long-term urethral stenting<br />
D. Colleselli, J. Siegel, S. Huber, D. Schilling, K. Brechtel, A. Stenzl, C. Radmayr, C. Schwentner (Tübingen,<br />
Germany; Innsbruck, Austria)<br />
217 Withdrawn<br />
96 Programme Book
Sunday, 18 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
09.15 - 10.45 Medical therapy, ESWL and stents<br />
Vienna Room<br />
Poster Session 14<br />
Chairs: C. Imbimbo, Naples (IT)<br />
R.J. Opsomer, Brussels (BE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
218 Validation of a prediction model for spontaneous passage of ureteral stones<br />
P. Sountoulides, D. Kikidakis, A. Bantis, N. Koletsas, A. Theodosiou, M. Koptsis, K. Paschalidis (Veria,<br />
Alexandroupolis, Greece)<br />
219 Withdrawn<br />
220 Assessment of short and long term effects of ESWL on the treated and non-treated contralateral kidneys<br />
with diffusion tensor imaging at 3T<br />
F. Yencilek, M. Kiliçkesmez, H. Koyuncu, K. Sarica (Istanbul, Turkey)<br />
221 Non contrast computed tomography criteria predictive of shock wave lithotripsy success for renal calculi<br />
A.M. Maarouf, F.M. Zaiton (Zagazig, Egypt)<br />
222 The efficacy of non-enhanced spiral computed tomography (NESCT) in predicting the outcome of<br />
extracorporeal shock wave lithotripsy (ESWL) when treating patients with ureteral calculi<br />
P.H. Song, J.S. Park , J.H. Bae, J.W. Choi, H.T. Kim, H.C. Jung, T.C. Park, J.H. Seo, J.S. Hyun, K.H. Moon,<br />
J.M. Kim (Daegu, Gumi, Jinju, South Korea)<br />
223 Is slower rate always preferred? A comprehensive assessment of the effect of different shockwave delivery<br />
rate on patients and stones<br />
A. Lo, M.D.I. Gohel, K.K. Wong, N.Y. Lam, C.F. Ng (Shatin, Hung Hom, Hong Kong)<br />
224 Withdrawn<br />
225 Initial experience with a new dual-shockwave lithotripter in the management of upper urinary tract<br />
calculi<br />
J. Abbaraju, F.H. Anjum, A. Sahai, S. Madaan, H. Marsh, S.I. Sriprasad (Dartford, United Kingdom)<br />
226 Prognostic parameters for SWL treatment success: No impact of BMI in 3rd generation lithotripters<br />
G. Hatiboglu, V. Popeneciu, M. Kurosch, J. Huber, S. Pahernik, J. Pfitzenmaier, A. Haferkamp,<br />
M. Hohenfellner (Heidelberg, Germany)<br />
227 Predictive factors of successful treatment with ESWL in the patients with ureteric calculi; A retrospective<br />
analysis of the parameters from computed tomography (CT)<br />
C. Yoo, S.T. Cho, S.J. Lee, W.M. Kang, J.S. Cho, K.K. Kim, Y.G. Lee, N.G. Choi, C.Y. Oh (Chuncheon, South<br />
Korea)<br />
228 Emergency inpatient extra-corporeal shockwave lithotripsy (ESWL): A safe and effective alternative<br />
A. Panah, K. Moraitis, T. El-Husseiny, D. Lamrani, K. Masood, N.P. Buchholz (London, United Kingdom)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
97
229 Extracorporeal shock wave therapy versus ureteroscopic lithotripsy for the treatment of distal ureteral<br />
stones: Results from a prospective randomized study<br />
M. Creta, C. Imbimbo, A. Palmieri, N. Longo, P. Verze, F. Fusco, F. Mangiapia, D. Arcaniolo, R. Buonopane,<br />
V. Mirone (Naples, Italy)<br />
230 A retrospective comparative validated questionnaire study comparing stent-related symptoms between<br />
conventional JJ stents and a novel thermo-expandable segmental ureteric metal stent<br />
D. Patel, Z. Maan, K. Moraitis, T. El-Husseiny, J. Masood, I. Junaid, N.P. Buchholz (London, United Kingdom)<br />
231 Google ureteric stent register<br />
P.J.S. Charlesworth, P.V.S. Kumar (Reading, United Kingdom)<br />
232 Effect of tamsulosin in decreasing lower urinary tract symptoms related to ureteric stenting<br />
A.S. Bedair, A. El Shenoufy, H.M. El Fayoumy, A. Hussein (Cairo, Egypt)<br />
98 Programme Book
Sunday, 18 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
09.15 - 10.45 Male incontinence<br />
Athens Room<br />
Poster Session 15<br />
Chairs: T.A. Borkowski, Warsaw (PL)<br />
G. Novara, Padua (IT)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
233 Long term results after Advance Male Sling procedure in male stress urinary incontinence (SUI)<br />
A. Hegele, C. Frohme, P. Olbert, R. Hofmann (Marburg, Germany)<br />
234 Treatment of male postoperative stress urinary incontinence with polydimethylsiloxane periuretheral<br />
injection: A patient-reported outcomes evaluation<br />
E. Sacco, D. Tienforti, A. D’Addessi, F. Pinto, A. Volpe, M. Gardi, F. Marangi, D. D’Agostino, P. Bassi (Rome,<br />
Italy)<br />
235 A simple, low-cost and valid plastic device, Uflow-meter, to categorise males having LUTS with different<br />
peak micturition flow rates: Prospective clinical diagnostic study<br />
C.K. Chan, S.K.H. Yip, M.L. Li, P.H. Wu (Hong Kong, Hong Kong)<br />
236 Transrectal ultrasound-guided implantation of the ProACT system in patients with post-radical<br />
prostatectomy stress urinary incontinence: Clinical results after a mean follow-up of 2 years<br />
A. Gregori, A.L. Romano, F. Scieri, F. Pietrantuono, G.P. Incarbone, A. Salvaggio, A. Granata, F. Gaboardi<br />
(Milan, Italy)<br />
237 Prevalence of lower urinary tract symptoms and erectile dysfunction: A population-based survey of<br />
Swedish men<br />
M. Frånlund, J. Stranne, C. Dahlstrand (Gothenburg, Skövde, Sweden)<br />
238 2D and 3D/4D perineal ultrasound: First experiences in men with urinary incontinence after radical<br />
prostatectomy<br />
R. Kirschner-Hermanns, L. Naijjari, N. Maass, A. Heidenreich (Aachen, Germany)<br />
239 Clinical prognosis of urinary incontinence in patients who do not achieve continence within one year after<br />
radical prostatectomy<br />
S.J. Jeong, C.J. Lee, D. Kim, W.K. Lee, H. Park, S.H. Doo, M. Abdullajanov, J.H. Kim, C.Y. Yoon, S.K. Hong,<br />
S.S. Byun, S.E. Lee (Seongnam, Chuncheon, South Korea)<br />
240 Real time MRI: Anatomical changes during physiological voiding in men<br />
Y. Hocaoglu, C. Gozzi, M.E. Mayer, A. Roosen, C.G. Stief, R.M. Bauer (Munich, Germany)<br />
241 Periurethral injection of autologous adipose-derived stem cells for the treatment of stress urinary<br />
incontinence in patients undergoing radical prostatectomy: Outcome of a preliminary clinical trial<br />
M. Gotoh, T. Yamamoto, Y. Matsukawa, R. Hattori (Nagoya, Japan)<br />
242 Evaluation and classification of sphincter lesions due to radical prostatectomy (RP)<br />
C. Eimer, S. Quast, H. Gerullis, T. Otto (Neuss, Germany)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
99
243 Urodynamic effects of adjustable continence therapy for men with stress urinary incontinence (SUI) after<br />
radical prostatectomy (RP)<br />
B.F.M. Blok, J. Groen (Rotterdam, The Netherlands)<br />
244 Our results after 26 years of experience with the artificial urinary sphincter<br />
V. Diez Nicolas, R. Gonzalez Lopez, R. Garcia Navas, E. Sanz Mayayo, G. Bueno Serrano, E. Fernandez<br />
Fernandez (Madrid, Spain)<br />
245 Argus adjustable bulbourethral male sling – experience after 94 cases<br />
H. Gallistl, M. Rutkowski, C. Ghawidel, E. Huber, S. Meier-Drioli, W. Hübner (Korneuburg, Austria)<br />
246 Preoperative ultrasound study of the urethral sphincter predicts urinary incontinence after radical<br />
prostatectomy<br />
L. Dell’Atti, G. Ughi, L. Spisani, C. Ippolito, G.P. Daniele, G. Capparelli, L. Fornasiari, C. Daniele (Ferrara,<br />
Italy)<br />
247 Orgasm associated incontinence (climacturia) after bladder neck-sparing radical prostatectomy: Clinical<br />
and video-urodynamic evaluation<br />
F. Manassero, D. Paperini, D. Pistolesi, G. Di Paola, M. De Maria, A. Mogorovich, M. Andreuccetti,<br />
N. Armillotta, C. Selli (Pisa, Italy)<br />
100 Programme Book
Sunday, 18 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
09.15 - 10.45 Tissue engineering, reconstructive urology and gender reassignment<br />
Istanbul Room<br />
Poster Session 16<br />
Chairs: G. Barbagli, Arezzo (IT)<br />
D. Pushkar, Moscow (RU)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
248 Hair stem cells for bladder regeneration in rats, preliminary results<br />
T.D. Drewa, R. Joachimiak, A. Kaznica, V. Sarafian, M. Pokrywczynska (Bydgoszcz, Poland; Plovdiv, Romania)<br />
249 One stage metoidioplasty in female to male transgender patients: The role of genital flaps for urethral<br />
reconstruction<br />
M. Bizic, M. Majstorovic, V. Kojovic, D. Stanojevic, G. Korac, B. Stojanovic, M. Djordjevic (Belgrade, Serbia)<br />
250 Total urethral reconstruction with the radial artery based forearm free flap<br />
G. Garaffa, A.N. Christopher, D.J. Ralph (London, United Kingdom)<br />
251 The effect of acoustic energy induced by UroShield on foley catheter related trauma and inflammation in a<br />
rabbit model<br />
I. Appelbaum, Y. Levi, O.Z. Shenfeld (Jerusalem, Israel)<br />
252 Bladder tissue regeneration with a collagen-based biomatrix in a model for bladder exstrophy compared<br />
to regeneration in normal bladder<br />
L.A.J. Roelofs, B.B.M. Kortmann, R.M.H. Wijnen, A.J. Eggink, T.M. Tiemessen, A.J. Crevels, E. Oosterwijk,<br />
W.F. Daamen, T.H. Van Kuppevelt, P.J. Geutjes, W.F.J. Feitz (Nijmegen, The Netherlands)<br />
253 Postnatal repair of bladder exstrophy with a collagen-heparin biomatrix with growth factors in a sheep<br />
model<br />
L.A.J. Roelofs, B.B.M. Kortmann, R.M.H. Wijnen, A.J. Eggink, T.M. Tiemessen, A.J. Crevels, E. Oosterwijk,<br />
W.F. Daamen, T.H. Van Kuppevelt, P.J. Geutjes, W.F.J. Feitz (Nijmegen, The Netherlands)<br />
254 Biomechanic and urodynamic characterization of a new self-anchoring suture material for pyeloplasty<br />
B. Amend, U. Leichtle, O. Müller, S. Kruck, J. Hennenlotter, J. Bedke, A. Stenzl, K.D. Sievert (Tübingen,<br />
Germany)<br />
255 Improvements of smooth muscle regeneration and vascularization in tissue-engineered bladder using<br />
autologous endothelial progenitor cells and exogenous bioactive factors<br />
B. Yang, L.H. Zhou, J.H. Zheng, Z.Y. Sun, Y.T. Dai (Shanghai, Nanjing, China)<br />
256 In vitro test system for the evaluation of the biocompatibility of alloplastic materials<br />
C. Eimer, H. Gerullis, J. Bagner, B.J. Lammers, I. Theuerkauf, A. Ramon, T. Otto (Neuss, Bad Aachen,<br />
Germany)<br />
257 To investigate the changes of concentration of TGF-β1 in the urine of patients with urethral strictures<br />
H. Xie, X. Yue-Min, F. Qiang (Shanghai, China)<br />
258 A newly developed collagen I-based matrix for the tissue engineering of urothelial implants<br />
G. Feil, S. Maurer, L. Just, J. Krug, K. Kohler, A. Stenzl, K.D. Sievert (Tübingen, Germany)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
101
259 Rectosigmoid vaginoplasty and its impact on psychosocial and sexual life in patients with vaginal agenesis<br />
M.L. Djordjevic, L. Labus, M. Bizic, D. Stanojevic (Belgrade, Serbia)<br />
260 Remodeling of buccal mucosa by bladder microenvironment<br />
M.J. Lu, Z. Wang, G.D. Zhou, W. Liu, Y.L. Cao (Shanghai, China)<br />
261 Urethral replacement under employment of the vena saphena magna in an animal model<br />
D. Osmonov, C. Wang, D. Melchior, G. Boeller, B. Klein, K.P. Jünemann (Kiel, Germany)<br />
262 Dorsal inlay thin-skin graft for anterior urethral reconstruction with a follow-up of 3 years<br />
P. Rehder, M.J. Mitterberger, R. Pichler, A. Kerschbaumer, F. Frauscher (Innsbruck, Austria)<br />
102 Programme Book
Sunday, 18 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
09.15 - 10.45 Bladder pharmacology 2<br />
Padua Room<br />
Poster Session 17<br />
Chairs: K. Everaert, Ghent (BE)<br />
M.C. Michel, Amsterdam (NL)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
263 Stimulation of muscarinic receptors induces cell proliferation of human detrusor muscle cells<br />
N. Arrighi, S. Bodei, A. Lucente, D. Zani, A. Peroni, G. Mirabella, C. Simeone, S. Cosciani Cunico, P.F. Spano,<br />
S. Sigala (Brescia, Italy)<br />
264 Detrusor contractile response resistant to cholinergic and purinergic pathway blockade<br />
L. Peri, A. Franco De Castro, B. Lecea Lopez, I. Goicoechea Maturana, A. Molina Cabeza, P. Clavé Civit,<br />
A. Alcaraz Asensio (<strong>Barcelona</strong>, Mataró, Spain)<br />
265 Beta-NAD+ and cyclic ADP-ribose induce relaxation of the human detrusor smooth muscle<br />
P. Bouchelouche, K. Bouchelouche, J. Nordling (Koege, Herlev, Denmark)<br />
266 Mirabegron (YM178), a novel β3-adrenoceptor (AR) agonist, increased functional bladder capacity and<br />
decreased micturition frequency in conscious water-loaded cynomolgus monkeys<br />
A. Someya, M. Ukai, H. Yanai, M. Watanabe, A. Ohtake, K. Ueshima, M. Suzuki, S. Sato, M. Sasamata<br />
(Ibaraki, Japan)<br />
267 Obstruction enhances Rho-kinase pathway and diminishes protein kinase C pathway in carbachol-induced<br />
calcium sensitization in alpha-toxin permeabilized guinea-pig detrusor smooth muscle<br />
N. Shahab, N. Seki, S. Kajioka, R. Takahashi, T. Yunoki, S. Naito (Fukuoka, Japan)<br />
268 Rho-kinase inhibition impacts neurogenic detrusor overactivity in chronic spinalized rats<br />
D. Broquères-You, D. Behr-Roussel, S. Oger, S. Compagnie, S. Caisey, P. Denys, E. Chartier-Kastler,<br />
F. Giuliano (Orsay, Garches, Paris, France)<br />
269 Rho-kinase inhibition relaxes detrusor from neurogenic patients<br />
S. Oger, D. Behr-Roussel, D. Gorny, J. Bernabe, E. Comperat, E. Chartier-Kastler, P. Denys, F. Giuliano (Orsay,<br />
Paris, Garches, France)<br />
270 Effect of the KCa2/KCa3 channel modulator NS4591 on contractility in pig detrusor muscle strips<br />
P. Bouchelouche, J.S. Nielsen, F. Rode, M. Rahbek, L.B.C. Ronn, J. Nordling, K. Bouchelouche (Koege,<br />
Ballerup, Herlev, Denmark)<br />
271 Withdrawn<br />
272 Cytokines modulate spontaneous calcium activity in cultured human suburothelial myofibroblasts<br />
F. Scigalla, P. Speroni Di Fenizio, A.K. Seth, J.U. Stolzenburg, J. Neuhaus (Leipzig, Germany; Coimbra,<br />
Portugal; Brighton, United Kingdom)<br />
273 The effects of α-defensin 1 on the contraction and relaxation of rat bladder<br />
T.H. Kim, M.S. Kim, S.Y. Lee, M.S. Ha, B.H. Chi, Y.W. Kwon, J.S. Hyun, K.D. Kim (Seoul, Jinju, South Korea)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
103
274 Effect of a moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy<br />
subjects<br />
B. Malhotra, C. Alvey, Z. Jumadilova, X. Li, K. Gandelman (New York, United States of America)<br />
275 Altered detrusor function in female caveolin-1-deficient mice<br />
M. Karbalaei, M. Ekman, B. Uvelius, K. Swärd (Lund, Sweden)<br />
276 Changes in bladder wall perfusion in the overactive obstructed bladder<br />
J.R. Scheepe, A. Amelink, K.P. Wolffenbuttel, B.W.D. De Jong, D.J. Kok (Rotterdam, The Netherlands)<br />
277 The inhibitory role of melatonin on isolated rat urinary bladder contraction: The novel pathway for the<br />
pharmacological management of nocturia<br />
T.H. Kim, I.H. Chang, M.S. Ha, Y.W. Kwon, M.Y. Lee, W.Y. Kim, J.S. Kim, J.S. Hyun, S.C. Myung (Seoul, Jinju,<br />
South Korea)<br />
104 Programme Book
Sunday, 18 April - <strong>EAU</strong> Programme<br />
Sub-plenary Session 1<br />
11.00 - 12.00 Bladder cancer: Management of non muscle invasive disease<br />
eURO Auditorium<br />
Chair: M.S. Soloway, Florida (US)<br />
11.00 - 11.20 State-of-the-art lecture TURB staging: Standard quality and optimising<br />
techniques<br />
J.W. Thüroff, Mainz (DE)<br />
Aims and objectives<br />
In non muscle invasive bladder cancer, TURB is generally staging and treatment in one procedure. However,<br />
to ascertain that one is actually dealing with a non muscle invasive tumor, additional biopsies are taken from<br />
the detrusor at the base of resection.<br />
To assure completeness of resection, biopsies from the resection margins are taken. To rule out additional<br />
carcinoma in situ, either random biopsies are necessary, or biopsies of suspicious areas are taken under<br />
immunofluorescence after installation of photoactive porphyrin. Confocal laser endomicroscopy might in the<br />
future enhance in vivo diagnostic possibilities even more.<br />
In all high-grade tumors and in very large or multifocal low-grade tumors, where complete resection<br />
remains uncertain, re-TURB after 6-12 weeks is mandatory.<br />
Strategies of TURB are illustrated in discussing case presentations.<br />
11.20 - 11.40 State-of-the-art lecture Early single instillation chemotherapy<br />
E. Solsona, Valencia (ES)<br />
Aims and objectives<br />
The aim of this presentation is to analyse the scientific evidence and the clinical relevance of administration<br />
of a single early instillation chemotherapy in patients with non-muscle invasive bladder cancer. In <strong>EAU</strong><br />
and AUA Guidelines, this approach has been considered as the gold standard for these patients due to<br />
the final outcome of a meta-analysis including 7 randomised trials. This meta-analysis proved the early<br />
single instillation efficacy in reducing recurrence and its good tolerance. However, more recently publications<br />
question the scientific evidence of this approach, at least in intermediate and high risk groups and the<br />
clinical relevance in low risk group. In this presentation a critical assessment of early single instillation is<br />
done in order to clarify what is the current status of this approach.<br />
11.40 - 12.00 State-of-the-art lecture Management of high risk disease<br />
J.A. Witjes, Nijmegen (NL)<br />
Aims and objectives<br />
To recognise high risk NMIBC, among others with markers. To know the risk of progression in these patients.<br />
To know how to treat these patients with conservative therapy, even in case of failure on initial conservative<br />
therapy<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
105
Sunday, 18 April - <strong>EAU</strong> Programme<br />
11.00 - 12.00 Andrology<br />
106 Programme Book<br />
Sub-plenary Session 2<br />
Amsterdam Room<br />
Chair: V. Mirone, Naples (IT)<br />
11.00 - 11.20 State-of-the-art lecture Modern management of Peyronie’s disease<br />
W. Weidner, Giessen (DE)<br />
Aims and objectives<br />
The condition is initially associated with an inflammatory, than a fibrotic alteration of the tunica albugina.<br />
Major symtoms are plaque formation, penile pain under erection, penile deviation, shrinkage of the corpora<br />
cavernosa and erectile dysfunction in about 20% of men. Diagnosis is based upon plaque palpation,<br />
sonography of the shaft, and measuremant of penile deviation under erection. Peronies disease is an entity<br />
with undulating symptomatic activity. Normally, pain as symptom of inflammation, ceases after one of to<br />
two years. Medical treatment, oral or intralesional, is debatable in efficacy and only indicated in the first<br />
period of the disease. Surgical procedures are mainly directed to correct penile deviation and corporal<br />
malformations. Methods with and without plaque incision/excision are suggested. In men with concomitant<br />
erectile dysfunction, the implantation of a hydraulic penile implant is necessary. In these cases additional<br />
straightening and grafting may be necessary.<br />
11.20 - 11.40 State-of-the-art lecture Male circumcision and its role in HIV prevention. The<br />
WHO programme<br />
T.B. Hargreave, Edinburgh (GB)<br />
Aims and objectives<br />
There is now grade 1 evidence that Male Circumcision (MC) reduces the risk of a man acquiring HIV.<br />
Modelling studies indicate MC could in the next 10 years save up to 2 million lives in those African countries<br />
with high HIV prevalence; furthermore modelling studies indicate that even if men are more promiscuous<br />
after MC there will still be community benefit in terms of reduced numbers of people with HIV. In the context<br />
of limited resources the most effective public health impact is to target young adults (18 - 20 yrs old) and<br />
several adult programmes are now well established. In the longer term there is a need for infant circumcision<br />
programmes and infant MC programmes are now being established. In order to implement widespread MC it<br />
has been necessary to standardise and simplify surgical procedures so that safe operations can be performed<br />
by paramedical staff. The World Health Organisation manual of male circumcision under local anaesthetic<br />
was written with these objectives in mind. Included in the manual are three adult techniques and four<br />
paediatric procedures. The adult procedures are the dorsal slit, the forceps guided and the sleeve resection<br />
methods. Paediatric methods are described in the WHO manual but in addition a separate manual has been<br />
prepared for infant circumcision (up to 60 days). The paediatric methods are described are the Plastibell<br />
technique, the Mogen and Gomco devices and for older children a standard surgical dorsal slit procedure.<br />
Each method is described in a step by step manner with photographs and line drawing illustrations. Using<br />
the WHO manual and an associated teaching course it has been possible in one week to train a circumcision<br />
surgeon who has had no or minimal previous surgical experience. Training workshops and train the trainer<br />
workshops have been run on a regular basis. In the future there is a need to develop new simple safe adult<br />
methods including development of devices suitable for adults and these will have to be compared with one<br />
of the standard methods by randomised clinical trials.<br />
For an e-copy of the WHO Manual visit http://www.malecircumcision.org/programs/documents/WHO_MC_<br />
Manual_Local_Anaesthesia_v2-5C_Jan08.pdf
11.40 - 12.00 State-of-the-art lecture The role of micro-TESE in the management of nonobstructive<br />
azoospermia<br />
P.N. Schlegel, New York (US)<br />
Aims and objectives<br />
To understand the potential treatment options for severe male infertility, including non-obstructive<br />
azoospermia.<br />
To identify the appropriate evaluation of men with severe male infertility, including genetic testing and the<br />
significance of hormonal testing and treatment.<br />
To recognize the potential role and effects of microdissection TEsticular Sperm Extraction in treatment of<br />
severe male infertility.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
107
Sunday, 18 April - <strong>EAU</strong> Programme<br />
108 Programme Book<br />
Sub-plenary Session 3<br />
11.00 - 12.00 <strong>EAU</strong> Guidelines Office<br />
<strong>Barcelona</strong> Room<br />
A Guideline Panel EBM report on lasers in urology<br />
Chair: K.F. Parsons, Liverpool (GB)<br />
11.00 - 11.10 Introduction<br />
K.F. Parsons, Liverpool, (GB)<br />
11.10 - 11.35 State-of-the-art lecture EBM technology assessment<br />
A.S. Merseburger, Hanover (DE)<br />
Aims and objectives<br />
An ad hoc guideline panel has been established to apply the methodology to the evidence base relating to<br />
new technologies in urology and specifically to analyse data in relation to lasers which have been used and<br />
are currently promoted for a variety of urological procedures.<br />
From this data the panel will stratify the evidence and from it draw conclusions about the grade of<br />
recommendation for the reasonable use of the various techniques.<br />
11.35 - 12.00 State-of-the-art lecture Guidelines and medico-legal aspects<br />
D. Watson, Halifax (GB)
Sunday, 18 April - <strong>EAU</strong> Programme<br />
Sub-plenary Session 4<br />
11.00 - 12.00 Urological follow-up of the transplant patient<br />
Paris Room<br />
Chair: D. Cranston, Oxford (GB)<br />
11.00 - 11.15 State-of-the-art lecture Upper tract dilatation<br />
A.J. Figueiredo, Coimbra (PT)<br />
Aims and objectives<br />
Urethral obstruction leading to upper tract dilatation is the most common urinary complication following<br />
renal transplantation. It usually presents with pain, oliguria or urinary infection and may occur at any time<br />
in the postoperative course. Its causes include extrinsic compression, ureteral fibrosis secondary to ischemia,<br />
rejection and lithiasis. In order to fully address this complication, experience in both endourological<br />
manoeuvres and lower urinary tract surgery is mandatory. Even in centres where renal transplantation is<br />
performed by other specialties, it is the urologist who is called to address this common complication.<br />
11.15 - 11.30 State-of-the-art lecture Bladder dysfunction<br />
G. Karam, Nantes (FR)<br />
Aims and objectives<br />
Can we estimate the risk for bladder dysfunction following renal transplantation? The reasons for bladder<br />
dysfunction following renal transplantation are different and depend on the age and condition of the bladder<br />
prior to the transplantation. This is to emphasise the importance of pre-transplant bladder assessment<br />
and especially that achieved before the onset of anuria. The presentation will deal with the assessment<br />
strategies as well as therapeutic options for renal transplant recipients facing voiding problems following<br />
transplantation.<br />
11.30 - 11.45 State-of-the-art lecture Erectile dysfunction<br />
I. Moncada, Madrid (ES)<br />
Aims and objectives<br />
Erectile dysfunction is quite common in male kidney transplant recipients. The pathophysiology of ED in<br />
these patients can be altered due to co-morbidities, the renal transplant operation itself, medication adverse<br />
effects, relationship problems and changes in mental health. A treatment-oriented evaluation of erectile<br />
dysfunction allows the development of treatment plans that are patient-specific. Hypo-gonadal men whose<br />
testosterone parameters do not improve after renal transplantation may respond to testosterone replacement<br />
therapy. Use of recommended doses of the phosphodiesterase-5 inhibitors does not significantly modify<br />
trough concentrations of the calcineurin inhibitors ciclosporin and tacrolimus or result in impaired renal<br />
allograft function and can be used safely after kidney transplantation. Intracavernosal injections of alprostadil,<br />
with or without papaverine and phentolamine, are effective treatments for erectile dysfunction after renal<br />
transplantation and have not resulted in alterations of ciclosporin concentrations or in deterioration of<br />
renal function. Penile prostheses can be successfully implanted after pelvic organ transplantation without<br />
significant risk of infection.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
109
11.45 - 12.00 State-of-the-art lecture Urological neoplasms<br />
110 Programme Book<br />
F. Manassero, Pisa (IT)<br />
Aims and objectives<br />
Immunosuppression following kidney transplantation increases the risk of tumour development. Urological<br />
neoplasms present a low overall incidence, but deserve early recognition and treatment since they can<br />
negatively affect the graft fate. Excluding the renal cell carcinoma of native kidneys, transitional cell carcinoma<br />
and prostate cancer are the most frequent and can be successfully treated with radical surgery. Ileal<br />
orthotopic neobladder and radical prostatectomy are increasingly used with satisfactory graft preservation.
Sunday, 18 April - <strong>EAU</strong> Programme<br />
Sub-plenary Session 5<br />
11.00 - 12.00 Female urology<br />
Stockholm Room<br />
Coordinator: F. Cruz, Porto (PT)<br />
Chair: D. De Ridder, Leuven (BE)<br />
11.00 - 11.20 State-of-the-art lecture Optimising therapy for overactive bladder: Current<br />
concepts and future directions<br />
C.R. Chapple, Sheffield (GB)<br />
11.20 - 11.40 State-of-the-art lecture Mini-slings: Are they as good as they are marketed?<br />
P. Dinis, Porto (PT)<br />
Aims and objectives<br />
The presentation will deliver a brief overview of the rationale supporting the development of mini-slings:<br />
the need to minimize dissection and tape trajectory, hence minimize bulk of foreign material, pain, bleeding,<br />
anaesthesia and operating time.<br />
An overview of published material on mini slings, emphasizing results and morbidity, will follow.<br />
Mini-slings may or may not be as good as they are marketed: differing teaching needs and learning curves,<br />
points of technique to bear in mind, success rates and follow-up times will be approached.<br />
In conclusion mini-slings will be shown to have very acceptable results. However surgery with presently<br />
available mini-slings requires supervised learning. Next generation mini-slings will probably refine minor<br />
flaws in order to definitely establish their position in the urologist’s surgical armamentarium.<br />
11.40 - 12.00 State-of-the-art lecture Pelvic organ prolapses: Can laparoscopy beat vaginal<br />
meshes?<br />
P. Palma, Campinas (BR)<br />
Aims and objectives<br />
Minimally invasive procedures are replacing open traditional ones as they offer the same rate of cure and<br />
less complications.<br />
Pelvic organs prolapse are very prevalent, along with urinary stress incontinence. Because most patients are<br />
elderly and have less than optimal tissue quality, meshes are used to reinforce fascias or to replace weak<br />
ligaments.<br />
Besides the increasing popularity of laparoscopy, including for vesicovaginal fistulas, meshes, especially in<br />
the apical and anterior compartment produces better and long lasting results.<br />
As far as posterior compartment, when used in selected cases allows for repairing levels I, II and III and<br />
laparoscopy does not.<br />
The evolution of the mini meshes as self anchoring system improved success and decreased exposure rates.<br />
The new trend toward meshes is here to stay and evidence will support this as it already does in anterior<br />
compartment.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
111
Sunday, 18 April - <strong>EAU</strong> Programme<br />
112 Programme Book<br />
Abstract Session<br />
12.15 - 13.45 How to handle complications<br />
eURO Auditorium<br />
Video Session 3<br />
Chairs: E.J. Messelink, Groningen (NL)<br />
P.C.M.S. Verhagen, Rotterdam (NL)<br />
All presentations have a maximum length of 10 minutes, followed by 4 minutes of discussion.<br />
V15 Complications during robotic radical prostatectomy<br />
R. Sotelo Noguera, O.C. Carmona, C.M. Mejia, E. Di Grazia, V.P. Patel, K.P. Palmer, D.C. Canes, R. Abaza,<br />
I. Tuerk, A. Moinzadeh, P. Carpentier, A. Mottrie (Caracas, Venezuela; Orlando, Burlington, Columbus,<br />
Boston, United States of America; Aalst, Belgium)<br />
V16 Repair of rectovesical fistula using the York Mason approach<br />
H. Zecha, G. Hellmich, F. Steinbach (Dresden, Germany)<br />
V17 Laparoscopic resolution of complications during radical prostatectomy<br />
R. Sanseverino, G. Napodano, O. Intilla, U. Di Mauro, T. Realfonso (Nocera Infedriore, Italy)<br />
V18 Recognition and management of rectal injury during laparoscopic or robotic radical prostatectomy<br />
O. Carmona, D. Canes, D. Ramirez, E. Herrera, F. Santinelli, V. Patel, K. Palmer, S. Deger, R. Sotelo (Caracas,<br />
Venezuela; Burlington, Orlando, United States of America; Berazategui, Argentina; Berlin, Germany)<br />
V19 Laparoscopic resolution of vascular complications in laparoscopic surgery<br />
C. Nuñez Mora, J.M. Garcia Mediero, A. Garcia Tello, P. Cabrera Castillo, J. Angulo Cuesta (Madrid, Spain)<br />
V20 Haemostasis during nerve-sparing endoscopic extraperitoneal radical prostatectomy (nsEERPE)<br />
J-U. Stolzenburg (Leipzig, Germany)<br />
V21 Combined endoscopic and surgical treatment for bladder erosion by prolene mesh<br />
S. Guercio, A. Ambu, F. Mangione, M. Mari, F. Vacca, E. Guercio, M. Bellina (Turin, Italy)
Sunday, 18 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
12.15 - 13.45 Prostate cancer stem/initiating cells and the microenvironment<br />
Amsterdam Room<br />
Oral Session 5<br />
Chairs: N.W. Clarke, Manchester (GB)<br />
R.W.G. Watson, Dublin (IE)<br />
All presentations are 7 minutes in length, followed by 2 minutes of discussion.<br />
Introduction<br />
N.W. Clarke, Manchester (GB)<br />
278 Role of stromal fibroblasts interaction with prostatic cancer cells in achievement of metastatic phenotype<br />
S. Serni, E. Giannoni, L. Masieri, L. Calorini, M. Lanciotti, A. Ierardi, A. Minervini, A. Lapini, M. Carini,<br />
P. Chiarugi (Florence, Italy)<br />
279 Stroma reaction in mouse xenograft models of prostate cancer bone metastasis<br />
B. Özdemir, C. Secondini, R. Schwaninger, A. Wetterwald, M. Delorenzi, M.G. Cecchini, G.N. Thalmann<br />
(Berne, Lausanne, Switzerland)<br />
280 Arachidonic acid primes human bone marrow stroma for prostate cancer metastasis<br />
M.D. Brown, C.A. Hart, E. Gazi, P. Gardner, N.W. Clarke (Manchester, United Kingdom)<br />
281 Noggin contributes to the osteolytic response in bone metastasis of prostate cancer (CaP)<br />
C. Secondini, A. Wetterwald, R. Schwaninger, G.N. Thalmann, M.G. Cecchini (Berne, Switzerland)<br />
282 Androgen deprivation up regulates stem cell and neuroendocrine markers in prostate cancer cells during<br />
progression towards castration-resistance<br />
M. Germann, M.G. Cecchini, A. Wetterwald, U.E. Studer, G.N. Thalmann (Berne, Switzerland)<br />
283 Label retaining stem cells in the developing and adult mouse prostate<br />
J.A. Ceder, T. Aalders, K. Jansen, P.A. Abrahamsson, J.A. Schalken (Malmö, Sweden; Nijmegen, The<br />
Netherlands)<br />
284 Expression of matrix metalloproteases and their inhibitors by stromal cells in prostate carcinoma<br />
compared to their expression in non malignant conditions of the prostate (PIN, BPH)<br />
S. Escaf Barmadah, J.M. Fernandez-Gomez, L.O. Gonzalez, A. Suarez, S. Gonzalez-Reyes, S. Junquera,<br />
J.M. Gonzalez, O. Miranda, F. Vizoso (Gijon, Oviedo, Spain)<br />
285 Prognostic value of quantifying circulating tumoural cells (CTC), circulating endothelial cells (CEC) and<br />
vascular endothelial growth factor (VEGF) in hormone sensitive metastatic prostate cancer<br />
L. San Jose Manso, C. Olivier Gomez, L. Resel Folkersma, I. Galante Romo, M.E. Leon Rueda, F. Campanario,<br />
J. Casado, A. Hernando Arteche, E. Useros, M.T. Sanz Casla, M. Vidaurreta, V. De La Orden, E. Diaz Rubio,<br />
M. Maestro De Las Casas (Madrid, Spain)<br />
Summary<br />
R.W.G. Watson, Dublin (IE)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
113
Sunday, 18 April - <strong>EAU</strong> Programme<br />
114 Programme Book<br />
Abstract Session<br />
12.15 - 13.45 Renal tumours: Diagnosis and imaging 1<br />
<strong>Barcelona</strong> Room<br />
Poster Session 18<br />
Chairs: D. Jacqmin, Strasbourg (FR)<br />
A. Zisman, Zerifin (IL)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
286 External validation of a nomogram predicting disease-specific survival of patients with papillary renal cell<br />
carcinoma<br />
G.C. Hutterer, T.F. Chromecki, R. Zigeuner, S. Mannweiler, T. Klatte, K. Kampel-Kettner, K. Pummer, M. Remzi<br />
(Graz, Vienna, Austria)<br />
287 Pretreatment neutrophil-to-lymphocyte ratio is an independent predictor of metastasis in patients with<br />
non-metastatic renal cell carcinoma<br />
Y. Ohno, J. Nakashima, A. Tanaka, M. Ohori, T. Hatano, M.O. Tachibana (Tokyo, Japan)<br />
288 Assessment of mortality for non cancer-related mortality in patients with histologically proven small renal<br />
masses managed non-surgically<br />
C. Jeldres, G. Lughezzani, L. Budäus, D. Liberman, M. Sun, S.F. Shariat, P. Perrotte, M. Graefen, F. Montorsi,<br />
P.I. Karakiewicz (Montreal, Canada; Milan, Italy; Hamburg, Germany)<br />
289 CA9 mRNA is highly detectable in the serum of patients with clear cell renal cell carcinoma<br />
G. Li, G. Feng, A. Zhao, A. Gentil-Perret, S. Paul, C. Genin, M. Gigante, J. Tostain (Saint-Etienne, France)<br />
290 Activation of the aryl hydrocarbon receptor is associated with cigarette smoke, poor prognosis and cancer<br />
cell invasion in renal cell carcinoma<br />
M. Ishida, S. Mikami, T. Kosaka, H. Kono, E. Kikuchi, H. Nagata, A. Miyajima, K. Nakagawa, M. Mukai,<br />
Y. Okada, M. Oya (Tokyo, Japan)<br />
291 Peripherally located renal masses carry a higher risk of histologically proven benign disease when<br />
compared with central masses<br />
R.J. Mason, M. Abdolell, R.A. Rendon (Halifax, Canada)<br />
292 Long term overall survival in renal cell carcinoma patients: Analysis of the Austrian cancer registry<br />
M. Marszalek, C. Wehrberger, M. Rauchenwald, S. Madersbacher (Vienna, Austria)<br />
293 Risk factors in renal cell carcinoma with venous extension<br />
C. Gingu, S. Patrascoiu, C. Chibelean, C. Surcel, M.A. Manu, L. Domnisor, V. Cerempei, D. Tica, C. Balsanu,<br />
I. Sinescu (Bucharest, Romania)<br />
294 Tumour-associated macrophages are a favourable prognostic indicator in patients with papillary renal cell<br />
carcinoma<br />
T.F. Chromecki, G.C. Hutterer, R. Zigeuner, T. Klatte, K. Kampel-Kettner, K. Pummer, M. Remzi,<br />
S. Mannweiler (Graz, Vienna, Austria)<br />
295 Renal neoplasms: Is it possible to diagnose the grade with core biopsies?<br />
F. Villacampa, M. Dominguez, A. Tejido, V. Maartinez, J.M. Duarte, F. De La Rosa, H. Muñoz, G. Usera,<br />
D. Castellano (Madrid, Spain)
296 Imprint cytology: An alternative to frozen section diagnosis in renal tumours removed by partial<br />
nephrectomies<br />
J.R. Schmidbauer, H. Wiener, M. Remzi, M. Marberger (Vienna, Austria)<br />
297 Should renal cell carcinoma histology be reported like Gleason scoring?<br />
K. Yildiz, T.A. Ozkan, L. Ozkan, E. Kus, O. Dillioglugil (Kocaeli, Turkey)<br />
298 Complex renal cystic masses: Interpersonal variability of Bosniak classification is significant – fact or<br />
fiction<br />
P. Weibl, T. Klatte, B. Kollarik, B. Geryk, G. Schüller, M. Marberger, M. Remzi (Vienna, Austria; Bratislava,<br />
Slovakia)<br />
299 Differentiation between normal renal tissue and renal cell carcinoma (RCC) using OCT<br />
K. Barwari, E. Cauberg, D.M. De Bruin, D.J. Faber, T.G. Van Leeuwen, H. Wijkstra, J.J.C.M.H. De La Rosette,<br />
M.P. Laguna Pes (Amsterdam, The Netherlands)<br />
300 Elevated blood calcium level as an independent prognostic factor in renal cell carcinoma<br />
J.C. Bernhard, M. Crepel, G. Verhoest, K. Bensalah, J. Tostain, J.J. Patard (Bordeaux, Rennes, Saint-Etienne,<br />
France)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
115
Sunday, 18 April - <strong>EAU</strong> Programme<br />
116 Programme Book<br />
Abstract Session<br />
12.15 - 13.45 Treatment of male sexual dysfunction<br />
Paris Room<br />
Poster Session 19<br />
Chairs: I. Moncada, Madrid (ES)<br />
E. Wespes, Brussels (BE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
301 Intracavernous delivery of COMP-angiopoietin-1 protein rescues erectile function through enhanced<br />
cavernous endothelial regeneration in the streptozotocin-induced diabetic mice<br />
H.R. Jin, J.S. Song, W.J. Kim, S. Piao, M.J. Choi, M. Tumurbaatar, S.H. Shin, B. Tuvshintur, D.H. Seong,<br />
S.M. Yoon, G.Y. Koh, J.K. Ryu, J.K. Suh (Incheon, Daejeon, South Korea)<br />
302 In vitro and in vivo investigation of erectile properties of the novel Rho-Kinase inhibitor SAR407899 in<br />
diabetic animals<br />
F. Guagnini, M. Ferazzini, M. Grasso, M. Lohn, O. Plettenburg, T. Croci (Milan, Monza, Italy; Frankfurt,<br />
Germany)<br />
303 The role of platelet cGMP and cAMP values in predicting response to oral phosphodiesterase treatment in<br />
men with erectile dysfunction<br />
M. Akand, O. Gülpınar, G. Ersöz, E. Gencer, O. Yaman, E. Özdiler (Ankara, Turkey)<br />
304 Do patients’ baseline characteristics predict PDE5 inhibitors’ efficacy and patients’ preference? A<br />
comparative, randomized, open-label, crossover study<br />
C. Toutziaris, G. Salpigidis, K. Hatzimouratidis, D. Hatzichristou (Thessaloniki, Greece)<br />
305 Can androgen status, duration of ED or partnership-status predict PDE5- inhibitor success in the first-line<br />
treatment of men with ED?<br />
A. Ponholzer, S. Madersbacher, N. Schmeller, B. Esterbauer (Vienna, Salzburg, Austria)<br />
306 Sexual self-confidence following tadalafil once-a-day versus sildenafil citrate as needed in the treatment<br />
of men with erectile dysfunction<br />
E. Rubio Aurioles, H. Porst, B. Stuckey, A. Martin Morales, E.D. Kim, G. Hackett, F. Montorsi, E. Lenero,<br />
H. Buttner, N.N. Huynh, P. Pinton (Mexico City, Mexico; Hamburg, Bad Homburg, Germany; Nedlands,<br />
Western Australia, Macquarie Park, Australia; Malaga, Spain; Knoxville, Indianapolis, United States of<br />
America; Sutton, Coldfield, United Kingdom; Milan, Italy)<br />
307 Efficacy and safety of an orodispersible tablet formulation of vardenafil for the treatment of erectile<br />
dysfunction<br />
H. Sperling, F. Debruyne, A. Boermans, M. Beneke, E. Ulbrich, S. Ewald (Mönchengladbach, Wuppertal,<br />
Leverkusen, Germany; Arnhem, Losser, The Netherlands)<br />
308 Efficacy of udenafil for the treatment of erectile dysfunction up to 12 hours after dosing: A randomized<br />
placebo-controlled trial<br />
H.J. Park, J.K. Park, K. Park, K. Min, N.C. Park (Busan, Jeonju, Gwangju, South Korea)<br />
309 The efficacy of atorvastatin to improve ED in men unresponsive to sildenafil<br />
S.A. Asgari, F. Pourreza, H. Neiroomand (Rasht, Iran)
310 Can erection hardness grading scale use instead of international index of erectile function in men with<br />
erectile dysfunction treated with sildenafil citrate?<br />
Y. Aslan, A. Tuncel, O. Aydin, T. Sezgin, M. Balci, A. Atan (Ankara, Turkey)<br />
311 Time course of erectile function and responsiveness to type V phosphodiesterase inhibitor in<br />
streptozotocin-induced diabetic rats<br />
S.Y. Cho, K.J. Park, J.S. Paick, S.W. Kim (Seoul, South Korea)<br />
312 Effect of vardenafil treatment in the plasma proteome of patients with erectile dysfunction and diabetes<br />
mellitus<br />
C. Olivier Gomez, L. San Jose Manso, P.J. Mateos Caceres, P. Lanzat, I. Galante Romo, E. Mahillo,<br />
P. Rodriguez, C. Macaya, A.J. Lopez Farre (Madrid, Spain)<br />
313 Characteristics of men with premature ejaculation (PE) continuing long-term treatment with dapoxetine<br />
(DPX)<br />
R. Shabsigh, G. Broderick, C. Steidle, F. Tesfaye, S. Bull, B. Levy, J. Aquilina (Brooklyn, Jacksonville, Fort<br />
Wayne, Raritan, United States of America)<br />
314 Clinical Global Impression of Change (CGIC): Predictors and correlates following treatment in men with<br />
premature ejaculation (PE)<br />
D.L. Rowland, S.E. Althof, G. Brock, R.C. Rosen, M. Rothman, S. Bull, K.F. Ho, F. Tesfaye, J.W. Aquilina<br />
(Valparaiso, West Palm Beach, Watertown, Raritan, United States of America; London, Ontario, Canada)<br />
315 Withdrawn<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
117
Sunday, 18 April - <strong>EAU</strong> Programme<br />
118 Programme Book<br />
Abstract Session<br />
12.15 - 13.45 Analysis of risk factors and outcome: Urothelial cancer<br />
Stockholm Room<br />
Poster Session 20<br />
Chairs: M. Brausi, Carpi (IT)<br />
J. Huguet Pérez, <strong>Barcelona</strong> (ES)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
316 Substratification in node-negative pT2 bladder cancer is an independent predictor for recurrence-free<br />
survival: A contemporary series<br />
G. Gakis, D. Schilling, M. Renninger, J. Seibold, K.D. Sievert, A. Stenzl (Tübingen, Germany)<br />
317 Oncological outcomes of radical cystectomy for bladder cancer. Laparoscopy versus open surgery<br />
J. Guillotreau, X. Game, M. Roumiguie, J.B. Roche, N. Doumerc, B. Malavaud, P. Rischmann (Toulouse,<br />
France)<br />
318 Extended vs limited lymph node dissection in bladder cancer: The improved survival is not (entirely) a<br />
staging phenomenon<br />
J.B. Jensen, B.P. Ulhøi, K.M. Jensen (Aarhus, Denmark)<br />
319 Pathological results and prognosis after radical cystectomy of clinical T1 stage bladder cancer<br />
K.S. Han, Y.H. Lee, H.S. Ryu, G.H. Kim, Y.D. Choi, S.C. Yang, S.J. Hong (Seoul, South Korea)<br />
320 Squamous cell carcinoma of the bladder: Which is the prognostic role of the variant histology?<br />
M. Ferriero, G. Simone, R. Papalia, S. Guaglianone, A. Bove, M. Gallucci (Rome, Italy)<br />
321 Radical cystectomy outcome and prognostic parameters - combined result from two large series<br />
P.J. Bostrom, S. Alkhateeb, P.J. Athanasopoulos, T. Mirtti, N.E. Fleshner, M.A. Jewett, A.R. Zlotta (Toronto,<br />
Canada; Turku, Finland)<br />
322 Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: A<br />
retrospective international study of 583 patients<br />
O. Reich, D. Tilki, R.S. Svatek, P.I. Karakiewicz, H. Isbarn, W. Kassouf, Y. Fradet, G. Novara, H.M. Fritsche,<br />
P.J. Bastian, J.I. Izawa, V. Ficarra, S.P. Lerner, M. Schoenberg, P. Dinney, E. Skinner, Y. Lotan, A.I. Sagalowsky,<br />
C.G. Stief, S.F. Shariat (Munich, Regensburg, Bonn, Germany; Houston, Baltimore, Los Angeles, Dallas,<br />
United States of America; Montreal, London, Canada; Padua, Italy)<br />
323 International validation of the prognostic value of lymphovascular invasion in radical cystectomy patients<br />
S.F. Shariat, R. Svatek, D. Tilki, E. Skinner, P.I. Karakiewicz, U. Capitanio, P.I. Bastian, B.G. Volkmer,<br />
W. Kassouf, G. Novara, H.M. Fritsche, J.I. Izawa, V. Ficarra, S.P. Lerner, A.I. Sagalowsky, Y. Lotan,<br />
M.P. Schoenberg, A.M. Kamat, C.P. Dinney, M.J. Marberger, Y. Fradet (New York, Houston, Los Angeles,<br />
Dallas, Baltimore, United States of America; Munich, Ulm, Regensburg, Germany; Montreal, London,<br />
Quebec, Canada; Milan, Padua, Italy; Vienna, Austria)<br />
324 Clinical outcomes of single lymph node positive urothelial carcinoma after radical cystectomy<br />
I.G. Jeong, S.C. Kim, D. You, J. Park, C. Song, J.H. Hong, H. Ahn, C.S. Kim (Seoul, Daejeon, South Korea)<br />
325 Influence of patient characteristics in the results of lymphadenectomy performed at the time of<br />
laparoscopic radical cystectomy (LRC)<br />
C. Nuñez, J.M. García Mediero, P. Cabrera, A. García-Tello, F. Ramón De Fata, F. Cáceres, J.C. Angulo<br />
(Madrid, Spain)
326 Incidental and clinically relevant prostate cancer is found more frequently in thorough versus standard<br />
histopathological processing in radical cystoprostatectomy specimen and should be considered in younger<br />
men<br />
M. Burger, S. Denzinger, A. Hartmann, W.F. Wieland, W. Otto, H.M. Fritsche (Regensburg, Erlangen,<br />
Germany)<br />
327 HER-2 expression status provides independent prognostic information in patients with urothelial<br />
carcinoma of the bladder: A rationale for targeted therapy<br />
C.B. Bolenz, S.F. Shariat, P.I. Karakiewicz, R. Ashfaq, R. Ho, A.I. Sagalowsky, Y. Lotan (Dallas, United States<br />
of America; Montreal, Canada)<br />
328 Impact of hospital volume in local recurrence and distant metastasis in patients with bladder cancer<br />
treated with radical cystectomy in Sweden<br />
E. Sabir, S. Jahnson, O. Damm, F. Liedberg, S. Holmäng, B. Ljungberg, W. Månsson, P.U. Malmström,<br />
H. Wijkström (Linköping, Växjö, Gothenburg, Umeå, Lund, Uppsala, Stockholm, Sweden)<br />
329 Bladder preservation by tri-modality approach for treatment of muscle-invasive bladder carcinoma:<br />
Alexandria experience<br />
W.M. Sameh, A.M. Darweesh, W.M. Arafat, G. Alhoseeny (Alexandria, Egypt)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
119
Sunday, 18 April - <strong>EAU</strong> Programme<br />
120 Programme Book<br />
Abstract Session<br />
12.15 - 13.45 Kidney transplantation: Clinical<br />
Milan Room<br />
Poster Session 21<br />
Chairs: F.J. Burgos Revilla, Madrid (ES)<br />
E. Lechevallier, Marseille (FR)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
330 Assessment of health-related quality of life in renal transplant recipients and dialysis patients<br />
N. Maglakelidze, T. Pantsulaia, I. Chokhonelidze, L. Managadze, A.B. Chkhotua (Tbilisi, Georgia)<br />
331 Cost analysis of kidney transplantation<br />
F.J. Burgos, S. Diaz Naranjo, M. Jimenez, V. Gomez, C. Galeano, R. Marcen (Madrid, Spain)<br />
332 First experience of transvaginally notes-assisted laparoscopic living donor nephrectomy<br />
A. Alcaraz, M.M. Musquera, L.L.P. Peri, A.M. Molina, P.C. Campillo, M.P. Piqueras, M.J.R. Ribal (<strong>Barcelona</strong>,<br />
Spain)<br />
333 A comparison of augmentation enterocystoplasty and ureterocystoplasty before kidney transplantation<br />
with control group<br />
R. Mahdavi Zafarghandi, M. Naghibi, F. Nazemian, F. Sharifipoor, R. Taghavi, M.R. Darabi Mahboub,<br />
M. Mahdavi Zafarghandi (Mashhad, Iran)<br />
334 Endoscopic application of dextranomer and hyaluronic acid (Deflux®) in patients post renal transplant<br />
with recurrent urinary tract infections and vesicoureteral reflux<br />
R. Pichler, M. Mitterberger, A. Kerschbaumer, P. Rehder, J. Oswald (Innsbruck, Austria)<br />
335 Anatomical localization of urinary tract leaks and stenoses after kidney transplantation: Different risk<br />
factors for different sites<br />
F.J. Burgos, J. Pascual, J. Zamora, A. Muriel, N. Planas (Madrid, Spain)<br />
336 Second and third kidney transplants in the paediatric patient population: Complications and long-term<br />
functional results<br />
J. Tabares, E. Lledo-Garcia, D. Subira-Rios, M. Moralejo-Garate, F. Herranz-Amo, D. Morales San Jose,<br />
J.M. Diez-Cordero, G. Bueno-Chomon, R. Duran-Merino, C. Hernandez-Fernandez, A. Luque De Pablos<br />
(Madrid, Spain)<br />
337 Third and fourth kidney transplant: Still a reasonable option<br />
L. Izquierdo, Ll. Peri, M. Piqueras, R. Alvarez-Vijande, A. Alcaraz (<strong>Barcelona</strong>, Spain)<br />
338 Extended criteria donor kidney transplantation: Comparative outcome analysis between single versus<br />
double kidney transplantation at 5-year<br />
G. Lucarelli, S. Impedovo, S. Palazzo, A. Vavallo, C. Bettocchi, M. Battaglia, F.P. Selvaggi, P. Ditonno (Bari,<br />
Italy)<br />
339 Asystolic donors: Results of our program<br />
F. Villacampa, F. De La Rosa, M. Pamplona, A. Rodriguez, J. Passas, F. Aguirre, A. De Andres, R. Diaz<br />
(Madrid, Spain)
340 Outcome of paediatric donor kidney transplant to adult recipients compared to standard kidney transplant<br />
T. Pastor, M. Beamud, S. Beltrán, L.M. Moratalla, L. Bermell, V. Rodrigo, L. Pallardó, J.M. Osca, M. Gil<br />
(Valencia, Spain)<br />
341 Fallacies of 16-multidetector CT angiography in the preoperative evaluation of vascular and ureteral<br />
anatomy of donor nephrectomy<br />
R. Ismail, W. Wael, O. Motawae, A. Foad (Alexandria, Egypt)<br />
342 Major vascular complications in laparoscopic donor nephrectomy<br />
H.I. Abou El Fettouh, H. Abdel Raouf Morsy, A. El Shenoufy, H.M. Agabo, S. Helmy, I. Abouel Fettouh (Giza,<br />
Cairo, Egypt)<br />
343 Kidney transplant after right-sided laparoscopic live donor nephrectomy: Outcomes of donors and<br />
recipients<br />
A. Ciudin, J. Huguet Perez, M. Musquera Felip, L. Peri Cusi, J.R. Alvarez-Vijande Garcia, A. Alcaraz Asensio<br />
(<strong>Barcelona</strong>, Spain)<br />
344 Prospective non-randomized comparison between right- and left-sided hand-assisted laparoscopic donor<br />
nephrectomy<br />
R. Hoda, A. Hamza, O. Reichelt, F. Greco, P. Fornara (Halle, Germany)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
121
Sunday, 18 April - <strong>EAU</strong> Programme<br />
122 Programme Book<br />
Abstract Session<br />
12.15 - 13.45 Percutaneous stone removal 2<br />
Vienna Room<br />
Poster Session 22<br />
Chairs: P. Alken, Mannheim (DE)<br />
M. Grabe, Malmö (SE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
345 Percutaneous nephrolithotomy for urolithiasis in solitary kidney: Early surgical results and long-term<br />
functional outcome<br />
N.A.M. El-Tabey, M.R. El-Kenawy, E.I. Eraky, A.M.S. Shoma, A.R. El-Nahas, A.M. El-Assmy, S.A.S. Shady,<br />
T.M. Tarek, A.S. Ahmed, H.A. Hamdy, E.I. El-Houssiny (Mansoura, Egypt)<br />
346 Long-term results of percutaneous nephrolithotomy for treatment of staghorn stones<br />
A.R. Elnahas, E. Eraky, M.R. Elkenawy, A.M. Shoma, A.A. Shokeir, N.A. Eltabey, A.M. Elassmy,<br />
H.A. Elkappany, E.I. Ibrahiem (Mansoura, Egypt)<br />
347 ECIRS (Endoscopic Combined Intra-Renal Surgery) for urolithiasis in galdakao-modified supine valdivia<br />
position: Our experience<br />
C.M. Scoffone, C.M. Cracco, M. Cossu, M. Poggio, S. Grande, A. Di Stasio, R.M. Scarpa (Orbassano, Italy)<br />
348 Supine versus prone position in percutaneous nephrolithotomy: A systematic review<br />
K.J. Wang, P. Wu, L. Wang (Chengdu, China)<br />
349 Percutaneous endourological procedures in high risk patients in the lateral decubitus position<br />
T. El-Husseiny, J. Masood, K. Moraitis, H. Wazait, P. Saunders, N.P. Buchholz (London, United Kingdom)<br />
350 Non-contact infrared temperature measurement of ultrasonic lithotripsy devices - an in vitro comparison of<br />
commonly used lithotripters<br />
C. Keil, P. Olbert, A. Hegele, A.J. Schrader, R. Hofmann (Marburg, Germany)<br />
351 Prospective comparison of standard versus tubeless mini percutaneous nephrolithotomy<br />
G. Wendt-Nordahl, P. Honeck, F. Felix, M.S. Michel, T. Knoll (Sindelfingen, Mannheim, Germany)<br />
352 Flexible cystoscope assisted PCNL in treating complicated renal calculi<br />
G. Wang, X.C. Zhang, L.Q. Zhou (Beijing, China)<br />
353 Impacted upper-ureteral calculi: Which is the best; Percutaneous antegrade removal or laparoscopy or<br />
extracorporeal shockwave lithotripsy or retrograde approach?<br />
H. Karami, I. Rezaei, M.M. Mazloomfard (Tehran, Iran)<br />
354 ‘Nephrostomy-free’ percutaneous nephrolithotomy for staghorn and multiple stones: Our 1 year of<br />
experience<br />
F.R. Nosirov, S.T. Mukhtarov, F.A. Akilov, N.N. Fidaev, D.S. Yunusov (Tashkent, Uzbekistan)<br />
355 Safety and efficacy of tubeless percutaneous nephrolithotomy in cirrhotic patients and patients on<br />
anticoagulant therapy<br />
Y.C. Jou, C.T. Lin, C.H. Shen, M.C. Cheng, P.C. Chen, Y.S. Tsai (Chiayi, Tainan, Taiwan)
356 Urologist versus radiologist for percutaneous nephrolithotomy access under fluoroscopic guidance: A<br />
systematic review<br />
K.J. Wang, L.H. Jiang, L. Wang, H. Li (Chengdu, China)<br />
357 23-hour stay PCNL: The new safe and cost effective method of managing renal calculi!<br />
P. Aluru, B. Gowardhan, R. Marsh, P. Johnson (Sunderland, United Kingdom)<br />
358 Percutaneous nephrolithotomy using spinal anesthesia: Safety and efficacy<br />
N. Rasyid, P. Birowo, P. Pryambodho, R.A. Hamid, H.E. Rahardjo, I. Wahyudi, A. Rodjani, A. Mochtar,<br />
A. Taher, R. Umbas, F. Firdaoessaleh, C. Susilo, D. Rahardjo (Jakarta, Indonesia)<br />
359 General anesthesia for percutaneous nephrolithotomy: No thanks<br />
M.O. Istanbulluoglu, R. Dogan, R. Sari, M. Dursun, T. Cicek, B. Ozturk (Konya, Turkey)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
123
Sunday, 18 April - <strong>EAU</strong> Programme<br />
12.15 - 13.45 Prostatitis<br />
124 Programme Book<br />
Abstract Session<br />
Athens Room<br />
Poster Session 23<br />
Chairs: H.M. Çek, Istanbul (TR)<br />
P. Tenke, Budapest (HU)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
360 Microbiological survey on young prostatitis outpatients: Changes in the last 10 years<br />
S. Mazzoli, T. Cai, F. Meacci, R. Bartoletti (Florence, Italy)<br />
361 Comparative analysis of diagnostic significance of Toll-like receptors, cytokines and human neutrophil<br />
peptides determination in diagnostics of patients with chronic prostatitis of the categories II and IIIA with<br />
urogenital infection<br />
M. Grigoriev, L. Kovalchuk, L. Gankovskaya, A. Viryasov, D. Surenkov (Moscow, Russia)<br />
362 In vitro bacterial biofilm production from patients with chronic bacterial prostatitis (NIH-II) biological<br />
fluids<br />
S. Mazzoli, F. Meacci, T. Cai, S. Albanese, R. Chitarrai, R. Bartoletti (Florence, Italy)<br />
363 “Chronic Ischaemic Disease” of the prostate based on the results of transrectal biopsy of the prostate in<br />
chronic pelvic pain syndrome IIIB patients<br />
M.I. Kogan, I. Belousov, A.E. Matcionis, P.E. Povilaitite, A.V. Shangichev, R.E. Ametov (Rostov on Don,<br />
Russia)<br />
364 Prostatic calcifications and symptoms of chronic prostatitis/chronic pelvic pain syndrome<br />
A. Trinchieri, G. Perletti, V. Magri (Lecco, Busto Arsizio, Milan, Italy)<br />
365 Prostate calcifications: Answers to a clinical “enigma”<br />
S. Mazzoli, F. Meacci, T. Cai, R. Bartoletti (Florence, Italy)<br />
366 Evaluation of patients with chronic prostatitis-chronic pelvic pain syndrome by clinical phenotyping in two<br />
specialized European institutions<br />
F.M.E. Wagenlehner, V. Magri, G. Perletti, S.O. Schneider, W. Weidner (Giessen, Germany; Busto Arsizio,<br />
Italy)<br />
367 Testpsychological interactions between NIH-CPSI and IPSS, HADS-D, and IIEF results: Associations to LUTS,<br />
depression, and erectile dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome (CP/<br />
CPPS)<br />
W. Weidner, K. Wilbrandt, H. Schneider, E. Brähler, F. Wagenlehner (Giessen, Leipzig, Germany)<br />
368 Clinically – chronic prostatitis, and what is – morphologically?<br />
A.Z. Vinarov, A.M. Pshikhachev, V.A. Varshavskij, S.V. Stoilov (Moscow, Russia)<br />
369 The comparison of 5-alpha reductase with ciprofloxacin for the prevention of chronic bacterial prostatitis<br />
in rat model<br />
S.H. Yim, H.R. Lee, U.S. Ha, D.W. Sohn, S.D. Kim, S.W. Kim, D.B. Kim, Y.H. Cho (Seoul, Jeju, South Korea)<br />
370 Is there a role for “anaerobic microbial factor” in the aetiology of chronic bacterial prostatitis?<br />
Y.L. Naboka, M.I. Kogan, H.S. Ibishev, I.A. Gudima, L.E. Bragina, A.A. Afoko, A. Asante-Asamani (Rostov on<br />
Don, Russia)
371 The effectiveness of bio-regulatory magneto-laser therapy of chronic pelvic pain syndrome/chronic<br />
prostatitis IIIA<br />
M.I. Kogan, A.A. Shangichev, I.I. Belousov, A.A. Afoko, E.A. Chernogubova (Rostov on Don, Russia)<br />
372 A prospective study of multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome using the<br />
UPOINT clinical phenotype system<br />
D.A. Shoskes, R. Dolinga (Cleveland, United States of America)<br />
373 Randomized open label comparative study of efficacy and safety of combination (ciprofloxacin+doxazosin)<br />
vs. monotherapy (ciprofloxacin) in patients with category II or category IIIa prostatitis<br />
K.L. Lokshin, Y.G. Alyaev, A.Z. Vinarov, L.G. Spivak (Moscow, Russia)<br />
374 Pathogen eradication by phage therapy in patients with chronic bacterial prostatitis<br />
S. Letkiewicz, R. Miedzybrodzki, M. Kłak, B. Weber Dabrowska, A. Górski (Wrocław, Poland)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
125
Sunday, 18 April - <strong>EAU</strong> Programme<br />
126 Programme Book<br />
Abstract Session<br />
12.15 - 13.45 Urethral repair<br />
Istanbul Room<br />
Poster Session 24<br />
Chairs: J. Hosseini, Tehran (IR)<br />
S. Perovic, Belgrade (RS)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
375 Algorithm for management of rectourethral fistulas after radical prostatectomy<br />
C. Thomas, J. Jones, W. Jaeger, C. Hampel, J.W. Thüroff, R. Gillitzer (Mainz, Germany)<br />
376 Low-power holmium: Yaglaser urethrotomy for urethral stricture disease: Comparison of outcomes with<br />
the cold-knife technique<br />
M. Atak, H. Tokgoz, B. Akduman, B. Erol, I. Donmez, V. Hanci, O. Turksoy, N.A. Mungan (Zonguldak, Turkey)<br />
377 Complications and patient satisfaction in 349 patients who underwent oral graft harvesting from a single<br />
cheek<br />
G. Barbagli, G. Romano, M. De Angelis, M. Lazzeri, F. Fabbri, S.A. Vallasciani (Arezzo, Florence, Milan, Italy)<br />
378 Dorsal inlay skin-graft urethroplasty in patients older than 65 years<br />
C. Schwentner, J. Seibold, D. Colleselli, J. Mundhenk, D. Schilling, K.D. Sievert, A. Stenzl, C. Radmayr<br />
(Tübingen, Germany; Innsbruck, Austria)<br />
379 Safety of optical urethrotomy under spongiosum block<br />
H. Ather, A.A. Zehri (Karachi, Pakistan)<br />
380 Minimizing the risk of recurrence of urethral strictures and urine incontinence during surgery for long<br />
posterior urethral strictures<br />
M.I. Kogan, V.V. Mitusov, V.V. Krasulin, A.A. Afoko, M.A. Lavrus, J.B. Tampuori (Rostov on Don, Russia)<br />
381 Dorsal or ventral or dorsal plus ventral buccal mucosa graft bulbar urethroplasty using a ventral sagittal<br />
urethrotomy approach<br />
E. Palminteri, E. Berdondini, C. De Nunzio, G. Barbanti, G. Franco, V. Gentile (Arezzo, Rome, Siena, Italy)<br />
382 Two stage hypospadias cripples buccal mucosa graft repair<br />
C. Gingu, S. Patrascoiu, C. Chibelean, C. Surcel, M. Harza, M.A. Manu, V. Zogas, L. Domnisor, V. Cerempei,<br />
D. Tica, C. Balsanu, I. Sinescu (Bucharest, Romania)<br />
383 Reconstruction of extended urethral strictures with buccal mucosal graft. Success rates after 60 months of<br />
follow up: Analysis of 184 patients<br />
A. Pandey, L. Dobkowicz, J. Beier, H. Keller (Hof, Germany)<br />
384 Redo hypospadias repair: Surgical problems faced in adults<br />
S. Perovic, G. Barbagli, R.P. Djinovic, S. Tomovic, M.Z. Milosavljevic, S. Sansalone (Belgrade, Serbia; Arezzo,<br />
Rome, Italy)<br />
385 Urethral reconstruction in female, efficacy and outcome<br />
O.M. Abou Farha, M. El Refai, M.M. Ragab, M.H. Radwan, M.O. Abou Farha, A.M. Shaaban (Tanta,<br />
Alexandria, Elmenia, Egypt)
386 Long-term follow-up of dorsal onlay graft urethroplasty using penile skin or buccal mucosa in adult bulbar<br />
urethral strictures<br />
S. Tran, F. Fateri, G. Venzi, C. Iselin (Geneva, Switzerland)<br />
387 Buccal mucosa urethroplasty: Long-term results of 76 patients using urethral ultrasound, uroflowmetry<br />
and IPSS-Score: Do we still need retrograde urethrography?<br />
M. Werther, S.H. Alloussi, K.D. Sievert, A. Stenzl, J. Seibold (Tübingen, Germany)<br />
388 Buccal mucosal graft harvest for urethroplasty: Closure or nonclosure of the donor site?<br />
I.P. Wharton, P.C.B. Anderson (Dudley, United Kingdom)<br />
389 End-to-end repair or buccal mucosa graft or one-stage bulbar urethroplasty?<br />
K. Vander Eeckt, S. Joniau (Leuven, Belgium)<br />
390 Anterior urethral spatulation in posterior urethroplasty: Dorsal or ventral incision?<br />
J. Hosseini, A. Kaviani, M. Jabbari, M.M. Mazloomfard (Tehran, Iran)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
127
Sunday, 18 April - <strong>EAU</strong> Programme<br />
128 Programme Book<br />
Abstract Session<br />
12.15 - 13.45 Surgery for female stress incontinence<br />
Padua Room<br />
Poster Session 25<br />
Chairs: D. Castro-Diaz, Santa Cruz de Tenerife (ES)<br />
J.P.F.A. Heesakkers, Nijmegen (NL)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
391 Randomized clinical trial comparing TVT-O, TVT-Secur and Mini-Arc. Outcome at 12 months followup<br />
R. Santos Oliveira, F. Botelho, P. Silva, C.M.P.M. Silva, P. Dinis, F.J.M.R. Cruz (Porto, Portugal)<br />
392 Clinical outcome of spiral sling techniques for devastating recurrent stress urinary incontinence in females<br />
A. Rodriguez, R. Ordorica, M. Hoffman, J. Lockhart (Tampa, United States of America)<br />
393 Influence of tension-free vaginal mesh (TVM) procedure on the urinary incontinence in patients with<br />
cystocele<br />
M. Takeyama, A. Yamaguchi, C. Kato, T. Kimura (Sakai City, Osaka City, Japan)<br />
394 Clinical efficacies of tension-free vaginal mesh procedure for pelvic organ prolapse: Single center<br />
experience of 310 cases with one year follow-up<br />
S. Takahashi, D. Obinata, T. Sakuma, K. Sato, Y. Nagane, J. Mochida, T. Ichinose, K. Yamaguchi (Tokyo, Japan)<br />
395 Long-term outcome of anti-incontinence procedure during pelvic organ prolapse repair in patients with or<br />
without urinary incontinence: Results from two randomised surgical trials<br />
E. Costantini, M. Lazzeri, V. Bini, M. Del Zingaro, A. Zucchi, E. Frumenzio, L. Mearini, R. Bruno, M. Porena<br />
(Perugia, Italy)<br />
396 Female sexual function after vaginal surgery using transobturator mesh for cystocele and rectocele repair<br />
R. Hoda, S. Wagner, P. Fornara (Halle, Germany)<br />
397 Adjustable continence therapy for recurrent female stress urinary incontinence from severe intrinsic<br />
sphincter deficiency<br />
E. Kocjancic, S. Crivellaro, L. Jones, S. Ranzoni, D. Bonvini, B. Grosseti, B. Frea (Chicago, United States of<br />
America; Udine, Novara, Italy)<br />
398 Medium term results of the Adjustable Continence Therapy (ACT®) in the treatment of recurrent SUI<br />
S.E. Sutherland, S.R. Aboseif, S.D. Nash, N.H. Baum, L.M. Tu, P.J. Pommerville, J.N. Slutsky, N.T. Galloway,<br />
J.F. Bresette (Plymouth, Los Angeles, Leawood, New Orleans, Kankakee, Atlanta, Burlington, United States<br />
of America; Sherbrooke, Victoria, Canada)<br />
399 Factors affecting the results of midurethral sling for mixed urinary incontinence women<br />
J.G. Lee, M.M. Oh, H. Choi, J.Y. Park, H.A. Jang (Seoul, South Korea)<br />
400 Withdrawn<br />
401 SPARC outcome based on body mass index<br />
E. Puchwein, K. Pummer, G. Primus (Graz, Austria)
402 Laparoscopic artificial urinary sphincter implantation for female genuine stress incontinence: A 4-year<br />
experience<br />
J. Bacle, A. Papatsoris, P.E. Bryckaert, J. Piussan, E. Mandron (Angers, Le Mans, France; Athens, Greece)<br />
403 Management of refractory chronic pelvic pain after TVT or TOT suburethral sling: Medium-term functional<br />
results after tape removal<br />
J. Rigaud, F. Luyckx, J.J. Labat, T. Riant, R. Robert, O. Bouchot (Nantes, France)<br />
404 The efficacy of trans-section of synthetic sub-urethral sling tape for treatment of obstructive voiding<br />
symptoms following transobturator sling surgery after 3 years follow up<br />
J.H. Seo, G.N. Kim, E.S. Yoo, T.G. Kwon, H.C. Jung, C.H. Park, B.H. Kim, D.Y. Kim, Y.J. Seo, K.H. Kim,<br />
J.B. Kwon, K.S. Shim (Gumi, Daegu, Gyeongju, Andong, South Korea)<br />
405 Bladder neck closure/urethral occlusion in intractable stress incontinence<br />
T. Nielsen, H.J.K. Kirkeby (Aarhus, Denmark)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
129
Sunday, 18 April - <strong>EAU</strong> Programme<br />
130 Programme Book<br />
Abstract Session<br />
14.00 - 15.30 Endourology<br />
eURO Auditorium<br />
Video Session 4<br />
Chairs: P.A. Geavlete, Bucharest (RO)<br />
O. Traxer, Paris (FR)<br />
All presentations have a maximum length of 10 minutes, followed by 4 minutes of discussion.<br />
V22 Supine percutaneous nephrolithotomy<br />
A. Hoznek, S. Esquivel, K. De Laet, A. De La Taille, L. Salomon, C.C. Abbou (Creteil, France; Antwerp,<br />
Belgium)<br />
V23 Staghorn calculi: Single percutaneous traject (experience on 263 cases)<br />
P.A. Geavlete, V.A. Mirciulescu, V. Cauni, D.A. Georgescu, D.R. Multescu (Bucharest, Romania)<br />
V24 Combined endoscopic and laparoscopic treatment of bilateral staghorn urolithiasis in a horseshoe kidney<br />
C.M. Scoffone, C.M. Cracco, M. Poggio, M. Cossu, F. Porpiglia, S. Grande, A. Di Stasio, R.M. Scarpa<br />
(Orbassano, Italy)<br />
V25 Ureteroscopic “cut to the light”: A new technique<br />
P.A. Geavlete, V.A. Mirciulescu, D.R. Multescu, D.A. Georgescu, B.F. Geavlete (Bucharest, Romania)<br />
V26 TURis plasma vaporization of the prostate: Experience on 200 cases<br />
P.A. Geavlete, B.F. Geavlete, M. Jecu, D.A. Georgescu, D.R. Multescu, M.D. Dragutescu (Bucharest, Romania)<br />
V27 Dr. Son’s arterial bleeding control technique during photoselective vaporization of the prostate (PVP) of<br />
120W GreenlightTM High Power System<br />
J.H. Park, C.J. Lee, J.B. Bae, S.B. Lee, H. Jeong, H.C. Son (Seoul, South Korea)
Sunday, 18 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
14.00 - 15.30 Techniques and outcome of urinary diversion<br />
Amsterdam Room<br />
Oral Session 6<br />
Chairs: J.M.O. N’Dow, Aberdeen (GB)<br />
J.W. Thüroff, Mainz (DE)<br />
All presentations are 7 minutes in length, followed by 2 minutes of discussion.<br />
Introduction<br />
J.W. Thüroff, Mainz (DE)<br />
406 Quality of Life (QoL) following cystectomy and urinary diversion depends on pre-op counselling and<br />
expectation of patients: Prospective study using SEIQoL-DW, VAS, SWLS and EORTC SAT32<br />
B.K. Somani, D. Gimlin, P. Fayers, J. N’dow (Aberdeen, United Kingdom)<br />
407 Long-term outcome of renal function in bladder cancer patients after radical cystectomy<br />
O. Takahiro, S. Maruyama, T. Abe, S. Maru, T. Aoyagi, A. Sazawa, N. Shinohara, K. Nonomura (Sapporo,<br />
Japan)<br />
408 Continent cutaneous urinary reservoir using the serous lined extramural valve: Functional outcome<br />
A.M. Elshal, H. Abolenein, M. Kamal, A.O. Mosbah, M. Abdellatif, M.A. Ghoneim (Mansoura, Egypt)<br />
409 Y-Neobladder: An Italian multi-institutional retrospective study<br />
P. Destefanis, A. Bosio, M. Carchedi, C. Negro, G. Fasolis, M. Bellina, M. Mari, B. Frea, C. Terrone, G. Morgia,<br />
G. Carrieri, M. Maffezzini, D. Fontana (Turin, Alba, Rivoli, Udine, Novara, Messina, Foggia, Genova, Italy)<br />
410 Ileal-conduit vs colonic-conduit – a matched-pair analysis<br />
R. Stein, A. Schröder, T. Hagen, J.W. Thüroff (Mainz, Germany)<br />
411 Quality of life after a Mitrofanoff continent urinary diversion<br />
M. Hadj Slimen, H. Ketata, K. Chabchoub, M. Fourati, S. Fakhfakh, N. Rebai, H. Fakhfakh, A. Bahloul,<br />
M.N. Mhiri (Sfax, Tunisia)<br />
412 Ileal ureteric replacement with implantation into the native urinary bladder: Long-term results<br />
A. Kocot, A. Loeser, M. Spahn, H. Riedmiller (Würzburg, Germany)<br />
413 High urinary diversions (transverse colon pouch- transverse colon conduit) in irradiated patients: The<br />
encouraging results suggesting extension of their indications<br />
K.A.M. Sayedahmed, S. Ahyai, R. Dahlem, M. Fisch (Hamburg, Germany)<br />
Summary<br />
J.M.O. N’Dow, Aberdeen (GB)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
131
Sunday, 18 April - <strong>EAU</strong> Programme<br />
132 Programme Book<br />
Abstract Session<br />
14.00 - 15.30 Renal tumours: Diagnosis and imaging 2<br />
<strong>Barcelona</strong> Room<br />
Oral Session 7<br />
Chairs: A. Cestari, Milan (IT)<br />
G. Mickisch, Bremen (DE)<br />
All presentations are 7 minutes in length, followed by 2 minutes of discussion.<br />
Introduction<br />
G. Mickisch, Bremen (DE)<br />
414 Sporadic renal cell carcinoma in adults 40 years old or less: Renal translocation carcinoma rate,<br />
characteristics and survival<br />
T. Ghoneim, X. Leroy, L. Lemaitre, J. Biserte, A. Villers, L. Zini (Lille, France)<br />
415 Comparison of renal cell carcinomas in end stage renal disease and general population patients<br />
Y. Neuzillet, J.A. Long, P. Paparel, L. Salomon, L. Bastien, J. Petit, S. Saint, X. Tillou, N. Rioux-Leclercq,<br />
R. Mathieu, F. Bruyere, J.M. Boutin, N. Brichart, J. Rigaud, G. Karam, J. Branchereau, J.M. Ferriere,<br />
H. Wallerand, S. Barbet, H. Elkentaoui, J. Hubert, B. Feuillu, P.E. Theveniaud, A. Villers, L. Zini,<br />
A. Descazeaux, M. Roupret, B. Barrou, K. Fehri, T. Lebret, J. Tostain, J.E. Terrier, L. Badet, L. Poissonnier,<br />
N. Terrier, F. Kleinclauss, L. Martin, C. Pfister, F. Dugardin, I. Galliot, F. Staerman, M.D. Azemar, J. Irani,<br />
B. Tisserand, A. Mejean, M.O. Timsit, M. Soulie, F. Sallusto, P. Rischmann, L. Guy, A. Valeri, C. Deruelle,<br />
M. Gigante, A.R. Azzouzi, D. Chautard, P. Bigot, B. Escudier, J.M. Correas, H. Lang, H. Baumert, J.J. Patard<br />
(Suresnes, Grenoble, Lyon, Creteil, Amiens, Rennes, Tours, Nantes, Bordeaux, Nancy, Lille, Limoges, Paris,<br />
Saint-Etienne, Besançon, Rouen, Reims, Poitiers, Toulouse, Clermont-Ferrand, Brest, Nice, Angers, Villejuif,<br />
Strasbourg, France)<br />
416 Obesity is associated with better pathologic features and improved outcome among patients treated<br />
surgically for renal cell carcinoma<br />
S. Waalkes, A.S. Merseburger, M.W. Kramer, T.R.W. Herrmann, G. Wegener, A. Hegele, R. Hofmann,<br />
M.A. Kuczyk, A.J. Schrader (Hanover, Marburg, Germany)<br />
417 Predicting occult multifocality of renal cell carcinoma<br />
M. Tsivian, D.M. Moreira, J.R. Caso, V. Mouraviev, F. Madden, G. Bratslavsky, D.M. Albala, T.J. Polascik<br />
(Durham, Bethesda, United States of America)<br />
418 New prognostic stratification system in locally advanced renal cell carcinoma patients who are candidates<br />
for adjuvant treatment<br />
J.C. Bernhard, A. Ravaud, A.J. Pantuck, M. Crepel, G. Verhoest, K. Bensalah, L. Cindolo, A. De La Taille,<br />
J.M. Ferriere, L. Salomon, J. Tostain, V. Ficara, G. Novara, L. Zini, A. Villers, A.S. Belldegrun, J.J. Patard<br />
(Bordeaux, Rennes, Creteil, Saint-Etienne, Lille, France; Los Angeles, United States of America; Vasto,<br />
Padua, Italy)<br />
419 Comparison of contrast-enhanced ultrasound (CE-US) and computed tomography (CT) in the evaluation of<br />
complex cystic renal masses<br />
D. Garcia-Rojo, E. Ballesteros, A. Malet, A. Prera, C. Abad, E. Vicente, R. Martos, J.L. Gonzalez-Sala,<br />
J. Martín, M. Barrio, J. Muñoz, J. Puig, N. Hannaoui, A. Darnell, J. Prats (Sabadell, Spain)<br />
420 The value of the Bosniak classification for pathology outcome in laparoscopic partial nefrectomy<br />
V.C. Franken, H.M. Dekker, P.F.A. Mulders, J.F. Langenhuijsen (Nijmegen, The Netherlands)
421 ImmunoPET imaging of renal cell carcinoma with 124I- and 89Zr-labeled anti-CAIX monoclonal antibody<br />
cG250<br />
A. Stillebroer, G.M. Franssen, O.C. Boerman, E. Oosterwijk, P. Laverman, W.J.G. Oyen, P.F.A. Mulders<br />
(Nijmegen, The Netherlands)<br />
Summary<br />
A. Cestari, Milan (IT)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
133
Sunday, 18 April - <strong>EAU</strong> Programme<br />
14.00 - 15.30 Infertility<br />
134 Programme Book<br />
Abstract Session<br />
Paris Room<br />
Poster Session 26<br />
Chairs: E.J.H. Meuleman, Amsterdam (NL)<br />
S. Micic, Belgrade (RS)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
422 Delayed fatherhood in European Caucasian infertile couples with male factor infertility: A significant shift<br />
throughout a 7-year time frame<br />
A. Salonia, L. Rocchini, A. Saccà, A. Gallina, F. Castiglione, M. Ferrari, A. Cestari, M. Roscigno, N. Suardi,<br />
G. Guazzoni, P. Rigatti, F. Montorsi (Milan, Italy)<br />
423 Associations between semen quality, body mass index and metabolic syndrome parameters in young male<br />
K. Ausmees, M. Zarkovski, G. Timberg, P. Korrovits, M. Punab (Tartu, Tallinn, Estonia)<br />
424 The accessibility of human sperm chromatin for H4K12ac-binding is not limited by DNA methylation<br />
A. Paradowska, D. Miller, M. Bartkuhn, S. Schumacher, W. Weidner, K. Steger (Giessen, Germany; Leeds,<br />
United Kingdom)<br />
425 Diagnostic value of testicular fine-needle aspiration in non obstructive azoospermia: The role of hormonal<br />
profile and testis size<br />
H. Ahmadi, L. Montaser-Kouhsari, M.R. Nowroozi (Tehran, Iran)<br />
426 Evaluation of diagnostic testis biopsy in infertility patients<br />
A.F. Hussein (El-Minia, Egypt)<br />
427 Accurate diagnosis of sertoli cell only syndrome<br />
L. Vaucher, A. Mielnik, P.N. Schlegel, D.A. Paduch (Lausanne, Switzerland; New York, United States of<br />
America)<br />
428 The age of 35 years is the critical age for successful testicular sperm extraction with intracytoplasmic<br />
sperm injection (TESE-ICSI) in nonobstructive azoospermic patients with normal karyotype and nonmosaic<br />
Klinefelter’s syndrome<br />
H. Okada, Y. Kobori, K. Terai, R. Sato, Y. Ashizawa, H. Yagi, S. So, G. Arai, O. Maruyama (Koshigaya, Tokyo,<br />
Japan)<br />
429 Predictive factors of the success of MESA in patients with primary obstructive azoospermia<br />
I. Sinescu, S. Voinea, I. Manea, B. Haineala, C. Gagiu, A. Preda, C. Pavel, M. Harza, M. Matei, G. Dohle<br />
(Bucharest, Romania; Rotterdam, The Netherlands)<br />
430 Does the aetiology of azoospermia affect the outcome of ICSI<br />
J.S. Kalsi, M.Y. Thum, H. Abdullah, J. Pryor, A. Muneer, S. Minhas (London, United Kingdom)<br />
431 In the era of microdissection TESE – are there any histopathological/ biochemical factors predictive for<br />
successful sperm retrieval in men with Sertoli cell only?<br />
J.S. Kalsi, E. Zacharakis, A. Muneer, S. Minhas (London, United Kingdom)<br />
432 The sperm retrieval rate in patients with nonobstructive azoospermia associated with cryptorchidism<br />
K. Inci, M. Hascicek, O. Kara, H. Kiziloz, T. Gurgan, A. Ergen (Ankara, Turkey)
433 Withdrawn<br />
434 Changes in testicular arterial hemodynamics and semen quality in adolescents with left sided varicocele<br />
randomized to surgery OR observation and followed up for 18 months<br />
A.A. Afoko, M.I. Kogan, D.V. Siziakin, V.V. Sizonov, J.B. Tampuori, A.A. Asante-Asamani (Rostov on Don,<br />
Russia)<br />
435 Aberrant expression of androgen receptor in the internal spermatic veins of the patients with varicocele<br />
Y.Q. Zheng, Z.J. Li, G. Luo, W. Li, H.X. Huang, Y.J. Shi, F.J. Li, X.M. Li, X. Gao (Zhongshan City, Guangzhou<br />
City, China)<br />
436 Testicular contrast harmonic imaging: A new diagnostic tool for the evaluation of intratesticular perfusion<br />
alterations in patients with varicocele<br />
C. Foresta, P.F. Palego, M. Schipilliti, M. Torino, M.A. Pati, N. Caretta (Padua, Italy)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
135
Sunday, 18 April - <strong>EAU</strong> Programme<br />
136 Programme Book<br />
Abstract Session<br />
14.00 - 15.30 Renal tumours: Innovation in surgical treatment<br />
Stockholm Room<br />
Poster Session 27<br />
Chairs: V. Ficarra, Padua (IT)<br />
Z. Kirkali, Izmir (TR)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
437 External validation of the preoperative anatomical classification (PADUA) for prediction of complications<br />
related to nephron-sparing surgery<br />
M. Remzi, M. Waldert, T. Klatte, P. Weibl, G. Schüller, H.C. Klingler, M. Marberger (Vienna, Austria)<br />
438 Predictors of early or late recurrence after partial or radical nephrectomies for renal cell carcinoma<br />
K.T. Chong, A. Adamy, S.F. Shariat, D.S. Yee, W.T. Lowrance, D. Chade, M. Kaag, P. Russo (Singapore,<br />
Singapore; New York, United States of America)<br />
439 Tumour size is not an independent predictor of recurrence-free survival in small renal cell carcinoma<br />
M.C. Park, J.W. Kim, I.G. Jeong, D. You, C. Song, J.H. Hong, H. Ahn, C.S. Kim (Seoul, South Korea)<br />
440 Recurrence after nephron-sparing surgery for monolateral conventional renal cell carcinoma: Evaluation<br />
about risk factors in 168 patients with long-term follow-up<br />
A. Antonelli, N. Arrighi, T. Zanotelli, L. Perucchini, A. Cozzoli, D. Zani, S. Cosciani Cunico, C. Simeone<br />
(Brescia, Italy)<br />
441 Surgical treatment of bilateral synchronous kidney tumors: Long-term functional and oncological outcomes<br />
M.N. Simmons, R. Brandina, A. Hernandez, I.S. Gill (Cleveland, Los Angeles, United States of America)<br />
442 Long term survival rates after resection for locally advanced kidney cancer<br />
M. O’Brien, L. Jang, M. Cronin, C. Von Bodman, T. Lowrance, B. Bernstein, E. Karellas, P. Russo (New York,<br />
United States of America)<br />
443 Local recurrence after simple tumor enucleation for renal cell carcinoma: Results of a prospective single<br />
center study<br />
A. Minervini, M.R. Raspollini, C. Di Cristofano, A. Lapini, A. Tuccio, V. Vittori, S. Serni, M. Carini, G. Siena<br />
(Florence, Latina, Italy)<br />
444 Photodynamic detection of the renal cell carcinoma during the kidney-preserving tumor resection<br />
O.I. Apolikhin, I.V. Chernishev, A.V. Sivkov, Y.V. Samsonov, D.V. Altunin, R.A. Kuznetsov (Moscow, Russia)<br />
445 Impact of nephron sparing surgery compared to radical nephrectomy on renal function and survival: A<br />
matched comparison analysis<br />
S.A. Pahernik, J. Pfitzenmaier, J. Huber, A. Haferkamp, M. Hohenfellner (Heidelberg, Germany)<br />
446 Radical nephrectomy is associated with decreased overall survival compared with partial nephrectomy<br />
S. Waalkes, A.S. Merseburger, M.W. Kramer, G. Wegener, M.A. Kuczyk, T.R.W. Herrmann (Hanover,<br />
Germany)<br />
447 Renal functional degradation in patients with renal masses less than 4 cm treated with ablative and<br />
extirpative techniques<br />
Y. Iwamoto, N. Soga, K. Arima, Y. Sugimura (Tsu City, Japan)
448 Long term experience with laparoscopic partial nephrectomy following superselective transarterial<br />
embolization<br />
G. Simone, R. Papalia, S. Guaglianone, G. Pizzi, L. Carpanese, E. Forastiere, M. Gallucci (Rome, Italy)<br />
449 Different survival of histologic subtype in patients with renal renal cell carcinoma<br />
M. Roscigno, D. Angiolilli, E. Strada, G. Petralia, F. Sozzi, L. Da Pozzo, N. Suardi, F. Abdollah, A. Salonia,<br />
M. Freschi, F. Montorsi, P. Rigatti, R. Bertini (Milan, Italy)<br />
450 Complete metastasectomy is an independent predictor of cancer-specific survival in patients with clinically<br />
metastatic renal cell carcinoma<br />
G. Petralia, M. Roscigno, R. Zigeuner, E. Strada, F. Sozzi, L. Da Pozzo, G. Guazzoni, A. Cestari, A. Salonia,<br />
V. Scattoni, F. Montorsi, P. Rigatti, R. Bertini (Milan, Italy; Graz, Austria)<br />
451 Kidney cancer with a thrombus of the retro-hepatic or extra-diaphragmatic inferior vena cava: Results of<br />
surgical treatment<br />
L. Bellec, E. Grunenwald, M. Khedis, C. Cron, M. Thoulouzan, P. Rischmann, M. Soulié, B. Marcheix<br />
(Toulouse, France)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
137
Sunday, 18 April - <strong>EAU</strong> Programme<br />
138 Programme Book<br />
Abstract Session<br />
14.00 - 15.30 Kidney transplantation: From lab to clinic<br />
Milan Room<br />
Poster Session 28<br />
Chairs: A.J. Figueiredo, Coimbra (PT)<br />
K. Junker, Jena (DE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
452 Sulforaphane prolongs survival after experimental kidney transplantation<br />
A. Cekauskas, M. Manikas, H. Bruns, E. Mohr, A. Nickkholgh, I. Herr, M.L. Gross, M. Zorn, F. Jankevicius,<br />
K. Strupas, M.W. Büchler, P. Schemmer (Vilnius, Lithuania; Heidelberg, Germany)<br />
453 Is dose-dependent the renal protective effect of intravenous sildenafil against warm ischemia:<br />
Experimental study<br />
D. Subira-Rios, E. Lledo-Garcia, D. Rodriguez, E. Dulin, A. Tejedor-Jorge, C. Hernandez-Fernandez, J.F. Del<br />
Cañizo-Lopez (Madrid, Spain)<br />
454 Nonpeptide inhibitor of cathepsin G attenuates neutrophil-mediated kidney injury following renal ischemia<br />
and reperfusion<br />
N.S. Naohiko, M.M. Midori, K.H. Kiyohiko, K.N. Katsuya (Sapporo, Japan)<br />
455 Pulsatile perfusion machine effect on preservation and evaluation of NHBD Maastricht class II kidneys<br />
L. Peri, V. De La Fuente, D. Paredes Zapata, A. Ruiz, B. Miranda Serrano, A. Alcaraz Asensio (<strong>Barcelona</strong>,<br />
Spain)<br />
456 Prognostic value of intraoperative renal tissue oxygenation measurement on early renal transplant function<br />
O.W. Hakenberg, C. Protzel, K. Martin, G. Noeldge-Schomburg, M. Maruschke, T.W.L. Scheeren (Rostock,<br />
Germany)<br />
457 Differential effects of immunosuppressive drugs on regulatory T-cell function<br />
M.W.W. Janssen, J. Mohrbach, F. Becker, S. Siemer, M. Stöckle, D. Fliser, M.L. Sester, U. Sester (Homburg/<br />
Saar, Germany)<br />
458 Serum Human Leukocyte Antigen-G expression after kidney transplantation: An initial prospective study<br />
H. Ismail, M. Elsawy (Alexandria, Egypt)<br />
459 Withdrawn<br />
460 Microbial biofilm formation on ureteral stents in renal transplant recipients: Frequency and influence on<br />
short time functional outcome<br />
G. Bonkat, I. Gröschl, M. Rieken, C.A. Rentsch, S. Wyler, T.C. Gasser, A.F. Widmer, A. Bachmann (Basel,<br />
Switzerland)<br />
461 BK viremia and viruria in recipients receiving alemtuzumab for induction therapy in renal transplantation<br />
S.V. Kirillov, M.M. Kaabak, A.K. Zokoev, N.N. Babenko, A.A. Abovyan (Moscow, Russia)<br />
462 Bladder augmentation with SIS (Small Intestine Submucosa, Stratasis®) in patients’ candidate for kidney<br />
transplant. Our experience<br />
F. Liberale, F. Lasaponara, O. Sedigh, A. Bosio, G. Pasquale, A. Ranghino, G.P. Segoloni, D. Fontana (Turin,<br />
Italy)
463 Renal cell carcinomas arising in native kidneys of dialyzed and transplant patients: Are they different<br />
entities?<br />
Y. Neuzillet, L. Badet, M. Gigante, L. Salomon, L. Bastien, J. Petit, F. Saint, X. Tillou, N. Rioux-Leclercq,<br />
R. Mathieu, F. Bruyere, J.M. Boutin, N. Brichart, J. Rigaud, G. Karam, J. Branchereau, J.M. Ferriere,<br />
H. Wallerand, S. Barbet, H. Elkentaoui, J. Hubert, B. Feuillu, P.E. Theveniaud, A. Villers, L. Zini,<br />
A. Descazeaux, M. Roupret, B. Barrou, K. Fehri, T. Lebret, J. Tostain, J.E. Terrier, P. Paparel, L. Poissonnier,<br />
J.A. Long, N. Terrier, F. Kleinclauss, L. Martin, C. Pfister, F. Dugardin, I. Galliot, F. Staerman, M.D. Azemar,<br />
J. Irani, B. Tisserand, A. Mejean, M.O. Timsit, M. Soulie, F. Sallusto, P. Rischmann, L. Guy, A. Valeri,<br />
C. Deruelle, A.R. Azzouzi, D. Chautard, P. Bigot, B. Escudier, J.M. Correas, H. Lang, H. Baumert, J.J. Patard<br />
(Suresnes, Lyon, Nice, Créteil, Amiens, Rennes, Tours, Nantes, Bordeaux, Nancy, Lille, Limoges, Paris, Saint-<br />
Etienne, Grenoble, Besançon, Rouen, Reims, Poitiers, Toulouse, Clermont-Ferrand, Brest, Angers, Villejuif,<br />
Strasbourg, France)<br />
464 Renal cell carcinoma in native kidneys in a renal transplant population<br />
M.M. Musquera, M.L. Leveridge, M.R. Robinette, M.J. Jewett, Y.P. Pei, C.C. Cardella, A.F. Finelli (<strong>Barcelona</strong>,<br />
Spain; Toronto, Canada)<br />
465 Management of localized prostate cancer by retropubic radical prostatectomy in patients after renal<br />
transplantation<br />
R. Hoda, A. Hamza, O. Reichelt, P. Fornara (Halle, Germany)<br />
466 Withdrawn<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
139
Sunday, 18 April - <strong>EAU</strong> Programme<br />
140 Programme Book<br />
Abstract Session<br />
14.00 - 15.30 Basic research and epidemiology of urinary stones<br />
Vienna Room<br />
Poster Session 29<br />
Chairs: S. Oehlschläger, Dresden (DE)<br />
H-G. Tiselius, Stockholm (SE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
467 Calcium lithiasis and bone mineral density loss. Relationship betacrosslaps marker with both pathologies<br />
M.A. Arrabal-Polo, M. Arrabal-Martin, A. Jimenez-Pacheco, C. Lahoz-Garcia, J.L. Mijan-Ortiz, F. Palao-Yago,<br />
A.Z. Zuluaga-Gomez (Granada, Spain)<br />
468 Randall’s plaque as metastatic calcification in renal papillary interstitium, evidence from an experimental<br />
animal model<br />
S.R. Khan (Gainesville, United States of America)<br />
469 Diagnostic approach to hereditary renal hypouricemia<br />
I. Sebesta, B. Stiburkova (Prague, Czech Republic)<br />
470 Hypercalciuria in idiopathic calcium nephrolithiasis: An acid-base metabolic disorder?<br />
P.J.S. Osther (Fredericia, Denmark)<br />
471 Withdrawn<br />
472 Expression of the gene encoding oxalate decarboxylase from Bacillus subtilis and purification of the<br />
recombinant enzyme<br />
E. Lee, Y.H. Park, B.C. Jeong, S.B. Lee, J.H. Ku, H. Jeong, C. Kwak, H.H. Kim (Seoul, South Korea)<br />
473 Comparison of plasma, cellular and urinary oxalate in primary calcium oxalate monohydrate stone formers<br />
vs. recurrent calcium oxalate monohydrate stone formers<br />
S. Oehlschläger, S. Füssel, J. Herrmann, U. Lotzkat, S. Albrecht, M.P. Wirth (Dresden, Germany)<br />
474 Erythrocyte oxidant stress in patients with urolithiasis correlates with stone size and renal tubular damage<br />
H.S. Huang, M.C. Ma, H.J. Yu (Taipei, Hsinchuang, Taiwan)<br />
475 Evaluation and clinical application of the Urolizer®-device for determination of the BONN-Risk-Index of<br />
calcium oxalate stone formation<br />
R. Bechler, W. Berg, H. Wunderlich, N. Laube (Jena, Bonn, Germany)<br />
476 Nutritional, environmental and family history determinants of recurrent nephrolithiasis versus primary<br />
nephrolithiasis<br />
A. Rentschler, S. Oehlschläger, M.P. Wirth (Dresden, Germany)<br />
477 Relationship between nephrolithiasis and components of metabolic syndrome in Korean adults<br />
Y.S. Cho, K.J. Joo, H.J. Park, C.H. Kwon (Seoul, South Korea)<br />
478 Cystinuria in Europe: First results of a newly established multicentre database<br />
T. Knoll, J.J. De La Rosette, D. Jocham, P. Laguna, F. Liedberg, W. Mannson, J.R. Rassweiler, I. Riedler,<br />
F. Rocco, S. Siemer, G. Wendt-Nordahl, R. Zigeuner, P. Alken (Sindelfingen, Lübeck, Heilbronn, Homburg,<br />
Mannheim, Germany; Amsterdam, The Netherlands; Växjö, Lund, Sweden; Graz, Austria; Milan, Italy)
479 Where are we in upper urinary system stone disease interventions? 2008 estimations for Turkey<br />
N.D.G. Guner, T.A. Alp, A. Aydın, M.D. Mehmet, S.A. Aydın (Istanbul, Ankara, Turkey)<br />
480 Urolithiasis through the ages: Data from more than 200,000 urinary stone analyses<br />
T. Knoll, B. Schubert, D.B. Leusmann, D. Fahlenkamp, G. Schubert (Sindelfingen, Berlin, Cologne, Chemnitz,<br />
Germany)<br />
481 Visceral fat as a predictive factor for urinary stone formation<br />
C.H. Park, H.S. Chang, S.J. Jung, B.H. Kim, C.I. Kim, D.S. Ryu, J.H. Seo, D.Y. Kim, H.C. Jung (Daegu, Seoul,<br />
Gumi, South Korea)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
141
Sunday, 18 April - <strong>EAU</strong> Programme<br />
142 Programme Book<br />
Abstract Session<br />
14.00 - 15.30 Urinary tract infection<br />
Athens Room<br />
Poster Session 30<br />
Chairs: T.E. Bjerklund Johansen, Aarhus (DK)<br />
F.M.E. Wagenlehner, Giessen (DE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
482 Infectivity of the bladder mucosa in women with recurrent lower urinary tract infection<br />
M.I. Kogan, Y.L. Naboka, H.S. Ibishev, A.A. Afoko, I.A. Gudima (Rostov on Don, Russia)<br />
483 Withdrawn<br />
484 Contribution of mutation in parE to quinolone resistance in extended-spectrum-lactamase-producing<br />
escherichia coli isolates<br />
A. Jimenez-Pacheco, M. Arrabal-Polo, C. Lahoz-Garcia, A. Lopez-Luque, J. Martinez-Torres, M. Nogueras<br />
Ocaña, F. Palao Yago, A. Zuluaga Gomez (Granada, Spain)<br />
485 Assessment of the microbial spectrum of the urine of healthy young women<br />
Y.L. Naboka, M.I. Kogan, I.A. Gudima, H.S. Ibishev, L.I. Vasilyeva, A.A. Afoko (Rostov on Don, Russia)<br />
486 Prevalence of nosocomial urinary tract infections: What has changed in years<br />
Z. Tandogdu, M. Cek, P. Tenke, K. Naber, T.E. Bjerklund Johansen. (Istanbul, Turkey; Budapest, Hungary;<br />
Straubing, Germany; Aarhus, Denmark)<br />
487 The association between inpatients antibiotic consumption and development of antibiotic resistance - a 14<br />
years surveillance in a urological university department<br />
M. Gans, F.M.E. Wagenlehner, B. Altinkilic, R. Füssle, T. Chakraborty, D. Wieczorek, W. Weidner (Giessen,<br />
Germany)<br />
488 MRSA screening: Sense or defense?<br />
P. Kumar, S. Omorphos, H. Forrest, D. Gnanarajah, S.T. Williams (Derby, United Kingdom)<br />
489 Descriptive analysis of a series of urinary tuberculosis with emphasis on diagnostic and therapeutic data<br />
A. García-Tello, J. Cacho, J. González, J. Palou, M. Sánchez-Chapado, H. Villavicencio, J.C. Angulo (Madrid,<br />
<strong>Barcelona</strong>, Alcalá de Henares, Spain)<br />
490 Acute epididymitis: Etiology and inflammatory parameters in a prospective study<br />
A. Pilatz, F.M.E. Wagenlehner, N. Brauckmann, H. Hossain, W. Weidner (Giessen, Delmenhorst, Germany)<br />
491 Azithromycin vs. clarithromycin and both combination in treatment of mycoplasma genitalium<br />
K. Drasa, E. Koci (Tirana, Albania)<br />
492 Male urethritis caused by Neisseria gonorrhoeae: Resistance patterns have changed in a metropolitan<br />
sanitary area of Madrid<br />
A. García-Tello, J. Cacho, A. García-Cañas, A. González-Torralba, G. Torres, E. Mateo, F. Cáceres, J.C. Angulo<br />
(Madrid, Spain)
493 Descriptive analysis of a series of male genital tuberculosis with emphasis on diagnostic and therapeutic<br />
data<br />
A. García-Tello, J. Cacho, E. Hernández, J. Palou, M. Sánchez-Chapado, H. Villavicencio, J.C. Angulo (Madrid,<br />
<strong>Barcelona</strong>, Alcalá de Henares, Spain)<br />
494 An intra-urethral mini-catheter (IUC) for prevention of indwelling catheter-induced morbidity and<br />
mortality in aging male<br />
L. Lobik, I. Nissenkorn (Rehovot, Tel-Aviv, Israel)<br />
495 Withdrawn<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
143
Sunday, 18 April - <strong>EAU</strong> Programme<br />
144 Programme Book<br />
Abstract Session<br />
14.00 - 15.30 Epidemiology and evaluation of BPH<br />
Istanbul Room<br />
Poster Session 31<br />
Chairs: T. Esen, Istanbul (TR)<br />
A. Paez Borda, Fuenlabrada (ES)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
496 The relation between nocturnal polyuria and nocturia, a community based study in older men: The<br />
Krimpen study<br />
B. Van Doorn, M.H. Blanker, E.T. Kok, J.L.H.R. Bosch (Utrecht, Groningen, The Netherlands)<br />
497 Ultrasound assessment of intravesical prostatic protusion and detrusor wall thickness: New standards for<br />
the non-invasive diagnosis of bladder outlet obstruction?<br />
L.C. Leonardo, D.C. De Nunzio, T.A. Tubaro, C.A. Cantiani, D.C. De Dominicis, T.N. Tartaglia, F.G. Franco<br />
(Rome, Italy)<br />
498 Evaluation of prostatic symptoms in patients with obstructive sleep apnea syndrome (OSAS)<br />
B.S. Bercea, R.M. Bercea, T. Mihaescu (Iasi, Romania)<br />
499 The prevalence of a decreased nocturnal bladder capacity in older men in the community with nocturia:<br />
the Krimpen study<br />
B. Van Doorn, E.T. Kok, M.H. Blanker, J.L.H.R. Bosch (Utrecht, Groningen, The Netherlands)<br />
500 The accuracy of captiflow portable home flow measuring device and its use as a diagnostic tool in the<br />
management of LUTS: A randomised cross over study<br />
J.P.F.A. Heesakkers, K. Katie, T. Borkowski, A. Pantuck, M. Lucas, P. Piotr (Nijmegen, The Netherlands;<br />
Swansea, United Kingdom; Warsaw, Poland; Los Angeles, United States of America)<br />
501 Are lower urinary tract symptoms a risk factor for future cardiovascular events<br />
C. Wehrberger, A. Ponholzer, C. Temml, I. Berger, M. Rauchenwald, S. Madersbacher (Vienna, Austria)<br />
502 Nocturnal functional bladder capacity versus diurnal functional bladder capacity, is there a difference? A<br />
community-based study in older men: The Krimpen study<br />
B. Van Doorn, E.T. Kok, M.H. Blanker, J.L.H.R. Bosch (Utrecht, Groningen, The Netherlands)<br />
503 Outcomes of lower urinary tract symptoms in men with and without prostatic enlargement<br />
S.J. Jacobsen, D.J. Jacobson, M.E. McGree, A.V. Sarma, C.J. Girman, M.M. Lieber, J.L. St. Sauver (Pasadena,<br />
Rochester, Ann Arbor, North Wales, United States of America)<br />
504 Quantification of the three ring model of T. Hald in 455 BPH patients<br />
H. Tezval, A. Rettkowski, T. Herrmann, M.A. Kuczyk, M. Oelke (Hanover, Germany)<br />
505 Correlation between PSA, prostate volume, IPSS and BMI in BPH patients<br />
P.H. Song, J.S. Park , J.H. Bae, J.M. Kim, H.C. Jung, T.C. Park, J.H. Seo, K.H. Moon, H.T. Kim (Daegu, South<br />
Korea)<br />
506 Do patients think they are coerced into treatment decisions? A perceived coercion study<br />
A. Patel, D. Dryhurst, M. Ahmed (Orpington, United Kingdom)
507 New classification of patients with benign prostatic hyperplasia based on international prostate symptom<br />
score<br />
K. Aikawa, K. Shishido, K. Ishibashi, T. Yanagida, M. Nomiya, N. Kushida, O. Yamaguchi, T. Yoshiyasu,<br />
T. Kobayashi (Fukushima, Tokyo, Japan)<br />
508 Residual urine as a predictive factor in the prognosis of BPH-related clinical event<br />
Y.H. Ko, J.G. Lee, S.H. Kang, H.S. Park, D.G. Moon, J. Cheon, J.J. Kim, D.K. Yoon (Seoul, South Korea)<br />
509 Association between symptom of urinary hesitancy and the time of urinary hesitancy measured by<br />
uroflowmetry in men with lower urinary tract symptoms<br />
K.K. Park, Y.G. Chung, S.H. Lee, S.U. Park, S.Y. Mah (Seoul, South Korea)<br />
510 Analysis of metabolic factors which affect prostate growth and voiding function in elderly men<br />
Y.H. Lee, K.S. Han, H.J. Jung, H.S. Yu, K.H. Choi, S.W. Kwon, S.J. Hong (Seoul, South Korea)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
145
Sunday, 18 April - <strong>EAU</strong> Programme<br />
146 Programme Book<br />
Abstract Session<br />
14.00 - 15.30 Neuromodulation and the urinary tract<br />
Padua Room<br />
Poster Session 32<br />
Chairs: E. Chartier-Kastler, Paris (FR)<br />
M. Spinelli, Milan (IT)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
511 An experimental spinal cord injury model to show the objective effects of chronic sacral neuromodulation<br />
S. Kumsar, U. Keskin, S. Kosdak, S.R. Erdem, L. Peskircioglu, H. Özkardes (Ankara, Turkey)<br />
512 Sacral neuromodulation for neurogenic lower urinary tract dysfunction: A valuable treatment option?<br />
T.M. Kessler, D. La Framboise, S. Elneil, C.J. Fowler, G. Kiss, J. Pannek, B. Schurch, K.D. Sievert, D.S. Engeler<br />
(Berne, St. Prex, Nottwil, Zurich, St. Gallen, Switzerland; London, United Kingdom; Innsbruck, Austria;<br />
Tübingen, Germany)<br />
513 Sacral root stimulation for treatment of urinary retention: A novel intracanalar approach using self sizing<br />
nerve cuff electrodes. Technique description and preliminary results<br />
M.P. Bertapelle, M. Vottero, L. Squintone, R. Carone, T. Camps, S. Salazzari, G. Giardiello (Turin, Sesto San<br />
Giovanni, Italy; Maastricht, The Netherlands)<br />
514 Treatment of neurogenic overactive bladder (NOAB) in incomplete lesions by low frequency chronic<br />
pudendal nerve stimulation (CPNS): Long term follow-up<br />
M. Spinelli, L. Zanollo, M. Citeri, S. Malaguti, J. Tarantola (Milan, Italy)<br />
515 Electrode dislocation under chronic sacral neuromodulation<br />
B. Amend, J. Bedke, S. Kruck, G. Gakis, A. Stenzl, K.D. Sievert (Tübingen, Germany)<br />
516 Efficiency of transcutaneous posterior tibial nerve stimulation for treatment of overactive bladder<br />
syndrome in multiple sclerosis. Results of a multicenter prospective study<br />
M. De Seze, P. Raibaut, P. Gallien, P. Denys, A. Even Schneider, B. Parratte, V. Bonniaud, G. Amarenco, M. De<br />
Seze (Bordeaux, Paris, Rennes, Garches, Besançon, France)<br />
517 Sacral neuromodulation for the treatment of neurogenic lower urinary tract symptoms in patients with<br />
multiple sclerosis<br />
D.S. Engeler, D. Meyer, H.P. Schmid (St. Gallen, Switzerland)<br />
518 Cortical substrate of bladder control in SCI and the effect of peripheral dorsal genital nerve stimulation<br />
M.Z. Zempleni, L.M. Michels, U. Mehnert, B.S. Schurch, S.K. Kollias (Zurich, Switzerland)<br />
519 Functional brain imaging (fMRI) and natural bladder filling in healthy volunteers<br />
W.C. Tsang, J. Kong, A. Yadav, J.P. O’Donaghue, B. Andrews, J.G. Noble, C.F. Beckmann, J.R. Reynard,<br />
I. Tracey (Oxford, United Kingdom)<br />
520 Psychophysiological brain interactions in voluntary control of urinary bladder sensations<br />
M.F. Hamann, C. Van Der Horst, S. Wolff, O. Jansen, K.P. Jünemann, J.P. Kuhtz-Buschbeck (Kiel, Germany)<br />
521 Which is the most accurate biomarker to assess renal functions in neurogenic patients?<br />
N. Mingat, J. Allard, E. Villard, J. Guillotreau, P. Paparel, J.B. Roche, F. Sallusto, B. Malavaud, I. Tack,<br />
P. Rischmann, A. Ruffion, X. Gamé (Toulouse, Lyon, France)
522 The UroLume Wallstent in the treatment of detrusor external sphincter dyssynergia in male spinal cord<br />
injury patients: A 20 year follow-up<br />
A. Abdul-Rahman, S. Ismail, R. Hamid, P.J.R. Shah (London, United Kingdom)<br />
523 Does modern urological management help to preserve renal function in patients with spina bifida?<br />
R. Hsu, S.A. Boddy, F. Lee (London, United Kingdom)<br />
524 Bladder symptoms in Parkinson’s disease: A study with the overactive bladder questionnaire in a large<br />
cohort of patients<br />
G. Palleschi, A.L. Pastore, L. Silvestri, D. Autieri, A. Ripoli, D. Stefaina, F. Gilio, C. Marini Bettolo,<br />
M. Inghilleri, A. Carbone (Terracina, Rome, Italy)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
147
Sunday, 18 April - <strong>EAU</strong> Programme<br />
148 Programme Book<br />
Abstract Session<br />
15.45 - 17.15 Open oncological surgery<br />
eURO Auditorium<br />
Video Session 5<br />
Chairs: P. Albers, Düsseldorf (DE)<br />
H. Kynaston, Cardiff (GB)<br />
All presentations have a maximum length of 10 minutes, followed by 4 minutes of discussion.<br />
V28 Surgical management of renal cell cancer with tumour thrombus using liver transplantation techniques<br />
J. Gonzalez, J.C. Angulo, G. Ciancio (Madrid, Spain; Miami, United States of America)<br />
V29 Elective vacuum assisted cardiopulmonary bypass in the surgical treatment of renal neoplasms extending<br />
into the right atrium<br />
F. Nigro, P. Ferrarese, E. Scremin, G. Benedetto, P. Magagna, C. Piccin, A. Fabbri, A. Tasca (Vicenza, Italy)<br />
V30 The intrafascial nerve sparing radical perineal prostatectomy<br />
J. Beier, H. Keller (Hof, Germany)<br />
V31 Ileal neobladder with substitution of the urethral mucosa and sphincter preservation in female multifocal<br />
bladder cancer<br />
J. Palou, J. Caffaratti, J.M. Santillana, J.M. Gaya, H. Villavicencio (<strong>Barcelona</strong>, Spain)<br />
V32 Nerve sparing cystectomy in a male patient<br />
U.E. Studer, F.C. Burkhard, G.N. Thalmann (Berne, Switzerland)<br />
V33 Pelvic lymph node dissection in a female patient with bladder cancer<br />
U.E. Studer, B. Roth, F.C. Burkhard (Berne, Switzerland)
Sunday, 18 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
15.45 - 17.15 Penile surgery<br />
Amsterdam Room<br />
Oral Session 8<br />
Chairs: A. Kadioglu, Istanbul (TR)<br />
D. Ralph, London (GB)<br />
All presentations are 7 minutes in length, followed by 2 minutes of discussion.<br />
Introduction<br />
A. Kadioglu, Istanbul (TR)<br />
525 Autologous tissue engineering with biodegradable scaffolds is a new treatment option for real penile girth<br />
enhancement: A clinical and histomorphometric study<br />
S. Sansalone, S.V. Perovic, R. Djinovic, A. Ferlosio, G. Vespasiani, A. Orlandi (Rome, Italy; Belgrade, Serbia)<br />
526 Extracorporeal shock wave therapy as first line treatment for patients with Peyronie’s disease<br />
D. Arcaniolo, C. Imbimbo, A. Palmieri, N. Longo, F. Fusco, P. Verze, F. Mangiapia, M. Creta, V. Mirone<br />
(Naples, Italy)<br />
527 Egydio’s procedure for the surgical treatment of Peyronie’s disease<br />
S. Sansalone, S. Perovic, S. Pecoraro, A. Zucchi, M. Silvani, R. Djinovic, B. Giammusso, G. Vespasiani (Rome,<br />
Avellino, Perugia, Biella, Catania, Italy; Belgrade, Serbia)<br />
528 Surgical reconstruction of severe Peyronie’s disease for maximum penile length and girth restoration<br />
P.H. Egydio, S.V. Perovic, S. Sansalone (São Paulo, Brazil; Belgrade, Serbia; Rome, Italy)<br />
529 Management of Peyronie’s disease using porcine small intestinal submucosal (SIS) grafts: Long-term<br />
results<br />
J. Pierrevelcin, J. Menard, T. Ripert, F. Staerman (Reims, France)<br />
530 Penile prosthesis insertion in Peyronie’s disease<br />
G. Garaffa, A.M.M. Abdel Raheem, E. Zacharakis, A. Muneer, A.N. Christopher, D.J. Ralph (London, United<br />
Kingdom)<br />
531 Re-implantation of penile prosthesis: The role of artificial grafting materials<br />
S. Perovic, R.P. Djnovic, S. Tomovic, M.Z. Milosavljevic, V. Pesic, N. Stanojevic (Belgrade, Serbia)<br />
532 Simultaneous placement of the advance male sling and an inflatable penile prosthesis<br />
B.S. Christine, A.J. Bella, S.K. Wilson (Birmingham, Indio, United States of America; Ottawa, Canada)<br />
Summary<br />
D. Ralph, London (GB)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
149
Sunday, 18 April - <strong>EAU</strong> Programme<br />
150 Programme Book<br />
Abstract Session<br />
15.45 - 17.15 Renal tumours: Total and partial nephrectomy<br />
<strong>Barcelona</strong> Room<br />
Poster Session 33<br />
Chairs: J. Rassweiler, Heilbronn (DE)<br />
M.E. Sullivan, Oxford (GB)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
533 Periarterial papaverine improves postoperative renal function after retroperitoneoscopic partial<br />
nephrectomy<br />
M. Marszalek, C. Pitzler, H. Meixl, D. Unger, M. Rauchenwald, S. Madersbacher, K. Jeschke (Klagenfurt,<br />
Vienna, Austria)<br />
534 Assessment of renal damage following warm ischemia time during LPN: Results of a prospective study<br />
F. Porpiglia, C. Fiori, P. Angusti, R. Bertolo, S. Grande, A. Di Stasio, V. Podio, R.M. Scarpa (Orbassano, Italy)<br />
535 Laparoscopic radical nephrectomy for renal cell carcinoma > 7cm: A multicenter study on 158 patients<br />
L.G. Luciani, V. Vattovani, O. Maugeri, A. Piccinelli, G. Giusti, A. Celia, G. Breda, M.R. Scarpa, F. Porpiglia,<br />
P. Parma, G. Malossini (Trento, Milan, Bassano del Grappa, Orbassano, Mantova, Italy)<br />
536 “No clamp no suture” laparoscopic partial nephrectomy<br />
G. Simone, R. Papalia, S. Guaglianone, M. Ferriero, E. Forastiere, M. Gallucci (Rome, Italy)<br />
537 Robot-assisted laparoscopic partial nephrectomy: Results of first 50 cases with analysis of learning curve<br />
G. De Naeyer, M. Sangalli, P. Schatteman, P. Carpentier, E. Fonteyne, A. Mottrie (Aalst, Belgium; Milan, Italy)<br />
538 Two techniques of parenchymal reconstruction during laparoscopic partial nephrectomy: Results after 100<br />
procedures<br />
C. Fiori, F. Porpiglia, R. Bertolo, S. Grande, A. Di Stasio, R.M. Scarpa (Orbassano, Italy)<br />
539 Laparoscopic vs open partial nephrectomy: 5 years oncologic and functional outcomes of a prospective<br />
study in 250 patients<br />
F. Greco, S. Wagner, M.R. Hoda, F. Kawan, A. Inferrera, P. Fornara (Halle Saale, Germany)<br />
540 A new parenchymal clamp (kidney clamp®) for laparoscopic partial nephrectomy: Initial evaluation<br />
E. Huyghe, J. Nohra, A. Salloum, M. Thoulouzan, L. Bellec, G. Ghazal, M. Khedis, M. Soulie, P. Plante<br />
(Toulouse, France; Beirut, Lebanon)<br />
541 Endoscopic partial nephrectomy: Matched pair comparative analysis of transperitoneal and retroperitoneal<br />
approach<br />
M. Marszalek, T. Chromecki, B. Mohamad Al Ali, H. Meixl, S. Madersbacher, K. Jeschke, K. Pummer,<br />
R. Zigeuner (Klagenfurt, Graz, Vienna, Austria)<br />
542 Safety and efficacy of robot-assisted laparoscopic partial nephrectomy during the learning curve in a high<br />
volume urological centre<br />
M.N. Sangalli, E. Scapaticci, F. Montorsi, N.M. Buffi, A. Cestari, F. Fabbri, G. Lughezzani, G. Gadda,<br />
M. Lazzeri, P. Rigatti, G. Guazzoni (Milan, Italy)<br />
543 Renal damage caused by warm ischemia during laparoscopic and robotic assisted partial nephrectomy: An<br />
assessment using 99mTc-DTPA GFR<br />
J.D. Choi, B.K. So, H.S. Kim, W.S. Kim, B.C. Jeong, H.M. Lee, H.Y. Choi, S.S. Jeon, S.I. Seo (Seoul, South Korea)
544 Alpha melanocyte stimulating hormone analog ap214 protects against ischemia-induced acute kidney<br />
injury in a porcine surgical model<br />
M.N. Simmons, V.S. Subramanian, S. Crouzet, G.P. Haber, J.R. Colombo, O. Ukimura, S. Neilsen, I.S. Gill<br />
(Cleveland, Los Angeles, United States of America; Sao Paolo, Brazil; Kyoto, Japan; Aarhus, Denmark)<br />
545 Cold ischemia in open and laparoscopic partial nephrectomy: Ex-vivo and in-vivo preliminary experiments<br />
with a new material - Freka Gelice<br />
G.M. Schöppler, E. Klippstein, J. Hell, C. Weiss, A. Häcker, L. Trojan, P. Alken, M.S. Michel (Mannheim,<br />
Germany)<br />
546 Laparoscopic partial nephrectomy (LPN) for tumors >4cm<br />
M. Tsivian, A. Tsivian, S. Benjamin, A.A. Sidi (Holon, Israel)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
151
Sunday, 18 April - <strong>EAU</strong> Programme<br />
152 Programme Book<br />
Abstract Session<br />
15.45 - 17.15 Penis cancer<br />
Paris Room<br />
Poster Session 34<br />
Chairs: O.W. Hakenberg, Rostock (DE)<br />
N. Watkin, London (GB)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
547 Allelic losses in tumour suppressor genes are frequently found in penile squamous cell carcinomas<br />
C. Protzel, M. Hemmerich, C. Kakies, O.W. Hakenberg, M. Poetsch (Rostock, Essen, Germany)<br />
548 Identification of deregulated pathways in penile cancer using gene set enrichment analysis (GSEA) – a pilot<br />
study<br />
A. Buchner, E. Hungerhuber, D. Tilki, C. Gratzke, C.G. Stief, B. Schlenker (Munich, Germany)<br />
549 First establishment of paired primary tumour and lymph node metastasis cell lines for repetitive in-vivo<br />
and in-vitro investigations in penile squamous cell carcinoma<br />
C.M. Naumann, H. Kalthoff, I. Leuschner, D. Emme, L. Weder, A. Al Najar, M.F. Hamann, K.P. Jünemann,<br />
C. Van Der Horst, J. Sperveslage (Kiel, Germany)<br />
550 Identification of serum protein patterns in patients with penile carcinoma<br />
W. Dieker, I. Romics, A. Szendroi, R. Pilchowski, M. Walter, H. Wunderlich, K. Junker (Jena, Germany;<br />
Budapest, Hungary)<br />
551 Human papillomavirus prevalence and correlation to histopathological status in penile carcinoma<br />
P. Kirrander, A. Kolaric, G. Helenius, T. Windahl, O. Andrén, F. Elgh, M.G. Karlsson (Örebro, Umeå, Sweden)<br />
552 Significance of positive surgical margins in organ-sparing surgery for invasive squamous carcinoma of the<br />
penis<br />
W. Lam, D. Magrill, B.E. Ayres, M.J.A. Perry, C.M. Corbishley, N. Watkin (London, United Kingdom)<br />
553 Detection of inguinal lymph node involvement in penile squamous cell carcinoma by<br />
18F-fluorodeoxyglucose PET/CT<br />
B. Schlenker, C. Gratzke, O. Reich, D. Tilki, P. Schneede, R. Tiling, P. Bartenstein, S. Siegert, C.G. Stief,<br />
M. Seitz (Munich, Memmingen, Germany)<br />
554 A prospective study to evaluate the performance of ultrasound with or without fine needle aspiration of<br />
inguinal nodes in patients with squamous cell carcinoma of the penis<br />
S. Ivaz, W. Lam, T. Swallow, C.M. Corbishley, M.J.A. Perry, J. Pilcher, N.A. Watkin (London, United Kingdom)<br />
555 Dynamic sentinel node biopsy after previous penile tumour resection<br />
N.M. Graafland, W. Meinhardt, R.A. Valdés Olmos, A. Bex, H.G. Van Der Poel, H.H. Van Boven, S. Horenblas<br />
(Amsterdam, The Netherlands)<br />
556 Does size of sentinel lymph node metastasis in squamous cell carcinoma of the penis predict risk of further<br />
nodal disease?<br />
B.E. Ayres, W. Lam, S. Heenan, J. Pilcher, C.M. Corbishley, M. Perry, N. Watkin (London, United Kingdom)<br />
557 Predictive measures for complications of inguinal lymphadenectomy for penile cancer<br />
A.G. Brett, D. Magrill, N. Watkin, M. Perry (London, United Kingdom)
558 Inguinofemoral lymphadenectomy: Evolution of a modified endoscopic approach to minimise morbidity<br />
C.D. Colleselli, D.S. Schilling, U.N. Nagele, K.D.S. Sievert, A.S. Stenzl, C.S. Schwentner (Tübingen, Germany;<br />
Hall in Tirol, Austria)<br />
559 Prognostic significance of extranodal extension in pathological node-positive patients with penile<br />
squamous cell carcinoma<br />
N.M. Graafland, H.H. Van Boven, E. Van Werkhoven, L.M.F. Moonen, S. Horenblas (Amsterdam, The<br />
Netherlands)<br />
560 Adjuvant nodal radiotherapy in squamous cell carcinoma of the penis<br />
K. Kancherla, B. Sethugavalar, I. Eardley, P. Whelan, K. Franks, A.E. Kiltie (Leeds, United Kingdom)<br />
561 A combination of cisplatin and 5-fluorouracil plus a taxane for advanced squamous-cell carcinoma (SCC) of<br />
the penis. A single institution series<br />
N. Nicolai, A. Necchi, L. Piva, T. Torelli, M. Catanzaro, D. Biasoni, S. Stagni, A. Milani, R. Salvioni (Milan,<br />
Italy)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
153
Sunday, 18 April - <strong>EAU</strong> Programme<br />
154 Programme Book<br />
Abstract Session<br />
15.45 - 17.15 Renal tumours: Basic research<br />
Stockholm Room<br />
Poster Session 35<br />
Chairs: M. Remzi, Vienna (AT)<br />
H. Wunderlich, Jena (DE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
562 Additive effects for the association of temsirolimus with either sunitinib or sorafenib<br />
J. Edeline, P. Bigot, B. Martin, F. Jouan, S. Zerrouki, C. Vigneau, S. Mottier, J.J. Patard, N. Rioux-Leclercq<br />
(Rennes, France)<br />
563 Sorafenib reduces uptake of 111 -Indium labeled bevacizumab in clear cell renal cell carcinoma<br />
A. Stillebroer, I.M. Desar, E. Oosterwijk, W.J.G. Oyen, O.C. Boerman, P.F.A. Mulders (Nijmegen, The<br />
Netherlands)<br />
564 Neoadjuvant sorafenib decreases T-regulatory cells intratumorally in renal cell carcinoma (RCC) patients<br />
A. Stillebroer, J.F.M. Jacobs, I.M.E. Desar, P.F.A. Mulders, W.T.A. Van Der Graaf, I.J.M. De Vries, C.M.L. Van<br />
Herpen (Nijmegen, The Netherlands)<br />
565 Prevalence and prognostic significance of alpha-methyl CoA racemase (AMACR) expression in 1000 renal<br />
tumours<br />
C. Eichelberg, T. Schlomm, H. Isbarn, S. Minner, H. Moch, L. Terracciano, A. Kell, R. Heuer, F.K. Chun,<br />
M. Rink, H. Heinzer, M. Fisch, R. Simon, G. Sauter (Hamburg, Germany; Zurich, Switzerland)<br />
566 Serum pro-matrix metalloproteinase-7 (pro-mmp-7) as a predictive marker for early progression after<br />
nephrectomy in renal cell carcinoma<br />
P. Bigot, P. Fergelot, N. Rioux-Leclercq, G. Sarkissian, K. Bensalah, P.J. Lamy, S. Culine, R. Thuret, P. Jouin,<br />
B. Darbouret, J-J. Patard (Angers, Rennes, Nimes, Montpellier, France)<br />
567 Analysis of SFRP1 RNA expression in renal cell cancer and oncocytoma and association with<br />
clinicopathological parameters<br />
F. Atschekzei, J. Hennenlotter, S. Jänisch, S. Waalkes, H. Tezval, A.S. Merseburger, M.A. Kuczyk, J. Serth<br />
(Hanover, Tübingen, Germany)<br />
568 Global histone H3 lysine 27 (H3K27) methylation levels and there prognostic relevance in renal cell<br />
carcinoma<br />
S. Rogenhofer, J. Ellinger, P. Kahl, C. Mertens, S. Hauser, W. Hartmann, R. Büttner, S.C. Müller, A. Von<br />
Ruecker (Bonn, Germany)<br />
569 Down-regulation of PARK2 and PACRG in clear cell renal cell carcinoma is associated with tumour<br />
aggressiveness<br />
D. Wuttig, M.I. Toma, S. Kaiser, S. Füssel , T. Weber, M.O. Grimm, G. Baretton, M.P. Wirth (Dresden,<br />
Germany)<br />
570 Enhancer of zeste homolog 2 (EZH2) is a powerful independent prognostic factor in renal cell carcinoma<br />
and contributes to cell proliferation and apoptosis resistance in renal cancer cells<br />
N. Wagener, S. Macher-Goeppinger, D. Holland, I. Crnkovic-Mertens, K. Hoppe-Seyler, M. Pritsch,<br />
A. Haferkamp, P. Schirmacher, F. Hoppe-Seyler, M. Hohenfellner (Heidelberg, Germany)
571 Expression of pyruvate dehydrogenase kinase-1 (PDK-1) and DJ-1/PARK7 in renal cell carcinoma (RCC) and<br />
its association with pathology and outcome<br />
D. Baumunk, U. Reichelt, J. Ebbing, F. Jentzmik, K. Miller, M. Schostak, S. Weikert (Berlin, Germany)<br />
572 Decreased expression of hypoxia-inducible factor 1A and p27kip1 in patients with renal cell cancer<br />
M.W.K. Kramer, S. Waalkes, S. Füssel, C. Hammerschmied, A. Hartmann, F. Becker, H. Taubert, J. Bedke,<br />
B. Gunawan, B. Kreiner, K. Junker, B. Walter, H. Wunderlich, J. Serth, M.A. Kuczyk, A.S. Merseburger<br />
(Hanover, Dresden, Erlangen, Homburg, Halle, Tübingen, Göttingen, Jena, Germany)<br />
573 The developmental LIM-class homeobox gene Lim1 is critical for human renal cell carcinoma growth<br />
V. Dormoy, C. Béraud, V. Lindner, L. Thomas, C. Coquard, J.J. Helwig, D. Jacqmin, H. Lang, T. Massfelder<br />
(Strasbourg, Mulhouse, France)<br />
574 Loss of von Hippel-Lindau tumour suppressor protein in renal cell carcinoma cells enhances susceptibility<br />
to encephalomyocarditis virus via HIF2α-and NFκB-dependent mechanism<br />
F.C. Roos, I.I.L. Huang, A.M. Roberts, I.R. Watson, L. Carneiro, S. Girardin, J.C. Bell, W. Brenner, J.W. Thüroff,<br />
M. Ohh (Mainz, Germany; Toronto, Ottawa, Canada)<br />
575 An assessment of tissue hypoxia in human renal tumours in patients undergoing nephrectomy using<br />
“gold-standard” direct oxygen probe measurements and immunohistochemistry<br />
N. Lawrentschuk, C. Murone, A.M.T. Poon, L. Johns-Putra, I.D. Davis, D.M. Bolton, A.M. Scott (Toronto,<br />
Melbourne, Australia)<br />
576 Towards photodynamic therapy as novel minimally invasive treatment of renal cell carcinoma<br />
S.G.C. Kroeze, J.L.H.R. Bosch, J.J.M. Jans (Utrecht, The Netherlands)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
155
Sunday, 18 April - <strong>EAU</strong> Programme<br />
156 Programme Book<br />
Abstract Session<br />
15.45 - 17.15 Evaluating indolent prostate cancer 2<br />
Milan Room<br />
Poster Session 36<br />
Chairs: M. Emberton, London (GB)<br />
B. Tombal, Brussels (BE)<br />
Pilot session: Poster viewing and individual questioning for 45 minutes, during which presenters will have<br />
1 minute to give an introduction of the poster, followed by a 2 minute discussion lead by the chair.<br />
Four posters will be selected for further discussion; 3 minutes presentation followed by 4 minutes of<br />
discussion.<br />
577 Can unilateral prostate cancer be predicted? Implications for focal therapies<br />
A. Gallina, F. Abdollah, A. Briganti, N. Suardi, U. Capitanio, M. Freschi, G. Guazzoni, A. Cestari,<br />
G. Lughezzani, P. Karakiewicz, P. Rigatti, F. Montorsi (Milan, Italy; Montreal, Canada)<br />
578 Histopathologic and functional outcomes for active surveillance candidates who opt for prostatectomy<br />
J.S. Brajtbord, H.J. Lavery, F. Nabizada-Pace, S. Senaratne, D.B. Samadi (New York, United States of<br />
America)<br />
579 Concordance between biopsy and prostatectomy specimens regarding Gleason sum<br />
M.I. Volkova, V.D. Ermilova, V.B. Matveev, A.A. Mitin (Moscow, Russia)<br />
580 Is screen-detected prostate cancer in high risk families eligible for active surveillance?<br />
A. Valeri, G. Papin, M.P. Moineau, A.R. Azzouzi, L. Cormier, F. Baschet, I. Cussenot, J. L’Her, L. Doucet,<br />
V. Joulin, C. Deruelle, P. Mangin, O. Cussenot, G. Fournier (Brest, Angers, Dijon, Paris, France)<br />
581 Independent risk factors for Gleason score downgrading in patients with extended prostate biopsy<br />
M. Waldert, T. Klatte, M. Remzi, M. Marberger (Vienna, Austria)<br />
582 Characteristics of single core positive compared to multiple core positive prostate cancer on radical<br />
prostatectomy following 12-core transrectal biopsy<br />
Y.H. Ko, J.J. Kim, S.H. Kang, H.S. Park, D.G. Moon, J.G. Lee, D.K. Yoon, J. Cheon (Seoul, South Korea)<br />
583 Updating the nomogram to predict indolent prostate cancer towards more extended contemporary biopsy<br />
schemes<br />
M.J. Roobol, E.W. Steyerberg, N.B. Delongchamps, F.H. Schröder, G.P. Haas (Rotterdam, The Netherlands;<br />
Cyracuse, United States of America)<br />
584 Performance of diffusion-weighted MR imaging (DWI) in the localisation and characterisation of peripheral<br />
zone prostate carcinoma, a whole mount radical prostatectomy specimen correlated series<br />
D.M. Somford, T. Hambrock, C.A. Hulsbergen-Van De Kaa, J.J. Fütterer, I.M. Van Oort, J.P. Van Basten,<br />
H.F. Karthaus, J.A. Witjes, J.O. Barentsz (Nijmegen, The Netherlands)<br />
585 Prospective comparison of T2w-MRI and dynamic-contrast-enhanced MRI, 3D-MR spectroscopic imaging<br />
or diffusion-weighted MRI in repeat TRUS-guided biopsies<br />
D. Portalez, G. Rollin, P. Leandri, B. Elman, P. Mouly, F. Jonca, B. Malavaud (Toulouse, France)<br />
586 Prospective randomised multicenter trial comparing prostate cancer detection rates of end fire and side<br />
fire transrectal ultrasound probe configuration: Interim results<br />
T. Klatte, C. Seitz, M. Waldert, C. Wiunig, A. Reissigl, A. Pycha, M. Marberger, M. Remzi (Vienna, Bregenz,<br />
Austria; Bolzano, Italy)
587 Anterior prostate biopsies reveal a sanctuary site of prostate cancer in patients with previous negative<br />
extended prostate biopsies<br />
N. Kanaroglou, B. Shayegan, E. Matsumoto, M. Greenspan, M.A. Fischer, J. Zikman, J.H. Pinthus (Hamilton<br />
Ontario, Canada)<br />
588 Withdrawn<br />
589 Real time-elastography (RTE) vs. multiple core biopsies in the detection of prostate cancer: A prospective<br />
randomised study<br />
O. Lenherr, A. Fayyazi, P. Liske, S. Lahme (Pforzheim, Germany)<br />
590 Development of preoperative nomogram for predicting pelvic lymph node invasion in patients undergoing<br />
radical prostatectomy<br />
Y.D. Choi, J.S. Chung, H.S. Yu, K.H. Choi, K.S. Han, K.H. Kim, Y.S. Lee, W.J. Jeong, W.S. Ham, H.J. Ju, J.S. Lee<br />
(Seoul, South Korea)<br />
591 Extended biopsy-based criteria for predicting clinically insignificant prostate cancer<br />
Y. Komai, S. Kawakami, N. Numao, Y. Fujii, K. Saito, F. Koga, S. Yamamoto, J. Yonese, I. Fukui, K. Kihara<br />
(Tokyo, Japan)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
157
Sunday, 18 April - <strong>EAU</strong> Programme<br />
158 Programme Book<br />
Abstract Session<br />
15.45 - 17.15 Ureterorenoscopic stone treatment<br />
Vienna Room<br />
Poster Session 37<br />
Chairs: B. Dore, Poitiers (FR)<br />
A. Patel, London (GB)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
592 Efficacy, safety and direct cost of two minimally invasive techniques for the treatment of proximal ureteral<br />
lithiasis: A prospective and comparative study<br />
S. Luján Marco, C. Di Capua, P. Bahílo, A. Budía, E. Broseta, F. Boronat, J.F. Jiménez-Cruz (Valencia, Spain)<br />
593 Clinical applicability of endoluminal administration of isoproterenol during upper urinary tract endoscopy<br />
H.U. Jung, B. Nørby, P.C. Frimodt-Møller, P.J. Osther (Fredericia, Denmark)<br />
594 Retrograde intrarenal surgery (RIRS) in the treatment of renal stones between 2 and 4 cm<br />
G. Giusti, O. Maugeri, A. Piccinelli, A. Benetti, S. Zandegiacomo, R. Peschechera, G. Taverna, M. Seveso,<br />
P. Graziotti (Rozzano, Milan, Italy)<br />
595 The new generation Invisio® DUR-D “chip on the tip” ureteroscopes: Evaluation of changes in physical<br />
properties over time<br />
T. El-Husseiny, K. Moraitis, H. Wazait, M. Birch, J. Masood, N.P. Buchholz (London, United Kingdom)<br />
596 Digital vs. fiberoptic: A critical comparison of two different generation flexible ureteroscopes<br />
D.R. Multescu, B.F. Geavlete, D.A. Georgescu, P.A. Geavlete (Bucharest, Romania)<br />
597 A semi-disposable flexible ureterorenoscope system: The PolyScope®<br />
M.J. Bader, S. Walther, Y. Hocaoglu, B. Schlenker, C. Gratzke, C.G. Stief, O. Reich (Munich, Germany)<br />
598 Defining the factors influencing the decision on post-ureteroscopic stenting: A multivariate analysis<br />
G. Keren-Paz, N.J. Mabjeesh, A. Greenstein, J. Ben-Chaim, H. Matzkin, M. Sofer (Tel-Aviv, Israel)<br />
599 Ureteroscopy in pregnant women with clinically acute ureteral obstruction<br />
O. Ulvik, J.G. Høstmark, A.M. Bakke, P. Gjengstø, T.K. Torkelsen, N.M. Ulvik (Bergen, Norway)<br />
600 Cost analysis of flexible ureterorenoscopy after 630 interventions<br />
P. Liske, P. Ober, Y. Aguilar, V. Zimmermanns, S. Lahme (Pforzheim, Germany)<br />
601 Efficiency and morbidity of flexible uretero-nephroscopy in obese patients<br />
G. Delorme, Y. Nguyen Huu, G. Guillaume, E. Chabannes, S. Bernardini, P.Y. Loock, H. Bittard, K. Kleinclauss<br />
(Besançon, France)<br />
602 Requirement of ureteric introducer access sheaths for obtaining ureteric access: A retrospective<br />
comparative study between old generation fibre-optic flexible ureteroscope and the new “chip on the tip”<br />
digital flexible ureteroscope<br />
T. El-Husseiny, Z. Maan, K. Moraitis, J. Masood, N.P. Buchholz (London, United Kingdom)<br />
603 Comparison between the results of shock wave lithotripsy (SWL) and ureteroscopy (URS) according to<br />
location of ureter calculus : Multicenter study<br />
K.T. Lim, J.S. Park, S.Y. Park, H.Y. Choi, H.S. Moon, T.W. Jeong, S.W. Lee, T.K. Yoo (Seoul, Goyang, South<br />
Korea)
604 Water cooling in ureteral stone fragmentation is mandatory to avoid thermal tissue injury by the<br />
holmium:YAG laser<br />
J. Bedke, B. Amend, S. Kruck, K.D. Sievert, A. Stenzl (Tübingen, Germany)<br />
605 Endoluminal pressure in the renal pelvis correlates positively to pain VAS score<br />
K.V. Pedersen, S.S. Osther, P.J.S. Osther (Fredericia, Denmark)<br />
606 Complication rate of day-surgery ureteroscopy for ureteral lithiasis<br />
A. Paez Borda, E. Redondo, J. Saenz, L. Crespo, L. Llanes, L. Fernandez, D. Rendon, J. Olarra, M. Alvarez<br />
(Fuenlabrada, Madrid, Spain)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
159
Sunday, 18 April - <strong>EAU</strong> Programme<br />
160 Programme Book<br />
Abstract Session<br />
15.45 - 17.15 Active surveillance and brachy-/radiotherapy<br />
Athens Room<br />
Poster Session 38<br />
Chairs: T.M. De Reijke, Amsterdam (NL)<br />
H-P. Schmid, St. Gallen (CH)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
607 Careful selection and close monitoring of low-risk prostate cancer patients on an active surveillance<br />
protocol minimises the need for treatment<br />
M.S. Soloway, C. Soloway, K. Acosta, A. Eldefrawy, D. Katkoori, B. Kava, M. Manoharan (Miami, United<br />
States of America)<br />
608 Outcomes of surveillance for localised prostate cancer: Population-based, nation-wide cohort study in the<br />
National Prostate Cancer Register (NPCR) of Sweden<br />
P.E. Stattin, E. Holmberg, J.E. Johansson, L. Holmberg, J. Adolfsson, J. Hugosson (Umeå, Gothenburg,<br />
Örebro, Stockholm, Sweden; London, United Kingdom)<br />
609 Age adjusted validation of the most stringent criteria for active survelliance: Implications for patient<br />
selection<br />
N. Suardi, A. Briganti, U. Capitanio, A. Gallina, A. Salonia, M. Bianchi, M. Tutolo, L. Villa, G. Guazzoni,<br />
P. Rigatti, F. Montorsi (Milan, Italy)<br />
610 Adenocarcinoma of the prostate: Is endorectal MRI at 1,5 tesla helpful to select candidates for active<br />
surveillance?<br />
F. Luyckx, P. Hallouin, P. Chauveau, C. Barré, G. Aillet, O. Bouchot, J. Rigaud (Nantes, France)<br />
611 Rule-based versus probabilistic selection for active surveillance for prostate cancer and outcomes after<br />
radical prostatectomy<br />
R.C.N. Van Den Bergh, E.W. Steyerberg, P.J. Van Leeuwen, T. Wolters, G. Aus, M.J. Roobol, C.H. Bangma,<br />
J. Hugosson, F.H. Schröder (Rotterdam, The Netherlands; Gothenburg, Sweden)<br />
612 Influence of non-genetic factors on incidence of familial prostate cancer. Nation-wide population-based<br />
study in PCBaSe Sweden<br />
P.E. Stattin, H. Garmo, J. Adolfsson, A. Bill-Axelson, L. Holmberg, M. Lambe, O. Bratt (Umeå, Uppsala,<br />
Stockholm, Helsingborg, Sweden; London, United Kingdom)<br />
613 Results from brachytherapy for patients aged 60 years and younger<br />
K.A. Hinnen, J.G.H. Van Roermund, J.J. Battermann, M. Van Vulpen (Utrecht, The Netherlands)<br />
614 Recommendations for real time brachytherapy prescriptions using ESTRO/<strong>EAU</strong>/EORTC 2007 volume<br />
definitions to reduce the chance of PSA failure<br />
N.L. Dallas, P.R. Malone, A. Jones, A.J. Doggart, J.C. Jones, P.B. Rogers (Reading, United Kingdom)<br />
615 Withdrawn<br />
616 Re-implantation after insufficient primary 125-I permanent brachytherapy of prostate cancer<br />
D.S. Engeler, P. Putora, L. Plasswilm, W.W. Seelentag, H. Schiefer, H.P. Schmid (St. Gallen, Switzerland)
617 Interstitial low-dose-rate mono-brachytherapy with I125 - relapse-free survival and dosimetric outcome<br />
for localised prostate cancer in a single European institution<br />
S. Neubauer, P. Derakhshani, C. Weise, G. Spira (Cologne, Germany)<br />
618 Prospective study on quality-of-life and toxicity of high-dose-rate brachytherapy as an interstitial boost<br />
for localised prostate cancer<br />
P. Derakhshani, S. Neubauer, C. Weise, G. Spira (Cologne, Germany)<br />
619 The risk of Gleason sum upgrading represents an important consideration in patients eligible for low dose<br />
brachytherapy<br />
L. Budäus, P.I. Karakiewicz, G. Salomon, H. Isbarn, G. Lughezanni, M. Sun, K.H. Chun, T. Schlomm,<br />
T. Steuber, A. Haese, G. Sauter, M. Fisch, H. Heinzer, H. Huland, M. Graefen (Hamburg, Germany; Montreal,<br />
Canada)<br />
620 Pathological Gleason score dictates survival in patients with seminal vesicle invasion treated with radical<br />
prostatectomy and adjuvant radiation therapy. Results from a two-institution series analysis<br />
A. Briganti, J. Karnes, N. Suardi, A. Gallina, U. Capitanio, C. Cozzarini, N. Di Muzio, L.F. Da Pozzo, P. Rigatti,<br />
M.L. Blute, F. Montorsi (Milan, Bergamo, Italy; Rochester, United States of America)<br />
621 PT2-3N0M0 prostate cancer with positive and negative margins: Clinical outcome and time to salvage<br />
radiotherapy<br />
M. Lodde, L. Lacombe, Y. Fradet (Bolzano, Italy; Québec, Canada)<br />
622 Radiotherapy strategy after radical prostatectomy: Salvage radiotherapy upon PSA recurrence may be<br />
preferable to adjuvant radiotherapy for high-risk patients<br />
R.G.H.M. Cremers, I.M. Van Oort, C.A. Hulsbergen-Van De Kaa, E.N.J.T. Van Lin, J.A. Witjes (Nijmegen,<br />
The Netherlands)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
161
Sunday, 18 April - <strong>EAU</strong> Programme<br />
162 Programme Book<br />
Abstract Session<br />
15.45 - 17.15 Basic research of BPH<br />
Istanbul Room<br />
Poster Session 39<br />
Chairs: C.L. Eaton, Sheffield (GB)<br />
G. Kramer, Vienna (AT)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
623 Evaluating the significance of arginase enzymes in the control of the human prostate: In vitro studies<br />
G.T. Kedia, S. Ückert, F. Scheller, V. Steffenhagen, J.E. Sonnenberg, M.A. Kuczyk (Hanover, Germany)<br />
624 Initial cellular adaptation of bladder to the hypoxia in bladder outlet obstruction<br />
Y.S. Song, H.J. Lee, J.I. Koh, W.J. Yang, S.U. Kim (Seoul, South Korea)<br />
625 Comparison of CD49f, CD44 and CD133 as markers of stem-like cells from the benign human prostate<br />
H. Yamamoto, J.R. Masters, P. Dasgupta, R. Popert, A. Chandra, A. Freeman, H. Patel, A. Ahmed (London,<br />
United Kingdom)<br />
626 New quantification method for estradiol in the prostatic tissues of benign prostatic hyperplasia using<br />
liquid chromatography–tandem mass spectrometry<br />
S. Arai, Y. Miyashiro, Y. Shibata, B. Kashiwagi, Y. Tomaru, M. Kobayashi, S. Honma, K. Suzuki (Ota,<br />
Kawasaki, Maebashi, Kiryu, Isesaki, Japan)<br />
627 Combined effect of α-blocker and 5-α reductase inhibitor on transforming growth factor-1 and<br />
cyclooxygenase-2 in benign prostatic hyperplasia<br />
Y.G. Na, C.K. Sul, H.S. Kim, I.R. Cho, K.H. Song, J.S. Lim, J.H. Shin, Y.S. Chang, E.G. Hwang (Deajeon,<br />
Chungju, Ilsan, South Korea)<br />
628 Is there a significance of the cyclic AMP-mediated signalling in the control of the human prostate? A<br />
functional and biochemical study<br />
M. Seidler, D.J. Schönfeld, G.T. Kedia, M.A. Kuczyk, S. Ückert (Hanover, Germany)<br />
629 Expression of apoptosis-regulating genes in the rat prostate after BoNT/A injection<br />
T. Gorgal, A. Charrua, J.F.A. Silva, R. Pinto, A. Avelino, P. Dinis, F.R. Cruz (Porto, Portugal)<br />
630 Anti-inflammatory properties of permixon lipidosterolic extract of serenoa repens: In vitro and in vivo<br />
results<br />
A. Latil, F. Lantoine-Adam, L. Aguilar, T. Nguyen (Toulouse, France)<br />
631 Expression of human cathelicidin (CAMP) and upregulation of its expression by vitamin D3 in human<br />
prostate epithelial cells<br />
S.C. Myung, H.J. Kim, S.Y. Lee, J.L. Jung, H.J. Kim, M.S. Ha, B.H. Chi, T.H. Kim (Seoul, South Korea)<br />
632 Effects of Serenoa repens, lyocopene and selenium, on pro-inflammatory phenotype activation: An “in<br />
vitro” and “in vivo” comparison study<br />
G. Bonvissuto, M. Madonia, L. Minutoli, A. Bitto, F. Polito, N. Irrera, D. Altavilla, F. Squadrito, S. Cimino,<br />
A. Lazzara, T. Castelli, V. Favilla, Z. Collura, M. Russo, G. Morgia (Catania, Messina, Italy)<br />
633 Rimonabant reduces prostate enlargement and prevents histological alterations in models of benign<br />
prostatic hyperplasia (BPH) in rats<br />
R. Avallone, M. Ferazzini, F. Guagnini, E. Scanziani, T. Croci (Milan, Italy)
634 Effect of vardenafil on RHoA/Rho kinase signaling in vivo (SHR rats) and cell cultures of human bladder<br />
smooth muscle<br />
M. Gacci, G. Vittori, S. Giancane, A. Morelli, S. Filippi, P. Sandner, B. Fibbi, A.K. Chavelmane, E. Silvestrini,<br />
E. Sarchielli, L. Vignozzi, G. Vannelli, M. Carini, M. Maggi (Florence, Italy)<br />
635 Comparative effects of rosuvastatin and simvastatin on growth of normal prostatic epithelial cells at<br />
clinically relevant drug concentrations<br />
T. Murtola, H. Syvälä, P. Pennanen, M. Bläuer, T. Ylikomi, T.L.J. Tammela (Jyväskylä, Tampere, Finland)<br />
636 Nitric oxide synthase 2 gene polymorphisms are associated with benign prostatic hyperplasia in Korean<br />
population<br />
K.H. Yoo, S.H. Jeon, S.G. Chang (Seoul, South Korea)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
163
Sunday, 18 April - <strong>EAU</strong> Programme<br />
164 Programme Book<br />
Abstract Session<br />
15.45 - 17.15 Painful bladder and beyond<br />
Padua Room<br />
Poster Session 40<br />
Chairs: J. Nordling, Herlev (DK)<br />
M. Porena, Perugia (IT)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
637 Optical coherence tomography in patients with bladder pain syndrome/interstitial cystitis: Preliminary<br />
results<br />
A. Zaitcev, A.B. Matcaev, S.O. Yudovskiy, G.R. Kasyan, V.M. Gelikonov, D.Y. Pushkar (Moscow, Nizhniy<br />
Novgorod, Russia)<br />
638 Expression level of CXCL10 peptide in bladder urothelium and urine as possible biomarkers for diagnosis<br />
of ulcerative interstitial cystitis<br />
T. Imamura, Y. Igawa, T. Ogawa, T. Homma, S. Seki, O. Ishizuka, A. Satoshi, Y. Homma, O. Nishizawa<br />
(Matsumoto, Tokyo, Japan)<br />
639 Efficacy and safety of tanezumab for the treatment of interstitial cystitis<br />
R.M. Moldwin, R.J. Evans, N. Cossons, A. Darekar, D. Scholfield, I. Mills (New York, North Carolina, United<br />
States of America; Sandwich, United Kingdom)<br />
640 Tacrolimus in the treatment of bladder pain syndrome/interstitial cystitis (BPS/IC): A pilot study<br />
J. Sairanen, T.L. Tammela, M. Ruutu (Helsinki, Tampere, Finland)<br />
641 A prospective randomised study of intravesical pentosan polysulfate and botulinum toxin A for the<br />
treatment of painful bladder syndrome/interstitial cystitis<br />
M. Taha Rasheed, A. Farahat, M. Bahnasy, A. Bindary, H. Tatawy, M. Damhougy (Tanta, Egypt)<br />
642 Intra-trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial<br />
cystitis: Long term results<br />
R.M.Correia de Almaida Pinto, T.A. Lopes, A.S. Silva, J.F. Alturas Silva, C.P. Martins Da Silva, P.D. Oliveira,<br />
F.R. Cruz (Porto, Portugal)<br />
643 Botulinum toxin type A in men with chronic pelvic pain syndrome (CPPS) in combination with obstructive<br />
voiding<br />
G.G. Krivoborodov, D.V. Shumilo, A.V. Vasilev, E.I. Tur (Moscow, Russia)<br />
644 Botulinum A toxin intravesical injections for painful bladder syndrome: Impact on pain, psychological<br />
functioning and quality of life<br />
A. Giannantoni, R. Cagini, M. Piselli, S. Giovannozzi, S. Proietti, E. Nunzi, R. Quartesan (Perugia, Italy)<br />
645 One year follow up of extracorporeal shock wave therapy (ESWT) for chronic pelvic pain syndrome (CPPS)<br />
in a randomised placebo-controlled double-blind study<br />
R.P. Posch Zimmermann, A. Cumpanas, F. Miclea, G. Janetschek (Salzburg, Austria; Timisoara, Romania)<br />
646 Sacral nerve root neuromodulation for the treatment of intractable painful bladder syndrome/interstitial<br />
cystitis (PBS/IC): 14 years experience of one center<br />
J. Gajewski, A. Alzahrani (Halifax, Canada)
647 Aetiologies and results of the treatment of obturator neuralgias by a laparoscopic neurolysis<br />
J. Rigaud, F. Luyckx, J.J. Labat, T. Riant, O. Bouchot, R. Robert (Nantes, France)<br />
648 Novel murine experimental prostatitis model<br />
C.Z. Altuntas, L.N. Byrne, B. Bakhautdin, C. Sakalar, P.L. Fox, V.K. Tuohy, F. Daneshgari (United States of<br />
America)<br />
649 Immunization with self uroplakin II causes autoimmune cystitis; Novel murine experimental autoimmune<br />
cystitis model<br />
C.Z. Altuntas, L.N. Byrne, C. Sakalar, M.F. Gulen, E. Bakhautdin, J. Qin, X. Li, V.K. Tuohy, F. Daneshgari<br />
(Cleveland, United States of America)<br />
650 Method of high pressure local, intravesical medicine application by using special balloon catheter<br />
S. Lovász, P. Tenke (Budapest, Hungary)<br />
651 Axonopathic changes of visceral nerve endings in urinary bladder in interstitial cystitis: An ultra structural<br />
study<br />
L. Zamecnik, J. Zamecnik, J. Hacek, V. Soukup, T. Hanus (Prague, Czech Republic)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
165
Sunday, 18 April - <strong>EAU</strong> Programme<br />
166 Programme Book<br />
Workshop Overview<br />
12.15 - 13.45 Advancing your skills in endourology <strong>page</strong> 334<br />
Genoa Room Sponsored by BOSTON SCIENTIFIC<br />
15.45 - 17.15 Ureteral access: Situation and new perspectives <strong>page</strong> 335<br />
Genoa Room Sponsored by COLOPLAST<br />
Symposia Overview<br />
17.30 - 19.00 Proven surgical solutions for today’s incontinent patients <strong>page</strong> 336<br />
Athens Room Sponsored by AMERICAN MEDICAL SYSTEMS<br />
17.30 - 19.00 NEWS FLASH: RANK Ligand inhibitor reduces the risk of fracture in men receiving ADT <strong>page</strong> 337<br />
Istanbul Room Sponsored by AMGEN<br />
17.30 - 19.00 OAB – the test of TIME <strong>page</strong> 338<br />
Amsterdam Room Sponsored by ASTELLAS<br />
17.30 - 19.00 Physical and psychological aspects of LUTS/BPH <strong>page</strong> 339<br />
Padua Room Sponsored by BERLIN CHEMIE MENARINI<br />
17.30 - 19.00 New perspectives and challenges in androgen deprivation therapies: Can we improve the<br />
treatments further? <strong>page</strong> 340<br />
eURO Auditorium Sponsored by FERRING PHARMACEUTICALS<br />
17.30 - 19.00 Clinical experience in premature ejaculation: An expert roundtable debate <strong>page</strong> 341<br />
<strong>Barcelona</strong> Room Sponsored by JANSSEN-CILAG EMEA a division of JANSSEN PHARMACEUTICA NV<br />
17.30 - 19.00 Strategies for optimising outcomes in patients with GU malignancies <strong>page</strong> 342<br />
Paris Room Sponsored by NOVARTIS ONCOLOGY<br />
17.30 - 19.00 The evolving role of the urologist in the management of RCC <strong>page</strong> 343<br />
Milan Room Sponsored by PFIZER INC<br />
17.30 - 19.00 Inflammation: A common target for BPH and PCA therapies? <strong>page</strong> 344<br />
Birmingham Room Sponsored by PIERRE FABRE MÉDICAMENT<br />
17.30 - 19.00 Urgency: The problems and the solutions <strong>page</strong> 345<br />
Stockholm Room Sponsored by ROTTAPHARM|MADAUS<br />
For detailed information see programmes from <strong>page</strong>s 323-357
Monday, 19 April - <strong>EAU</strong> Programme<br />
Plenary Session 3<br />
07.45 - 11.00 Plenary session 3<br />
eURO Auditorium<br />
Chairs: A. Alcaraz, <strong>Barcelona</strong> (ES)<br />
F.R. Cruz, Porto (PT)<br />
07.45 - 08.15 Highlight Session 2<br />
Andrology<br />
N. Tomada, Porto (PT)<br />
Prostate disease<br />
P. Chlosta, Kielce (PL)<br />
Reconstruction<br />
J.M.O. N’Dow, Aberdeen (GB)<br />
08.15 - 08.35 Société Internationale d’Urologie (SIU) lecture Review of urethral<br />
stricture disease: Hamilton Russell to present<br />
G.H. Jordan, Norfolk (US)<br />
Aims and objectives<br />
• To review the techniques, current and historical, for reconstruction of urethral stricture disease.<br />
• To review the anatomy and techniques of tissue transfer that account for these techniques<br />
• The attendee will have been exposed to the history/progression of modern techniques for urethral<br />
reconstruction<br />
• The attendee will understand the anatomy of the urethra and perineum as it applies to urethral<br />
reconstruction<br />
• Techniques of tissue transfer will be reviewed<br />
08.35 - 08.50 State-of-the-art lecture Bladder sensation: Have we got it wrong all<br />
along?<br />
S.G.G. De Wachter, Maastricht (NL)<br />
Aims and objectives<br />
Erectile dysfunction is quite common in male kidney transplant recipients. The pathophysiology of ED in<br />
these patients can be altered due to co-morbidities, the renal transplant operation itself, medication adverse<br />
effects, relationship problems and changes in mental health. A treatment-oriented evaluation of erectile<br />
dysfunction allows the development of treatment plans that are patient-specific. Hypo-gonadal men whose<br />
testosterone parameters do not improve after renal transplantation may respond to testosterone replacement<br />
therapy. Use of recommended doses of the phosphodiesterase-5 inhibitors does not significantly modify<br />
trough concentrations of the calcineurin inhibitors ciclosporin and tacrolimus or result in impaired renal<br />
allograft function and can be used safely after kidney transplantation. Intracavernosal injections of alprostadil,<br />
with or without papaverine and phentolamine, are effective treatments for erectile dysfunction after renal<br />
transplantation and have not resulted in alterations of ciclosporin concentrations or in deterioration of<br />
renal function. Penile prostheses can be successfully implanted after pelvic organ transplantation without<br />
significant risk of infection.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
167
08.50 - 09.35 Debate Open surgery, robotics and beyond<br />
168 Programme Book<br />
Moderator: C-C. Abbou, Creteil (FR)<br />
Panel: G. Janetschek, Salzburg (AT)<br />
A. Mottrie, Aalst (BE)<br />
J. Rassweiler, Heilbronn (DE)<br />
U. Studer, Berne (CH)<br />
P. Wiklund, Stockholm (SE)<br />
Aims and objectives<br />
<strong>2010</strong> is the 10th anniversary of the first RALP. Thanks to the pioneers of the lap surgery present in this panel,<br />
this debate aims to clarify the role of open surgery, pure laparoscopy, robotics, and the future developments<br />
of MIS in the next 10 years. Which one will disappear or fail? Which one will explode? Which one will<br />
dramatically evolve? How training must be adapted to progress? Are we able to evaluate the new technologies<br />
or are we simple users of industry products? The panelists should be provocative and visionaries as they are<br />
pioneers<br />
09.35 - 09.55 American Urological Association (AUA) lecture The AUA meeting the<br />
challenges of surgical education in the 21st century<br />
E. McDougall, Orange (US)<br />
Aims and objectives<br />
To provide <strong>EAU</strong> attendees an understanding of the ongoing educational endeavors of the American<br />
Urological Association and the new developments in post-graduate continuing medical education for the<br />
AUA membership.<br />
Following this lecture <strong>EAU</strong> attendees will be able to:<br />
1. Describe the AUA Core Curriculum and the application of this standardised educational curriculum for<br />
urologists at both a residency training and post-graduate continuing medical education level.<br />
2. Outline the Hands-On Laboratory Courses provided at the AUA <strong>Annual</strong> Meeting and as stand-alone courses<br />
throughout the year.<br />
3. Explain the new Evidence Based Reviews in Urology (EBRU) program, that was introduced in October 2009,<br />
as an opportunity to learn critical appraisal skills in the context of the urologic literature.<br />
4. Describe the development of a focus on Non-Physician Providers in the educational opportunities at the<br />
AUA <strong>Annual</strong> Meeting as these professionals are increasingly becoming integral members of the urological<br />
healthcare team.<br />
09.55 - 10.10 State-of-the-art lecture Surgical education in Europe: The EBU<br />
S. Müller, Bonn (DE)<br />
Aims and objectives<br />
Standardisation of urological training in Europe!<br />
The EBU has produced a urology curriculum in the hope of providing a template against which national,<br />
individual and institutional curricula can be compared with. To ensure quality the assessment of special<br />
urological core competencies seems more suitable than just listing them in a logbook. Unlike in the past<br />
surgery will only be part of the global assessment of the urological trainee. A urologist should be able<br />
to manage urological disease by himself, choosing appropriate treatments, whether surgical, medical or<br />
technological.
10.10 - 10.50 Debate Energy ablative surgery<br />
Moderator: M. Marberger, Vienna (AT)<br />
Panel: A. Blana, Fürth (DE)<br />
M. Brausi, Modena (IT)<br />
M. Emberton, London (GB)<br />
M.P. Laguna, Amsterdam (NL)<br />
Aims and objectives<br />
Patient demand for less invasive ablative therapy, but also the increasing number of malignant tumours<br />
diagnosed in elderly and infirm patients have augmented interest in energy ablative techniques avoiding<br />
incisional surgery. RFA, cryoablation and HIFU are increasingly being utilised to treat prostate and renal<br />
cancer. In view of the completely different physical principles involved they clearly cannot be the panacea for<br />
all problems. Objective of the debate is to clarify the optimal utilisation of these techniques as well as their<br />
caveats and potential risks in clinical practice<br />
10.50 - 11.00 Award session 1<br />
<strong>EAU</strong> Prize for the Best Paper published in the Urological Literature on Fundamental Research in 2009<br />
Supported by an unrestricted educational grant from ELI LILLY AND COMPANY<br />
<strong>EAU</strong> Prize for the Best Paper published in the Urological Literature on Clinical Research in 2009<br />
Supported by an unrestricted educational grant from ELI LILLY AND COMPANY<br />
<strong>EAU</strong> Prize for the Best Scientific Paper published in European Urology in 2009<br />
Supported by an unrestricted educational grant from ELSEVIER<br />
<strong>EAU</strong> Prize for the Best Scientific Paper on Fundamental Research published in European Urology in<br />
2009 by a young urologist<br />
Supported by an unrestricted educational grant from ELSEVIER<br />
<strong>EAU</strong> Prize for the Best Scientific Paper on Clinical Research published in European Urology in 2009 by<br />
a young urologist<br />
Supported by an unrestricted educational grant from ELI LILLY AND COMPANY<br />
European Urology Platinum Award<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
169
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
09.15 - 10.45 Neuropathic bladder dysfunction in children<br />
Vienna Room<br />
Oral Session 9<br />
Chairs: M. Eissa, Cairo (EG)<br />
S. Tekgül, Ankara (TR)<br />
All presentations are 7 minutes in length, followed by 2 minutes of discussion.<br />
Introduction<br />
S. Tekgül, Ankara (TR)<br />
652 Long term outcome of artificial urinary sphincter in children and adolescents with neurogenic incontinence<br />
R.S. Surange, C. Saunders, B. Hickerton, N. Ragavan, S. Kenny, H.F. Mcandrew, A. Baird (Liverpool, United<br />
Kingdom)<br />
653 Catheterisable serous lined urinary outlet in children and adolescents: Mansoura experience<br />
A.M. Elshal, H. Abol-Enein, O. Sarhan, A.T. Hafez, A.M. Ghaly, A.O. Mosbah, M. Abdel-Latif, M.A. Ghoneim<br />
(Mansoura, Egypt)<br />
654 Umbilical rotation: A new technique for providing a tension-free cutaneous fixation for continent<br />
catheterizable vesicostomy<br />
E. Weikert, S. Kraske, G.E. Schott, B. Wullich, K. Hirsch (Erlangen, Germany)<br />
655 Comparison of the clinical features between CIC and non-CIC children with neurogenic bladder due to<br />
myelodysplasia<br />
M.C. Park, J.Y. Han, K.S. Kim (Seoul, South Korea)<br />
656 Antimuscarinics in children: A review of literature from a clinical perspective<br />
S.H. Alloussi, G.E. Mürtz, J. Seibold, G. Strugala, H. Madersbacher, A. Stenzl, S. Alloussi (Tübingen, Dresden,<br />
Neunkirchen, Germany; Innsbruck, Austria)<br />
657 Intravesical electromotive botulinum toxin type A administration: Preliminary findings for the treatment of<br />
children with myelomeningocele and refractory neurogenic netrusor overactivity<br />
H. Ahmadi, L. Montaser-Kouhsari, A.M. Kajbafzadeh (Tehran, Iran)<br />
658 Effectiveness of vesico-ureteral refluxes treatment in neurogenic bladder with detrusor overactivity or<br />
small compliance according to different methods<br />
L. Skobejko-Wlodarska, P. Gastol, K. Felberg, M. Baka-Ostrowska (Warsaw, Poland)<br />
659 Vitamin B12 deficiency in children after continent urinary diversion by MAINZ pouch technique<br />
R. Stein, A. Schröder, K. Davis, J.W. Thüroff (Mainz, Germany)<br />
660 Half-century follow-up after Coffey diversion in early childhood<br />
O.K. Jonsson, K. Abrahamsson, C. Andersson, S. Pettersson, U. Sillén (Gothenburg, Sweden)<br />
170 Programme Book<br />
Summary<br />
M. Eissa, Cairo (EG)
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
09.15 - 10.45 Experimental therapy and diagnostics in prostate cancer<br />
<strong>Barcelona</strong> Room<br />
Poster Session 41<br />
Chairs: F. Pina, Porto (PT)<br />
H.G. Van Der Poel, Amsterdam (NL)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
661 Apoptosis of human androgen-dependent prostate cancer LNCaP cells treated with androgen receptor<br />
element decoy oligonucleotides<br />
Y. Lifeng (Shanghai, China)<br />
662 Simvastatin induces apoptosis in androgen-independent prostate cancer through a nuclear factor-ĸBdependent<br />
mechanism<br />
Y.H. Park, E. Lee, J.H. Park, C. Lee, S.B. Lee, J.H. Ku, H. Jeong, C. Kwak, H.H. Kim (Seoul, South Korea)<br />
663 Effect of parathyroid hormone in orchiectomized rat: A possible alternative for testosterone in therapy<br />
of osteoporosis in high-risk localised prostate cancer patients under adjuvant or neoadjuvant hormonal<br />
therapy<br />
M. Tezval, H. Tezval, S. Sehmisch, T. Rack, L. Kolios, G. Serferaz, M.A. Kuczyk, K.M. Stuermer, E.K. Stuermer<br />
(Goettingen, Hanover, Germany)<br />
664 Utilising metformin to enhance the efficacy of androgen deprivation therapy in the treatment of prostate<br />
cancer<br />
A.J. Colquhoun, N.A. Venier, N.E. Fleshner, M. Pollak, L.H. Klotz, V. Venkateswaran (Toronto, Montreal,<br />
Canada)<br />
665 Multifunctional anti-cancer agents based on cisplatin loaded carbon encapsulated magnetic nanoparticles<br />
A. Taylor, Y. Krupskaya, K. Kraemer, S. Füssel , R. Klingeler, B. Buechner, M.P. Wirth (Dresden, Germany)<br />
666 Migration ability of cytosine deaminase gene expressing human neural stem cells toward prostate cancer<br />
Y.S. Song, H.J. Lee, J.I. Koh, W.J. Yang, S.U. Kim (Seoul, South Korea)<br />
667 Withdrawn<br />
668 Enhanced ERG expression on exon 1.0 ST arrays can identify TMPRSS2-ERG fusions in prostate cancer<br />
patients<br />
F.P. Smit, M. Salagierski, J.A. Schalken (Nijmegen, The Netherlands; Lodz, Poland)<br />
669 Expression of estrogen related proteins in hormone-refractory prostate cancer: Association with tumour<br />
progression<br />
O. Celhay, M. Yacoub, J. Irani, B. Doré, O. Cussenot, G. Fromont (Poitiers, Paris, France)<br />
670 The TMPRSS2-ERG gene fusion status in prostate cancer patients treated by radical prostatectomy defines<br />
a different prognostic panel of clinico-pathological factors<br />
J. Rubio-Briones, A. Fernández-Serra, A. Calatrava, L. Rubio, M.A. Bonillo, Z. García-Casado, I. Iborra,<br />
E. Solsona, J.A. López-Guerrero (Valencia, Spain)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
171
671 Withdrawn<br />
672 Expression of metalloproteases (MMPs) and their inhibitors (TIMPs) in tumour and stromal cells as<br />
markers of recurrence after radical prostatectomy. Univariate and multivariate study combined with<br />
cluster analysis of the protein expression in prostate cancer tissue array samples<br />
J.M. Fernandez-Gomez, S. Escaf, L.O. Gonzalez, A. Suarez, S. Gonzalez-Reyes, S. Junquera, J.M. Gonzalez,<br />
O. Miranda, F. Vizoso (Oviedo, Gijon, Spain)<br />
673 Anti-tumor effect of dual PI3K/mTOR inhibitor NVP-BEZ235 against docetaxel- and hormone-resistant<br />
human prostate cancer cell line<br />
C.Y. Yoon, M.J. Park, S.W. Doo, H.Z. Park, D.S. Kim, W.K. Lee, S.H. Paick, S.J. Jeong, S.K. Hong, S.S. Byun,<br />
E.S. Lee, S.E. Lee (Bundang, Gyunggi, Hwayang-Dong, Gwangjjin-Ku, South Korea)<br />
674 Expression of integrin alpha 2 and alpha 6 and c-met in primary prostate carconima: Impact on bone<br />
metastasis free survival<br />
E. Ricci, E. Bourrelly, F. Mege Lechevallier, X. Martin, P. Clezardin, M. Colombel (Lyon, France)<br />
675 Improved prediction of biochemical recurrence after radical prostatectomy by DNA microarrays<br />
J. Morote, J. Del Amo, A. Borque, J. Planas, C.X. Raventós, J. Larrinaga, R. Llarena, J.M. Campá, M.J. Viso,<br />
D. Tejedor, L. Simón, A. Martínez, L.A. Rioja (<strong>Barcelona</strong>, Bilbao, Zaragoza, Vitoria, Spain)<br />
676 Axial versus peripheral DXA scan to assess osteoporosis in prostate cancer patients<br />
J. Morote, J. Planas, C.X. Raventos, J. Placer, G. Encabo (<strong>Barcelona</strong>, Spain)<br />
172 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
09.15 - 10.45 Management of high risk disease<br />
Paris Room<br />
Poster Session 42<br />
Chairs: K. Touijer, New York (US)<br />
H. Van Poppel, Leuven (BE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
677 Radical prostatectomy for clinically localised, high risk prostate cancer: Impact of the definition and<br />
surgical approach on outcome<br />
K. Touijer, D. Katz, C. Savage, V. Reuter, J.A. Eastham, P.T. Scardino, B. Guillonneau (New York, United States<br />
of America)<br />
678 Laparoscopic radical prostatectomy for high-risk prostate cancer<br />
C. Hutton, P. Rouse, G. Eden (Broad Oak, Guildford, United Kingdom)<br />
679 Is surgery for high-risk localised prostate cancer valid in the elderly population? An analysis of the<br />
influence of age an cancer-specific and overall survival<br />
P. Gontero, M. Spahn, A. Briganti, G. Marchioro, B. Tombal, C.Y. Hsu, K. Vander Eeckt, P. Bader, J. Walz,<br />
D. Frohneberg, M. Graefen, F. Montorsi, A. Tizzani, P. Van Cangh, H. Van Poppel, S. Joniau (Turin, Milan,<br />
Novarra, Italy; Würzburg, Karlsruhe, Hamburg, Germany; Brussels, Leuven, Belgium)<br />
680 Elderly patients are at a more elevated risk of pt 3 prostate cancer: Results of a European single center<br />
L. Budäus, J. Spethmann, G. Salomon, G. Salomon, H. Isbarn, M. Auprich, T. Steuber, A. Haese, T. Schlomm,<br />
H. Heinzer, H. Huland, P.I. Karakiewicz, M. Graefen (Hamburg, Germany; Montreal, Canada)<br />
681 Nerve sparing radical prostatectomy in properly selected patients with pt3 prostate cancer does not<br />
undermine the rates of positive surgical margins<br />
L. Budäus, G. Salomon, J. Spethmann, H. Isbarn, T. Steuber, A. Haese, G. Lughezzani, M. Sun, T. Schlomm,<br />
K.H.F. Chun, H. Heinzer, H. Huland, P.I. Karakiewicz, M. Graefen (Hamburg, Germany; Montreal, Canada)<br />
682 Role of positive surgical margins in patients with organ confined prostate cancer. Implications for adjuvant<br />
treatments<br />
A. Briganti, N. Suardi, U. Capitanio, M. Freschi, A. Salonia, A. Russo, L. Rocchini, C. Doglioni, C. Cozzarini,<br />
G. Guazzoni, P. Rigatti, F. Montorsi (Milan, Italy)<br />
683 The role of positive section margins in patients with high risk prostate cancer treated by radical<br />
prostatectomy: Prospective analysis of 566 patients<br />
M. Spahn, P. Gontero, B. Kneitz, G. Marchioro, P. Bader, H. Van Poppel, D. Frohneberg, S. Joniau (Würzburg,<br />
Karlsruhe, Germany; Turin, Novarra, Italy; Leuven, Belgium)<br />
684 Biochemical recurrence after radical prostatectomy: A case of multiplicative interaction between surgical<br />
margin status and pathological stage<br />
H. Isbarn, C. Eichelberg, L. Budäus, F.K.H. Chun, T. Steuber, S.A. Ahyai, M. Fisch, T. Schlomm, G. Salomon,<br />
A. Haese, H. Heinzer, H. Huland, M. Graefen, P. Karakiewicz (Hamburg, Germany; Montreal, Canada)<br />
685 Predictors of the risk of androgen-independent progression after salvage radical prostatectomy for locally<br />
recurrent prostate cancer following initial radiation therapy<br />
E. Chiong, N. Long, D. Urbauer, C.L. Warneke, L.L. Pisters (Singapore, Singapore; Houston, United States of<br />
America)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
173
686 The role of adjuvant hormonal treatment after surgery for high-risk localised prostate cancer-results of a<br />
multi-institutional matched analysis<br />
P. Gontero, S. Kneitz, B. Kneitz, B. Tombal, J. Walz, G. Marchioro, P. Bader, D. Frohneberg, M. Graefen,<br />
A. Tizzani, H. Van Poppel, S. Joniau, M. Spahn (Turin, Novarra, Italy; Würzburg, Hamburg, Karlsruhe,<br />
Würzburg, Germany; Brussels, Leuven, Belgium)<br />
687 Prospective trial with radical prostatectomy and intraoperative radiation therapy for clinical locally<br />
advanced prostate cancer: Clinical aspects and results after 5 years experience<br />
G. Marchioro, A. Volpe, M. Krengli, M. Vidali, R. Tarabuzzi, M. Billia, G. Maso, M. Zacchero, A. Ballarè,<br />
D. Beldì, B. Frea, C. Terrone (Novara, Udine, Italy)<br />
688 Neoadjuvant combination therapy of docetaxel and complete androgen deprivation for localised high risk<br />
prostate cancer before radical prostatectomy<br />
M.K. Thalgott, U. Treiber, T. Maurer, M. Heck, M. Eiber, B. Reimer, K. Herkommer, R. Paul, M. Retz,<br />
J.E. Gschwend, H. Kübler (Munich, Germany)<br />
689 HIFU as a salvage treatment method for PCa local recurrence after radical prostatectomy<br />
Y.G. Alyaev, E.A. Bezrukov, G.E. Krupinov, P.A. Shestiperov, V.N. Kuijuclu (Moscow, Russia)<br />
690 Nerve-sparing radical prostatectomy in selected high-risk and locally advanced prostate cancers<br />
is associated with low positive margin rates using a combination of preoperative MRI, special<br />
instrumentation and intra-operative frozen sections<br />
A.R. Zlotta, G. Trottier, B. Van Rhijn, P. Bostrom, S. Alkhateeb, S. Hanna, A. Evans, N. Fleshner,<br />
N. Lawrentschuk, T. Van Der Kwast (Toronto, Canada)<br />
691 Pathological findings and PSA outcomes after laparoscopic radical prostatectomy for high risk prostate<br />
cancer<br />
G. Ploussard, L. Salomon, Y. Allory, S. Terry, D. Vordos, A. Hoznek, F. Vacherot, C. Abbou (Creteil, France)<br />
174 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
09.15 - 10.45 LUT testing and dysfunctions<br />
Stockholm Room<br />
Poster Session 43<br />
Chairs: T. Hánuš, Prague (CZ)<br />
H. Hashim, Bristol (GB)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
692 Urodynamical benchmarks: A retrospective analyses of 976 combined urodynamics with no pathological<br />
findings to evaluate standard values<br />
S.H. Alloussi, C. Lang, R. Eichel, M. Ziegler, A. Stenzl, S. Alloussi (Tübingen, Neunkirchen, Homburg,<br />
Germany)<br />
693 A comparative study of the diagnostic effectiveness and concordance of bladder diary and urodynamics in<br />
women with idiopathic overactive bladder<br />
L. López-Fando Lavalle, M.A. Jiménez, V. Diez Nicolás, S. Díaz Naranjo, L. Córdoba, F.J. Burgos (Madrid,<br />
Spain)<br />
694 Effect of transurethral cystometry catheter on the measurement of abdominal leak point pressare (ALPP) in<br />
women with SUI<br />
T. Realfonso, U. Di Mauro, O. Intilla, M. Iacone, A. Campitelli, R. Sanseverino (Nocera Inferiore, Italy)<br />
695 Does pressure flow study improve the outcome of surgery in women with SUI?<br />
J. Romero Maroto, M.A. Ortiz Gorraiz, L. Gómez Pérez, A. López López, A. Sánchez, J.J. Pacheco Bru<br />
(Alicante, San Juan De Alicante, Spain)<br />
696 Executive summary: The International Consultation on Incontinence 2008 -Committee on: ‘Dynamic testing’;<br />
for urinary or faecal incontinence<br />
G.L. Hosker, P.F.W.M. Rosier, J.B. Gajewski, P.K. Sand, L. Szábo, A. Capewell (Manchester, St. Helens, United<br />
Kingdom; Utrecht, The Netherlands; Halifax, Canada; Chicago, United States of America; Miskolc, Hungary)<br />
697 The efficacy of visual analogue scale questionnaire to identify the most significant symptom to be treated<br />
for leading patients’ satisfaction<br />
Y. Yamada, O. Ukimura, A. Fujihara, J. Fujiwara, S. Ushijima, K. Okihara, A. Kawauchi, T. Miki (Kyoto, Japan)<br />
698 OABSS, a validate, simple questionnaire for OAB, is well correlated with I-PSS urgency score in treatmentnaive<br />
patients on the out-patient settings<br />
Y. Haneda, T. Miyamoto, H. Inuzuka, M. Kamiyama, S. Kudo, T. Tsuchida, M. Fukazawa, H. Zakohji,<br />
M. Takeda (Chuo, Japan)<br />
699 Identifying ICS bladder sensations using functional brain imaging (fMRI) and conventional urodynamics in<br />
healthy subjects and OAB patients<br />
W.C. Tsang, J. Kong, A. Yadav, J.R. O’Donaghue, B. Andrews, J.N. Noble, I. Tracey, J.R. Reynard (Oxford,<br />
United Kingdom)<br />
700 Withdrawn<br />
701 Clinical pravalence of preoperative combined urodynamics in patients with bladder outlet obstruction<br />
S. Alloussi, C. Lang, R. Eichel, A. Stenzl, S. Alloussi (Tübingen, Neunkirchen, Germany)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
175
702 Do patients with postoperative thoracic epidural analgesia need an indwelling transurethral catheter?<br />
P.Y. Wuethrich, T.M. Kessler, B. Kiss, F.C. Burkhard (Berne, Switzerland)<br />
703 Prevalence of lower urinary tract symptoms and changes associated with sacral neuromodulation for fecal<br />
incontinence<br />
D.S. Engeler, D. Meyer, F. Hetzer, H.P. Schmid (St. Gallen, Switzerland)<br />
704 Validation and standardisation of the pelvic floor inventories in English: An ongoing study<br />
P.J. Voorham-Van der Zalm, K. Berzuk, A.A.B. Lycklama À Nijeholt, H. Putter, B. Shelly, R.C.M. Pelger,<br />
B. Kamin, A.M. Stiggelbout (Leiden, The Netherlands; Winnipeg, Canada; Moline, Chicago, United States of<br />
America)<br />
705 Assessment of the reproducibility of the maximum bladder capacity in women with idiopathic overactive<br />
bladder measured with bladder diaries, flowmetry and urodynamics<br />
L. López-Fando Lavalle, M.A. Jiménez, J. Mayor, J.J. Vázquez, F.J. Burgos (Madrid, Spain)<br />
706 Association between symptoms and video-urodynamic parameters in patients who were undergoing<br />
pelvic radiotherapy<br />
E.S.B. Bezerra, A.N.N. Amstalden, S.B. Bisogni, J.S.C. Casado, M.D. Dambros (Campinas, São Paulo, Brazil;<br />
Madrid, Spain)<br />
176 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
09.15 - 10.45 Imaging and new techniques<br />
Milan Room<br />
Poster Session 44<br />
Chairs: P.A. Geavlete, Bucharest (RO)<br />
H. Özen, Ankara (TR)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
707 Value of magnetic resonance spectroscopy imaging (MRSI) and dynamic contrast-enhanced imaging MR<br />
(DCEMR) for the detection of prostate adenocarcinoma foci in men with prior negative prostate biopsy and<br />
elevated prostate specific antigen (PSA) levels<br />
A. Sciarra, V. Panebianco, S. Salciccia, A. Gentilucci, U. Parente, A. Alfarone, S. Cattarino, D. Lisi,<br />
R. Passariello, V. Gentile (Rome, Italy)<br />
708 Prostate cancer localisation with MRI and MRI-targeted transperineal template biopsy (MTTB)<br />
D. Takayoshi, T. Hioka, T. Kaneta, W. Sakai, T. Hasegawa, S. Nishino, H. Gotoda, S. Muraoka (Sapporo,<br />
Japan)<br />
709 External surface coil and endorectal coil magnetic resonance imaging: Which is more accurate for local<br />
staging of prostate cancer?<br />
B.S. Kim, E.S. Yoo, K.M. Kang, T.H. Kim, S.K. Chung, Y.K. Park, T.G. Kwon (Daegu, South Korea)<br />
710 Preoperative endorectal coil MRI: Sensitivity and specificity vary in different regions of the prostate<br />
D. Colleselli, C. Schwentner, D. Schilling, J. Hennenlotter Jörg, M.P. Lichy, C. Schneider, A. Stenzl, U. Vogel,<br />
H.P. Schlemmer (Tübingen, Germany)<br />
711 Prostate cancer: Value of inapparent tumour at endorectal MR (1,5 Tesla PPA) in evaluating local extension<br />
F. Luyckx, P. Chauveau, P. Hallouin, C. Barré, G. Aillet, O. Bouchot, J. Rigaud (Nantes, France)<br />
712 Multi-parametric magnetic resonance imaging (mp-MRI) and localisation of significant prostate cancer:<br />
Can it be used as a triage tool?<br />
N. Arumainayagam, H.U. Ahmed, C. Moore, A. Freeman, C. Allen, A. Sohaib, A. Kirkham, M. Emberton<br />
(London, United Kingdom)<br />
713 Withdrawn<br />
714 Functional MRI (diffusion weighted and dynamic contrast enhanced imaging) in patients with low risk<br />
prostate cancer<br />
F. Cornud, N. Barry, F. Beuvon, M. Liberatore, M. Rouanne, T. Flam (Paris, France)<br />
715 A prospective trial of the role of magnetic resonance imaging findings as a marker for men at risk of<br />
prostate cancer progression with low risk disease otherwise suitable for active surveillance<br />
N. Lawrentschuk, M. Jewett, A. Finelli, M. Haider, N.E. Fleshner (Toronto, Canada)<br />
716 Thin slice thickness (1mm) 3D-T2-weighted MRI and local staging of prostate cancer<br />
M. Rouanne, N. Barry, F. Beuvon, M. Liberatore, T. Flam, F. Cornud (Paris, France)<br />
717 Vibroacoustic imaging during permanent prostate brachytherapy and biopsy<br />
B. Davis, L. Mynderse, F. Mitri, R. Kinnick, A. Alizad, T. Kinter, T. Wilson, J. Greenleaf, M. Fatemi (Rochester,<br />
United States of America)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
177
718 Inapparent tumour in endorectal magnetic resonance imaging of the prostate: Should we perform a biopsy<br />
or not?<br />
A.P. Labanaris, K. Engelhard, R. Nützel, R. Smiszek, R. Kühn (Nuremberg, Germany)<br />
719 Can MR images improve the predictive ability of extended prostate biopsy to predict unilateral prostate<br />
cancer?<br />
I.G. Jeong, J.K. Kim, D. You, C. Song, J.H. Hong, H. Ahn, C.S. Kim (Seoul, South Korea)<br />
178 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
09.15 - 10.45 Testis cancer<br />
Athens Room<br />
Poster Session 45<br />
Chairs: W. Albrecht, Mistelbach (AT)<br />
G. Cohn Cedermark, Stockholm (SE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
720 Core 2 N-acetylglucosaminyltransferase-1 (C2GnT-1) expression induces aggressive potential of testicular<br />
germ cell tumour<br />
S. Hatakeyama, A. Kyan, H. Yamamoto, A. Okamoto, N. Sugiyama, Y. Suzuki, K. Imanishi, T. Okamoto,<br />
S. Kudo, T. Yoneyama, Y. Hashimto, T. Koie, N. Kamimura, C. Ohyama (Hirosaki, Japan)<br />
721 Ultrastructural cellular heterogeneity of the embryonal carcinoma (EC) of testis<br />
A.V. Sakalo, S.A. Vozianov, V.S. Sakalo, V.V. Mrachkovskiy, P.G. Yakovlev, A.M. Romanenko (Kiev, Ukraine)<br />
722 Specific protein patterns characterize metastatic potential in advanced bladder cancer<br />
R. Pilchowski, R. Stöhr, F. Von Eggeling, A. Hartmann, H. Wunderlich, K. Junker (Jena, Erlangen, Germany)<br />
723 Prevalence and localisation of intratubular germ cell neoplasia in patients with germ cell tumours.<br />
Implications in organ sparing surgery of the testis<br />
G. Gulino, F. Pierconti, A. D’Onofrio, G. Palermo, E. Sacco, P.F. Bassi (Rome, Italy)<br />
724 Testicular tumorectomy: A new algorithm<br />
G. Franco, D. Dente, C. Leonardo, C. De Nunzio, A. De Cillis, C. Caliolo, A. Cavaliere, E. Palminteri, D. Carlo<br />
(Rome, Italy)<br />
725 Laparoscopic retroperitoneal lymph node dissection for clinical stage I non-seminomatous germ cell cancer<br />
(NSGCC). Analysis of 178 cases<br />
J.P. Rioja Zuazu, I. Vidal-Mora, E. Ramos-Barcelo, M.P. Laguna-Pes, O.A. Castillo Cadiz (Zaragoza, Santander,<br />
Spain; Santiago, Chile; Amsterdam, The Netherlands)<br />
726 Open (O) and laparoscopic (L) retroperitoneal lymph-node dissection (RPLND) for clinical stage I non<br />
seminomatous germ-cell testis tumours (NSGCT): Experience of a single center<br />
N. Nicolai, D. Biasoni, A.M. Autran Gomez, M. Catanzaro, A. Milani, A. Necchi, L. Piva, S. Stagni, T. Torelli,<br />
R. Salvioni (Milan, Italy)<br />
727 Long term outcome after postchemotherapy retroperitoneal lymphadenectomy in patients with residual<br />
teratoma<br />
D. Argirovic, A. Argirovic, V. Stanic (Belgrade, Serbia)<br />
728 Management of growing teratoma syndrome: Aachen University experience<br />
D. Pfister, D. Thüer, S. Richter, A. Heidenreich (Aachen, Germany)<br />
729 Recurrences in nonseminomatous testicular tumours with no viable cancer at postchemotherapy<br />
retroperitoneal lymphadnectomy<br />
D. Argirovic, V. Stanic, A. Argirovic (Belgrade, Serbia)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
179
730 Complications of post-chemotherapy retroperitoneal lymph node dissection (PCRPLND) in advanced<br />
nonseminomatous germ cell tumours: First results of the German testicular cancer study group<br />
A. Heidenreich, C. Winter, M. Angerer-Shpilenya, D. Pfister, B. Brehmer, P. Albers (Aachen, Dusseldorf,<br />
Germany)<br />
731 The sword of Damocles in clinical stage A (I) seminoma: Late sequels of radiotherapy vs carboplatin<br />
chemotherapy<br />
D. Argirovic, L. Radosevic-Jelic, A. Argirovic (Belgrade, Serbia)<br />
732 Influence of paternity on quality of life in testicular cancer survivors<br />
B. Stöhr, L. Schachtner, F. Zangerl, A. Fritzer, J. Giesinger, B. Holzner, H. Steiner (Innsbruck, Austria)<br />
180 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Sub-plenary Session 6<br />
11.00 - 12.00 New developments in tissue engineering and reconstructive surgery<br />
eURO Auditorium<br />
Chairs: J.A. Schalken, Nijmegen (NL)<br />
A. Stenzl, Tübingen (DE)<br />
11.00 - 11.15 State-of-the-art lecture Adult stem cells in tissue engineering<br />
M. Renninger, Tübingen (DE)<br />
Aims and objectives<br />
Adult stem cells in tissue engineering:<br />
Despite the rapidly evolving field of basic research in pluripotency and plasticity of human embryonic stem<br />
cell (hESCs) and induced pluripotent stem cells (iPS), tissue engineering with these approaches is still far<br />
away from clinical practice. Still remaining major disadvantages of both cell sources are on the one hand<br />
ethical concerns and on the other hand their safety and efficiency. HESCs are still the gold standard and<br />
iPS are a reverse but useful tool in pluripotency and differentiation research, but the abundance and safety<br />
for the use of these pluripotent mechanisms for a functional integration without tumorigenicity is still a<br />
question. Perhaps closer to a clinical translation and potential application is tissue engineering (TE) based<br />
on adult stem cells. Increasing data suggest that specific adult stem cells are capable of multi-leanage<br />
transdifferentiation and are thereby closer to a successful application in culture of biomimetic tissue than<br />
hESCs and iPS. A preliminary model of adult stem cell research and widely used in TE were bone marrowderived<br />
stem cells. Several new data suggest that a broad range of adult tissue derived stem cells can also<br />
be successfully used for engineering cells and tissues in vitro and in vivo, e.g. adipose-derived stem cells<br />
or human adult germline stem cells (haGSCs). Advantages are their relative useful potency, their frequency<br />
(depending on the stem cell source) and uncomplicated technical harvesting, but disadvantages are still<br />
remaining like pre-aging or affection of the donor tissue due to disease in autologous approaches or a<br />
bad health condition of the receiving host tissue. Promising candidates for adult stem cell sources will be<br />
discussed and assessed for tissue engineering in urology and their further translation into clinical practice.<br />
11.15 - 11.30 State-of-the-art lecture Biomaterial development and clinical<br />
applications<br />
J. Hilborn, Uppsala (SE)<br />
11.30 - 11.45 State-of-the-art lecture Urological tissue engineering, biomaterials and<br />
cell interactions<br />
S. MacNeil, Sheffield (GB)<br />
Aims and objectives<br />
The aim of this presentation is to review our progress in making clinically useful tissues for substitution<br />
urethroplasty and for repair of weakened pelvic tissues.<br />
The presentation will evaluate progress in developing cell populated scaffolds against clinical needs. Thus<br />
in recent years we developed autologous tissue engineered buccal mucosa (TEBM) for use in substitution<br />
urethroplasties. These have been evaluated clinically with three years of follow up. More recently we have<br />
begun to develop tissue engineered approaches to repair damaged pelvic tissues in women, comparing<br />
biological and synthetic matrices, again using buccal mucosa as the source of cells. Issues of mechanical<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
181
182 Programme Book<br />
strength, and sterilisation and biodegradation of the scaffolds and production of new matrix will be<br />
discussed.<br />
11.45 - 12.00 State-of-the-art lecture Paediatric urological reconstructions and tissue<br />
engineering in the clinic<br />
W.F.J. Feitz, Nijmegen (NL)<br />
Aims and objectives<br />
In this session new developments in the field of paediatric urology and reconstructive surgery in combination<br />
with regenerative medicine and tissue engineering will be presented. For future care and consultation of<br />
your patients you should be aware of these developments for your clinical paediatric and adult urological<br />
practice in the coming years.
Monday, 19 April - <strong>EAU</strong> Programme<br />
Sub-plenary Session 7<br />
11.00 - 12.00 Paediatric urology<br />
Amsterdam Room<br />
Chairs: G.A. Bogaert, Leuven (BE)<br />
J.M. Nijman, Groningen (NL)<br />
11.00 - 11.20 State-of-the-art lecture Renal transplantation in children<br />
P. Lopez Pereira, Madrid (ES)<br />
Aims and objectives<br />
Chronic renal failure in a child is an irreversible disease with important consequences on growth and<br />
psychosocial development and living donor transplantation is the treatment of choice. Donor and recipient´s<br />
age are important factors in predicting RT outcome. Grafts under 6 years of age, as well as recipients under<br />
2 years of age have a poorer outcome. An obstructive uropathy is a common cause of ESRD, therefore<br />
urological evaluation in these children is mandatory to determine if bladder behaviour is normal. The<br />
incidence of surgical complications is about 6% but only 1-2% cause graft loss. In children, most protocols<br />
use an induction therapy with monoclonal or polyclonal antibodies to delay the use of nephrotoxic drugs<br />
until graft function is normal. Today, there is no difference in graft survival between children and adults and<br />
the most common cause of graft loss is chronic rejection. Overall mortality has decreased to 6.5%.<br />
11.20 - 11.40 State-of-the-art lecture Undescended testis: Is it worth doing surgery?<br />
M. Riccabona, Linz (AT)<br />
Aims and objectives<br />
The rationale to perform orchidopexy in UDT are possible improved fertility, reducing the risk of developing<br />
testicular cancer, prevention of testicular torsion, correction of associated hernia and to deal the psychological<br />
effects of empty scrotum. Most paediatric urologists recommend treatment at 6 – 12 months. Histologic<br />
data supports early treatment, since older patients demonstrate decreased testicular volume, decreased<br />
spermatogonia and smaller seminiferous tubules. Meta-analysis of randomized studies revealed a success<br />
rate of 20-25% of primary hormonal therapy to induce testicular descent. Perhaps the role of neoadjuvant<br />
hormonal therapy (GnRH) is in restoration of a normal endocrine milieu and maximizing future fertility<br />
potential.<br />
11.40 - 12.00 State-of-the-art lecture Vesicoureteral reflux: New diagnostic categories<br />
and a treatment shift?<br />
U. Sillén, Gothenburg (SE)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
183
Monday, 19 April - <strong>EAU</strong> Programme<br />
184 Programme Book<br />
Sub-plenary Session 8<br />
11.00 - 12.00 NOTES and SILS<br />
<strong>Barcelona</strong> Room<br />
Chairs: G. Janetschek, Salzburg (AT)<br />
L. Martínez-Piñeiro, Madrid (ES)<br />
11.00 - 11.15 State-of-the-art lecture The concept of NOTES<br />
M.J. Ribal Caparros, <strong>Barcelona</strong> (ES)<br />
Aims and objectives<br />
The endoscopic surgery through natural orifices, known as NOTES (Natural Orifice Transluminal Endoscopic<br />
Surgery) is an emerging surgical approach that uses endoscopic instruments through hollow viscera for<br />
access to the peritoneal cavity and allows surgical acts without the need for incisions. Mainly the entrance<br />
doors are mouth, anus, vagina and urethra, and the viscera in question are perforated to access the peritoneal<br />
cavity. Avoiding abdominal incision could provide a significant improvement in the postoperative recovery,<br />
the needs of analgesics, the hospital stay, the recovery of the routine activity and the possibility of wound<br />
hernia. The field of the minimal invasive surgery is in full expansion, being the Urology one of the areas in<br />
which is experiencing a major expansion. Nowadays there are several reports in NOTES or hybrid NOTES<br />
applied to different areas within the Urological diseases.<br />
11.15 - 11.30 State-of-the-art lecture NOTES nephrectomy and transvesical approach<br />
E. Lima, Porto (PT)<br />
Aims and objectives<br />
Overview: NOTES is a rapidly evolving area of preclinical research and several groups worldwide are<br />
developing this novel surgical approach together with industrial support. This session is designed to provide<br />
the practitioner an update of the state of transvesical approach to the peritoneal cavity and nephrectomy by<br />
NOTES.<br />
Objectives: After attending this session, the participants should be able to:<br />
- understand rationale for transvesical approach to the peritoneal cavity<br />
- identify limitations and opportunities of transvesical port<br />
- identify future human applications of transvesical port for NOTES procedures<br />
- discover the latest and future technological developments for NOTES nephrectomy<br />
- identify future human applications of transvesical port for NOTES procedures<br />
11.30 - 11.45 State-of-the-art lecture The concept of SILS<br />
J-U. Stolzenburg, Leipzig (DE)<br />
Aims and objectives<br />
SILS or LESS surgery is the further development of laparoscopic surgery. Almost all urologic intra-abdominal<br />
and pelvic procedures have already been successfully and safely performed with the LESS approach. Current<br />
experience is limited. The technical challenges presented for the performance of the approach should be<br />
addressed before the technique can be adopted by several institutions worldwide. For the wider application,<br />
refinement of the LESS instrumentation is necessary in order to overcome the technical challenges of the<br />
approach. The ongoing intense technological advancement in terms of LESS instrumentation is probably the<br />
key to the further development of the technique. The pioneering studies are promising but further clinical<br />
evaluation is deemed necessary for the technique to be established.
11.45 - 12.00 State-of-the-art lecture SILS procedures in urology<br />
M.M. Desai, Los Angeles (US)<br />
Aims and objectives<br />
The lecture will provide the attendees with a summary of the current clinical status of laparo-endoscopic<br />
single site (LESS) surgery in urology. The lecture aims to:<br />
1. Enumerate the indications and patient selection of LESS surgery procedures.<br />
2. Discuss and evaluate the equipment and technology to perform LESS urologic procedures and understand<br />
how the equipment differs from conventional laparoscopy.<br />
3. Discuss complications and safety issues with LESS surgery<br />
4. Present clinical experience with LESS urologic Surgery<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
185
Monday, 19 April - <strong>EAU</strong> Programme<br />
186 Programme Book<br />
Sub-plenary Session 9<br />
11.00 - 12.00 European Society of Urogenital Radiology (ESUR): State of the art in<br />
imaging<br />
Paris Room<br />
Chair: J. Barentsz, Nijmegen (NL)<br />
11.00 - 11.20 State-of-the-art lecture Haematuria<br />
N. Cowan, Oxford (GB)<br />
Aims and objectives<br />
Introduction: Haematuria, macroscopic (MACH) or microscopic (MICH), may herald a wide spectrum of<br />
underlying disease of which urological cancer and stones are the most common. Prompt and accurate<br />
diagnosis is essential for initiating appropriate treatment, optimising prognosis. The investigative pathway<br />
is often complicated and lengthy utilising multiple imaging tests. Many diagnostic algorithms exist without<br />
rigorous evaluation. MDCTU offers a single test with high diagnostic accuracy. MDCTU is defined as CT<br />
examination of the kidney, ureters and bladder with at least one series acquired post-contrast enhancement<br />
during the excretory-phase. By substituting MDCTU for other tests, the imaging pathway is simplified,<br />
improving diagnostic accuracy and reducing time from presentation to diagnosis.<br />
Purpose: The purpose of this lecture is to make sense of the development of MDCTU and its place within<br />
the diagnostic algorithm for investigating haematuria, with the primary goal of defining the most effective<br />
diagnostic strategy.<br />
Conclusion: The patient pathway for investigating haematuria may be optimised by judicious use of MDCTU.<br />
Unenhanced CT KUB is proposed as first-line imaging test for patients presenting with haematuria in the low<br />
risk group for urological cancer. CT kidneys with contrast and MDCTU are proposed as the first-line imaging<br />
test for patients in the high risk group, based on assessment using of a clinical risk score.<br />
11.20 - 11.40 State-of-the-art lecture Recent advances in staging prostatic cancer<br />
J. Barentsz, Nijmegen (NL)<br />
Aims and objectives<br />
With the increasing number and earlier detection of men with PCa the call for adequate imaging becomes<br />
urgent, not only for decision making in more advanced cancers but in particular for earlier stage cancers<br />
(specific diagnosis of significant tumors). Functional and molecular MR methods are excellent potential tools<br />
for this purpose. Since the introduction of MR to address diagnostic and biomedical questions in PCa there<br />
is a continuing quest for better spatial resolution, sensitivity and specificity. Recent MR developments, such<br />
as higher field magnets in combination with approaches to assess anatomy at high resolution, vascularity,<br />
metabolism, cellular density and visualisation of contrast targeted or loaded cells, promise to provide the<br />
required specifications.<br />
The clinical capabilities of new techniques (and contrast agents) will be shown using modern clinical MR<br />
scanners (3T systems), with the help of advanced post-processing tools.<br />
There are 4 clinical issues of importance concerning MRI of prostate cancer:<br />
Detection: Reliable detection of PCa without an endorectal coil (ERC) is possible at 3, using dynamic contrast<br />
enhanced (DCE) and diffusion weighted (DWI) MR images. The use of these functional MR exam, will be
discussed. In addition, the value of a recently developed, clinically approved, 3T MR-biopsy device to detect<br />
PCa in patients with persisting increased PSA and negative TRUS biopsy will be shown.<br />
Localisation: High accuracy can be obtained in localising prostate cancer with DCE, high resolution<br />
T2-weighted images and MRSI at 1.5T. The use of diffusion weighted and DCE MRI at 3T, and TRUS and<br />
MR-guided biopsy will give more representative biopsy results and thus a better pre-operative prediction of<br />
tumor aggression. Also, the fusion of molecular MR data with CT, showing the dominant lesion will be used<br />
to guide IMRT with subsequent evaluation of and the clinical outcome.<br />
Local Staging: Improved detection of even minimal (0.5 mm) capsular penetration using 3T ERC MRI<br />
(sensitivity 87%, specificity 96%) is currently possible at 3T. The information where minimal capsular<br />
penetration is located, will most likely alter surgical management and results (e.g. % of free resection<br />
margins, possibility for nerve sparing surgery).<br />
Nodal Staging: Using iron-nanoparticle MR-contrast to detect lymph node metastasis (MRL), results in high<br />
detection accuracy for small nodes. These findings of a recently completed multi-center study (sensitivity<br />
and specificity both 93%) will be shown. In patients with a negative MRL lymph node dissection could be<br />
safely omitted. Even better results are obtained at 3T; currently 3 mm nodal metastases can be detected. The<br />
accuracy of this technique with high-resolution 3T MRI will be discussed. In addition, the role in patients<br />
with PSA relapse after therapy will be presented. By prospectively investigating the impact of local treatment<br />
of MRL detected metastatic lymph nodes, on patient outcome, the true additive value of MRL will be shown.<br />
11.40 - 12.00 State-of-the-art lecture Scrotal masses<br />
L.E. Derchi , Genova (IT)<br />
Aims and objectives<br />
In patients with a scrotal mass, imaging is basically requested to answer to five questions:<br />
Is there a definite mass? US is nearly 100% sensitive in the identification of scrotal masses. False negatives are<br />
rare, mostly due to presence of isoechogenic intratesticular lesions or diffuse testicular involvement. In these<br />
cases, MRI may can be helpful. Palpable abnormalities of the scrotum which are not actually space occupying<br />
lesions of scrotal tissues can be recognized. Is the mass intra vs extratesticular? Differentiation can be made<br />
by US in almost all cases; scrotal palpation during US can help to localise the mass. Is the mass bilateral?<br />
Since testicular tumors may be bilateral, careful examination of both testes with US is essential, especially for<br />
possible small, non palpable lesions.<br />
Is the lesion cystic or solid? US can easily differentiate a solid from a cystic lesion. If any doubt exists, MRI<br />
examination may help to further characterise the mass since contrast-enhanced studies have been shown<br />
useful to show enhancement of solid portions. Is the nature of the lesion identifiable? Identification cannot<br />
be based on imaging methods alone. Epidemiogical, clinical and laboratory findings are important for the<br />
differential diagnosis. Location and structure of the mass can address the diagnosis: Most extratesticular<br />
lesions are benign while most intratesticular masses are malignant; most cystic lesions are benign, while<br />
solid nodules are more often malignant. Solid lesions, however, whether intra or extratesticular, cannot be<br />
classified with certainty, and most of them have no special US or MRI character to help identification of their<br />
nature.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
187
Monday, 19 April - <strong>EAU</strong> Programme<br />
188 Programme Book<br />
Sub-plenary Session 10<br />
11.00 - 12.00 Androgen suppression: Who and how?<br />
Stockholm Room<br />
Chair: L.N. Türkeri, Istanbul (TR)<br />
11.00 - 11.20 State-of-the-art lecture Immediated versus deferred hormonal therapy:<br />
When, why and how?<br />
B. Tombal, Brussels (BE)<br />
Aims and objectives<br />
Conventional wisdom assumes that every patient who is diagnosed with prostate cancer and is not a<br />
candidate for local therapy should receive hormonal treatment. Unfortunately, evidence from the literature<br />
does not supports that assertion. When taken alone, hormone therapy is and remains mostly a palliative<br />
treatment and gain in survival, if existing, are extremely modest. In addition, recent literature has unveiled<br />
complications, especially cardiovascular and osseous, that we have clearly underestimated for a long time.<br />
Therefore it has become crucial to apply a better selection of patients who are candidate for immediate<br />
hormonal therapy and to develop surveillance strategies for the others.<br />
11.20 - 11.40 State-of-the-art lecture Managing complications of androgen suppression<br />
J. Morote Robles, <strong>Barcelona</strong> (ES)<br />
Aims and objectives<br />
Most common complications of androgen suppression such us hot flashes, loss of libido, erectile dysfunction<br />
and gynecomastia are visible. They reduce QoL but do not compromise survival of men with prostate cancer.<br />
Bone mass loss and metabolic syndrome are non-visible complications that cause fractures and cardiovascular<br />
diseases reducing QoL and non specific survival. Urologists should prevent and detect these non visible<br />
complications by assessing at baseline and during the follow up BMD, lipid profile, blood pressure and<br />
waist circumference. In order to prevent these complications, healthy lifestyle habits (exercise, no alcohol, no<br />
tobacco), hypo-caloric diet, calcium and vitamin D supplements should be always recommended. Urologists<br />
should also be trained on the use of bisphosfonates and denosumab as drug prevention or treatment of bone<br />
loss and they also share with GP the diagnosis and treatment of hypertension and dyslipemia.<br />
11.40 - 12.00 State-of-the-art lecture New approaches to hormonal therapy<br />
A. Zivi, Sutton, Surrey (GB)<br />
Aims and objectives<br />
There is evidence of enhanced intracrine biosynthesis of testosterone in metastatic CRPC. Abiraterone acetate<br />
(AA) is an oral, selective, irreversible inhibitor of CYP17A1 (an enzyme with 17α-hydroxylase and C17,20lyase<br />
activity) essential for adrenal and intratumoral de novo biosynthesis of androgen hormones. The<br />
phase I/II trials results (activity, toxicitiy and management) will be discussed as well as the potential benefit<br />
from addition of low dose steroids. The phase III randomised trials (AA/placebo plus prednisolone in postchemotherapy<br />
and in chemo-naïve metastatic CRPC patients) will be discussed.
Monday, 19 April - <strong>EAU</strong> Programme<br />
Sub-plenary Session 11<br />
11.00 - 12.00 <strong>EAU</strong> Guidelines Office<br />
Milan Room<br />
Chair: K.F. Parsons, Liverpool (GB)<br />
Test yourself against the evidence<br />
R.J. Sylvester, Brussels (BE)<br />
Guidelines topics:<br />
Prostate cancer<br />
A. Heidenreich, Aachen (DE)<br />
Paediatric urology<br />
S. Tekgül, Ankara (TR)<br />
Urethral trauma<br />
N. Djakovic, Heidelberg (DE)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
189
Monday, 19 April - <strong>EAU</strong> Programme<br />
190 Programme Book<br />
Abstract Session<br />
12.15 - 13.45 Retroperitoneal and ureteral surgery<br />
eURO Auditorium<br />
Video Session 6<br />
Chairs: I.J. De Jong, Groningen (NL)<br />
A. Hoznek, Creteil (FR)<br />
All presentations have a maximum length of 10 minutes, followed by 4 minutes of discussion.<br />
V34 Direct access to UPJ in robot-assisted pieloplasty<br />
F. Gaboardi, A. Salvaggio, A.L. Romanò, A.M. Granata, G.P. Incarbone, F. Scieri, F. Pietrantuono, A. Gregori<br />
(Milan, Italy)<br />
V35 Robot-assisted pyeloplasty with two working trocars: Optimal cosmetic and functional results<br />
G.M. Schoen, N. Harke, S. Plhal, F. Schiefelbein (Würzburg, Germany)<br />
V36 Transmesololic robot-assisted pyeloplasty<br />
G. Bianchi, G. Pini, F. Annino, S. Micali, M.C. Sighinolfi, S. De Stefani (Modena, Italy)<br />
V37 Right laparoscopic retroperitoneal lymph node dissection in Leydig-Sertoli testis tumour<br />
A. Alcaraz, Ll. Peri, M. Musquera, A. Bohorquez, M.J. Ribal (<strong>Barcelona</strong>, Spain)<br />
V38 Post-chemotherapy robot-assisted laparoscopic resection of a residual retroperitoneal tumour in testicular<br />
cancer<br />
G.M. Schoen, N. Harke, T. Egner, F. Schiefelbein (Würzburg, Germany)<br />
V39 Laparoscopic partial nephroureterectomy in the treatment of hydronephrosis of the upper pole of duplex<br />
kidney with megaureter<br />
P. Wisniewski, P. Jarzemski, S. Listopadzki, R. Kalinowski (Bydgoszcz, Poland)
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
12.15 - 13.45 Diagnostics, VUR and enuresis in children<br />
Amsterdam Room<br />
Oral Session 10<br />
Chairs: J.M. Nijman, Groningen (NL)<br />
J. Seibold, Tübingen (DE)<br />
All presentations are 7 minutes in length, followed by 2 minutes of discussion.<br />
Introduction<br />
J.M. Nijman, Groningen (NL)<br />
733 Uroflowmetry in children with lower urinary tract problems: Intra- and inter-observer agreement and the<br />
value of repeated assessments<br />
H.F. Cheung, J.M.P. Kroesen, E.J.H. Van Der Horst, M.P. Hageman, R. Brohet, T. Van Der Ploeg, M.A. Noordzij<br />
(Hoofddorp, Amsterdam, Heemstede, The Netherlands)<br />
734 Accuracy of a portable ultrasound bladder scanner in very young paediatric patients: Is pre-scan function<br />
helpful?<br />
Y.H. Park, J.H. Ku, K.J. Park, H. Choi, S. Oh (Seoul, South Korea)<br />
735 An evaluation of current surgical techniques used for vesicoureteric anastomosis in paediatric renal<br />
transplantation in the United Kingdom: A national and regional perspective<br />
N. Vasdev, D. Rix, D. Talbot, N. Soomro (Newcastle upon Tyne, United Kingdom)<br />
736 Is real time 3D-ultrasonography in synopsis with clinical follow up studies a sufficient tool for surveillance<br />
after endoscopic treatment of children with vesicoureteral reflux?<br />
A. Buttazzoni, M. Mitterberger, J. Bektic, B. Schlenck, G. Bartsch, C. Radmayr, J. Oswald (Innsbruck, Austria)<br />
737 Improvement of nocturnal enuresis after adenotonsillectomy in children with obstructive sleep apnea<br />
syndrome<br />
A. Gökçe, S. Aslan, F.R. Yalçınkaya, M. Davarcı, Y.S. Kaya, N. Savas, S. Gorur, S. Dagli, A.N. Kiper,<br />
M.D. Balbay (Hatay, Turkey)<br />
738 Melatonin treatment in children with therapy-resistant monosymptomatic nocturnal enuresis<br />
B.T. Merks, T.P.V.M. De Jong, H. Burger (Utrecht, The Netherlands)<br />
739 Prospective evaluation of factors affecting the response and relapse rates to desmopressin therapy in<br />
postadolescent monosymptomatic enuretic males<br />
B. Burgu, M.I. Gökce, A. Gucuk, T. Soygur (Ankara, Turkey)<br />
740 Predictive factors for discontinuation of medical treatment in children with nocturnal enuresis: The<br />
meaning of first voided volume<br />
D.G. Moon, M.M. Oh, D.K. Youn, M.G. Park (Seoul, South Korea)<br />
Summary<br />
J. Seibold, Tübingen (DE)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
191
Monday, 19 April - <strong>EAU</strong> Programme<br />
192 Programme Book<br />
Abstract Session<br />
12.15 - 13.45 Molecular basis of prostate cancer<br />
<strong>Barcelona</strong> Room<br />
Poster Session 46<br />
Chairs: H. Klocker, Innsbruck (AT)<br />
B. Malavaud, Toulouse (FR)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
741 Clinical significance of BRAF and KRAS mutations in prostate cancer<br />
S. Choi, J.M. Chung (Pusan, South Korea)<br />
742 Association of transforming growth factor-beta1 (TGF-ĸ1) gene polymorphism at codon 10 with prostate<br />
cancer and benign prostatic hyperplasia (BPH)<br />
S. Taghipour Bazargani, M.D. Omrani, S. Samadzadeh, B. Farshid, S. Salari Lak, H. Yazdannejad (Tehran,<br />
Urmieh, Iran)<br />
743 Withdrawn<br />
744 Absence of activating mutations of EGFR and Her-2/neu as predictive markers for response to tyrosinekinase<br />
inhibitors in patients with castration resistant prostate cancer<br />
C.H. Ohlmann, G. Braun, V. Jung, M. Stöckle, U. Engelmann, A. Heidenreich (Homburg, Cologne, Aachen,<br />
Germany)<br />
745 Profiling of microRNAs in prostate cancer identifies distinct changes in microRNA expression patterns<br />
A. Schäfer, J. Busch, M. Jung, H.J. Mollenkopf, M. Lein, C. Stephan, G.O. Kristiansen, K. Jung, K. Miller<br />
(Berlin, Germany; Zurich, Switzerland)<br />
746 Epigenetic inactivation of RASSF10, a novel member of Ras association domain family, in prostate cancer<br />
T. Dansranjav, F. Wagenlehner, A. Paradowska, K. Steger, W. Weidner, R.H. Dammann, U. Schagdarsurengin<br />
(Giessen, Germany)<br />
747 Down-regulation of selected microRNAs correlates with expression of prostate cancer associated genes<br />
E. Erdmann, C. Thomae, S. Tomasetti, K. Kraemer, M. Sergon, M.O. Grimm, S. Füssel , M.P. Wirth (Dresden,<br />
Germany)<br />
748 Prostate cancer risk association with SNP polymorphic variants of CYP1B1 gene in the Bulgarian<br />
population<br />
E.P. Popov, D. Kachakova, A. Mitkova, R. Kaneva, A. Vlahova, T. Dikov, C.K. Slavov, V. Mitev, I. Kremensky<br />
(Sofia, Bulgaria)<br />
749 PTEN gene mutation and primary prostate cancer progression<br />
S. Salem, A. Abedi, A. Mehrsai, M. Rezaeidanesh, G. Pourmand (Tehran, Iran)<br />
750 Gene expression analysis of ETS transcription factor family genes and androgen receptor in laser capture<br />
microdissected human prostate cancer tissue<br />
M. Ladurner Rennau, P. Massoner, G. Schäfer, C. Seifart, M. Summerer, A. Brandstätter, H. Klocker,<br />
G. Bartsch (Innsbruck, Austria)
751 A novel candidate gene of susceptibility to prostate cancer, farnecyl-diphosphate farnecyltransferase 1<br />
(FDFT1) gene: Association between the variants of the FDFT1 gene and the prostate cancer risk, and the<br />
evaluation of the FDFT1 protein function to the prostate cancer cells<br />
H. Matsui, Y. Fukuma, T. Hamano, H. Koike, Y. Sekine, N. Ohtake, S. Nakata, K. Suzuki (Maebashi, Takasaki,<br />
Ashikaga, Japan)<br />
752 Genetic variability within 8q24 is associated with aggressiveness of advanced prostate cancer suitable for<br />
hormonotherapy<br />
S.J. Drouin, M. Roupret, M.O. Bitker, A.R. Azzouzi, S. Mallick, S. Vincendeau, P. Mangin, A. Valeri, L. Guy,<br />
A. Ruffion, F. Grima, P. Sebe, G. Cancel-Tassin, O. Cussenot (Paris, Angers, Caen, Rennes, Nancy, Brest,<br />
Clermont Ferrand, Lyon, Versailles, France)<br />
753 Prostate specific deletion of the mismatch repair (MMR) gene Mlh1 in mice cause neoplastic alterations of<br />
the prostate<br />
B. Kneitz, C. Reiß, P. Adam, P. Ströbel, H. Riedmiller, M. Spahn (Würzburg, Tübingen, Mannheim, Germany)<br />
754 The joint association of plasma 1, 25-dihydroxyvitamin D3 and IGFBP-3 levels and VDR Fok1 polymorphism<br />
with prostate cancer risk in Korean men<br />
J.H. Kim, S.W. Lee, S.J. Jeong, K. Park, E. Lee (Chuncheon, Seoul, South Korea)<br />
755 Prostate cancer risk in the Swedish AMORIS study: The interplay between triglycerides, total cholesterol<br />
and glucose<br />
M.J.J. Van Hemelrijck, L. Holmberg, H. Garmo, G. Walldius, I. Jungner, N. Hammar, M. Lambe (London,<br />
United Kingdom; Stockholm, Sweden)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
193
Monday, 19 April - <strong>EAU</strong> Programme<br />
194 Programme Book<br />
Abstract Session<br />
12.15 - 13.45 Renal tumours: Ablative techniques and single port surgery<br />
Paris Room<br />
Poster Session 47<br />
Chairs: M.P. Laguna, Amsterdam (NL)<br />
J-U. Stolzenburg, Leipzig (DE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
756 Single incision triangulated umbilical surgery (SITUS)<br />
U. Nagele, U. Walcher, M. Kugler, F. Imkamp, A.S. Merseburger, M. Burchardt, M.A. Kuczyk,<br />
T.R.W. Herrmann (Hall in Tirol, Austria; Hanover, Germany)<br />
757 Comparative assessment of laparoscopic single site surgery instruments to conventional laparoscopic in<br />
laboratory setting<br />
P. Kallidonis, E. Liatsikos, M.A. Oh, N. Ghulam, M. Do, T. Haefner, A. Dietel, H. Till, J.U. Stolzenburg (Patras,<br />
Greece; Leipzig, Germany; Aberdeen, United Kingdom)<br />
758 Comparison of laparoendoscopic single-site radical nephrectomy with conventional laparoscopic radical<br />
nephrectomy for localised renal cell carcinoma<br />
Y.H. Park, J.H. Park, C.W. Jeong, J.H. Ku, C. Kwak, H.H. Kim (Seoul, South Korea)<br />
759 LESS radical and partial nephrectomy compared to the conventional laparoscopic approach<br />
J. Chan, J. Watson, R.E. Sanchez-Salas, O. Stakhovsky, J. Riviere, J.E. Rocha Jr, F. Rozet, M. Galiano,<br />
X. Cathelineau, E. Barret, G. Vallancien (Paris, France)<br />
760 Laparoendoscopic single-site nephrectomy using a modified umbilical incision and a homemade<br />
transumbilical port<br />
H.S. Yu, W.S. Chang, W.K. Han, K.H. Rha, S.W. Han, Y.D. Choi, S.J. Hong, W.S. Ham (Seoul, South Korea)<br />
761 Accelerated growth of renal carcinoma cells after radiofrequency ablation: An animal study<br />
S.G.C. Kroeze, L.J.W. Kruijssen, P.J. Van Diest, J.L.H.R. Bosch, J.J.M. Jans (Utrecht, The Netherlands)<br />
762 Radiofrequency ablation (RFA) of renal tumors: Clinical, radiographic, and pathologic results from a<br />
tertiary cancer centre<br />
J.A. Karam, K. Ahrar, E. Jonasch, N. Tannir, R. Vikram, C. Romero, C.G. Wood, S.F. Matin (Houston, United<br />
States of America)<br />
763 Long-term (5 years) outcome of laparoscopic cryoablation for renal cell carcinoma in a single high volume<br />
urological department<br />
M. Lazzeri, L.D. Nava, A. Losa, F. Montorsi, A. Cestari, E. Scapaticci, N. Buffi, G. Lughezzani, P. Rigatti,<br />
G. Guazzoni (Milan, Italy)<br />
764 Mid term oncological follow up of laparoscopic renal cryoablation (LRC) with third generation cryoprobes<br />
in 100 small renal masses (SRM)<br />
K. Barwari, C. Mamoulakis, P. Beemster, H. Wijkstra, J.J.M.C.H. De La Rosette, M.P. Laguna (Amsterdam, The<br />
Netherlands)
765 Multicentre comparison of intermediate oncologic and renal functional outcomes of laparoscopic partial<br />
nephrectomy and renal cryoablation<br />
C.W. Wong, S.P. Stroup, R. Mehrazin, J.B. Malcolm, K.H. Strom, X. Xiao, J. L’Esperance, K. Kerrin Palazzi-<br />
Churas, R. Wake, R. Gold, D. Fabrizio, I.H. Derweesh (Oklahoma City, San Diego, Memphis, Norfolk, United<br />
States of America)<br />
766 Complications and oncological outcome after cryoablation of small renal tumours - national results after 4<br />
years<br />
U. Moldrup, O. Østraat, L. Lund, L. Hansen, J. Solvig, T.E. Johansen (Aarhus, Viborg, Odense, Denmark)<br />
767 Does high intensity focused ultrasound for renal cancer upregulate anti-tumour immunity in vivo?<br />
R.W. Ritchie, C. De Santo, R. Arscott, T.A. Leslie, V. Cerundulo, D. Cranston (Oxford, United Kingdom)<br />
768 The use of nephron sparing surgery may favourably impact the risk of non cancer related death in renal<br />
cell carcinoma survivors<br />
P. Bigot, M. Crepel, G. Verhoest, K. Bensalah, A. De La Taille, L. Salomon, C.C. Abbou, J. Tostain, L. Bellec,<br />
M. Soulié, P. Rischmann, J.C. Bernhard, J.M. Ferrière, C. Pfister, B. Albouy, M. Colombel, L. Zini, A. Villers,<br />
J. Rigaud, O. Bouchot, F. Montorsi, R. Bertini, A.S. Belldegrun, A.J. Pantuck, J.J. Patard (Angers, Rennes,<br />
Creteil, Saint-Etienne, Toulouse, Bordeaux, Rouen, Lyon, Lille, Nantes, France; Milan, Italy; Los Angeles,<br />
United States of America)<br />
769 Hospital volume is a determinant of the type of surgery, length of stay and perioperative mortality at<br />
nephrectomy<br />
C. Jeldres, G. Lughezzani, L. Budäus, R. Thuret, D. Liberman, M. Sun, S.F. Shahrokh, P. Arjane, H. Widmer,<br />
P. Perrotte, F. Montorsi, P.I. Karakiewicz (Montreal, Canada; Milan, Italy; Hamburg, Germany)<br />
770 Fiducial-free frameless real-time image guided single-fraction radiosurgery using the Cyberknife<br />
effectively controls spinal and cerebral metastases from renal cell carcinoma under systemic angiogenic<br />
therapy<br />
M. Staehler, P. Nuhn, C. Nordhaus, C.G. Stief, B. Wowra, A. Muacevic (Munich, Germany)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
195
Monday, 19 April - <strong>EAU</strong> Programme<br />
196 Programme Book<br />
Abstract Session<br />
12.15 - 13.45 Overactive bladder<br />
Stockholm Room<br />
Poster Session 48<br />
Chairs: S.G.G. De Wachter, Maastricht (NL)<br />
M.J. Drake, Bristol (GB)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
771 How many days do patients with overactive bladder (OAB) take new anti-cholinergic agents? Results from<br />
real clinical practice<br />
N. Itoh, K. Kobayashi, S. Sakai, S. Miyamoto, N. Masumori, T. Tsukamoto (Sapporo, Japan)<br />
772 Adverse event assessment of antimuscarinics for treating overactive bladder: A network meta-analytic<br />
approach<br />
T.M. Kessler, L.M. Bachmann, C. Minder, D. Loehrer, M. Umbehr, A.G.H. Kessels (Berne, Zurich, Switzerland;<br />
Maastricht, The Netherlands)<br />
773 Overactive bladder medication compliance when patients co-pay the anticholinergic agents<br />
A. Zahariou, P. Papaioannou, A. Stavrou, A. Kyriakides (Volos, Greece)<br />
774 Dose-ranging study of once-daily mirabegron (YM178), a novel selective β3-adrenoceptor agonist, in<br />
patients with overactive bladder (OAB)<br />
C. Chapple, J.J. Wyndaele, P. Van Kerrebroeck, P. Radziszewski, V. Dvorak, P. Boerrigter (Sheffield, United<br />
Kingdom; Antwerp, Belgium; Maastricht, Leiderdorp, The Netherlands; Warsaw, Poland; Brno, Czech<br />
Republic)<br />
775 Withdrawn<br />
776 Relationships between changes in overactive bladder (OAB) symptoms and in subjective assessments of<br />
symptom bother and health-related quality of life (HRQL) in patients taking solifenacin or placebo in the<br />
VIBRANT study<br />
R.D. Crosby, S.D. Mathias, T. Marshall (Fargo, Winter Park, Deerfield, United States of America)<br />
777 Safety, tolerability and pharmacokinetic of multiple ascending doses of the EP-1 receptor antagonist ONO-<br />
8539, a potential new and novel therapy to overactive bladder in healthy young and elderly subjects<br />
D. Wilbraham, T. Masuda, S. Deacon, T. Kuwayama, S. Vincent (London, United Kingdom)<br />
778 Evaluation of fesoterodine efficacy over 24 hours following once-daily dosing in subjects with overactive<br />
bladder<br />
M.C. Michel, D. Staskin, V. Nitti, J.D. Morrow, W. Joseph (Amsterdam, The Netherlands; Boston, New York,<br />
United States of America)<br />
779 Effect of antimuscarinics on the linear correlation and regression between severity of urge sensation (SUS)<br />
and voided volume (VV) in patients with overactive bladder (OAB)<br />
Z. Guan, J.G. Blaivas, M. Harel, J. Wang, J.P. Weiss (New York, Brooklyn, United States of America)<br />
780 Effect of repeated intradetrusor injections of botulinum-A toxin on urodynamics and clinical parameters in<br />
patients with refractory idiopathic detrusor overactivity<br />
D.M. Schmid, S. Roy-Guggenbuehl, B. Schurch, T. Sulser (Zurich, Switzerland)
781 Application of noninvasive near infra red spectroscopy in diagnosis of detrusor overactivity<br />
F. Farag, F.M.J. Martens, J.P.F.A. Heesakkers (Nijmegen, The Netherlands)<br />
782 Serum NOx levels associated with the average voided volume in women with OAB<br />
H. Honjo, N. Nakao, J. Ueyama, T. Kondo, U. Ukimura, K. Kawauchi, K. Kitakoji, H. Hamajima, M. Miki<br />
(Nantan, Nagoya, Kyoto, Japan)<br />
783 Urinary prostaglandin E2 levels are elevated in patients with overactive bladder and painful bladder<br />
syndrome and correlate with bladder diary symptoms<br />
P. Abrams, G. Amarenco, F. Haab, T. Masuda, M. Maria, T. Kuwayama, S. Vincent, S. Deacon (Bristol, London,<br />
United Kingdom; Paris, France)<br />
784 Relation between smoking and urinary storage symptoms in women: A population-based study<br />
K.A.O. Tikkinen, R.M. Tähtinen, A. Auvinen, R. Cartwright, T.M. Johnson, T.L.J. Tammela (Helsinki, Tampere,<br />
Finland; London, United Kingdom; Decatur and Atlanta, United States of America)<br />
785 The relationship between autonomic nervous system activity and detrusor overactivity in women with<br />
urinary incontinence<br />
J.B. Choi, J.C. Kim, Y.Y. Won, H.J. Kim, Y.S. Kim, J.G. Lee, J.T. Seo (Suwon, Seoul, Cheonan, South Korea)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
197
Monday, 19 April - <strong>EAU</strong> Programme<br />
198 Programme Book<br />
Abstract Session<br />
12.15 - 13.45 Surgical management of localised prostate cancer: Technical issues<br />
Milan Room<br />
Poster Session 49<br />
Chairs: C-C. Abbou, Creteil (FR)<br />
P. Hammerer, Braunschweig (DE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
786 Age at surgery and educational level affect long-term urinary incontinence after radical<br />
A.E. Nilsson, M.C. Schumacher, S. Carlsson, G. Steineck, N.P. Wiklund (Stockholm, Sweden)<br />
787 Long-term erectile function after radical retropubic prostatectomy: A comparison to age-matched healthy<br />
controls<br />
M. Auprich, A. Ponholzer, H. Augustin, C. Wehrberger, B. Al-Ali Mohamad, K. Pummer, S. Madersbacher<br />
(Graz, Vienna, Austria)<br />
788 Anastomotic strictures after laparoscopic radical prostatectomy: A single-center analysis of 2200<br />
consecutive patients<br />
M. Hruza, D. Teber, M. Schulze, J. Rassweiler (Heilbronn, Germany)<br />
789 True day case laparoscopic radical prostatectomy (LRP) – proof of principle<br />
S. Agrawal, P.W. Doyle, J.A. Taylor, E.K. Mayer, T.D. Dudderidge, M.H. Winkler, J.U. Stolzenburg (London,<br />
United Kingdom; Leipzig, Germany)<br />
790 Influence of modified posterior reconstruction of the rhabdosphincter on early recovery of continence and<br />
anastomotic leak rates after RALP<br />
R.F.C. Coelho, S. Chauhan, M. Orvieto, K.J. Palmer, V.R. Patel (Celebration, United States of America)<br />
791 Anterior and posterior reconstruction technique and its impact on early return of continence in robot<br />
assisted radical prostatectomy operation<br />
A.R. Kural, F. Atug, I. Tufek, S. Aksit, H. Akpinar (Istanbul, Turkey)<br />
792 Comparison between complication rates, length of stay and costs of minimal invasive vs. open radical<br />
prostatectomy<br />
L. Budäus, G. Lughezzani, M. Sun, D. Liberman, S.F. Shariat, C. Jeldres, T. Steuber, H. Isbarn, A. Haese,<br />
G. Salomon, H. Heinzer, H. Huland, M. Graefen, P.I. Karakiewicz (Hamburg, Germany; Montreal, Canada)<br />
793 The severity of short-term complications following laparoscopic radical prostatectomy (LRP) is more<br />
strongly related to comorbidity than chronological age<br />
G. Vallancien, R. Sanchez-Salas, D. Prapotnich, A. Mombet, N. Cathala, F. Rozet, E. Barret, M. Galiano,<br />
X. Cathelineau (Paris, France)<br />
794 Standardised reporting of complications: Martin criteria and Clavien-Dindo classification in a<br />
contemporary series of 1945 open retropubic radical prostatectomies<br />
B. Löppenberg, J. Noldus, A. Holz, R.J. Palisaar (Herne, Germany)<br />
795 Classification of peri-operative complications in 1250 cases of extra peritoneal robot assisted radical<br />
prostatectomy (RARP)<br />
A. Ghazi, M. Lux, M. Drnevich, H. Patel, J.V. Joseph (Rochester, United States of America)
796 Intrafascial nerve sparing retropubic radical prostatectomy; our technique and one year follow up results<br />
W.Y. Khoder, M. Seitz, O. Reich, A.J. Becker, A. Buchner, C.S. Stief (Munich, Germany)<br />
797 Use of a flexible carbon dioxide laser fiber for precise dissection of the neurovascular bundle during<br />
robotic assisted laparoscopic prostatectomy<br />
P.J. Cheetham, M.J. Truesdale, K.K. Badani (New York, United States of America)<br />
798 Lateral temperature spread of mono- and bipolar robotic instruments: Are they safe for nerve sparing<br />
radical prostatectomy?<br />
L.J. Hefermehl, T. Sulser, D. Eberli (Zurich, Switzerland)<br />
799 Full functional length urethral sphincter preservation during open radical prostatectomy<br />
T. Schlomm, O. Engel, T. Steuber, H. Heinzer, A. Haese, G. Salomon, H. Huland, M. Graefen (Hamburg,<br />
Germany)<br />
800 Preventing ocular injuries during robotic prostatectomy: A simple technique<br />
H.J. Lavery, D.B. Samadi, D.M. Gainsburg (New York, United States of America)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
199
Monday, 19 April - <strong>EAU</strong> Programme<br />
200 Programme Book<br />
Abstract Session<br />
12.15 - 13.45 Hypospadias, testicular function in children<br />
Vienna Room<br />
Poster Session 50<br />
Chairs: M. Eissa, Cairo (EG)<br />
M.M. Fisch, Hamburg (DE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
801 The single stage dorsal inlay skin graft for complex hypospadias reoperations: Long-term follow-up<br />
C. Schwentner, J. Seibold, J. Mundhenk, C. Colleselli, D. Schilling, K.D. Sievert, A. Stenzl, C. Radmayr<br />
(Tübingen, Germany; Innsbruck, Austria)<br />
802 Buccal mucosa onlay graft in hypospadias repair - long-term results<br />
A. Schröder, R. Stein, M. Mascha, J.W. Thüroff (Mainz, Germany)<br />
803 Small intestine submucosa [SIS] as a shelf substitute to buccal mucosa in one stage Snod-graft<br />
urethroplasty for hypospadias repair<br />
Y.A. Farahat, A.R. Abu-Ramadan, M. Rasheed (Tanta, Egypt)<br />
804 Long-term outcome of males with disorders of sexual differentiation (DSD)<br />
C.S. Schwentner, D.S. Schilling, J.S. Seibold, A.S. Stenzl, J.C. Czyzc, M.B.O. Baka-Ostrowska, C.R. Radmayr<br />
(Tübingen, Germany; Warsaw, Poland; Innsbruck, Austria)<br />
805 Can we optimise fertility in undescended testes with orchidopexy and adjuvant hormone therapy?<br />
S.M. Biers, P.S. Malone (Southampton, United Kingdom)<br />
806 Treatment outcome with cryptorchism in Prader-Willi Syndrome<br />
T. Kwon, K.S. Kim, M.C. Park, J.Y. Han (Seoul, South Korea)<br />
807 Surgical outcome of exploration for acute scrotal pain: A consecutive case series of 173 patients<br />
C.N. Molokwu, B.K. Somani, C.M. Goodman (Dundee, United Kingdom)<br />
808 Anti-oxidant and selective cyclooxygenase 2 inhibitor combination in a rat testicular torsion model: Does it<br />
really work?<br />
S. Gurocak, I. Ure, A. Cumaoglu, I.I. Gonul, A. Aricioglu, I. Bozkirli (Ankara, Turkey)<br />
809 Testicular size and catch-up growth after lymphatic-sparing and lymphatic non-sparing varicocele repair<br />
in children and adolescents<br />
R. Kocvara, J. Sedlácek, Z. Díte, J. Dvorácek (Prague, Czech Republic)<br />
810 Modified clavien classification in percutaneous nephrolithotomy: Assessment of complications in children<br />
E. Özden, M.N. Mercimek, Y.K. Yakupoglu, O. Özkaya, S. Sarıkaya (Samsun, Turkey)<br />
811 Transitioning care of complex paediatric urological to adult services<br />
D.N. Wood, B. Carr, K. Robinson, C.R.J. Woodhouse (London, United Kingdom)
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
12.15 - 13.45 Urothelial tumours: Basic research 1<br />
Athens Room<br />
Poster Session 51<br />
Chairs: M. Babjuk, Prague (CZ)<br />
J.W.F. Catto, Sheffield (GB)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
812 Genetic variability within 8q24 confers enhanced risk of urothelial cell carcinoma of the upper urinary tract<br />
M. Rouprêt, E. Comperat, S.J. Drouin, G. Cancel-Tassin, C. Gaffory, M. Sibony, M.O. Bitker, O. Cussenot (Paris,<br />
France)<br />
813 Molecular characterisation of upper urinary tract tumours<br />
L. Izquierdo, L. Mengual, C. Gazquez, M. Ingelmo-Torres, A. Alcaraz (<strong>Barcelona</strong>, Spain)<br />
814 Importance of allelic instability of urinary microsatellites markers for conservative management of upper<br />
urinary tract urothelial cell carcinoma<br />
J-N. Cornu, M. Roupret, S. Gil Diez De Medina, R. Lacave, O. Traxer, O. Cussenot (Paris, France)<br />
815 Low frequency of epigenetic events in urothelial tumours from young patients<br />
J.W.F. Catto, H.C. Owen, J. Giedl, P.J. Wild, S.W. Fine, J.I. Epstein, P.A. Humphrey, L.P. Dehner, M.B. Amin,<br />
H. Blaszyk, D. Hughes, A. Hartmann, R. Stoehr (Sheffield, United Kingdom; Erlangen, Germany; Zurich,<br />
Switzerland; Baltimore, St Louis, Atlanta, Burlington, United States of America)<br />
816 The utilisation of urinary microRNA as a potential biomarker for bladder cancer<br />
S. Miah, E. Dudziec, D. Rosario, F. Hamdy, J. Catto (Sheffield, United Kingdom)<br />
817 Myopodin methylation is a prognostic and predictive marker to the bacillus of Calmette-Guérin (BCG)<br />
response in patients with T1G3 bladder cancer<br />
M. Álvarez Múgica, V. Cebrían, J.M. Fernández Gómez, F. Fresno, S. Escaf Barmadah, M. Sánchez-Carbayo<br />
Martín (Langreo, Madrid, Oviedo, Gijón, Spain)<br />
818 Human gene polymorphism and response to bacillus Calmette-Guerin immunotherapy for superficial<br />
bladder cancer<br />
E. Chiong, A. Kesavan, R. Mahendran, Y.H. Chan, T.M.C. Tan, K. Esuvaranathan (Singapore, Singapore)<br />
819 Loss of heterozygosis on IFN-alfa locus is a prognostic indicator of BCG response in non-muscle invasive<br />
bladder cancer<br />
T. Cai, G. Nesi, N. Mondaini, P. Geppetti, R. Bartoletti (Florence, Italy)<br />
820 Polymorphisms in DNA repair genes and bladder cancer<br />
P. Gontero, G. Casetta, A. Tizzani, A. Zitella, P. Destefanis, D. Fontana, C. Sacerdote, G. Matullo, F. Ricceri,<br />
P. Vineis (Turin, Italy)<br />
821 MiR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder<br />
cancer<br />
T. Chiyomaru, H. Enokida, S. Tatarano, K. Kawahara, K. Nishiyama, N. Seki, M. Nakagawa (Kagoshima, Aira-<br />
Cho, Chiba, Japan)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
201
822 Splicing variants of carbonic anhydrase IX in bladder cancer and urine sediments<br />
C. Selli, F. Malentacchi, S. Vinci, A. Della Melina, J. Kuncova, G. Giannarini, D. Villari, C. Orlando (Pisa,<br />
Florence, Italy)<br />
823 Combined treatment with cisplatin and dual PI3K-mTOR inhibitor NVP-BEZ235 can restore caspase<br />
dependent apoptosis in cisplatin resistant human bladder cancer cell through the down-regulation of<br />
c-FLIP<br />
S.S. Byun, C.Y. Yoon, M.J. Park, S.W. Doo, H.Z. Park, D.S. Kim, W.K. Lee, S.H. Paick, S.J. Jeong, S.K. Hong,<br />
E.S. Lee, S.E. Lee (Bundang, Gyunggi, Seoul, South Korea)<br />
824 PI3K/Akt/mTOR signaling in urothelial carcinoma and its value in cancer therapy<br />
R. Nawroth, F. Stellwagen, R. Stöhr, J.E. Gschwend, A. Hartmann, M. Retz (Munich, Erlangen, Germany)<br />
825 Synergistic anti-tumour effect of trichostatin A (TSA) and cisplatin against chemo-resistant human bladder<br />
cancer cells<br />
C.Y. Yoon, M.J. Park, S.W. Doo, H.Z. Park, D.S. Kim, W.K. Lee, S.H. Paick, S.J. Jeong, S.K. Hong, S.S. Byun,<br />
E.S. Lee, S.E. Lee, M.J. Park (Bundang, Gyunggi, Hwayang-Dong, Gwangjjin-Ku, South Korea)<br />
826 Blockade of sonic hedgehog pathway inhibits the proliferation and contributes to the enhancement of<br />
chemosensitivity of bladder cancer cells<br />
Y. Matsui, S. Narita, B.A. Hadaschik, M.E. Gleave, A.I. So (Kyoto, Japan; Vancouver, Canada)<br />
202 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
12.15 - 13.45 PLND and oncological outcome in advanced disease<br />
Padua Room<br />
Poster Session 52<br />
Chairs: A. Briganti, Milan (IT)<br />
M.C. Schumacher, Stockholm (SE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
827 Is the region of pelvic lymph node dissection associated with lymphorrhea after radical prostatectomy and<br />
pelvic lymph node dissection?<br />
U. Capitanio, A. Briganti, A. Salonia, L. Villa, N. Passoni, G. Gandaglia, G. Guazzoni, G. Petralia, G. Zanni,<br />
F. Pellucchi, P.I. Karakiewicz, P. Rigatti, F. Montorsi (Milan, Italy; Montreal, Canada)<br />
828 Can we predict lymphorrhea and clinically significant lymphoceles after radical prostatectomy and pelvic<br />
lymph node dissection?<br />
U. Capitanio, A. Briganti, N. Fossati, A. Russo, L. Rocchini, G. Gadda, G. Guazzoni, F. Sozzi, F. Pellucchi,<br />
P. Karakiewicz, P. Rigatti, F. Montorsi (Milan, Italy; Montreal, Canada)<br />
829 The impact of pelvic lymph-node dissection and of its extent on biochemical relapse after radical<br />
prostatectomy in patients with pathological N0 or NX at intermediate and high risk of lymph-node invasion<br />
R. Schiavina, A. Franceschelli, A. Bertaccini, F. Manferrari, M. Garofalo, U. Dababne, R. Pernetti, M. Guidi,<br />
V. Vagnoni, S. Molducci, G. Martorana (Bologna, Italy)<br />
830 Pelvic lymphoceles post radical prostatectomy; a search for answers<br />
W.Y. Khoder, M. Trottmann, A. Buchner, C.G. Stief, A.J. Becker (Munich, Germany)<br />
831 Sentinel-lymphadenectomy in radical prostatectomy: Can we rely on this technique?<br />
M.C. Klitsch, M. Schenner, C. Broessner, P. Schramek (Vienna, Austria)<br />
832 Value of extended lymph node dissection in node positive high-risk localised prostate cancer is uncertain<br />
S. Joniau, P. Gontero, A. Briganti, G. Marchioro, B. Akdogan, C.Y. Hsu, K. Vander Eeckt, P. Bader, B. Kneitz,<br />
J. Walz, D. Frohneberg, M. Graefen, F. Montorsi, A. Tizzani, B. Tombal, P. Van Cangh, H. Van Poppel,<br />
M. Spahn (Leuven, Brussels, Belgium; Turin, Milan, Novarra, Italy; Karlsruhe, Würzburg, Hamburg,<br />
Germany)<br />
833 The impact of the extent of lymph-node dissection on biochemical relapse after radical prostatectomy in<br />
node-negative and node-positive patients: Behind the Will Rogers phenomenon?<br />
R. Schiavina, A. Franceschelli, E. Brunocilla, S. Concetti, M. Garofalo, V. Vagnoni, S. Molducci, R. Pernetti,<br />
C. Bizzarri, A. Baccos, F. Borgatti, F. Manferrari, G. Martorana (Bologna, Italy)<br />
834 The majority of patients with locally advanced prostate cancer have good long term survival after radical<br />
prostatectomy and extended lymph node dissection<br />
F.C. Burkhard, P.Y. Wuethrich, G.N. Thalmann, U.E. Studer (Berne, Switzerland)<br />
835 Oncologic results for extraperitoneal versus transperitoneal radical prostatectomy<br />
R.E. Sanchez-Salas, X. Cathelineau, F. Bianco Jr, F. Rozet, E. Barret, F.P. Secin, M. Galiano, D. Prapotnich,<br />
A. Mombet, N. Cathala, G. Vallancien (Paris, France; Miami, United States of America; Buenos Aires,<br />
Argentina)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
203
836 Long-term outcome of Gleason 8-10 node negative prostate cancer: The importance of local control<br />
A. Gallina, A. Briganti, N. Suardi, A. Salonia, L. Barbieri, L. Villa, G. Gandaglia, M. Bianchi, G. Gadda, D. Di<br />
Trapani, A. Losa, P. Rigatti, F. Montorsi (Milan, Italy)<br />
837 PSA > 20ng/ml does not rule out radical prostatectomy in high risk patients following NCCN criteria<br />
attending metastatic progression free survival<br />
J. Rubio-Briones, I. Iborra, A. Collado, A. Gómez-Ferrer, J. Casanova, J.L. Monrós, J.V. Ricós, M. Trassierra,<br />
E. Solsona (Valencia, Spain)<br />
838 Predicting prostate cancer specific outcome among men with PSA > 20 ng/ml and multiple unfavourable<br />
risk factors: A multi-institutional outcome study of 712 Patients<br />
M. Spahn, P. Gontero, B. Kneitz, B. Tombal, C.Y. Hsu, K. Van Der, G. Marchioro, P. Bader, D. Frohneberg,<br />
A. Tizzani, H. Van Poppel, S. Joniau (Würzburg, Karlsruhe, Germany; Turin, Italy; Brussels, Leuven, Belgium)<br />
839 Long-term oncological outcome in men with high risk prostate cancer treated with antegrade radical<br />
prostatectomy with intended wide resection<br />
S. Yamamoto, J. Yonese, S. Kawakami, S. Urakami, S. Kitsukawa, N. Numao, Y. Fujii, H. Masuda, Y. Ishikawa,<br />
I. Fukui (Tokyo, Japan)<br />
840 Prospective evaluation of combined oncologic and functional outcomes after laparoscopic radical<br />
prostatectomy: Rate of achieving continence, potency and cancer control at 2 years<br />
G. Ploussard, A. De La Taille, Y. Allory, D. Vordos, A. Hoznek, C. Abbou, L. Salomon (Creteil, France)<br />
841 Positive margin rate, location, and size following laparoscopic versus robotic-assisted laparoscopic radial<br />
prostatectomy<br />
A. Kasraeian, E. Barret, X. Xavier, F. Rozet, M. Galiano, G. Vallancien (Paris, France)<br />
204 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
14.00 - 15.30 Reconstructive surgery and innovations<br />
eURO Auditorium<br />
Video Session 7<br />
Chairs: C.E. Iselin, Geneve (CH)<br />
M. Zerbib, Paris (FR)<br />
All presentations have a maximum length of 10 minutes, followed by 4 minutes of discussion.<br />
V40 Posterior urethroplasty using a combined surgical and endoscopical technique<br />
E. Palminteri, E. Berdondini, M. Poluzzi, A. Molon, G. Franco, V. Gentile (Arezzo, Negrar, Rome, Italy)<br />
V41 Hypospadias repair - inlay-onlay urethroplasty<br />
A. Oeztuerk, N. Djakovic, B. Hadaschik, J. Nyarangi-Dix, J. Pfitzenmaier, S. Pahernik, A. Haferkamp,<br />
M. Hohenfellner (Heidelberg, Germany)<br />
V42 One sided urethral dissection for full length stricture<br />
S.B. Kulkarni, G.V. Barbagli (Pune, India; Arezzo, Italy)<br />
V43 Reconstruction of a completely destroyed urethra from the sphincter up to the meatus by bucal mucosa<br />
graft<br />
J. Beier, H. Keller (Hof, Germany)<br />
V44 GreenLEP, Greenlight laser enucleation of the prostate<br />
F. Gomez Sancha (Madrid, Spain)<br />
V45 Intraoperative photodynamic evaluation of surgical margins in endoscopic extra peritoneal radical<br />
prostatectomy with the use of 5-aminolevulinic acid<br />
R. Ganzer, A. Blana, S. Denzinger, W.F. Wieland, C. Adam, A. Becker, W. Khoder, S. Walther, C.G. Stief,<br />
D. Zaak, G. Salomon, A. Hartmann, S. Bertz, R. Knuechel, G. Popken (Regensburg, Munich, Hamburg,<br />
Erlangen, Aachen, Berlin, Germany)<br />
V46 Robotic anterior pelvic exenteration with intracorporeal urinary diversion in the female<br />
G. D’Elia, P. Emiliozzi, G. Ortolani, A. Iannello (Rome, Italy)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
205
Monday, 19 April - <strong>EAU</strong> Programme<br />
206 Programme Book<br />
Abstract Session<br />
14.00 - 15.30 History of Urology 1<br />
Amsterdam Room<br />
Oral Session 11<br />
Chairs: D. Schultheiss, Giessen (DE)<br />
R. Vela Navarrete, Madrid (ES)<br />
All presentations are 7 minutes in length, followed by 2 minutes of discussion.<br />
842 Alexander von Lichtenberg (1880-1949), the scientist and his fate in Nazi Germany<br />
F.H. Moll, M. Krischel, H. Fangerau (Cologne, Ulm, Germany)<br />
843 Celsus’ De Medicina. The first reference book in Urology?<br />
V.P. Simaioforidis, S. Kontos, M. Karavitakis, C. Komninos, V. Politis, S. Koritsiadis (Piraeus, Greece)<br />
844 Sir Harold Gillies: Pioneer of phalloplasty and the birth of uroplastic surgery<br />
R. Nair, S. Sriprasad (London, Dartford, United Kingdom)<br />
845 Withdrawn<br />
846 The second oldest urological department in Europe is 90 years old: A historical review<br />
A. Szendröi, I. Romics (Budapest, Hungary)<br />
847 The legacy of Eugen von Hippel and Arvid Lindau<br />
R. Barod, S. Sriprasad (London, Dartford, United Kingdom)<br />
848 Management of urolithiasis in the kingdom of Valencia<br />
A.A. Mohammed, I.S. Shergill, A. Goyal, M. Palmer (Glasgow, London, United Kingdom)<br />
849 Josep Trueta I Raspall and studies of the renal circulation: Descriptions by a surgeon from <strong>Barcelona</strong><br />
A.A. Mohammed, A. Goyal, I.S. Shergill, M. Palmer (Glasgow, Essex, United Kingdom)
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
14.00 - 15.30 Tumor cell biology and (molecular) endocrinology of prostate cancer<br />
<strong>Barcelona</strong> Room<br />
Poster Session 53<br />
Chairs: M. Cecchini, Berne (CH)<br />
H. Uemura, Osaka-Sayama (JP)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
850 Differential androgen receptor expression and downregulation in matched lymph node metastases<br />
G.N. Thalmann, C. Rocha, S. Schobinger, R. Seiler, A. Fleischmann (Berne, Switzerland)<br />
851 Pim1 and androgen regulation through 17-beta-HSD type 2<br />
H.G. Van Der Poel, J. Van Zevenhoven, A.M. Bergman (Amsterdam, The Netherlands)<br />
852 Effects of endocrine therapy on mRNA- and microRNA expression profiles in prostate cancer<br />
T.L.J. Tammela, S. Lehmusvaara, T. Erkkilä, H. Lähdesmäki, P. Kujala, T. Visakorpi (Tampere, Finland)<br />
853 Proteomic investigation of diethylstilbestrol action on a prostate cancer cell line 22RV1 by 2D-difference gel<br />
electrophoresis and mass spectrometry<br />
P. Bigot, A. Bourreau, S. Lebdai, A. Moulière, O. Coqueret, E. Gamelin, F.R. Bataille, O. Cussenot, C. Guette,<br />
A.R. Azzouzi (Angers, Paris, France)<br />
854 Sex steroids metabolism in benign and malignant prostate tissue: An ex-vivo model to characterise the<br />
role of enzymatic profile in biological behaviour<br />
L.C. Leonardo, I.A. Isidori, T.N. Tartaglia, P.S. Pierotti, S.M. Salvitti, C.M. Ciccariello, L.A. Lenzi, D.C. De<br />
Dominicis (Rome, Italy)<br />
855 Targeted knockdown of SEPT9_v1 inhibits tumour growth and angiogenesis of human prostate cancer cells<br />
concomitant with disruption of HIF-1 pathway<br />
S. Amir, M. Golan, N. Mabjeesh (Tel Aviv, Israel)<br />
856 Downregulation of mir-221 promotes cancer cell proliferation, is related to the development of aggressive<br />
prostate cancer and predicts clinical recurrence<br />
M. Spahn, S. Kneitz, C.J. Scholz, C. Kalogirou, P. Ströbel, M. Possner, H. Riedmiller, B. Kneitz (Würzburg,<br />
Mannheim, Germany)<br />
857 Sarcosine induces increase in HER2/neu expression in prostate cancer cells<br />
M. Dahl, P. Bouchelouche, G. Kramer-Marek, J. Capala, J. Nordling, K. Bouchelouche (Koege, Herlev,<br />
Denmark; Bethesda, United States of America)<br />
858 Core3 o-glycan synthase suppresses tumour formation and metastasis of prostate carcinoma PC3 and<br />
LNCaP cells through down-regulation of α2β1 integrin complex<br />
S. Hatakeyama, S.H. Lee, H. Yamamoto, A. Okamoto, T. Okamoto, K. Imanishi, Y. Suzuki, N. Sugiyama,<br />
S. Kudo, T. Yoneyama, Y. Hashimto, T. Koie, N. Kamimura, C. Ohyama, M. Fukuda (Hirosaki, Japan; La Jola,<br />
United States of America)<br />
859 Zoledronic acid and GGTI can augment docetaxel-induced growth inhibition in prostate cancer cells<br />
N. Fujimoto, B. Han, M. Shiota, I. Tomisaki, M. Kobayashi, A. Yokomizo, S. Naito, T. Matsumoto (Kitakyushu,<br />
Fukuoka, Japan)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
207
860 What can the hair follicles and salivary glands tell us about the oxidative stress status of the prostate? A<br />
preclinical step towards individualisation of prostate cancer prevention strategies<br />
J.H. Pinthus, K. Whelan, J.P. Lu, E. Fridman (Hamilton Ontario, Canada)<br />
861 Statin inhibits the proliferation of human prostate cancer cells via down-regulation of the survivin<br />
H. Koike, Y.S. Sekine, Y.F. Furuya, Y.M. Morikawa, M.H. Matsui, Y.S. Shibata, K.S. Suzuki (Maeabshi, Japan)<br />
862 Differential distribution of nNOS and PGP 9.5 stained prostate peripheral nerve tissue – evidence for main<br />
locations of erectile nerve tissue along a basolateral-towards-dorsoapical track along the prostate<br />
J. Hennenlotter, U. Kuehs, T. Dillenburg, S. Kruck, B. Amend, A. Stenzl, K.D. Sievert (Tübingen, Germany)<br />
863 Heme oxygenase-1 and carbon monoxide modulate responses to DNA damage and arrest tumour growth<br />
B. Wegiel, A. Bjartell, C. Harris, J. Belcher, G. Vercellotti, D. Gallo, E. Csizmadia, A. Ahmed, L. Helczynski,<br />
J. Persson, L. Otterbein (Boston, Minneapolis, United States of America; Malmo, Sweden; Birmingham,<br />
United Kingdom)<br />
864 Monoamine oxidase A: A new candidate therapeutic target for advanced prostate cancer<br />
V. Flamand, H. Zhao, D.M. Peehl (La Madeleine, France; Stanford, United States of America)<br />
208 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
14.00 - 15.30 Prognostic biomarkers<br />
Paris Room<br />
Poster Session 54<br />
Chairs: M. Kwiatkowski, Aarau (CH)<br />
S. Larré, Sheffield (GB)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
865 Ultrasensitive prostate-specific antigen nadir and time to nadir as independent predictors of biochemical<br />
recurrence in patients after radical prostatectomy for localised prostate cancer<br />
S. Vesely, L. Jarolim, M. Babjuk, P. Dusek, V. Kaliska, M. Schmidt (Prague, Czech Republic)<br />
866 Withdrawn<br />
867 Parameters associated with the absence of biochemical recurrence in patients with positive surgical<br />
margins after radical prostatectomy<br />
S. Tyritzis, I. Anastasiou, I. Adamakis, D. Mitropoulos, K.G. Stravodimos, K. Pavlakis, C.A. Constantinides<br />
(Athens, Greece)<br />
868 Pilot trial for the quantitative detection of circulating tumor cells in patients with prostate cancer<br />
M.K. Thalgott, R. Nawroth, U. Andergassen, B.K. Rack, T. Maurer, M. Heck, T. Horn, K. Herkommer,<br />
J.E. Gschwend, M. Retz (Munich, Germany)<br />
869 Preoperative low serum testosterone levels are associated with tumour aggressiveness in radical<br />
prostatectomy treated cancer patients: A new insight<br />
Y. Neuzillet, H. Botto, P. Camparo, V. Molinié, T. Lebret, J.P. Raynaud (Suresnes, Paris, France)<br />
870 CEACAM1 expression distinguishes indolent from lethal prostate cancer<br />
D. Tilki, M.A. Svensson, S.F. Shariat, B.B. Singer, O. Reich, C.G. Stief, O. Andrén, S.O. Andersson,<br />
J.E. Johansson, F. Demichelis, M.A. Rubin, S. Ergün, S. Rafii (New York, United States of America; Essen,<br />
Munich, Germany; Örebro, Sweden)<br />
871 Urine measurement of TMPRSS2:ERG for the early detection of significant prostate cancer<br />
J. Groskopf, S.M.J. Aubin, S.A. Tomlins, K. Sakamoto, J. Silberstein, J. Siddiqui, Y. Penabella, Y. Fradet,<br />
H. Rittenhouse, A. Chinnaiyan (San Diego, Ann Harbor, United States of America; Quebec, Canada)<br />
872 Proteolitic activity of prostate secretions in prostate cancer patients<br />
M.I. Kogan, M.B. Chibichyan, A.A. Afoko, E.A. Chernogubova (Rostov on Don, Russia)<br />
873 High CD10 expression in primary prostate cancer and matched nodal metastases predicts early deaths in<br />
surgically treated patients<br />
A. Fleischmann, C. Rocha, N. Seculic, I. Slobek, G. Sauter, G.N. Thalmann (Berne, Basel, Switzerland;<br />
Hamburg, Germany)<br />
874 Cytoplasmic Cyclin D1 in lymph node metastases independently predicts survival in surgically treated<br />
prostate cancer patients<br />
A. Fleischmann, C. Rocha, N. Seculic, I. Zlobec, G. Sauter, G.N. Thalmann (Berne, Basel, Switzerland;<br />
Hamburg, Germany)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
209
875 A shorter time to prostate-specific antigen nadir following androgen suppression therapy predicts poorer<br />
survival in prostate cancer patients<br />
A. Gagnat, O. Celhay, C. Pirès, G. Fromont, B. Doré, J. Irani (Poitiers, France)<br />
876 Increased sphingosine kinase-1 activity and expression in prostate cancer<br />
B. Malavaud, D. Pchejetski, C. Mazerolles, G. Russano De Paiva Silva, C. Calvet, D. Doumerc, S. Pitson,<br />
P. Rischmann, O. Cuvillier (Toulouse, France; Adelaide, Australia)<br />
877 Body mass index and serum lipid profile influence serum prostate-specific antigen in Chinese men<br />
younger than 50 years of age<br />
M. Liu, J.Y. Wang, L. Zhu (Beijing, China)<br />
878 Design and validation of novel transgenic models over-expressing catalytic or non-catalytic prostatespecific<br />
antigen (PSA) in the mouse prostate: Association with release of PSA into blood<br />
C. Von Bodman, A. Byers, M.P. Matikainen, A. Benchikh, D. Mehta, S. Wenske, T.R. Hricik, H.I. Scher,<br />
P.T. Scardino, H. Lilja (New York, United States of America)<br />
210 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
14.00 - 15.30 Intervention therapy in BPH<br />
Stockholm Room<br />
Poster Session 55<br />
Chairs: G.J. Alivizatos, Athens (GR)<br />
O. Reich, Munich (DE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
879 The Prostatic Urethral Lift: Update on a novel treatment for lower urinary tract symptoms secondary to<br />
BPH conducted with local anesthesia<br />
P.T. Chin, H.H. Woo, T.A. Mc Nicholas, H.S. Gill, M.K. Plante, R.C. Bruskewitz, C.G. Roehrborn (Wahroonga,<br />
Sydney, Australia; Hatfield, United Kingdom; Stanford, Burlington, Madison, Dallas, United States of<br />
America)<br />
880 The risk factors for sustained bladder irritation symptoms after transurethral resection of the prostate<br />
J.M. Song, H.C. Chung, D.I. Kim, J.W. Chun (Won Ju, South Korea)<br />
881 Is surgical smoke produced by combined transurethral resection and vaporisation of the prostate toxic to<br />
operating personnel?<br />
J.K. Park, C. Zhao, M.K. Kim, Y.B. Jung, S.W. Kim (Jeonju, Seoul, South Korea)<br />
882 TURP and sex - patient and partner prospective 12 years follow-up study<br />
S.F. Mishriki, C.N. Molokwu, S.J.S. Grimsley, T. Lam, G. Nabi, N.P. Cohen (Aberdeen, United Kingdom)<br />
883 Does changes of serum prostate specific antigen concentration after laser prostatectomy reflect the<br />
completeness of adenoma resection? Comparison between KTP-PVP and holmium laser enucleation of the<br />
Prostate (HoLEP)<br />
D.H. Koo, J.S. Yi, M.C. Cho, J.H. Ku, S.W. Kim, J.S. Paick (Seoul, South Korea)<br />
884 Comparison between bipolar versus monopolar transurethral resection of the prostate: A randomised<br />
prospective trial<br />
D.M. Gulur, M.H.C. Goh, J.J. Anning, A.A. Okeke, H.W. Gilbert, R.B. Kinder, A.G. Timoney (Bristol, Gloucester,<br />
Cheltenham, United Kingdom)<br />
885 TURis plasma vaporisation of the prostate versus standard TURP: “The better choice” in BPH?<br />
B. Geavlete, D.R. Multescu, M.D. Dragutescu, M. Jecu, D.A. Georgescu, P.A. Geavlete (Bucharest, Romania)<br />
886 Endoscopic resection of prostate using bipolar system (Gyrus plasma kinetic): Over 2000 procedures with 5<br />
years follow-up. Critical review of our department experience<br />
R. Giulianelli, F. Pisanti, B.C. Gentile, S. Brunori, L. Mavilla, L. Albanesi, F. Attisani, T. Shestani, G. Vincenti<br />
(Rome, Italy)<br />
887 <strong>EAU</strong> Real-Life Data Registry: Long-term efficacy and safety of transurethral needle ablation (TUNA®) in<br />
over 500 men with LUTS/BPH<br />
A. Tubaro, K. Hoefner, H. Villavicencio, J.J. De La Rosette, C.R. Chapple (Rome, Italy; Oberhausen, Germany;<br />
<strong>Barcelona</strong>, Spain; Amsterdam, The Netherlands; Sheffield, United Kingdom)<br />
888 Usefulness of real-time transrectal ultrasound navigation for shortening the learning curve when<br />
mastering the holmium laser enucleation technique for symptomatic benign prostatic hyperplasia<br />
Y. Shibata, S. Arai, H. Koike, K. Ito, K. Suzuki (Maebashi, Japan)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
211
889 Antegrade dissection HoLEP requires shorter learning curves<br />
F. Endo, S. Shiga, S. Minagawa, T. Iwabuchi, A. Fujisaki, T. Sugimura, M. Yashi, K. Hattori, O. Muraishi<br />
(Tokyo, Japan)<br />
890 Photoselective vaporisation of the prostate (PVP) using the greenlight laser versus transurethral<br />
prostatectomy (TURP): A comparing cost analysis<br />
I. Kyriazis, P. Kallidonis, N. Flaris, C. Rigopoulos, E. Liatsikos (Patras, Greece)<br />
891 Long-term results of photoselective vaporisation of the prostate in patients with ongoing anticoagulation,<br />
thrombocyte aggregation inhibition and large prostates<br />
M. Rieken, G. Bonkat, C. Rentsch, S. Wyler, T. Gasser, A. Bachmann (Basel, Switzerland)<br />
892 TUR-P (E): Endoscopic enucleation of benign prostatic hyperplasia: A new resection technique<br />
J. Raßler, J.U. Kempter (Leipzig, Germany)<br />
893 Photoselective LBO-green light-laser vaporisation versus Thulium laser vaporesection of the prostate: A<br />
prospective bi-centre comparison of peri-operative and early functional outcome<br />
T. Hermanns, W. Batzill, L.J. Hefermehl, O. Gross, D.D. Strebel, S. Talimi, T. Krings, H. Schwarz, H.H. Seifert,<br />
T. Sulser, J. Westphal (Zurich, Switzerland; Krefeld, Germany)<br />
212 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
14.00 - 15.30 Hormone refractory prostate cancer<br />
Milan Room<br />
Poster Session 56<br />
Chairs: K. Miller, Berlin (DE)<br />
J. Morote Robles, <strong>Barcelona</strong> (ES)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
894 Is 3-months post-treatment RECIST evaluation of bone metastases by MRI of the axial skeleton (asMRI) a<br />
surrogate endpoint for predicting overall survival (OS) of prostate cancer (PCa) patients?<br />
B. Tombal, J.P. Machiels, A. Stainier, B. Vanden Berg, F. Lecouvet (Brussels, Belgium)<br />
895 Pretreatment PSA growth pattern predicts early death after chemotherapy in patients with androgenindependent<br />
prostate cancer<br />
K.S. Han, Y.H. Lee, H.G. Jeon, H.S. Ryu, K.H. Choi, Y.D. Choi, S.C. Yang, S.J. Hong (Seoul, South Korea)<br />
896 Re-treatment with docetaxel in metastatic castration resistant prostate cancer (CRPC)<br />
A.G. Gernone, G.T. Troccoli, V.P. Pagliarulo, A.P. Pagliarulo (Bari, Italy)<br />
897 Docetaxel is effective to estrogen-refractory prostate cancer but not to estrogen- and glucocorticoidrefractory<br />
prostate cancer<br />
T. Kijima, S. Kawakami, A. Yano, Y. Okada, Y. Sakai, K. Saito, F. Koga, H. Masuda, Y. Fujii, K. Kihara (Tokyo,<br />
Japan)<br />
898 Docetaxel: Rechallenge at PSA relapse after docetaxel chemotherapy at hormone refractory prostate cancer<br />
P. Firek, D. Pfister, D. Thüer, B. Brehmer, R. Epplen, A. Heidenreich (Aachen, Germany)<br />
899 Docetaxel rechallenge versus docetaxel/bevacizumab in castration-resistant prostate cancer following first<br />
line docetaxel<br />
A. Heidenreich, D. Thüer, D. Pfister, B. Bernhard (Aachen, Germany)<br />
900 Phase II study of a combination of a LHRH analogue, dezamethasone and a somatostatin analogue (SM-A)<br />
versus a LHRH analogue with dexamethasone in refractory prostate cancer patients<br />
F. Calais Da Silva Junior, F.E. Calais Da Silva, T. Oliver, G. Frederico (Lisbon, Portugal; London, United<br />
Kingdom; Bratislava, Slovakia)<br />
901 Somatostatin analog in the treatment of androgen–independent prostate cancer before and after<br />
chemotherapy<br />
B.Y. Alekseev, I.G. Rusakov, A.D. Kaprin, O.I. Apolihin, A.V. Sivkov, R.A. Gafanov, S.V. Bystrov,<br />
G.V. Vereshagin, V.N. Oshepkov, N.G. Keshishev (Moscow, Russia)<br />
902 Withdrawn<br />
903 Impact of zoledronic acid on fractures and mortality in patients with prostate cancer and bone metastases<br />
H.J. Henk, S. Kaura (Eden Prairie, Florham Park, United States of America)<br />
904 Initial results from Phase I/II trial with dendritic cells loaded with an allogeneic prostate cancer-lysate in<br />
hormone-refractory prostate cancer patients<br />
D. Reyes, M.N. Lopez, C. Pereda, R. Aguilera, F. Salazar-Onfray (Santiago, Chile)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
213
905 Antitumour activity of MDV3100 in a phase 1-2 study of advanced prostate cancer<br />
H.I. Scher, T.M. Beer, C. Higano, M. Taplin, E. Efstathiou, M. Hirmand (New York, Portland, Seattle, Boston,<br />
Houston, San Francisco, United States of America)<br />
214 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
14.00 - 15.30 Outcomes in the surgical management of prostate cancer<br />
Vienna Room<br />
Poster Session 57<br />
Chairs: S. Brewster, Oxford (GB)<br />
M. Graefen, Hamburg (DE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
906 Pathological evaluation of radical prostatectomy specimens in 605 patients eligible for active surveillance<br />
(AS)<br />
J.B. Beauval, M. Thoulouzan, N. Doumerc, C. Bastide, S. Van Agt, C. Pfister, J.A. Long, M. Peyromaure,<br />
F. Iborra, J. Rigaud, S. Larue, M. Roupret, N. Gashignard, S. Vincendeau, J.J. Patard, M. Soulie, L. Salomon<br />
(Toulouse, Marseille, Rouen, Grenoble, Paris, Montpellier, Nantes, La Roche Sur Yon, Rennes, Creteil,<br />
France; Sydney, Australia)<br />
907 Outcome of patients potentially suitable for active surveillance undergoing radical prostatectomy as first<br />
treatment choice. Results of intermediate-term follow-up<br />
N. Suardi, U. Capitanio, A. Briganti, A. Gallina, F. Abdollah, N. Fossati, M. Freschi, P. Karakiewicz, D. Di<br />
Trapani, P. Rigatti, F. Montorsi (Milan, Italy; Montreal, Canada)<br />
908 Inverse stage migration of organ confined prostate cancer in the 21st century: A retrospective analysis of<br />
8346 radical prostatectomy patients<br />
T. Steuber, J. Spethmann, H. Isbarn, H. Heinzer, A. Haese, G. Sauter, M. Graefen (Hamburg, Germany)<br />
909 Primary vs. deferred radical prostatectomy in the National Prostate Cancer Register (NPCR) of Sweden<br />
B. Holmström, E. Holmberg, L. Egevad, J. Adolfsson, J.E. Johansson, J. Hugosson, P. Stattin (Gävle,<br />
Gothenburg, Stockholm, Örebro, Umeå, Sweden)<br />
910 International validation of the CAPRA score for predicting recurrence following radical prostatectomy (RP):<br />
Results from an Australian cohort<br />
S. Chopra, C. Pinnock, D. Tamblyn, T. Kopsaftis, P. Sutherland (Adelaide, Australia)<br />
911 Time trends in surgical treatment of prostate cancer (PCa): Findings from a German internet-based quality<br />
assurance project<br />
S. Weikert, D. Baumunk, A. Jagota, C. Klopf, A. Winter, S. Schäfers, R. Kössler, K. Miller, M. Schostak (Berlin,<br />
Germany)<br />
912 Withdrawn<br />
913 UK radical prostatectomy experience and outcomes: Based on an analysis of the BAUS Section of Oncology<br />
Complex Operations Database<br />
S.G. Vesey, J.E. McCabe, S. Fowler (Liverpool, Southport, London, United Kingdom)<br />
914 An analysis of learning curve, margin status and early post operative outcomes in 1200 robotic assisted<br />
laparoscopic prostatectomies; an Australian experience<br />
D.V. Gyomber, D.M. Bolton, A. Crosthwaite, L. Harewood, D. King, P. Ruljancich, D.R. Webb (Melbourne,<br />
Australia)<br />
915 The influence of body mass index on the cost of radical prostatectomy for prostate cancer<br />
C. Bolenz, A. Gupta, T. Hotze, R. Ho, J.A. Cadeddu, C.G. Roehrborn, Y. Lotan (Dallas, United States of<br />
America)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
215
916 High body mass index does not affect outcomes of robotic-assisted laparoscopic prostatectomy<br />
F. Nabizada-Pace, H. Lavery, J. Brajtbord, P. Senaratne, D. Samadi (New York, United States of America)<br />
917 What is the age limit for radical therapy in prostate cancer patients? Analysis on patient survival<br />
N. Suardi, A. Briganti, U. Capitanio, A. Gallina, F. Abdollah, R. Colombo, L.F. Dapozzo, P.I. Karakiewicz,<br />
P. Rigatti, F. Montorsi (Milan, Italy; Montreal, Canada)<br />
918 Robotic-assisted radical prostatectomy in older men<br />
B.J. Challacombe, D. Murphy, M. Hong, R. Weston, M. Kerger, J. Peters, A.J. Costello (Melbourne, Australia)<br />
919 Prospective longitudinal comparative study of quality of life among elderly men undergoing invasive<br />
treatment for localised prostate cancer<br />
S. Namiki, S. Shigeto, T. Tochigi, A. Arai (Sendai, Natori, Japan)<br />
920 Robot-assisted laparoscopic radical prostatactomy versus retropubic radical prostatectomy: A costeffectiveness<br />
study<br />
L. Hohwü, L. Ehlers, M. Borre, K.V. Pedersen (Aarhus N, Aalborg, Denmark)<br />
216 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
14.00 - 15.30 Urothelial tumours: Basic research 2<br />
Athens Room<br />
Poster Session 58<br />
Chairs: R. Bartoletti, Florence (IT)<br />
P. Bastian, Munich (DE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
921 Level of expression of EpCAM and response to vicinium in non muscle-invasive transitional cell<br />
carcinoma of the bladder<br />
M.M. Kowalski, N. Jones, D. Niforos, W. Chapman, J. Entwistle, G. Macdonald (Mississauga, Winnipeg,<br />
Canada)<br />
922 Prognostic factors for T1 bladder carcinoma<br />
H. Olsson, S. Jahnson (Linköping, Sweden)<br />
923 Plasmacytoid urothelial carcinoma: Rare variant of aggressive urothelial carcinoma<br />
B. Keck, R. Stoehr, S. Wach, A. Rogler, H.M. Fritsche, J. Lehmann, B. Wullich, A. Hartmann (Erlangen,<br />
Regensburg, Kiel, Germany)<br />
924 Cytoplasmic expression of prothymosin-α predicts bladder tumor recurrence in urothelial carcinoma of<br />
urinary bladder and is associated with tumor grade and stage<br />
Y.S. Tsai, Y.C. Jou, T.S. Tzai, A.L. Shiau, C.L. Wu, H.T. Tsai (Tainan, Chia-Yi, Taiwan)<br />
925 The combined investigation of molecular proteins predicts cancer-specific survival in patients with highgrade<br />
non-muscle invasive bladder cancer<br />
K. Matsumoto, Y. Satoh, T. Satoh, K. Tabata, T. Fujita, M. Iwamura, K. Yoshida, S. Baba (Sagamihara, Japan)<br />
926 Expression of tumour-associated trypsin inhibitor (TATI) and its correlation with molecular markers,<br />
pathologic features and clinical outcomes of urothelial bladder cancer<br />
O. Patschan, S.F. Shariat, D.C. Chade, P.I. Karakiewicz, R. Ashfaq, Y. Lotan, K. Hotakainen, U.H. Stenman,<br />
A. Bjartell (Malmö, Sweden; Dallas, United States of America; Montreal, Quebec, Canada; Helsinki, Finland)<br />
927 Loss of p63 (ΔNp63α) promotes invasion of urothelial carcinomas<br />
F. Koga, H. Fukushima, S. Kawakami, Y. Fujii, S. Yoshida, E. Ratovitski, B. Trink, K. Kihara (Tokyo, Japan;<br />
Baltimore, United States of America)<br />
928 Circulating tumour cells in non-metastatic bladder cancer are associated with worse outcome<br />
M. Rink, S. Minner, F.K. Chun, O. Balzer, M.G. Friedrich, H. Heinzer, H. Huland, K. Pantel, M. Fisch,<br />
S. Riethdorf (Hamburg, Krefeld, Germany)<br />
929 High risk non-muscle invasive bladder cancer: Prognostic factor of circulating tumour cells<br />
E. De Berardinis, G.M. Busetto, A. Sciarra, C. Cristini, F. Minisola, G. Di Pierro, A. Petracca, C. Nicolazzo, F. Di<br />
Silverio, P. Gazzaniga (Rome, Italy)<br />
930 Intravesical α-radioimmunotherapy of human urothelial carcinoma in an orthotopic xenograft mouse<br />
model: A promising new therapy for superficial bladder cancer<br />
M. Autenrieth, B. Pfost, C. Seidl, U. Treiber, J.E. Gschwend, R. Senekowitsch-Schmidtke (Munich, Germany)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
217
931 Antitumour effects of cis-urocanic acid, an intravesical protodynamic drug, in experimental urothelial cell<br />
carcinoma of the bladder<br />
H.C. Arentsen, J. Falke, C.F.J. Jansen, C.A. Hulsbergen-Van De Kaa, J.K. Laihia, L. Pylkkänen, L. Leino,<br />
E. Oosterwijk, J.A. Witjes (Nijmegen, The Netherlands; Turku, Finland)<br />
932 Pharmacokinetics and toxicity of intravesical TMX-101: A preclinical study in pigs<br />
H.C. Arentsen, J. Falke, C.A. Hulsbergen-Van De Kaa, C.F.J. Jansen, R. Maj, L.M. Leoni, E. Oosterwijk,<br />
J.A. Witjes (Nijmegen, The Netherlands; Bioggio, Switzerland)<br />
933 Endothelial cell therapy to prevent radiation-induced cystitis in a rat model<br />
A. Vianello, R. Soler, C. Fuhllase, S. Soker, A. Atala, J.J. Yoo, K. Williams (Sant’Andrea Delle Fratte, Italy;<br />
Winston Salem, United States of America)<br />
934 Edaravone, a radical scavenger, inhibits cisplatin-induced acute renal injury and chronic renal cyst<br />
formation by protecting renal mitochondria<br />
T. Iguchi, M. Nishikawa, M. Inoue, Y. Nitta, T. Naganuma, K. Kuratsukuri, J. Uchida, H. Kawashima,<br />
T. Nakatani (Osaka, Japan)<br />
935 Synergistic antitumoral effects of interleukin-12 gene therapy and chemotherapy in the treatment of<br />
urothelial bladder cancer<br />
Y. Cao, W. Wangpeng, M. Mario, Y. Youcheng (Qingdao, Haerbin, China; Santiago, Chile)<br />
218 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
14.00 - 15.30 Focal and systemic therapies<br />
Padua Room<br />
Poster Session 59<br />
Chairs: M. Colombel, Lyon (FR)<br />
J. Trachtenberg, Toronto (CA)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
936 Tookad® soluble (Padeliporfin) second generation vascular targeted photodynamic therapy (VTP) for<br />
prostate cancer: Safety and feasibility<br />
N. Arumainayagam, C. Allen, C.M. Moore, N. Barber, R. Hindley, G. Muir, J. Trachtenberg, L. Cormier,<br />
E. Barret, A.R. Azzouzi, A. Villers, M. Emberton (London, Basingstoke, United Kingdom; Toronto, Canada;<br />
Dijon, Paris, Angers, Lille, France)<br />
937 Real time MRI guided focal laser therapy of prostate cancer<br />
O. Raz, U. Lindner, S.R.H. Davidson, E. Hlasny, W. Kucharcyzk, M.A. Haider, J. Trachtenberg (Toronto,<br />
Canada)<br />
938 Long term follow-up of salvage cryotherapy for locally recurrent prostate cancer following initial radiation<br />
therapy<br />
E. Chiong, N. Long, D. Urbauer, C.L. Warneke, L.L. Pisters (Singapore, Singapore; Houston, United States of<br />
America)<br />
939 Selection of patients for salvage cryosurgical ablation of the prostate (CSAP) utilizing fused capromab<br />
pendetide scanning (CPS)<br />
A.M. El-Zawahry, M.R. Eskridge, H.S. Clarke, T.E. Keane (Charleston, United States of America)<br />
940 Salvage high intensity focused ultrasound (HIFU) for the treatment of locally recurrent prostate cancer after<br />
external beam radiation therapy (EBRT): Factors influencing the outcome<br />
F.-J. Murat, S. Crouzet, O. Rouviere, L. Poissonnier, X. Martin, G. Pasticier, J.Y. Chapelon, A. Gelet (Lyon,<br />
Bordeaux, France)<br />
941 Correlation of PSA-nadir and biochemical failure after high-intensity focussed ultrasound (HIFU) of<br />
localised prostate cancer based on the Stuttgart failure criteria – analysis from the @-Registry<br />
R. Ganzer, S.C.W. Brown, G.N. Conti, F.J. Murat, G. Pasticier, A. Gelet, C.N. Robertson, S. Thüroff, J.F. Ward,<br />
A. Blana (Regensburg, Munich, Fuerth, Germany; Stockport, United Kingdom; Como, Italy; Lyon, Bordeaux,<br />
France; Durham, Houston, United States of America)<br />
942 Total HIFU as a primary therapy for localised prostate cancer: Outcomes from the @-Registry database<br />
A. Blana, C.N. Robertson, G.N. Conti, R. Ganzer, S. Thüroff, J.F. Ward, S.C.W. Brown, A. Gelet, G. Pasticier,<br />
F.J. Murat (Fürth, Regensburg, Munich, Germany; Durham, Huston, United States of America; Como, Italy;<br />
Stockport, United Kingdom; Lyon, Bordeaux, France)<br />
943 Are results of focal therapy for localised prostate cancer only due to tumour ablation? Critical analysis of<br />
definitions for success applied in a cohort of active surveillance patients<br />
A. Adamy, D.S. Yee, D.C. Chade, V.E. Reuter, K. Touijer, J.A. Eastham, P.T. Scardino, B. Guillonneau (New<br />
York, United States of America)<br />
944 Transurethral ultrasound therapy of the prostate guided by MRI derived real-time thermal mapping in<br />
localised prostate cancer patients: Early experience<br />
K. Siddiqui, R. Chopra, L. Sugar, M. Haider, S. Vedulas, A. Boyes, M.J. Bronskill, L.H. Klotz (Toronto, Canada)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
219
945 Metabolic syndrome and risk of prostate cancer: Prospective cohort study in Me-Can<br />
P.E. Stattin, C. Häggström, D. Ulmert, H. Ulmer, T. Bjørge, J. Manjer, K. Rapp, A. Engeland, D. Johansen,<br />
G. Hallmans, H. Jonsson, T. Stocks (Umeå, Malmö, Sweden; Innsbruck, Austria; Bergen, Norway; Ulm,<br />
Germany)<br />
946 Prevention of prostate cancer with dutasteride in case of high grade intraepithelial neoplasia: Intermediate<br />
results<br />
S. Auskalnis, D. Milonas, M. Jievaltas, D. Trumbeckas, M. Kincius, K. Vaiciunas, A. Matjosaitis (Kaunas,<br />
Lithuania)<br />
947 Functional inactivation of insulin-like growth factor-1 in the bone may be relevant to osteoporosis during<br />
androgen deprivation therapy<br />
N. Hara, T. Nishiyama, E. Isahaya, K. Takahashi (Niigata, Japan)<br />
948 Use of a decision aid regarding treatment options for early prostate cancer: A single-institutional report on<br />
pattern of treatment choice in 230 patients<br />
S. Junius, C. Van Audenhove, K. Haustermans, S. Joniau, F. Ameye, H. Van Poppel (Leuven, Belgium)<br />
949 The development and validation of immunological assays in patients with prostate cancer<br />
R.P.C. Viney, A. Doherty, P. Gopar, P.F. Searle (Birmingham, United Kingdom)<br />
950 Results from the first phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine<br />
in patients with prostate cancer<br />
S. Mpisias, T. Karaolides, A. Pappas, E. Koutsiaris, A. Konandreas, S. Perez, V. Klapsas, L. Fasoulis,<br />
K. Baxevanis, A. Thanos (Athens, Greece)<br />
220 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
15.45 - 16.55 Video Award Session<br />
eURO Auditorium<br />
Video Session 8<br />
Chairs: I.J. De Jong, Groningen (NL)<br />
R.J.A. Van Moorselaar, Amsterdam (NL)<br />
All presentations have a maximum length of 10 minutes, followed by 4 minutes of discussion.<br />
Prize for the Best Video published in the EUVJ 2009:<br />
V47 Ejaculation preserving (EP) technique in endourological treatment of BPH -<br />
epLaservaporesection and epTUR of the prostate<br />
C. Lang, Neunkirchen (DE)<br />
Supported by an unrestricted educational grant from ASTELLAS<br />
Third Video Prize:<br />
V16 Repair of rectovesical fistula using the York Mason approach<br />
H. Zecha, G. Hellmich, F. Steinbach (Dresden, Germany)<br />
Supported by an unrestricted educational grant from ASTELLAS<br />
Second Video Prize:<br />
V1 Gasless two port access total nephroureterectomy: MIES total nephroureterectomy<br />
K. Saito, K. Kihara, S. Kawakami, Y. Fujii, H. Masuda, F. Koga (Tokyo, Japan)<br />
Supported by an unrestricted educational grant from ASTELLAS<br />
First Video Prize:<br />
V22 Supine percutaneous nephrolithotomy<br />
A. Hoznek, S. Esquivel, K. De Laet, A. De La Taille, L. Salomon, C.C. Abbou (Creteil, France; Antwerp,<br />
Belgium)<br />
Supported by an unrestricted educational grant from ASTELLAS<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
221
Monday, 19 April - <strong>EAU</strong> Programme<br />
222 Programme Book<br />
Abstract Session<br />
15.45 - 17.15 History of Urology 2<br />
Amsterdam Room<br />
Oral Session 12<br />
Chairs: L.A. Fariña-Pérez, Vigo (ES)<br />
J. Mattelaer, Kortrijk (BE)<br />
All presentations are 7 minutes in length, followed by 2 minutes of discussion.<br />
951 Harold Hopkins: Lighting the world of urology<br />
J.R. Bhatt, A. Jones, S.J. Foley, Z. Shah, P.R. Malone, D.P. Fawcett, P.V.S. Kumar (Reading, United Kingdom)<br />
952 Ancient surgical treatment of hypospadias from Hippocrates (5th - 4th century B.C.) to the 12th century A.D<br />
S. Musitelli (Pavia, Italy)<br />
953 The practice of circumcision and subincision in Australian aboriginal tribes<br />
R. Thomson, M.F. Bultitude (Melbourne, Australia; London, United Kingdom)<br />
954 The history of percutaneous nephrolithotomy: Through the keyhole to a wider world<br />
A. Rogers, T. Page, P. English (Sunderland, United Kingdom)<br />
955 Phallic decoration represented in Palaeolithic art in Europe<br />
J.C. Angulo, M. Garcia-Diez, M. Martinez (Getafe, Cuevas de Monte Castillo, Spain; Grotte De Pair-Non-Pair,<br />
France)<br />
956 The evolution of bladder management in spinal cord injured patients over the last 90 years<br />
S.M. Biers, P. Guy (Salisbury, United Kingdom)<br />
957 ‘De Urinis Tractatus Duo’ by H.J. Rega: A contradictory tract that was the beginning of the end of uroscopy<br />
J. Mattelaer (Kortrijk, Belgium)<br />
958 The living witness oral history project<br />
D.J. Hodgson, P.M. Thompson (Portsmouth, London, United Kingdom)
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
15.45 - 17.15 Prevention and screening of prostate cancer<br />
<strong>Barcelona</strong> Room<br />
Poster Session 60<br />
Chairs: A. Tubaro, Rome (IT)<br />
L.N. Türkeri, Istanbul (TR)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
959 Effect of baseline prostate cancer risk on dutasteride efficacy in the REDUCE (REduction by DUtasteride of<br />
prostate Cancer Events) study<br />
M. Marberger, C. Pettaway, T. Tammela, D.J. Tindall, C. Teloken, T.H. Wilson, R. Castro (Vienna, Austria;<br />
Houston, Rochester, Research Triangle Park, United States of America; Tampere, Finland; Porto Alegre,<br />
Brazil)<br />
960 The influence of a positive family history on prostate cancer incidence and dutasteride efficacy in the<br />
REDUCE study<br />
T.L.J. Tammela, G.L. Andriole, C. Teloken, T.H. Wilson, I.L. Fowler, R. Castro (Tampere, Finland; St. Louis,<br />
Research Triangle Park, United States of America; Porto Alegre, Brazil)<br />
961 External validation of the prostate cancer prevention trial risk calculator in a Canadian cohort<br />
G. Trottier, K. Fernandes, P.J. Bostrom, A. Finelli, A. Toi, G.A. Lockwood, A. Evans, K. Chadwick,<br />
N.E. Fleshner (Toronto, Canada)<br />
962 How screening does affect erectile function and urinary continence following radical prostatectomy:<br />
Results from the European Randomized Study of Screening for Prostate Cancer (ERSPC)<br />
S.V. Carlsson, G. Aus, J. Hugosson (Gothenburg, Sweden)<br />
963 Balance the risks and benefits of screening and early detection<br />
P.J. Van Leeuwen, D. Connolly, T.L.J. Tammela, J. Hugosson, M.J. Roobol, A. Gavin, F.H. Schröder (Rotterdam,<br />
The Netherlands; Belfast, United Kingdom; Tampere, Finland; Gothenburg, Sweden)<br />
964 Withdrawn<br />
965 No excess mortality after prostate biopsy: Results from the European Randomized study of Screening for<br />
Prostate Cancer (ERSPC)<br />
S.C. Carlsson, E. Holmberg, A.P. Auvinen, S.M. Moss, M.J. Roobol, F.H. Schröder, T.L.J. Tammela,<br />
G. Aus, J. Hugosson (Gothenburg, Sweden; Tampere, Finland; Surrey, United Kingdom; Rotterdam, The<br />
Netherlands)<br />
966 Detection of prostate cancer by urine proteomics<br />
M. Rigau, J. Morote, N. Colome, M.C. Mir, C. Ballesteros, M. Garcia, M. Abal, F. Canals, J. Reventós, A. Doll<br />
(<strong>Barcelona</strong>, Santiago de Compostela, Spain)<br />
967 Prostate cancer risk in the PSA range 1-4ng/ml in the prospective screening study<br />
M. Kwiatkowski, D. Seiler, M. Baumgartner, S. Bauer, G. Koritsiadis, A. Huber, M. Kurrer, K. Lehmann,<br />
F. Recker (Aarau, Baden, Switzerland)<br />
968 Japanese Prospective Cohort Study of Screening for Prostate Cancer (JPSPC): Analyses on compliance,<br />
contamination and mortality until 2008 (Gunma section)<br />
K. Ito, M. Miyakubo, T. Yamamoto, K. Suzuki, M. Kobayashi, Y. Tomaru, H. Tanaka, H. Yamanaka (Maebashi,<br />
Isesaki, Kiryu, Kurashiki, Tokyo, Japan)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
223
969 Disease specific mortality may underestimate the total effect of prostate cancer screening<br />
P.J. Van Leeuwen, R. Kranse, T. Hakulinen, M.J. Roobol, C.H. Bangma, F.H. Schröder (Rotterdam, The<br />
Netherlands; Helsinki, Finland)<br />
970 The diagnostic performance of the PCA3-Score in relation to the number of biopsy (Bx) sessions: Results of<br />
a multinational analysis of 1251 European men<br />
A. Haese, M. Auprich, A. De La Taille, T. De Reijke, P. Kil, P. Gontero, J. Jacques, M. Graefen, F. Chun<br />
(Hamburg, Germany; Graz, Austria; Paris, Poitiers, France; Amsterdam, Tilburg, The Netherlands; Turin,<br />
Italy)<br />
971 Interval cancers in the screening of prostate cancer: Results from the Helsinki area of the ERSPC Study<br />
H. Santti, T. Joutsi, L. Määttänen, T. Tammela, M. Ruutu, A. Auvinen (Helsinki, Pori, Tampere, Finland)<br />
972 Testosterone level is related to diagnose of adenocarcinoma of the prostate in hypogonadic patients but<br />
not in eugonadal patients<br />
E. García-Cruz, J. Huguet Pérez, M.J. Ribal Caparrós, M. Pérez Márquez, M. Piqueras Bartolomé, A. Alcaraz<br />
Asensio (<strong>Barcelona</strong>, Spain)<br />
973 Evaluation of different fractionation strategies to identify serum markers for prostate cancer<br />
V. Scattoni, I. Fermo, F. Basilico, C. Magagnotti, M. Ferrari, N. Fossati, F. Castiglione, N.M. Passoni, A. Russo,<br />
L. Rocchini, P. Rigatti, F. Montorsi, A. Andolfo (Milan, Italy)<br />
974 Predicting prostate biopsy outcome in a screening setting PSA, PCA3, a kallikrein panel, the riskcalculator<br />
or a combination? ERSPC Rotterdam<br />
M.J. Roobol, D. Hessels, A.J. Vickers, J.A. Schalken, P. Van Leeuwen, T. Wolters, R.C.N. Van Den Bergh,<br />
F.H. Schröder, H. Lilja (Rotterdam, Nijmegen, The Netherlands; New York, United States of America)<br />
224 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
15.45 - 17.15 Diagnostic biomarkers<br />
Paris Room<br />
Poster Session 61<br />
Chairs: H.G. Lilja, New York (US)<br />
F. Rozet, Paris (FR)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
975 Validation of the PCA3 molecular urine test for predicting repeat prostate biopsy outcome in the placebo<br />
arm of the dutasteride REDUCE trial<br />
R. Rittmaster, S.M.J. Aubin, J. Reid, M.J. Sarno, A. Blase, J. Aussie, H. Rittenhouse, G.L. Andriole, J. Groskopf<br />
(Research Triangle Park, San Diego, St. Louis, United States of America)<br />
976 PCA3 predicts prostate biopsy outcome in men receiving dutasteride: Results from the dutasteride REDUCE<br />
trial<br />
G. Andriole, S.M.J. Aubin, J. Reid, M.J. Sarno, A. Blase, J. Aussie, H. Rittenhouse, R. Rittmaster, J. Groskopf<br />
(St. Louis, San Diego, Research Triangle Park, United States of America)<br />
977 Prostate cancer antigen (PCA3)-score is most useful for prediction of biopsy (Bx)-outcome in low (below 4)<br />
and intermediate (4-10 ng/ml) PSA-ranges: Analysis of 1251 European men<br />
A. Haese, M. Auprich, H. Van Poppel, A. Stenzl, M. Marberger, T. De Reijke, J. Irani, A. De La Taille, P. Kil,<br />
M. Graefen, F. Chun (Hamburg, Tübingen, Germany; Graz, Vienna, Austria; Leuven, Belgium; Amsterdam,<br />
Tilburg, The Netherlands; Poitiers, Creteil, France)<br />
978 Evidence for an age dependence of the prostate cancer antigen 3 (PCA3) score<br />
D. Schilling, J. Hennenlotter, J. Siegel, V. Wagner, C. Schwentner, A. Stenzl (Tübingen, Germany)<br />
979 PSA velocity and PCA3 score as risk factors for prostate cancer in a repeat biopsy setting improves the<br />
predictive accuracy in a multivariate model<br />
M. Auprich, L. Budäus, F. Luger, M. Pichler, G. Gallè, S. Mannweiler, F.K.H. Chun, P. Pürstner, K. Pummer,<br />
H. Augustin (Graz, Austria; Hamburg, Germany)<br />
980 External validation of PCA3- based nomograms for predicting positive biopsy for prostate cancer<br />
M. Auprich, A. Haese, M. Graefen, A. Stenzl, M. Marberger, A. De La Taille, T. De Reijke, P. Kil, P. Gontero,<br />
H. Van Poppel, J. Irani, F. Chun (Graz, Vienna, Austria; Hamburg, Tübingen, Germany; Creteil, Poitiers,<br />
France; Amsterdam, Tilburg, The Netherlands; Turin, Italy; Leuven, Belgium)<br />
981 Relationship between insulin resistance, obesity and serum prostate-specific antigen levels in healthy men<br />
S.Y. Oh, J.H. Han, S.H. Ahn, K.W. Kwak, S.C. Myung, I.H. Chang, T.H. Kim, J.S. Hyun, S.H. Bang, S.W. Park,<br />
N.Y. Choi, Y.T. Lee (Namyangju, Seoul, Jin Joo, South Korea)<br />
982 Lifetime risk of death from prostate cancer predicted by kallikrein markers in blood taken at age 60<br />
A.J. Vickers, A.M. Cronin, T. Bjork, J. Manjer, P.M. Nilsson, A. Dahlin, A. Bjartell, P.T. Scardino, D. Ulmert,<br />
H. Lilja (New York, United States of America; Malmö, Sweden)<br />
983 Utility of combining final PSA and PSA dynamics (change from month 6 to final PSA) for prostate cancer<br />
and high grade cancer diagnosis in the REDUCE study<br />
F. Montorsi, S.J. Freedland, T.L.J. Tammela, D.J. Tindall, C. Teloken, M.C. Somerville, T.H. Wilson,<br />
R.S. Rittmaster (Milan, Italy; Durham, Rochester, Research Triangle Park, United States of America;<br />
Tampere, Finland; Porto Alegre, Brazil)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
225
984 Faulty risk prediction of prostate cancer by nomograms without considering PSA inter-assay variability<br />
C. Stephan, K. Siemßen, F. Friedersdorff, H. Cammann, S. Deger, M. Schrader, M. Lein, K. Jung, H.A. Meyer,<br />
K. Miller (Berlin, Germany)<br />
985 Access [-2]proPSA and Beckman Coulter prostate health index (phi) and early detection of aggressive<br />
prostate cancers<br />
J. Bektic, C. Darte, V. Skradski, E. Steiner, G. Schaefer, G. Bartsch, W. Horninger, H. Klocker (Innsbruck,<br />
Austria)<br />
986 The Beckman Coulter prostate health index (phi) improves diagnostic accuracy in prostate cancer detection<br />
S. Vincendeau, J. Ramirez, X. Durand, E. Deligne, A. Houlgatte (Rennes, Paris, France)<br />
987 Potential clinical value of circulating Dj-1 in patients with prostate cancer<br />
O.B. Loran, E.I. Veliev, V.E. Okhrits, K.V. Lisitskaya, L.S. Eremina, L.I. Kovalyov, M.A. Kovalyova, S.S. Shishkin<br />
(Moscow, Russia)<br />
988 A novel localisation of low affinity nerve growth factor receptor (p75) in normal and neoplastic human<br />
prostate. An immunohistochemical and immunocytochemical study<br />
E. Mearini, E. Cottini, G. Cochetti, M.R. Serva, C. Vivacqua, F. Barillaro, M.G. Rambotti, A.M. Stabile,<br />
A. Pistilli, M. Rende (Perugia, Italy)<br />
989 Investigating promoter methylation of Wnt signalling antagonists in prostate cancer<br />
O.A. Raheem, A.S. Perry, A.M. Kennedy, T.M. Murphy, R. Foley, L. Marignol, L. Suillvan, B. Loftus, M. Lawler,<br />
T.H. Lynch (Dublin, Ireland)<br />
226 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
15.45 - 17.15 Medical therapy and injection for BPH treatment<br />
Stockholm Room<br />
Poster Session 62<br />
Chairs: K.M. Anson, London (GB)<br />
S. Madersbacher, Vienna (AT)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
990 Clinical outcomes after combination therapy with dutasteride and tamsulosin in men with benign prostatic<br />
hyperplasia (BPH) by baseline characteristics: 4 year results from the randomised, double-blind, Combat<br />
trial<br />
A. Tubaro, C.G. Roehrborn, J. Barkin, F. Montorsi, T.H. Wilson, B. Morill, R.P. Gagnier (Rome, Milan, Italy;<br />
Dallas, Research Triangle Park, United States of America; Toronto, Canada)<br />
991 Combination therapy with dutasteride plus tamsulosin reduces medical resource utilisation in men with<br />
benign prostatic hyperplasia: 4-year data from the CombAT study<br />
M. Montlleo Gonzalez, G. Geiges, V. Cicalese, B. Morrill, L. Black, R. Castro, P. Gagnier (<strong>Barcelona</strong>, Spain;<br />
Berlin, Germany; Avellino, Italy; North Carolina, United States of America)<br />
992 Comparing the efficacy of a selective cyclooxygenase-2 inhibitor and an anticholinergic in patients with<br />
benign prostatic hyperplasia and refractory nocturia<br />
C.I. Kim, B.H. Kim, H.S. Chang, C.H. Park, D.S. Ryu, J.H. Seo, D.Y. Kim, H.C. Jung (Daegu, Seoul, Gumi, South<br />
Korea)<br />
993 Tamsulosin versus transurethral prostatectomy in the treatment of nocturia in men with benign prostatic<br />
hyperplasia as only causal factor: A prospective randomised trial<br />
V. Simaioforidis, M. Chrisofos, A. Papatsoris, S. Kontos, S. Koritsiadis, C. Deliveliotis (Piraeus, Athens,<br />
Greece)<br />
994 The long-term safety and efficacy of tadalafil 5mg once-daily in men with lower urinary tract symptoms<br />
secondary to benign prostatic hyperplasia (BPH-LUTS)<br />
C. Donatucci, G. Brock, E. Goldfischer, P. Pommerville, A. Elion-Mboussa, J. Kissel, L. Viktrup (Durham,<br />
Poughkeepsie, Indianapolis, United States of America; London, Ontario, Victoria, Canada)<br />
995 Intraprostatic injection of botulinum toxin type A causes a long-lasting improvement in LUTS and urinary<br />
flow in patients with benign prostatic enlargement refractory to standard medical therapy<br />
T.G. Gorgal, J.F.A. Silva, R.A. Pinto, F. Botelho, P.N. Silva, C.M. Silva, P.O. Dinis, F.J.M.R. Cruz (Porto, Portugal)<br />
996 Intraprostatic botulinum toxin type A (BTX-A) injection in benign prostatic hyperplasia (BPH): Initial<br />
experience with dysport<br />
M.R. Nikoobakht, A. Daneshpajooh, H. Ahmadi, M. Rezaeidanesh, F. Namdari, S. Amini, A.R. Mehrsai,<br />
G. Pourmand (Tehran, Iran)<br />
997 Comparative study of efficiency and safety of intraprostatic injections of botulinum toxin and polidocanol<br />
in men with BPH and LUTS<br />
Y.B. Mirkin, D. Bedredtdinova (Krasnodar, Moscow, Russia)<br />
998 Intraprostatic Dysport is a safe and efficacious treatment for benign prostatic hyperplasia<br />
M.R. Nikoobakht, H. Ahmadi, A. Daneshpajouh, M. Rezaeidanesh, S. Amini, A. Mehrsai, G. Pourmand<br />
(Tehran, Iran)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
227
999 Efficacy of silodosin as compared with tamsulosin and placebo for the treatment of the signs and<br />
symptoms of benign prostatic hyperplasia. A multicentre, randomised, double-blind, controlled trial<br />
C.R. Chapple, F. Montorsi, F. Desgrandchamps (Sheffield, United Kingdom; Milan, Italy; Paris, France)<br />
1000 Alfuzosin 10mg once daily improves ejaculatory dysfunction in real life practice: Results of a 6-month<br />
study in 1681 men with LUTS suggestive of BPH<br />
J.M. Fitzpatrick, R.C. Rosen (Dublin, Ireland; Watertown, United States of America)<br />
1001 Effect of dutasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia<br />
S.K. Hong, S.H. Doo, H. Park, W.K. Lee, D.S. Kim, S.J. Jeong, C.Y. Yoon, S.S. Byun, S.E. Lee (Seongnam, South<br />
Korea)<br />
1002 Early efficacy of silodosin on storage and voiding function in patients with benign prostatic hyperplasia,<br />
based on pressure-flow study<br />
Y. Matsukawa, R. Hattori, T. Komatsu, T. Yamamoto, M. Gotoh (Nagoya, Japan)<br />
228 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
15.45 - 17.15 Staging: From focal to advanced prostate cancer<br />
Milan Room<br />
Poster Session 63<br />
Chairs: X. Cathelineau, Paris (FR)<br />
U.E. Studer, Berne (CH)<br />
Pilot session: Poster viewing and individual questioning for 45 minutes, during which presenters will have<br />
1 minute to give an introduction of the poster, followed by a 2 minute discussion lead by the chair.<br />
Four posters will be selected for further discussion; 3 minutes presentation followed by 4 minutes of<br />
discussion.<br />
1003 Routine preoperative prognostic factors cannot predict unilaterality of prostate cancer in patients with<br />
localised disease<br />
B.Y. Alekseev, I.G. Rusakov, N.V. Vorobyev, G.A. Frank, Y. Andreeva (Moscow, Russia)<br />
1004 The whole extent of prostate cancer cannot be precisely identified using current standard tools in initial<br />
prostate cancer (PCa) diagnosis – implications for focal therapy<br />
J. Pfitzenmaier, T. Höfner, A. Rabadi, S. Pahernik, A. Haferkamp, N. Djakovic, N. Wagener, B. Hadaschik,<br />
M. Hohenfellner (Heidelberg, Germany)<br />
1005 Absence of residual tumour (pT0 status) at radical prostatectomy: Oncologic outcome and predictors<br />
Y.A. Ahallal, F.R. Rabbani, R.F. Favaretto, V.R. Reuter, P.T.S. Scardino, B.G. Guillonneau, K.T. Touijer (New<br />
York, United States of America)<br />
1006 Long term progression-free, overall and cancer-specific survival in familial cancer patients in Germany<br />
K. Herkommer, M.M. Heck, C. Winkler, J.E. Gschwend, M. Kron (Munich, Ulm, Germany)<br />
1007 Are the <strong>EAU</strong> guidelines on prostate cancer followed by Italian urologists? Results from the M.I.R.R.O.R.<br />
(Multicenter Italian Report on Radical prostatectomy Outcomes and Research) group<br />
V. Varca, A. Simonato, M. Carini, G. Nicita, A. Decensi, F. De Rose, M. Maffezzini, O. De Cobelli, R. Salvioni,<br />
A. Briganti, V. Mirone, G. Carmignani (Genoa, Florence, Milan, Naples, Italy)<br />
1008 The phosphorylation status of FADD in biopsy specimens is associated with biochemical recurrence of<br />
prostate cancer after prostatectomy<br />
T. Ikeda, N. Tanaka, K. Shimada, Y. Matsumura, M. Miyake, S. Anai, T. Tomioka, E. Okajima, K. Fujimoto,<br />
N. Konishi, Y. Hirao (Nara, Japan)<br />
1009 Cumulative number of high-risk factors is highly predictive of cancer-related outcomes and overall survival<br />
in patients with high-risk localized prostate cancer<br />
S. Joniau, P. Gontero, A. Briganti, B. Tombal, G. Marchioro, J. Walz, K. Vander Eeckt, C.Y. Hsu, B. Kneitz,<br />
P. Bader, D. Frohneberg, A. Tizzani, M. Graefen, P. Van Cangh, F. Montorsi, H. Van Poppel, M. Spahn<br />
(Leuven, Brussels, Belgium; Turin, Milan, Novarra, Italy; Hamburg, Würzburg, Karlsruhe, Germany)<br />
1010 Assessing the risk of lymph node invasion in patients with intermediate risk prostate cancer. A novel<br />
prediction tool<br />
A. Briganti, N. Suardi, A. Gallina, U. Capitanio, V. Scattoni, F. Abdollah, M. Bianchi, M. Tutolo, N. Passoni,<br />
L. Villa, N. Fossati, R. Bertini, P. Rigatti, F. Montorsi (Milan, Italy)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
229
1011 Laparoscopic sentinel lymph node (SLN) dissection for clinically localised prostate carcinoma: Preliminary<br />
results<br />
T. Rousseau, J. Lacoste, C. Curtet, G. Aillet, G. Le Coguic, A. Pallardy, C. Rousseau (Saint-Herblain, Nantes,<br />
France)<br />
1012 Sentinel lymph node surgery in prostate cancer: Results of a prospective study with a 10 years follow up<br />
G. Marchioro, M. Vidali, A. Volpe, M. Billia, G. Maso, E. Inglese, M. Rudoni, S. Crivellaro, B. Frea, C. Terrone<br />
(Novara, Udine, Italy)<br />
1013 Predicting favourable pathological outcome in patients with clinical high risk prostate cancer. A novel<br />
nomogram based on a multi-institutional analysis<br />
A. Briganti, M. Spahn, S. Joniau, P. Gontero, F. Montorsi, G. Marchioro, B. Tombal, D. Frohneberg, H. Isbarn,<br />
C.H. Bangma, F.H. Schroder, B. Kneitz, P. Bader, M. Graefen, A. Tizzani, H. Van Poppel (Milan, Turin, Novara,<br />
Italy; Würzburg, Karlsruhe, Hamburg, Germany; Leuven, Brussels, Belgium; Rotterdam, The Netherlands)<br />
230 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
15.45 - 17.15 Cystectomy and urinary diversion: Technical considerations<br />
Vienna Room<br />
Poster Session 64<br />
Chairs: H. Abol-Enein, Mansoura (EG)<br />
J.K. Mellon, Leicester (GB)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
1014 Older patients suffer from delayed radical cystectomy<br />
M. Rink, O. Balzer, R. Dahlem, C. Eichelberg, N. Hripko, H. Huland, M. Fisch, F.K. Chun (Hamburg, Germany)<br />
1015 Urethrectomy is seldom required for urethral recurrence after radical cystectomy and ileal orthotopic<br />
bladder substitution if regular follow-up is implemented<br />
G. Giannarini, T.M. Kessler, B. Kiss, G.N. Thalmann, U.E. Studer (Berne, Switzerland)<br />
1016 Early enteral versus parenteral nutrition following cystectomy and ileal urinary diversion: Results of a<br />
prospective randomized trial<br />
B. Roth, F.C. Burkhard, U.E. Studer (Berne, Switzerland)<br />
1017 Where are the primary lymphatic landing sites of the bladder?<br />
B. Roth, M.P. Wissmeyer, P. Zehnder, F.D. Birkhaeuser, G.N. Thalmann, T.M. Krause, U.E. Studer (Berne,<br />
Switzerland)<br />
1018 Prospective assessment of ureteral frozen-section margins among risk factors for distal ureteric<br />
malignancy at radical cystectomy<br />
G. Gakis, D. Schilling, S. Perner, K.D. Sievert, A. Stenzl (Tübingen, Germany)<br />
1019 Predictors of major complications after radical cystectomy for bladder cancer<br />
O. Sukonko, S. Krasny, S. Polyakov, A. Minich, A. Rolevich, A. Volkov (Minsk, Belarus)<br />
1020 Robot-assisted radical cystectomy and pelvic lymph node dissection: A multi-institutional study from<br />
Korea<br />
S.H. Kang, C.J. Cheon, K.H. Rha, Y.G. Lee, T.G. Kwon, S.C. Park, S.G. Kang, S.I. Jung, K.T. Sung, H.H. Kim<br />
(Seoul, Daegu, Iksan, Busan, South Korea)<br />
1021 Functional and metabolic characteristics of smaller ileal orthotopic neobladder created according to<br />
modify Camey II technique<br />
V.M. Bancevic, J.B. Kosevic, R.P. Aleksic, N.M. Milovic, S.D. Stamenkovic, J.M. Jovanovic, M.D. Mocovic,<br />
M.R. Milosevic, P.R. Prelevic, C.Z. Campara (Belgrade, Serbia)<br />
1022 Renal function decline after urinary diversion – a retrospective comparison study of ileal conduit and ileal<br />
orthotopic neobladder in consideration of patient comorbidity<br />
T. Hofner, A. Haferkamp, S. Milakovic, J. Pfitzenmaier, S. Pahernik, N. Djakovic, N. Wagener, B. Hadaschik,<br />
M. Hohenfellner (Heidelberg, Germany)<br />
1023 Complications of radical cystourethrectomy using modified clavien grading system; prepubic versus<br />
perineal urethrectomy<br />
A.M. Elshal, T.S. Barakat, A.O. Mosbah, M. Abdel-Latif, H. Abol-Enein (Mansoura, Egypt)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
231
1024 Reduced physiological stress and improved bowel recovery: Achievement in radical cystectomy by intraoperative<br />
fluid optimisation using trans-oesophageal doppler monitoring<br />
P.L. Pillai, G.C. Durkan, M.I. Johnson, I. Nesbitt, C. Snowden, J. Cosgrove, A.C. Thorpe (Newcastle upon Tyne,<br />
United Kingdom)<br />
1025 Mininvasive anatomical extraperitoneal radical cystectomy (RC): A simple, safe and effective technique for<br />
patients with Bladder Cancer (BC)<br />
M. Brausi, G. De Luca, G. Peracchia, G.L. Giliberto, M. Viola, G. Verrini (Carpi, Italy)<br />
1026 Robot-assisted radical cystectomy with intracorporeal urinary diversion in patients with bladder cancer:<br />
Oncological and functional outcomes<br />
N.M. Jonsson, C.M. Schumacher, A. Hosseini, A. Thorstenson, A.E. Nilsson, N.P. Wiklund (Stockholm,<br />
Sweden)<br />
1027 Oncological outcomes for open and laparoscopic nephroureterectomy: A multi-institutional external<br />
validation study from the upper tract urothelial carcinoma collaboration<br />
G. Novara, T. Walton, A. Gupta, K. Matsumoto, P. Bastian, W. Kassouf, H.M. Fritsche, J.I. Martínez-<br />
Salamanca, C. Seitz, V. Ficarra, P.I. Karakiewicz, S.F. Shariat (Padua, Bolzano, Italy; Derby, United Kingdom;<br />
Dallas, United States of America; Kanagawa, Japan; Munich, Regensburg, Germany; Montreal, Canada;<br />
Madrid, Spain)<br />
1028 A comparison of perioperative morbidity and oncological outcomes of open, laparoscopic and robotic<br />
radical cystectomy<br />
O. Elhage, B. Challacombe, P. Rimington, M.S. Khan, P. Dasgupta (London, Eastbourne, United Kingdom)<br />
232 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
15.45 - 17.15 Management of non muscle invasive urothelial tumours 2<br />
Athens Room<br />
Poster Session 65<br />
Chairs: M. Burger, Regensburg (DE)<br />
W. Oosterlinck, Ghent (BE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
1029 Percutaneous resection of renal pelvis urothelial carcinoma: Indications and analysis of outcome<br />
G. Simone, R. Papalia, M. Ferriero, S. Guaglianone, E. Forastiere, M. Gallucci (Rome, Italy)<br />
1030 Can protocol based instillation of mitomycin C (MMC) post ablation of upper urinary tract TCC prevent the<br />
need for nephroureterectomy<br />
B.K. Somani, N. Townell, S.G. Kata (Dundee, United Kingdom)<br />
1031 The effect of the early ligation of the ureter in nephrouretectomy for upper urinary tract urothelial<br />
carcinoma<br />
Y. Kobayashi, S. Uehara, T. Watanabe, T. Saika, Y. Nasu, H. Kumon (Okayama, Japan)<br />
1032 Bladder cancer pT1 G3 N0 M0: Results of early cystectomy<br />
K. Kamecki, J. Siekiera, K. Krasnicki, W. Mikołajczak, A. Petrus, A. Wronczewski (Bydgoszcz, Poland)<br />
1033 Radical cystectomy after BCG: Has the timing of surgery improved in recent years?<br />
M.S. Soloway, D. Katkoori, K. Acosta, M. Arianayagam, M. Manoharan (Miami, United States of America)<br />
1034 Clinical outcomes of primary bladder carcinoma in situ in a contemporary series<br />
D. Chade, S.F. Shariat, G. Godoy, C. Savage, A. Cronin, B. Bochner, S.M.D. Donat, H. Herr, G. Dalbagni (New<br />
York, United States of America)<br />
1035 Variability of treatment selection among surgeons in patients with cT1 urothelial carcinoma<br />
G. Dalbagni, M. Kaag, A. Cronin, K. Vora, B. Bochner, S.M. Donat, H. Herr (New York, United States of<br />
America)<br />
1036 Validation of Sylvester predictive model in cases of progression on top of non-muscle invasive bladder TCC<br />
B. Ali-El-Dein, T.S. Barakat, A. Nabeeh, E.I. Ibrahiem (Mansoura, Egypt)<br />
1037 External validation and applicability of the EORTC risk tables for non muscle-invasive bladder cancer<br />
V. Hernández, E. De La Peña, M.D. Martín, N. Amaruch, C. Blázquez, D. García, C. Capitán, J.M. De La<br />
Morena, C. Llorente (Madrid, Spain)<br />
1038 Hexaminolevulinate fluorescence cystoscopy improves detection and resection of bladder cancer:<br />
Experience of the Spanish B.L.U.E. group<br />
J.P. Burgues, G. Conde, I. Iborra, M. Puertas, F. Ordoño (Palma de Mallorca, Valencia, Villajoyosa, Spain)<br />
1039 Photodynamic diagnosis in patients with T1G3 bladder cancer: Influence on recurrence and rate of<br />
deferred cystectomies<br />
A. Karl, P. Stanislaus, T. Stadler, S. Tritschler, R. Knuechel, D. Zaak, C. Stief (Munich, Aachen, Germany)<br />
1040 Adjuvant Photodynamic Therapy (PDT) in combination treatment of bladder cancer<br />
O.I. Apolikhin, I.V. Chernyshev, D.V. Altunin, D.A. Bedretdinova (Moscow, Russia)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
233
1041 Monthly maintenance after early intravesical chemotherapy<br />
V. Serretta, V. Altieri, G. Morgia, D. Melloni, A. Ruggirello, G. Carrieri, P. Annese, G. Ruggiero, A. Di Lallo,<br />
F.P. Selvaggi, M. Iadevaia, M. Falsaperla, D. Daricello, F. Vacirca, R. Allegro (Palermo, Naples, Messina,<br />
Foggia, Matera, Telese Terme, Campobasso, Bari, Maddaloni, Catania, Caltanissetta, Italy)<br />
1042 Location of the tumours in early and late recurrences in patients with T1G3 bladder tumours treated with<br />
or without BCG: Is there any difference?<br />
G. Urdaneta, J. Palou, M. Serrano, R. Parada, O. Rodríguez, L. Gausa, A. Breda, H. Villavicencio (<strong>Barcelona</strong>,<br />
Spain)<br />
1043 Bladder perforation during transurethral resection of tumour requiring open surgical revision: Clinical<br />
characteristics and oncological outcomes<br />
S. Golan, J. Baniel, D. Lask, P.M. Livne, O. Yossepowitch (Petach Tikva, Israel)<br />
234 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Abstract Session<br />
15.45 - 17.15 Tissue engineering and beyond<br />
Padua Room<br />
Poster Session 66<br />
Chairs: Y. Igawa, Matsumoto (JP)<br />
K.D. Sievert, Tübingen (DE)<br />
Poster viewing for 25 minutes. Presentations are 1 minute in length, followed by 3 minutes of discussion.<br />
1044 Implantation of human amniotic mesenchymal cells promotes morphological and functional recovery of the<br />
freeze-injured mouse urinary bladder<br />
T. Minagawa, T. Imamura, N. Aizawa, O. Ishizuka, Y. Igawa, O. Nishizawa (Matsumoto, Japan)<br />
1045 New concept of artificial muscle for urinary incontinence treatment<br />
M. Valerio, P. Jichlinski, M. Wieland, P.A. Conus, P. Thévenaz, F. Salchli, P. Tozzi, A.R. Mundy (Lausanne,<br />
Yverdon-Les-Bains, Switzerland; London, United Kingdom)<br />
1046 Detection of cardiac troponin T in detrusor smooth muscle - does troponin system operate in smooth<br />
muscle?<br />
S. Kajioka, N. Shahab, R. Takahashi, F. Takahashi-Yanaga, S. Nakayama, N. Seki, S. Naito (Fukuoka, Ngoya,<br />
Japan)<br />
1047 Human mesenchymal stem cells transplanted into rectus abdominis muscle of athymic rats differentiate<br />
into skeletal muscle cells with connection to motor end plates<br />
G. Feil, S. Baumann, R. Schäfer, J. Schäfer, R. Möhle, A. Stenzl, K.D. Sievert (Tübingen, Germany)<br />
1048 Differential response of stem cell homing chemokine among models of stress urinary incontinence in mice<br />
A. Hijaz, J.C. Hou, M. Tao, L.N. Byrne, G. Liu, Y. Lin, M. Kavran, F. Daneshgari (Cleveland, Syracuse, United<br />
States of America)<br />
1049 A novel tissue engineering approach for creating prostheses for the treatment of stress urinary<br />
incontinence (SUI) & pelvic organ prolapse (POP)<br />
A. Mangera, A.J. Bullock, S. Mac Neil, C.R. Chapple (Sheffield, United Kingdom)<br />
1050 Expression of monocyte chemotactic protein-3 following birth trauma in a murine model of obesity<br />
G.J. Vricella, N.A. Boncher, M. Tao, G. Liu, F. Daneshgari, A. Hijaz (Cleveland, United States of America)<br />
1051 Therapy of refractory postoperative urinary stress incontinence by the use of autologous skeletal muscle-<br />
derived cells (MDC)<br />
H. Gerullis, C. Eimer, R. Karig, P. Goretzki, A. Ramon, T. Otto (Neuss, Bad Aachen, Germany)<br />
1052 Expression of aquaphorins (AQPs) decreased in the urinary bladder of menopausal rats<br />
S.O. Kim, D.D. Kwon, K. Park, S.H. Song, K. Ahn (Gwangju, South Korea)<br />
1053 Impact of aging on degree of injury and recovery to continence mechanism, and expression of stem cell<br />
homing chemokine in rat model of simulated birth trauma<br />
N.A. Boncher, M. Tao, M. Kavran, N. Xiao, G. Spana, F. Daneshgari, A. Hijaz (Cleveland, Syracuse, United<br />
States of America)<br />
1054 Pharmacological characterisation of human male urethral smooth muscle: An in vitro approach<br />
G.T. Kedia, S. Ückert, M. Seidler, J.E. Sonnenberg, M.A. Kuczyk (Hanover, Germany)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
235
1055 Results of intraspinal nerve re-routing to re-establish bladder function in spinal cord injured patients: A<br />
single center experience<br />
K.D. Sievert, B. Amend, F. Roser, M. Tatagiba, A. Stenzl (Tübingen, Germany)<br />
1056 Urodynamic and functional imaging proof of successful latissimus dorsi detrusor myoplasty for acontractile<br />
bladder<br />
G. Gakis, M. Ninkovic, G. Sturtz, K.D. Sievert, A. Stenzl (Tübingen, Germany)<br />
1057 A prospective study to evaluate the impact of modern management in spina bifida patients and renal<br />
morbidity<br />
T.W. Swallow, S. Khan, S. Boddy, F. Lee (London, United Kingdom)<br />
1058 Characteristics of neurogenic lower urinary tract dysfunction associated with spinal lipoma: Impact of<br />
lipoma removal<br />
Y. Igawa, M. Ichino, T. Ogawa, O. Nishizawa (Matsumoto, Japan)<br />
236 Programme Book
Monday, 19 April - <strong>EAU</strong> Programme<br />
Special Session<br />
14.00 - 17.00 European Urological Scholarship Programme (EUSP) Session<br />
Istanbul Room<br />
Chairs: C-C. Abbou, Creteil (FR)<br />
C.R. Chapple, Sheffield (GB)<br />
14.00 - 14.10 Introduction<br />
C-C. Abbou, Creteil (FR)<br />
14.10 - 14.20 Outcome of one year of EUSP programme: Poll from the hosts and applicants<br />
C-C. Abbou, Creteil (FR)<br />
14.30 - 15.15 EUSP Session on “How to train Endourology”<br />
Chair: A. Patel, London (GB)<br />
15.15 - 15.30 Promotion Clinical Research Fellowship projects<br />
J.A. Schalken, Nijmegen (NL)<br />
15.30 - 16.30 Final report of five EUSP scholars<br />
15.30 - 15.40 Impact of aberrant promoter methylation on urothelial carcinoma behaviour<br />
S. Larré, Paris (FR)<br />
15.40 - 15.50 Indications and realisation of a partial or complete treatment in localised prostate cancer. Use<br />
of dynamic MRI and targeted prostatic biopsies<br />
E. Lecornet, Lille (FR)<br />
15.50 - 16.00 Biomarkers for prostatic inflammation diagnosis in benign prostatic hyperplasia<br />
G. Robert, Bordeaux (FR)<br />
16.00 - 16.10 New targets for molecular diagnostic of prostate cancer<br />
M. Salagierski, Lodz (PL)<br />
16.10 - 16.20 Identification, propagation and differentiation of putative stem cells in normal human<br />
urothelial (NHU) cells in vitro<br />
F. Wezel, Mannheim (DE)<br />
16.20 - 16.30 Award presentation Best Scholar<br />
C-C. Abbou, Creteil (FR)<br />
Award is supported by an unrestricted education grant from ELI LILLY AND COMPANY<br />
16.30 - 17.00 EUSP Cocktail for all scholars & hosts<br />
In front of Istanbul room<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
237
Monday, 19 April - <strong>EAU</strong> Programme<br />
238 Programme Book<br />
Workshop Overview<br />
10.00 - 11.30 Early stage localised prostate cancer: Local tumour ablation by Focal Vascular Occluding Agent<br />
[ F(VOA) ] - Tookad® Soluble <strong>page</strong> 346<br />
Genoa Room Sponsored by STEBA BIOTECH<br />
10.30 - 12.00 da Vinci Prostatectomy <strong>page</strong> 347<br />
Copenhagen Room Sponsored by INTUITIVE SURGICAL<br />
13.00 - 14.30 Ablatherm® HIFU for PCa. From real clinical background to virtual training <strong>page</strong> 348<br />
Genoa Room Sponsored by EDAP TMS<br />
15.30 - 17.00 da Vinci Prostatectomy <strong>page</strong> 347<br />
Copenhagen Room Sponsored by INTUITIVE SURGICAL<br />
15.45 - 17.15 Cryoablation: Setting the standard <strong>page</strong> 349<br />
Genoa Room Sponsored by GALIL MEDICAL<br />
Symposia Overview<br />
17.30 - 19.00 New developments in the understanding and management of Chronic Prostatitis/Chronic Pelvic<br />
Pain Syndrome (CP/CPPS) <strong>page</strong> 350<br />
Padua Room Sponsored by AB CERNELLE<br />
17.30 - 19.00 The new world of managing male LUTS: Focus on storage symptoms? <strong>page</strong> 351<br />
Amsterdam Room Sponsored by ASTELLAS<br />
17.30 - 19.00 Prostate Health Index (phi) – A simple blood test significantly improves on PSA in the selection<br />
of men for biopsy and is a major advance in prostate cancer risk assessment <strong>page</strong> 352<br />
Vienna Room Sponsored by BECKMAN COULTER INC.<br />
17.30 - 19.00 Time for change: Optimising metastatic Renal Cell Carcinoma (mRCC) <strong>page</strong> 353<br />
<strong>Barcelona</strong> Room Sponsored by GLAXOSMITHKLINE<br />
17.30 - 19.00 New trends in laparoscopy: Single portal and mini-laparoscopy <strong>page</strong> 354<br />
Stockholm Room Sponsored by KARL STORZ GMBH & CO.KG<br />
17.30 - 19.00 Testosterone deficiency: Sharing our experience between countries and specialities <strong>page</strong> 355<br />
Athens Room Sponsored by PIERRE FABRE MÉDICAMENT<br />
17.30 - 19.00 The value of maintenance therapy in the management of NMIBC: What does the data tell us?<br />
Milan Room <strong>page</strong> 356<br />
Sponsored by SANOFI PASTEUR<br />
17.30 - 19.00 Expert analysis on new treatment options in advanced prostate cancer <strong>page</strong> 357<br />
Istanbul Room Sponsored by SANOFI-AVENTIS<br />
For detailed information see programmes from <strong>page</strong>s 323-357
Tuesday, 20 April - <strong>EAU</strong> Programme<br />
Plenary Session 4<br />
08.00 - 12.15 Controversies<br />
eURO Auditorium<br />
Chairs: W. Artibani, Verona (IT)<br />
I. Eardley, Leeds (GB)<br />
08.00 - 10.00 Souvenir Session by the the <strong>EAU</strong> Scientific <strong>Congress</strong> Office<br />
Oncology<br />
X. Cathelineau, Paris (FR)<br />
Prostate disease<br />
C. Selli, Pisa (IT)<br />
Neurourology and voiding dysfunction<br />
F.R. Cruz, Porto (PT)<br />
Transplantation, trauma and reconstruction<br />
A. Stenzl, Tübingen (DE)<br />
Stone disease<br />
M. Marberger, Vienna (AT)<br />
Andrology<br />
I. Eardley, Leeds (GB)<br />
Incontinence<br />
P. Radziszewski, Warsaw (PL)<br />
Paediatrics<br />
G.A. Bogaert, Leuven (BE)<br />
10.00 - 10.35 Is botulinium toxin the new magic bullet?<br />
State-of-the-art lecture Overactive bladder<br />
E. Chartier-Kastler, Paris (FR)<br />
State-of-the-art lecture Prostate<br />
R. Dmochowski, Nashville (US)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
239
10.35 – 11.05 The best <strong>EAU</strong> papers<br />
279 Stroma reaction in mouse xenograft models of prostate cancer bone metastasis<br />
B. Özdemir, Berne (CH)<br />
(For co-authors see abstract)<br />
240 Programme Book<br />
80 Activated RhoA/Rho-Kinase leads to impaired erectile function in a cavernous nerve injury rat model<br />
C.J. Gratzke, Munich (DE)<br />
(For co-authors see abstract)<br />
755 Hypertriglyceridemia, hypercholesterolemia and risk of prostate cancer: A Swedish cohort study including<br />
4,278 prostate cancers<br />
M. Van Hemelrijck, London (GB)<br />
(For co-authors see abstract)<br />
11.05 - 11.40 Case discussion Postprostatectomy incontinence - treatment<br />
Moderator: H. Özen, Ankara (TR)<br />
Panel: F. Haab, Paris (FR)<br />
J.P.F.A. Heesakkers, Nijmegen (NL)<br />
A.R. Mundy, London (GB)<br />
C. Stief, Munich (DE)<br />
11.40 - 12.00 Award session 2<br />
Third Prize for the Best Abstract (Oncology)<br />
Third Prize for the Best Abstract (Non-Oncology)<br />
Second Prize for the Best Abstract (Oncology)<br />
Second Prize for the Best Abstract (Non-Oncology)<br />
First Prize for the Best Abstract (Oncology)<br />
Supported by an unrestricted educational grant from PFIZER INC<br />
First Prize for the Best Abstract (Non-Oncology)<br />
Supported by an unrestricted educational grant from ELI LILLY AND COMPANY<br />
<strong>2010</strong> Award for the Best Booth<br />
12.00 - 12.15 Closing remarks<br />
P-A. Abrahamsson, Malmö (SE)<br />
F.C. Hamdy, Oxford (GB)
ESU Courses, 18 April<br />
ESU Course 1<br />
08.30 - 11.30 Laparoscopic and robot-assisted laparoscopic radical cystectomy<br />
Monte Carlo Room<br />
Chair: P. Wiklund, Stockholm (SE)<br />
Introduction laparoscopic cystectomy; pre-surgery considerations<br />
Patient selection<br />
Contraindications<br />
Patient positioning<br />
Trocar placements<br />
R.F. Van Velthoven, Brussels (BE)<br />
Introduction robot-assisted laparoscopic cystectomy<br />
P. Wiklund, Stockholm (SE)<br />
Female cystectomy<br />
J. Rassweiler, Heilbronn (DE)<br />
Male cystectomy<br />
R.F. Van Velthoven, Brussels (BE)<br />
Lymph node dissection<br />
J. Rassweiler, Heilbronn (DE)<br />
Extracorporeal urinary diversion<br />
R.F. Van Velthoven, Brussels (BE)<br />
Intracorporeal urinary diversion<br />
P. Wiklund, Stockholm (SE)<br />
Outcome after laparoscopic cystectomy; oncological, functional and complications<br />
J. Rassweiler, Heilbronn (DE)<br />
Outcome after robot-assisted laparoscopic cystectomy; oncological, functional and complications<br />
P. Wiklund, Stockholm (SE)<br />
Aims and objectives<br />
At the conclusion of this educational activity, participants should be able to:<br />
• Identify the current indications and contraindications for laparoscopic and robot assisted laparoscopic<br />
radical cystectomy with extended lymph node dissection.<br />
• Illustrate the operative steps and techniques for laparoscopic and robot assisted laparoscopic radical<br />
cystectomy and extended pelvic lymph node dissection.<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
241
242 Programme Book<br />
• Identify the current indications and contraindications for laparoscopic and robot-assisted laparoscopic<br />
creation of an intracorporeal and extracorporeal urinary diversion.<br />
• Discuss surgical tricks and tips learned from review of video clips of laproscopic and robot-assisted<br />
laparoscopic radical cystectomy.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40
ESU Courses, 18 April<br />
ESU Course 2<br />
08.30 - 11.30 Evaluation and management of female pelvic floor disorders<br />
London Room<br />
Chair: E.J. Messelink, Groningen (NL)<br />
Evaluation and conservative treatment by the urologist<br />
E.J. Messelink, Groningen (NL)<br />
Evaluation and conservative treatment by the physical therapist<br />
S. Morkved, Trondheim (NO)<br />
Case discussion part 1<br />
Pelvic floor reconstruction by open surgery<br />
F.C. Burkhard, Berne (CH)<br />
Pelvic floor reconstruction by laparoscopic surgery<br />
J. Deprest, Leuven (BE)<br />
Case discussion part 2<br />
Aims and objectives<br />
The patient with a pelvic floor disorder will often report a combination of symptoms. These symptoms may<br />
originate in the bladder, the vagina and the ano-rectum. The aim of this course is to teach the urologist how<br />
to assess and treat these patients. The methods used to achieve this are: presenting literature reviews and<br />
personal expertise, showing pictures and videos of diagnostic and surgical procedures.<br />
The assessment of the function of the pelvic floor muscles is done by palpation or by intravaginal EMG.<br />
Classification of the function will be done using the terminology accepted by the International Continence<br />
Society. The function of the pelvic organs is assessed by physical examination and by imaging techniques.<br />
Special attention will be paid to the Pelvic Organ Prolaps Quantification (POPQ) and to MRI.<br />
According to the International Consultation on Incontinence flowcharts, treatment should start with a<br />
conservative approach: pelvic floor muscle education and lifestyle interventions. Open surgical reconstruction<br />
of the pelvic floor is done either by vaginal or abdominal route. It should be performed by an experienced<br />
pelvic floor surgeon or by a team of surgeons: urologist, gynaecologist, ano-rectal surgeon. Laparoscopic<br />
surgery is an appealing alternative to open surgery. It also provides a clear view on the anatomy of the pelvic<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
243
244 Programme Book<br />
organs in relation to the pelvic floor. The course will include an interactive discussion with the audience, on<br />
assessment and treatment, by means of a case presentation.<br />
At the end of this course the participants will be aware of the multidisciplinary nature of female pelvic floor<br />
disorders. They will also know how to use this awareness in diagnosing and treating these patients.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40
ESU Courses, 18 April<br />
ESU Course 3<br />
08.30 - 11.30 Update on stone disease<br />
Geneva Room<br />
Introduction<br />
M. Marberger, Vienna (AT)<br />
Medical therapy<br />
M.P. Laguna, Amsterdam (NL)<br />
Ureteroscopy<br />
A. Patel, London (GB)<br />
SWL – back to basics<br />
M.P. Laguna, Amsterdam (NL)<br />
Percutaneous nephrolithotripsy<br />
M. Marberger, Vienna (AT)<br />
Chair: M. Marberger, Vienna (AT)<br />
Interactive case presentations to demonstrate modern stone management<br />
Faculty<br />
Aims and objectives<br />
Although stone management has not changed dramatically in the last few years technical advances, mainly<br />
in diagnostic evaluation and endourological therapy, have implications for therapy. After a brief review of<br />
the new approaches, present treatment strategies of upper tract urolithiasis will be demonstrated in detailed<br />
case presentations.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
245
ESU Courses, 18 April<br />
ESU Course 4<br />
08.30 - 11.30 Retropubic radical prostatectomy – tips, tricks and pitfalls<br />
246 Programme Book<br />
Arnhem Room<br />
Surgical anatomy<br />
O.W. Hakenberg, Rostock (DE)<br />
Chair: H. Van Poppel, Leuven (BE)<br />
Step by step radical retropubic prostatectomy<br />
H. Van Poppel, Leuven (BE)<br />
Tips, tricks and pitfalls<br />
O.W. Hakenberg, Rostock (DE)<br />
Treatment of complications<br />
H. Van Poppel, Leuven (BE)<br />
Discussion and interaction<br />
Faculty<br />
Aims and objectives<br />
In many parts of Europe, open retropubic radical prostatectomy is still the gold standard for treating localised<br />
prostate cancer. Although laparoscopic, eventually robot assisted, radical prostatectomy is getting more<br />
popular in selected centres, and the open surgical approach is still the most often performed operative<br />
procedure in many countries throughout Europe. Localised prostate cancer is being more and more detected<br />
in its earlier stages and surgery undoubtedly offers the best local control. The urologist’s surgical skills must<br />
be outstanding and the urological community is responsible for guaranteeing optimal surgical quality through<br />
adequate training. The competition with external beam radiotherapy, brachytherapy and novel minimally<br />
invasive techniques like cryosurgery and HIFU, should encourage young urologists to optimally perform the<br />
surgical resection with the best possible tumour control and the least impact on continence and potency.<br />
This course aims to bring to the modern urologist the different technical steps of the classical ‘retropubic<br />
prostatectomy’ with an emphasis on the preservation of continence and potency and discusses the special tips<br />
and tricks that must enable every contemporary urologist to obtain good results with minimal complications.<br />
Also, the prevention and treatment of complications are discussed.<br />
This teaching course is a must for the elder resident and the younger urologist beginning his career but<br />
well trained urologists, who do not treat many patients with localised prostate cancer, will benefit. The<br />
participants will get inside the detailed surgical anatomy, the pre-operative measures and the intra-operative<br />
steps of a very systematic and safe operation. Also the experienced uro-oncological surgeon will enjoy the<br />
tricks and pitfalls and will learn how to solve intra- and postoperative complications.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour
ESU Courses, 18 April<br />
ESU Course 5<br />
08.30 - 11.30 Robot surgery in urology – how to start<br />
Budapest Room<br />
Introduction<br />
H.G. Van Der Poel, Amsterdam (NL)<br />
Why robotics in urology<br />
B.S.E.P. Van Cleynenbreugel, Leuven (BE)<br />
Financial aspects of robotics<br />
M. Stöckle, Homburg (DE)<br />
Hardware requirements<br />
H.G. Van Der Poel, Amsterdam (NL)<br />
Instrumental preparation/sterilisation<br />
B.S.E.P. Van Cleynenbreugel, Leuven (BE)<br />
Training for robotics<br />
M. Stöckle, Homburg (DE)<br />
Initial tips and tricks for RALP<br />
H.G. Van Der Poel, Amsterdam (NL)<br />
Initial tips and tricks for robot cystectomy<br />
M. Stöckle, Homburg (DE)<br />
Expanding the robotic repertoire<br />
B.S.E.P. Van Cleynenbreugel, Leuven (BE)<br />
Take home messages<br />
H.G. Van Der Poel, Amsterdam (NL)<br />
Chair: H.G. Van Der Poel, Amsterdam (NL)<br />
Aims and objectives<br />
Minimal invasive surgical procedures require expertise and equipment not always present in all urological<br />
practices. The speed of introduction of robot-assisted surgical applications in urology urges urologists to join<br />
in this field. Is your institute capable of supporting such a programme? What are the financial consequences?<br />
What equipment is needed? What are the indications of the most frequently performed procedures and who<br />
will perform those procedures? Consequently, who needs training and how will this training take place? All<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
247
248 Programme Book<br />
essential questions that need a solid answer before you decide to spend over €2 million on a surgical robotic<br />
system.<br />
During the course three experienced robotic surgeons from differently sized institutes will address these<br />
questions. The course will address the basics for a robotic programme and allows for interaction on specific<br />
questions.<br />
After the course you should be able to oversee what is needed in your department to make a robot<br />
programme feasible.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40
ESU Courses, 18 April<br />
ESU Course 6<br />
08.30 - 10.30 Surgical management of locally advanced & metastatic renal cancer<br />
Brussels Room<br />
Radical nephrectomy for T3 & T4 disease<br />
Z. Kirkali, Izmir (TR)<br />
Metastasectomy in mRCC<br />
M. Kuczyk, Hanover (DE)<br />
Chair: Z. Kirkali, Izmir (TR)<br />
Timing of surgery & systemic therapy in mRCC<br />
Z. Kirkali, Izmir (TR)<br />
Surgery for local recurrence & palliative surgery<br />
M. Kuczyk, Hanover (DE)<br />
Aims and objectives<br />
Although most renal cancers are small and incidentally found, still some patients present with locally<br />
advanced or even metastatic renal cell carcinoma (RCC). In addition, one third of patients treated for localised<br />
RCC develop local or systemic recurrences.<br />
RCC is a unique disease where we had important developments in the last 2 decades both in surgical as<br />
well as non-surgical and systemic therapies. Although we have now at least 7 drugs with proven efficacy in<br />
metastatic RCC, surgery still remains to be the only curative therapy.<br />
The aim of this course is to highlight the role of the urologist in the management of locally advanced and<br />
metastatic RCC. Surgery for locally advanced disease particularly in patients with vena caval thrombus is a<br />
challenging situation and tips and tricks of this type of surgery will be presented. In metastatic patients, the<br />
place of nephrectomy and metastasectomy, palliative surgery and surgery for local recurrences will also be<br />
dealt with. The timing and sequencing of surgery and medical therapies in metastatic RCC is another issue<br />
which will be addressed. At the end of the course the attendees will be able to understand and learn:<br />
• The place of surgery in locally advanced and metastatic RCC such as difficult T4 tumours and tumours with<br />
vena cava thrombus<br />
• Indications and role of surgery in metastatic RCC<br />
• The current positioning of surgery and systemic therapies.<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
249
250 Programme Book<br />
This course is an excellent opportunity to learn what the urologist can offer to renal cancer patients with<br />
difficult tumours and metastatic RCC. The course is an ideal opportunity for all; residents, the practicing<br />
urologist and the oncologic urologist. Don’t miss this course if you see patients with advanced RCC in your<br />
practice!<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 32.10<br />
Non-<strong>EAU</strong> members € 48.15<br />
Residents (members/non-members) € 21.40
ESU Courses, 18 April<br />
ESU Course 7<br />
08.30 - 11.30 Safe outpatient operations: How and where?<br />
Madrid Room<br />
Introduction<br />
H. Haas, Heppenheim (DE)<br />
Patient’s preparation<br />
L.J.G. Grenabo, Gothenburg (SE)<br />
Anaesthetics<br />
M.S. Michel, Mannheim (DE)<br />
Genital surgery<br />
L.J.G. Grenabo, Gothenburg (SE)<br />
Endoscopic operations<br />
M.S. Michel, Mannheim (DE)<br />
Chairs: H.Haas, Heppenheim (DE)<br />
M. Hanus, Prague (CZ)<br />
Demands on institution; Which operation in which institution?<br />
L.J.G. Grenabo, Gothenburg (SE)<br />
M. Hanus, Prague (CZ)<br />
Conclusions<br />
M. Hanus, Prague (CZ)<br />
Aims and objectives<br />
Outpatient operations are common in urology with increasing number in order to avoid hospitalisation and<br />
to save costs for health care systems. Operation techniques are part of specialists’ education and mainly well<br />
known.<br />
Every surgeon fears complications. Especially in outpatient operations, because his patient is not under<br />
permanent control, geographic distances to patient’s domicile might evoke problems, and after surgery in an<br />
office the tie to hospital is not as close as if done in hospital’s outpatient department.<br />
The surgical part of this course aims to give substantial information - from patient’s preparation to follow-up<br />
- on good surgical practice, tips and tricks, troubleshooting, prevention and management of complications<br />
(and nightmares), illustrated by case reports and worked out by discussion together with the audience.<br />
Which operations can be run safely, depends on the institutions (office, operation centre, outpatient<br />
department) where they are done. This course will discuss the institution’s demands regarding e.g. staff,<br />
equipment, experience, also with regard to troubleshooting and the possibility of immediately admitting the<br />
patient to hospital in the case of complications.<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
251
252 Programme Book<br />
The session will be presented in an interactive way, including case-scenarios for discussion, and the<br />
participants will have enough time to ask questions and discuss their own cases. This course aims to give<br />
reliable information to elder residents and younger urologists in the beginning of their career, to welltrained<br />
urologists who do not often do outpatient operations, but also to the experienced surgeon who will<br />
benefit from tips and tricks, and troubleshooting.<br />
After the session the attendants should know how and in which institution they can run which operation and<br />
anaesthetics safely and what to do in case of emergency.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40
ESU Courses, 18 April<br />
ESU Course 8<br />
12.00 - 15.00 Prostate cancer – screening, diagnosis and staging<br />
Monte Carlo Room<br />
Screening<br />
F.C. Hamdy, Oxford (GB)<br />
Diagnosis and staging<br />
I. Romics, Budapest (HU)<br />
Chair: F.C. Hamdy, Oxford (GB)<br />
Aims and objectives<br />
The incidence of prostate cancer has increased dramatically over the last 10 to 15 years and it is now the<br />
most common cancer in males in developed countries. The increase is mainly caused by the growing use<br />
of opportunistic screening or case-finding based on the use of prostate-specific antigen (PSA) testing in<br />
serum. Using this approach, prostate cancer is detected 5 to 10 years before giving rise to symptoms and on<br />
average 17 years before causing the death of the patient. While this has led to detection of prostate cancer<br />
at a potentially curable stage, it has also led to substantial overdiagnosis, i.e. detection of cancers that<br />
would not surface clinically in the absence of screening. This is confounded by recent evidence that screening<br />
reduces disease-specific mortality. A major challenge is thus to identify the cases that need to be treated<br />
while avoiding diagnosing patients who will not benefit from being diagnosed and who will only suffer from<br />
the stigma of being a cancer patient. Therefore, prognostic markers, which can predict those patients who<br />
need to be diagnosed and those who do not, are of major importance. This course is designed for urological<br />
trainees and established urologists, who wish to update themselves on the latest information regarding<br />
screening, diagnosis and staging in prostate cancer. The course allows interaction with the audience and is<br />
in part based on case-scenarios for discussion with the delegates, followed by state-of-the-art presentations.<br />
In addition, emphasis will be placed on controversial issues and recent progress in terms of diagnostic tools,<br />
staging procedures and prognostic factors. At the end of the course, the participants should have obtained<br />
good insights on the following:<br />
• What are the best approaches to screening and early detection of prostate?<br />
• How can we reduce the risk of overdiagnosis and overtreatment?<br />
• How can we identify patients who are best managed by active monitoring/surveillance rather than<br />
immediate more active treatment?<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
253
ESU Courses, 18 April<br />
254 Programme Book<br />
ESU Course 9<br />
12.00 - 15.00 Advanced management of urethral stricture disease<br />
Arnhem Room<br />
Anatomy and basic principles<br />
C.R. Chapple, Sheffield (GB)<br />
Panel discussion<br />
Chair: C.R. Chapple, Sheffield (GB)<br />
Urethroplasty for posterior urethral injuries<br />
L. Boccon-Gibod, Paris (FR)<br />
Panel discussion<br />
Urethroplasty for anterior urethral stricture disease<br />
C.R. Chapple, Sheffield (GB)<br />
Panel discussion<br />
New developments in urethral stricture disease<br />
G. Barbagli, Arezzo (IT)<br />
• Should we preserve the bulbospongiosus muscle?<br />
• Should we transect the urethra?<br />
• Should we suture or use fibrin glue?<br />
• Which tissue is best?<br />
Panel discussion<br />
Case discussion<br />
G. Barbagli, Arezzo (IT)<br />
Round table discussion<br />
Faculty<br />
Aims and objectives<br />
• To review the treatments available for urethral stricture disease<br />
• To detail the role of treatments available for specific patient scenarios<br />
• To provide a clearer understanding of the role of anastomotic and substitution urethroplasty in the<br />
management of urethral stricture disease<br />
ESU Courses are EU-ACME accredited with 1 credit per hour
• To outline the principles of the surgical management of patients with urethras that have been injured by<br />
trauma. Participants of the course will obtain a clear view on the current role of surgery for the management<br />
of urethral stenosis affecting both the anterior and posterior urethra in contemporary clinical practice.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
255
ESU Courses, 18 April<br />
256 Programme Book<br />
ESU Course 10<br />
12.00 - 15.00 Paediatric urology for the adult urologist: A practical update<br />
Geneva Room<br />
Chair: J.M. Nijman, Groningen (NL)<br />
Obstructive uropathy: What to do when, from neonate till puberty<br />
G.A. Bogaert, Leuven (BE)<br />
How to deal with congenital malformations of the external genitalia, when is surgery indicated and how<br />
to do it<br />
S. Tekgül, Ankara (TR)<br />
Urinary infection, reflux and voiding dysfunction: New insights in pathology, diagnostic work-up and<br />
management<br />
J.M. Nijman, Groningen (NL)<br />
Aims and objectives<br />
During this course an update is provided on common problems of the genito-urinary tract in children<br />
by means of state-of-the-art lectures, cases and interactive participation. Also the interaction between<br />
paediatric urologist, adult urologist, gynaecologist and paediatrician will be discussed. Corrections of<br />
congenital malformations of the urogenital tract have major implications for the quality of life, but also for<br />
long-term follow-up, future interventions and treatment of complications. Over the past few years our ideas<br />
about treatment of reflux and obstructive uropathy have changed; many so-called dogmas had to be revised.<br />
During this 3 hour course we will try to give an overview of the latest developments in the field of paediatric<br />
urology, focussing on topics of interest to the general urologist.<br />
The course is of particular interest to general urologists and those in training. Participants are encouraged to<br />
participate in the course as much as possible and there will be ample time for discussion and presentation<br />
of cases.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour
ESU Courses, 18 April<br />
ESU Course 11<br />
12.00 - 15.00 Office management of male sexual dysfunction<br />
London Room<br />
Diagnostics - what is necessary?<br />
I. Eardley, Leeds (GB)<br />
Testosterone replacement<br />
C. Stief, Munich (DE)<br />
Oral therapy for ED<br />
I. Eardley, Leeds (GB)<br />
Therapy of ED when pills fail<br />
D. Ralph, London (GB)<br />
Chair: C. Stief, Munich (DE)<br />
Medical therapy for premature ejaculation<br />
I. Eardley, Leeds (GB)<br />
Surgical topics: a) Penile implants b) Priapism c) Peyronie’s<br />
D. Ralph, London (GB)<br />
Management of ED in the patient with cardiovascular disease<br />
I. Eardley, Leeds (GB)<br />
What to do after radical prostatectomy?<br />
C. Stief, Munich (DE)<br />
Aims and objectives<br />
The course is aimed at providing practical advice on how to diagnose and treat a patient with premature<br />
ejaculation or ED. It will allow an up-to-date understanding of the underlying mechanisms of the erectile<br />
process and the aetiology of ED. The recent development of various orally available drugs with different<br />
modes of action and distinctly different side-effect profiles enables individually tailored therapies. However,<br />
an individually adopted regimen requires an adequate work up that will be comprehensively presented.<br />
Although currently available and future oral drugs will be covered in-depth, alternative options such as<br />
testosterone supplementation, local pharmacotherapy or various devices will be presented with special<br />
emphasis since their adequate indication and appropriate use by the urologist makes the distinctive difference<br />
in comparison to other specialists in the field. The indications for, and specific aspects for penile prosthesis<br />
will be discussed since prostheses still represent an important option for select patients. Then, specific topics<br />
with high practical importance such as the cardiovascular patient with ED or the post-prostatectomy case<br />
will be covered.<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
257
258 Programme Book<br />
The course will be very interactive allowing in-depth information on the various aspects of the cutting edge<br />
of ED.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40
ESU Courses, 18 April<br />
ESU Course 12<br />
12.00 - 15.00 Lower urinary tract dysfunction and urodynamics<br />
Budapest Room<br />
The scientific basics of urodynamics<br />
P. Abrams, Bristol (GB)<br />
Chair: P. Abrams, Bristol (GB)<br />
Urodynamics - getting philosophy and technique correct<br />
P. Abrams, Bristol (GB)<br />
Urodynamics in female urology and neurourology<br />
K. Hoefner, Oberhausen (DE)<br />
Urodynamics in the child and in men<br />
S. Madersbacher, Vienna (AT)<br />
Aims and objectives<br />
Having attended the course, the attendee should:<br />
• Understand the basic physical principles referable to urodynamics<br />
• Be able to assess the quality of a urodynamic trace<br />
• Recognise common artefacts and know how to correct them<br />
• Know the indications for urodynamic studies in children, men, women and neurological patients.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
259
ESU Courses, 18 April<br />
260 Programme Book<br />
ESU Course 13<br />
12.00 - 15.00 Chronic Pelvic Pain Syndromes (CPPS) with special focus on Chronic<br />
Prostatitis (CP) and Painful Bladder Syndrome/Interstitial Cystitis<br />
(PBS/IC)<br />
Brussels Room<br />
Welcome<br />
J.J. Wyndaele, Antwerp (BE)<br />
The phenomena of chronic pain<br />
J.J. Wyndaele, Antwerp (BE)<br />
Causes of pelvic pain. Confusable diseases<br />
J.J. Wyndaele, Antwerp (BE)<br />
Chair: J.J. Wyndaele, Antwerp (BE)<br />
Chronic prostatitis clinical picture and diagnosis<br />
J.C. Nickel, Kingston (CA)<br />
Treatment of chronic prostatitis<br />
J.C. Nickel, Kingston (CA)<br />
Bladder Pain Syndrome BPS/IC clinical picture and diagnosis<br />
J.J. Wyndaele, Antwerp (BE)<br />
BPS/IC conservative treatment<br />
J. Nordling, Herlev (DK)<br />
BPS surgical treatment<br />
J. Nordling, Herlev (DK)<br />
Discussion and conclusion<br />
Faculty<br />
Aims and objectives<br />
Painful diseases of the pelvis are not rare. The clinical entity is not an easy one, both in diagnosis and in<br />
treatment. Interactions between organs complicate the approach. The list of ‘confusable’ diseases is long and<br />
the most direct way to the most probable diagnosis needs to be determined while avoiding the danger of<br />
overlooking another dangerous pathology.<br />
ESU Courses are EU-ACME accredited with 1 credit per hour
An increase in knowledge has been important during the last couple of years. The scope of the course is to<br />
bring participants up to date, so that after the course they can perform the most optimal evaluation of the<br />
patients with chronic pelvic pain and give the treatment best adapted to our actual knowledge.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
261
ESU Courses, 18 April<br />
262 Programme Book<br />
ESU Course 14<br />
15.30 - 17.30 Renal transplantation: Technical aspects, diagnosis and management<br />
of early and late urological complications<br />
London Room<br />
Chair: K. Dreikorn, Bremen (DE)<br />
Selection and urological preparation of transplant recipients; surgical aspects of nephrectomy in living and<br />
deceased donors<br />
K. Dreikorn, Bremen (DE)<br />
Laparoscopic living donor nephrectomy<br />
F.J. Burgos Revilla, Madrid (ES)<br />
Avoiding complications by proper techniques of renal transplantation; tricks and tips<br />
K. Dreikorn, Bremen (DE)<br />
How to diagnose and manage postoperative and long-term surgical/urological complications following<br />
renal transplantation<br />
F.J. Burgos Revilla, Madrid (ES)<br />
Aims and objectives<br />
Given the dramatic improvement in short- and long-term graft and patient survival, renal transplantation<br />
has become the most effective treatment of end stage renal failure. Recipients considered for transplantation<br />
are currently older and pose more problems than in the past, in some cases requiring specific urological<br />
preparation. We would like to share our experience concerning the selected items with the audience. These<br />
include how to select and to prepare transplant recipients with surgical or urological problems, how to<br />
choose the most safe technique for performing deceased donor and living donor nephrectomy, how to deal<br />
with unusual situations of renal procurement or transplantation and finally, for urologists, how to diagnose<br />
and manage postoperative and long-term urological and other complications.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 32.10<br />
Non-<strong>EAU</strong> members € 48.15<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour
ESU Courses, 18 April<br />
ESU Course 15<br />
15.30 - 17.30 Laparoscopy for beginners<br />
Monte Carlo Room<br />
Indications for laparoscopy<br />
A.D. Joyce, Leeds (GB)<br />
Instrumentation and haemostasis<br />
X. Cathelineau, Paris (FR)<br />
Chair: A.D. Joyce, Leeds (GB)<br />
Peritoneal access and effects of pneumoperitoneum<br />
A.D. Joyce, Leeds (GB)<br />
Avoiding complications<br />
X. Cathelineau, Paris (FR)<br />
Aims and objectives<br />
Urologists interested in undertaking laparoscopy must be properly trained in order to minimise the risk of<br />
potential complications and to ensure patient safety. Currently training in urological laparoscopy is limited<br />
due to several factors:<br />
• A shortage of designated training centres<br />
• A shortage of recognised trainers<br />
• Lack of either appropriate facilities, limitations of equipment, expertise or support<br />
All of which restrict the trainee from access to high quality training. This course aims to provide the potential<br />
trainee with the recognised core knowledge with regard to case selection, correct use of the equipment and<br />
imaging systems, and the important protocols for accessing and exiting the abdomen, including how to<br />
recognise and avoid potential complications prior to starting with the skills acquisition. The central highlight<br />
of the course is the use of video clips to illustrate many of the essential points and to promote discussion<br />
amongst the delegates.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 32.10<br />
Non-<strong>EAU</strong> members € 48.15<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
263
ESU Courses, 18 April<br />
264 Programme Book<br />
ESU Course 16<br />
15.30 - 17.30 Management and outcome in invasive and locally advanced bladder<br />
cancer<br />
Geneva Room<br />
Chair: A. Alcaraz, <strong>Barcelona</strong> (ES)<br />
Cystectomy in the management of bladder invasive and locally advanced bladder cancer<br />
A. Alcaraz, <strong>Barcelona</strong> (ES)<br />
Case discussion<br />
B. Malavaud, Toulouse (FR)<br />
Bladder sparing approcaches to muscle invasive bladder cancer<br />
A. Alcaraz, <strong>Barcelona</strong> (ES)<br />
Case discussion<br />
B. Malavaud, Toulouse (FR)<br />
Cytotoxic chemotherapy in bladder cancer: Neoadjuvant and adjuvant setting and treatment of metastatic<br />
disease<br />
B. Malavaud, Toulouse (FR)<br />
Aims and objectives<br />
Bladder cancer is the second most common oncological malignancy in Europe. Invasive and locally advanced<br />
bladder tumour is the urological malignancy with the highest mortality.<br />
The course will begin with the definition of the disease and different prognostic factors. Among<br />
prognosticators of outcome will be discussed the role of early cystectomy in T1 patients with poor prognosis<br />
indicators and the limitations of cystectomy in elderly and poor performance status patients. The course will<br />
continue with the discussion of the different treatment options. Rationale for considering cystectomy as gold<br />
standard, as well as a clear definition of multidisciplinary strategies for bladder sparing treatments with<br />
special emphasis in patient selection and potential limitations will be discussed. Finally, the role of systemic<br />
chemotherapy in the neoadjuvant and adjuvant to cystectomy setting will be presented, as well as in the<br />
treatment of metastatic disease.<br />
Specially recommended for elder residents and young urologists starting their career in the field of urooncology.<br />
Also experienced uro-oncological surgeons will benefit from this course through an update,<br />
focused on clinical issues and a practical approach.<br />
At the conclusion of this course, the participants should get better insights in terms of:<br />
• Stratifying the patients with invasive and locally advanced bladder cancer in different groups of risk.<br />
• Understanding the rationales outcome and limitations of cystectomy and bladder sparing treatments.<br />
ESU Courses are EU-ACME accredited with 1 credit per hour
• Defining the current role of neoadjuvant and adjuvant chemotherapy for invasive and locally advanced<br />
bladder cancer.<br />
• Measuring the benefits of systemic chemotherapy in terms of progression free survival and overall<br />
survival.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 32.10<br />
Non-<strong>EAU</strong> members € 48.15<br />
Residents (members/non-members) € 21.40<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
265
ESU Courses, 18 April<br />
266 Programme Book<br />
ESU Course 17<br />
15.30 - 17.30 Minimally invasive treatment for localised prostate cancer<br />
Arnhem Room<br />
Introduction<br />
G. Morgia, Catania (IT)<br />
Cryotherapy<br />
G. Morgia, Catania (IT)<br />
Discussion<br />
Brachytherapy<br />
S. Machtens, Bergisch Gladbach (DE)<br />
Discussion<br />
HIFU<br />
S. Thüroff, Munich (DE)<br />
Discussion<br />
Chair: G. Morgia, Catania (IT)<br />
Focal therapy and Cyberknife: Two different ways to look at the future<br />
G. Morgia, Catania (IT)<br />
S. Thüroff, Munich (DE)<br />
Discussion<br />
Clinical cases<br />
Aims and objectives<br />
The challenge of modern medicine is to increasingly use mini-invasive techniques.<br />
Nowadays, while surgery and radiation therapy must be considered the standard forms of treatment for<br />
prostatic cancer, nonetheless mini-invasive techniques are greeted with ever more enthusiasm by patients.<br />
In addition the first long term results, indispensible for correct oncological evaluation of the technique, are<br />
also being reported.<br />
Brachytherapy, cryotherapy and HIFU must be recognised by urology, and proposed for patients with prostate<br />
cancer, albeit only in cases where the indications are correct.<br />
This course will demonstrate the techniques, the results and the complications of these procedures,<br />
highlighting those essential aspects which may sometimes make the use of these procedures preferable to<br />
conventional techniques.<br />
ESU Courses are EU-ACME accredited with 1 credit per hour
Also in this course we like to treat something of the future. In fact focal therapy could represent an<br />
improvement in terms of mini-invasivity and quality of life and Cyberknife is, for prostate cancer too, the<br />
most recent evolution of the radiation therapy.<br />
Finally clinical cases will be discussed. Practical examples of the use of mini-invasive therapy will be<br />
examined, and there will be time for an exchange of opinions with the audience on the practical applications<br />
of the techniques.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 32.10<br />
Non-<strong>EAU</strong> members € 48.15<br />
Residents (members/non-members) € 21.40<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
267
ESU Courses, 18 April<br />
268 Programme Book<br />
ESU Course 18<br />
15.30 - 17.30 Metastatic prostate cancer<br />
Budapest Room<br />
First and second line hormonal therapy<br />
K. Pummer, Graz (AT)<br />
Chemotherapy and targeted therapies<br />
K. Miller, Berlin (DE)<br />
Chair: K. Pummer, Graz (AT)<br />
Aims and objectives<br />
The aims of this course are to provide state-of-the-art information about the design, the indication and<br />
the optimal timing of current hormone therapy regimens including the possible role of the 6-months<br />
LHRH depots and the LHRH antagonists. In addition, the place and precise design of second-line hormonal<br />
manipulations will be presented.<br />
The role of chemotherapy will be critically discussed at the time of hormone resistance and as a first line<br />
treatment in selected patients.<br />
Additionally, the role and the mechanism of action of experimental targeted therapies will be briefly<br />
reviewed.<br />
The presentations will be based on interactive cases to be discussed with the course participants and there<br />
will be time for questions and answers.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 32.10<br />
Non-<strong>EAU</strong> members € 48.15<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour
ESU Courses, 18 April<br />
ESU Course 19<br />
15.30 - 17.30 Robot renal surgery<br />
Brussels Room<br />
Introduction<br />
A. Mottrie, Aalst (BE)<br />
Pyeloplasty<br />
G. Guazzoni, Milan (IT)<br />
Clinical cases UPJ Obstruction<br />
Nephrectomy for RCC<br />
J. Hubert, Nancy (FR)<br />
Partial nephrectomy<br />
A. Mottrie, Aalst (BE)<br />
Clinical cases RCC<br />
Nephroureterectomy<br />
J. Hubert, Nancy (FR)<br />
Conclusion<br />
G. Guazzoni, Milan (IT)<br />
Chair: A. Mottrie, Aalst (BE)<br />
Aims and objectives<br />
1. Explain the advantages of robotics over classical laparoscopy in surgery of the upper urinary system<br />
2. Teach the different operations step-to-step<br />
3. Discuss difficult clinical cases<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 32.10<br />
Non-<strong>EAU</strong> members € 48.15<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
269
ESU Courses, 18 April<br />
270 Programme Book<br />
ESU Course 39<br />
08.30 - 10.30 How to become the best reviewer for European Urology<br />
Genoa Room<br />
Chair: F. Montorsi, Milan (IT)<br />
What is the Editor-in-Chief expecting from reviewers and how to use the Elsevier system<br />
F. Montorsi, Milan (IT)<br />
How to write the perfect peer review of an original article: How to assess the various sections of the<br />
manuscript<br />
S. Madersbacher, Vienna (AT)<br />
What should a reviewer consider in terms of statistical analysis and methodology<br />
R.J. Sylvester, Brussels (BE)<br />
Why are tables, figures and references important within the peer-review process<br />
G. Giannarini, Berne (CH)<br />
How to write the perfect peer review for a review article: How to assess the various sections of the<br />
manuscript<br />
V. Ficarra, Padua (IT)<br />
Questions and answers<br />
Aims and objectives<br />
The objective of this course is to give a detailed explanation of how to execute the “perfect” review process.<br />
This year, a distinguished faculty made up of experienced reviewers will provide “tips and tricks” on how<br />
to assess every aspect of a scientific manuscript in order to provide the author with constructive criticism to<br />
further improve their work. Reviewers will be taught how to consider the methodology, statistical analysis<br />
and understand the importance of the tables figures and references. The format of this course will be an<br />
interactive workshop which encourages attendees to ask questions and initiate discussions.<br />
ESU Courses are EU-ACME accredited with 1 credit per hour
ESU Courses, 19 April<br />
ESU Course 20<br />
08.30 - 11.30 How to write a manuscript and get it published in European Urology<br />
London Room<br />
Chair: F. Montorsi, Milan (IT)<br />
How to get your manuscript published in European Urology<br />
F. Montorsi, Milan (IT)<br />
Clinical research original article: How to write the best introduction section<br />
S.F. Shariat, New York (US)<br />
Clinical research original article: How to write the methods section and on the importance of statistical<br />
analysis<br />
G. Novara, Padua (IT)<br />
Clinical research original article: How to write the results and discussion sections<br />
A.R. Zlotta, Toronto (CA)<br />
Clinical research original article: Why tables, figures and references are important<br />
S.F. Shariat, New York (US)<br />
Clinical research original article: The Editor’s tricks<br />
F. Montorsi, Milan (IT)<br />
Basic science/translational research original article: How to write the best manuscript for a clinicallyoriented<br />
journal<br />
C.J. Gratzke, Munich (DE)<br />
Review article: How to perform the best meta-analysis, systematic and non-systematic review of the<br />
literature<br />
G. Novara, Padua (IT)<br />
Review article: How to summarise the evidence<br />
S.F. Shariat, New York (US)<br />
Review article: The critical interpretation of the summarised evidence; why is the author’s “touch of class”<br />
essential to write the perfect manuscript<br />
A.R. Zlotta, Toronto (CA)<br />
Questions and answers<br />
Faculty<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
271
272 Programme Book<br />
Aims and objectives<br />
The objectives of the course are to provide the fundamentals of writing top level manuscripts. This year, a<br />
distinguished faculty will provide “tips and tricks” on how to successfully draft Clinical Research Original<br />
Articles, Basic Science/Translational Research articles and Review articles. The “how to do it” represents the<br />
core of the course and each member of the faculty will provide the attendees with “insider” information to<br />
maximize their scientific writing skills. This will be demonstrated by case studies specific to each aspect of<br />
the paper and thoroughly discussed in the interactive workshop style discussion with the students. Attendees<br />
are expected to leave the course with a full knowledge of the fundamental requirements to be successful in<br />
having a scientific paper accepted by a major journal.
ESU Courses, 19 April<br />
ESU Course 21<br />
08.30 - 11.30 Vaginal surgery for urologists<br />
Monte Carlo Room<br />
Chair: D. Pushkar, Moscow (RU)<br />
Vaginal surgery 2008 – what‘s new?<br />
D. Pushkar, Moscow (RU)<br />
Pelvic anatomy – salient points for the newest surgical approaches<br />
D.J.M.K. De Ridder, Leuven (BE)<br />
D. Pushkar, Moscow (RU)<br />
Surgery for SUI and management of its complications; MINIs are we there yet ?<br />
D.J.M.K. De Ridder, Leuven (BE)<br />
D. Pushkar, Moscow (RU)<br />
Prolapse surgery for urologist and mesh<br />
D.J.M.K. De Ridder, Leuven (BE)<br />
Urogenital fistulae and more<br />
D. Pushkar, Moscow (RU)<br />
Video session<br />
D. Pushkar, Moscow (RU)<br />
D.J.M.K. De Ridder, Leuven (BE)<br />
Aims and objectives<br />
Surgeons involved in the care of female patients should be familiar with vaginal surgery. A specific goal of the faculty is<br />
to employ scientific principles, published information and clinical experience to describe and position newly developed<br />
techniques in current clinical practice.<br />
The main theories of the development of stress urinary incontinence (SUI) will be explored with the audience in an<br />
interactive format. Special attention will be given to new techniques that use synthetic tapes in SUI surgery. This course<br />
will also cover the management of complications of surgery for stress incontinence. This course will include detailed<br />
coverage of pelvic anatomy so that urologist may better understand and apply modern surgical approaches to pelvic<br />
organ prolapse. Vaginal approach to prolapse and the use of different meshes will be covered in a critical way based<br />
upon personal experience.<br />
Management of periurethral cysts, fistulae and other rare conditions will be shown both during podium and video<br />
presentations. Carefully prepared clinical cases and video demonstration of various surgical techniques and tricks will<br />
provide a clear understanding of the most common procedures to all participants.<br />
An interactive course means active participation by the audience, and participants are encouraged to prepare and<br />
present interesting and challenging clinical cases for consultation by the faculty. After this course, participants should<br />
know how to apply the newest techniques in patients with stress incontinence, prolapse and iatrogenic injuries of lower<br />
urinary tract. This course will facilitate the decision making process for those who are just starting their careers.<br />
A specially prepared CD-rom with some videos will be given to every participant after the course.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
273
ESU Courses, 19 April<br />
274 Programme Book<br />
ESU Course 22<br />
08.30 - 11.30 Diagnosis and management of Non-Muscle Invasive Bladder Cancer<br />
(NMIBC)<br />
Geneva Room<br />
Introduction and objective of course<br />
J.A. Witjes, Nijmegen (NL)<br />
Chair: J.A. Witjes, Nijmegen (NL)<br />
Diagnostic strategy in bladder cancer including markers and TUR technique according to guidelines<br />
J. Palou, <strong>Barcelona</strong> (ES)<br />
Case on diagnosis and discussion<br />
J. Palou, <strong>Barcelona</strong> (ES)<br />
New diagnostic innovations such as NBI, OCT, PDD<br />
M. Babjuk, Prague (CZ)<br />
Guideline treatment and follow-up according to prognostic stratification<br />
J.A. Witjes, Nijmegen (NL)<br />
Case on guideline therapy and discussion<br />
Comments on guideline recommendations<br />
M. Babjuk, Prague (CZ)<br />
Case on non guideline therapy<br />
M. Babjuk, Prague (CZ)<br />
BCG failures and indication for cystectomy<br />
J.A. Witjes, Nijmegen (NL)<br />
Case on BCG failures<br />
Extravesical recurrences<br />
J. Palou, <strong>Barcelona</strong> (ES)<br />
Case<br />
J. Palou, <strong>Barcelona</strong> (ES)<br />
ESU Courses are EU-ACME accredited with 1 credit per hour
Aims and objectives<br />
After we gave this course for several years in a rather unchanged format, we have now changed the format<br />
slightly. We realise that some of the attendees are residents, who really appreciate thorough discussion of<br />
guideline recommendation. However, urologists following this course would like to see news and exceptions<br />
to the rule, and what to do with that.<br />
In the first lecture Joan Palou from <strong>Barcelona</strong> will discuss the basics of diagnosis, including white light<br />
cystoscopy, cytology and urinary markers, the technique of TURB and indications for a re-TUR , all according<br />
to the guidelines. This lecture will be illustrated with some cases. In the second lecture, Prof Babjuk from<br />
Prague (chairman of the <strong>EAU</strong> NMIBC Guideline!) might comment on this, for example his opinion on a<br />
re-TUR. He will also discuss some diagnostic innovations like NBI, PDD, OCT and Raman spectroscopy. After<br />
this, Prof Witjes from Nijmegen will again follow the guidelines in discussing patient risk classification, and<br />
therapy/follow-up based on this classification. Also during this presentation cases will be discussed.<br />
After the break, however, we will try to illustrate potential pitfalls and shortcomings in the guidelines. Prof<br />
Babjuk will address several points that could be criticised. Is a single shot intravesical instillation really<br />
necessary in all patients? What about BCG versus chemotherapy, is BCG really better? What is the best BCG<br />
schedule to use? How can we deal with BCG toxicity? Obviously, again cases will serve as guide for the<br />
discussion in this presentation. Next, Prof Witjes will address another important issue: what to do with BCG<br />
failures. When to do or not to do a cystectomy, the guideline therapy in these patients. Finally, Prof Palou will<br />
end the course with discussion of urothelial carcinoma outside the bladder, its implications and therapy<br />
After the course, attendees will know when to follow the guideline in NMIBC, when there are points of<br />
discussion, and what potential alternatives might be.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
275
ESU Courses, 19 April<br />
276 Programme Book<br />
ESU Course 23<br />
08.30 - 11.30 Surgery or radiotherapy for localised and locally advanced prostate<br />
cancer<br />
Arnhem Room<br />
Localised prostate cancer<br />
Chair: B. Djavan, New York (US)<br />
Treatment options and strategies in localised prostate cancer<br />
B. Djavan, New York (US)<br />
How to use nomograms and networks<br />
T. Wiegel, Ulm (DE)<br />
Oncological and functional results of radical prostatectomy<br />
B. Djavan, New York (US)<br />
Oncology results of radiation therapy<br />
T. Wiegel, Ulm (DE)<br />
Advanced prostate cancer<br />
Radiotherapy with or without hormonal treatment in advanced PCA<br />
T. Wiegel, Ulm (DE)<br />
Results of radical prostatectomy for T3 disease<br />
B. Djavan, New York (US)<br />
Radiotherapy after radical prostatectomy (adjuvant and for PSA-increase)<br />
T. Wiegel, Ulm (DE)<br />
Take home messages<br />
B. Djavan, New York (US)<br />
Aims and objectives<br />
The decision process towards surgery/active surveillance or radiation is a constantly evolving matter that<br />
requires a multitude of various information and inputs. In localised disease old habits have been jeopardised<br />
and surgical management seems to be fused with active surveillance in an increasing number of patients<br />
with good prognosticators. This course will summarise the decision process and indications for patients<br />
ESU Courses are EU-ACME accredited with 1 credit per hour
with clinically localised disease and help select the optimal treatment based on most recent oncological and<br />
functional data.<br />
In locally advanced disease, growing evidence supports the notion of radical surgery to improve outcome.<br />
US and European data endorse this policy in a selected group of patients. New radiation protocols and<br />
strategies combined with hormone therapy offer as much adequate alternatives. In the second part of this<br />
course, controversies regarding the optimal management of locally advanced prostate cancer patients will be<br />
discussed and clear recommendations made to facilitate patient counselling and treatment.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
277
ESU Courses, 19 April<br />
278 Programme Book<br />
ESU Course 24<br />
08.30 - 11.30 The infertile couple – urological aspects<br />
Budapest Room<br />
Diagnostic work-up, medical treatment<br />
W. Weidner, Giessen (DE)<br />
Chair: W. Aulitzky, Vienna (AT)<br />
Pathophysiology, diagnosis and treatment of varicocele<br />
W. Aulitzky, Vienna (AT)<br />
Microsurgical refertilisation<br />
W. Aulitzky, Vienna (AT)<br />
Sperm retrieval techniques and genetic aspects of IVF/ICSI<br />
W. Weidner, Giessen (DE)<br />
Aims and objectives<br />
This course provides state-of-the-art information on urological aspects of diagnosis and therapy of modern<br />
reproductive medicine. Diagnostic procedures should be standardised and coordinated in a timely fashion<br />
for both partners, focussing on the possible urological, hormonal and genetic causes of male infertility. In<br />
terms of therapy, this course will provide updated information on evidence-based data and will discuss the<br />
importance of varicoceles in male infertility. We will show microsurgical techniques on video and explain<br />
why proper training and skills perfection is key to successful case management. A successful IVF/ICSI outcome<br />
depends upon the use of state-of-the-art techniques for sperm retrieval and sperm preparation. We will<br />
also provide information on genetic aspects and stress the responsibility of the urologist as an adviser and<br />
gatekeeper for the treatment of the infertile couple.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour
ESU Courses, 19 April<br />
ESU Course 25<br />
08.30 - 11.30 Management of small renal tumours<br />
Brussels Room<br />
Active surveillance<br />
P. Gontero, Turin (IT)<br />
Ablative therapies<br />
J. De La Rosette, Amsterdam (NL)<br />
Surgery<br />
D. Jacqmin, Strasbourg (FR)<br />
Chair: D. Jacqmin, Strasbourg (FR)<br />
Aims and objectives<br />
The aims of this course are to review the various therapeutic strategies in small localised RCC.<br />
The techniques such as surgery (open and laparoscopy) radical and nephron sparing, cryotherapy,<br />
radiofrequency and HIFU will be presented. Their respective indications including surveillance will be<br />
discussed. An overview of the published results will be presented and analysed. Interaction is the most<br />
important way to have an efficient course.<br />
Video and clinical cases will be used as a tool to stimulate exchange.<br />
We hope to meet you in <strong>Barcelona</strong> during the <strong>EAU</strong> <strong>Annual</strong> <strong>Congress</strong> to enjoy lots of discussions on this<br />
interesting topic.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
279
ESU Courses, 19 April<br />
280 Programme Book<br />
ESU Course 26<br />
12.00 - 15.00 Radical cystectomy and orthotopic bladder substitution – surgical<br />
tricks and management of complications<br />
Monte Carlo Room<br />
Chair: U.E. Studer, Berne (CH)<br />
Preoperative investigations and selection of patients for orthotopic bladder substitution<br />
J.E. Gschwend, Munich (DE)<br />
Arguments for nerve sparing cystectomy with orthotopic bladder substitution<br />
A. Stenzl, Tübingen (DE)<br />
How to do a nerve-sparing cystectomy in male and female patients, surgical tricks to avoid complications<br />
with orthotopic bladder substitution<br />
U.E. Studer, Berne (CH)<br />
Tips on how to obtain good functional results in female patients<br />
A. Stenzl, Tübingen (DE)<br />
Active post-operative management is the most important step<br />
U.E. Studer, Berne (CH)<br />
How to treat complications during follow-up<br />
J.E. Gschwend, Munich (DE)<br />
Discussion<br />
Aims and objectives<br />
In this course, special emphasis is placed on patient selection and on practical surgical steps: on how to do<br />
meticulous pelvic lymph node dissection and nerve-sparing cystectomy in male and female patients, as well<br />
as how to do various types of orthotopic bladder substitutes with good long-term functional results. The<br />
course aims to be interactive with 50% of the time reserved for questions and discussions with the audience.<br />
At the end of the course, participants should know all the essential and practical steps needed in order to<br />
achieve good results with cystectomy and orthotopic bladder substitution.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour
ESU Courses, 19 April<br />
ESU Course 27<br />
12.00 - 15.00 Advanced course on upper tract laparoscopy (UPJ, adrenal and<br />
stones)<br />
London Room<br />
Chair: G. Janetschek, Salzburg (AT)<br />
Transperitoneal approach to the kidney and adrenal gland: Standard technique and modifications<br />
G. Janetschek, Salzburg (AT)<br />
Retroperitoneoscopy: Lateral and posterior approach<br />
F. Porpiglia, Turin (IT)<br />
Dismembered pyeloplasty: Technique – problems – complications<br />
P. Fornara, Halle/Saale (DE)<br />
Non-dismembered pyeloplasty: Indication – technique<br />
G. Janetschek, Salzburg (AT)<br />
Adrenalectomy<br />
P. Fornara, Halle/Saale (DE)<br />
Partial adrenalectomy<br />
G. Janetschek, Salzburg (AT)<br />
Stone surgery<br />
F. Porpiglia, Turin (IT)<br />
Questions and discussion<br />
Aims and objectives<br />
Surgery of the kidney and adrenal gland by means of laparoscopy has become standard of care. Most<br />
frequently this surgery is performed transperitoneally; this approach has been standardised. However, the<br />
anatomy of the right and left side differs substantially and this has to be taken into consideration. Also<br />
several modifications have been developed such as a direct approach to the left renal pelvis through the<br />
colonic mesentery. Retroperitoneoscopy is an alternative which should also be mastered.<br />
Adrenalectomy was the first widely recognised indication for laparoscopy in urology, and open surgery<br />
has almost vanished for this indication. Partial adrenalectomy may be considered as an alternative<br />
in benign solitary tumours such as Conn adenoma but is strongly recommended in familial bilateral<br />
phaeochromocytoma.<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
281
282 Programme Book<br />
For the treatment of UPJ, obstruction laparoscopy has to compete with both open surgery and endopyelotomy.<br />
Compared to open surgery the results are the same but morbidity is lower. Morbidity of endopyelotomy is<br />
lower, however, but the results are not as good in the long-term. The technique of dismembered and nondismembered<br />
pyeloplasty will be discussed in detail.<br />
Laparoscopic stone surgery is usually not a first line therapy. In specific situations it may however be<br />
helpful.<br />
All the mentioned techniques will be presented in an interactive way. Essential steps will be highlighted by<br />
video clips.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40
ESU Courses, 19 April<br />
ESU Course 28<br />
12.00 - 15.00 Interventional therapies for BPH<br />
Geneva Room<br />
Introduction<br />
K.M. Anson, London (GB)<br />
Chair: K.M. Anson, London (GB)<br />
The science behind the devices (what you need to know)<br />
K.M. Anson, London (GB)<br />
Update on HoLEP<br />
R.M. Kuntz, Berlin (DE)<br />
Update on TURP and bipolar technologies<br />
T.E. Bjerklund Johansen, Århus (DK)<br />
Update on laser technologies<br />
R.M. Kuntz, Berlin (DE)<br />
Update on microwave and novel therapies<br />
T.E. Bjerklund Johansen, Århus (DK)<br />
Case discussion (illustrating the patient, prostate and technological factors that influence decision making)<br />
Faculty<br />
Aims and objectives<br />
• To help delegates understand the physical principles behind the technologies and how they interact with<br />
prostate tissue<br />
• To inform delegates of the likely clinical outcomes with each technology<br />
• To summarise the evidence base for each intervention by teasing out fact from fiction<br />
• To help delegates understand the patient factors that influence technology choice using case presentations<br />
and delegate participation<br />
• To debate the different health care system factors across Europe that influence patient and surgeon choice<br />
of treatment modalities<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
283
ESU Courses, 19 April<br />
284 Programme Book<br />
ESU Course 29<br />
12.00 - 15.00 Advanced course on laparoscopic nephrectomy<br />
Arnhem Room<br />
Chair: V. Pansadoro, Rome (IT)<br />
Advanced course on laparoscopic nephrectomy<br />
Chair V. Pansadoro, Rome (IT)<br />
Introduction<br />
V. Pansadoro, Rome (IT)<br />
Indications for laparoscopic nephrectomy<br />
V. Pansadoro, Rome (IT)<br />
Transperitoneal access<br />
V. Pansadoro, Rome (IT)<br />
Extraperitoneal access<br />
H.P. Beerlage, ‘s-Hertogenbosch (NL)<br />
Transperitoneal safe control of the renal pedicle<br />
V. Pansadoro, Rome (IT)<br />
Extraperitoneal safe control of the renal pedicle<br />
H.P. Beerlage, ‘s-Hertogenbosch (NL)<br />
Use of proper instruments and high energy tools<br />
H.P. Beerlage, ‘s-Hertogenbosch (NL)<br />
Indications for transperitoneal partial nephrectomy. Size, location, etc.<br />
V. Pansadoro, Rome (IT)<br />
Indications for extraperitoneal partial nephrectomy. Size, location, etc.<br />
H.P. Beerlage, ‘s-Hertogenbosch (NL)<br />
Pedicle control. Advantages and disadvantages of the different systems. (Bulldog clamp, tourniquet, vascular<br />
clamp)<br />
V. Pansadoro, Rome (IT)<br />
H.P. Beerlage, ‘s-Hertogenbosch (NL)<br />
Hemostatis<br />
V. Pansadoro, Rome (IT)<br />
H.P. Beerlage, ‘s-Hertogenbosch (NL)<br />
ESU Courses are EU-ACME accredited with 1 credit per hour
Classical laparoscopy or robotic enucleation?<br />
V. Pansadoro, Rome (IT)<br />
H.P. Beerlage, ‘s-Hertogenbosch (NL)<br />
Surgical tips for the nephroureterectomy<br />
V. Pansadoro, Rome (IT)<br />
H.P. Beerlage, ‘s-Hertogenbosch (NL)<br />
Vascular emergencies during renal surgery<br />
V. Pansadoro, Rome (IT)<br />
H.P. Beerlage, ‘s-Hertogenbosch (NL)<br />
Conclusion<br />
V. Pansadoro, Rome (IT)<br />
H.P. Beerlage, ‘s-Hertogenbosch (NL)<br />
Aims and objectives<br />
Different access to radical nephrectomy will be discussed.<br />
Best way to control the pedicle with the different approaches.<br />
Indications and surgical technique to partial nephrectomy.<br />
Pedicle control and efficient haemostasis.<br />
All the subjects will be discussed from a practical point of view with tips, tricks and pitfalls .<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
285
ESU Courses, 19 April<br />
286 Programme Book<br />
ESU Course 30<br />
12.00 - 15.00 Robot-assisted laparoscopic prostatectomy<br />
Budapest Room<br />
Introduction<br />
P. Piechaud, Bordeaux (FR)<br />
Chair: P. Piechaud, Bordeaux (FR)<br />
General principles of robotic radical prostatectomy<br />
My way of access, how I place the ports<br />
W. Artibani, Verona (IT)<br />
My way of access, how I place the ports<br />
P. Dasgupta, London (GB)<br />
Step by step procedure – How I do it<br />
Bladder neck dissection<br />
W. Artibani, Verona (IT)<br />
P. Dasgupta, London (GB)<br />
P.T. Piechaud, Bordeaux (FR)<br />
Approach posterior plain<br />
W. Artibani, Verona (IT)<br />
P. Dasgupta, London (GB)<br />
P.T. Piechaud, Bordeaux (FR)<br />
Dissection of bundles<br />
W. Artibani, Verona (IT)<br />
P. Dasgupta, London (GB)<br />
P.T. Piechaud, Bordeaux (FR)<br />
Approach of apex<br />
W. Artibani, Verona (IT)<br />
P. Dasgupta, London (GB)<br />
P.T. Piechaud, Bordeaux (FR)<br />
Anastomosis<br />
W. Artibani, Verona (IT)<br />
P. Dasgupta, London (GB)<br />
P.T. Piechaud, Bordeaux (FR)<br />
ESU Courses are EU-ACME accredited with 1 credit per hour
Specific complications of robotic radical prostatectomy<br />
W. Artibani, Verona (IT)<br />
P.T. Piechaud, Bordeaux (FR)<br />
Functional consequences of different techniques of neurovascular bundles dissection<br />
P. Dasgupta, London (GB)<br />
Conclusion<br />
P.T. Piechaud, Bordeaux (FR)<br />
Aims and objectives<br />
Give to the participants a complete description of a safe, reproducible, operative technique of radical<br />
prostatectomy performed by robotic assisted laparoscopy.<br />
Presentation of different options: Transperitoneal or extraperitoneal access.<br />
Different approach of specific steps: Bundles dissection, anatomises.<br />
Each of these technical presentations will be supported by movies describing these techniques.<br />
For each part of the technical description, sufficient time to ask questions will be left to the participants.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 48.15<br />
Non-<strong>EAU</strong> members € 69.55<br />
Residents (members/non-members) € 21.40<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
287
ESU Courses, 19 April<br />
288 Programme Book<br />
ESU Course 31<br />
12.00 - 14.00 Palliative treatment of advanced genito urinary cancer<br />
Brussels Room<br />
Chair: A. Heidenreich, Aachen (DE)<br />
Bone metastasis, pathophysiology, diagnosis and treatment<br />
B. Tombal, Brussels (BE)<br />
Radiotherapy, surgery and medical treatment metastatic urogenital cancer<br />
A. Heidenreich, Aachen (DE)<br />
Aims and objectives<br />
About 50% of all patients with urogenital cancer present with metastatic disease at time of diagnosis or will<br />
develop metastases after local therapy with curative intent. Besides testicular cancer, systemic treatment<br />
options such as chemotherapy or multi-tyrosine-kinase inhibitors are merely palliative and do not result<br />
in long-term cure. The majority of patients with advanced disease will develop symptoms such as pain,<br />
vesicourethral or upper urinary tract obstruction, nausea, vomiting due to extensive metastatic disease.<br />
This course is intended<br />
· To educate urologists about the pathophysiology, diagnosis and management of cancer-induced pain and<br />
cancer-related symptoms<br />
· To educate urologists about the indication, techniques and outcomes of palliative surgical procedures for<br />
the treatment of symptomatic metastases<br />
· To educate urologists about the indication, techniques and outcomes of palliative radiation therapy and<br />
radionuclide treatment<br />
· To educate urologists on options of palliative chemotherapy and the management of its side effects<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 32.10<br />
Non-<strong>EAU</strong> members € 48.15<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour
ESU Courses, 19 April<br />
ESU Course 32<br />
15.30 - 17.30 Advanced course on laparoscopic prostatectomy<br />
Monte Carlo Room<br />
Chair: J-U. Stolzenburg, Leipzig (DE)<br />
Anatomy of the prostate and urethral sphincter<br />
K. Touijer, New York (US)<br />
Anatomy of the neurovascular bundles and fascias - extrafascial, interfascial, intrafascial – where is the<br />
difference<br />
J-U. Stolzenburg, Leipzig (DE)<br />
Operative set-up, access, trocar position: Extra versus transperitoneal approach<br />
J-U. Stolzenburg, Leipzig (DE)<br />
K. Touijer, New York (US)<br />
Pelvic lymphadenectomy – how to perform<br />
K. Touijer, New York (US)<br />
Steps of the procedure (video): Endoscopic extraperitoneal radical prostatectomy<br />
J-U. Stolzenburg, Leipzig (DE)<br />
Steps of the procedure (video): Transperitoneal laparoscopic radical prostatectomy<br />
K. Touijer, New York (US)<br />
How can we reduce the positive margins?<br />
J-U. Stolzenburg, Leipzig (DE)<br />
K. Touijer, New York (US)<br />
Management of complications (based on real cases)<br />
J-U. Stolzenburg, Leipzig (DE)<br />
K. Touijer, New York (US)<br />
Tips and tricks for difficult cases<br />
J-U. Stolzenburg, Leipzig (DE)<br />
K. Touijer, New York (US)<br />
Conclusion<br />
J-U. Stolzenburg, Leipzig (DE)<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
289
290 Programme Book<br />
Aims and objectives<br />
Laparoscopic/endoscopic radical prostatectomy needs to be well standardised to be reproduced. Besides the<br />
approaches the results of radical prostatectomy are based on our understanding of the prostatic anatomy.<br />
Thus, we will first give precise information on the anatomy of the prostate, the sphincter muscle, fascias<br />
and the bundles in order to have a better understanding of the operative laparoscopic anatomy. The experts<br />
will then go through each step of the surgery. For this, short well-selected video clips will be presented and<br />
discussed e.g. the best way to perform the space for the extraperitoneal approach, how to spare the bladder<br />
neck, to make easy dorsal vein complex control, the apical dissection and the anastomosis. Different aspects<br />
(interfascial, intrafascial) of nerve-sparing surgery will be addressed. The participants will be aware of the<br />
risk of complications or difficulties for each part of the procedure. The tricks for shortening the operative time<br />
will also be discussed. Finally, complications and their management will be addressed and discussed on the<br />
basis of real cases. At the end of the session, the participants, if they are beginners, should have a better<br />
comprehension of each step of the technique. If they are experienced, the course should help to improve<br />
their technique by picking out some important tricks.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 32.10<br />
Non-<strong>EAU</strong> members € 48.15<br />
Residents (members/non-members) € 21.40
ESU Courses, 19 April<br />
ESU Course 33<br />
15.30 - 17.30 Testicular cancer<br />
London Room<br />
Testis cancer – early stages<br />
N.W. Clarke, Manchester (GB)<br />
Testis cancer – case discussion<br />
N.W. Clarke, Manchester (GB)<br />
Testis cancer – advanced stages<br />
P. Albers, Düsseldorf (DE)<br />
Testis cancer – case discussion<br />
P. Albers, Düsseldorf (DE)<br />
Chair: P. Albers, Düsseldorf (DE)<br />
Aims and objectives<br />
The updated guidelines on testicular cancer have been published in 2008. Based on this European consensus,<br />
this ESU course will provide the auditorium with the latest information on diagnostic tools, staging and<br />
treatment of testis cancer stage by stage. In early-stage cancer, organ-sparing surgery, the question of<br />
testicular microlithiasis, the conflicting issue of testis biopsy and current histopathological prognostic factors<br />
for surveillance and individualised treatment options will be discussed with the auditorium including case<br />
presentations. The role of conventional as well as laparoscopic RPLND in early stages will be clarified.<br />
In advanced-stage cancer, the course participants will learn about stage by stage treatment according to<br />
IGCCCG classification. Detailed information on chemotherapy regimens and the handling of side-effects will<br />
be provided. In this section of the course, tips and tricks of residual tumour resection will be presented<br />
using case reports and intra-operative pictures. In addition, salvage strategies will be discussed in cases of<br />
treatment failures. Participants will have enough time to ask questions and discuss their own cases.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 32.10<br />
Non-<strong>EAU</strong> members € 48.15<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
291
ESU Courses, 19 April<br />
292 Programme Book<br />
ESU Course 34<br />
15.30 - 17.30 Urinary tract and genital trauma<br />
Geneva Room<br />
Introduction<br />
L. Martínez-Piñeiro, Madrid (ES)<br />
Blunt and penetrating renal trauma<br />
L. Martínez-Piñeiro, Madrid (ES)<br />
Chair: L. Martínez-Piñeiro, Madrid (ES)<br />
Ureteric, bladder, and genital (penile and testicular) trauma. Aetiology, diagnosis and treatment<br />
W. Månsson, Lund (SE)<br />
Aims and objectives<br />
1. To review the current classifications of renal, bladder and genital trauma<br />
2. To outline the principles of diagnosis and management of renal, bladder and genital trauma<br />
3. To provide a clearer understanding of the role of the treatments which are available for specific patient<br />
scenarios<br />
4. To interact with the audience and discuss together management and treatment of real cases<br />
Participants of the course will obtain a clear view on the current management of blunt and penetrating<br />
injuries affecting the kidney, bladder or genitals in contemporary clinical practice.<br />
More than 50% of the time of the course will be spent with the discussion of real clinical cases.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 32.10<br />
Non-<strong>EAU</strong> members € 48.15<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour
ESU Courses, 19 April<br />
ESU Course 35<br />
15.30 - 17.30 Ultrasound for the urologist - TRUS and TRUS guided biopsies<br />
Arnhem Room<br />
Indications for TRUS and biopsy<br />
P. Hammerer, Braunschweig (DE)<br />
Chair: P. Hammerer, Braunschweig (DE)<br />
Practical aspects of TRUS and TRUS guided biopsies<br />
P. Hammerer, Braunschweig (DE)<br />
Indications for rebiopsy<br />
V. Scattoni, Milan (IT)<br />
Update on new technical developments<br />
V. Scattoni, Milan (IT)<br />
Aims and objectives<br />
The purpose of this ESU course is to define the optimal transrectal ultrasound and to discuss new ultrasound<br />
techniques for prostate cancer detection, as well as defining a new standard for transrectal ultrasoundguided<br />
prostate biopsies. In addition, techniques to reduce morbidity and to increase patient acceptance will<br />
be discussed. Transrectal ultrasound has been performed for more than 15 years, and this technique is now<br />
an important part of prostate cancer diagnosis and staging. Anatomic studies of prostatectomy specimens<br />
that defined the zonal anatomy of the prostate and provided a detailed mapping of the tumour location<br />
have increased our understanding of transrectal ultrasound images, as well as enabling optimal placement<br />
of the biopsy needles. The stage migration revealed by PSA-based screening has resulted in most tumours<br />
being non-palpable at diagnosis. Therefore in the PSA arena, with tumours at an early stage (non-palpable<br />
and sometimes ultrasonografically isoechoic) transrectal ultrasound is needed to enable sampling of all<br />
relevant areas of the prostate including those that appear normal. The systematic sampling of the prostate<br />
by the sextant biopsy technique improved the detection rate of prostate cancer over sampling hypoechoic or<br />
palpable suspicious lesions. However, in men with initially negative biopsies a second set of sextant biopsies<br />
will be positive in about 20-30%. Several groups have demonstrated that the sextant technique is inadequate<br />
for sampling of larger prostates and advocated additional samples. Will an increase of prostate biopsies<br />
result in patient discomfort? Although some studies report no additional morbidity from the more extensive<br />
biopsy protocols, it seems likely that discomfort for the patient would be increased. What can be done to<br />
reduce pain and discomfort and improve tolerance for additional biopsies? Simple and efficacious methods<br />
are now available to provide anaesthesia in men undergoing prostate biopsies.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 32.10<br />
Non-<strong>EAU</strong> members € 48.15<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
293
ESU Courses, 19 April<br />
294 Programme Book<br />
ESU Course 36<br />
15.30 - 17.30 Medical uro-oncology<br />
Budapest Room<br />
Chair: G. Mickisch, Bremen (DE)<br />
Application of chemotherapeutic agents in prostate cancer<br />
G. Mickisch, Bremen (DE)<br />
Application of chemotherapeutic agents in bladder cancer<br />
C.N. Sternberg, Rome (IT)<br />
Immunotherapy, antibody-based therapy and tumour vaccination<br />
G. Mickisch, Bremen (DE)<br />
Small molecules as novel anticancer agents: “Smart drugs”?<br />
C.N. Sternberg, Rome (IT)<br />
Aims and objectives<br />
Modern urologic oncology consists of surgical and medical principles which are strongly interconnected to<br />
each other by neoadjuvant, adjuvant, or combination strategies such as cytoreductive surgery and systemic<br />
medical therapies. The knowledge of the practising urologist on systemic therapies has thus evolved to be<br />
of utmost importance.<br />
This holds true for the established chemotherapeutic agents with regard to prostate and bladder cancer<br />
as well as for new targeted agents in renal cell carcinoma. The encouraging treatment results with newly<br />
available agents in medical treatment of urological malignancies urges the urologist not only to take notice of<br />
these developments but also to understand their mechanisms. Even more important is to learn how to select<br />
patients for the wide variety of distinct novel agents and combinatory managements.<br />
This course is an excellent opportunity to learn what a modern urologist can offer to patients with advanced<br />
and difficult to treat common urological malignancies such as prostate, bladder or renal cell cancer. In<br />
particular, principles as well as tips and tricks in timing and application of the new agents and management<br />
of side effects will be interactively discussed. There will be an overview of the different targets that can be<br />
identified in malignant cells for current and future therapies; special attention will be paid to the use of<br />
so-called small molecules or ‘smart drugs’, and pivotal clinical trial data with these agents will be critically<br />
evaluated.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 32.10<br />
Non-<strong>EAU</strong> members € 48.15<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour
ESU Courses, 19 April<br />
ESU Course 37<br />
15.30 - 17.30 Post-surgical urinary incontinence in males<br />
Madrid Room<br />
Introduction (incidence, pathophysiology)<br />
E. Chartier-Kastler, Paris (FR)<br />
Investigations and work-up<br />
M.M. Fisch, Hamburg (DE)<br />
Conservative therapy<br />
E. Chartier-Kastler, Paris (FR)<br />
Operative therapy<br />
M.M. Fisch, Hamburg (DE)<br />
Interactive case discussion<br />
Chair: M.M. Fisch, Hamburg (DE)<br />
Aims and objectives<br />
Post-surgical incontinence has a severe impact on the social life of the patient. This course will answer<br />
the questions, how much and which investigations are needed for an adequate diagnosis and what the<br />
therapeutic options are that can we offer to the patient. The available conservative therapy is described and<br />
data on success and failure rates are provided. There is also a focus on new and alternative treatment options.<br />
The surgical procedures to solve the problem are presented and data of the literature critically analysed. The<br />
main part of the course will be the interactive case discussion with the panel and participants.<br />
At the end of the course the participants should know:<br />
• How to diagnose post surgical urinary incontinence and how to make symptoms objective<br />
• Which conservative therapy should be offered and for how long<br />
• Which operative procedures will provide the best long-term results for the individual situation of the<br />
patient<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 32.10<br />
Non-<strong>EAU</strong> members € 48.15<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
295
ESU Courses, 19 April<br />
296 Programme Book<br />
ESU Course 38<br />
15.30 - 17.30 General neuro-urology<br />
Brussels Room<br />
Introduction<br />
F.R. Cruz, Porto (PT)<br />
Diagnostics<br />
M. Spinelli, Milan (IT)<br />
Therapy<br />
F.R. Cruz, Porto (PT)<br />
Case discussion<br />
Faculty<br />
Chair: F.R. Cruz, Porto (PT)<br />
Aims and objectives<br />
The course aims at introducing neuro-urology to urologists and residents who want to have a preliminary<br />
contact with the topic.<br />
Neuro-urology is frequently a neglected matter in Urology. However, nowadays patients with micturition<br />
problems of neurogenic origin are not only more and more numerous but also have a life span very close to<br />
that of normal individuals. In consequence more patients will demand from the urologist additional expertise<br />
in this field in order to recognise and manage the most common cases at least.<br />
Neuro-urology is considered less appealing due to the use of a peculiar terminology, specific methods of<br />
diagnosis and evaluation and individualised management. For many residents neuro-urology is not part of<br />
their training. Therefore most recent neuro-urology terminology will be refreshed as it is a necessary step to<br />
facilitate communication between caregivers and to increase access to relevant literature. Investigation is a<br />
decisive part of the evaluation of any patient with micturition problems of neurogenic origin. Although this<br />
includes urodynamics, the course is not planned as an urodynamic course but rather as a review of all tools<br />
useful to investigate a neuro-urological patient. Management of these patients will be reviewed. Available<br />
options will be presented in a clinically oriented form instead of a classical pharmacological oriented<br />
presentation. This is expected to facilitate the transfer of information into the everyday practice. Particular<br />
attention will be given to the use of botulinum toxin. Ultimately, different conditions will be simulated in<br />
order to rehearse the main topics.<br />
By the end of the course it is expected that participants will be able to adequately recognise, investigate and<br />
manage the most frequent neuro-urological situations.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 32.10<br />
Non-<strong>EAU</strong> members € 48.15<br />
Residents (members/non-members) € 21.40<br />
ESU Courses are EU-ACME accredited with 1 credit per hour
ESU/ESUT Hands-on training courses<br />
Prague Room<br />
Course director: J. Rassweiler, Heilbronn (DE)<br />
Sunday 18 April<br />
Course coordinators: J. Klein, Heilbronn (DE)<br />
E. Liatsikos, Patras (GR)<br />
09.00 – 11.00 ESU/ESUT Hands-on training laparoscopy/LESS course 1<br />
Chair: C-C. Abbou, Creteil (FR)<br />
Tutors: F. Keeley, Bristol (GB)<br />
E. Liatsikos, Patras (GR)<br />
D. Teber, Heilbronn (DE)<br />
R.T. Bardan, Timisoara (RO)<br />
12.00 – 14.00 ESU/ESUT Hands-on training laparoscopy/LESS course 2<br />
Chair: G. Breda, Bassano Del Grappa (IT)<br />
Tutors: H. Baumert, Paris (FR)<br />
A. Cestari, Milan (IT)<br />
T. Erdogru, Antalya (TR)<br />
O. Reichelt, Halle (DE)<br />
15.00 – 17.00 ESU/ESUT Hands-on training laparoscopy/LESS course 3<br />
Chair: F. Gaboardi, Milan (IT)<br />
Tutors: A. Gözen, Istanbul (TR)<br />
H.C. Klingler, Vienna (AT)<br />
P.J. Nyirady, Budapest (HU)<br />
Aims and objectives<br />
Laparoscopic procedures are continuously evolving in urology based on the increasing expertise of urologic<br />
surgeons. This includes ablative procedures, such as radical nephrectomy as well as reconstructive techniques,<br />
such as pyeloplasty. Some advanced procedures (i.e. radical prostatectomy, radical cystectomy) have both,<br />
ablative and recontructive steps. Since the number of centres with laparoscopic expertise is still limited in<br />
Europe, laparoscopic training programmes have become very important. Hands-on training courses at the<br />
pelvi-trainer represent one of the main steps of such courses.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
297
298 Programme Book<br />
The European School of Urology (ESU) and the European Society of Uro-technology (ESUT) offer an intensive<br />
hands-on-training course with different models focussing on both ablative as well as reconstructive<br />
laparoscopic techniques. For this purpose standardised models for endoscopic suturing techniques (i.e.<br />
vesico-urethral anastomosis) are provided, which allow a step-wise approach to this technically difficult<br />
task.<br />
Perfused pulsating models of porcine aorta and kidney (P.O.P.-trainer) enable the training of retroperitoneal<br />
lymph node dissection, partial and simple nephrectomy as well as the management of vascular<br />
complications.<br />
The extent of the exercises depends on the educational level of the trainee.<br />
European experts will serve as trainers after a short introduction. According to the flexibility and variety of<br />
models, this course is not only directed to beginners, but may also serve for experienced surgeons to extend<br />
their technical capabilities.<br />
For experienced laparoscopic surgeons we will offer a training model for Laparo-endoscopic, Single port<br />
Surgery (LESS-nephrectomy at a P.O.P trainer)<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 32.10<br />
Non-<strong>EAU</strong> members € 48.15<br />
Residents (members/non-members) € 21.40<br />
Supported by an unrestricted educational grant from KARL STORZ GMBH & CO. KG and COOK MEDICAL
ESU/ESUT/EULIS Hands-on training courses<br />
Prague Room<br />
Monday 19 April<br />
Course coordinators: P.J. Osther, Fredericia (DK)<br />
O. Traxer, Paris (FR)<br />
09.00 – 10.30 ESU/ESUT/EULIS Hands-on training Ureterorenoscopy course 1<br />
Chair: O. Traxer, Paris (FR)<br />
Tutors: F. Millán-Rodríguez, <strong>Barcelona</strong> (ES)<br />
G. Guisti, Milan (IT)<br />
R. Muschter, Rotenburg (DE)<br />
11.00 - 12.30 ESU/ESUT/EULIS Hands-on training Ureterorenoscopy course 2<br />
Chair: P.J. Osther, Fredericia (DK)<br />
Tutors: V. Bucuras, Timisoara (RO)<br />
A.J. Gross, Hamburg (DE)<br />
A. Breda, <strong>Barcelona</strong> (ES)<br />
14.30 - 16.00 ESU/ESUT/EULIS Hands-on training Ureterorenoscopy course 3<br />
Chair: M.S. Michel, Mannheim (DE)<br />
Tutors: T. Knoll, Sindelfingen (DE)<br />
G. Tailly, Brasschaat (BE)<br />
N.P. Bucholz, London (GB)<br />
Aims and objectives<br />
The European School of Urology (ESU), the <strong>EAU</strong> Section of Uro-technology (ESUT) and the <strong>EAU</strong> Section<br />
of Urolithiasis (EULIS) offer an intensive hands-on training course with different models focusing on the<br />
endoscopic management of urolithiasis. The delegates will be taken through a sequential programme of<br />
ureterorenoscopy using normal endoscopic instruments in different models. The use of various guide-wires,<br />
baskets, and intracorporeal lithotripters will be demonstrated. The ESUT and the EULIS faculty consist of<br />
experienced surgeons in the field of ureterorenoscopy. A video demonstrating the different steps and tasks of<br />
the procedures will be presented and afterwards the delegates will be instructed according to their level of<br />
experience in small teams at the models.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 32.10<br />
Non-<strong>EAU</strong> members € 48.15<br />
Residents (members/non-members) € 21.40<br />
Supported by an unrestricted educational grant from KARL STORZ GMBH & CO. KG and COOK MEDICAL<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
299
ESU Interactive virtual training courses<br />
Madrid Room<br />
Sunday 18 April <strong>2010</strong><br />
ESU<br />
Interactive virtual training course: Session 1<br />
12.30 - 14.30 Interactive virtual training in laparoscopic radical prostatectomy<br />
300 Programme Book<br />
Chair: A. Messas, Nanterre (FR)<br />
Faculty: F. Rozet, Paris (FR)<br />
ESU<br />
Interactive virtual training course: Session 2<br />
15.30 - 17.30 Interactive virtual training in laparoscopic radical prostatectomy<br />
Chair: A. Messas, Nanterre (FR)<br />
Faculty: H. Van Der Poel, Amsterdam (NL)<br />
Monday 19 April <strong>2010</strong><br />
ESU<br />
Interactive virtual training course: Session 3<br />
08.30 - 10.30 Interactive virtual training in laparoscopic radical prostatectomy<br />
Chair: A. Messas, Nanterre (FR)<br />
Faculty: J. Van Moorselaar, Amsterdam (NL)
ESU<br />
Interactive virtual training course: Session 4<br />
11.30 - 13.30 Interactive virtual training in laparoscopic radical prostatectomy<br />
Chair: A. Messas, Nanterre (FR)<br />
Faculty: J. Van Moorselaar, Amsterdam (NL)<br />
Interactive video laparoscopic training<br />
Today, medical professionals who want to learn a new technique have to face a learning curve which<br />
may be a high-risk period for patients, and the physicians. The interactive video laparoscopic training<br />
offers medical professionals a way to practice on real situations before beginning their first cases.<br />
The main goal of this unique teaching method (Onlinemasterclass.com) is to shorten and to secure the<br />
learning period of medical professionals. Through the video simulator they will have the opportunity to<br />
face and to react to difficult situations or complications usually occurring during the learning period.<br />
This training is recommended for surgeons who have performed more than 1 and less than 30<br />
laparoscopic radical prostatectomies.<br />
Registration fee including 7% VAT<br />
<strong>EAU</strong> members € 32.10<br />
Non-<strong>EAU</strong> members € 48.15<br />
Residents (members/non-members) € 21.40<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
301
http://esuberlin.uroweb.org<br />
3 rd ESU Masterclass on<br />
Female and functional<br />
reconstructive urology<br />
5-7 November <strong>2010</strong>, Berlin, Germany
Saturday, 17 April - <strong>EAU</strong> Section Meetings<br />
Meeting of the <strong>EAU</strong> Section of Uropathology<br />
(ESUP)<br />
10.00 - 14.00 Precancerous lesions of the urogenital organs<br />
Vienna Room<br />
Chairs: Z. Kirkali, Izmir (TR)<br />
G. Mikuz, Innsbruck (AT)<br />
10.00 - 10.20 Prostatic Intraepithelial Neoplasia (PIN)<br />
R. Montironi, Torrette Di Ancona (IT)<br />
10.20 - 10.40 Atypical Small Acinar Proliferations (ASAP)<br />
F. Algaba, <strong>Barcelona</strong> (ES)<br />
10.40 - 11.00 Proliferative Inflammatory Atypia (PIA)<br />
G. Mikuz, Innsbruck (AT)<br />
11.00 - 11.20 Clinical importance and therapeutic consequences<br />
J. De La Rosette, Amsterdam (NL)<br />
11.20 - 11.40 IGCNU: Morphology and therapeutic consequences<br />
M.P. Laguna, Amsterdam (NL)<br />
11.40 - 12.00 Dysplasia and CIS of the urinary bladder<br />
A. Lopez-Beltran, Cordoba (ES)<br />
12.00 - 12.20 Clinical importance and therapeutic consequences<br />
Z. Kirkali, Izmir (TR)<br />
12.20 - 12.40 Eosinophilic tumors of the kidney: Oncocytoma vs. chromophobe carcinoma<br />
E. Compérat, Paris (FR)<br />
12.40 - 13.00 Papillary adenoma vs. papillary carcinoma<br />
M. Scarpelli, Ancona (IT)<br />
13.00 - 13.20 Clinical importance and therapeutic consequences<br />
H. Van Poppel, Leuven (BE)<br />
13.20 - 13.40 Precancerous lesions of the penis<br />
M. Colecchia, Milan (IT)<br />
13.40 - 14.00 Clinical importance and therapeutic consequences<br />
N. Nicolai, Milan (IT)<br />
Aims and objectives<br />
The aim of the session is to discuss the morphology and the clinical importance of the precancerous lesions<br />
of the urogenital organs.In all urological neoplasm precancerous lesions play an important role not only from<br />
the theoretical but also from the clinical point of view. Carcinoma in situ of the urinary bladder is perhaps<br />
the most important of these lesions because of its therapeutic and prognostic consequences. High-grade PIN<br />
refers to the precancerous end of a morphologic spectrum involving cellular proliferation within prostatic ducts<br />
which is, however, clinically not as important as the in situ carcinoma of the urinary bladder. The intratubular<br />
germ cell neoplasia (IGCNU) of the testis is important when encountered in testis without tumor but there<br />
is no general consensus on its therapy. Precancerous lesions of the kidney are unknown; there are however<br />
some cancer types with excellent prognosis and their own biology which is very similar to those of cancer<br />
forerunner. Precancerous lesions of the penis are rare in Europe and mostly easily detected and resected.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
303
Saturday, 17 April - <strong>EAU</strong> Section Meetings<br />
304 Programme Book<br />
Meeting of the <strong>EAU</strong> Section of Andrological<br />
Urology (ESAU)<br />
10.00 - 14.00 The role of the uro-andrologist in managing a couple’s sexuality<br />
<strong>Barcelona</strong> Room<br />
Chair: V. Mirone, Naples (IT)<br />
10.00 - 10.45 Erectile dysfunction - Is chronic daily administration the preferred solution in<br />
treating erectile dysfunction?<br />
Moderator: C.C. Schulman, Brussels (BE)<br />
Frontal lecture<br />
V. Mirone, Naples (IT)<br />
Pro:<br />
E. Wespes, Brussels (BE)<br />
Con:<br />
P. Verze, Napels (IT)<br />
10.45 - 11.30 Premature ejaculation - Managing premature ejaculation: Are we treating a<br />
condition or simply a disease?<br />
Moderator: D. Ralph, London (GB)<br />
Frontal lecture<br />
E.J.H. Meuleman, Amsterdam (NL)<br />
Pro:<br />
C. Bettocchi, Bari (IT)<br />
Con:<br />
M.R. Safarinejad, Tehran (IR)<br />
11.30 - 12.15 Female sexual dysfunction - Does the uro-andrologist have a role in<br />
managing female sexual dysfunction?<br />
Moderator: A. Kadioglu, Istanbul (TR)<br />
Frontal lecture<br />
R. Nappi, Pavia (IT)<br />
Pro:<br />
A. Salonia, Milan (IT)<br />
Con:<br />
F. Fusco, Naples (IT)
12.15 - 13.00 Male infertility - Is there a relationship between prostatitis and male<br />
infertility?<br />
Moderator: G.R. Dohle, Rotterdam (NL)<br />
Frontal lecture<br />
W. Weidner, Giessen (DE)<br />
Pro:<br />
N. Sofikitis, Ioannina (GR)<br />
Con:<br />
T. Diemer, Giessen (DE)<br />
13.00 - 13.30 European Society for Sexual Medicine (ESSM) lecture<br />
Exploring the relationship between ED and LUTS<br />
I. Eardley, Leeds (GB)<br />
13.30 - 14.00 Sexual Men’s Health (SMH) lecture<br />
Men’s health and sexual health: An emerging new paradigm<br />
S. Meryn, Vienna (AT)<br />
Aims and objectives<br />
This year our ESAU board has decided to present our program on “The Role of the Uro-Andrologist in<br />
Managing a Couple’s Sexuality” as we consider both the male and female perspective intrinsic to a<br />
couple’s sexuality and fundamental to andrological research. The lectures will cover current “hot topics”<br />
in andrological urology including erectile dysfunction, premature ejaculation, female sexual dysfunction.<br />
Each topic will be introduced as a question to be debated. An introductory frontal lecture will first be given<br />
providing general scientific background and the medical community’s overall perspective. Following this<br />
will be 2 presentations, one “pro” and one “con” with the intention being to present opposing sides of the<br />
issue and in this way each topic is covered fully and in-depth as experience and opinions are exchanged.<br />
An audience discussion will follow each topic and conclusions will be noted. There will also be two lectures<br />
given by two highly related organisations as part of an information exchange of common research interests<br />
in the field of andrology: the European Society of Sexual Medicine (ESSM) who will lecture on: “Exploring<br />
the relationship between ED and LUTS” and the International Society of Men’s Health (ISMH) who will<br />
be lecturing on “Men’s health and sexual health: an emerging new paradigm”. It is felt that sharing and<br />
comparing information with these important organisations strengthens relationships and brings benefits to<br />
the European research community at large.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
305
Saturday, 17 April - <strong>EAU</strong> Section Meetings<br />
Meeting of the <strong>EAU</strong> Section of Uro-Technology<br />
(ESUT)<br />
10.00-17.30 The Future of MIS – the real facts in real-time<br />
eURO Auditorium<br />
Live broadcast from the Fundació Puigvert Hospital, <strong>Barcelona</strong> (ES)<br />
Coordinators: M.P. Laguna, Amsterdam (NL)<br />
J. Palou, <strong>Barcelona</strong> (ES)<br />
R.F. Van Velthoven, Brussels (BE)<br />
10.00 - 13.00 Moderators: G. Breda, Bassano Del Grappa (IT)<br />
T. Piechaud, Bordeaux (FR)<br />
C. Abbou, Creteil (FR)<br />
10.00 - 10.05 Introduction and Certificate to first ESUT-fellows<br />
J. Rassweiler, Heilbronn (DE)<br />
C. Mamoulakis, Athens (GR)<br />
A. Gözen, Heilbronn (DE)<br />
10.05 - 11.05 New techniques of prostate biopsy<br />
Target<br />
G. Boustedt, Stevenage (GB)<br />
Histoscanning<br />
F. Zatura, Olomovc (CZ)<br />
C-TRUS<br />
T. Loch, Flensburg (DE)<br />
Elastography<br />
A. Pelzer, Mannheim (DE)<br />
M.S. Michel, Mannheim (DE)<br />
11.05 - 13.00 Treatment of localized prostate cancer<br />
Extraperitoneal intrafascial radical prostatectomy<br />
M. Truss, Dortmund (DE)<br />
E. Liatsikos, Patras (GR)<br />
Transperitoneal robotic radical prostatectomy<br />
G. Guazzoni, Milan (IT)<br />
L. Gausa, <strong>Barcelona</strong> (ES)<br />
Focal HIFU<br />
M. Emberton, London (GB)<br />
13.00 - 15.00 Moderators: J. De la Rosette, Amsterdam (NL)<br />
G. Janetschek, Salzburg (DE)<br />
G. Alivizatos, Athens (GR)<br />
13.00 - 13.30 Real-time pathology<br />
Biopsies and prostate specimen<br />
F. Algaba, <strong>Barcelona</strong> (ES)<br />
J. Arce, <strong>Barcelona</strong> (ES)<br />
306 Programme Book
13.30 - 15.00 Treatment of BPH<br />
Bipolar TURP<br />
A. De La Taille, Creteil (FR)<br />
V. Bucuras, Timisoara (RO)<br />
Vaporisation<br />
C. Hernández, Madrid (ES)<br />
P. Ostri, Frederickstadt (DK)<br />
The optimal diagnosis of TCC<br />
Bipolar TUR B + PDD<br />
T. O`Brien, London (GB)<br />
D. Zaak, Munich (DE)<br />
PDD and NBI<br />
B. Malavaud, Toulouse (FR)<br />
R. Muschter, Rotenburg (DE)<br />
15.00 - 17.30 Moderators: A. Alcaraz, <strong>Barcelona</strong> (ES)<br />
A. Joyce, Leeds (GB)<br />
D. Tolley, Edinburgh (GB)<br />
15.00 - 17.25 Minimally invasive renal surgery<br />
Robotic partial nephrectomy<br />
A. Mottrie, Aalst (BE)<br />
A. Breda, <strong>Barcelona</strong> (ES)<br />
LESS- nephrectomy<br />
J. Stolzenburg, Leipzig (DE)<br />
A. Dietel, Leipzig (DE)<br />
SMART-retroperitoneal pyeloplasty<br />
J. Rassweiler, Heilbronn (DE)<br />
A. Gözen, Heilbronn (DE)<br />
Supine PCNL and flexible URS<br />
J.Valdivia, Valencia (ES)<br />
O. Traxer, Paris (FR)<br />
17.25 - 17.30 Closing remarks<br />
A. Joyce, Leeds (GB)<br />
Aims and objectives<br />
The <strong>EAU</strong>-section of Uro-technology follows a 10 year-tradition of showing novel endourologic, laparoscopic,<br />
and robot-assisted techniques in a Live-surgery session on the Wednesday of the <strong>EAU</strong>-<strong>Congress</strong>. This<br />
year, with the “Real facts in real time”, we want to focus on new techniques in minimally invasive procedures<br />
and new imaging and diagnostic possibilities for early and precise detection of prostate and urothelial<br />
cancer. Real-time pathology will enable us to demonstrate the diagnostic and therapeutic efficacy of these<br />
new methods.<br />
The ESUT-faculty consists of internationally well-known experts in their field serving as surgeons, moderators<br />
or presenters of video-clips. The different surgical procedures will be transmitted from four operating<br />
theatres in the Urologic Department of Fundacion Puigvert, Universitat Autonoma in <strong>Barcelona</strong>. Prof<br />
Humberto Villavicencio will be the local coordinator. Traditionally, the format of the ESUT-live surgery will<br />
allow all delegates to ask questions during the procedure and discuss every aspect of the presented technique.<br />
For this purpose, interactive moderation will be provided by the ESUT-experts.<br />
We acknowledge the enormous help provide by the Team at Fundacio Puigvert, namely by Drs. A. Breda, M.<br />
Cosentino, S. Esquena, L. Gausa, J. M. Gaya, A. Rosalez, O. Rodríguez, and last not least Mrs. Lluisa Ponsa.<br />
Supported by unrestricted educational grants from ADVANCED MEDICAL DIAGNOSTICS, B-K MEDICAL,<br />
FRESENIUS KABI, GE HEALTHCARE, HITACHI MEDICAL SYSTEMS, INTERNATIONAL HIFU,<br />
INTUITIVE SURGICAL, KARL STORZ GMBH & CO.KG, OLYMPUS, PERGENTIUM LTD.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
307
Saturday, 17 April - <strong>EAU</strong> Section Meetings<br />
308 Programme Book<br />
Joint meeting of the European Organisation<br />
for Research and Treatment of Cancer Genito-<br />
Urinary Group (EORTC-GU Group) in conjunction<br />
with the <strong>EAU</strong> Section for Urological Research<br />
(ESUR) and the European Section of Oncological<br />
Urology (ESOU)<br />
10.00 - 14.00 New insights in uro-oncology<br />
Paris Room<br />
10.00 - 12.00 EORTC GU-Group and ESUR<br />
Chairs: A. Bjartell, Malmö (SE)<br />
T.M. De Reijke, Amsterdam (NL)<br />
10.00 - 11.00 Non-coding RNAs. How can recent discoveries be used in the future diagnostic and therapeutics?<br />
T. Orntoft, Århus (DK)<br />
N. Zaffaroni, Milan (IT)<br />
11.00 - 11.20 Advanced bladder cancer: What we know and where to go<br />
J. Bellmunt, <strong>Barcelona</strong> (ES)<br />
11.20 - 11.40 Testicular cancer: Do we need more trials?<br />
S. Osanto, Leiden (NL)<br />
11.40 - 12.00 Report on the EORTC quality of life questionnaire PR25<br />
B. Tombal, Brussels (BE)<br />
12.00 - 14.00 ESOU<br />
Chairs: M. Brausi, Capri (IT)<br />
V. Ravery, Paris (FR)<br />
12.00 - 12.30 Testis cancer: Difficult cases<br />
Moderator: S. Brewster, Oxford (GB)<br />
Panel: P.F. Bassi, Padua (IT)<br />
K. Fizazi, Villejuif (FR)<br />
A. Heidenreich, Aachen (DE)<br />
M. Kuczyk, Hanover (DE)
12.30 - 13.00 Results and potential of LHRH antagonists: Should we use them?<br />
Moderators: B. Djavan, New York (US)<br />
A. Govorov, Moscow (RU)<br />
L. Boccon-Gibod, Paris (FR)<br />
13.00 - 13.30 Superficial TCC: New chemotherapeutics in sight<br />
Moderators: M. Brausi, Carpi (IT)<br />
G.N. Thalmann, Berne (CH)<br />
J. Palou Redorta, <strong>Barcelona</strong> (ES)<br />
13.30 - 14.00 RCC point / counter point - cytoreductive tumorectomy in the era of targeted<br />
therapies: Appropriate or dispensable<br />
Moderators: G. Mickisch, Bremen (DE)<br />
H. Özen, Ankara (TR)<br />
Pro:<br />
A. Bex, Amsterdam (NL)<br />
Con:<br />
Z. Kirkali, Izmir (TR)<br />
Aims and objectives<br />
EORTC GU<br />
A clinically-based overview of current therapy dilemmas faced by clinicians managing bladder and testicular<br />
cancer patients will be provided. The aim is to deliver a comprehensive but concise insight into the stateof-the-art<br />
approach in the treatment of advanced bladder and testicular cancer patients. Pressing questions<br />
in the field will be answered while achievements of collaborative groups which had an impact on today’s<br />
evidence-based medicine will be highlighted. The usefulness and clinical impact of the EORTC quality of life<br />
questionnaire PR25 in prostate cancer will be discussed.<br />
ESUR<br />
How can recent discoveries be used in the future diagnostic and therapeutics? Two distinguished speakers<br />
will discuss the emerging important role of non-coding RNAs in prostate and urinary bladder cancer.<br />
Professor Nadia Zaffaroni, Milan, Italy, will review the major issues that have hindered the identification of<br />
prostate cancer-related microRNAs, outlining a way for the rational validation of candidates that might be<br />
clinically relevant in the management of this disease. Professor Torben Orntoft, Århus, Denmark will give his<br />
view on the role of miRNAs in cancer of the urinary bladder.<br />
ESOU<br />
The attendees will be provided with some updates on the most recent advances in the management of<br />
prostate, bladder and kidney cancers.<br />
New hormonal approaches for prostate cancer will be discussed and criticised. Some tricky testis cancer<br />
cases will be extensively discussed in a very practical way. The place of the RCC tumorectomy in the era of<br />
targeted therapies will be discussed during a “point-counterpoint” debate.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
309
Saturday, 17 April - <strong>EAU</strong> Section Meetings<br />
310 Programme Book<br />
Meeting of the <strong>EAU</strong> Section of Genito-Urinary<br />
Reconstructive Surgeons (ESGURS)<br />
10.00 - 15.00 Long term results in genitourinary reconstructive surgery<br />
10.00 - 12.00 Part I<br />
Milan Room<br />
Chair: S. Deger, Berlin (DE)<br />
Moderators: V. Pansadoro, Rome (IT)<br />
K.D. Sievert, Tübingen (DE)<br />
10.00 - 10.20 Pelvic fracture related urethral injuries<br />
A.R. Mundy, London (GB)<br />
10.20 - 10.40 Long term outcome of male-to-female reassignement surgery<br />
C. Trombetta, Trieste (IT)<br />
10.40 - 11.00 Long term outcome of female-to-male reassignment surgery<br />
M. Sohn, Frankfurt am Main (DE)<br />
11.00 - 11.20 Long term results of microsurgery for seminal pathways<br />
E. Belgrano, Trieste (IT)<br />
11.20 - 11.40 Long term results after urethral reconstruction<br />
M.M. Fisch, Hamburg (DE)<br />
11.40 - 12.00 Long term results of surgery for peyronie disease<br />
E. Austoni, Milan (IT)<br />
12.10 - 13.30 Part II<br />
Moderators: D.E. Andrich, Kingston upon Thames (GB)<br />
E. Palminteri, Arezzo (IT)<br />
12.10 - 12.30 Long term results after laparoscopic pyeloplasty<br />
S. Deger, Berlin (DE)<br />
12.30 - 12.50 Long term outcome of ileal ureteral replacement<br />
H. Riedmiller, Würzburg (DE)<br />
12.50 - 13.10 Hypospadias repair in childhood - late outcome reaching adulthood<br />
O.Z. Shenfeld, Jerusalem (IL)<br />
13.10 - 13.30 Salvage surgery after unsuccessful hypospadias repair<br />
S. Perovic, Belgrade (RS)
13.40 - 15.00 Part III<br />
Moderators: O. Demirkesen, Istanbul (TR)<br />
W. Månsson, Lund (SE)<br />
13.40 - 14.00 Orthotopic bladder substitutes: Are they all the same? Results from prospective multicenter study<br />
W. Månsson, Lund (SE)<br />
14.00 - 14.20 Incontinent and continent diversion in patients with benign disorders - results from prospective multicenter<br />
study<br />
A. Schultz, Oslo (NO)<br />
14.20 - 14.40 Long term results following orthotopic neobladder<br />
H. Abol-Enein, Mansoura (EG)<br />
14.40 - 15.00 Long term outcome of continent urinary diversion using ileocecal reservoirs, as well in children as in<br />
adults<br />
H. Riedmiller, Würzburg (DE)<br />
Aims and objectives<br />
During this meeting, the <strong>EAU</strong> Section of Genitourinary Reconstructive Surgeons (ESGURS) will look at longterm<br />
follow up data of genitourinary and reconstructive surgery during the <strong>EAU</strong> 25th Anniversary <strong>Congress</strong>.<br />
Normally reconstruction of any system aims to achieve good functional long-term data. ESGURS asked<br />
experts in their fields to share their data, opinions and suggestions. ESGURS will present a large repertoire<br />
of long-term data in pelvic trauma management, penile-urethral reconstruction in adult and childhood,<br />
surgical techniques for urinary tract reconstruction including urinary diversion. Minimal invasive procedures<br />
like laparoscopic pyeloplasty will also be presented.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
311
Saturday, 17 April - <strong>EAU</strong> Section Meetings<br />
312 Programme Book<br />
Meeting of the <strong>EAU</strong> Section of Transplantation<br />
Urology (ESTU)<br />
10.00 - 13.40 Renal transplantation – what urologists must know in <strong>2010</strong><br />
Athens Room<br />
Chairs: A.J. Figueiredo, Coimbra (PT)<br />
M. Giessing, Dusseldorf (DE)<br />
10.00 - 10.10 Introduction<br />
M. Giessing, Dusseldorf (DE)<br />
10.10 - 11.25 Condition and conditioning of donors, kidneys and recipients<br />
Moderators: A.J. Figueiredo, Coimbra (PT)<br />
E. Lledo-garcia, Madrid (ES)<br />
10.10 - 10.25 Brain death and its impact on donor organs<br />
A.J. Figueiredo, Coimbra (PT)<br />
10.25 - 10.40 Optimising outcome: Preconditioning of the donor<br />
E. Lledo-Garcia, Madrid (ES)<br />
10.40 - 10.55 Optimising outcome: Pulsatile kidney perfusion and perfusion solutions<br />
L. Peri, <strong>Barcelona</strong> (ES)<br />
10.55 - 11.10 Impact of graft mass and donor gender<br />
G. Karam, Nantes (FR)<br />
11.10 - 11.25 Impact BMI and gender of donor and recipient<br />
P. Di Tonno, Bari (IT)<br />
11.35 - 12.35 Role of the urologist after kidney transplantation<br />
Moderators: F.J. Burgos Revilla, Madrid (ES)<br />
A.B. Chkhotua, Tbilisi (GE)<br />
11.35 - 11.50 Early and late vascular complications: How long can a graft stand?<br />
F.J. Burgos Revilla, Madrid (ES)<br />
11.50 - 12.05 Transplant ureter stricture: Surgical options<br />
M. Giessing, Dusseldorf (DE)<br />
12.05 - 12.20 Post-KTX voiding dysfunction: Prevalence and relevance<br />
J. Jones, Mainz (DE)<br />
12.20 - 12.35 Infections and antibiotics in the transplanted patient<br />
J.O. Olsburgh, London (GB)
12.35 - 13.05 Cooperation with other faculties<br />
12.35 - 12.50 Anaesthesiology: Influence of medication and hemodynamics<br />
C. Monsalve, <strong>Barcelona</strong> (ES)<br />
12.50 - 13.05 Immunology: Options for the sensitized kidney recipient<br />
J. Pascual, <strong>Barcelona</strong> (ES)<br />
13.05 - 13.35 Transplant politics<br />
13.05 - 13.20 The Istanbul Declaration on organ trafficking and transplant tourism<br />
A.B. Chkhotua, Tbilisi (GE)<br />
13.20 - 13.35 The EU Interreg Program: Italian-Albanian experience<br />
F.P. Selvaggi, Bari (IT)<br />
M. Xhani, Tirana (AL)<br />
13.35 - 13.40 Closing remarks<br />
A.J. Figueiredo, Coimbra (PT)<br />
Aims and objectives<br />
As donor and recipient characteristics change towards an increase in age and co-morbidities the transplanting<br />
urologist has to increase his knowledge on factors affecting graft-function and survival. The first part of our<br />
session aims to give the transplanting urologist arguments to better judge on graft quality and the promise<br />
of success in a respective donor and recipient pairing. We will evaluate and discuss relevant donor factors<br />
like brain death and the chance of preconditioning of the deceased donor, the impact of gender and renal<br />
mass as well as the impact of kidney preservation and transport and finally the relevance of recipients<br />
co-morbidities for graft function and survival.<br />
The second part focuses on peri- and post operative problems of a kidney transplantation (KTX). While<br />
problems of the vessels and the ureter mainly cause peri- or early post-operative complications we will also<br />
look at the long term complications like voiding dysfunction and recurrent urinary tract infections.<br />
As cooperation between the different departments is the only way to achieve good results for the recipient<br />
(and living donor) we will present an update on transplant anaesthesiology and immunology. For this third<br />
part we are happy to have two well known speakers from <strong>Barcelona</strong> who will share their expertise with<br />
us. The session will be concluded by political topics on renal transplantation: the Istanbul declaration on<br />
organ trafficking, a milestone for worldwide ethical aspects of renal transplantation, and the EU project of<br />
interregional cooperation in the area of renal transplantation.<br />
At the end of the meeting delegates will have learned about the most up-to-date medical and political issues<br />
in renal transplantation.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
313
Saturday, 17 April - <strong>EAU</strong> Section Meetings<br />
314 Programme Book<br />
Meeting of the <strong>EAU</strong> Section of Urological<br />
Imaging (ESUI)<br />
10.00 - 14.00 What do we need to know about prostate imaging in <strong>2010</strong>?<br />
Istanbul Room<br />
Chairs: H. Heynemann, Halle/Saale (DE)<br />
J. Walz, Marseilles (FR)<br />
10.00 - 10.10 Introduction<br />
T. Loch, Flensburg (DE)<br />
10.10 - 10.30 Forum: Imaging in Europa: Who, where, what, how many?<br />
M.F. Coelho, Lisboa (PT)<br />
J. Walz, Marseilles (FR)<br />
10.30 - 10.50 Ultrasound imaging in urology: Basics and technical ‘must knows’<br />
H. Heynemann, Halle/Saale (DE)<br />
10.50 - 13.10 Imaging of the prostate<br />
10.50 - 11.10 Randomised TRUS guided biopsies<br />
M.F. Coelho, Lisbon (PT)<br />
11.10 - 11.30 C-TRUS in prostate cancer<br />
T. Loch, Flensburg (DE)<br />
11.30 - 11.50 Contrast enhanced ultrasound in prostate cancer<br />
H. Wijkstra, Amsterdam (NL)<br />
11.50 - 12.10 Elastography in prostate cancer<br />
J. Walz, Marseilles (FR)<br />
12.10 - 12.30 MRI in prostate cancer<br />
G. Schneider, Homburg/Saar (DE)<br />
12.30 - 12.50 3D and 4D ultrasound in prostate cancer<br />
P.A. Geavlete, Bucharest (RO)<br />
12.50 - 13.10 Panel: How to manage a patient with persistent risk of prostate cancer and negative biopsies<br />
P.A. Geavlete, Bucharest (RO)<br />
T. Loch, Flensburg (DE)<br />
G. Schneider, Homburg/Saar (DE)<br />
J. Walz, Marseilles (FR)<br />
H. Wijkstra, Amsterdam (NL)<br />
13.10 - 13.50 Staging of urological malignancies<br />
13.10 - 13.30 What is new in lymph node staging in urological malignancies?<br />
C. Trombetta, Trieste (IT)<br />
13.30 - 13.50 What is the current value of PET-CT in urological malignancies?<br />
S. Machtens, Bergisch Gladbach (DE)
13.50 - 14.00 Conclusion and discussion<br />
H. Heynemann, Halle/Saale (DE)<br />
Aims and objectives<br />
In the domain of prostate cancer imaging, important activities have been recently observed. The most promising<br />
and currently used imaging studies are addressed during the session. Especially several innovative<br />
imaging studies prone to improve the diagnosis of prostate cancer will be discussed. These studies are:<br />
contrast enhanced ultrasound, artificial neuronal network analysis based transrectal ultrasound (C-TRUS),<br />
real time elastography, magnetic resonance imaging (MRI), and 3D-4D ultrasound. The diagnostic value of<br />
the studies will be compared to the current “Goldstandard” of the randomised multicore biopsy. Moreover,<br />
due to the relevance of the topic, an up to date overview of the value of PET-scanning in urological malignancies<br />
as well as the value of imaging in the staging of lymph node metastases in urological malignancies<br />
will be given.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
315
Saturday, 17 April - <strong>EAU</strong> Section Meetings<br />
316 Programme Book<br />
Meeting of the eUrolithiasis Section (eULIS)<br />
10.00 - 14.00 Advances in the management of stones<br />
Padua Room<br />
Chair: P.N. Rao, Manchester (GB)<br />
10.00 - 10.05 Introduction<br />
P.N. Rao, Manchester (GB)<br />
10.05 - 12.00 Session 1<br />
Moderator: K. Sarica, Istanbul (TR)<br />
10.05 - 10.35 Technical advances in lithotriptor machines<br />
J. Rassweiler, Heilbronn (DE)<br />
10.35 - 11.05 Ureteroscopy and intrarenal surgery: Technical advances<br />
O. Traxer, Paris (FR)<br />
11.05 - 11.30 Radiologically assessing stone composition and fragility<br />
S.S. Osther, Fredericia (DK)<br />
11.30 - 12.00 How can we get rid of fragments after ESWL?<br />
N.P. Buchholz, London (GB)<br />
12.00 - 14.00 Session 2<br />
12.00 - 13.20 Debate: PCNL which approach?<br />
Moderator: H-G. Tiselius, Stockholm (SE)<br />
Supine position<br />
R.M. Scarpa, Orbassano (IT)<br />
Prone position<br />
T. Knoll, Sindelfingen (DE)<br />
Mini Perc<br />
S. Lahme, Pforzheim (DE)<br />
Combined approach<br />
S.S. Osther, Fredericia (DK)<br />
13.20 - 13.45 Radiological safety during ESWL<br />
J.M. Reis dos Santos, Lisbon (PT)
13.45 - 14.00 Closing remarks<br />
Aims and objectives<br />
The aims and objectives are to provide an update on diagnosis and surgical management of renal and<br />
ureteric stones. The lectures cover the value of imaging in assessing stone composition and fragility both of<br />
which are useful if ESWL is planned. The lectures cover recent technical advances in ureteroscopy and shock<br />
wave lithotripsy. In recent years there have been many advances in percuaneous approach. There are four<br />
short presentations on conventional prone approach, supine approach, mini PERC and combined antegrade<br />
and retrograde approach. These presentations will be followed by discussion with audience participation.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
317
Saturday, 17 April - <strong>EAU</strong> Section Meetings<br />
318 Programme Book<br />
Meeting of the <strong>EAU</strong> Section of Female and<br />
Functional Urology (ESFFU)<br />
10.00 - 14.00 Functional urology: Transition from science to clinical practice<br />
Amsterdam Room<br />
Chair: J.P.F.A. Heesakkers, Nijmegen (NL)<br />
10.00 - 10.30 Basic Science<br />
Ultrasound of the pelvic flooor<br />
C. Constantinou, Stanford (US)<br />
10.30 - 12.00 Neurourology<br />
10.30 - 11.00 Urinary retention in women - farewell speech<br />
C.J. Fowler, London (GB)<br />
11.00 - 11.20 Becoming an adult with a neurogenic bladder: Where does paediatrics stop and adult urology starts?<br />
G.A. Bogaert, Leuven (BE)<br />
11.20 - 11.40 Treatment and results of SUI in neurogenic patients<br />
J.R. Shah, London (GB)<br />
11.40 - 12.00 What is the neurologic effect of chronic visceral pain, and how does this influence treatment<br />
J.J. Wyndaele, Antwerp (BE)<br />
12.00 - 12.40 Functional urology<br />
12.00 - 12.20 Update on BPS / IC What do we have and what do we need?<br />
J. Nordling, Herlev (DK)<br />
12.20 - 12.40 Care about neobladder, how do we follow them up?<br />
F. Van Der Aa, Leuven (BE)<br />
12.40 - 14.00 Female urology<br />
12.40 - 13.00 Advantages of robotics in reconstructive functional urology?<br />
J.L. Hoepffner, Bordeaux (FR)<br />
13.00 - 13.20 Posterior Vault Prolaps and urgency<br />
E. Costantini, Perugia (IT)
13.20 - 13.40 Debate: There is no limit to tape minimalisation<br />
Pro:<br />
S. Arlandis Guzman, Valencia (ES)<br />
Con:<br />
E. Chartier-Kastler, Paris (FR)<br />
13.40 - 14.00 Case studies with discussion - who and what?<br />
P. Dinis Oliveira, Porto (PT)<br />
Aims and objectives<br />
Good and dedicated research has given us better insight into the functioning and malfunctioning of the lower<br />
urinary tract. Based on new concepts of pathophysiology, treatment options are becoming available and can<br />
be put into clinical practice. Another area of research is the applicability of advanced technology in functional<br />
urological problems.<br />
A third and very actively moving corner of the functional urology field is the rapidly progressing introduction<br />
of synthetic products for pelvic floor prolapse repair and stress incontinence.<br />
A last cornerstone that is evolving is the ‘classic’ scientific development of our profession. The developments<br />
are so rapid that it is sometimes difficult for functional urologists to stay ahead of their own daily activities.<br />
Did you ever have a slightly desperate thought that a new product has just arrived in your practice and you<br />
are just getting acquainted with it when an even newer product appears. The ESFFU meeting in <strong>Barcelona</strong><br />
will try to guide you through the evolving functional urological field.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
319
Saturday, 17 April - <strong>EAU</strong> Section Meetings<br />
320 Programme Book<br />
Meeting of the <strong>EAU</strong> Section of Infections in<br />
Urology (ESIU)<br />
10.00 - 14.00 Improving practice - facing threats<br />
Genoa Room<br />
Chair: T.E. Bjerklund Johansen, Århus (DK)<br />
10.00 - 11.25 Preventing infective complications<br />
Moderators: R. Bartoletti, Pistoia (IT)<br />
W. Weidner, Giessen (DE)<br />
10.00 - 10.20 Infective complications following TURB, TURP and prostate biopsies<br />
B. Wullt, Lund (SE)<br />
10.20 - 10.40 Infective complications following radical cystectomy and radical prostatectomy<br />
J. Palou Redorta, <strong>Barcelona</strong> (ES)<br />
10.40 - 11.00 Infective complications following ESWL, PCNL and URS<br />
R. Dasgupta, London (GB)<br />
11.00 - 11.20 What is written in our guidelines?<br />
M. Grabe, Malmö (SE)<br />
11.20 - 11.25 Discussion<br />
11.25 - 12.30 Facing threats from outside<br />
Moderators: H. Botto, Suresnes (FR)<br />
R.S. Pickard, Newcastle upon Tyne (GB)<br />
11.25 - 11.45 Zoonoses affecting the urogenital tract<br />
G. Pappas, Ioannina (GR)<br />
11.45 - 12.05 Resistant urogenital tuberculosis<br />
E. Kulchavenya, Novosibirsk (RU)<br />
12.05 - 12.25 Schistosomiasis and bladder cancer<br />
H. Abol-Enein, Mansoura (EG)<br />
12.25 - 12.30 Discussion<br />
12.30 - 14.00 Facing threats from inside<br />
Moderators: K.G. Naber, Straubing (DE)<br />
T. Perepanova, Moscow (RU)<br />
12.30 - 12.50 The threat from multiresistant pathogens in urology departments<br />
F.M.E. Wagenlehner, Giessen (DE)
12.50 - 13.15 The threat from hospital acquired UTI<br />
H.M. Çek, Istanbul (TR)<br />
13.15 - 13.35 Biofilm and the threat from catheter associated infections<br />
P. Tenke, Budapest (HU)<br />
13.35 - 13.55 ESIU proposes a new clasification of UTI<br />
T.E. Bjerklund Johansen, Århus (DK)<br />
13.55 - 14.00 Discussion<br />
Aims and objectives<br />
The first part of the ESIU session will provide an up-to-date discussion of how to prevent infective<br />
complications in the most common open urological interventions, endoscopic surgery and treatment of<br />
kidney stones and ESWL. Particular focus will be put on <strong>EAU</strong> guidelines. The second part will give urologists<br />
a unique opportunity to improve their knowledge about emerging threats such as zoonoses (i.e swine flu),<br />
resistant urogenital tuberculosis and schistosomiasis. The external third part will focus on internal threats<br />
such as multiresistant pathogens, hospital acquired infections and biofilm.<br />
By the end of the ESIU session, delegates should understand the principles of preventing infective<br />
complications in urological surgery. The delegates will be aware of new threats from infectious diseases,<br />
new recommendations in <strong>EAU</strong> guidelines and they will have received an update on the Global Prevalence<br />
study on Infections in Urology as well as the new classification of urological infections.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
321
http://esgurs-esau.uroweb.org<br />
ESGURS-ESAU Joint Meeting<br />
Genito-Urinary<br />
Reconstructive<br />
Surgery:<br />
What’s New?<br />
1-2 October <strong>2010</strong>, Trieste, Italy<br />
European<br />
Association<br />
of Urology
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Sponsored Session<br />
12.30 - 16.30 Challenges in non-muscle invasive bladder cancer - interactive case<br />
discussions<br />
Geneva Room<br />
Workshop<br />
12.30 - 14.00 Workshop 1<br />
Chair: J.A. Witjes, Nijmegen (NL)<br />
Welcome and introductions<br />
Setting the scene<br />
Case study one<br />
Case study two<br />
Case study three<br />
Questions, Chair’s summary and close<br />
15.00 - 16.30 Workshop 2<br />
Chair: T. O’Brien, London (GB)<br />
Welcome and introductions<br />
Setting the scene<br />
Case study one<br />
Case study two<br />
Case study three<br />
Questions, Chair’s summary and close<br />
Aims and objectives:<br />
• Communicate the recommendations made in the forthcoming publication: Hexaminolevulinate-Guided<br />
Fluorescence Cystoscopy in the Diagnosis and Follow-Up of Patients with Non–Muscle-Invasive Bladder<br />
Cancer: Review of the Evidence and Recommendations, Witjes et al<br />
• Provide an opportunity for the discussion and debate of a number of case studies regarding the current<br />
diagnosis / management of bladder cancer tumours<br />
• Provide an opportunity for in-depth discussion with a panel of European bladder cancer experts<br />
Sponsored by GE HEALTHCARE AND PHOTOCURE ASA<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
323
Saturday, 17 April - <strong>EAU</strong> Programme<br />
324 Programme Book<br />
Sponsored Session<br />
17.45 - 19.15 Multidisciplinarity in prostate cancer: A promising approach?<br />
eURO Auditorium<br />
Symposium<br />
Chair: F. Montorsi, Milan (IT)<br />
Expert panel: A. Bossi, Villejuif (FR)<br />
N. James, Birmingham (GB)<br />
S.G. Joniau, Leuven (BE)<br />
Aims and objectives<br />
During the last years there has been an increasing interest in a multidisciplinary approach for the diagnosis<br />
and treatment of prostate cancer. However, except for a few initiatives, there is still a long way to go.<br />
This satellite symposium will further evaluate the potential importance of a multidisciplinary approach in<br />
the management of prostate cancer. Prior to the symposium, an extensive web-based survey exploring in<br />
depth the current expert vision on the management of prostate cancer will be sent to a random sample of<br />
urologists, radiotherapists and oncologists. The outcomes of this survey will be presented and discussed<br />
during the symposium. The audience will have the opportunity to interact with the expert panel.<br />
Sponsored by ASTELLAS
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Sponsored Session<br />
17.45 - 19.15 Advances in the treatment of castration-resistant prostate cancer:<br />
Targeted therapies, better prognoses<br />
Milan Room<br />
Symposium<br />
Chair: P.F.A. Mulders, Nijmegen (NL)<br />
Introduction<br />
P.F.A. Mulders, Nijmegen (NL)<br />
Targeting the endothelin pathway in prostate cancer<br />
J.B. Nelson, Pittsburgh (US)<br />
Emerging data on the use of novel therapies in CRPC<br />
M. Gleave, Vancouver (CA)<br />
A more specific prognosis? Discussion on the role of biomarkers in prostate cancer trials<br />
Proposer: N.W. Clarke, Manchester (GB)<br />
Discussants: M. Gleave, Vancouver (CA)<br />
P.F.A. Mulders, Nijmegen (NL)<br />
J.B. Nelson, Pittsburgh (US)<br />
Summary<br />
P.F.A. Mulders, Nijmegen (NL)<br />
Aims and objectives<br />
Castration-resistant prostate cancer (CRPC) is a complex condition encompassing a broad range of disease<br />
states. Current treatment options are limited in both efficacy and tolerability, prompting investigation of<br />
a range of novel treatment approaches. This symposium will explore recent advances in CRPC research<br />
highlighting:<br />
• The role of the endothelin axis in multiple tumour types, particularly CRPC, and the rationale for endothelin<br />
A receptor antagonism, which leads to inhibition of multiple tumourigenic pathways<br />
• New therapeutic approaches being investigated for CRPC, including the specific endothelin A receptor<br />
antagonist zibotentan 1<br />
• The importance of novel biomarkers to indicate disease prognosis both in clinical trials and clinical<br />
practice<br />
1 Zibotentan is not approved or marketed for clinical use.<br />
Zibotentan es un producto en investigación clínica. No está aún comercializado para uso clínico.<br />
Sponsored by ASTRAZENECA<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
325
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Sponsored Session<br />
17.45 - 19.15 Managing metastatic renal cell carcinoma as a chronic disease:<br />
Weighing up the evidence<br />
326 Programme Book<br />
Istanbul Room<br />
Symposium<br />
Chair: Z. Kirkali, Izmir (TR)<br />
Welcome and introduction<br />
Z. Kirkali, Izmir (TR)<br />
Treating RCC as chronic disease: Is the verdict still out?<br />
Z. Kirkali, Izmir (TR)<br />
Witness 1. Combination therapy with targeted agents is the future<br />
A. Bamias, Athens (GR)<br />
Witness 2. Planning the future: Sequencing targeted treatments<br />
M. Kuczyk, Hanover (DE)<br />
The prosecution. Critiquing the current evidence<br />
P. Karakiewicz, Montreal (CA)<br />
Judge’s summing up<br />
Z. Kirkali, Izmir (TR)<br />
The verdict<br />
Z. Kirkali, Izmir (TR)<br />
Aims and objectives<br />
With our growing experience of targeted therapy we may now have the real opportunity to change the<br />
perspective of advanced renal cell carcinoma (RCC) management from that of an acute disease to that of a<br />
chronic disease. At this symposium, a faculty of experts will discuss the feasibility of this goal and debate<br />
how best to achieve it. Two ‘witnesses’ will present evidence to argue the case for alternative strategies:<br />
combination treatment with targeted therapies or sequential treatment with targeted therapies. A third<br />
member of the faculty, the ‘prosecution’, will critique the evidence and cross-examine the presenters.<br />
Delegate participation will be encouraged through the use of voting and question cards. The symposium will<br />
end with a weighing up of the evidence by the chairman (the ‘judge’) and presentation of the final verdict.<br />
Sponsored by BAYER SCHERING PHARMA
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Sponsored Session<br />
17.45 - 19.15 Night-time urology: Why daytime symptoms do not drive night-time<br />
diagnosis<br />
Athens Room<br />
Symposium<br />
Chair: P.E. Van Kerrebroeck, Maastricht (NL)<br />
Nocturia - not just another LUTS<br />
P.E. Van Kerrebroeck, Maastricht (NL)<br />
Does nocturia need public health attention?<br />
R.C. Rosen, Watertown (US)<br />
Why does sleep matter?<br />
D. Bliwise, Atlanta (US)<br />
Night-time Urology: Why daytime symptoms do not drive night-time diagnosis<br />
M.P. Fitzgerald, Chicago (US)<br />
New <strong>EAU</strong> treatment guidelines for nocturia<br />
M. Oelke, Hanover (DE)<br />
Question and answer session<br />
P.E. Van Kerrebroeck, Maastricht (NL)<br />
Summary and close<br />
P.E. Van Kerrebroeck, Maastricht (NL)<br />
Aims and objectives<br />
The symposium will outline the growing recognition of nocturia as a public health concern. Nocturia<br />
should be seen as an independent entity and not just as part of the overactive bladder syndrome (OAB) or<br />
a consequence of benign prostatic obstruction (BPO) especially since, Nocturnal polyuria (the production of<br />
an abnormally large volume of urine at night) is present in 60–80% of patients with nocturia, even when<br />
they suffer from the daytime symptoms of OAB and LUTS/BPO. This differentiation of daytime and night-time<br />
symptom gives rise to the emerging concept of night-time urology. Nocturia is not only common but also<br />
has a strong impact on sleep. The serious consequences of fragmented sleep on quality of life, productivity<br />
and overall health will be highlighted. The misconception that nocturia is just night-time voiding will be<br />
challenged as new data reveal increased morbidity and mortality in patients suffering from nocturia. The<br />
symposium will therefore explore the relevance of proper evaluation and diagnosis for the selection of<br />
appropriate nocturia therapy.<br />
Sponsored by FERRING PHARMACEUTICALS<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
327
Saturday, 17 April - <strong>EAU</strong> Programme<br />
328 Programme Book<br />
Sponsored Session<br />
17.45 - 19.15 The impact of BPH on men’s lives: New evidence for disease<br />
management<br />
<strong>Barcelona</strong> Room<br />
Symposium<br />
Chair: F. J. Burgos Revilla, Madrid (ES)<br />
Welcome and introduction<br />
F.J. Burgos Revilla, Madrid (ES)<br />
The impact of BPH on men’s lives<br />
P. Hammerer, Braunschweig (DE)<br />
Effective management of BPH with combination therapy: Insights from recent trials<br />
J. Barkin, Toronto (CA)<br />
The impact of combination therapy in different subsets of patients with BPH<br />
S. Madersbacher, Vienna (AT)<br />
Combination therapy for BPH: Who, when, and why? A case-based discussion session<br />
J. Barkin, Toronto (CA)<br />
Summary and conclusions<br />
F.J. Burgos Revilla, Madrid (ES)<br />
Aims and objectives<br />
This symposium will explore practical topics in the medical management of men with BPH and associated<br />
lower urinary tract symptoms. Audience participation will be sought using keypad voting, and cases will be<br />
presented to provide a clinical context for the topics discussed. The objectives are to:<br />
• Discuss the impact of BPH, and in particular the impact of moderate disease, on men’s lives, and the<br />
implications for disease management and treatment<br />
• Explore the evidence supporting the use of combination therapy with an alpha blocker and 5ARI for clinical<br />
BPH, with a focus on combination therapy in patients with moderate-to-severe symptoms in the CombAT<br />
trial<br />
• Review the safety and tolerability of combination therapy from the CombAT trial<br />
• Explore the 4-year data from the CombAT study in greater detail by reviewing the AUR/BPH-related surgery<br />
outcomes according to baseline prostate volume, IPSS and PSA levels<br />
• Provide guidance for clinicians on the appropriate management of patients with BPH in clinical practice<br />
Sponsored by GLAXOSMITHKLINE
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Sponsored Session<br />
17.45 - 19.15 Challenges in individualising management of patients with prostate<br />
cancer<br />
Paris Room<br />
Symposium<br />
Chair: A. Heidenreich, Aachen (DE)<br />
Prostate cancer patient management – what is our current approach?<br />
A. Heidenreich, Aachen (DE)<br />
Optimising hormone treatment and patient follow up – what hormone therapy can offer today?<br />
J. Irani, Poitiers (FR)<br />
Radiation therapy in <strong>2010</strong> and beyond what is the way forward?<br />
M. Bolla, Grenoble (FR)<br />
Personalised patient diagnosis and prognosis in prostate cancer - what are the future perspectives<br />
L. Martínez-Piñeiro, Madrid (ES)<br />
Conclusion<br />
A. Heidenreich, Aachen (DE)<br />
Aims and objectives<br />
Recent advances in medicine are allowing physicians to increasingly tailor their therapeutic strategies to<br />
specific patient profiles. These trends are particularly important in the cancer setting in which the number of<br />
new therapeutic options is rising probably faster than in any other therapeutic area.<br />
While hormone therapy continues to represent the standard of care in locally advanced and metastatic<br />
prostate cancer, current investigations are pointing to several opportunities for individualizing patient care<br />
through:<br />
• Tailoring treatment according to the patient’s risk profile<br />
• Multidisciplinary approaches involving urologists, radiotherapists and oncologists<br />
• New biomarkers that are more prostate cancer specific and can better identify aggressive from indolent<br />
cancer<br />
• New approaches to prostate cancer prevention and disease management<br />
The symposium aims to address these points in interactive sessions in order for you to gain new insights for<br />
your practice in the evolving field of medicine.<br />
Sponsored by IPSEN<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
329
Saturday, 17 April - <strong>EAU</strong> Programme<br />
330 Programme Book<br />
Sponsored Session<br />
17.45 - 19.15 BPH treatment - from laser to plasma<br />
Stockholm Room<br />
Symposium<br />
Chairs: P. Rischmann, Toulouse (FR)<br />
J-U. Stolzenburg, Leipzig (DE)<br />
Welcome<br />
P. Rischmann, Toulouse (FR)<br />
TransUrethral Bipolar Vaporisation of the Prostate (TUBVP): Our experience and indications<br />
P. Rischmann, Toulouse (FR)<br />
Bipolar plasma vaporisation in BPH and NMIBT endoscopic treatment – A better choice than standard TUR?<br />
B. Geavlete, Bucharest (RO)<br />
Plasmavaporization, Laservaporisation, TURis and TURP: Advantages, differences and recommendations<br />
A. Bachmann, Basel (CH)<br />
Plasmavaporisation of the prostate: The Munich experience<br />
O. Reich, Münich (DE)<br />
Plasma vaporisation: Why and when ?<br />
B. Cleyenbreugel, Leuven (BE)<br />
Transurethral bipolar vaporisation of the prostate for patients under anti-thrombotic therapy: Planification<br />
for a comprehensive assessment of outcomes<br />
R. Sanchez-Salas, Paris (FR)<br />
Discussion and summary<br />
Aim:<br />
Outline the transurethral treatment options available for BPH and evaluate the newest standard.<br />
Objectives:<br />
Newest studies of the current treatments need to be analysed and reviewed in order to allow assumptions<br />
and identify future golden standard(s).<br />
Sponsored by OLYMPUS
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Sponsored Session<br />
17.45 - 19.15 Advances in prostate cancer management: The first once-yearly<br />
LH-RH agonist<br />
Birmingham Room<br />
Symposium<br />
Chair: J. Palou, <strong>Barcelona</strong> (ES)<br />
Introduction<br />
J. Palou, <strong>Barcelona</strong> (ES)<br />
Long-term hormonal therapy: Who would benefit?<br />
F. Desgrandchamps, Paris (FR)<br />
Introducing Vantas: The first once-yearly LH-RH agonist<br />
N. Shore, Myrtle Beach (US)<br />
Prostate cancer management: What does the future hold?<br />
B. Tombal, Brussels (BE)<br />
Conclusion<br />
J. Palou, <strong>Barcelona</strong> (ES)<br />
Aims and objectives<br />
Over the years, long-acting luteinising hormone-releasing hormone (LH-RH) agonists have become the<br />
mainstay for hormonal therapy for the palliative treatment of advanced and metastatic prostate cancer.<br />
However, to date, the majority of LH-RH agonists have only been available as short-term depot injections and<br />
therefore patients receiving long-term LH-RH therapy have required multiple injections per year. During this<br />
symposium we will introduce Vantas®, the first once-yearly LH-RH agonist subcutaneous implant containing<br />
histrelin acetate. Clinical trial data demonstrating the efficacy, reversibility and tolerability of treatment<br />
with Vantas in patients with advanced prostate cancer will be presented, and practical advice on implant<br />
insertion and removal will be provided. Finally, we will consider the future role of hormonal therapy and the<br />
developments that are likely to occur in the evolution of prostate cancer management.<br />
Sponsored by ORION PHARMA<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
331
Saturday, 17 April - <strong>EAU</strong> Programme<br />
332 Programme Book<br />
Sponsored Session<br />
17.45 - 19.15 The clinician as architect: Building a strong foundation for patient<br />
satisfaction<br />
Amsterdam Room<br />
Symposium<br />
Chair: S. Arlandis Guzman, Valencia (ES)<br />
The current and emerging landscape of OAB therapy<br />
S. Arlandis Guzman, Valencia (ES)<br />
Translation of PK profile into clinical practice<br />
T. Schneider, Mülheim (DE)<br />
New head-to-head superiority data: Fesoterodine Assessment and Comparison versus Tolterodine (FACT)<br />
study<br />
S. Herschorn, Toronto (CA)<br />
Understanding patient-reported outcomes: Key to optimising treatment<br />
D. Marschall-Kehrel, Frankfurt (DE)<br />
Panel discussion with question and answer session<br />
Aims and objectives<br />
The importance of physician-patient communication and increasing patient engagement in OAB management<br />
are key to optimising care. Clinicians play a critical role in facilitating discussions about treatment goals with<br />
their patients. To that end, this symposium will introduce a questionnaire designed to help patients identify<br />
their treatment goals for urinary symptoms and measure if their goals were achieved. This symposium will<br />
also highlight the latest scientific evidence for the clinical efficacy and tolerability of fesoterodine fumarate<br />
prolonged release tablets, an antimuscarinic compound indicated for the treatment of OAB symptoms. The<br />
importance of individualised therapy will be underscored with data from the first head-to-head superiority<br />
trial, Fesoterodine Assessment and Comparison versus Tolterodine (FACT) study, being presented here for<br />
the first time. This programme will consider the applicability of the latest data to the individual treatment<br />
pathway.<br />
Sponsored by PFIZER INC
Saturday, 17 April - <strong>EAU</strong> Programme<br />
Sponsored Session<br />
17.45 - 19.15 A novel approach to the needs of the BPH patient<br />
Padua Room<br />
Symposium<br />
Chair: C.R. Chapple, Sheffield (GB)<br />
Opening remarks<br />
C.R. Chapple, Sheffield (GB)<br />
New concepts in patho-physiology and epidemiology of LUTS in man<br />
F.R. Cruz, Porto (PT)<br />
Contemporary management of LUTS in man<br />
E. Chartier-Kastler, Paris (FR)<br />
Silodosin pharmacological profile<br />
M.C. Michel, Amsterdam (NL)<br />
Silodosin in clinical practice<br />
C.L.L. Llorente, Madrid (ES)<br />
Discussion<br />
Closing remarks<br />
C.R. Chapple, Sheffield (GB)<br />
Aims and objectives<br />
At the 25th <strong>Annual</strong> <strong>Congress</strong> of the <strong>EAU</strong>, Recordati holds a Satellite Symposium on “A novel approach<br />
to the needs of the BPH patient”. The main objective of this symposium is to identify what is truly<br />
important to patients with symptoms thought to be associated with benign prostatic hyperplasia (BPH).<br />
During the symposium, five world-renowned speakers review the epidemiological data on BPH and key<br />
pathophysiological elements underlying the lower urinary tract symptoms (LUTS) associated with BPH, and<br />
their overlap with other co-morbidities. The presentations focus on the most bothersome LUTS and their<br />
current management. It is important that urologists be involved at an early stage in the diagnosis of LUTS<br />
/ BPH and intervene with an appropriate disease management plan. The speakers review the present-day<br />
knowledge on alpha-blockers in the management of LUTS / BPH, and discuss the pharmacological features<br />
of the new agent, silodosin. Emphasis is given to the role of silodosin in a modern urological practice that<br />
takes into account physicians’ as well as patients’ needs.<br />
Sponsored by RECORDATI<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
333
Sunday, 18 April - <strong>EAU</strong> Programme<br />
334 Programme Book<br />
Sponsored Session<br />
12.15 - 13.45 Advancing your skills in endourology<br />
Genoa Room<br />
Workshop<br />
Advances in ureteroscopy - from theory to practice<br />
F.X. Keeley, Bristol (GB)<br />
PCNL - prone, supine or both - different approaches for a successful outcome<br />
G. Ibarluzea Gonzalez, Galdakao (ES)<br />
R.M. Scarpa and C. Scoffone, Orbassano (IT)<br />
Aims and objectives<br />
Our elite panel of physicians will share and demonstrate their advanced techniques for performing<br />
Ureteroscopy and PCNL. Session participants will have the opportunity to discuss and share their ideas and<br />
experiences in this interactive session.<br />
Sponsored by BOSTON SCIENTIFIC
Sunday, 18 April - <strong>EAU</strong> Programme<br />
Sponsored Session<br />
15.45 - 17.15 Ureteral access: Situation and new perspectives<br />
Genoa Room<br />
Workshop<br />
Chair: O. Traxer, Paris (FR)<br />
Introduction<br />
O. Traxer, Paris (FR)<br />
Ureteral access, state of the art<br />
M. Pearle, Dallas (USA)<br />
What about difficult access? Tips and trics to optimise ureteral access<br />
A.Breda, <strong>Barcelona</strong> (ES)<br />
Initial experience on a new concept<br />
O. Traxer, Paris (FR)<br />
Panel discussion and conclusion<br />
O. Traxer, Paris (FR)<br />
Aims and objectives<br />
Endourology still is a young technique and is in constant evolution. One major advancement is the size<br />
reduction and the increased flexibility of endoscopes. Many questions arise in parallel related to ureteral and<br />
renal access. Presentation of state of the art will be completed by technical tip and tricks currently in use. It<br />
thereby highlights the opportunity for improving the flexible URS procedure. New perspectives for ureteral<br />
access will be proposed with an innovating concept and documented by clinical experience.<br />
Sponsored by COLOPLAST<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
335
Sunday, 18 April - <strong>EAU</strong> Programme<br />
336 Programme Book<br />
Sponsored Session<br />
17.30 - 19.00 Proven surgical solutions for today incontinent patients<br />
Athens Room<br />
Symposium<br />
Chair: D.J.M.K. De Ridder, Leuven (BE)<br />
Patient indications and evaluation: Are there ideal characteristics<br />
G.D. Webster, Durham (US)<br />
Evolving concepts in male incontinence: To sling or not to sling?<br />
D.J.M.K. De Ridder, Leuven (BE)<br />
Lessons learned from cumulative experience: Operative technique<br />
P. Rehder, Innsbruck (AT)<br />
Experience and outcomes from a USA academic center<br />
G.D. Webster, Durham (US)<br />
AdVance® male sling for PPI: A three year experience<br />
F. Haab, Paris (FR)<br />
Innsbruck AdVance® experience and long term outcomes<br />
P. Rehder, Innsbruck (AT)<br />
Aims and objectives<br />
This Symposium will cover the latest knowledge and updates on the treatment of Male Stress Urinary<br />
Incontinence (SUI) using the AdVance® Male Sling. The expert faculty will emphasize the importance of<br />
pre-operative patient assessment with lessons learned on the diagnostics and pre-operative evaluation of<br />
sphincteric urethral coap¬tive response. The role of sphincter laxity in the pathophysiology of male incontinence<br />
will be presented with review of our current understanding on the mechanism of incontinence.<br />
The participants will be able to gain knowledge on the important steps in the surgical technique, with<br />
emphasis on the perineal dissection with preparation of the urethal bulb and the assessment of the sling<br />
function. All speakers will review their latest clinical data with up to 3 year clinical outcomes. This cumulative<br />
international faculty experience will be able to reinforce the safety and efficacy and expand our latest<br />
knowledge on the treatment of mild to moderate Male Stress Urinary Incontinence patients.<br />
Sponsored by AMERICAN MEDICAL SYSTEMS
Sunday, 18 April - <strong>EAU</strong> Programme<br />
Sponsored Session<br />
17.30 - 19.00 NEWS FLASH: RANK Ligand inhibitor reduces the risk of fracture in<br />
men receiving ADT<br />
Istanbul Room<br />
Symposium<br />
Chairs: K. Miller, Berlin (DE)<br />
C.N. Sternberg, Rome (IT)<br />
The under-recognised burden of bone loss in men undergoing ADT<br />
Presented by professional facilitator<br />
Denosumab: Treating bone loss and reducing the risk of fractures in men receiving ADT<br />
K. Miller, Berlin (DE)<br />
Who should be treated? Identifying patients at risk<br />
Panel discussion<br />
The spectrum of bone disease in prostate cancer patients<br />
M. Colombel, Lyons (FR)<br />
The potential of denosumab across the prostate cancer continuum of care<br />
C.N. Sternberg, Rome (IT)<br />
Meeting close<br />
Aims and objectives<br />
Androgen-deprivation therapy (ADT) is a cornerstone of therapy for non-metastatic prostate cancer but results<br />
in accelerated bone loss and increases the risk of fracture, which is associated with decreased survival.<br />
Guidelines for the management of cancer treatment-induced bone loss (CTIBL) associated with androgen<br />
deprivation have not been universally adopted, in part due to the lack of an approved therapy for this underrecognised<br />
complication.<br />
The upcoming arrival of denosumab*, a RANK Ligand inhibitor, for this indication requires urologists to<br />
thoughtfully identify men receiving ADT who are at high risk of fracture. The considered management of<br />
these patients is imperative for improving morbidity and mortality in this population.<br />
Looking forward, clinical trial results of denosumab are awaited for their potential to offer a new option<br />
across the full continuum of bone disease in prostate cancer patients.<br />
*Denosumab is an investigational medicinal product and is not approved anywhere in the world<br />
Sponsored by AMGEN<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
337
Sunday, 18 April - <strong>EAU</strong> Programme<br />
338 Programme Book<br />
Sponsored Session<br />
17.30 - 19.00 OAB – the test of TIME<br />
Amsterdam Room<br />
Symposium<br />
Chair: J.J. Wyndaele, Antwerp (BE)<br />
Introduction<br />
J.J. Wyndaele, Antwerp (BE)<br />
A look at the natural history of OAB over TIME<br />
K.D. Sievert, Tübingen (DE)<br />
TIME to update our knowledge on pathophysiology<br />
M.J. Drake, Bristol (GB)<br />
Looking back in TIME: Meta-analyses and clinical data<br />
G. Novara, Palermo (IT)<br />
TIME to meet patient needs<br />
D. Castro-Diaz, Tenerife (ES)<br />
Discussion<br />
Aims and objectives<br />
The meeting will be focused on aspects of time associated with the management of patients with overactive<br />
bladder - specifically time to keep moving forward with knowledge to enable improvement in daily clinical<br />
practice. The speakers will each consider a different aspect of this topical challenge, these will include;<br />
• Our current knowledge of the natural history of OAB over time, including epidemiology – incidence,<br />
progression and remission patterns<br />
• The development of our knowledge of mechanisms and pathophysiology over time and how this could<br />
impact on treatment choice now and in the future<br />
• Factors impacting on our choice of treatment, what clinical data over time have provided us with in terms<br />
of management strategy and how over time we have evolved a pattern for treating patients<br />
• A focus on patient needs and how time and depth of understanding are critical factors associated with the<br />
impact on clinical and healthcare resources hence service provision<br />
Sponsored by ASTELLAS
Sunday, 18 April - <strong>EAU</strong> Programme<br />
Sponsored Session<br />
17.30 - 19.00 Physical and psychological aspects of LUTS/BPH<br />
Padua Room<br />
Symposium<br />
Chair: F.M.J. Debruyne, Arnhem (NL)<br />
Recent and future aspects of the management of LUTS/BPH<br />
P. Radziszewski, Warsaw (PL)<br />
Psychological impact in the management of LUTS/BPH<br />
M. Hanus, Prague (CZ)<br />
Inflammation associated to BPH and chronic prostatitis - psychological aspects and treatment<br />
S. Micic, Belgrade (RS)<br />
Latest results of phytotherapy (Prostamol ® Uno) in the management of LUTS/BPH<br />
A.Z. Vinarov, Moscow (RU)<br />
Aims and objectives<br />
Benign prostatic hyperplasia (BPH) is a highly prevalent condition in ageing men. Although it is not lifethreatening,<br />
BPH affects sufferer’s quality of life to a great extent causing embarrassment and reduced selfesteem.<br />
When choosing therapy urologists sometimes miss to consider patient’s current psychological status<br />
and possible consequences of the treatment. Faculty of experts will present their ideas and experiences how<br />
to cover both physical and psychological aspects of symptomatic BPH treatment.<br />
Sponsored by BERLIN CHEMIE MENARINI<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
339
Sunday, 18 April - <strong>EAU</strong> Programme<br />
340 Programme Book<br />
Sponsored Session<br />
17.30 - 19.00 New perspectives and challenges in androgen deprivation therapies:<br />
Can we improve the treatments further?<br />
eURO Auditorium<br />
Symposium<br />
Chair: J. Anderson, Sheffield (GB)<br />
Introduction<br />
J. Anderson, Sheffield (GB)<br />
Is there still a need for hormonal therapy?<br />
P.C. Albertsen, Farmington (US)<br />
Have the goals of hormonal therapy changed over time?<br />
L. Boccon-Gibod, Paris (FR)<br />
Challenges in current therapy<br />
J. Morote, <strong>Barcelona</strong> (ES)<br />
New perspectives<br />
H. Van Poppel, Leuven (BE)<br />
Patient cases<br />
J. Anderson, Sheffield (GB)<br />
Conclusion<br />
J. Anderson, Sheffield (GB)<br />
Aims and objectives<br />
Today’s prostate cancer patient has high expectations that his disease can be successfully treated. Urologists<br />
need to be continually updated about treatment developments - no longer is it as simple as surgery or<br />
radiotherapy for localised tumours and hormonal treatment for those with advanced disease. New agents<br />
and the expansion of standard therapies, make the available choices more complex. Androgen deprivation<br />
therapy (ADT) remains the most important medical treatment for prostate cancer. A thorough evaluation<br />
of the risks/benefits, including when best to initiate ADT is important. Intermittent therapy regimens can<br />
be of interest to men worried about side effects of ADT. During this symposium, a faculty of international<br />
prostate cancer experts will explore current ADT, and will discuss the newly-introduced GnRH blockers.<br />
The participants will gain knowledge on the best available hormonal treatments for their prostate cancer<br />
patients.<br />
Sponsored by FERRING PHARMACEUTICALS
Sunday, 18 April - <strong>EAU</strong> Programme<br />
Sponsored Session<br />
17.30 - 19.00 Clinical experience in premature ejaculation: An expert roundtable<br />
debate<br />
<strong>Barcelona</strong> Room<br />
Symposium<br />
Chair: I. Moncada, Madrid (ES)<br />
Panel: J. Buvat, Lille (FR)<br />
E.A. Jannini, L’Aquila (IT)<br />
H. Porst, Hamburg (DE)<br />
Aims<br />
Following the symposium, participants will have a good understanding of:<br />
• Diagnosing and screening premature ejaculation (PE) in clinical practice<br />
• The utility of treatment guidelines and patient-reported outcomes in the management of PE<br />
• Current management practices, including use of dapoxetine and optimised approach to patient follow-up<br />
Objectives<br />
• Share expert perspectives on key topics and clinical challenges in the management of PE<br />
• Provide practical, case-based tips on the diagnosis, treatment and long-term management of men and<br />
couples with PE<br />
Sponsored by JANSSEN-CILAG EMEA a division of JANSSEN PHARMACEUTICA NV<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
341
Sunday, 18 April - <strong>EAU</strong> Programme<br />
342 Programme Book<br />
Sponsored Session<br />
17.30 - 19.00 Strategies for optimising outcomes in patients with GU malignancies<br />
Paris Room<br />
Symposium<br />
Chair: J. Bellmunt, <strong>Barcelona</strong> (ES)<br />
Evidence of potential anticancer effect of bisphosphonates<br />
F. Saad, Montreal (CA)<br />
Factors that contribute to optimal patient outcomes in advanced GU malignancies: Bone health and beyond<br />
A. Tubaro, Rome (IT)<br />
Factors that contribute to optimal patient outcomes in advanced GU malignancy: Managing mRCC patients in<br />
a TKI-refractory setting<br />
J. Bellmunt, <strong>Barcelona</strong> (ES)<br />
Sequential therapies in the treatment of metastatic RCC - optimising outcomes through switching targets<br />
S. Oudard, Paris (FR)<br />
Aims and objectives<br />
· Emphasize the importance of maintaining bone health and improving patient outcomes through targeted<br />
therapies in patients with GU malignancies throughout the treatment continuum<br />
· Discuss factors that contribute to improved treatment outcomes in patients with advanced GU malignancies<br />
receiving bone-targeted therapies (ie, pain control, improved quality of life, efficacy)<br />
· Review the preclinical and emerging clinical potential anticancer properties of bisphosphonates in patients<br />
with GU malignancies<br />
· Review emerging treatment strategies to optimise clinical outcomes for patient with metastatic RCC after<br />
failure of initial VEGF-TKI therapy<br />
· Discuss rationale and strategies for improving metastatic RCC patient outcomes through sequential therapies<br />
targeting different pathways<br />
Sponsored by NOVARTIS ONCOLOGY
Sunday, 18 April - <strong>EAU</strong> Programme<br />
Sponsored Session<br />
17.30 - 19.00 The evolving role of the urologist in the management of RCC<br />
Milan Room<br />
Symposium<br />
Chair: D. Jacqmin, Strasbourg (FR)<br />
Welcome and introduction<br />
D. Jacqmin, Strasbourg (FR)<br />
Urologists, mRCC and targeted agents: Applying clinical evidence to clinical practice<br />
D. Jacqmin, Strasbourg (FR)<br />
Exploring optimal mRCC treatment: The next decade<br />
T. Powles, London (GB)<br />
If and when: Debating the role of surgery in the era of targeted agents<br />
Facilitator: J. Carballido, Madrid (ES)<br />
Debaters: P. Albers, Düsseldorf (DE)<br />
T. Powles, London (GB)<br />
Summary and close<br />
D. Jacqmin, Strasbourg (FR)<br />
Aims and objectives<br />
• Review the critical role urologists play in ensuring patients with advanced RCC derive optimal benefit from<br />
targeted agents<br />
• Evaluate the evolving role of surgery in the era of targeted agents, including the value and optimal timing<br />
of nephrectomy when using targeted therapy<br />
• Provide an update on the latest clinical evidence supporting the use of targeted agents in advanced RCC<br />
• Consider how treatment with targeted agents can be optimised through the use of therapy management<br />
strategies<br />
• Discuss the future management of RCC, considering targeted agents in development and the optimum<br />
sequencing of targeted agents<br />
Sponsored by PFIZER INC<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
343
Sunday, 18 April - <strong>EAU</strong> Programme<br />
344 Programme Book<br />
Sponsored Session<br />
17.30 - 19.00 Inflammation: A common target for BPH and PCA therapies?<br />
Birmingham Room<br />
Symposium<br />
Chair: A. Alcaraz, <strong>Barcelona</strong> (ES)<br />
Introduction<br />
A. Alcaraz, <strong>Barcelona</strong> (ES)<br />
Inflammation and prostate cancer: A clear link?<br />
M.J. Ribal Caparros, <strong>Barcelona</strong> (ES)<br />
Inflammation and BPH: A clear link?<br />
A.R. Zlotta, Toronto (CA)<br />
Biopsies and inflammation markers<br />
A. De La Taille, Creteil (FR)<br />
Synthesis<br />
M. Emberton, London (GB)<br />
Aims and objectives<br />
Emerging evidence indicates that prostatic inflammation may contribute to prostate growth either in terms of<br />
hyperplastic (BPH) or neoplastic (prostate cancer) changes.<br />
During this symposium, the relation between inflammation and prostate diseases will be discussed. On top<br />
of the literature review, some recent findings will be presented. A third part will stress on inflammatory<br />
markers involved in those prostatic pathologies.<br />
Sponsored by PIERRE FABRE MÉDICAMENT
Sunday, 18 April - <strong>EAU</strong> Programme<br />
Sponsored Session<br />
17.30 - 19.00 Urgency: The problems and the solutions<br />
Stockholm Room<br />
Symposium<br />
Chair: L.D. Cardozo, London (GB)<br />
Introduction<br />
L.D. Cardozo, London (GB)<br />
Urgency and obstruction<br />
V. Mirone, Naples (IT)<br />
Post-interventional urgency<br />
M. Marberger, Vienna (AT)<br />
Urivesc: The clinical control of urgency<br />
C.J. Gratzke, Munich (DE)<br />
Panel discussion and conclusion<br />
L.D. Cardozo, London (GB)<br />
Aims and objectives<br />
The Symposium will focus on “urgency” as a core symptom not only in OAB but also in patients with BPH<br />
and in post-interventional conditions. Among the pharmacological options for the clinical treatment of<br />
urgency, some distinct properties of ER trospium chloride formulation (Urivesc) may favour earlier control of<br />
symptomatology in OAB patients.<br />
Sponsored by ROTTAPHARM|MADAUS<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
345
Monday, 19 April - <strong>EAU</strong> Programme<br />
346 Programme Book<br />
Sponsored Session<br />
10.00 - 11.30 Early stage localised prostate cancer: Local tumour ablation by Focal<br />
Vascular Occluding Agent [ F(VOA) ] - Tookad® Soluble<br />
Genoa Room<br />
Workshop<br />
Chair: P-A Abrahamsson, Malmö (SE)<br />
Moderator: F.M.J. Debruyne, Arnhem (NL)<br />
Welcome and introduction<br />
P-A Abrahamsson, Malmö (SE)<br />
Overdiagnosis of early detected prostate cancer: Overtreatment or Active Surveillance modality. What does<br />
it mean?<br />
J. Trachtenberg, Toronto (CA)<br />
The essentials of the mechanism of action of Tookad® Soluble: The Focal Vascular Occluding Approach<br />
[ F(VOA) ]<br />
A. Scherz, Rehovot (IL)<br />
The results of the phase 2 multicenter clinical program: Could we predict future results based on therapeutic<br />
index?<br />
M. Emberton, London (GB)<br />
Investigators panel: A-R. Azzouzi, Angers (FR)<br />
A. Villers, Lille (FR)<br />
The clinical protocol of the randomised, parallel group European phase 3 study comparing Tookad® Soluble<br />
versus Active Surveillance: Methodological issues?<br />
L. Abenhaim, Paris (FR)<br />
C. Moore, London (GB)<br />
Summary and conclusions<br />
F.M.J. Debruyne, Arnhem (NL)<br />
Aims and objectives:<br />
Different therapeutic approaches are currently applied to the different stages of tumour progression. Surgery<br />
or radiotherapy or focal treatments (cryoablation or HiFu) are usually employed at the early localised stage<br />
for removing the tumour and surrounding tissue. In the last decade a new therapeutic approach, aiming<br />
at the tumour vasculature has gained increasing use. Tookad® Soluble is the first-in-class Focal Vascular<br />
Occluding Agent [F(VOA)] for a novel, focal therapeutic modality that enables ablation of the prostatic tumour<br />
tissue second to occlusion of the entire tumour vasculature in a few minutes of treatment. At the conclusion<br />
of this Workshop, participants will gain new information on this molecule: Tookad® Soluble, have a good<br />
understanding of the pharmacology, efficacy, safety and tolerability of the product as well as the Phase 3<br />
protocol to be implemented soon.<br />
Sponsored by STEBA BIOTECH
Monday, 19 April - <strong>EAU</strong> Programme<br />
Sponsored Session<br />
10.30 - 17.00 da Vinci Prostatectomy<br />
Copenhagen Room<br />
Live Surgery<br />
10.30 - 12.00 Live Surgery broadcast from the Fundació Puigvert Hospital, <strong>Barcelona</strong> (ES)<br />
Operator: H. Villavicencio, <strong>Barcelona</strong> (ES)<br />
Moderator: J.A. Peña, <strong>Barcelona</strong> (ES)<br />
15.30 - 17.00 Live Surgery broadcast from the Fundació Puigvert Hospital, <strong>Barcelona</strong> (ES)<br />
Operator: A. De La Taille, Paris (FR)<br />
Moderator: M. Roupret, Paris (FR)<br />
Sponsored by INTUITIVE SURGICAL<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
347
Monday, 19 April - <strong>EAU</strong> Programme<br />
348 Programme Book<br />
Sponsored Session<br />
13.00 - 14.30 Ablatherm® HIFU for PCa. From real clinical background to virtual<br />
training<br />
Genoa Room<br />
Workshop<br />
Introduction<br />
Clinical expertise from the literature 1/2 (Outcome for first line)<br />
A. Blana, Fürth (DE)<br />
Live demo! Practical expertise from e-learning (Step 1-6 theoretical modules)<br />
H.G. Van Der Poel, Amsterdam (NL)<br />
Clinal expertise from e-learning (Outcome for salvage)<br />
F.J. Murat, Lyon (FR)<br />
Live demo! Practical expertise from e-learning (Step 2 - On-line hands on training)<br />
S. Thüroff, Munich (DE)<br />
Questions/Answers<br />
Aims and objectives<br />
EDAP TMS presents potential HIFU users an innovative way to learn the fundamentals of the procedure<br />
from home without travel cost and time out of the practice. For urologists, the decision to add HIFU in<br />
their armamentarium is mainly based on the clinical literature and supported by society guidelines (latest<br />
outcomes will be reported). After more than 16 years of clinical experience in the field, the background<br />
knowledge can be standardised and summarised online in e-learning modules (a live demo of the <strong>EAU</strong><br />
Education Online platform is proposed). Today we can go even further by simulating the clinical procedure<br />
via a software that is easily included in the on-line course. The second part of the live demo will demonstrate<br />
these new possibilities.<br />
Sponsored by EDAP TMS
Monday, 19 April - <strong>EAU</strong> Programme<br />
Sponsored Session<br />
15.45 - 17.15 Cryoablation: Setting the standard<br />
Genoa Room<br />
Workshop<br />
Chair: T.E. Bjerklund Johansen, Århus (DK)<br />
Cryoablation as a true “Gold Standard” for small renal masses<br />
J. Landman, New York (US)<br />
Visualisation and procedure of CT and MRI guidance for renal masses<br />
J. Landman, New York (US)<br />
The science and technology of 17-gauge cryoablation<br />
A. Breda, <strong>Barcelona</strong> (ES)<br />
European multi-centre results in small renal masses<br />
M.P. Laguna, Amsterdam (NL)<br />
Template biopsy principles and techniques for focal prostate cryoablation<br />
D. Greene, Sunderland (GB)<br />
A focal prostate protocol<br />
T. Polascik, Durham (US)<br />
Sponsored by GALIL MEDICAL<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
349
Monday, 19 April - <strong>EAU</strong> Programme<br />
350 Programme Book<br />
Sponsored Session<br />
17.30 - 19.00 New developments in the understanding and management of Chronic<br />
Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)<br />
Padua Room<br />
Symposium<br />
Chair: T.E. Bjerklund Johansen, Århus (DK)<br />
The man with CP/CPPS: Who is he and how do we evaluate him?<br />
M. Grabe, Malmö (SE)<br />
What treatments work, what treatments do not and why<br />
J. Nickel, Kingston (CA)<br />
Results of a multicentre study with Cernilton ® in patients with CP/CPPS<br />
W. Weidner, Giessen (DE)<br />
Further clinical and pre-clinical aspects of Cernilton’s ® role in the management of CP/CPPS<br />
F.M.E. Wagenlehner, Giessen (DE)<br />
Aims and objectives<br />
The symposium will provide an up-to-date discussion of chronic prostatitis/chronic pelvic pain syndrome,<br />
and aims to provide useful overview and guidance for the urologist interested in obtaining a better<br />
understanding of diagnostic and therapeutic challenges related to this very large and heterogeneous group<br />
of urological patients.<br />
Upon the completion of the symposium the delegates should understand how to evaluate patients with CP/<br />
CPPS, they should know which treatments work, and which do not, and they will be updated on the latest<br />
multicenter clinical trials on new treatments, especially on the pollen extract Cernilton ®<br />
Sponsored by AB CERNELLE
Monday, 19 April - <strong>EAU</strong> Programme<br />
Sponsored Session<br />
17.30 - 19.00 The new world of managing male LUTS: Focus on storage symptoms?<br />
Amsterdam Room<br />
Symposium<br />
Chair: J.M. Fitzpatrick, Dublin (IE)<br />
Introduction<br />
J.M. Fitzpatrick, Dublin (IE)<br />
Diagnosing male LUTS: Walking on water?<br />
J.E. Batista Miranda, <strong>Barcelona</strong> (ES)<br />
Controlling nocturia: A difference of day and night<br />
N. Stanley, Norwich (GB)<br />
Managing LUTS: Can we predict the future?<br />
M.J. Speakman, Taunton (GB)<br />
Closing remarks<br />
J.M. Fitzpatrick, Dublin (IE)<br />
Aims and objectives<br />
Lower urinary tract symptoms (LUTS) are a common condition in older men which require tailoring treatment<br />
to symptoms, but how do we best manage these patients with voiding and storage symptoms? The current<br />
expert view on the treatment of male LUTS from a symptom perspective will be evaluated in a web-based<br />
survey prior to the symposium. Outcomes of the survey will be discussed during the symposium, and the<br />
audience will be stimulated to interact with the faculty. The symposium will give guidance on best practice in<br />
the management of this complex condition.<br />
Sponsored by ASTELLAS<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
351
Monday, 19 April - <strong>EAU</strong> Programme<br />
352 Programme Book<br />
Sponsored Session<br />
17.30 - 19.00 Prostate Health Index (phi) – A simple blood test significantly<br />
improves on PSA in the selection of men for biopsy and is a major<br />
advance in prostate cancer risk assessment<br />
Vienna Room<br />
Symposium<br />
Chair: A. Semjonow, Münster (DE)<br />
Urologists’ dilemmas in prostate cancer detection<br />
A. Semjonow, Münster (DE)<br />
Serum Prostate Health Index (phi) significantly increases specificity when selecting men for biopsy<br />
K.M. Slawin, Houston (US)<br />
Implementation of the Prostate Health Index (phi) in a prostate cancer risk assessment tool (ERSPC Prostate<br />
Cancer Risk Calculator www.uroweb.org)<br />
M.J. Roobol, Rotterdam (NL)<br />
Predicting an unfavourable outcome in men enrolled in active surveillance for prostate cancer<br />
D.V. Markarov, New Haven (US)<br />
Aims and objectives<br />
Serum Beckman Coulter phi is a multivariate index incorporating PSA, free PSA and<br />
[-2]proPSA concentrations into a single result to estimate the probability of cancer in men aged 50 and older<br />
with total PSA in the 2.0-10.0 ng/mL range and a non-suspicious DRE.<br />
[-2]proPSA is a novel serum marker strongly associated with prostate cancer and delivers added specificity<br />
to PSA. As a result, phi contributes to significantly reduce the number of negative biopsies resulting from<br />
suspicious PSA or %free PSA results.<br />
Sponsored by BECKMAN COULTER INC
Monday, 19 April - <strong>EAU</strong> Programme<br />
Sponsored Session<br />
17.30 - 19.00 Time for change: Optimising metastatic Renal Cell Carcinoma (mRCC)<br />
<strong>Barcelona</strong> Room<br />
Symposium<br />
Chairs: J. Gschwend, Munich (DE)<br />
C. Porta, Pavia (IT)<br />
Welcome and introduction<br />
J. Gschwend, Munich (DE)<br />
Evolution of systemic treatments for mRCC<br />
C. Porta, Pavia (IT)<br />
Surgical perspectives for the management of RCC in the era of targeted therapies<br />
J. Gschwend, Munich (DE)<br />
What promises do current treatments hold for patients with mRCC?<br />
J-J. Patard, Rennes (FR)<br />
Tyrosine kinase inhibitors in the management of mRCC – how do they differ?<br />
J. Wagstaff, Swansea (GB)<br />
Closing remarks and adjourn<br />
J. Gschwend, Munich (DE)<br />
Sponsored by GLAXOSMITHKLINE<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
353
Monday, 19 April - <strong>EAU</strong> Programme<br />
354 Programme Book<br />
Sponsored Session<br />
17.30 - 19.00 New trends in laparoscopy: Single portal and mini-laparoscopy<br />
Stockholm Room<br />
Symposium<br />
Chair: E. Liatsikos, Patras (GR)<br />
Technical consideration of single portal: Possibilities and limits<br />
O. Reichelt, Halle (DE)<br />
Single portal nephrectomy<br />
E. Liatsikos, Patras (GR)<br />
J-U. Stolzenburg, Leipzig (DE)<br />
Single-portal laparoscopic surgery and mini-laparoscopy: 3 mm in combination with single-portal – the<br />
future?<br />
E. Liatsikos, Patras (GR)<br />
J-U. Stolzenburg, Leipzig (DE)<br />
Mini-laparoscopy in urology: Current indications and future development – what are the limits?<br />
F. Porpiglia, Orbassano (IT)<br />
Aims and objectives<br />
This session is a review of the most recent advancements in Mini-Laparoscopy and Single Port Surgery.<br />
Those new developments allow physicians to propose to their patients the most convenient surgical strategies<br />
to each individual profile. The session will outline different strategies and gives the participants a good<br />
understanding of the challenging new techniques for laparoscopy.<br />
Sponsored by KARL STORZ GMBH & CO.KG
Monday, 19 April - <strong>EAU</strong> Programme<br />
Sponsored Session<br />
17.30 - 19.00 Testosterone deficiency: Sharing our experience between countries<br />
and specialities<br />
Athens Room<br />
Symposium<br />
Chairs: A. Salonia, Milan (IT)<br />
M. Zitzmann, Münster (DE)<br />
Introduction<br />
Transversal European Survey on Testosterone deficiency diagnosis: TESTO-Dia final results<br />
J. Tostain, Saint Etienne (FR)<br />
Testosterone and prostate cancer: Intriguing correlation?<br />
A. Morgentaler, Boston (US)<br />
Testosterone and metabolic syndrome: Physiopathologic and clinical aspects<br />
M. Zitzmann, Münster (DE)<br />
Testosterone substitution therapy in men: Effectiveness and risk of new therapies<br />
A. Salonia, Milano (IT)<br />
Conclusion<br />
Aim:<br />
To expose a wide view of Testosterone deficiency syndrome (TDS) knowledge, diagnosis and therapeutic<br />
management accross countries and specialities, without leaving out contraversial questions such as prostate<br />
cancer and testosterone.<br />
To discuss possible metabolic abnomalities that link up with TDS and create cardiovascular dysfunction/<br />
damage and to make an update on new therapies in Testosterone deficiency management<br />
Objectives:<br />
- To present , through an European survey, the current therapeutic management of TDS as well as the main<br />
opinions concerning the different galenic formulations available.<br />
- To think a step forward on Testosterone and prostate cancer taking into account the controversies and the<br />
current guidelines.<br />
- To describe the processes that create a pathophysiologic triangle between Testosterone deficiency, the<br />
metabolic syndrome/diabetes mellitus type 2 and cardiovascular morbidities.<br />
- To review testosterone substitution therapies bringing in all the new therapies.<br />
Sponsored by PIERRE FABRE MÉDICAMENT<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
355
Monday, 19 April - <strong>EAU</strong> Programme<br />
356 Programme Book<br />
Sponsored Session<br />
17.30 - 19.00 The value of maintenance therapy in the management of NMIBC: What<br />
does the data tell us?<br />
Milan Room<br />
Symposium<br />
Chair: R. Persad, Bristol (GB)<br />
Panel: M. Brausi, Capri (IT)<br />
M. Colombel, Lyon (FR)<br />
D.L. Lamm, Scottsdale (US)<br />
Aims and objectives<br />
• Review the data in support of an effective maintenance BCG regimen in the management of non-muscle<br />
invasive bladder cancer (NMIBC)<br />
• Understand how the optimisation of therapy affects outcome for the NMIBC patient<br />
Sponsored by SANOFI PASTEUR
Monday, 19 April - <strong>EAU</strong> Programme<br />
Sponsored Session<br />
17.30 - 19.00 Expert analysis on new treatment options in advanced prostate<br />
cancer<br />
Istanbul Room<br />
Symposium<br />
Chair: C.N. Sternberg, Rome (IT)<br />
Welcome and introduction<br />
C.N. Sternberg, Rome (IT)<br />
Current and emerging treatment options for patients with advanced prostate cancer<br />
A. Heidenreich, Aachen (DE)<br />
Evidence-based approaches to treatment of mCRPC patients who progressed after first-line docetaxel<br />
S. Oudard, Paris (FR)<br />
Analysis of key findings and future directions<br />
C.N. Sternberg, Rome (IT)<br />
Sponsored by SANOFI-AVENTIS<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
357
ESRU Meeting, 17 April<br />
ESRU Meeting<br />
10.00 - 16.45 17th Meeting of the European Society of Residents in Urology (ESRU)<br />
Stockholm Room<br />
Chairs: T. Esen, Istanbul (TR)<br />
T.G. Zóber, Budapest (HU)<br />
10.00 - 10.15 Opening and introduction<br />
Chairs: P-A. Abrahamsson, Malmö (SE)<br />
T.G. Zóber, Budapest (HU)<br />
10.15 - 11.45 Debate Alternatives for radical prostatectomy<br />
Open: M. Garofalo, Bologna (IT)<br />
Laparoscopic: A.S. Gözen, Heilbronn (DE)<br />
Robot-assisted: B.S.E.P. Van Cleynenbreugel, Leuven (BE)<br />
11.15 - 11.45 Surgery for penile cancer. Reducing the morbidity associated with the surgical management<br />
A. Pytel, Pecs (HU)<br />
11.45 - 12.15 Test your knowledge: ‘The Campbell’s quest’ An interactive quiz testing the European residents on their<br />
urological knowledge. The winner will receive the urological bible: The new Campbell-Walsh Urology<br />
12.15 - 13.15 Lunch<br />
13.15 - 13.55 Interactive quiz: ‘Who is the winning team of ESRU <strong>2010</strong>?’ Three groups of residents will compete in answering<br />
questions, medical and paramedical, related to urology<br />
Chair: S. Al-Hayek, Bristol (GB)<br />
13.55 - 14.25 NOTES and LESS nephrectomy<br />
A. Alcaraz, <strong>Barcelona</strong> (ES)<br />
14.25 - 15.45 Debate Present and future of training in urology<br />
C-C. Abbou, Creteil (FR)<br />
M. Brehmer, Stockholm (SE)<br />
C.R. Chapple, Sheffield (GB)<br />
G.P. Haas, Syracuse (US)<br />
H. Van Poppel, Leuven (BE)<br />
T.G. Zóber, Budapest (HU)<br />
15.45 - 16.30 Nightmare session: Presentations of clinical problems that have startled and perplexed residents all over<br />
Europe<br />
15.45 - 16.30 Chairs: L. Martínez-Piñeiro, Madrid (ES)<br />
D. Pushkar, Moscow (RU)<br />
16.30 - 16.45 Prizes and awards<br />
First Prize for the Best Abstract by a resident and the Resident’s Corner Awards are supported by an<br />
unrestricted educational grant from ELI LILLY AND COMPANY<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
359
360
Saturday, 17 April<br />
<strong>EAU</strong>N Workshop<br />
09.00 - 11.00 Cryoablation for prostate and kidney cancer; an overview on<br />
background, procedure and nurses’ responsibilities<br />
Birmingham Room<br />
09.00 - 09.35 Introduction<br />
U. Witzsch, Bad Soden am Taunus (DE)<br />
09.35 - 10.05 Cryotherapy of the prostate<br />
S. Hieronymi, Frankfurt am Main (DE)<br />
U. Witzsch, Bad Soden am Taunus (DE)<br />
10.05 - 10.30 Cryotherapy of the kidney<br />
S. Hieronymi, Frankfurt am Main (DE)<br />
U. Witzsch, Bad Soden am Taunus (DE)<br />
10.30 - 11.00 How to start cryotherapy<br />
S. Hieronymi, Frankfurt am Main (DE)<br />
U. Witzsch, Bad Soden am Taunus (DE)<br />
Aims and objectives<br />
Improvements in cryotechnology have made cryoablation a true alternative or standard of care in patients<br />
with specific indications or in case of contraindications for other therapeutic modalities.<br />
A thorough understanding of the technology, procedure and cryothermal effects is challenging to both<br />
medical and nursing teams. A commitment to initial training and ongoing education is important to ensure<br />
continued optimal outcomes for the patients.<br />
This workshop aims to present an overview of both the practical and theoretical procedures that are currently<br />
in vogue in cryotherapy to improve the understanding of the nurse.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
361
Saturday, 17 April<br />
362 Programme Book<br />
<strong>EAU</strong>N Workshop<br />
09.00 - 11.00 Quality of life in urology stoma patients<br />
Prague Room<br />
S.P. Fillingham, Kent (GB)<br />
B. Kiesbye, Risskov (DK)<br />
Indications for urostomy and different types of urostomy<br />
Surgery types: Laparoscopic versus open surgery<br />
Pre-operative care including a training session on stoma siting<br />
Post-operative care - what is important?<br />
Body image<br />
Sexuality<br />
Aims and objectives<br />
The aim of the workshop is to look at various management options and ways of care with an emphasis<br />
on aspects that can increase confidence and ultimately improve the quality of life of people with a urinary<br />
stoma. The workshop comprises a theoretical and a practical part.
Saturday, 17 April<br />
Sponsored Session<br />
11.15 - 12.15 Building on the vital framework to improve outcomes with<br />
bisphosphonates<br />
Birmingham Room<br />
Symposium<br />
Chair: B.T. Jensen, Århus (DK)<br />
11.15 - 11.20 Welcome and introduction<br />
B.T. Jensen, Århus (DK)<br />
11.20 - 11.30 Breaking down the scaffold: Cancer effects on bone<br />
B.T. Jensen, Århus (DK)<br />
11.30 - 11.45 Helping to strengthen the foundation: Bisphosphonates to prevent skeletal complications<br />
A. Tubaro, Rome (IT)<br />
11.45 - 11.55 Beyond the surface: Nursing strategies for patient adherence, safety, and communication during treatment<br />
L. Drudge-Coates, London (GB)<br />
11.55 - 12.05 Question and answer session<br />
12.05 - 12.15 Helping patients sculpt their futures<br />
Aims and objectives<br />
The Novartis-sponsored satellite titled, “Building on the Vital Framework to Improve Outcomes With<br />
Bisphosphonates” will provide insights for nurses on how they can support patients receiving bisphosphonate<br />
treatment. The symposium will educate the attendees on the importance of maintaining bone health<br />
throughout the treatment continuum in patients with GU malignancies through the administration of<br />
bone-targeted therapies. In addition, nursing strategies will be discussed that can contribute to improved<br />
treatment outcomes in patients with advanced GU malignancies receiving bone-targeted therapies (ie, pain<br />
control, improved quality of life, efficacy).<br />
Sponsored by NOVARTIS ONCOLOGY<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
363
Saturday, 17 April<br />
<strong>EAU</strong>N Lectures<br />
14.00 - 15.00 Special Session of the Spanish Association of Urology Nurses<br />
Birmingham Room<br />
A. Quintanilla Sanz, Lleida (ES)<br />
M. Gea-Sánches, Lleida (ES)<br />
15.15 - 15.30 <strong>EAU</strong>N Opening<br />
Birmingham Room<br />
P-A. Abrahamsson, Malmö (SE), <strong>EAU</strong> Secretary General<br />
B.T. Jensen, Århus (DK), <strong>EAU</strong>N Chair<br />
15.30 - 15.45 Good Practice in Health Care - Continent Urinary Diversion –<br />
introduction of the new guideline<br />
Birmingham Room<br />
S.V. Lauridsen, Copenhagen (DK)<br />
Aims and objectives<br />
Introduction to the latest evidence-based guideline on continent urinary diversion.<br />
Publication of this booklet was made possible by an unrestricted educational grant from ASTRA TECH AB<br />
17.00 - 18.00 Bienvenida Espanola – Welcome Reception<br />
364 Programme Book<br />
Location: Outside the Birmingham Room
Saturday, 17 April<br />
Sponsored Session<br />
16.00 - 17.00 “Ins and outs” of intermittent catheterisation<br />
Birmingham Room<br />
Symposium<br />
Chair: R. Pieters, Ghent (BE)<br />
D. Newman, Berwyn, Pennsylvania (US)<br />
Aims and objectives<br />
This workshop will provide an overview of the use of intermittent catheterization in clinical practice by<br />
focusing on the types of intermittent catheterization: no touch (or sterile) and clean technique. Historically,<br />
no touch intermittent self catheterization was the recommended procedure of choice. However, recently<br />
released intermittent catheterization guidelines have recommended changes to this practice by incorporating<br />
the use of “clean” intermittent catheterization, especially in the home environment. In light of these<br />
guidelines, nurses still base intermittent catheterization procedures on other factors as well: differential<br />
costs and medical insurance coverage; clinical judgment; and patient preference. All of these aspects will be<br />
reviewed and discussed.<br />
Sponsored by HOLLISTER<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
365
Sunday, 18 April<br />
366 Programme Book<br />
ESU Course<br />
08.00 - 10.15 Erectile dysfunction<br />
Birmingham Room<br />
Chair: P.J. Nyirády, Budapest (HU)<br />
08.00 - 08.20 Pathophysiology of E.D.<br />
P.J. Nyirády, Budapest (HU)<br />
08.20 - 08.30 Discussion<br />
08.30 - 08.50 Overview of medical treatment of E.D.<br />
S. Minhas, London (GB)<br />
08.50 - 09.00 Discussion<br />
09.00 - 09.15 Break<br />
09.15 - 09.35 Surgical therapy of E.D.<br />
S. Minhas, London (GB)<br />
09.35 - 09.45 Discussion<br />
09.45 - 10.05 Nursing aspects of patients with E.D.<br />
I. Van Neyghen, Antwerp (BE)<br />
10.05 - 10.15 Discussion
Sunday, 18 April<br />
<strong>EAU</strong>N Lectures<br />
10.30 - 11.10 State-of-the-art lecture - New developments in urological cancer care<br />
including the nursing aspects<br />
Birmingham Room<br />
H.A.M. Van Muilekom, Amsterdam (NL)<br />
Aims and objectives<br />
Urological tumours are quite common solid tumours among all human malignancies. Prostate cancer is<br />
the most common cancer in the male population. But also the incidence of bladder and renal cell cancer<br />
is increasing. New developments in diagnosis and treatment, like specific tumour markers, robot assisted<br />
surgery, (neo) adjuvant chemo- or immunotherapy do have a positive effect on treatment outcome but they<br />
also cause a change in nursing care and support. Quality of life is becoming more important and symptom<br />
management or management of late effects in, for example testicular and penile cancer patients, needs our<br />
full attention. In this lecture the nursing implications of new treatments will be covered, together with most<br />
important nursing care strategies in quality of life aspects in urological tumours.<br />
11.10 - 11.25 <strong>EAU</strong>N urology nursing quiz<br />
Birmingham Room<br />
Chair: T. Christiansen, Lund (SE)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
367
Sunday, 18 April<br />
368 Programme Book<br />
<strong>EAU</strong>N Workshop<br />
12.30 - 14.30 Nursing tools for patient instruction on prostate cancer<br />
Birmingham Room<br />
Chair: W.M. De Blok, Amsterdam (NL)<br />
12.30 - 12.35 Introduction<br />
W.M. De Blok, Amsterdam (NL)<br />
12.35 - 12.55 Nurse aspects and side effects<br />
S. Faithfull, Guildford (GB)<br />
12.55 - 13.15 Hormone treatment and possible nursing interventions<br />
M. Borre, Århus C (DK)<br />
13.15 - 13.35 Role of the nurse in diagnostics and bone health<br />
L. Drudge-Coates, London (GB)<br />
13.35 - 14.15 Patient perspective and patient education<br />
L. Denis, Antwerpen (BE)<br />
14.15 - 14.30 Discussion<br />
K. Redmond, Milan (IT)<br />
Aims and objectives<br />
Nurses often experience difficulty in explaining different aspects of prostate cancer. In this session the<br />
speakers will each give a presentation on a subject concering prostate cancer. In conclusion there is time for<br />
a discussion and questions. After the session we hope that the audience will find themselves more equiped<br />
to speak with patients about prostate cancer<br />
Supported by unrestricted educational grants from AMGEN, FERRING PHARMACEUTICALS,<br />
NOVARTIS ONCOLOGY
Sunday, 18 April<br />
Abstract Session<br />
14.30 - 16.15 Poster Session<br />
Birmingham Room<br />
Chairs: T. Christiansen, Lund (SE)<br />
K. Fitzpatrick, Dublin (IE)<br />
P1-s Is there a role for a nurse specialist within a tertiary referral stone unit?<br />
N. Dickens, N.P. Buchholz, J. Masood (London, United Kingdom)<br />
P2-s/p Patient evaluation of intermittent self catheterisaion (ISC) focus group meeting<br />
M.E. Lester, E. Robinson, I. Pearce (Manchester, United Kingdom)<br />
P3-s Withdrawn<br />
P4-p How to instil post-operative Mitomycin (MMC) in the bladder<br />
R. Terkelsen, I.M. Thiele, L. Lieberkind (Copenhagen, Denmark)<br />
P5-s Outpatient work-up for LUTS, an assignment for Specially Trained Nurses (STN)?<br />
V. Elf, A.K. Eleholt, I. Erlandsson, B. Larsson, P. Ströberg (Jönköping, Sweden)<br />
P6-s Preoperative teaching and informaton by urologic nurses to patients scheduled for robot-assisted radical<br />
prostatectomy<br />
A. Fredriksen (Oslo, Norway)<br />
P7-s Developing a novel approach to follow up for patients with prostate cancer<br />
J.E. Kinsella, L. Fleure, A. Ashfield, P. Acher, D. Cahill, K. Chatterton (London, United Kingdom)<br />
P8-s Educating health professionals about sexual dysfunction improves the experience of men on hormone<br />
treatment for prostate cancer<br />
J. Kinsella, L. Fleure, K. Chatterton, P. Acher, D. Cahill (London, United Kingdom)<br />
P9-s The demonstration of erectile management techniques to men scheduled for radical prostatectomy reduces<br />
long-term regret: a comparative cohort study<br />
J.E. Kinsella, P. Acher, K. Chatterton, D. Cahill, P. Dasgupta, R. Popert, T. O’brien (London, United Kingdom)<br />
P10-s Parameters important for patient recovery undergoing radical retropubic prostatectomy<br />
L. Gruschy, S.T. Nielsen, M.B. Andersen (Copenhagen, Denmark)<br />
Abstract code explanation<br />
P : Poster abstract<br />
p : Daily practice<br />
s : Scientific research<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
369
Sunday, 18 April<br />
370 Programme Book<br />
<strong>EAU</strong>N Workshop<br />
16.15 - 17.15 Ensuring continence in difficult cases<br />
18.00 - 20.00 Urowalk<br />
Birmingham Room<br />
Chair: W.M. De Blok, Amsterdam (NL)<br />
Aims and objectives<br />
In this session nurses can present experiences they have had with a difficult case of incontinence and discuss<br />
them with the audience; a unique opportunity to learn from each other. After the congress the cases will be<br />
published on the <strong>EAU</strong>N website and in European Urology Today.<br />
Meeting point: In front of the Tourist Information office on Plaza de Catalunya at 18.00 hrs.<br />
Participants should be registered for the Urowalk.<br />
The Urowalk registration is listed on the entitlement list.
Monday, 19 April<br />
Sponsored Session<br />
07.45 - 08.45 Optimising patient benefits in bladder cancer management<br />
Birmingham Room<br />
Breakfast Symposium<br />
Chair: K. Chatterton, London (GB)<br />
Welcome and introductions<br />
K. Chatterton, London (GB)<br />
Data review: The latest European recommendations<br />
A. Sommerhuber, Linz (AT)<br />
Patient throughput: A nurse perspective<br />
K. Egge, Oslo (NO)<br />
Technique and equipment: Key considerations<br />
J. Hendrickx, Leuven (BE)<br />
Making a difference: Fluorescence cystoscopy in day-to-day practice<br />
D. Amsellem-Ouazana, Paris (FR)<br />
Patient perspective<br />
K. Chatterton, London (GB)<br />
Questions, Chair’s summary and close<br />
K. Chatterton, London (GB)<br />
As of 7.30 hrs a small breakfast will be served.<br />
Sponsored by GE HEALTHCARE AND PHOTOCURE ASA<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
371
Monday, 19 April<br />
372 Programme Book<br />
Hospital Visits<br />
09.30 - 14.00 Vall d’Hebron Hospital Visit<br />
09.30 - 11.00 Transfer<br />
Meeting point: In front of the main entrance of Fira Gran Via (Entrada Norte).<br />
11.00 - 13.30 Hospital visit<br />
13.30 - 14.00 Lunch<br />
The Vall d’Hebron Hospital has organised a lunch for the Hospital Visit participants.<br />
14.30 - 18.00 Fundació Puigvert Hospital Visit<br />
14.30 - 15.30 Transfer<br />
Meeting point: In front of the main entrance of Fira Gran Via (Entrada Norte).<br />
15.30 - 17.30 Hospital visit<br />
17.30 - 18.00 Cocktail<br />
The Fundació Puigvert Hospital has organised a drink for the Hospital Visit participants.<br />
Participants should be registered for the Hospital Visits. The Hospital Visit registration is listed on the entitlement<br />
list.
Monday, 19 April<br />
<strong>EAU</strong>N Lectures<br />
09.00 - 10.30 <strong>EAU</strong>N Nursing Research Competition - learning session<br />
Birmingham Room<br />
Chair: R. Pieters, Ghent (BE)<br />
09.00 - 09.05 Introduction<br />
R. Pieters, Ghent (BE)<br />
09.05 - 09.15 How do we instruct patients on the use of a vacuum device for the management of their erectile dysfunction<br />
RP09-04 - preliminary results<br />
D. Smit - Van Den Hof, Arnhem (NL)<br />
09.15 - 09.25 Discussion<br />
09.25 - 09.30 How to increase patient comfort during treatment with intravesical chemotherapy – a randomized controlled<br />
RP10-01 trial<br />
B. Bonfils-Rasmussen, Herlev (DK)<br />
09.30 - 09.40 Discussion<br />
09.40 - 09.45 Quality of life issues after treatment of penile cancer<br />
RP10-02 H.A.M. Van Muilekom, Leiden (NL)<br />
09.45 - 09.50 Discussion<br />
09.55 - 10.00 Urinary incontinence among dependent women and men over 85 years in relation to staff attitudes and<br />
RP10-03 knowledge<br />
K. Stenzelius, Lund (SE)<br />
10.00 - 10.10 Discussion<br />
10.10 - 10.15 Adherence to fast-track programmes within urology nursing care 2008-<strong>2010</strong><br />
RP10-04 E. Grainger, Århus N (DK)<br />
B.T. Jensen, Århus (DK)<br />
W.A.K. Sahl, Hinnerup (DK)<br />
10.15 - 10.20 Discussion<br />
10.20 - 10.30 Closing<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
373
Monday, 19 April<br />
374 Programme Book<br />
Sponsored Session<br />
10.45 - 11.45 Urological management of Spina bifida during childhood and<br />
adolescence – what happens when entering adulthood?<br />
Birmingham Room<br />
Symposium<br />
Chair: E. Jaureguizar Monereo, Madrid (ES)<br />
10.45 - 11.05 Introduction; Spina bifida– urologic management from childhood to adolescence<br />
E. Jaureguizar Monereo, Madrid (ES)<br />
11.05 - 11.20 Working with children and adolescents with myelomeningocele - what is the role of a pediatric<br />
urotherapist?<br />
M. Vu Minh Arnell, Gothenburg (SE)<br />
11.20 - 11.35 Adults with myelomeningocele - what happened urologically after leaving childhood?<br />
M. Vu Minh Arnell, Gothenburg (SE)<br />
11.35 - 11.45 Discussion<br />
Aim<br />
To convey the importance of good urological management, clean intermittant catheterisation (CIC) training<br />
and education. To discuss that CIC changed the survival of Spina bifida – patients reach adulthood. Discuss<br />
the importance of follow-up on bladder management, independently of age.<br />
Objective<br />
To discuss the urological management of Spina bifida during childhood and adolescence, and raise the issue<br />
concerning what happens when entering adulthood?<br />
Sponsored by ASTRATECH AB
Monday, 19 April<br />
<strong>EAU</strong>N Lectures<br />
12.00 - 12.30 State-of-the-art lecture - Quality of life after cystectomy<br />
Birmingham Room<br />
H. Thulin, Stockholm (SE)<br />
Aims and objectives<br />
How can a cystectomy affect the individual quality of life? The aim of this presentation is to better understand<br />
the daily-life situation in individuals who have undergone a cystectomy. The objectives are to pay attention<br />
to a wide range of symptoms that may occur after a cystectomy and to how we can improve the care in order<br />
to support the affected individuals.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
375
Monday, 19 April<br />
376 Programme Book<br />
Sponsored Session<br />
12.45 - 13.45 Vantas: A nurse’s perspective on the first once-yearly LH-RH agonist<br />
Birmingham Room<br />
Lunch Symposium<br />
Chair: N. Shore, Myrtle Beach (US)<br />
12.45 - 13.05 Vantas: A new era for prostate cancer management<br />
N. Shore, Myrtle Beach (US)<br />
13.05 - 13.25 From theory to practice: A nurse’s experience<br />
A. McCormack, Taunton, Somerset (GB)<br />
13.25 - 13.40 Once-yearly therapy: A patient’s perspective<br />
Guest European patient and consultant<br />
13.40 - 13.45 Concluding remarks<br />
N. Shore, Myrtle Beach (US)<br />
Aims and objectives<br />
During this symposium we will introduce the first once-yearly LH-RH agonist subcutaneous implant<br />
containing histrelin acetate and will discuss its practical use within the nursing community. LH-RH agonists<br />
have become the standard of care for hormonal therapy in the palliative treatment of advanced and<br />
metastatic prostate cancer. However, to date, they have only been available as 1-, 2-, 3- and 6-monthly<br />
preparations. With real-world presentations from the nurse and patient perspective, this will be one of<br />
the first opportunities to learn more about how this new treatment option could benefit both groups as it<br />
becomes available in Europe.<br />
As of 12.30 hrs lunch boxes will be handed out.<br />
Sponsored by ORION PHARMA
Monday, 19 April<br />
<strong>EAU</strong>N Lectures<br />
13.45 - 14.15 <strong>EAU</strong>N General Assembly<br />
Birmingham Room<br />
Chair: B.T. Jensen, Århus (DK)<br />
Agenda<br />
• Welcome by the chair<br />
• Formal installation of new members and chair<br />
• Voting on change of rules Fellowship (dd June 2009)<br />
• Minutes AGM 2009<br />
• The report of the chair with presentation of the achievements of 2009/<strong>2010</strong><br />
• Masterplan, growth targets and budget<br />
• Cooperation with other organisations<br />
• Report on the <strong>Barcelona</strong> meeting with national societies<br />
• Subjects for the next <strong>Congress</strong> in 2011 in Vienna<br />
• Proposals from the members<br />
• Other business<br />
14.15 - 15.00 State-of-the-art lecture - Managing erectile dysfunction and quality<br />
of life<br />
Birmingham Room<br />
J. Albaugh, Chicago (US)<br />
Aim<br />
This presentation will explore the underlying causes of erectile dysfunction, in particular neuropraxia<br />
and cavernosal changes after radical prostatectomy. In addition, the various treatment options for erectile<br />
dysfunction and for penile rehabilitation after prostatectomy will be reviewed. The impact of erectile<br />
dysfunction on quality of life will also be discussed.<br />
Objectives<br />
- Identify some underlying diseases that may contribute to erectile dysfunction<br />
- Describe the treatment options for erectile dysfunction after radical prostatectomy<br />
- Discuss the impact of erectile dysfunction after radical prostatectomy on quality of life<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
377
Monday, 19 April<br />
378 Programme Book<br />
Abstract Session<br />
15.15 - 16.30 Oral Session<br />
Birmingham Room<br />
Chairs: V. Geng, Lobbach (DE)<br />
U.L.M. Haase, Nieuwegein (NL)<br />
O1-s Enuresis in children; prevalence and quality of life<br />
S.S. Savaser, N.K.B. Kizilkaya Beji, E.A. Aslan, D.G. Gozen (Istanbul, Turkey)<br />
O2-s Realization of a pediatric pathway in an adult urological division: a bet for nurse<br />
C.F. Ferrero, D.D.C.D. Da Costa Duarte, E.C. Cecchelli, M.T. Trabucatto, C.V. Villanova, Z. Trajkov, P.D. Denarier,<br />
P.P. Pierini, E.B. Baldassarre (Aosta, Italy)<br />
O3-s Withdrawn<br />
O4-s Fears, pain and anxiety during bilateral vasectomy under local anaesthesia<br />
M. Marin, N. Juarez, R. Alarcon, A. Paez, R. Valiente, B. Sandin, R. Ruiz, S. Nuñez (Fuenlabrada, Madrid,<br />
Madrid, Spain)<br />
O5-s Nursing trainee ward for urology patients<br />
W.C. Jansen (Amsterdam, The Netherlands)<br />
O6-s Efficacy of tele-nursing consultations after radical prostatectomy<br />
B.T. Jensen, S. Kristensen, M. Borre (Århus, Denmark)<br />
O7-s Living with incurable prostate cancer - The wifes perspective<br />
P. Bruun, B.D. Pedersen, P.J. Osther, L. Wagner (Odense, Fredericia, Denmark)<br />
O8-p Does clamping of the hematuria catheter before removal decrease the feeling of unpleasantness and<br />
increase satisfactory voiding in patients who have undergone transurethral resection of the prostate?<br />
A. Hjuler (Randers Nø, Denmark)<br />
O9-p Assessment of nurses’ support program for self-removal of ureteral stents with external strings by<br />
patients at their home guided by telephonic assistance<br />
A. Shafir, N. Yarsko, T. Bar-Adon (Tel-Aviv, Israel)<br />
O10-s Profile of urology nurses in Turkey<br />
A.O. Ozbas, E.A. Aslan, N.K. Kanan (Istanbul, Turkey)<br />
Abstract code explanation<br />
O : Oral abstract<br />
p : Daily practice<br />
s : Scientific research
Monday, 19 April<br />
<strong>EAU</strong>N Lectures<br />
16.45 - 17.15 State-of-the-art lecture - The importance of patient positioning and<br />
safety on a urology OR<br />
Birmingham Room<br />
K. Fitzpatrick, Dublin (IE)<br />
Aims and objectives<br />
Perioperative personnel become advocates for the anaesthetised patients. Much is written about the<br />
psychological aspects and pain management of patients undergoing surgery. However the physical stress<br />
imposed on the body during surgery is often underestimated. I hope through this talk to demonstrate the<br />
importance of positioning safely the patient undergoing the urological surgical intervention.<br />
17.15 - 17.30 Award session<br />
Birmingham Room<br />
Chair: B.T. Jensen, Århus (DK)<br />
Aims and objectives<br />
• Prize for the Best <strong>EAU</strong>N Poster Presentation (Daily Practice)<br />
• Prize for the Best <strong>EAU</strong>N Poster Presentation (Scientific Research)<br />
• Prize for the Best <strong>EAU</strong>N Oral Presentation (Daily Practice)<br />
• Prize for the Best <strong>EAU</strong>N Oral Presentation (Scientific Research)<br />
• Prize for the Best <strong>EAU</strong>N Nursing Research Project<br />
The Prizes for the Best <strong>EAU</strong>N Poster and Oral Presentations are supported by an unrestricted educational<br />
grant from AMGEN<br />
The Prize for the Best <strong>EAU</strong>N Nursing Research Project is supported by an unrestricted educational grant from<br />
FERRING PHARMACEUTICALS<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
379
www.emucbarcelona2011.org<br />
Embracing Excellence<br />
in Prostate, Bladder<br />
and Kidney Cancer<br />
November 2011<br />
<strong>Barcelona</strong>, Spain<br />
3 th European Multidisciplinary Meeting on Urological Cancers organised by:
<strong>EAU</strong> Membership<br />
What are benefits of being<br />
a member of the European<br />
Association of Urology?<br />
As a member of the <strong>EAU</strong> you will benefit from many<br />
advantages included in the membership fees:<br />
Publications<br />
• European Urology, the official scientific<br />
journal of the <strong>EAU</strong> (12 issues per year, plus all<br />
published supplements).<br />
• European Urology Today, the official newsletter<br />
of the <strong>EAU</strong> (6 issues each year). This publications<br />
aims at distributing information about<br />
the Association and about European urology in<br />
the broadest sense.<br />
• European Urology Video Journal, an quarterly<br />
published DVD aiming to distribute the best<br />
information on urological diseases and techniques.<br />
• The <strong>EAU</strong> Urology Updates, a quarterly<br />
published educational publication, published<br />
as a supplement of European urology.<br />
• <strong>EAU</strong> Guidelines, a extensive series of guidelines<br />
on many urological diseases produced by<br />
the <strong>EAU</strong> Health Care Office.<br />
• Historia Urologiae Europaeae (one volume<br />
each year on European historical subjects).<br />
• Uroweb, the official <strong>EAU</strong> website, to which<br />
you as a member have access to all different<br />
activities and programmes on the web, such<br />
as slide library, European Urology on-line,<br />
webcasts of the congress, on-line ESU courses<br />
etc.<br />
<strong>EAU</strong> <strong>Congress</strong> and Meetings<br />
As an <strong>EAU</strong> member you will receive regular information<br />
on the <strong>Annual</strong> <strong>EAU</strong> <strong>Congress</strong>, as well as the<br />
meetings organised by the different <strong>EAU</strong> Sections, the<br />
<strong>EAU</strong> Education Office and the <strong>EAU</strong> Regional Office.<br />
Moreover, as a member you will be able to receive a<br />
considerable discount on the registration fees on all<br />
<strong>EAU</strong> related meetings and events.<br />
<strong>EAU</strong> Education Programme<br />
Being an <strong>EAU</strong> member you will receive regular information<br />
on all the activities organised by the European<br />
School of Urology, the <strong>EAU</strong> Office of Education. You<br />
will be able to participate in the post-graduate<br />
teaching activities at reduced registration fees. As an<br />
<strong>EAU</strong> member you are also entitled to apply for the<br />
European Urological Scholarship Programme, which<br />
provides grants and organises clinical fellowships,<br />
short term visits and scholarship programmes.<br />
EU-ACME Programme<br />
Being an Active and Active International member of<br />
the <strong>EAU</strong> you will be automatically participating in the<br />
European Urology - Accredited Continuing Medical<br />
Education (EU-ACME) Programme. The EU-ACME<br />
Programme is based on the EBU/UEMS rules and its<br />
primary task is the implementation, promotion and<br />
organisation of Continual Medical Education (CME)<br />
among European Urologists. It provides the urologists<br />
with the system which helps them to keep track of<br />
their educational activities, irrespective of the country<br />
they practice in or where they have participated in<br />
CME and/or CPD activities.<br />
So if you are not yet an <strong>EAU</strong> member, make certain<br />
to become one in <strong>Barcelona</strong> and visit the <strong>EAU</strong> Square<br />
(booth B20). For more information see also <strong>page</strong> 384<br />
and 385.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
381
<strong>EAU</strong> Offices<br />
<strong>EAU</strong> Board<br />
Executive Committee<br />
Secretary General<br />
P-A. Abrahamsson, Malmö (SE)<br />
Adjunct Secretary General<br />
Executive Member related to<br />
Science<br />
W. Artibani, Verona (IT)<br />
Adjunct Secretary General<br />
Executive Member related to<br />
Education<br />
C.R. Chapple, Sheffield (GB)<br />
Treasurer and Executive Member<br />
related to Communication<br />
M. Wirth, Dresden (DE)<br />
Board Members<br />
C-C. Abbou, Creteil (FR)<br />
P. Abrams, Bristol (GB)<br />
T. Esen, Istanbul (TR)<br />
F.C. Hamdy, Oxford (GB)<br />
D. Jacqmin, Strasbourg (FR)<br />
H.G. Madersbacher, Innsbruck (AT)<br />
M. Marberger, Vienna (AT)<br />
L. Martínez-Piñeiro, Madrid (ES)<br />
K.F. Parsons, Liverpool (GB)<br />
D. Schultheiss, Giessen (DE)<br />
I.C. Sinescu, Bucharest (RO)<br />
H. Van Poppel, Leuven (BE)<br />
Offices related to<br />
education<br />
<strong>EAU</strong> Education Office (ESU)<br />
Chairman<br />
H. Van Poppel, Leuven (BE)<br />
Members<br />
W. Aulitzky, Vienna (AT)<br />
B. Djavan, New York (US)<br />
G. Janetschek, Salzburg (AT)<br />
Z. Kirkali, Izmir (TR)<br />
J.M. Nijman, Groningen (NL)<br />
J. Palou Redorta, <strong>Barcelona</strong> (ES)<br />
I. Romics, Budapest (HU)<br />
H. Van Der Poel, Amsterdam (NL)<br />
382 Programme Book<br />
Ex-officio Members<br />
L. Martínez-Piñeiro, Madrid (ES)<br />
D. Pushkar, Moscow (RU)<br />
R.J.A. Van Moorselaar,<br />
Amsterdam (NL)<br />
R. Van Velthoven, Brussels (BE)<br />
EU-ACME Office<br />
Chairman<br />
H.G. Madersbacher, Innsbruck (AT)<br />
Members<br />
G.J. Alivizatos, Athens (GR)<br />
C.R. Chapple, Sheffield (GB)<br />
S. Müller, Bonn (DE)<br />
J.M. Nijman, Groningen (NL)<br />
P.J. Nyirády, Budapest (HU)<br />
H. Van Poppel, Leuven (BE)<br />
European Urological Scholarship<br />
Programme Office<br />
Chairman<br />
C-C. Abbou, Creteil (FR)<br />
Members<br />
M. Burchardt, Hanover (DE)<br />
T. Kalogeropoulos, Athens (GR)<br />
V. Mirone, Naples (IT)<br />
N. Sofikitis, Ioannina (GR)<br />
J. Witjes, Nijmegen (NL)<br />
Ex-officio Members<br />
Ex-officio ESUT<br />
A. Mottrie, Aalst (BE)<br />
Ex-officio Residents Office<br />
T. Esen, Istanbul (TR)<br />
Ex-officio Research Foundation<br />
A. Patel, London (GB)<br />
J.A. Schalken, Nijmegen (NL)<br />
Guidelines Office<br />
Chairman<br />
K.F. Parsons, Liverpool (GB)<br />
Members<br />
T. Hánus˛, Prague (CZ)<br />
J. Irani, Poitiers (FR)<br />
T. Loch, Flensburg (DE)<br />
C. Llorente, Madrid (ES)<br />
D.N. Mitropoulos, Athens (GR)<br />
H-P. Schmid, St. Gallen (CH)<br />
R.J. Sylvester, Brussels (BE)<br />
Resident’s Office<br />
Chairman<br />
T. Esen, Istanbul (TR)<br />
Members<br />
M. Emberton, London (GB)<br />
S. Erikson, Norrköping (SE)<br />
S. Keskin, Istanbul (TR)<br />
S. Larré, Oxford (GB)<br />
P. Nunes, Coimbra (PT)<br />
O. Reich, Munich (DE)<br />
E. Serafetinides, Athens (GR)<br />
Offices related to<br />
science<br />
Regional Office<br />
Chairman<br />
M. Marberger, Vienna (AT)<br />
Scientific <strong>Congress</strong> Office<br />
Chairman<br />
F.C. Hamdy, Oxford (GB)<br />
Members<br />
A. Alcaraz, <strong>Barcelona</strong> (ES)<br />
G.A. Bogaert, Leuven (BE)<br />
X. Cathelineau, Paris (FR)<br />
F.R. Cruz, Porto (PT)<br />
I. Eardley, Leeds (GB)<br />
G. Janetschek, Salzburg (AT)<br />
M.S. Michel, Mannheim (DE)<br />
P. Radziszewski, Warsaw (PL)<br />
J.A. Schalken, Nijmegen (NL)<br />
C. Selli, Pisa (IT)<br />
A. Stenzl, Tübingen (DE)<br />
A. De La Taille, Creteil (FR)<br />
G.N. Thalmann, Berne (CH)<br />
B. Tombal, Brussels (BE)<br />
Ex-officio Members<br />
P-A. Abrahamsson, Malmö (SE)<br />
W. Artibani, Verona (IT)<br />
C.R. Chapple, Sheffield (GB)<br />
M. Marberger, Vienna (AT)<br />
L. Martínez-Piñeiro, Madrid (ES)<br />
H. Van Poppel, Leuven (BE)<br />
M. Wirth, Dresden (DE)
Video <strong>Congress</strong> Committee<br />
Chairman<br />
R.J.A. Van Moorselaar,<br />
Amsterdam (NL)<br />
Members<br />
P. Albers, Düsseldorf (DE)<br />
P. Geavlete, Bucharest (RO)<br />
I.J. De Jong, Groningen (NL)<br />
A. Messas, Nanterre (FR)<br />
M. Zerbib, Paris (FR)<br />
Section Office<br />
Chairman<br />
L. Martínez-Piñeiro, Madrid (ES)<br />
Chairmen Sections<br />
ESAU: V. Mirone, Napels (IT)<br />
ESFFU: J. Heesakkers,<br />
Nijmegen (NL)<br />
ESGURS: S. Deger, Berlin (DE)<br />
ESIU: T.E. Bjerklund Johansen,<br />
Århus (DK)<br />
ESOU: V. Ravery, Paris (FR)<br />
ESTU: M. Giessing,<br />
Düsseldorf (DE)<br />
ESUI: J. Walz, Marsseille (FR)<br />
ESUP: G. Mikuz, Innsbruck (AT)<br />
ESUR: A. Bjartell, Malmö (SE)<br />
ESUT: J. Rassweiler,<br />
Heilbronn (DE)<br />
EULIS: P. Osther,<br />
Fredericia (DK)<br />
Offices related to<br />
communication<br />
History Office<br />
Chairman<br />
D. Schultheiss, Giessen (DE)<br />
Members<br />
C. Alamanis, Athens (GR)<br />
J. Elo, Helsinki (FI)<br />
R.M.E. Engel, Linthicum (US)<br />
L.A. Fariña, Vigo (ES)<br />
J. Felderhof, The Hague (NL)<br />
P.P. Figdor, Vienna (AT)<br />
A. Jardin, Paris (FR)<br />
P. Marandola, Torre D’Isola (IT)<br />
J.J. Mattelaer, Kortrijk (BE)<br />
S. Musitelli, Pavia (IT)<br />
P. Rathert, Düren (DE)<br />
I. Romics, Budapest (HU)<br />
M. Skopec, Vienna (AT)<br />
R. Sosnowski, Warsaw (PL)<br />
A. Verit, San Liurfa (TR)<br />
Offices related to the<br />
governance<br />
International Relations Office<br />
Chairman<br />
D. Jacqmin, Strasbourg (FR)<br />
Consultants<br />
P. Alken, Mannheim (DE)<br />
C. Llorente, Madrid (ES)<br />
V. Mirone, Napels (IT)<br />
A. Patel, London (GB)<br />
Membership Office<br />
Chairman<br />
I.G. Sinescu, Bucharest (RO)<br />
Strategy Planning Office<br />
Chairman<br />
P. Abrams, Bristol (GB)<br />
Members<br />
M. Brausi, Modena (IT)<br />
S. Buntrock, Lubeck (DE)<br />
T. Ebert, Fürth (DE)<br />
H. Hashim, London (GB)<br />
H.G. Tiselius, Stockholm (SE)<br />
J-J. Wyndaele, Antwerp (BE)<br />
Additional<br />
<strong>EAU</strong> Foundation for Urological<br />
Research<br />
Chairman<br />
P. Mulders, Nijmegen (NL)<br />
Members<br />
A. Patel, London (GB)<br />
J.A. Schalken, Nijmegen (NL)<br />
A. Tubaro, Rome (IT)<br />
B. Watson, Dublin (IE)<br />
W. Witjes, Arnhem (NL)<br />
Ex-officio Member<br />
C-C. Abbou, Creteil (FR)<br />
Academy of Urology<br />
Chairman<br />
A. Le Duc, Paris (FR)<br />
Members<br />
R. Ackermann, Düsseldorf (DE)<br />
L. Boccon-Gibod, Paris (FR)<br />
P. Van Cangh, Brussels (BE)<br />
F. Debruyne, Arnhem (NL)<br />
P.E. Ekman, Stockholm (SE)<br />
U. Jonas, Hanover (DE)<br />
H-J. Leisinger, Jouxtens (CH)<br />
R. Vela-Navarrete, Madrid (ES)<br />
European Urology<br />
Offical journal of the <strong>EAU</strong><br />
Editor in chief<br />
M. Francesco Montorsi, Milan (IT)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
383
Accreditation<br />
CME Accreditation statement<br />
The 25 th Anniversary <strong>EAU</strong> <strong>Congress</strong> is accredited by<br />
the European Board of Urology in compliance with the<br />
UEMS/EACCME regulations – 1 European CME credit<br />
per 1 hour with a maximum of 6 European CME credits<br />
per day. The EBU works according to the quality<br />
standards of the European Accreditation Council for<br />
Continuing Medical Education (EACCME).<br />
Both the EBU and the EACCME are the institutions of<br />
the European Union of Medical Specialists (UEMS),<br />
www.uems.net<br />
For detailed information, please go to<br />
www.eaubarcelona<strong>2010</strong>.org<br />
Number of credits per country<br />
All CME activities approved by the EBU/EACCME are<br />
valid for recognition in the following countries:<br />
Austria, Belgium, Cyprus, Denmark, Finland, Georgia,<br />
Greece, Hungary, Ireland, Latvia, Luxembourg, Malta,<br />
The Netherlands, Norway, Region Lombardia, Romania,<br />
Slovakia, Slovenia, Spain, Sweden, Turkey<br />
Number of credits per speciality<br />
All CME activities approved by the EBU/EACCME are<br />
valid for recognition in the following specialities:<br />
Dermatology & Venerolog, Paediatric Surgery, Physical<br />
and Rehabilitation Medicine, Anaesthesiology,<br />
Child and Adolescent Psychiatry and Psychotherapy,<br />
Endocrinology, Geriatrics, Intensive Care (MJC),<br />
Internal Medicine, Neurology, Neurosurgery, Nuclear<br />
Medicine, Oral and Maxillofacial Surgery, Pathology,<br />
Plastic Surgery, Cardiology (EBAC), Sports Medicine<br />
(MJC), Genetics (MJC), Microbiology, Pneumology<br />
(EBAP), Infectious Diseases (EBAID), Surgery, Urology,<br />
Oncology (ACCO)<br />
384 Programme Book<br />
If your country or speciality is not listed above please<br />
either contact the EU-ACME office for more information<br />
by e-mail, fax or phone or send the copy of the<br />
certificate of attendance to your National Urological<br />
Society and/or National Accreditation Body.<br />
You will find the EU-ACME information desk in the<br />
registration are.<br />
Recognition by the AMA<br />
All CME activities approved by the EBU/EACCME<br />
are valid for recognition by the American Medical<br />
Association towards the Physician’s Recognition Award<br />
(PRA). To convert EACCME credit to AMA PRA category<br />
1 credit, contact the AMA.<br />
Certificate of attendance<br />
All Certificates of Attendance (attendance certificates<br />
and ESU course certificates) for the 25th Anniversary<br />
<strong>EAU</strong> <strong>Congress</strong> can either be printed in the registration<br />
area during the last two days of the congress or<br />
online after the meeting at www.eaubarcelona<strong>2010</strong>.<br />
org. To print your Certificate of Attendance online, you<br />
need your <strong>EAU</strong> ID card number. You can print your<br />
Certificates of Attendance at any time as this online<br />
service is permanently available.<br />
Overview of attended sessions<br />
As of (day or date) you may print online at www.<br />
eaubarcelona<strong>2010</strong>.org an overview of the attended<br />
sessions which you may send to your National<br />
Urological Society and/or National Accreditation Body<br />
together with a copy of the Certificate of Attendance.<br />
Please do not forget to scan your <strong>EAU</strong> Id Card when<br />
entering the sessions!
EU-ACME Programme<br />
The EU-ACME Programme - the initiative resulting<br />
from a close collaboration between the European<br />
Board of Urology (EBU) and the European Association<br />
of Urology (<strong>EAU</strong>) - stands for European Urology -<br />
Accredited Continuing Medical Education. Its primary<br />
task is assistance in the implementation, promotion<br />
and organization of Continuing Medical Education<br />
(CME) and Continuing Professional Development (CPD)<br />
among European urologists. Urologists have access to<br />
an online system - in compliance with the EBU/UEMS<br />
regulations - which helps them to keep track of their<br />
educational activities, irrespective of the country they<br />
practice in or where they have participated in accredited<br />
CME/CPD activities.<br />
CME/CPD activities are generally geared towards<br />
practising physicians and are designed to provide<br />
information that is both relevant and essential to<br />
medical practice.<br />
The EU-ACME office acts as a central ‘institution’<br />
where all information forwarded by urologists, (inter)<br />
national urological associations and CME organisers/<br />
providers is kept.<br />
As a service institution the EU-ACME office offers:<br />
• registration of credit points for members of the<br />
urological society participating in the EU ACME<br />
programme,<br />
• access to the online CME/CPD credit system via<br />
web<strong>page</strong> www.eu-acme.org,<br />
• the EU ACME membership card for urologist participating<br />
in the programme,<br />
• yearly Credit Registry Report listing all collected<br />
CME/CPD credit points,<br />
• registration of accredited on national and/or<br />
European level CME events,<br />
• assistance in obtaining European Accreditation.<br />
The international urological societies as European<br />
Association of Urology, European Society of Paediatric<br />
Urology and International Continence Society as well<br />
as national urological societies from: Austria, Bulgaria,<br />
Czech Republic, Cyprus, Denmark, Estonia, Finland,<br />
Greece, Hungary, Italy, Latvia, Malta, The Netherlands,<br />
Norway, Poland, Romania, Serbia, Slovakia, Slovenia,<br />
Spain, Turkey have already joined the programme.<br />
For more information, please visit the website: www.<br />
eu-acme.org.<br />
Information on the EU-ACME programme, your<br />
acquired CME/CPD credits and membership cards can<br />
be obtained at the EU-ACME information desk in the<br />
registration are.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
385
Join the European Association of Urology,<br />
become a member,<br />
get involved!<br />
The <strong>EAU</strong> is the voice of European Urologists, a non-profit scientific organisation<br />
dedicated to serving their members and representing their professional interests!<br />
Learn about the many benefits of being a member of the European Association of<br />
Urology.<br />
Free subscriptions to:<br />
l <strong>EAU</strong> Scientific journal: European Urology, Supplements, <strong>EAU</strong>-EBU Update Series<br />
l <strong>EAU</strong> Newsletter: European Urology Today<br />
l European Urology Video Journal<br />
l Historia Urologiae Europaeae<br />
l <strong>EAU</strong> Guidelines<br />
l Member Discounts on <strong>EAU</strong> products and services<br />
l Registration benefits for <strong>EAU</strong> meetings<br />
The <strong>EAU</strong> have a number of membership categories catering to all professionals<br />
involved in the speciality of urology. We invite you to become a member today!<br />
www.uroweb.org
The <strong>EAU</strong> presents interesting recent developments in the field of education and technological<br />
innovations. Education & Innovation offers you a hands-on experience with exciting devices, such as<br />
virtual simulators, 3D anatomy and the newest technologies.<br />
Visit Education & Innovation in the Exhibition Hall, booth B30.<br />
We would like to thank the participating organisations for their support: KArl STorz GmBH & Co. KG,<br />
PrImAl PICTUrES lTD., SImBIonIx, SImEnDo, Dr. TEBEr from HEIlBronn ClInIC (DE)
Floorplan<br />
<strong>EAU</strong> Exhibition Hall 8 level 1<br />
A37 A30 B29<br />
FAU<br />
A35<br />
SMU<br />
A33<br />
AUA<br />
Tex- MCube<br />
tile<br />
Hi- B27<br />
Tec iSurgicals<br />
A31<br />
CUA<br />
A28 B25 B20<br />
Pergen- Istem<br />
tium Medikal<br />
A29<br />
ICS-<br />
IUGA<br />
A27<br />
ISSM/<br />
ICUD<br />
A26 B23<br />
SIU<br />
Prosurg<br />
Italia<br />
B21<br />
Trime-<br />
A24 dyne<br />
A25<br />
EndoControl &<br />
Koelis<br />
B19<br />
USI<br />
ISMH<br />
A23<br />
Europa<br />
Uomo<br />
A22 B17<br />
Miro<br />
Med Kessel<br />
A21<br />
Silimed<br />
A19<br />
Dyna-<br />
Mesh<br />
A17<br />
Socomed/<br />
Rocamed<br />
A15<br />
Bard<br />
A09<br />
SIU<br />
A07<br />
Beckman<br />
Coulter<br />
A01<br />
medac<br />
A16<br />
Galil<br />
Medical<br />
B16<br />
C30 D27<br />
AST Physion<br />
C28 D25<br />
Prous<br />
Science Teleflex<br />
Medical<br />
C26<br />
D21<br />
Leica<br />
D19<br />
C22 Urotech<br />
Pnn D17<br />
Medical Synergo-<br />
MEL<br />
A14 B14 C10 D08<br />
Kyowa Hakko Kirin<br />
A10<br />
A06<br />
A02<br />
Gen-Probe<br />
Boston Scientific<br />
388 Programme Book<br />
B30 C32 D29<br />
Lenus ProUro-<br />
Pharma Care<br />
Education & Innovation<br />
<strong>EAU</strong><br />
Historical Exhibition<br />
Research Foundation<br />
<strong>EAU</strong> 2011 Vienna<br />
EBU<br />
ESRU<br />
Bayer Schering Pharma<br />
B10<br />
B06<br />
B02<br />
Medtronic<br />
Kitalpha<br />
Med<br />
ERBE<br />
B. BRAUN<br />
Aesculap<br />
C02<br />
Neo-<br />
Tract<br />
C18<br />
D15<br />
Aspide Pro-<br />
Medical surgics<br />
Bayer<br />
Schering<br />
Pharma<br />
Intuitive<br />
Surgical<br />
Hospitality<br />
Suite<br />
D30<br />
D26<br />
Uromed<br />
E25<br />
D24<br />
Ameco E19<br />
Medical<br />
Systems<br />
Aymed<br />
D20<br />
Covidien<br />
D18 E17<br />
Laser<br />
Peri- T-DOC<br />
pherals<br />
D14<br />
D06<br />
D02<br />
Inverness<br />
Medical<br />
Promedon<br />
Vision<br />
Sciences<br />
Karl Storz<br />
Storz Medical<br />
E32 E36 F29 F30<br />
Inter-<br />
Allergan national<br />
HIFU Quanta<br />
Medical<br />
E26 E30 System Measurement<br />
Anatomy<br />
Systems<br />
for ESSM<br />
Urology<br />
E24 F23<br />
E14<br />
Pfizer<br />
E08<br />
Hitachi<br />
Amgen<br />
Ferring<br />
Orion Pharma<br />
F22<br />
F14<br />
G26<br />
G14<br />
F08 G08<br />
F02<br />
LABORIE<br />
GE Healthcare<br />
Pierre<br />
Fabre<br />
Médicament<br />
Astellas<br />
G30 H29<br />
Endocare<br />
Arizant<br />
Healthcare<br />
H21<br />
G22<br />
Direx-<br />
Initia<br />
Bio<br />
G20 Wiley-B<br />
G18 Wisepre<br />
G06<br />
G02<br />
M<br />
w<br />
H27<br />
In<br />
Su<br />
H23<br />
E<br />
Dornie<br />
MedTec<br />
C<br />
Me<br />
Oly<br />
Novartis
F30<br />
Medical<br />
Measurement<br />
Systems<br />
F22<br />
GE Healthcare<br />
F14<br />
Pierre<br />
Fabre<br />
Médicament<br />
BORIE<br />
Astellas<br />
G30 H29<br />
Endocare<br />
G26<br />
Arizant<br />
Healthcare<br />
H21<br />
G22<br />
Direx-<br />
Initia<br />
Bioniche<br />
G20 Wiley-Blackwell<br />
G18 Wisepress<br />
G14<br />
G08<br />
G06<br />
G02<br />
Mediwatch<br />
H27<br />
Integra<br />
Surgical<br />
H23<br />
EMS<br />
Dornier<br />
MedTech<br />
Cook<br />
Medical<br />
Olympus<br />
Novartis Oncology<br />
H30<br />
H20 I19<br />
H14<br />
<strong>EAU</strong><br />
Digital<br />
Video<br />
Library<br />
Berlin-<br />
Chemie<br />
EDAP TMS<br />
H06<br />
H04<br />
I15<br />
Coloplast<br />
Medispec<br />
Albyn<br />
Medical<br />
Eli Lilly<br />
and<br />
Company<br />
I30<br />
H02 I02<br />
Ipsen<br />
Hospitality<br />
Suite<br />
Star<br />
Med<br />
Tec<br />
J29<br />
I26 J27<br />
ELMED<br />
Lumenis<br />
I22<br />
Astra<br />
Tech<br />
J25<br />
biolitec<br />
Pajunk<br />
I14 J14<br />
I08 J07<br />
Sanofi<br />
Pasteur<br />
J26<br />
J08<br />
I06 J06<br />
J30<br />
Neomedic<br />
K31 K33 K35<br />
HRA<br />
Research<br />
Vitacon LISA<br />
laser<br />
K27<br />
Allium<br />
K29<br />
Zephyr<br />
Recordati Janssen-Cilag<br />
sanofiaventis<br />
Rottapharm I Madaus<br />
GlaxoSmithKline<br />
J02<br />
K25<br />
Siemens<br />
K15<br />
Takeda<br />
Pharmaceuticals<br />
Europe Ltd<br />
Richard Wolf<br />
American<br />
Medical<br />
Systems<br />
BK Medical<br />
AMD<br />
K28<br />
RUDOLF<br />
MEDICAL<br />
K24<br />
Life-Tech<br />
K22<br />
Time<br />
Research<br />
K20<br />
K.F.F.<br />
K18<br />
Limmer<br />
Laser<br />
K16<br />
Elsevier<br />
K14<br />
Andromeda<br />
K08<br />
K06<br />
INTERmedic<br />
K04<br />
KLS<br />
Martin<br />
Group<br />
K02<br />
A.M.I.<br />
C atering<br />
A r<br />
e<br />
a<br />
H ospitality<br />
S u<br />
i<br />
t<br />
e s<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
389
Alphabetical list of Exhibitors<br />
Company Booth nr.<br />
A<br />
A.M.I. GMBH. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .K08<br />
ADVANCED MEDICAL DIAGNOSTICS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .K15<br />
ALBYN MEDICAL ............................................................................................................I15<br />
ALLERGAN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E32<br />
ALLIUM LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K27<br />
AMECO MEDICAL SYSTEMS ...............................................................................................D24<br />
AMERICAN MEDICAL SYSTEMS, INC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .J02<br />
AMERICAN UROLOGICAL ASSOCIATION (AUA) ..........................................................................A33<br />
AMGEN (EUROPE) GMBH .................................................................................................E08<br />
ANATOMY FOR UROLOGY-PRIMAL PICTURES LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E26<br />
ANDROMEDA MEDIZINISCHE SYSTEME GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .K14<br />
ARIZANT HEALTHCARE ....................................................................................................G26<br />
ASPIDE MÉDICAL .......................................................................................................... C18<br />
AST GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C30<br />
ASTELLAS PHARMA EUROPE LTD. ........................................................................................F02<br />
ASTRA TECH AB . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . I22<br />
AYMED MEDICAL TECHNOLOGY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .E19<br />
B<br />
B. BRAUN AESCULAP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B02<br />
BARD LIMITED . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A15<br />
BAYER SCHERING PHARMA AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B16 & C10<br />
BECKMAN COULTER, INC. .................................................................................................A07<br />
BERLIN-CHEMIE AG .......................................................................................................H20<br />
BIOLITEC AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .J29<br />
BIONICHE PHARMA GROUP LTD .........................................................................................H21<br />
BK MEDICAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .K15<br />
BOSTON SCIENTIFIC .......................................................................................................A02<br />
BRITISH JOURNAL OF UROLOGY INTERNATIONAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .G20<br />
C<br />
CHINESE UROLOGICAL ASSOCIATION (CUA) ............................................................................. A31<br />
COLOPLAST .................................................................................................................H06<br />
COOK MEDICAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .G08<br />
COVIDIEN. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .D20<br />
D<br />
DIREX - INITIA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G22<br />
DORNIER MEDTECH EUROPE GMBH .....................................................................................G14<br />
DYNAMESH-FEG TEXTILTECHNIK MBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A19<br />
E<br />
<strong>EAU</strong> .........................................................................................................................B20<br />
<strong>EAU</strong> DIGITAL VIDEO LIBRARY .............................................................................................H30<br />
<strong>EAU</strong> HISTORICAL EXHIBITION ............................................................................................B20<br />
<strong>EAU</strong> RESEARCH FOUNDATION ............................................................................................B20<br />
<strong>EAU</strong> VIENNA 2011 .........................................................................................................B20<br />
EUROPEAN BOARD OF UROLOGY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .B20<br />
390 Programme Book
EDAP TMS ..................................................................................................................H14<br />
EDUCATION & INNOVATION ..............................................................................................B30<br />
ELI LILLY AND COMPANY ..................................................................................................H04<br />
ELMED LITHOTRIPSY SYSTEMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .I26<br />
ELSEVIER ...................................................................................................................K16<br />
EMS ELECTRO MEDICAL SYSTEMS .......................................................................................H23<br />
ENDOCARE, INC. ..........................................................................................................G30<br />
ENDOCONTROL ...........................................................................................................A25<br />
ERBE ELEKTROMEDIZIN GMBH ..........................................................................................B06<br />
ESRU (EUROPEAN SOCIETY FOR RESIDENTS IN UROLOGY) ............................................................B20<br />
ESSM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E30<br />
EUROPA UOMO ............................................................................................................A23<br />
EUROPEAN UROLOGY .....................................................................................................K02<br />
F<br />
FAU (FEDERACION ARGENTINA DE UROLOGIA) ........................................................................A37<br />
FERRING INTERNATIONAL CENTER S.A. ..................................................................................E14<br />
G<br />
GALIL MEDICAL ............................................................................................................A16<br />
GE HEALTHCARE ........................................................................................................... F22<br />
GEN-PROBE INCORPORATED .............................................................................................A10<br />
GLAXOSMITHKLINE .........................................................................................................I02<br />
H<br />
HITACHI MEDICAL SYSTEMS EUROPE HOLDING AG. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . E24<br />
HRA RESEARCH ............................................................................................................K31<br />
I<br />
ICS-IUGA <strong>2010</strong> .............................................................................................................A29<br />
INTEGRA SURGICAL .......................................................................................................H27<br />
INTERMEDIC ..............................................................................................................K06<br />
INTERNATIONAL HIFU .....................................................................................................E36<br />
INTERNATIONAL SOCIETY FOR SEXUAL MEDICINE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A27<br />
INTERNET CORNER .................................................................................................A06 & J26<br />
INTUITIVE SURGICAL, INC. ................................................................................................C02<br />
INVERNESS MEDICAL .....................................................................................................D30<br />
IPSEN .......................................................................................................................H02<br />
ISMH (INTERNATIONAL SOCIETY FOR MEN’S HEALTH & GENDER) ....................................................B19<br />
ISTEM MEDIKAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B25<br />
ISURGICALS ................................................................................................................B27<br />
J<br />
JANSSEN-CILAG EMEA .....................................................................................................J14<br />
K<br />
KARL STORZ GMBH & CO. KG ............................................................................................D08<br />
KESSEL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .B17<br />
K.F.F. ........................................................................................................................K20<br />
KITALPHA MED LTD ........................................................................................................B10<br />
KLS MARTIN GROUP ......................................................................................................K04<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
391
Alphabetical list of Exhibitors<br />
KOELIS ......................................................................................................................A25<br />
KYOWA HAKKO KIRIN UK LTD. ............................................................................................A14<br />
L<br />
LABORIE ...................................................................................................................F08<br />
LASER PERIPHERALS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D18<br />
LEICA MICROSYSTEMS (SCHWEIZ) AG ................................................................................... D21<br />
LENUS PHARMA GESMBH ................................................................................................C32<br />
LIFE-TECH INTERNATIONAL ..............................................................................................K24<br />
LIMMER LASER GMBH ....................................................................................................K18<br />
LISA LASER PRODUCTS ...................................................................................................K35<br />
LUMENIS DEUTSCHLAND GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . J27<br />
M<br />
MCUBE TECHNOLOGY .....................................................................................................B29<br />
MEDAC GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A01<br />
MEDICAL MEASUREMENT SYSTEMS B.V. ................................................................................F30<br />
MEDISPEC LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . I19<br />
MEDIWATCH PLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .H29<br />
MEDTRONIC INTERNATIONAL TRADING SÀRL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . B14<br />
MIROMED PFLEIDERER GMBH ...........................................................................................A22<br />
N<br />
NEOMEDIC INTERNATIONAL S.L. ..........................................................................................J30<br />
NEOTRACT .................................................................................................................C26<br />
NOVARTIS ONCOLOGY .....................................................................................................G02<br />
O<br />
OLYMPUS MEDICAL SYSTEMS EUROPA GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .G06<br />
ORION PHARMA ........................................................................................................... F23<br />
P<br />
PAJUNK GMBH ..............................................................................................................J25<br />
PERGENTIUM ..............................................................................................................A28<br />
PFIZER FRANCE ...........................................................................................................D02<br />
PHYSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D27<br />
PIERRE FABRE MÉDICAMENT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .F14<br />
PNN MEDICAL A/S ........................................................................................................C22<br />
PROMEDON S.A. ..........................................................................................................E25<br />
PROSURG, INC .............................................................................................................B23<br />
PROSURGICS ............................................................................................................... D15<br />
PROUROCARE MEDICAL INC. .............................................................................................D29<br />
PROUS SCIENCE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . C28<br />
Q<br />
QUANTA SYSTEM SPA .....................................................................................................F29<br />
R<br />
RECORDATI ..................................................................................................................I14<br />
ROTTAPHARM | MADAUS ..................................................................................................I06<br />
RUDOLF MEDICAL GMBH + CO. KG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . K28<br />
392 Programme Book
S<br />
SANOFI-AVENTIS ...........................................................................................................J07<br />
SANOFI PASTEUR ...........................................................................................................I08<br />
SIEMENS AG HEALTHCARE SECTOR ......................................................................................K25<br />
SILIMED LTDA .............................................................................................................. A21<br />
SIU ITALIA ..................................................................................................................A26<br />
SOCIEDAD MEXICANA DE UROLOGIA (SMU) ............................................................................A35<br />
SOCIÉTÉ INTERNATIONALE D’UROLOGIE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A09<br />
SOCOMED & ROCAMED GROUP PROMEPLA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A17<br />
STARMEDTEC GMBH . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .I30<br />
STORZ MEDICAL AG .......................................................................................................D06<br />
SYNERGO-MEDICAL ENTERPRISES .......................................................................................D17<br />
T T-DOC COMPANY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .E17<br />
TAKEDA PHARMACEUTICALS EUROPE LTD . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .J08<br />
TELEFLEX MEDICAL EUROPE LTD. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D25<br />
TEXTILE HI-TEC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .A30<br />
TIME RESEARCH LIMITED .................................................................................................K22<br />
TRIMEDYNE, INC. .......................................................................................................... B21<br />
U UROLOGICAL SOCIETY OF INDIA (USI) ...................................................................................A24<br />
UROMED KURT DREWS GMBH ...........................................................................................D26<br />
UROTECH GMBH. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D19<br />
V VISION-SCIENCES, INC. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . D14<br />
VITACON AS ................................................................................................................K33<br />
W WILEY-BLACKWELL ........................................................................................................G20<br />
WISEPRESS ONLINE BOOKSHOP . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G18<br />
RICHARD WOLF GMBH .....................................................................................................J06<br />
Z<br />
ZEPHYR SURGICAL IMPLANTS ............................................................................................K29<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
393
Company and Product Description<br />
A.M.I. GMBH<br />
Im Letten 1, 6800 Feldkirch, Austria<br />
T : +43 5522 90505 0<br />
F : +43 5522 90505 4006<br />
W : www.ami.at<br />
E : info@ami.at<br />
Booth nr. : K08<br />
A.M.I. is dedicated to designing ingenious surgical instruments,<br />
as well as developing innovative solutions<br />
for treating a variety of common afflictions including<br />
haemorrhoids, obesity and incontinence. In addition<br />
to the adjustable TVA/TOA Slings for female stress urinary<br />
incontinence and ATOMS System for male stress<br />
urinary incontinence, we also offer a advanced pelvic<br />
floor repair system comprising a range of slings and<br />
meshes to cover a variety of pelvic floor disorders.<br />
ADVANCED MEDICAL DIAGNOSTICS<br />
Waterloo Office Park, Bat. I Bte 3, Drève Richelle 161,<br />
1410 Waterloo, Belgium<br />
T : +32 2 352 80 30<br />
F : +32 2 352 80 49<br />
W : www.histoscanning.com<br />
E : info@histoscanning.com<br />
Booth nr. : K15<br />
Advanced Medical Diagnostics (AMD) will be exhibiting<br />
Prostate HistoScanning, a proprietary tissue characterization<br />
technology developed to differentiate, characterize<br />
and visualize Prostate tissue based on analysis<br />
of backscattered ultrasound. HistoScanning can aid<br />
physicians in treatment selection, individual treatment<br />
planning, and triaging for Active Surveillance in<br />
patients diagnosed with prostate cancer.<br />
Prostate HistoScanning is released in Europe.<br />
HistoScanning for breast, thyroid and ovaries is in<br />
development.<br />
AMD is committed to providing innovative computeraided<br />
solutions to improve the diagnostic interpretation<br />
of ultrasound scans.<br />
ALBYN MEDICAL<br />
Polígono Industrial Cordovilla, 31191 Cordovilla -<br />
Navarra, Spain<br />
T : +34 948 29 33 24<br />
F : +34 948 29 34 18<br />
W : www.albynmedical.com<br />
E : sales@albynmedical.com<br />
Booth nr. : I15<br />
Established in 1985, Albyn Medical has extensive<br />
394 Programme Book<br />
experience in the design and manufacture of innovative<br />
Urodynamics equipment and consumables. With<br />
facilities in Spain and the U.K. and with a network of<br />
international distributors, we offer excellent worldwide<br />
support.<br />
At the <strong>EAU</strong> <strong>Barcelona</strong> we will present:<br />
New SmartDyn Wireless Urodynamics Systems<br />
SmartFlow Wireless Urine Flowmeter<br />
Urodynamics catheters and consumables<br />
New BioSmart Biofeedback System<br />
Please visit our booth to discuss your requirements<br />
with a product specialist.<br />
ALLERGAN<br />
Allergan Limited Marlow International, The Parkway,<br />
Marlow, SL7 1YL Buckinghamshire, United Kingdom<br />
T : +44 1628 494 444<br />
F : +44 1628 494 449<br />
W : www.allergan.co.uk<br />
Booth nr. : E32<br />
Allergan, Inc.<br />
Our pursuit is to discover, develop and commercialise<br />
innovative products that help people live fuller lives.<br />
Helping them see more clearly, move more freely and<br />
express themselves more fully. We do this by listening<br />
to, discussing with and acting upon the unmet needs<br />
of the medical world. It’s this strategy that’s driven our<br />
ongoing urology research and development.<br />
We measure success by the numbers of doctors and<br />
patients who place their trust in our products to enhance<br />
life’s potential.<br />
ALLIUM LTD<br />
2 Ha-Eshel St. P.O. Box 3081, 38900 Caesarea Industrial<br />
Park (South), Israel<br />
T : +972 462 77 166 Ext. 104<br />
F : +972 462 77 266<br />
W : www.allium-medical.com<br />
E : info@allium-medical.com<br />
Booth nr. : K27<br />
Allium develops the latest generation of site-specific<br />
stents, for non-vascular and peripheral vascular applications<br />
based on a proprietary technology platform.<br />
This technology makes it possible to build stents<br />
with different shapes complying with the shape and<br />
function of the organ. These self-expanding metal<br />
stents are fully covered with a proprietary co-polymer<br />
and have a unique unraveling feature for its safe and<br />
easy removal. For urological applications Allium has
focused on stents for the Prostate, Bulbar Urethra,<br />
Bladder-neck and lower Ureter as the first applications.<br />
The company received CE mark certification for<br />
all its stents. Allium stents are distributed all over<br />
Europe and South Africa through a chain of distributors.<br />
AMECO MEDICAL SYSTEMS<br />
Industrial Area B4-Plot 119# East, 44629 10th Ramadan<br />
City, Egypt<br />
T : +20 15 38 30 66<br />
F : +20 15 38 30 68<br />
W : www.amecath.com<br />
E : dr.bahr@amecath.com<br />
Booth nr. : D24<br />
Amecath mission is to build confidence by providing<br />
physician with easily introduced and free of complications<br />
consumables, to provide care for the patient by<br />
supplying excellent Quality, minimizing risk of side effects<br />
and to decrease cost of products to supply agents<br />
with best compatible prices. Amecath is taking care of<br />
the physician, patient & agent.<br />
AMERICAN MEDICAL SYSTEMS, INC<br />
10700 Bren Road West, MN 55343 Minnetonka, United<br />
States of America<br />
T : +1 952 930 6000<br />
F : +1 952 930 6157<br />
W : www.AmericanMedicalSystems.com<br />
E : info@AmericanMedicalSystems.com<br />
Booth nr. : J02<br />
American Medical Systems is a world leader in medical<br />
devices and procedures that treat four major<br />
diseases: incontinence, erectile dysfunction, vaginal<br />
vault prolapse and benign prostatic hyperplasia. Any<br />
one of these conditions can profoundly diminish a<br />
patient’s quality of life and significantly impact relationships.<br />
Our products provide a cure or reduce the<br />
incapacitating effects of these diseases, often through<br />
minimally invasive surgery.<br />
AMERICAN UROLOGICAL<br />
ASSOCIATION (AUA)<br />
1000 Corporate Blvd, 21090 Linthicium, United States<br />
of America<br />
T : +1 410 689 3700<br />
F : +1 410 689 3909<br />
W : www.auanet.org<br />
E : convention@auanet.org<br />
Booth nr. : A33<br />
The American Urological Association (AUA), founded<br />
in 1902, is the premier professional association for the<br />
advancement of urologic patient care, and works to<br />
ensure that its more than 16,000 members are current<br />
on the latest research and practices in urology. The<br />
AUA also pursues its mission of fostering the highest<br />
standards of urologic care by providing a wide range<br />
of services—including publications, research, the<br />
<strong>Annual</strong> Meeting, continuing medical education (CME)<br />
and the formulation of health policy.<br />
AUA’s <strong>Annual</strong> Meeting will be held on May 29 - June 3,<br />
<strong>2010</strong> in San Francisco, California. The <strong>Annual</strong> Meeting<br />
provides urology professionals from around the world<br />
with outstanding educational opportunities, including<br />
a comprehensive scientific program with 15 educational<br />
tracks and more than 1,500 studies in all fields of<br />
urology. The Science & Technology Hall features more<br />
than 300 exhibiting companies. For more information,<br />
please visit our website at www.aua<strong>2010</strong>.org.<br />
AMGEN (EUROPE) GMBH<br />
Dammstrasse 23, 6301 Zug, Switzerland<br />
T : +41 41 3690 392<br />
F : +41 41 3690 401<br />
W : www.amgen.com<br />
E : alessiob@amgen.com<br />
Booth nr. : E08<br />
Amgen (NASDAQ:AMGN), a biotechnology pioneer,<br />
discovers, develops and delivers innovative human<br />
therapeutics. Our medicines have helped millions of<br />
patients in the fight against cancer, kidney disease,<br />
rheumatoid arthritis and other serious illnesses. With<br />
a deep and broad pipeline of potential new medicines,<br />
we continue to advance science to serve patients.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
395
Company and Product Description<br />
ANATOMY FOR UROLOGY – PRIMAL<br />
PICTURES LTD<br />
4th Floor Tennyson House, W1W 5PA London, United<br />
Kingdom<br />
T : +44 207 637 1010<br />
F : +44 207 636 7776<br />
W : www.primalpictures.com<br />
E : catriona@primalpictures.com<br />
Booth nr. : E26<br />
Primal Pictures Ltd<br />
Anatomy for Urology DVD-Rom, published in 2009 by<br />
Primal Pictures Ltd, has been developed in collaboration<br />
with, and endorsed by the <strong>EAU</strong>.<br />
The representation of the body in Primal Picture’s<br />
range of software is unique because of its accuracy<br />
and detail. It is derived from medical scan data that<br />
has been interpreted by a team of in-house anatomists<br />
and then translated into three-dimensional images by<br />
an expert team of graphics specialists. The anatomy<br />
visuals are accompanied by three-dimensional animations<br />
that demonstrate function, biomechanics and<br />
surgical procedures. To supplement the core threedimensional<br />
anatomy data are surgical videos from the<br />
<strong>EAU</strong> digital library.<br />
Come see this and other titles such as Pelvic Floor<br />
Disorders DVD and Radiological Cross Sectional<br />
Anatomy: Trunk with exclusive <strong>EAU</strong> attendee discounts<br />
at Booth E26.<br />
ANDROMEDA MEDIZINISCHE<br />
SYSTEME GMBH<br />
Wallbergstrasse 5, 82024 Taufkirchen, Germany<br />
T : +49 896 141 561 15<br />
F : +49 896 141 561 1<br />
W : www.andromeda-ms.de<br />
E : ckolbeck@andromeda-ms.de<br />
Booth nr. : K14<br />
Andromeda is a German based medical service<br />
company which develops and produces urodynamic<br />
measurement systems and disposables. We are market<br />
leader for urodynamics in German speaking countries<br />
and market these products in 50 countries around the<br />
world.<br />
We offer urodynamic equipment from our computerized<br />
Conus PC Flowmeter up to complete solutions<br />
for video urodynamics with our Ellipse system.<br />
The new Ellipse colour offers wireless communication<br />
with a coloured screen.<br />
With our Ellipse Chair we set a new benchmark for<br />
396 Programme Book<br />
integrated urodynamic measurement systems. The<br />
concept behind this fully integrated system: all analysis<br />
functions are permanently installed in the urogynaecological<br />
chair, including the flow system, catheter puller<br />
and pressure transducers.<br />
The Helix can manage the entire spectrum of urodynamic<br />
measurements combined with simple, quick<br />
and effective operation. Clinicians can now delegate<br />
most of the work involved in preparing the urodynamic<br />
procedure.<br />
ARIZANT HEALTHCARE<br />
10393 West 70th Street, 55344 Eden Prairie, MN, United<br />
States of America<br />
T : +1 952 947 1200<br />
F : +1 952 947 1400<br />
W : www.arizant.com<br />
E : info@arizant.eu<br />
Booth nr. : G26<br />
Arizant Healthcare Inc. pioneered the concept of<br />
forced-air patient warming with the introduction of the<br />
Bair Hugger® therapy in 1987. Today, we have warmed<br />
more than 125 million surgical patients around the<br />
world and continue to lead in the development of<br />
ground-breaking temperature management products<br />
like the Bair Paws system and the Ranger blood/fluid<br />
warming system. Our market leadership and reinvestment<br />
into R&D allows us to continuously roll out new<br />
ideas and provide innovative, practical solutions to<br />
patient warming needs. Arizant Healthcare’s current<br />
product lines include Bair Hugger therapy, The Bair<br />
Paws patient adjustable warming system and the<br />
Ranger fluid warming systems.<br />
ASPIDE MÉDICAL<br />
246 Allée Lavoisier, 42350 La Talaudière, France<br />
T : +33 477 531 659<br />
F : +33 477 530 197<br />
W : www.aspide.com<br />
E : ericbouillet@wanadoo.fr<br />
Booth nr. : C18<br />
Design, manufacturing and sales of implantable medical<br />
devices and instruments for general and visceral,<br />
gynaecological and urological surgeries.<br />
Treatment of male and female urinary incontinence.<br />
Treatment of genito-urinary prolapses such as rectocele,<br />
cystocele and hyretrocele, either by laparoscopic<br />
route or by transparietal route.<br />
Forceps for laparoscopic prostatectomy.
AST GMBH<br />
Moritz-von-Rohr-Straße 1a, 07745 Jena, Germany<br />
T : +49 364 150 49 11<br />
F : +49 364 150 49 29<br />
W : www.ast-jena.de<br />
E : a.glum@ast-jena.de<br />
Booth nr. : C30<br />
The AST GmbH has developed a revolutionary new<br />
Lithotripter named LithoSpace® by applying scientific<br />
and technical advancements made within the last 10<br />
years of shockwave technology. The prime targets<br />
were to exceed the clinical performance of the HM3, to<br />
improve the ease of handling and to reduce the costs<br />
significantly.<br />
ASTELLAS PHARMA EUROPE LTD<br />
Lovett House, Lovett Road, TW18 3AZ Staines, United<br />
Kingdom<br />
T : +44 1784 419 400<br />
F : +44 1784 419 401<br />
W : www.astellas-europe.co.uk<br />
E : medical@eu.astellas.com<br />
Booth nr. : F02<br />
Astellas Pharma Europe Ltd. is a European subsidiary<br />
of Tokyo-based Astellas Pharma Inc. Astellas is dedicated<br />
to improving the health of people around the<br />
world through the provision of innovative pharmaceutical<br />
products. In addition to Urology, Astellas Pharma<br />
Europe is focused on Transplantation, Dermatology,<br />
Anti-infectives and Pain Management.<br />
With it’s commitment to research and development<br />
across the globe, Astellas supports urologists and urogynaecologists<br />
to improve the management of OAB,<br />
LUTS/BPH and prostate cancer. Astellas is passionate<br />
about introducing real solutions that address unmet<br />
medical need.<br />
ASTRA TECH AB<br />
Aminogatan 1, P.O. Box 14, 43121 Mölndal, Sweden<br />
T : +46 317 763 000<br />
F : +46 317 763 010<br />
W : www.lofric.com<br />
E : monica.thorsson@astratech.com<br />
Booth nr. : I22<br />
Astra Tech, a company in the AstraZeneca Group,<br />
develops, manufactures and markets medical devices.<br />
We are proud to present LoFric®, the world’s most<br />
documented hydrophilic urinary catheter. This year we<br />
are introducing LoFric® Sense, a new catheter specially<br />
designed for women. It is more hygienic, more<br />
discreet, and makes self-catheterisation as safe and<br />
comfortable as it can be. Astra Tech has its headquarters<br />
in Mölndal, Sweden.<br />
AYMED MEDICAL TECHNOLOGY<br />
Zumrutevler Mah. Nil Cad. Koc Sok No.13 34852<br />
Maltepe, Istanbul, Turkey<br />
T : +90 312 473 3410<br />
F : +90 312 473 3110<br />
W : www.aymed.com<br />
E : gizem@aymed.com<br />
Booth nr. : E19<br />
Aymed Medical Technology manufactures high-tech<br />
Video Urodynamic and Uroflow systems, Enuretic<br />
alarms, Lithopulse lithotriptors, Anorectal and<br />
Oesophageal manometers, Urotable Urologic and<br />
Gynaecologic operation tables. We also manufacture<br />
sterile disposable Urodynamic and Urological catheters<br />
and associated accessories in Class 10.000 clean room<br />
production conditions.<br />
Our all devices and their associated accessories have<br />
ISO 13485, ISO 9001:2000 and CE Certificate Production<br />
Quality Assurance.<br />
B. BRAUN AESCULAP<br />
Am Aesculap-Platz, 78532 Tuttlingen, Germany<br />
T : +49 7461 95 0<br />
F : +49 7461 95 2600<br />
W : www.bbraun.com<br />
E : information@aesculap.de<br />
Booth nr. : B02<br />
B. Braun Sharing Expertise<br />
Through exchanging knowledge with its customers,<br />
B. Braun helps to improve treatments and working<br />
procedures in hospitals and medical practices and to<br />
increase the safety of patients, doctors and nursing<br />
staff.<br />
B. Braun offers a wide range of products in the field of<br />
open and laparoscopic surgical instruments, continence<br />
care, urological specialties, wound closure and<br />
sutures. With useful products and process-oriented<br />
advice Aesculap – a B. Braun company is pursuing a<br />
goal: to improve therapies and make processes more<br />
efficient.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
397
Company and Product Description<br />
BARD LIMITED<br />
Forst House, Tilgate Forst Business Park, Brighton<br />
Road, RH11 9BP Crawley, United Kingdom<br />
T : +44 1293 527 888<br />
F : +44 1293 606 526<br />
W : www.crbard.com<br />
E : chris.cutbush@crbard.com<br />
Booth nr. : A15<br />
Bard is your partner. You do the procedures. We<br />
design the tools. Together, we collaborate – creating<br />
intuitive, innovative products designed to simplify,<br />
optimize, and revolutionize surgical procedures.<br />
With a breadth of products and service programs, Bard<br />
is the ideal single source to meet your clinical and<br />
procedural needs by providing solutions for superior<br />
patient care.<br />
BAYER SCHERING PHARMA AG<br />
Muellerstrasse 178, 13353 Berlin, Germany<br />
T : +49 30 468 1111<br />
F : +49 30 468 925 98<br />
W : www.bayerscheringpharma.de<br />
E : Marita.Ueckert@bayerhealthcare.com<br />
Booth nr. : B16 / C10<br />
Bayer Schering Pharma is one of the ten largest specialty<br />
pharmaceutical companies in the world and the<br />
company’s goal is a leading market position in each<br />
of its specialist fields. With its distinctive expertise in<br />
research, the company develops new medicines and<br />
therapies which make an essential contribution toward<br />
improving patient’s quality of life.<br />
Our outstanding research activities, together with our<br />
highly motivated staff, secure the sustainable success<br />
and growth of our company. We focus on four business<br />
areas, in which we make essential contributions to<br />
medical progress:<br />
Diagnostic Imaging<br />
General Medicine<br />
Specialty Medicine<br />
Women’s Healthcare<br />
BECKMAN COULTER, INC<br />
250 S. Kraemer Blvd, CA 92821 Brea, United States of<br />
America<br />
T : +1 714 993 53 21<br />
F : +1 714 961 45 04<br />
W : www.beckmancoulter.com<br />
E : CHuggins@beckman.com<br />
Booth nr. : A07<br />
398 Programme Book<br />
Helping to shape the future of disease management,<br />
Beckman Coulter offers an extensive immunoassay<br />
menu featuring markers that fulfill unmet patient care<br />
needs and a range of scalable instrument systems.<br />
These systems use the same reagents and similar assay<br />
protocols to deliver consistent patient results.<br />
BERLIN-CHEMIE AG<br />
Glienicker Weg 125, 12485 Berlin, Germany<br />
T : +49 306 707 24 89<br />
F : +49 306 707 33 88<br />
W : www.berlin-chemie.de<br />
E : JDamm@berlin-chemie.de<br />
Booth nr. : H20<br />
BERLIN-CHEMIE develops, produces and sells pharmaceutical<br />
products. BERLIN-CHEMIE is a German subsidiary<br />
of the MENARINI Group, which has been occupying<br />
a leading position in the Italian pharmaceutical<br />
market for many years. BERLIN-CHEMIE is responsible<br />
within the global MENARINI GROUP for activities in<br />
more than 30 countries of central and eastern Europe<br />
and central Asia. The company maintains subsidiaries<br />
or representative offices in most of those countries.<br />
BERLIN-CHEMIE as a member of the German<br />
Association of Research-Based Pharmaceutical<br />
Companies stands for innovation.<br />
BIOLITEC AG<br />
Winzerlaer Str. 2, 07745 Jena, Germany<br />
T : +49 228 979 6774<br />
F : +49 228 979 6799<br />
W : www.biolitec.com<br />
E : cemal.sagnak@biolitec.com<br />
Booth nr. : J29<br />
The biolitec group is involved in the development and<br />
production of photosensitisers for use in Photodynamic<br />
Therapy (PDT) and is a leading developer and manufacturer<br />
of diode lasers, optical fibers and accessories<br />
for application in a wide range of medical specialties.<br />
Biolitec is the manufacturer of LIFE, Laser Induced<br />
Flow Enhancement, which is a simple and effective<br />
procedure incorporating both the EVOLVE® Laser<br />
System and the patented TWISTER Fiber. The new<br />
TWISTER fiber was developed to offer unmatched ablation<br />
rates and excellent reliability. Due to the ability<br />
to work in contact mode, performance loss and fiber<br />
degradation are things of the past. In combination<br />
with the EVOLVE® Laser Series TWISTER achieves ablation<br />
rates of 2-3 grams per minute and reduces the
operating time by 50% or more compared to present<br />
laser therapies.<br />
BIONICHE PHARMA GROUP LTD<br />
4, Chemin Bizot, 1208 Geneva, Switzerland<br />
T : +41 223 477 317<br />
F : +41 223 477 319<br />
W : www.bionichepharma.com<br />
E : marine.gourguechon@bionichepharma.<br />
com<br />
Booth nr. : H21<br />
Bioniche Pharma Group Limited is a company focused<br />
on the development, manufacture and global sale of<br />
injectable pharmaceuticals. Bioniche Pharma sells its<br />
branded products Cystistat® and Suplasyn® in over<br />
50 countries, as well as generic injectables mainly<br />
in North America. Bioniche Pharma’s products serve<br />
a variety of niche markets and are sold to both the<br />
primary care and hospital markets.<br />
BK MEDICAL<br />
Mileparken 34, 2730 Herlev, Denmark<br />
T : +45 445 281 00<br />
F : +45 445 281 99<br />
W : www.bkmed.com<br />
E : info@bkmed.dk<br />
Booth nr. : K15<br />
Your upwardly mobile urology partner.<br />
BK Medical’s Flex Focus and Pro Focus UltraView<br />
scanners give you the best urology ultrasound imaging<br />
you’ve ever seen. Together with our state-of-the art<br />
transducers, our solutions give you superior image<br />
quality, triplane and simultaneous biplane, imageguided<br />
prostate therapy, system efficiency, single-use<br />
needle guides and HistoScanning. HistoScanning<br />
technology allow you to the ultrasound based application<br />
that visualizes the position and extent of differentiated<br />
tissue, suspicious of prostate cancer. With more<br />
than 30 years of commitment to ultrasound innovation,<br />
BK Medical specializes in dedicated ultrasound solutions.<br />
We understand – image is everything.<br />
BOSTON SCIENTIFIC<br />
100 Boston Scientific Way, MA 01752 Marlborough,<br />
United States of America<br />
T : +1 508 683 4000<br />
F : +1 508 683 5810<br />
W : www.bostonscientific.com<br />
E : weathers@bsci.com<br />
Booth nr. : A02<br />
Boston Scientific is a leading developer of less-invasive<br />
medical technologies. Our products include devices for<br />
the diagnosis and treatment of kidney stones, female<br />
urinary incontinence, and pelvic floor reconstruction.<br />
Please visit our exhibit to learn about our full line of<br />
products, our newest technologies, and our committment<br />
to physician education.<br />
BRITISH JOURNAL OF UROLOGY<br />
INTERNATIONAL<br />
47 Eccles Street, Dublin 7, Ireland<br />
T : +353 1 803 2098<br />
F : +353 1 803 4389<br />
W : www.bjui.org<br />
E : editor.bjuint@mater.ie<br />
Booth nr. : G20<br />
BJUI is a truly global and innovative journal, edited by<br />
Professor John M Fitzpatrick; it is published 23 times<br />
per annum. BJUI welcomes original contributions on<br />
topics of interest and importance to Urologists. It accepts<br />
original articles and research papers, after peerreview,<br />
focusing on urological oncology, conditions<br />
effecting lower urinary tract, laparoscopic and robotic<br />
urology, in addition to paediatric and reconstructive<br />
urology and sexual medicine. We also have special<br />
interest in academic investigative urology papers.<br />
Visit stand G20 or www.bjui.org to ensure you stay<br />
up-to-date with the latest developments.<br />
CHINESE UROLOGICAL<br />
ASSOCIATION<br />
Room 302 Xingyu Office Building,Shijingshan District,<br />
Beijing, P.R. 100043, China<br />
T : +86 10 5194 5166<br />
F : +86 10 5194 5166<br />
W : www.cuan.cn<br />
E : renyang@cuan.cn<br />
Booth nr. : A31<br />
Chinese Urological Association (CUA) of Chinese<br />
Medical Association (CMA) was established in 1981<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
399
Company and Product Description<br />
by Wu Jieping, Academician of Chinese Academy of<br />
Sciences, one of the founders of urology in China.<br />
Every council works for a term of 3 years. The presidents<br />
of councils are Wu Jieping, Gu Fangliu, Guo<br />
Yinglu and Na Yanqun(7th-8th councils). The work of<br />
CUA is academic communication and talent cultivation.<br />
Through the efforts of every council and urologists<br />
around the country, the number of professional urologists<br />
in our country is increasing to more than 13,000<br />
and the academic level is improving. CUA are paying<br />
more attention to collaboration with other international<br />
urological associations. WCE 2008 has been held<br />
in Shanghai successfully and SIU 2009 has been held<br />
in China in 2009. ICS 2012 will be held in Beijing also.<br />
COLOPLAST<br />
C.A. La Boursidière, 92357 Le Plessis-Robinson, France<br />
T : +33 140 836 868<br />
F : +33 140 836 855<br />
W : www.coloplast.com<br />
E : FRPBE@coloplast.com<br />
Booth nr. : H06<br />
Porgès, Urology division of Coloplast designs, develops,<br />
manufactures and markets worldwide disposable<br />
medical devices for hospital urology use and the home<br />
care treatment of urinary tract disorders.<br />
Porgès offers the urological surgeon the widest<br />
range of products used to diagnose or treat BPH<br />
(X-Flow catheters, Easivac), Stone disease (Dormia),<br />
Incontinence (Bonee injection needle, Aris TOT sling),<br />
Erectile Dysfonction (Titan OTR penile implants), and<br />
Pelvic Organs prolapse (NovaSilk mesh). Stepping<br />
toward innovation, PORGES from COLOPLAST is the<br />
global leader in listening and responding to the needs<br />
of its customers.<br />
COOK MEDICAL<br />
O’Halloran Road, National Technology Park, Limerick,<br />
Ireland<br />
T : +353 61 334 440<br />
F : +353 61 239 420<br />
W : www.cookmedical.com<br />
Booth nr. : G08<br />
Cook Medical integrates device design, biopharma,<br />
gene and cell therapy and biotech to enhance patient<br />
safety and improve clinical outcomes in the fields of<br />
aortic intervention; interventional cardiology; critical<br />
care medicine; gastroenterology; radiology, peripheral<br />
vascular, bone access and oncology; surgery and soft<br />
400 Programme Book<br />
tissue repair; urology; and assisted reproductive technology,<br />
gynecology and high-risk obstetrics. For more<br />
information, visit www.cookmedical.com or visit us at<br />
Booth number G08.<br />
COVIDIEN<br />
ZA LA Clef de St Pierre- 2 Rue Denis Diderot, 78990<br />
Elancourt, France<br />
Phone : +33 1 3079 8222<br />
Fax : +33 1 3079 8213<br />
Internet : www.covidien.com<br />
Email : isabelle.fafournoux@covidien.com<br />
Booth nr. : D20<br />
One of the world’s largest providers of advanced<br />
medical devices, supplies and pharmaceuticals for<br />
everything from saving lives to bringing new lives<br />
into the world. Formerly Tyco Healthcare, we’re now a<br />
dynamic, independent healthcare company committed<br />
to providing positive innovations and partnerships to<br />
the medical community.<br />
DIREX – INITIA<br />
Blumenstrasse 10, 65189 Wiesbaden, Germany<br />
T : +49 180 215 2152<br />
F : +49 180 215 1151<br />
W : www.direxgroup.com<br />
E : wbmaster@direxgroup.com<br />
Booth nr. : G22<br />
Duet Magna combines dual-head SWL and electromagnetic<br />
technology.<br />
Dual-head: speed and five-fold kidney damage reduction<br />
(Univ. of Indiana research)<br />
Magna: modularity and flexible electromagnetic features,<br />
separate or simultaneous dual-heads operation,<br />
a wide energy range with ElectroHydraulic-like performance<br />
at high end; a high quality range of fluoroscopy<br />
and ultrasonic imagers.<br />
Tempro Thermotherapy offers a unique bipolar Radio<br />
frequency technology which leads to personalized<br />
treatment for a short and simple treatment of<br />
Prostatitis and BPH.<br />
DORNIER MEDTECH EUROPE GMBH<br />
Im Argelsrieder Feld 7, 82234 Wessling, Germany<br />
T : +49 8153 888 625<br />
F : +49 8153 888 444<br />
W : www.dornier.com<br />
E : infoeurope@dornier.com<br />
Booth nr. : G14
Dornier MedTech is engaged in the development,<br />
manufacturing, and distribution of high-quality,<br />
minimally invasive medical devices for use in clinical<br />
as well as physician office settings.<br />
As a pioneering leader in urological and orthopaedic<br />
shock wave technology, Dornier MedTech also supplies<br />
multifunctional urological workstations and patient<br />
tables for diagnosis and therapy. Dornier MedTech<br />
also specializes in surgical and aesthetic lasers. As<br />
a service-oriented enterprise, the company provides<br />
services including technical and clinical application<br />
support and more.<br />
DYNAMESH-FEG TEXTILTECHNIK<br />
MBH<br />
Juelicher Str. 338a, 52070 Aachen, Germany<br />
T : +49 241 189 237 40<br />
F : +49 241 189 237 459<br />
W : www.dyna-mesh.com<br />
E : dyna-mesh@feg-textiltechnik.de<br />
Booth nr. : A19<br />
FEG Textiltechnik mbH is a German company, highly<br />
specialised in the development and production of textile<br />
medical implants and is certified according to DIN<br />
EN ISO 13485:2003 for manufacturing and distribution<br />
of medical devices. FEG Textiltechnik mbh is the worldwide<br />
only supplier of mesh implants made from the<br />
high-tech bio-inert material Polyvinylidene Fluoride<br />
(PVDF). A large variety of mesh implants for hernia<br />
and pelvic floor repair is offered.<br />
Our latest innovation DynaMesh®-SIS-minor is a specially<br />
designed implant for the treatment of<br />
stress incontinence with a minimally invasive procedure.<br />
All products are manufactured in Germany and distributed<br />
worldwide in more than 30 countries under the<br />
brand name DynaMesh®.<br />
<strong>EAU</strong> RESEARCH FOUNDATION<br />
Mr. E.N. van Kleffensstraat 5, 6842 CV Arnhem, The<br />
Netherlands<br />
T : +31 26 389 0677<br />
F : +31 26 389 0679<br />
W : www.uroweb.org/eaurf<br />
E : researchfoundation@uroweb.org<br />
Booth nr. : B20<br />
The <strong>EAU</strong> has established the <strong>EAU</strong> Research Foundation<br />
(<strong>EAU</strong>-RF), an independent body developed and<br />
governed by the <strong>EAU</strong> to improve urological research in<br />
Europe.<br />
With the <strong>EAU</strong> providing a solid platform, the <strong>EAU</strong>-RF is<br />
tasked to stimulate and coordinate basic, translational<br />
and clinical research.<br />
The Research Foundation is always looking for new<br />
urologists and scientists who are interested to get<br />
involved in our research projects. Visit our booth if you<br />
want to meet us!<br />
EDAP TMS<br />
4 rue du Dauphiné, 69120 Vaulx en Velin, France<br />
T : +33 472 153 150<br />
F : +33 472 153 151<br />
W : www.edap-tms.com<br />
E : aoczachowski@edap-tms.com<br />
Booth nr. : H14<br />
EDAP-TMS develops and markets Ablatherm® HIFU,<br />
the most advanced and clinically proven choice for<br />
High Intensity Focused Ultrasound (HIFU) treatment of<br />
localized prostate cancer.<br />
The company also produces and commercializes medical<br />
equipment for treatment of urinary tract stones<br />
using Extra-corporal Shockwave Lithotripsy (ESWL).<br />
EDAP TMS focuses daily on delivering technologies<br />
that guarantee reproducible positive outcomes, low<br />
side effects and preserved quality of life. As clinically<br />
proven therapeutic options, EDAP TMS’ devices are<br />
highly trusted among leading urologists worldwide.<br />
EDUCATION & INNOVATION<br />
P.O. Box 30016, 6803 AA Arnhem, The Netherlands<br />
T : +31 263 891 751<br />
F : +31 263 890 674<br />
W : www.uroweb.org<br />
E : m.hofstede@congressconsultants.com<br />
Booth nr. : B30<br />
The ESU and ESUT present interesting recent developments<br />
in the field of education and technological<br />
innovations. Education & Innovation offers you a<br />
hands-on experience with exciting devices, such as<br />
virtual simulators, 3D anatomy, augmented reality and<br />
the newest technologies.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
401
Company and Product Description<br />
ELI LILLY AND COMPANY<br />
Lilly Corporate Center, 46285 Indianapolis, United<br />
States of America<br />
T : +1 317 277 1433<br />
F : +1 317 276 6900<br />
W : www.Lilly.com<br />
E : vmcwatters@lilly.com<br />
Booth nr. : H04<br />
Lilly, a leading innovation-driven corporation, is<br />
developing a growing portfolio of pharmaceutical<br />
products by applying the latest research from its own<br />
worldwide laboratories and from collaborations with<br />
eminent scientific organizations. Headquartered in<br />
Indianapolis, Ind., Lilly provides answers - through<br />
medicines and information - for some of the world’s<br />
most urgent medical needs. Additional information<br />
about Lilly is available at www.lilly.com; Lilly’s clinical<br />
trial registry is available at www.lillytrials.com.<br />
ELMED LITHOTRIPSY SYSTEMS<br />
Istanbul Yolu, 13. km, Gersan Sanayi Sitesi, 2307. Sk.,<br />
No:46 Ergazi, 06370 Ankara, Turkey<br />
T : +90 312 256 92 22<br />
F : +90 312 257 06 08<br />
W : www.elmed-lithotripsy.com<br />
E : sales@elmed-lithotripsy.com<br />
Booth nr. : I26<br />
ELMED is involved in manufacturing, developing, exporting<br />
and servicing of advanced medical equipment<br />
mainly in the field of urology since 1991.<br />
ELMED is proud to offer the medical profession worldwide<br />
innovative, highly effective and advanced medical<br />
systems; Extracorporeal Shock Wave Lithotripters<br />
(ESWL) and Intracorporeal, Pneumatic and Ultrasonic<br />
combined Lithotripters for urology, Extracorporeal<br />
Shock Wave Therapy (ESWT) units for orthopedic applications.<br />
The entire range of products complies with international<br />
standards including CE in accordance with<br />
MDD/93/42/EEC, ISO9001 & ISO13485.<br />
ELSEVIER<br />
Radarweg 29, 1043 NX Amsterdam, The Netherlands<br />
T : +31 204 853 787<br />
F : +31 204 853 249<br />
W : www.elsevier.com<br />
E : s.visser@elsevier.com<br />
Booth nr. : K16<br />
402 Programme Book<br />
Elsevier is the leading international publisher of medical<br />
journals, books and electronic products. Imprints<br />
include Churchill Livingstone, Mosby and Saunders.<br />
Elsevier also is the preferred publishing partner of<br />
important international Societies. We are proud to<br />
publish European Urology, the official journal of the<br />
<strong>EAU</strong>. Stop by our booth to pick up free sample copies<br />
of our journals. For more information, please visit:<br />
www.elsevier.com<br />
EMS ELECTRO MEDICAL SYSTEMS<br />
CH. de la Vuarpilliere 31, 1260 Nyon, Switzerland<br />
T : +41 22 99 44 200<br />
F : +41 22 99 44 701<br />
W : www.ems-company.com<br />
E : welcome@ems-ch.com<br />
Booth nr. : H23<br />
EMS S.A. is the inventor of pneumatic intracorporeal<br />
lithotripsy, the Swiss LithoClast® Technology. Since<br />
1991 more than 8000 Swiss LithoClast® units have<br />
been put into service all over the world. A new level<br />
of efficiency for the fragmentation and evacuation<br />
of stones has been reached by introducing the Swiss<br />
LithoClast® Master in 2001. This device offers the possibility<br />
of using shockwave and ultrasound technology<br />
simultaneously to fragment stones. This results in<br />
much faster endoscopic stone removal compared to<br />
other modalities.<br />
ENDOCARE, INC<br />
9825 Spectrum Drive, Building 3, 78717 Austin, United<br />
States of America<br />
T : +1 512 328 2892<br />
F : +1 512 439 8303<br />
W : www.endocare.com<br />
E : jully.huang@healthtronics.com<br />
Booth nr. : G30<br />
Endocare, now owned by HealthTronics, offers a<br />
cryoablation product line that improves treatment of<br />
malignant and benign tumors throughout the body.<br />
With up to 10-years of clinical experience in percutaneous,<br />
laparoscopic, and open cryoablation for prostate,<br />
kidney and other tissues, we remain committed<br />
to innovative technology that improves and extends<br />
patients’ lives.
ENDOCONTROL<br />
5 Avenue de Grand Sablon, 38700 La Tronche, France<br />
T : +33 476 637 583<br />
F : +33 476 549 561<br />
W : www.endocontrol-medical.com<br />
E : infos@endocontrol-medical.com<br />
Booth nr. : A25<br />
EndoControl is an innovative company specializing<br />
in the development of robotic surgical solutions for<br />
endoscopic surgery, It markets a range of products<br />
including ViKY, a robotic assistant for laparoscopic,<br />
pelviscopic and thoracoscopic surgery.<br />
The ViKY System received EC marking in 2007 and FDA<br />
approval in 2008. Since then, over 1000 surgical procedures<br />
have been performed with ViKY. EndoControl has<br />
installed over 35 systems worldwide, with installations<br />
in: Austria, Germany, Belgium, France, Italy, Spain,<br />
Holland, the U.K, the US and Canada. EndoControl<br />
has also developed clinical relationships with many<br />
renowned clinicians and institutions in laparoscopic<br />
surgery. Founded in 2006 by Clément VIDAL and<br />
Patrick HENRI, EndoControl has revolutionized robotic<br />
surgery by developing a multi task, compact system,<br />
which easily integrates in the operating room.<br />
ERBE ELEKTROMEDIZIN GMBH<br />
Waldhornlestr. 17, 72072 Tübingen, Germany<br />
T : +49 707 175 51 11<br />
F : +49 707 175 51 79<br />
W : www.erbe-med.com<br />
E : TFrauendiener@erbe-med.de<br />
Booth nr. : B06<br />
ERBE Elektromedizin GmbH develops, manufactures<br />
and sells systems for electrosurgery, waterjet surgery<br />
and cryosurgery.<br />
About two thirds of ERBE’s approx. 520 employees<br />
worldwide are based in Tübingen, the headquarters of<br />
the company. Year of foundation: 1847. With subsidiary<br />
companies in the USA, France, the Netherlands,<br />
England, Austria, Switzerland, Poland, India etc.,<br />
representative offices in China, Russia, Singapore and<br />
more than 100 agencies the family business is present<br />
worldwide.<br />
Working in close cooperation with scientists and users,<br />
ERBE develops new therapeutic treatments which,<br />
after appropriate practical trials, will benefit patients.<br />
ESRU (EUROPEAN SOCIETY FOR<br />
RESIDENTS IN UROLOGY)<br />
P.O.Box 30016, 6803 AA Arnhem, The Netherlands<br />
F : +36 13 229 460 (Hungary)<br />
W : www.esru.eu<br />
E : see website<br />
Booth nr. : B20<br />
ESRU (European Society for Residents in Urology) is<br />
representing residents and young urologists from 43<br />
countries members and affiliated members of <strong>EAU</strong><br />
since 1999. Visiting our booth you can get information<br />
about the activities of ESRU by our representatives. Our<br />
booth is a meeting point for young colleges to exchange<br />
ideas, training experiences and making friendships.<br />
ESSM<br />
c/o AIM <strong>Congress</strong> S.r.l.-AIM Group,Via Ripamonti 129,<br />
20141 Milan, Italy<br />
T : +39 025 660 12 96<br />
F : +39 027 004 85 77<br />
W : www.essm.org<br />
E : admin@essm.org<br />
Booth nr. : E30<br />
The European Society for Sexual Medicine (ESSM)<br />
is a not-for-profit, multidisciplinary, academic and<br />
scientific organization dedicated to male and female<br />
sexual function and dysfunction. Founded in 1995 as<br />
ESIR (European Society for Impotence Research), it<br />
began an important journey into medical knowledge,<br />
research and innovation. The year 2005 marked the<br />
10th anniversary of ESSM, which has become the<br />
major scientific society in Europe; growing stronger<br />
and deeply rooted with 25 National Societies affiliated<br />
and more than 1700 members.<br />
EUROPA UOMO<br />
Lange Gasthuisstraat 35-37, 2000 Antwerpen, Belgium<br />
T : +32 333 891 50<br />
F : +32 333 891 52<br />
W : www.europa-uomo.org<br />
E : europauomo@skynet.be<br />
Booth nr. : A23<br />
Europa Uomo, the European Prostate Cancer Coalition,<br />
represents and supports patient groups with prostate<br />
diseases in general and cancer in particular. Our aims<br />
include increasing awareness of prostate diseases,<br />
the support of individualized treatment based on<br />
optimal medical treatment with personalized patient<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
403
Company and Product Description<br />
care and patients’ advocacy as a priority focused on<br />
quality of life based on solidarity and mutual respect.<br />
Our expansion is based on collaboration with the<br />
professional organizations to provide information on<br />
evidence based treatment, to educate men on holistic<br />
patient care and on solidarity in advocacy with other<br />
patient support groups.<br />
EUROPEAN UROLOGY<br />
Via Stamira d’Ancona 20, 20127 Milan, Italy<br />
T : +39 02 2643 6438<br />
F : +39 02 2643 6450<br />
W : www.europeanurology.com<br />
E : european.urology@hsr.it<br />
Booth nr. : K02<br />
European Urology, the official journal of the <strong>EAU</strong>, has<br />
been a respected urological forum for over 20 years,<br />
and is currently read by more than 15,000 urologists<br />
across the globe. With an impact factor of 6.512, the<br />
journal has become the leading scientific publication<br />
in the field of urology. European Urology is constantly<br />
updating and innovating its electronic and published<br />
features and layout in order to provide the best clinical<br />
guidance, research and education for urologists across<br />
Europe and the world. Come see European Urology<br />
for yourself - visit either the European Urology or <strong>EAU</strong><br />
booth at the exhibition.<br />
FAU (FEDERACIÓN ARGENTINA DE<br />
UROLOGIA)<br />
Av. Pueyrredon 76-Pb-Dto B, X 5000 BRN Cordoba,<br />
Argentina<br />
T : +54 351 468 3111<br />
F : +54 351 468 3111<br />
W : www.fau.org.ar<br />
E : fau@fau.org.ar<br />
Booth nr. : A37<br />
The Federación Argentina de Urologia is one national<br />
urology association that represents all the Argentinean<br />
provinces’ urologic societies (22 individual associations).<br />
We have 23 chapter between the sub-specialties,<br />
depending on the Scientific Secretariat.<br />
FAU has agreements with urological societies from<br />
countries such as Bolivia, Peru, Paraguay, Chile,<br />
Uruguay, Colombia and Brazil since the signing in<br />
2005 of the “Agreement for Scientific Cooperation”.<br />
Among the items on the agreed fees are in Urology,<br />
Urology in Residential, Title and Recertification<br />
404 Programme Book<br />
Specialist developed a project for the development<br />
of courses and cooperative work, and grants and<br />
Specialization Update.<br />
It is therefore of utmost importance that we create<br />
relationships with other inter-related institutions to<br />
create a space for reflection and exchange of experience,<br />
to promote cultural and scientific activities<br />
related to urology. Since 2006 our Institution joining<br />
the CAU/American Confederation of Urology.<br />
FERRING INTERNATIONAL CENTER<br />
S.A.<br />
Ch. De La Vergognausaz 50, 1162 Saint-Prex,<br />
Switzerland<br />
T : +41 583 010 000<br />
F : +41 583 010 010<br />
W : www.ferring.com<br />
Booth nr. : E14<br />
Ferring is a Swiss-headquartered, research driven,<br />
speciality biopharmaceutical group active in global<br />
markets. The company identifies, develops and<br />
markets innovative products in the areas of urology,<br />
gastroenterology & endocrinology and reproductive<br />
health. In recent years Ferring has expanded beyond<br />
its traditional European base and has offices in 45<br />
countries. To learn more about Ferring or our products<br />
please visit www.ferring.com.<br />
GALIL MEDICAL<br />
The Office Building Suite 21, Gatwick Road, Manor<br />
Royal, RH10 9RZ Crawley, United Kingdom<br />
T : +44 129 345 98 48<br />
F : +44 129 345 98 40<br />
W : www.galilmedical.com<br />
E : sally.rogers@galilmedical.com<br />
Booth nr. : A16<br />
Cryoablation for prostate and renal cancer. Galil<br />
Medical offers advanced cryoablation technology<br />
using unique 17-gauge needles and operator choice of<br />
iceball size. Cryoablation is gaining recognition as the<br />
therapy of choice for small renal masses, while excellent<br />
clinical results have led to the inclusion of cryoablation<br />
in the <strong>EAU</strong> and AUA guidelines as a treatment<br />
option for localised prostate cancer. Focal treatments,<br />
made possible by our unique small-gauge technology<br />
are improving outcomes still further. To find out more<br />
about the data and the technology, please visit us at<br />
the exhibition (stand A16) and come to the workshop,<br />
Cryoablation: Setting the Standard (Monday 19 April at
15.45 in Genoa room). There is also a dedicated <strong>EAU</strong>N<br />
nurses’ workshop on prostate and renal cryoablation<br />
on Saturday 17 April from 09:00-11:00 (room to be<br />
announced).<br />
GE HEALTHCARE<br />
Pollards Wood, Nightingales Lane, HP8 4SP Chalfont St<br />
Giles, Bucks, United Kingdom<br />
T : +44 1494 544 000<br />
F : +44 1494 542 266<br />
W : www.gehealthcare.com<br />
E : Nina.Taaje@ge.com<br />
Booth nr. : F22<br />
GE Healthcare is dedicated to helping you transform<br />
healthcare delivery by driving critical breakthroughs<br />
in biology and technology. Our expertise in medical<br />
imaging and information technologies, diagnostics,<br />
patient monitoring systems, drug discovery, and biopharmaceutical<br />
manufacturing technologies is<br />
enabling healthcare professionals around the world<br />
discover new ways to diagnose and treat disease<br />
earlier. We call this model “Early Health”. Our goal<br />
is more targeted treatments, so they can help their<br />
patients live their lives to the fullest. Re-think,<br />
Re-discover, Re-invent, Re-imagine. For additional<br />
information, please visit our booth while at <strong>EAU</strong> <strong>2010</strong>.<br />
GEN-PROBE INCORPORATED<br />
10210 Genetic Center Drive, 92121 San Diego, CA,<br />
United States of America<br />
T : +1 858 410 8997<br />
F : +1 858 410 9018<br />
W : www.gen-probe.com<br />
E : sues@gen-probe.com<br />
Booth nr. : A10<br />
The Gen-Probe PROGENSA PCA3 urine assay is a<br />
highly specific gene-based test to aid in the diagnosis<br />
of prostate cancer. Please visit booth A10 as well as<br />
www.pca3.org, to learn more about how the CEmarked<br />
PCA3 Assay can more accurately predict biopsy<br />
outcomes. Gen-Probe Incorporated is a global leader<br />
in the development, manufacture, and marketing of<br />
nucleic acid testing (NAT) products used for the diagnosis<br />
of human disease and blood screening.<br />
GLAXOSMITHKLINE<br />
C./ Severo Ochoa, 2, 28760 Tres Cantos (Madrid), Spain<br />
T : +34 918 070 336<br />
F : +34 918 070 310<br />
W : www.gsk.com<br />
E : matthew.x.goldsmith@gsk.com<br />
Booth nr. : I02<br />
GSK is a research-based pharmaceutical company. GSK<br />
makes a significant contribution to society by bringing<br />
products to market that address the medical needs<br />
of patients around the world. Our scientists work to<br />
discover new ways of treating and preventing<br />
diseases. By combining the wide-ranging talents of<br />
our employees with our leading edge science resources,<br />
we are dedicated to bringing more medicines of<br />
value to patients. Our mission is to improve the quality<br />
of human life by enabling people to do more, feel<br />
better and live longer.<br />
HITACHI MEDICAL SYSTEMS<br />
EUROPE HOLDING AG<br />
Sumpfstrasse 13, 6300 Zug, Switzerland<br />
T : +41 41 748 63 33<br />
F : +41 41 748 63 32<br />
W : www.hitachi-medical-systems.com<br />
E : welcome@hitachi-medical-systems.com<br />
Booth nr. : E24<br />
Hitachi Medical Systems with extensive experience in<br />
ultrasound imaging present a comprehensive range of<br />
specialized urological probes for standard trans-rectal<br />
procedures, laparoscopic transducers for cryotherapy<br />
through to mini-probes for stem cell therapy, all<br />
delivering a flexible system for complete urological<br />
investigations.<br />
Hitachi Real-time Tissue Elastography (HI-RTE) is<br />
a revolutionary procedure for the visualisation of<br />
prostate cancer by differentiating hard from soft tissue.<br />
A proven technology for targeted biopsies which<br />
decreases the number of core biopsies and offers great<br />
clinical potential.<br />
HRA RESEARCH<br />
400 Lanidex Plaza, NJ 07054 Parcippany, United States<br />
of America<br />
T : +1 973 240 1200<br />
F : +1 973 463 1888<br />
W : www.hraresearch.com<br />
E : knielsen@hraresearch.com<br />
Booth nr. : K31<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
405
Company and Product Description<br />
HRA Research is a market research firm whose team of<br />
experienced interviewers will be distributing carefully<br />
developed questionnaires. We’ll be gathering answers<br />
to vital marketing and clinical questions-answers that<br />
can affect the introduction of new products or the continuation<br />
of existing healthcare products and services.<br />
ICS-IUGA <strong>2010</strong><br />
1-3 rue de Chantepoulet, CH 1211 Geneva, Switzerland<br />
T : +41 22 908 0488<br />
F : +41 22 906 9140<br />
W : www.ics-iuga.com<br />
E : ics-iuga@kenes.com<br />
Booth nr. : A29<br />
The Joint Meeting of the International Continence<br />
Society and the International Urogynecology<br />
Association will be held in August <strong>2010</strong> to be held in<br />
Toronto, Canada. Join over 2,000 professionals specialising<br />
in uro-gynaecology and related fields at ICS-<br />
IUGA <strong>2010</strong>. Expand your knowledge during a multidisciplinary<br />
scientific program with presentations<br />
from internationally acclaimed experts in research and<br />
treatment of incontinence and disorders of the pelvic<br />
floor, abstract and poster presentations, roundtable<br />
discussions, meet the expert sessions, networking<br />
opportunities and more. Come and talk to us at Booth<br />
A29 to find out more.<br />
INTEGRA SURGICAL<br />
99 Hartwell Street, MA 01583 West Boylston, United<br />
States of America<br />
T : +1 508 835 9700<br />
F : +1 508 835 9976<br />
W : www.integra-surgical.com<br />
E : craig.stevens@integra-ls.com<br />
Booth nr. : H27<br />
Integra Surgical, a leading supplier of innovative,<br />
high quality operating room instrumentation, offers a<br />
comprehensive catalog of reusable surgical instruments<br />
that provide a complete solution for your needs<br />
in laparoscopic, general, cardiovascular, neuro, plastic<br />
and reconstructive surgical specialties. The products<br />
include Luxtec® Xenon illumination and digital video<br />
recording systems, fiber optic cables, surgical loupes<br />
and high quality surgical instrumentation from Jarit®,<br />
R&B (TM), Padgett Instruments® and Omni-Tract®<br />
table retractor systems.<br />
406 Programme Book<br />
INTERMEDIC<br />
Vallès Technology Park, Boters 8-10, 08290 Cerdanyola<br />
del Vallès (<strong>Barcelona</strong>), Spain<br />
T : +34 902 25 45 45<br />
F : +34 902 22 35 35<br />
W : www.inter-medic.net<br />
E : info@inter-medic.net<br />
Booth nr. : K06<br />
INTERmedic is a dynamic laser & light technology firm,<br />
dedicated to the development, production and marketing<br />
of innovative lasers, as well as many other new<br />
technologies for a wide range of medical applications.<br />
At the <strong>EAU</strong> congress, INTERmedic is proud to present<br />
the innovative MULTIDIODE SURGICAL Urology SST<br />
200, the diode laser for BPH treatment, which perfectly<br />
performs vaporization and enucleation of the prostate<br />
in one single device.<br />
INTERNATIONAL HIFU<br />
801 E. Morehead St, Suite 201 Charlotte, NC 28202,<br />
United States of America<br />
T : +1 704 332 4308<br />
F : +1 704 332 5628<br />
W : www.InternationalHIFU.com<br />
E : info@internationalhifu.com<br />
Booth nr. : E36<br />
International HIFU is committed to creating a new<br />
standard for the treatment of prostate cancer with<br />
high intensity focused ultrasound (HIFU) therapy<br />
through the distribution and use of Sonablate ® 500<br />
medical devices and HIFU therapy. The Sonablate 500<br />
obtains real-time ultrasound images of the prostate<br />
and surrounding areas. From these images, the doctor<br />
plans where the ultrasound energy will be delivered<br />
for tissue ablation. The device allows physicians<br />
to precisely define the treatment zones in order to<br />
destroy the entire gland or select tissue to be treated<br />
focally. Sonablate HIFU can treat large prostates up to<br />
40 grams, without need for a TURP, and incorporates<br />
three-dimensional imaging, monitoring of tissue<br />
changes and detection of neurovascular bundles<br />
during HIFU therapy.
INTERNATIONAL SOCIETY FOR<br />
SEXUAL MEDICINE<br />
P.O. Box 94, 1520 AB Wormerveer, The Netherlands<br />
T : +31 756 476 372<br />
F : +31 756 476 371<br />
W : www.issm.info<br />
E : secretariat@issm.info<br />
Booth nr. : A27<br />
The International Society for Sexual Medicine (ISSM) is<br />
a multidisciplinary, international, non profit society<br />
whose focus is research, education and clinical<br />
practice in sexual medicine. ISSM’s purposes and<br />
objectives are to:<br />
• Encourage the highest standards of practise, education<br />
and research in the field of human sexual<br />
medicine<br />
• Develop scientific methods for the diagnosis,<br />
prevention and treatment of conditions affecting<br />
human sexual function<br />
• Promote publication of medical and scientific literature<br />
in the field of sexual medicine<br />
The members of ISSM share their interest in human<br />
sexual medicine and science.<br />
The benefits of ISSM membership are:<br />
• Subscription to the JSM (Journal of Sexual<br />
Medicine), 12 issues per year;<br />
• Discounted registration fees on ISSM meetings;<br />
• Use of ISSM List for rapid communication between<br />
members;<br />
• ISSM news bulletin, 3 issues per year; and<br />
• Access to the ‘members-only’ section of the ISSM<br />
website.<br />
INTERNATIONAL SOCIETY OF MEN’S<br />
HEALTH (ISMH)<br />
Lazarettgasse 9/5, 1090 Vienna, Austria<br />
T : +43 409 60 10<br />
F : +43 409 60 11<br />
W : www.wcmh.info<br />
E : ismh@ismh.org<br />
Booth nr. : B19<br />
The only international organization dedicated to the<br />
unmet need of improving men’s health of all ages and<br />
committed to a comprehensive multi-disciplinary<br />
approach to men’s health.<br />
The mission is to advance all that is related in men’s<br />
health through education, raising awareness and<br />
recognition, establishment of men’s health programs,<br />
men’s health centres and men’s health initiatives as<br />
well as through promotion and advocacy and research<br />
on a global level to benefit the public.<br />
INTUITIVE SURGICAL, INC<br />
Chemin des Mûriers, 1, 1170 Aubonne, Switzerland<br />
T : +41 218 212 000<br />
F : +41 218 212 001<br />
W : www.intuitivesurgical.com<br />
E : catherine.pittet@intusurg.com<br />
Booth nr. : C02<br />
Intuitive Surgical, Inc. is the global technology leader<br />
in robotic-assisted, minimally invasive surgery. da<br />
Vinci Prostatectomy (dVP), performed with the groundbreaking<br />
da Vinci Surgical System, is the fastest<br />
growing treatment for prostate cancer today. dVP<br />
leverages da Vinci ‘s state-of-the-art technology,<br />
including high definition 3D vision, proprietary<br />
EndoWrist® instrumentation, Intuitive® motion and<br />
the 4th arm. Studies suggest that dVP may provide<br />
better clinical outcomes than conventional open or<br />
laparoscopic approaches can provide.<br />
INVERNESS MEDICAL<br />
c/o Biosite International, Rue des Vignerons 1A, 1110<br />
Morges, Switzerland<br />
T : +41 218 047 140<br />
F : +41 218 020 933<br />
W : www.invernessmedical.com<br />
E : professionaldiagnostics@invmed.com<br />
Booth nr. : D30<br />
Inverness Medical is a global leader in rapid pointof-care<br />
diagnostics. The products focus on infectious<br />
disease, cardiology, drugs of abuse, women’s health<br />
and oncology. The NMP22 Tests (POC & EIA) from<br />
Matritech, an Inverness Medical Company, are the only<br />
urine tests which are FDA approved for the diagnosis<br />
and monitoring of bladder cancer.<br />
IPSEN<br />
65 Quai Georges Gorse, 92650 Boulogne Billancourt,<br />
France<br />
T : +33 1 58 33 50 00<br />
F : +33 1 58 33 50 01<br />
W : www.ipsen.com<br />
E : contact.web@ipsen.com<br />
Booth nr. : H02<br />
Ipsen is an innovation-driven global specialty pharmaceutical<br />
group with over 20 products on the market<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
407
Company and Product Description<br />
and a total worldwide staff of nearly 4,200.<br />
Its development strategy is based on its activities in<br />
specialty medicine, growth drivers in targeted therapeutic<br />
areas (oncology, endocrinology, neurology and<br />
haematology), combined with primary care products<br />
which contribute significantly to its research financing.<br />
The location of its four Research & Development<br />
centres (Paris, Boston, <strong>Barcelona</strong>, London) and its<br />
peptide and protein engineering platform give the<br />
Group a competitive edge in gaining access to leading<br />
university research teams and highly qualified personnel.<br />
More than 800 people in R&D are dedicated to<br />
the discovery and development of innovative drugs<br />
for patient care. This strategy is also supported by an<br />
active policy of partnerships. In 2008, Research and<br />
Development expenditure was about €183 million,<br />
close to 19% of consolidated sales, which amounted to<br />
€971 million.<br />
ISTEM MEDIKAL<br />
661 Sokak No 4, Ostim, 06370 Ankara, Turkey<br />
T : +90 312 219 5385<br />
F : +90 312 219 5613<br />
W : www.istemmedikal.com<br />
E : begum.sahin@istemmedikal.com<br />
Booth nr. : B25<br />
Istem Medical is a progressive and innovative company<br />
dedicated to the design and manufacture of hydrophilic<br />
urinary catheters, catheter lubricant gel, various<br />
urology disposables and HYACYST (Interstitial Cystitis,<br />
Painful Bladder Syndrome & Recurrent Bacterial<br />
Cystitis) DEXELL VUR (Vesico Ureteral Reflux Treatment)<br />
DEXELL SUI (Stress Urinary Incontinance Treatment).<br />
Our goal is to provide worldwide high quality products<br />
for the medical sector. Thanks to the cooperation with<br />
leading medical doctors and technology partners in<br />
Turkish universities, our products meet the requirements<br />
to be successful in the medical field.<br />
We have also invested a considerable amount of time<br />
with patients and physicians to develop our own<br />
hydrophilic coating solution.<br />
Quality Policy/Mission Statement<br />
Our aim is to be one of the prime suppliers of medical<br />
devices to the international areas. We are committed<br />
to give quality product at competitive prices. Customer<br />
satisfaction is our top priority.<br />
408 Programme Book<br />
ISURGICALS<br />
109 Preston Road, Whittle-le-woods, PR6 7PJ Chorley,<br />
United Kingdom<br />
T : +44 17 72 46 85 40<br />
F : +44 12 57 23 42 21<br />
W : www.isurgicals.com<br />
E : info@isurgicals.com<br />
Booth nr. : B27<br />
iSurgicals is dedicated to providing high quality<br />
training solutions for surgeons. The i-Sim is the most<br />
advanced physical laparoscopy simulator, for both<br />
standard and Single Port surgery. The sharp real-time<br />
image, quick set-up time and ease of use make it<br />
perfect for regular practice. It offers a projection facility<br />
for group training, and video clips can be recorded<br />
for assessment. Its compact design makes ideal for a<br />
skills lab, operating theatre or office. We also provide<br />
skills models for hand-eye co-ordation, dissection and<br />
suturing, and can also supply laparoscopic instruments<br />
to accompany the i-Sim.<br />
JANSSEN-CILAG EMEA<br />
A division of Janssen Pharmaceutica N.V.<br />
Turnhoutseweg 30, 2340 Beerse, Belgium<br />
T : +32 14 60 21 11<br />
F : +32 14 60 28 41<br />
W : www.janssen-cilag.com<br />
Booth nr. : J14<br />
Janssen-Cilag is part of Johnson & Johnson, one of the<br />
world’s most diversified healthcare companies. Caring<br />
for the world, one person at a time, inspires and<br />
unites the people of Johnson & Johnson. We embrace<br />
research and science -- bringing innovative ideas,<br />
products and services to advance the health and wellbeing<br />
of people. Employees of the Johnson & Johnson<br />
Family of Companies work with partners in health care<br />
to touch the lives of over a billion people every day,<br />
throughout the world.<br />
The Janssen-Cilag companies have a long track record<br />
in developing and marketing treatments for central<br />
nervous system disorders, oncology, gastro-intestinal<br />
conditions, reproductive health and HIV. More information<br />
can be found at www.janssen-cilag.com or<br />
www.jnj.com
KARL STORZ GMBH & CO. KG<br />
Mittelstrasse 8, 78532 Tuttlingen, Germany<br />
T : +49 7461 708 0<br />
F : +49 7461 708 115<br />
W : www.karlstorz.com<br />
E : info@karlstorz.de<br />
Booth nr. : D08<br />
KARL STORZ is a renowned manufacturer that is well<br />
established in all fields of endo-scopy and can be<br />
considered as market leader in rigid endo-scopy. The<br />
still family held company was founded in 1945 in<br />
Tuttlingen, Germany, and has grown to one with a<br />
worldwide presence and 4000 employees. KARL STORZ<br />
offers a range of both rigid and flexible endo-scopes<br />
for a broad variety of applications. Today’s product<br />
range also includes fully integrated concepts for the OR<br />
and servicing.<br />
KESSEL<br />
Kelsterbacher Str. 28, 64546 Moerfelden-Walldorf,<br />
Germany<br />
T : +49 610 520 37 20<br />
F : +49 610 545 59 01<br />
W : www.kessel-marketing.de<br />
E : service@kessel-marketing.de<br />
Booth nr. : B17<br />
KESSEL personal healthcare founded in 1987.<br />
Today a specialised producer and distributor for sexual<br />
reproductive and personal healtcare.<br />
We have partners at Europe, Middle East, Asia,<br />
Australia, Africa and America.<br />
Our products: ACTIVE Erection System, MANUAL<br />
Erection System, Premeno duo, Sylk natural lubricant,<br />
Contragel green, Full love fluid for women and for<br />
men, Hyalofemme vaginal gel, RFSU condoms, Milex<br />
Wide Sealdiaphragms, FemCap cervical cap, IUDs<br />
Disposables for gynecologists. New line for this year:<br />
intimate organics (cosmetic+ medical devices).<br />
K.F.F.<br />
Espora 49, Sarandi (1872) Buenos Aires, Argentina<br />
T : +54 11 4265 4515<br />
F : +54 11 4265 4515<br />
W : www.kffmed.com<br />
E : jfontana@kffmed.com<br />
Booth nr. : K20<br />
K.F.F. is a manufacturer, development and commercial<br />
company. Our mission is to provide physicians mini-<br />
mally invasive surgery devices like: Uretheral catheters<br />
(dougle pigtails), Drainage catheters (Nephrostomy),<br />
female incontinence urinary devices, prolapse meshes<br />
with the highest quality.<br />
KITALPHA MED LTD<br />
Xaver-Weismor-Str. 22A, 81829 Munich, Germany<br />
T : +49 893 303 6974<br />
F : +49 893 468 94<br />
W : www.kitalpha-med.de<br />
E : info@kitalpha-med.de<br />
Booth nr. : B10<br />
Kitalpha Med LTD is the exclusive distributor of<br />
Neotonus products in all the European, Asian and<br />
Arab countries. The technology of the EXMI-therapie<br />
(Extracorporeal magnetic innervation) is based on<br />
pulsating and focused magnetic fields (neuromodulation).<br />
Neocontrol (the magnetic chair) is a system<br />
for the treatment of many pelvic floor diseases such<br />
as: urine and feces incontinence, incontinence after<br />
radical prostatectomie, pelvic pain, erectile disfunction<br />
and other sexual disturbances, cistitis interstitialis and<br />
much more. It is a noninvasive, painless and very<br />
effective therapie offered now in 54 countries around<br />
the globe. It is considered now, from many personalities<br />
of the urological and gynaecological societies<br />
around Europe as the only standard therapy of the<br />
pelvic floor. The other products (Neotone head and<br />
Neotoine table) are used in orthopedics, neurology,<br />
rehabilitation and sports medicine.<br />
All great ideas are simple.<br />
KLS MARTIN GROUP<br />
Ludwigstaler Str. 132, 78532 Tuttlingen, Germany<br />
T : +49 746 170 60<br />
F : +49 746 170 61 93<br />
W : www.klsmartin.com<br />
E : info@klsmartin.com<br />
Booth nr. : K04<br />
KLS Martin – Surgical Innovation is our Passion.<br />
Every day, KLS Martin starts out afresh to confront the<br />
high challenges of a global market head-on and with<br />
renewed energy. Our products stand for innovation<br />
and reliability. Our number one goal is always the<br />
same: people’s health.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
409
Company and Product Description<br />
KOELIS<br />
5 Avenue Grand Sablon, 38700 La Tronche, France<br />
T : +33 476 637 587<br />
F : +33 476 549 561<br />
W : www.koelis.com<br />
E : info@koelis.com<br />
Booth nr. : A25<br />
KOELIS is a Medtech innovative company that provides<br />
the urologist with breakthrough imaging solutions<br />
to bring quality and accuracy to kidney and prostate<br />
interventions.<br />
KOELIS introduces the UroStation.<br />
For the first time 3D ultrasound, image fusion and<br />
automatic organ-based tracking are combined into a<br />
single, easy to use platform that enables urologists<br />
to increase prostate biopsy precision and improve focal<br />
therapy outcomes for all patients.<br />
KYOWA HAKKO KIRIN UK LTD.<br />
258 Bath Road, SL1 4DX London, United Kingdom<br />
T : +44 1753 566 020<br />
F : +44 1753 566 030<br />
W : www.kyowa-kirin.co.jp<br />
E : amiller@kyowa-kirin.co.uk<br />
Booth nr. : A14<br />
Kyowa Hakko Kirin is a global specialty pharmaceutical<br />
company built on a robust foundation of biotechnology.<br />
We are marketing drugs for Oncological use, including<br />
Mitomycin-C Kyowa. Mitomycin-C is an essential<br />
chemotherapeautic agent in the treatment of nonmuscle<br />
invasive Bladder Cancer. Please visit us at<br />
stand A14 for information on prescribing and new<br />
developments.<br />
LABORIE<br />
6415 Northwest Drive, Unit 10, L4V 1X1 Mississauga,<br />
Ontario, Canada<br />
T : +1 905 612 1170<br />
F : +1 905 612 9731<br />
W : www.laborie.com<br />
E : marketing@laborie.com<br />
Booth nr. : F08<br />
LABORIE is pleased to present at the <strong>EAU</strong> <strong>2010</strong> <strong>Annual</strong><br />
<strong>Congress</strong> the most clinically advanced and innovative<br />
products in the field of Pelvic Floor Diagnostics.<br />
LABORIE is a pioneer and world leader in wireless<br />
Urodynamics technology. For more than 40 years we<br />
have designed and produced reference Urodynamics<br />
410 Programme Book<br />
technology to fit every budget and need - from small<br />
offices to world-class research institutions. LABORIE<br />
is dedicated to the exchange of knowledge and to discussing<br />
your interest in Pelvic Floor Health. LABORIE’s<br />
UDS systems for pelvic floor dysfunction diagnostics<br />
and therapy have made Urodynamics easier and faster<br />
to perform with wireless technology, and powerful, yet<br />
versatile software. Our products are supported by unparalleled<br />
service, training, educational courses, and<br />
powerful remote-access technical support. For more<br />
information about our products: please visit www.<br />
laborie.com or email us at marketing@laborie.com.<br />
LASER PERIPHERALS<br />
1000 Boone Ave No 300, MN 55427 Golden Valley,<br />
United States of America<br />
T : +1 763 525 8460<br />
F : +1 763 525 8461<br />
W : www.laserperipherals.com<br />
E : info@laserperipherals.com<br />
Booth nr. : D18<br />
Laser Peripherals designs, manufactures, distributes<br />
and OEM’s medical laser fibers for use in both hard<br />
and soft tissue surgical laser applications. We manufacture<br />
and market at least thirty different surgical<br />
fiber options for use with Diode, Holmium, KTP and<br />
Nd:YAG lasers. Fiber designs include freebeam, contact<br />
and lateral emitting. Laser Peripherals has recently<br />
completed our ISO/CE certification and we are now<br />
actively looking for distribution partners in a variety of<br />
International markets.<br />
LEICA MICROSYSTEMS (SCHWEIZ)<br />
AG<br />
Max Schmidheiny-Strasse 201, 9435 Heerbrugg,<br />
Switzerland<br />
T : +41 71 726 33 33<br />
F : +41 71 726 32 19<br />
W : www.leica-microsystems.com<br />
E : webmaster.som@leica-microsystems.<br />
com<br />
Booth nr. : D21<br />
Leica Microsystems operates globally in four divisions,<br />
where we rank with the market leaders. The<br />
Surgical Division’s focus is to partner with and support<br />
surgeons and their care of patients with the highestquality,<br />
most innovative surgical microscope technology<br />
today and into the future. Products, like the Leica<br />
HM500, the world’s first and only headmounted micro-
scope, combine freedom of movement with outstanding<br />
vision. When it comes to simplifying the workflow<br />
in your operating room, we leave nothing to chance.<br />
LENUS PHARMA GESMBH<br />
Seeböckgasse 59, 1160 Vienna, Austria<br />
T : +43 1 405 14 19 20<br />
F : +43 1 405 14 19 20<br />
W : www.lenuspharma.com,<br />
www.profertil.eu<br />
E : office@lenuspharma.com<br />
Booth nr. : C32<br />
Lenus Pharma is an innovative & ambitious, medium<br />
sized Austrian company specializing on the research,<br />
development and marketing of evidence-based<br />
nutriceutical and other medicinal products in the fields<br />
of urology, gynaecology and ophthalmology. We have<br />
developed and patented the specific composition of<br />
PROfertil®. It is a dietary food for special medical<br />
purposes for the dietary treatment of limited fertility of<br />
men who want a baby. Due to its specific and unique<br />
composition PROfertil® improves and increases<br />
all parameters of sperm health: sperm cell density,<br />
ejaculation volume, progressive and total motility.<br />
PROfertil® acts as a fitness centre for your sperm cells.<br />
Thanks to a mixture of eight separate substances, the<br />
preparation addresses and eliminates all those issues<br />
that disrupt sperm cell quality. Adequate sperm in only<br />
three months!<br />
For further information please do not hesitate to visit<br />
our booth C32 and feel free to take a look at our website<br />
www.profertil.eu<br />
LIFE-TECH INTERNATIONAL<br />
13235 N. Promenade Blvd., TX 77477 Stafford, United<br />
States of America<br />
T : +1 281 491 6600<br />
F : +1 281 491 6646<br />
W : www.life-tech.com<br />
E : urosales@life-tech.com<br />
Booth nr. : K24<br />
Life-Tech designs and manufactures the widest array of<br />
urodynamic products. Designed to be easy to use, the<br />
sixth generation of our networkable and DICOM ready<br />
urodynamic systems meet the clinical and budgetary<br />
needs of any practice. In our booth, will be featuring<br />
the new NovaFlo wireless urodynamic system and<br />
the new VesiScan bladder ultrasound system. If it has<br />
something to do with Urodynamics, Life-Tech does it,<br />
and does more of it than anyone else in the world.<br />
LIMMER LASER GMBH<br />
Schwarzschildstr. 1, 12489 Berlin, Germany<br />
T : +49 30 6392 557 0<br />
F : +49 30 6392 558 0<br />
W : www.limmerlaser.de<br />
E : bjoern.limmer@limmerlaser.de<br />
Booth nr. : K18<br />
At this year’s <strong>EAU</strong> <strong>Congress</strong>, Limmer Laser presents the<br />
unique multipurpose DIOLAS LFD 3000 laser system<br />
for:<br />
- Benign Prostatic Hyperplasia (BPH)<br />
- Destruction of Stones in Kidney, Bladder and Ureter<br />
- Tissue-protective Therapy of Strictures and Stenosis<br />
of Urethra or Ureter<br />
- Vaporization of Urothelial Tumors<br />
- Vaporization of Condylomata<br />
- and many more<br />
Limmer Laser GmbH is a German company, specializing<br />
in the design, manufacture and sale of medical<br />
lasers and accessories. Our products cover all the<br />
major disciplines of human, dental and veterinary<br />
medicine. For each discipline a broad range of high<br />
quality accessories is available. The product range<br />
includes CO2 Lasers, Diode Lasers and Specialty Lasers.<br />
We have a strong emphasis on research and development,<br />
production, service and training. Working in<br />
conjunction with hospitals and physicians is just as important<br />
as good communication. Product quality and<br />
an optimal patient outcome are our No. 1 priorities.<br />
LISA LASER PRODUCTS<br />
Max-Planck-Str. 1, 37191 Katlenburg Lindau, Germany<br />
T : +49 55 569 938 0<br />
F : +49 55 569 938 10<br />
W : www.lisalaser.com<br />
E : info@lisalaser.de<br />
Booth nr. : K35<br />
LISA laser products presents the latest evolution of the<br />
RevoLix laser. For the treatment of BPH this laser has<br />
the highest tissue ablation rate, superior haemostasis<br />
and best economics. Histology is available. The RevoLix<br />
DUO laser has an on-board Holmium laser for optional<br />
stone fragmentation. The RevoLix product covers the<br />
entire urological range including rigid and flexible<br />
stonework, open-, endo–, and laparoscopic surgery.<br />
LISA provides worldwide sales, after sales service and<br />
clinical training.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
411
Company and Product Description<br />
LUMENIS DEUTSCHLAND GMBH<br />
Heinrich-Hertz-Strasse 3, 63303 Dreieich<br />
(Dreieichenhain), Germany<br />
T : +49 610 383 350<br />
F : +49 610 383 353 00<br />
W : www.lumenis.com<br />
E : umberto.volpe@lumenis.com<br />
Booth nr. : J27<br />
Lumenis is the world leading manufacturer of lasers<br />
and other light-based energy sources for a variety of<br />
medical applications. Lumenis and its predecessor,<br />
Coherent Medical, has been developing Holmium:<br />
YAG lasers for lithotripsy and for treating BPH for over<br />
10 years ago with leading urologists. We promote<br />
therapies on the basis of clinical evidence. We have a<br />
worldwide distribution organisation in over 100 countries<br />
and an installed base of over 70,000 devices in<br />
use in Hospitals, Outpatient Centres and Private Offices.<br />
MCUBE TECHNOLOGY<br />
Sangbong-dong, Chungnang-Gu, 131-220 Seoul, South<br />
Korea<br />
T : +82 2 3421 7780 (ext. 103)<br />
F : +82 2 3421 7076<br />
W : www.mcubetech.co.kr<br />
E : mcube@mcubetech.co.kr<br />
Booth nr. : B29<br />
Mcube provides the medical devices of (a) Bladder<br />
Scanner (Bladder Volume Measurement System)<br />
and (b) Magnetic Stimulator (Magnetic Incontinence<br />
Therapy System) manufactured under the ISO13485 and<br />
CE since 1999.<br />
(a) 3D Ultrasonic Bladder Scanner (CUBEscan)<br />
* Portable 3D Ultrasonic Bladder Volume<br />
Measurement System<br />
* Non-invasively measuring Volume and Post-Void<br />
Residual (PVR)<br />
* Supporting real time ‘Pre-Scan’ function<br />
* PC-Upload and on-sight Printing of Scanned<br />
Information<br />
* Minimizing unnecessary catheter use.<br />
* Enhancing the quality of life and dignity (for<br />
patients)<br />
* Saving staff-time and total expense (for hospital)<br />
(b) Magnetic Stimulator<br />
* Magnetic Incontinence Therapy System.<br />
* Treatment: Urinary incontinence, chronic pelvic<br />
pain, constipation by causing contraction and<br />
relaxation of pelvic floor muscles.<br />
412 Programme Book<br />
* Non-Invasive & Non-Contact: Not requiring any<br />
insertion of electrodes into the vagina so that a<br />
patient can be treated with fully clothed.<br />
* No side-effect<br />
MEDAC GMBH<br />
Theaterstrasse 6, 22880 Wedel, Germany<br />
T : +49 410 380 060<br />
F : +49 410 380 061 00<br />
W : www.medac.de<br />
E : contact@medac.de<br />
Booth nr. : A01<br />
Medac has specialised in the treatment of malignant<br />
diseases since it’s foundation in 1970. Now, medac is<br />
one of the leading manufacturers of oncology products<br />
not only in Germany, but in many international markets.<br />
Medac offers both innovative and well proven<br />
therapeutic<br />
options in the fields of Oncology, Hematology, Urology,<br />
autoimmune diseases and fibrinolysis and is only one<br />
of a handful of companies to also specialise in the field<br />
of diagnostics.<br />
MEDICAL MEASUREMENT SYSTEMS<br />
B.V.<br />
Colosseum 25, 7521 PV Enschede, The Netherlands<br />
T : +31 53 480 3700<br />
F : +31 53 480 3701<br />
W : www.mmsinternational.com<br />
E : n.spit@mmsinternational.com<br />
Booth nr. : F30<br />
MMS is one of the world’s leading companies providing<br />
practical diagnostic equipment and accessories<br />
for both simple and advanced urodynamic studies. The<br />
Solar urodynamic system offers flexibility and ease-ofuse<br />
and can be expanded from an office-based configuration<br />
to a high-end video-urodynamic system. Our<br />
new and easy-to-use Solar Blue system is the smallest<br />
completely wireless urodynamic system on the market!<br />
Furthermore MMS offers wireless Uroflowmetry and<br />
Bluetooth Ambulatory Urodynamics. At the <strong>EAU</strong> <strong>2010</strong><br />
meeting we will introduce a new real-time bladder<br />
scanner to measure bladder volume and PVR.
MEDISPEC LTD<br />
20410 Observation Drive, suite #102, MD 20876<br />
Germantown, United States of America<br />
T : +1 301 944 1575<br />
F : +1 301 972 6098<br />
W : www.medispec.com<br />
E : marketing@medispec.com<br />
Booth nr. : I19<br />
Medispec - The Sound Alternative to Surgery<br />
Founded in 1992, Medispec develops, manufactures<br />
and markets high-tech medical equipment using<br />
shockwave technology for the fields of Urology<br />
(Extracorporeal and Intracorporeal lithotripsy – ESWL,<br />
Treatments for Erectile Dysfunction using Extracorporeal<br />
Shock Wave for Sexual Therapy – ESST),<br />
Thermotherapy (for Prostatitis & BPH), Cardiology<br />
(Extracorporeal Shockwave for Myocardial<br />
Revascularization – ESMR), Orthopedics (ESWT),<br />
Physiotherapy (Radial Wave Therapy – RWT) and<br />
Aesthetics (Cellulite reduction using Acoustic RWT), as<br />
well as Veterinary applications.<br />
Medispec has a proven track record of delivering high<br />
performance shockwave therapy products to international<br />
medical institutions. With more than 2000<br />
installations worldwide, Medispec products are sold to<br />
governments, universities and private medical institutions<br />
in over 80 markets through a global network of<br />
distributors.<br />
MEDIWATCH PLC<br />
Cosford Lane, Rugby, CV21 1QN Warwickshire, United<br />
Kingdom<br />
T : +44 178 854 78 88<br />
F : +44 178 853 64 34<br />
W : www.mediwatch.com<br />
E : jrp@mediwatch.com<br />
Booth nr. : H29<br />
Mediwatch - “Providing Complete Urological<br />
Diagnostic Services”<br />
Urodynamics:<br />
A NEW range of Urodynamic systems:<br />
• Clinic with Sensic: Fully featured touch-screen<br />
system with a range of upgrades<br />
• A complete range of urodynamics consumables.<br />
Ultrasound:<br />
• Multiscan PVR real-time live ultrasound bladder<br />
scanner<br />
Uroflowmetry:<br />
• Urodyn+ with weight cell or spinning disc<br />
• Portaflow Advanced for mobility and a PC database<br />
POCT:<br />
• PSAwatch, a quantitative 10 minute blood test for<br />
point of care use<br />
• New Bladderwatch<br />
Please visit us at stand H29.<br />
MEDTRONIC INTERNATIONAL<br />
TRADING SÀRL<br />
Route du Molliau 31, 1131 Tolochenaz, Switzerland<br />
T : +41 21 802 77 18<br />
F : +41 21 802 79 15<br />
W : www.medtronic.com<br />
E : nathalie.courtine@medtronic.com<br />
Booth nr. : B14<br />
At Medtronic, we’re committed to Innovating for Life<br />
by pushing the boundaries of medical technology and<br />
actually changing the way the world treats chronic<br />
disease. Driven by our deep understanding of the<br />
human body and our close partnerships with physicians,<br />
we’re transforming technology to treat patients<br />
across the entire care continuum. Our innovations help<br />
physicians diagnose diseases early, treat patients with<br />
the least amount of disruption possible, and minimize<br />
symptoms throughout the patient’s life. Today, we’re<br />
improving the lives of millions of people worldwide<br />
each year across numerous conditions—including<br />
heart disease, diabetes, neurological disorders, spinal<br />
conditions, and vascular diseases. But it isn’t enough.<br />
So we’re innovating beyond products. We’re breaking<br />
down barriers, challenging assumptions, and looking<br />
beyond the status quo—to continually find more ways<br />
to help people live better, longer.<br />
MIROMED PFLEIDERER GMBH<br />
Lindleystr. 12, 60314 Frankfurt, Germany<br />
T : +49 694 898 78 0<br />
F : +49 694 898 78 70<br />
W : www.miromed.eu<br />
E : h.bingemer@miromed.eu<br />
Booth nr. : A22<br />
Mirovalve - Automatic Catheter Valve<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
413
Company and Product Description<br />
NEOMEDIC INTERNATIONAL S.L.<br />
C/Maestrat, 41-43. 1° 1ª, 08225 Terrassa, Spain<br />
T : +34 937 804 505<br />
F : +34 937 804 799<br />
W : www.neomedicinternational.com<br />
E : elisenda@neomedic.com<br />
Booth nr. : J30<br />
Neomedic International manufactures and distributes<br />
urinary unique patented incontinence treatment options.<br />
All FDA, CE approved. The only readjustable system<br />
for Female Urinary Incontinence: TRT Tension free<br />
Readjustable Tape. The only office based TOT single<br />
incision minimally invasive sling without needleless:<br />
Needleless. The only readjustable system for Male<br />
Urinary Incontinence: MRS Male Readjustable System.<br />
The only mesh without Knotts: Knottless Incontinence<br />
Mesh. The optimal quality for each therapy.<br />
NEOTRACT<br />
4473 Willow Road, Suite 100, 94588 Pleasanton, United<br />
States of America<br />
T : +1 925 401 0700<br />
F : +1 925 401 0699<br />
W : www.neotract.com<br />
E : info@neotract.com<br />
Booth nr. : C26<br />
NeoTract, Inc. is dedicated to developing innovative,<br />
minimally invasive and clinically effective devices that<br />
address unmet needs in the field of urology. Our initial<br />
focus is to improve the standard of care for patients<br />
with BPH (Benign Prostatic Hyperplasia), a broadly<br />
underserved market. Our first product is the UroLift®<br />
System, a set of minimally invasive devices designed to<br />
treat lower urinary tract symptoms (LUTS) due to BPH.<br />
NOVARTIS ONCOLOGY<br />
180 Park Avenue, 07932 Florham Park, United States of<br />
America<br />
T : +1 862 778 8300<br />
F : +1 973 781 8265<br />
W : www.novartisoncology.com<br />
E : judith.picciuti@novartis.com<br />
Booth nr. : G02<br />
Novartis Oncology delivers innovative therapies that<br />
help change the way patients live with cancer and<br />
blood disorders. These include Glivec® (imatinib),<br />
Tasigna® (nilotinib), Afinitor® (everolimus), Zometa®<br />
(zoledronic acid), Femara® (letrozole), Sandostatin®<br />
414 Programme Book<br />
LAR® (octreotide) and Exjade® (deferasirox). Novartis<br />
Oncology has a robust pipeline that utilizes recent discoveries<br />
in molecular genomics, rational drug design<br />
and state-of-the-art drug discovery technologies.<br />
OLYMPUS MEDICAL SYSTEMS<br />
EUROPA GMBH<br />
Wendenstrasse 14-18, 20097 Hamburg, Germany<br />
T : +49 402 377 357 46<br />
F : +49 402 377 357 31<br />
W : www.olympus-europa.com<br />
E : stefanie.thiele@olympus-europa.com<br />
Booth nr. : G06<br />
The doctor’s mission is to provide high quality care for<br />
patients. Olympus contributes to this mission by<br />
developing new technology, maintaining high quality<br />
levels through optimal production systems, and by<br />
creating the optimal endoscopy environment.<br />
ORION PHARMA<br />
P.O. Box 65, 02101 Espoo, Finland<br />
T : +358 104 261<br />
F : +358 104 263 815<br />
W : www.orion.fi/english<br />
E : firstname.lastname@orion.fi<br />
Booth nr. : F23<br />
Orion is an innovative European R&D-based pharmaceuticals<br />
company developing and manufacturing<br />
medicinal treatments and diagnostic tests for global<br />
markets. The company’s extensive pharmaceutical<br />
product range includes both human and veterinary<br />
pharmaceuticals as well as active pharmaceutical<br />
ingredients. Orion’s core therapeutic areas are CNS<br />
disorders, oncology, critical care, asthma and COPD.<br />
Partnerships in R&D and global marketing are elementary<br />
for Orion in the company’s growth-oriented<br />
strategy. Orion’s shares are listed on NASDAQ OMX<br />
Helsinki. For more, please visit www.orion.fi/english.<br />
PAJUNK GMBH<br />
Karl-Hall-Str. 1, 78187 Geisingen, Germany<br />
T : +49 770 492 915 29<br />
F : +49 770 492 916 00<br />
W : www.pajunk.com<br />
E : petra.woelfle@pajunk.com<br />
Booth nr. : J25<br />
Pajunk offers a homogenous range of products, supplying<br />
just the right medical products to fully cover
the particular methods of application concerned. The<br />
Pajunk range of products are: Regional Anaesthesia,<br />
Interventional Pain, Laparoscopy, Organbiopsy and<br />
Dental.<br />
Pajunk is offering needles, instruments and complete<br />
kits for Regional Anäesthesia and Interventional Pain<br />
in particular for: Spinal, Epidural, CSE and Plexus.<br />
PERGENTIUM<br />
10 Martyn Close, BN5 9QH Henfield W. Sussex, United<br />
Kingdom<br />
T : +44 127 349 3989<br />
F : +49 251 974 5942<br />
W : www.pergentium.com<br />
E : info@pergentium.com<br />
Booth nr. : A28<br />
As an independent company Pergentium Ltd. have<br />
made their mission to source innovative products<br />
from around the globe and make them available to<br />
European, Mediterranean and North-African clinicians.<br />
At <strong>EAU</strong> we feature:<br />
TargetScan Touch - a stereotactic template guided<br />
biopsy system using a motionless US probe for prostate<br />
mapping, brachytherapy and cryotherapy.<br />
PerClot & FoamSeal - plant based haemomstasis<br />
products for both open and laprascopic surgery.<br />
PerClot & FoamSeal are products of Starch Medical<br />
Inc. a U.S.-based, medical device company engaged in<br />
the design, manufacture and sale of novel, absorbable<br />
surgical hemostats synthesized from proprietary<br />
Absorbable Modified Polymers (AMP®).<br />
Exablate 2000 - an MRI based focussed Ultrasound<br />
treatment for, among other applications, palliative<br />
bone metastases and prostate cancer.<br />
PFIZER FRANCE<br />
23-25 avenue du Dr. Lannelongue, 75668 Paris Cedex<br />
14, France<br />
T : +33 1 58 07 30 00<br />
F : +33 1 58 07 30 01<br />
W : www.pfizer.fr<br />
E : alex.cleveland@pfizer.com<br />
Booth nr. : D02<br />
At Pfizer, we apply science and our global resources to<br />
improve health and well-being at every stage of life.<br />
We strive to set the standard for quality, safety and<br />
value in the discovery, development and manufacturing<br />
of medicines for people and animals. Our diversified<br />
global health care portfolio includes human and<br />
animal biologic and small molecule medicines and<br />
vaccines, as well as nutritional products and many of<br />
the world’s best-known consumer products. Every day,<br />
Pfizer colleagues work across developed and emerging<br />
markets to advance wellness, prevention, treatments<br />
and cures that challenge the most feared diseases<br />
of our time. Consistent with our responsibility as the<br />
world’s leading biopharmaceutical company, we also<br />
collaborate with health care providers, governments<br />
and local communities to support and expand access<br />
to reliable, affordable health care around the world.<br />
For more than 150 years, Pfizer has worked to make a<br />
difference for all who rely on us.<br />
PHYSION<br />
Via Statale 12 Sud, 1/b, 41036 Medolla, Italy<br />
T : +39 0535 611 082<br />
F : +39 0535 610 420<br />
W : www.physion.it<br />
E : physion@tin.it<br />
Booth nr. : D27<br />
EMDA by Physion provides accelerated localized drug<br />
administration into the bladder wall and prostatic<br />
urethra. Chemotherapy for high risk bladder tumors,<br />
Interstitial Cystitis and IPP are treated on an ambulatory<br />
basis, cost-effectively. N-DO injector catheter needle<br />
provides Localized Anesthesia for TURB and biopsies<br />
for Day Surgery management.<br />
PIERRE FABRE MÉDICAMENT<br />
Parc Industrielle De La Chartreuse, 81100 Castres<br />
CEDEX, France<br />
T : +33 563 714 500<br />
F : +33 563 714 559<br />
W : www.pierre-fabre.com<br />
E : Delphine.deyzac@pierre-fabre.com<br />
Booth nr. : F14<br />
Pierre Fabre is the 2nd largest independent French<br />
pharmaceutical laboratory. “From Health to Beauty”,<br />
the Pierre Fabre Group is present with dermocosmetic,<br />
OTC and medical activities.<br />
Research & Development is the main growth driver of<br />
Pierre Fabre in the medical field: this investment in<br />
research has resulted in the discovery of new molecules,<br />
and this effort has enabled the firm to reinforce<br />
its world-wide development.<br />
Pierre Fabre Médicament is a successful partner in<br />
Urology with mainly:<br />
- Permixon: a recognized treatment for HBP, mar-<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
415
Company and Product Description<br />
keted in more than 60 countries worldwide<br />
- Testopatch: in launch phase in some major<br />
European countries<br />
Pierre Fabre Médicament is gold corporate sponsor of<br />
the <strong>EAU</strong>.<br />
Pierre Fabre Médicament<br />
www.pierre-fabre.com<br />
PNN MEDICAL A/S<br />
Oldenvej 13, 3490 Kvistgaard, Denmark<br />
T : +45 491 391 13<br />
F : +45 491 391 11<br />
W : www.pnnmedical.com<br />
E : info@pnnmedical.com<br />
Booth nr. : C22<br />
Pnn Medical specialises in minimally invasive medical<br />
devices. With the Memokath Stent Programme we<br />
provide healthcare professionals and their patients<br />
with a safe, simple, and reliable treatment for BPH<br />
and urinary tract obstruction.<br />
Memokath is a safe, simple and reliable Nickel-<br />
Titanium stent with thermal shape-memory effect<br />
making it very gentle, safe and easy to insert. Most<br />
patients tolerate the insertion procedure well which<br />
makes the stents an excellent option for patients who<br />
are not able or willing to go through major surgery.<br />
Patients will usually be discharged from hospital on<br />
the day of the procedure allowing them to return to<br />
their daily routines quickly.<br />
If necessary the Memokath stents can be removed as<br />
easily as they are inserted due to the unique design<br />
and thermal shape-memory effect.<br />
Pnn Medical has a close collaboration with medical<br />
professionals around the world which enables us to<br />
meet the demands of both healthcare professionals<br />
and patients.<br />
PROMEDON S.A.<br />
Av. Gral. Manuel Savio s/n - Lote 3 - Mza. 3., X5925<br />
XAD Cordoba, Argentina<br />
T : +54 351 450 2100<br />
F : +54 351 450 2130<br />
W : www.promedon.com<br />
E : internationalsales@promedon.com<br />
Booth nr. : E25<br />
Promedon is a leading international company in the<br />
research, development, production and distribution of<br />
innovative medical technology for the urology and<br />
urogynecology market, present in more than 30 coun-<br />
416 Programme Book<br />
tries around the world.<br />
Among a wide range of solutions, Promedon<br />
offers: ARGUS, Adjustable Sling for Male Urinary<br />
Incontinence; Ophira, single incision mini sling<br />
system for female SUI; NAZCA, System for Pelvic<br />
Organ Prolapse Repair; SAFYRE VS & SAFYRE T PLUS,<br />
Adjustable Slings for Female SUI; UNITAPE VS & T<br />
Plus polypropylene suburethral slings; and Vantris, an<br />
injectable bulking agent for VUR treatment.<br />
PROSURG, INC<br />
2195 Trade Zone Blvd San Jose CA 95131, United States<br />
of America<br />
T : +1 408 945 4044<br />
F : +1 408 945 1390<br />
W : www.Prosurg.com<br />
E : Ashvin@Prosurg.com<br />
Booth nr. : B23<br />
Prosurg Inc. located in Silicon Valley, California<br />
designs, manufactures, and markets single use<br />
medical devices for management of Urological,<br />
Gynecological & Uro-Gynecological disorders. These<br />
products are based on safe and proven state of the art<br />
technology and advance biomaterial science platform<br />
to provide cost effective solution for physicians,<br />
patients, and health care providers. Prosurg, Inc.<br />
currently markets a full line of Monopolar & Bipolar<br />
(Salintrode TM - saline friendly) Resection, Coagulation<br />
& Electrovaporization electrodes for BPH/TURP<br />
prostate surgery, Bladder tumor resection, Uterine<br />
fibroid resection & Endometrial Ablation treatment.<br />
Prosurg has also developed full line of single use<br />
Passageway TM / Snake TM Ureteral stents for short term<br />
and long term implantation, Relieve TM - Bioabsorbable<br />
Urethral Stent, GelTx TM - Intraprostatic Gel Injection<br />
Treatment, Mini Sling TM - Urethral Sling for SUI<br />
treatment and XScape TM - Tipless, Nitinol Stone<br />
retrieval Baskets for endourology application. All of<br />
our products are FDA approved and has been granted<br />
CE Mark clearance. For company information and<br />
Product portfolio, please refer to www.Prosurg.com<br />
PROSURGICS<br />
Venture House, Arlington Square, RG12 1WA Bracknell,<br />
United Kingdom<br />
T : +44 1344 742 896<br />
F : +44 1344 746 555<br />
W : www.freehandsurgeon.com<br />
E : enquire@prosurgics.com<br />
Booth nr. : D15
The FreeHand robotic camera controller is your most<br />
dependable camera assistant, providing an extra hand<br />
in every laparoscopic procedure. Taking only 2-minutes<br />
to set up, FreeHand will help you achieve new levels of<br />
efficiency and patient throughput. FreeHand provides<br />
the surgeon with simple and direct head-movement<br />
control of scope position. Now you can benefit from<br />
rock-steady visualisation of unparalleled clarity, no<br />
matter how long the procedure.<br />
FreeHand has been designed to bring affordable<br />
robotic assistance to every operating room.<br />
Visit Prosurgics on stand D15 to find out how your<br />
surgical team can become some of the world’s first<br />
FreeHand surgeons.<br />
PROUROCARE MEDICAL INC.<br />
6440 Flying Cloud Drive, Eden Prairie, MN 55344,<br />
United States of America<br />
T : +1 952 476 9093<br />
F : +1 952 843 7032<br />
W : www.ProUroCare.com<br />
E : rcarlson@prourocare.com<br />
Booth nr. : D29<br />
The ProUroScan System is an imaging system designed<br />
for use as an aid to the physician in visualizing and<br />
documenting abnormalities in the prostate that have<br />
been previously detected by a digital rectal exam<br />
for men (DRE). The ProUroScan System is used to<br />
generate a real time image and map of the prostate<br />
that can be stored electronically.<br />
PROUS SCIENCE<br />
Provenza 388, 2nd Floor, 08025 <strong>Barcelona</strong>, Spain<br />
T : +34 934 592 220<br />
F : +34 934 581 535<br />
W : www.prous.com<br />
E : alex.denovoa@thomsonreuters.com<br />
Booth nr. : C28<br />
Prous Science, as part of Thomson Reuters business, is<br />
a broad-scope international company whose core business<br />
is information management and dissemination<br />
in medicine and life sciences. The company has been<br />
providing scientific services on drug R&D, pharmacology,<br />
medicine and medicinal chemistry since 1958,<br />
and our information services, known for the accuracy<br />
and high quality of their content, have become<br />
industry standards. Prous Science provides quality and<br />
relevant content by working with local and international<br />
opinion leaders and fosters partnership with major<br />
international and national medical societies.<br />
QUANTA SYSTEM SPA<br />
Via IV Novembre 116, 21058 Solbiate Olona (VA), Italy<br />
T : +39 0331 376 797<br />
F : +39 0331 367 815<br />
W : www.quantasystem.com<br />
E : quanta@quantasystem.com<br />
Booth nr. : F29<br />
Quanta System produces cutting edge medical lasers.<br />
Key fractional and laser platform solutions for dermatology,<br />
vascular and aesthetic medicine, innovative<br />
systems for the treatment of psoriasis and vitiligo,<br />
together with advanced devices, including lasers, for<br />
surgical and urologic applications (ex. prostate BPH)<br />
complete the lineup.<br />
Our payoff, DNA Laser Technology, is not just a marketing<br />
promise: it’s also a way of thinking, working, and<br />
creating values to be shared. It is a concrete and profound<br />
commitment, the corporate policy of an expert<br />
and determined multinational group which makes<br />
technological research its own mission every days.<br />
RECORDATI INDUSTRIA CHIMICA E<br />
FARMACEUTICA S.P.A.<br />
Via Civitali 1, 20148 Milan, Italy<br />
T : +39 024 8787 468<br />
F : +39 024 8787 126<br />
W : www.recordati.com<br />
E : praolini.m@recordati.it<br />
Booth nr. : I14<br />
Recordati, established in 1926, is a European pharmaceutical<br />
group, listed on the Italian Stock Exchange,<br />
with consolidated revenue of € 747.5 million in 2009.<br />
With Headquarters in Milano, Italy, and Operations in<br />
the main European Countries, and a staff of over 2,950,<br />
Recordati is dedicated to the research, development,<br />
manufacturing and marketing of pharmaceuticals.<br />
A European Team of over 1,450 medical representatives<br />
inform physicians on a wide range of innovative<br />
pharmaceuticals in a number of therapeutic areas,<br />
including a specialized line dedicated to treatments for<br />
rare diseases. Recordati is a well known Company in<br />
the cardiovascular area and its products are marketed<br />
worldwide by its own organizations or under license.<br />
Recordati is also committed to the research of new<br />
drug entities within the urological area. It has rights<br />
in Europe, Middle East and Africa for silodosin, a<br />
highly selective alpha-blocker for the treatment of BPH<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
417
Company and Product Description<br />
symptoms. Silodosin is successfully marketed in Japan<br />
since 2006 and it has been recently launched in US,<br />
while the European Commission granted marketing<br />
authorization for silodosin under the brands Urorec<br />
and Silodyx on January 29, <strong>2010</strong>. Silodosin is expected<br />
to be marketed in Europe in the second half of <strong>2010</strong>.<br />
ROTTAPHARM | MADAUS<br />
Via Valosa di Sopra, 9, 20052 Monza, Italy<br />
T : +39 039 739 02 12<br />
F : +39 039 739 03 72<br />
W : www.rottapharm.com<br />
E : info@rottapharm.com<br />
Booth nr. : I06<br />
The Italian multinational company Rottapharm|Madaus<br />
has established a worldwide franchise and expertise<br />
in Urology with leading products such as Spasmolyt®/<br />
Spasmoplex®/Uraplex®/Ceris®/Regurin® (Trospium<br />
Chloride, antimuscarinic treatment for overactive<br />
bladder) and Uralyt-U (K+ Na+ citrate for prevention of<br />
urolythiasis). New developments in the same area include<br />
the once-daily formulation of Trospium Chloride<br />
(UriVesc®) and an extended-release once-daily<br />
formulation of Ciprofloxacin (UtiminX®) for treatment<br />
of uncomplicated UTI.<br />
RUDOLF MEDICAL GMBH + CO. KG<br />
Zollerstrasse 1, 78567 Fridingen, Germany<br />
T : +49 7463 99 56 0<br />
F : +49 7463 99 56 56<br />
W : www.rudolf-med.com<br />
E : mail@rudolf-med.com<br />
Booth nr. : K28<br />
RUDOLF MEDICAL GmbH + Co. KG, established in<br />
Fridingen/Germany in 1950, is represented in over 85<br />
countries.<br />
RUDOLF translates its belief in lasting values by<br />
fostering close customer relationships and offering<br />
innovative high-technology products and efficient<br />
service. The company’s product range includes<br />
instruments, endoscopes and equipment of excellent<br />
quality for numerous fields of open surgery as<br />
well as for minimally invasive surgery, i.e. UROLOGY,<br />
ARTHROSCOPY, LAPAROSCOPY, NEURO-SURGERY,<br />
GYNAECOLOGY.<br />
At the 25th <strong>Annual</strong> <strong>EAU</strong> <strong>Congress</strong> <strong>2010</strong> in <strong>Barcelona</strong><br />
RUDOLF MEDICAL proudly presents its consistent<br />
HD 1080 Concept including HDTV CAMERA,<br />
DOCUMENTATION SYSTEM, DISTRIBUTION and<br />
418 Programme Book<br />
STREAMING SOLUTION. RUDOLF MEDICAL’s product<br />
range for urology includes complete product lines<br />
for: cysto-urethroscopy, resectoscopy, urethrotomy,<br />
uretero-renoscopy and pediatric endo-urology.<br />
RUDOLF MEDICAL will be happy to welcome you at<br />
stand K 28.<br />
SANOFI-AVENTIS<br />
174 avenue de France, 75013 Paris, France<br />
T : +33 155 715 123<br />
F : +33 155 715 120<br />
W : http://en.sanofi-aventis.com<br />
E : joelle.sissmann@sanofi-aventis.com<br />
Booth nr. : J07<br />
Sanofi-aventis, the fourth largest pharmaceutical<br />
company, is a diversified global healthcare company,<br />
focused on patients’ needs.<br />
A worldwide presence, established expertise in diabetes<br />
and oncology, market leadership in vaccines, major<br />
biological products and a strong presence in emerging<br />
markets are the core strengths of sanofi-aventis.<br />
Company business activities also include consumer<br />
healthcare products, generics and animal health. As<br />
a healthcare leader, sanofi-aventis is concerned about<br />
global public health issues and implements a regional<br />
approach to make the most of local opportunities.<br />
SANOFI PASTEUR<br />
1755 Steeles Avenue West, M2R 3T4 Toronto, Canada<br />
T : +1 416 667 2840<br />
F : +1 416 667 7154<br />
W : www.sanofipasteur.com<br />
E : Immucyst.Mailbox@sanofipasteur.com<br />
Booth nr. : I08<br />
Sanofi Pasteur, the vaccines division of sanofi-aventis<br />
Group, provided more than 1.6 billion doses of vaccine<br />
in 2008, making it possible to immunize more than<br />
500 million people across the globe. A world leader<br />
in vaccine industry, Sanofi Pasteur offers the broadest<br />
range of vaccines protecting against 20 infectious<br />
diseases. The company’s heritage, to create vaccines<br />
that protect life, dates back more than a century.<br />
Sanofi Pasteur is the largest company entirely dedicated<br />
to vaccines. Every day, the company invests more<br />
than EUR 1 million in research and development. For<br />
more information, please visit www.sanofipasteur.com.
SIEMENS AG HEALTHCARE SECTOR<br />
Henkestr. 127, 91050 Erlangen, Germany<br />
T : +49 913 184 0<br />
F : +49 913 184 292 4<br />
W : www.siemens.com/healthcare<br />
E : med.gms@siemens.com<br />
Booth nr. : K25<br />
The Siemens Healthcare Sector is one of the world’s<br />
largest suppliers to the healthcare industry and a<br />
trendsetter in medical imaging, laboratory diagnostics,<br />
medical information technology and hearing<br />
aids. Siemens offers its customers products and<br />
solutions for the entire range of patient care from a<br />
single source – from prevention and early detection<br />
to diagnosis, and on to treatment and aftercare. By<br />
optimizing clinical workflows for the most common<br />
diseases, Siemens also makes healthcare faster, better<br />
and more cost-effective. Siemens Healthcare employs<br />
some 48,000 employees worldwide and operates<br />
around the world.<br />
http://www.siemens.com/healthcare.<br />
SILIMED LTDA<br />
Rua Figueirado Rocha, 374, 21240 660 Rio de Janeiro,<br />
Brazil<br />
T : +55 021 368 770 80<br />
F : +55 021 368 771 40<br />
W : www.silimed.com.br<br />
E : catarinalopes@silimed.com.br<br />
Booth nr. : A21<br />
Silimed is a Brazilian company present in the market<br />
since 1978, and manufacturer of silicone implants and<br />
devices for Urology, Plastic Surgery and other specialities.<br />
Being among the three major companies in this<br />
segment, Silimed exports to more than fifty countries<br />
in all five continents. Silimed’s products are manufactured<br />
with FDA approved raw materials and according<br />
to Brazilian, European and American standards, all of<br />
them bearing the CE Mark.<br />
SIU SOCIETÀ ITALIANA DI<br />
UROLOGIA<br />
Largo Lanciani 1, 00162 Rome, Italy<br />
T : +39 068 620 26 37<br />
F : +39 068 632 50 73<br />
W : www.siu.it<br />
E : educational@siu.it<br />
Booth nr. : A26<br />
The Italian Society of Urology, founded in 1908, is the<br />
most important Urologist Society in Italy. It has more<br />
than 2500 active members and is therefore involved<br />
in several scientific research projects, educational<br />
courses, clinical studies and awareness campaigns.<br />
SOCIEDAD MEXICANA DE<br />
UROLOGíA A.C.<br />
Montecito #38 Office 25, floor 26, Mexico<br />
T : +52 55 9000 3385<br />
F : +52 55 9000 3386<br />
W : www.smu.org.mx<br />
E : smu@wtcmexico.com.mx<br />
Booth nr. : A35<br />
Mexican association of medical specialists in urology.<br />
SOCIÉTÉ INTERNATIONALE<br />
D’UROLOGIE<br />
1155 University, Suite 1155, H3B 3A7 Montreal, Canada<br />
T : +1 514 875 56 65<br />
F : +1 514 875 02 05<br />
W : www.siu-urology.org<br />
E : susie.petrusa@siu-urology.org<br />
Booth nr. : A09<br />
The Société Internationale d’Urologie is a professional<br />
association that serves as an international platform<br />
for sustainable urological education and collaborative<br />
humanitarian activities to improve urological care<br />
worldwide.<br />
As the SIU continues to grow, its congresses will be<br />
held on an annual basis, starting in 2011. Visit booth<br />
A09 to hear about the SIU’s final topical meeting-the<br />
SIU World Meeting on Lower Urinary Tract Dysfunction<br />
in Marrakech, Morocco, October 13-16, <strong>2010</strong>-as well as<br />
our 2011 <strong>Congress</strong> in Berlin.<br />
SOCOMED & ROCAMED GROUP<br />
PROMEPLA<br />
c/o PROMEPLA- 9, avenue Albert II, le Copori, 98000<br />
Monaco, Monaco<br />
T : +377 979 842 32<br />
F : +377 920 561 50<br />
W : www.promepla.com; www.rocamed.eu;<br />
www.socomed.com<br />
E : info@rocamed.com<br />
Booth nr. : A17<br />
SOCOMED & ROCAMED: capital equipment & single use<br />
disposables for Urology, Endourology & Gynaecology.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
419
Company and Product Description<br />
SOCOMED manufacture & distribute the ENDOFLOW<br />
SYSTEM; A new standard in Fluid Management for<br />
Endourology. The unique ENDOFLOW SYSTEM offers<br />
heated liquid, a controlled pressure and constant<br />
liquid flow, as well as a large range of single use<br />
disposables.<br />
ROCAMED is offering a NEW complete range of single<br />
use disposables & implantables within the Urology<br />
and Endourology fields.<br />
Visit our booth A17.<br />
STARMEDTEC GMBH<br />
Kreuzstr. 22, 82319 Starnberg, Germany<br />
T : +49 815 126 861 17<br />
F : +49 815 126 861 35<br />
W : www.starmedtec.com<br />
E : info@starmedtec.com<br />
Booth nr. : I30<br />
StarMedTec - The Company<br />
StarMedTec GmbH is an established, dynamic company,<br />
leading the way in developing state-of-the-art medical<br />
laser systems for surgical applications, particularly<br />
in Urology, but also Neurophysiology. The innovative<br />
StarMedTec product line is based on long lasting<br />
expertise in engineering and application of medical<br />
laser systems. StarMedTec’s sophisticated technology<br />
provides unique and easy-to-use laser products to the<br />
medical field around the globe.<br />
STORZ MEDICAL AG<br />
Lohstampfestrasse 8, 8274 Tägerwilen, Switzerland<br />
T : +41 71 677 4545<br />
F : +41 71 677 4505<br />
W : www.storzmedical.com<br />
E : info@storzmedical.com<br />
Booth nr. : D06<br />
STORZ MEDICAL AG Tägerwilen, Switzerland offers<br />
latest shockwave technology for urological applications,<br />
the MODULITH SLX-F2, the MODULITH SLK and<br />
the DUOLITH SD1.<br />
The dual focus lithotripter MODULITH SLX-F2 provides<br />
unsurpassed shock wave performance for a complete<br />
range of urinary tract stones and includes diagnostic<br />
X-ray und ultrasound. A central touch screen control<br />
of peripheral urology devices makes the MODULITH<br />
SLX-F2 an integrated urological workstation. The<br />
MODULITH SLK is a transportable lithotripter with<br />
ultimate flexibility for the entire range of applications<br />
in SWL and ESWT. The DUOLITH SD1 is the first<br />
420 Programme Book<br />
device for urological pain therapy. Abacterial chronic<br />
prostatitis is successfully treated by low energy shock<br />
wave with the DUOLITH SD1. This focused shock wave<br />
device is easily used and does not require a localization<br />
device.<br />
SYNERGO-MEDICAL ENTERPRISES<br />
Assumburg 152B, 1081 GC Amsterdam, The Netherlands<br />
T : +31 20 64 23 719<br />
F : +31 20 64 21 161<br />
W : www.medical-enterprises.com<br />
E : synergo-med@planet.nl<br />
Booth nr. : D17<br />
Medical Enterprises group is committed to innovative<br />
medical technologies. The company’s R&D is focused<br />
on less-invasive therapies providing benefits for both<br />
patients and healthcare systems. The lead product,<br />
Synergo®, for the treatment of non muscle invasive<br />
bladder cancer, is based on the synergism of hypethermia<br />
and chemotherapy. The superficial layer of the<br />
bladder walls is heated by RF radiation, along with<br />
instillations of cooled chemotherapeutic substance<br />
(Mitomycin C). The treatment is performed on an out<br />
patient basis. Synergo has become a routine treatment<br />
in many countries, including Austria, Italy, Germany,<br />
Belgium, Netherlands, Switzerland, Turkey, UK, and<br />
Israel. The technology is clinically FDA approved.<br />
T-DOC COMPANY<br />
181 Edgemoor Road, 19809 Wilmington, United States<br />
of America<br />
T : +1 866 836 25 52<br />
F : +1 800 471 83 62<br />
W : www.tdoccllc.com<br />
E : info@tdocllc.com<br />
Booth nr. : E17<br />
Imagine Urodynamics studies without air bubbles,<br />
position changes, transducer height adjustments, presoaking<br />
catheters and/or Cidex. According to a recent<br />
study from the Cleveland Clinic, water-filled catheters<br />
“demonstrated significant motion and hydrostatic<br />
pressure artifacts” compared to Air-Charged catheters<br />
which are “significantly less sensitive to artifacts”.<br />
T-DOC Air-Charged disposable Catheters combine the<br />
advantage of microelectronics and transducer innovations<br />
making setup easy. T-DOC Catheters are used in<br />
more continence clinics than any other technology.<br />
Ask for your free trial today.
TAKEDA PHARMACEUTICALS<br />
EUROPE LTD<br />
61 Aldwych, WC2B 4AE London, United Kingdom<br />
T : +44 203 116 8000<br />
F : +44 203 116 8001<br />
W : www.takeda.com<br />
E : Nigel.Glover@tpeu.co.uk<br />
Booth nr. : J08<br />
Takeda is a global research-based company involved in<br />
the discovery, development, manufacturing and marketing<br />
of a broad range of innovative pharmaceutical<br />
products. As one of the global industry leaders, Takeda<br />
has strengthened its oncology portfolio by its acquisition<br />
of Millennium. Takeda is committed to improving<br />
the health and quality of life for people worldwide.<br />
Takeda’s booth features Leuprorelin Acetate, which<br />
with its advanced microsphere formulation, provides<br />
ease of injection, sustained drug release and the convenience<br />
of a 1, 3 or the new 6-month depot injection.<br />
TELEFLEX MEDICAL EUROPE LTD<br />
IDA Business Park, Garrycastle, Dublin Road, Co.<br />
Westhmeath, Athlone, Ireland<br />
T : +353 90 64 60 80 0<br />
F : +353 14 37 07 73<br />
W : www.teleflexmedical.com<br />
E : orders.intl@teleflexmedical.com<br />
Booth nr. : D25<br />
TELEFLEX MEDICAL provides under the trusted brands<br />
RÜSCH, RÜSCH CARE and MEDICAL SERVICE, comprehensive<br />
lines of bladder management products for<br />
patients in the Hospital and Home Care markets,<br />
mainly Foley-, intermittent-, and suprapubic catheters,<br />
urine collectors, catheterisation accessories and<br />
products for operative endourology. The brands WECK<br />
and TAUT represent the manual metal and polymer<br />
ligation systems, retrieval bags, endoscopic scissors<br />
and access devices. Each product and service we offer<br />
is the outcome of more than 100 years of product<br />
development, specialisation and product experience.<br />
TEXTILE HI-TEC<br />
1 Rue D’Albisson, 34000 Montpellier, France<br />
T : +33 499 581 092<br />
F : +33 467 543 584<br />
W : www.texhitec.com<br />
E : export@texhitec.com<br />
Booth nr. : A30<br />
Textile Hi-Tec has developed a hi-tech diversified<br />
biomedical industry out of its two centuries old core<br />
business. As a major independent player in the design,<br />
research, production and sale of surgical implants,<br />
Textile Hi-Tec is relied on by the medical world to develop<br />
highly technical solutions to answer the increasingly<br />
complex requirements of modern surgery.<br />
Dependable and innovative, its main surgery fields<br />
are uro-gynaecology (rectocele and cystocele ranges,<br />
stress urinary incontinence correction), orthopedics<br />
(absorbable arthroscopic range), neurology and<br />
visceral (dual-side mesh for intraperitoneal placement,<br />
artificial mesh for wall reinforcement for hernias and<br />
eventrations treatments).<br />
TIME RESEARCH LIMITED<br />
Time House, 56b Crewys Road, NW2 2AD London,<br />
United Kingdom<br />
T : +44 20 8209 2020<br />
F : +44 20 8209 2021<br />
W : www.timeresearch.co.uk<br />
E : lorraine.colley@timeresearch.co.uk<br />
Booth nr. : K22<br />
Time Research is an independent market research<br />
agency based in London, England. We have a team of<br />
highly experienced interviewers that will be interviewing<br />
healthcare professionals at this conference.<br />
Please join us at our stand to share your thoughts and<br />
opinions.<br />
TRIMEDYNE, INC.<br />
25901 Commercentre Dr., CA 92630-8805 Lake Forest,<br />
United States of America<br />
T : +1 949 951 3800<br />
F : +1 949 855 8821<br />
W : www.trimedyne.com<br />
E : info@trimedyne.com<br />
Booth nr. : B21<br />
Trimedyne, Inc. manufactures and sells the OmniPulse<br />
MAX® 80 Watt Holmium Laser, delivery systems<br />
including 200, 365, 550, and 1000 micron fibers and<br />
the VaporMAX® prostate ablation device. OmniPulse<br />
Lasers feature the exclusive Double Pulse technology,<br />
enabling the laser to perform lithotripsy 40% faster<br />
than conventional technology. Worldwide Service<br />
Support.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
421
Company and Product Description<br />
UROLOGICAL SOCIETY OF INDIA<br />
Ludhiana-141008, Punjab, India<br />
T : +91 981 403 4185<br />
F : +91 161 501 0909<br />
W : www.usi.org.in<br />
E : kjmammen@gmail.com<br />
Booth nr. : A24<br />
UROMED KURT DREWS GMBH<br />
Meessen 7/11, 22113 Oststeinbek, Germany<br />
T : +49 407 130 07 0<br />
F : +49 407 130 07 15<br />
W : www.uromed.de<br />
E : service@uromed.de<br />
Booth nr. : D26<br />
UROMED, a German company, was founded more than<br />
40 years ago and is a leading company for urological<br />
products since then. The excellent quality and detailed<br />
specifications of UROMED products are well-known<br />
to doctors in many countries. The comprehensive<br />
programme covers nearly all requirements in the<br />
urological field and a lot of innovative and exceptional<br />
items are included. Over the years the qualtiy of the<br />
products has been proven and updated permanently<br />
further more.<br />
UROTECH GMBH<br />
Medi-Globe-Strasse 1-5, 83101 Achenmuehle, Germany<br />
T : +49 803 297 32 00<br />
F : +49 803 297 32 11<br />
W : www.urotech.com<br />
E : b.gyoeri@urotech.com<br />
Booth nr. : D19<br />
Urotech GmbH was founded on 02 October 1989,<br />
specializing in the manufacturing and distribution of<br />
endourological devices. Our clean room and offices are<br />
located between Austria and Munich in the southern<br />
part of Bavaria/Germany. Urotech employs 35 people<br />
in-house and 8 sales representatives serving the<br />
national market. Internationally Urotech is present<br />
in over 40 markets. Urotech offers a complete line of<br />
endourology items as well as a unique product line<br />
of PC (Phosphorylcholine) coated ureteral stents and<br />
nephrostomy products.<br />
422 Programme Book<br />
VISION-SCIENCES, INC.<br />
40 Ramland Road South, NY 10962 Orangeburg, United<br />
States of America<br />
T : +1 845 365 0600<br />
F : +1 845 365 0620<br />
W : www.visionsciences.com<br />
E : customerservice@visionsciences.com<br />
Booth nr. : D14<br />
Vision-Sciences, Inc. brings to the urology community<br />
EndoSheath® Cystoscopy and is the manufacturer<br />
of state-of-the art, flexible video (Distal Chip) and<br />
fiberoptic endoscopy systems that employ the use<br />
of EndoSheath® technology, which is the sterile,<br />
disposable cover/barrier for flexible endoscopes.<br />
EndoSheath® Cystoscopy provides a sterile, disposable<br />
operative channel for every procedure, allows for rapid<br />
cystoscope cleaning, less exposure to toxic chemicals,<br />
enhanced Infection Control, less repair and maintenance<br />
costs, as well as an increase in staff productivity.<br />
With EndoSheath® Cystoscopy, urologists have the<br />
best in endoscopic imaging, optimal practice efficiency,<br />
along with enhanced patient and staff safety.<br />
VITACON AS<br />
Vegamot 8, 7048 Trondheim, Norway<br />
T : +47 738 21 300<br />
F : +47 738 21 301<br />
W : www.vitacon.com<br />
E : sales@vitacon.com<br />
Booth nr. : K33<br />
Vitacon has been in the uro-gynecology field for more<br />
than 20 years, manufacturing and marketing incontinence<br />
products. During the last years the company<br />
has moved into diagnostic ultrasound, and has newly<br />
launched the VitaScan Ultrasound Bladder Monitor,<br />
flexible and cost effective solutions in bladder scanning.<br />
Visit our booth and try how to scan your own bladder.<br />
Vitacon products are sold directly from Vitacon, and<br />
through distributors in different countries and territories.<br />
Ask for your local distributor sales@vitacon.com.<br />
WILEY-BLACKWELL<br />
The Atrium, Southern Gate, P.O. Box 19 8SQ Chichester,<br />
West Sussex, United Kingdom<br />
T : +44 1243 770500<br />
F : +44 1243 770154<br />
W : www.wiley.com/wiley-blackwell<br />
E : kaclarke@wiley.com<br />
Booth nr. : G20
Wiley-Blackwell is a leading society publisher<br />
with an essential collection of journals on behalf<br />
of scholarly societies including BJUI, The Prostate,<br />
Journal of Sexual Medicine and International Journal<br />
of Andrology. Wiley-Blackwell publications encompass<br />
urological oncology, upper and lower urinary tract,<br />
sexual medicine, reconstructive urology, paediatric<br />
urology and investigative urology.<br />
Visit stand G20 or www.wiley.com/wiley-blackwell to<br />
see for yourself the full range of our titles ensuring<br />
you stay up-to-date with latest in urological research.<br />
WISEPRESS ONLINE BOOKSHOP<br />
The Old Lamp Works, 25 High Path, Merton Abbey,<br />
SW19 2JL London, United Kingdom<br />
T : +44 208 715 1812<br />
F : +44 208 715 1722<br />
W : www.wisepress.com<br />
E : bookshop@wisepress.com<br />
Booth nr. : G18<br />
Europe’s leading conference bookseller, has a<br />
complete range of books and journals relevant to the<br />
themes of the meeting. Books can be purchased at the<br />
stand or, if you would rather not carry them, posted to<br />
you – Wisepress will deliver worldwide. In addition to<br />
attending 250 conferences per year, Wisepress has a<br />
comprehensive medical and scientific bookshop online<br />
with great offers, some up to 40% off the publisher<br />
list prices.<br />
RICHARD WOLF GMBH<br />
Pforzheimer Strasse 32, 75438 Knittlingen, Germany<br />
T : +49 704 335 299<br />
F : +49 704 335 122 3<br />
W : www.richard-wolf.com<br />
E : info@richard-wolf.com<br />
Booth nr. : J06<br />
Endoscopes from Richard Wolf GmbH<br />
- for the latest operating techniques!<br />
Modern surgery makes more and more use of the<br />
advantages of endoscopy. Operations, once using conventional<br />
surgical methods, today can be performed<br />
with the help of monitor-controlled video endoscopy.<br />
The smallest possible parts of entry cause the minimum<br />
of scars, thus combining medical and cosmetic<br />
benefits. Short stays in hospital make a fundamental<br />
contributions towards lowering the costs in health care.<br />
R. Wolf is one of the world’s leading manufacturers of<br />
medical instruments and electronic equipment making<br />
the new endoscopic operating techniques possible.<br />
ZEPHYR SURGICAL IMPLANTS<br />
Parc d’activité Atlantique, 13 rue Emile Decorps, 69100<br />
Villeurbanne, France<br />
T : +33 6 86 73 73 48<br />
F : +33 4 72 11 36 81<br />
W : www.zephyr-si.com<br />
E : r.gomezllorens@zephyr-si.com<br />
Booth nr. : K29<br />
The artificial urinary sphincter mimics a healthy<br />
sphincter in that it keeps the urethra closed until the<br />
patient wants to urinate.<br />
The artificial urinary sphincter ZSI 375 is a medical<br />
device that can be implanted in men. It is made of a<br />
silicone elastomer and is filled with saline solution. It<br />
mimics a healthy sphincter in that it keeps the urethra<br />
closed until the patient wants to urinate. This artificial<br />
urinary sphincter ZSI 375 is composed of two elements<br />
connected by kink-resistant tubing: a cuff is placed<br />
around the urethra and a control pump is placed in the<br />
scrotum.<br />
When the patient needs to urinate, he squeezes and<br />
releases the pump located in his scrotum. This action<br />
empties the cuff and releases the pressure around the<br />
urethra. The urine can flow out of the bladder. Few<br />
minutes after the bladder is empty, the cuff is automatically<br />
refilled, and the urethra is squeezed closed<br />
again.<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
423
Advancing<br />
Incontinence<br />
and Pelvic Floor<br />
Research and<br />
Treatment<br />
<strong>Annual</strong> Meeting Secretariat<br />
1-3 Rue de Chantepoulet, PO Box 1726<br />
CH 1211, Geneva 1, Switzerland<br />
Tel: + 41 22 908 04 88; Fax: + 41 22 906 9140<br />
email: ics@kenes.com<br />
JOINT ANNUAL MEETING OF THE<br />
INTERNATIONAL CONTINENCE SOCIETY (ICS) AND<br />
INTERNATIONAL UROGYNECOLOGICAL<br />
ASSOCIATION (IUGA)<br />
23 -27 AUGUST, <strong>2010</strong>, TORONTO, CANADA<br />
www.ics-iuga.com<br />
Register Early<br />
and SAVE!<br />
IUGA<br />
40th <strong>Annual</strong> Meeting 35th <strong>Annual</strong> Meeting<br />
Co-Chairs: Harold Drutz, Canada; Sender Herschorn, Canada
<strong>EAU</strong> Digital Video Library<br />
Volume 15.4 January <strong>2010</strong> 09 <strong>EAU</strong> 55<br />
150401 Evolution of the robotic continence preservation technique: An anatomical approach<br />
J. Jhaveri, P. Chhabra, Y.M. Tan, R. Rao, G. Bartsch, M. Menon, A. Leung, A. Yadav, E. Te E.D. Vaughan<br />
Jr. K. Tewari (New York, Detroit, United States of America; Innsbruck, Austria)<br />
150402 Tension- and energy-free robotic assisted laparoscopic radical prostatectomy: Modified technique<br />
for its application during the learning curve<br />
F. Annino, A. Beato, C. De Carne, S. Micali, S. De Stefani, G. Bianchi (Modena, Italy)<br />
150403 Optimization of robotic anatomical radical prostatectomy and preservation of neurovascular<br />
bundles<br />
H. Villavicenzio, L. Gausa, J.A. Peña, A. Rosales, J. Palou (<strong>Barcelona</strong>, Spain)<br />
150404 Duplicating open principles retrograde robotic radical prostatectomy<br />
R.J. Sotelo, O.J. Carmona, J. C. Astigueta, R.J. De Andrade, D. Canes (Caracas, Venuzuela)<br />
150405 Robotic radical female cystectomy with intracorporal Studer-pouch urinary reconstruction<br />
H. John, C. Moeckel, K. Horton, P. Wiklund (Zurich, Switserland; Stockholm, Sweden)<br />
150406 Robot-assisted laparoscopic radical cystoprostatectomy: Totally intracorpeal Studer neobladder<br />
N. Pardalidis, N. Andriopoulos, N. Giannakou, E. Karagianni, E. Kosmaoglou, P.N. Wiklund (Athens,<br />
Greece; Stockholm, Sweden)<br />
150407 Robotic-assisted extrafascial cystoprostatectomy extrafascial radical cystoprostatectomy and intracorporeal<br />
uretral Wallace technique anastomis<br />
J. Palou, L. Gausa, D. Renfigo, R. Sagrista, J. Huguet, J.A. Peña, H. Villavicencio (<strong>Barcelona</strong>, Spain)<br />
Volume 15.3 January <strong>2010</strong> 09 <strong>EAU</strong> 54<br />
150301 Penile prosthesis implantation and tunica albuginea incisions without grafting in the treatment of<br />
Peyronie’s disease.<br />
M.L.Djordjevic, M. Majstorovic, M. Bizic, V. Kojovic, A. Milosevic, S. Pandey (Belgrade, Serbia;<br />
Mumbai, India)<br />
150302 Total phalloplasty using latissimus dorsi flap-indications and technique<br />
S.V. Perovic, R.P. Djiinovic, M.Z. Milosavljevic (Belgrade, Serbia)<br />
150303 New refinements in male-to-female sex reassignment surgery<br />
S.V. Perovic, R.P. Djinovic,M.Z. Milosavljevic (Belgrade, Serbia)<br />
150304 The treatment of congenital penis curvature with modified Nesbit technique<br />
M. Acimovic, M. Djordjevic, T. Pejcic, J. Hadzi-Djokic (Belgrade, Serbia)<br />
150305 Laparoscopic sacrocolpopexy<br />
F. Curto, R. Gaston, T. Piechaud (Palermo, Italy ; Bordeaux, France)<br />
The <strong>EAU</strong> Digital Video Library is supported by an unrestricted educational grant from ASTELLAS<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
425
<strong>EAU</strong> Digital Video Library<br />
150306 Laparoscopic promontofixation: Modification of the poster mesh positioning<br />
G.H. Fournier, A. Erauso, M.A. Perrouin-Verbe, G. Papin, B. Rousseau, V. Joulin, C. Deruelle, A. Valeri<br />
(Brest, France)<br />
150307 Abdominal pelvic floor reconstruction with uterus preservation<br />
E. Constantini, A. Zucchi, M. Del Zingaro, M. Lazzeri, L. Mearini, F. Fioretti, M. Porena, (Perugia, Italy)<br />
150308 The use of omental pedicle flap in the surgical repair of vesicovaginal fistula<br />
J. Hadzi-Djokic, T. Pejcic, M.Acimovic, V. Krese, J. Miku, V. Colovic (Belgrade, Serbia)<br />
150309 Advance male sling TO- the transobturatoric tape to treat mild and moderate urinary stress incontinence<br />
in male patients.<br />
K.D. Sievert, B. Amend, P. Rehder, G. Gakis, A. Stenzl (Tübingen, Germany; Innsbruck, Austria)<br />
150310 Contemporary implant of trans obturatory sling advance and inflatable penile prosthesis AMS CX<br />
700<br />
E. Conti, P.P. Fasolo, S. Lacquaniti, M. Fiorio, L. Puccetti, R. Mandras, G. Fasolis (Alba, Italy)<br />
Volume 15.2 January <strong>2010</strong> 09 <strong>EAU</strong> 53<br />
150201 Complications after 5,000 ureteroscopies- single center experience<br />
D. Georgescu, R. Multescu, C. Moldoveanu, B. Geavlete, P.Geavlete (Bucharest, Romania)<br />
150202 Use and maintenance of laser fibers during flexible uretero-renoscopy<br />
A. Hoznek, K. de Laet, A. Paul, A. De La Taille, L. Salomon, R. Yiou, D. Vordos, C-C Abbou (Creteil,<br />
France)<br />
150203 Conservative treatments of upper tract tumours<br />
G. Simone, R. Papalia, M. Ferreiro, C. Leonardo, S. Guaglianone, M. Gallucci (Rome, Italy)<br />
150204 Transurethral plasma vaporization of the prostate in saline (TUVis-P) in patients under continuing<br />
oral anticoagulation<br />
A. Müller, K.D.B. Bigger, N. Blick, S. Suter (Zurich, Switzerland)<br />
150205 Ejaculation preserving (EP) technique in endourological treatment of BPH epLaservaporestion and<br />
epTUR of the prostate<br />
C. Lang, R. Eichel, S.H. Alloussi, S. Allousi (Neunkirchen, Germany)<br />
150206 Usefulness of real-time transrectal ultrasound navigation during holmium laser enucleation of the<br />
prostate<br />
Y. Shibata, S. Arai, H. Koike, M. Hatori, K.Ito, K. Suzuki (Maebashi, Japan)<br />
426 Programme Book<br />
The <strong>EAU</strong> Digital Video Library is supported by an unrestricted educational grant from ASTELLAS
Volume 15.1 January <strong>2010</strong> 09 <strong>EAU</strong> 52<br />
150101 Prize for the best video published in 2008<br />
Green light HPS laser prostatectomy: Recommendations on surgical technique<br />
F. Gomez-Sancha. G. Muir, B. Chor, E. Collins, J.J.M.C.H. De la Rosette, O. Reich, S. Tabatabaeti,<br />
H. Woo<br />
150102 First Video Prize<br />
Laparoscopic endoscopic single site surgery (LESS): Tumour nephrectomy<br />
J.U. Stolzenburg, G. O. Hellawell, M. Do, T. Haefner, A. Dietel, E.N. Liatsikos (Leipzig, Germany;<br />
London, United Kingdom; Patras, Greece)<br />
150103 Second Video Prize<br />
Hybrid transvaginal radical nephrectomy<br />
A. Alcaraz, L.Peri, L. Izquierdo, F. Carmona, A. Molina, M.J. Ribal (<strong>Barcelona</strong>, Spain)<br />
150104 Third Video Prize<br />
Chicken gizzard, A novel training model for laparoscopic urethro-vesical anastomosis<br />
R.J. Sotelo, J.C. Astigueta, O.J. Carmona, R.J. De Andrade, A. Velasquez, D. Canes (Caracas, Venezuela)<br />
Volume 14.4 November 2008 08 <strong>EAU</strong> 51<br />
140401 Laparoscopic extraperitoneal bladder diverticulectomy<br />
A. Celia, D. Zeccolini, G. Breda (Bassano de Grappa, Italy)<br />
140402 Vesico-vaginal fistula laparoscopic repair<br />
F. Porpoglia, I. Morra, A. Volpe, C. Cracco, J. Renard, R. M. Scarpa (Orbassano, Italy)<br />
140403 Vesico-colnic fistula laparoscopic repair<br />
C. Sanchez, V. Kibanov, M. Gonzalez, M. Occhipinti, J. Flores, A. Elizalde (Mexico City, Mexico)<br />
140404 Laparoscopic repair of the retrocaval ureter in a solitary kidney<br />
R. Sanseverino, O. Intalla, U. Di Mauro, G. Napodano, T. Realfonso, A. Campitelli (Nocera Inferiore,<br />
Italy)<br />
140405 Endoscopic treatment in calcified ureteral stents<br />
P. Geavlete, D. Georgescu, V. Mirciulescu, G. Nita, R. Multescu, B. Geavlete (Bucharest, Romania)<br />
140406 Antegrade flexible ureteroscopy in ureteral, uretero-enteric or uretero-vesical stenosis<br />
P. Geavlete, R. Multescu, D. Georgescu, V. Mirciulescu, B. Geavlete (Bucharest, Romania)<br />
140407 Ureteroscopic assisted laparoscopic segmental ureterectomy with psoas hitch procedure<br />
U. Nagele, H. Sherif, A.S. Mergeburger, W. Sturm, K.D. Sievert, M.A. Kuczyk, A. Stenzl (Tübingen,<br />
Germany)<br />
The <strong>EAU</strong> Digital Video Library is supported by an unrestricted educational grant from ASTELLAS<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
427
<strong>EAU</strong> Digital Video Library<br />
Volume 14.3 November 2008 08 <strong>EAU</strong> 50<br />
140301 Left laparoscopic radical nephrectomy with renal vein thrombus<br />
W. Massoud, N. Saheb, J. Schlosser, O. Dumonceau, M. Fennouri, B. Iliescu, H. Baumert (Paris,<br />
France)<br />
140302 Laparoscopic partial nephrectomy in a transplanted kidney<br />
A. Rosales, J. Salvador, J. Azuero, J. Caffaratti, M. Montlleo, J. Ponce De Leon (<strong>Barcelona</strong>, Spain)<br />
140303 Laparoscopic heminephrectomy in horshoe kidney<br />
A.Celia, G. Zeccollini, G. Breda (Bassanda del Grappa, Italy)<br />
140304 Transvaginal NOTES nephrectomy with two additional 5 mm laparoscopic ports<br />
A.W. Branco, A.J. Branco, R.W. Noda, A.H.L. Camargo, L.C. Stunitiz, W. Kondo, M.M.L. Miranda<br />
(Curitiba, Brazil)<br />
140305 Laparoscopic nephroureterectomy for upper tract urothelial cancer: A novel closed system pluck<br />
S. Pathak, V. Lavin, T. Watcyn-Jones, D. Doyle, N. Oakley (Sheffield, United Kingdom)<br />
140306 Management of complications during laparoscopic nephrectomy<br />
J.C.A. Milfont, V. Dubeux, L. Medeiros, E.G. Barcellos (Rio de Janeiro, Brazil)<br />
Volume 14.2 July 2008 08 <strong>EAU</strong> 49<br />
140201 E-Turp Technical evolution of TURP<br />
G. Breda, A. Celia, G. Zeccolini, S. Aldahashan (Bassano del Grappa, Italy)<br />
140202 Laparoscopic simple retropubic prostatectomy:<br />
Technique and preliminary series<br />
D.S. Stembler, G.I.S. Disick, W.A. Hassen (New York, United States of America)<br />
140203 Green light HPS laser prostatectomy:<br />
Recommendations on surgical technique<br />
F. Gomez Sancha, G. Muir, A. Bachmann, B. Choi, E. Collins, J. De La Rosette, O. Reich, S. Tabatabei,<br />
H. Woo (Madrid, Spain; London, United Kingdom; Basel, Switzerland; New York, San Francisco,<br />
Boston United States of America; Amsterdam, The Netherlands; Munich, Germany; Sydney, Australia)<br />
140204 Thulium laser enucleation of the prostate<br />
W. Massoud, O. Dumonceau, N. Saheb, B. Iliescu, J. Schlosser, T. Guetta, F. Fournier, M. Fennouri,<br />
H. Baumert (Paris, France)<br />
140205 Laser vaporisation for benign prostatic hyperplasia<br />
The initial Romanian experience<br />
M. Lucan, U. Witzsch, V. Lucan, F. Elec, S. Moga, G. Iacob, A. Barbos<br />
(Cluj Napoca, Romania; Frankfurt, Germany)<br />
428 Programme Book<br />
The <strong>EAU</strong> Digital Video Library is supported by an unrestricted educational grant from ASTELLAS
Volume 14.1 July 2008 08<strong>EAU</strong> 48<br />
140101 Prize for the best video published in EUVJ 2007<br />
Transureteral resection in urethral tumours-long term follow-up<br />
P. Geavlete, G. Nita, R. Multescu, V. Mirciulescu, B. Geavlete (Bucharest, Romania)<br />
140102 First video prize 23 rd <strong>EAU</strong> <strong>Annual</strong> <strong>Congress</strong>, 26-29 March 2008, Milan<br />
The antegrade inter/intra/extrafascial da Vinci prostatectomy after transrectal injection<br />
F. Recker, D. Seiler, P. Werthemann (Aarau, Switzerland)<br />
140103 Second video prize 23 rd <strong>EAU</strong> <strong>Annual</strong> <strong>Congress</strong>, 26-29 March 2008, Milan<br />
Laparoscopic robot assisted radical cystectomy with intracorporal urinary division<br />
H. John, J. Fehr, B. Fischer, N. Engel, P. Wiklund (Zurich, Switzerland)<br />
140104 Third video prize 23 rd <strong>EAU</strong> <strong>Annual</strong> <strong>Congress</strong>, 26-29 March 2008, Milan<br />
Argus male sling system-surgical technique and results<br />
W. Hübner, H. Gallistl (Korneuburg, Austria)<br />
Volume 13.4 February 2008 08 <strong>EAU</strong> 47<br />
130401 Extended pelvic lymphadenectomy during laparoscopic radical cystectomy<br />
A.Hoznek, D. Vordos, S. Larré, L. Salomon, A. De La Taille, R. Yiou, C.C. Abbou (Creteil,France)<br />
130402 Laparoscopic iliac lymphadenectomy could duplicate of open technique during radical cystectomy<br />
A. Shoma, (Mansoura, Egypt)<br />
130403 Laparoscopic nerve sparing cystectomy and orthotopic neobladder in female patients<br />
U. Nagele, A.G. Anastasiadis, K.D. Sievert, M. Kuczyk, J. Seibold, A. Stenzl (Tübingen, Germany)<br />
130404 Laparoscopic cystectomy and neobladder formation in woman<br />
H. Baumert, N. Rebai, N. Shah, W. Massoud, L. Peyrat, T. Aho, D. Neal (Paris, France; Cambridge,<br />
United Kingdom)<br />
130405 Potency- and continence preserving radical cystectomy with hemiprostatectomy<br />
H. Wunderlich,M. Wolf, J. Schubert (Jena, Germany)<br />
130406 Formation of S-shaped ileal neobladder<br />
J. Hadzi-Djokic (Belgrade, Serbia)<br />
The <strong>EAU</strong> Digital Video Library is supported by an unrestricted educational grant from ASTELLAS<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
429
<strong>EAU</strong> Digital Video Library<br />
Volume 13.3 February 2008 08 <strong>EAU</strong> 46<br />
130301 Robotic assisted laparoscopic radical cystectomy in the male: A technique illustrated step by step<br />
F. Gaboardi, S. Galli, A. Gregori, I. Goumas Kartalas, F. Sceri, R. Knez, S. Stener (Milan, Italy)<br />
130302 Laparoscopic pyeloplasy using robotic system<br />
F. Gaboardi, S. Galli, I. Kartalas-Goumas, A. Gregori, R. Knez, F. Scieri, S. Stener (Milan, Italy)<br />
130305 Periprostatic fascia preservation in da Vinci robotic radical prostatectomy<br />
S. Stener (Milan, Italy)<br />
130306 Total interfascial robot assisted prostatectomy<br />
A. Mottrie, G. De Naeyer, P. Van Migem, P. Schatteman, P. Carpentier, E. Fonteyne (Aalst, Belgium)<br />
Volume 13.2 September 2007 07 <strong>EAU</strong> 45<br />
130201 York Mason trans-sphynteric trans-rectal repair of iatrogenic recto-urinary fistula: Case report<br />
R. Sanseverino, O. Intilla, G. Napodano, A. Barela, U. Di Mauro, T. Realfonso ( Nocera Inferiore, Italy)<br />
130202 Simultaneous implantation of bone anchores sling and inflatable penile prosthesis through a single<br />
penoscrotal incision.<br />
I. Morra, L.Rolle, F. Ragni, A.Tamagnone, D. Vaccino, C. Ceruti, D. Fontatana, R. M. Scarpa (Orbassano,<br />
Torino, Italy)<br />
130203 Fast implantation of an artificial urethral sphincter through a peno-scrotal approach<br />
K.D. Sievert, B. Amend, S.K. Wilsson, A. Anastasiadis, U. Nagele, M. Kuczyk, A. Stenzl (Tübingen,<br />
Germany, Little Rock, United States of America)<br />
130204 The use of fibrin glue in bulbar urethral reconstruction<br />
G. Barbagli, S. De Stefani, F. Annino, M.C. Sighinolfi, S. Micali, G. Bianchi (Arezzo, Modena, Italy)<br />
130205 Endoscopic reconstruction after posttraumatic urethral disruption using a temporary urethral stent<br />
S. Kato, T. Takeuchi, N. Hagiwara, Y. Ban, H. Uno, T. Deguchi (Gifu, Japan)<br />
130206 Surgical treatment of urethral stricture associated with urethral diverticulum<br />
J. Hadzi-Djokic 1 , M. Acimovic 1 , T. Pejcic 1 , G. Jovanovic 2 (Belgrade, Serbia, Palanka Serbia)<br />
130207 Peyronie’s disease: Corporoplasty using buccal mucosa patch graft<br />
M. Porena, A. Zucchi, E. Mearini, E. Costantini, F. Fioretti, L. Mearini (Perugia,Italy)<br />
130208 TVT-Tension free vaginal tape in the treatment of stress urinary incontinence<br />
J.Hadzi-Djokic 1 , J. Filimonovic 1 , D. Basic 2 , V. Stamenkovic 3 , S. Velickovic 3 (Serbia, Belgrade, Nis, Vranje,<br />
Serbia)<br />
430 Programme Book<br />
The <strong>EAU</strong> Digital Video Library is supported by an unrestricted educational grant from ASTELLAS
Volume 13.1 September 2007 07 <strong>EAU</strong> 44<br />
130101 Prize for the best video published in EUVJ 2006<br />
Laparoscopic repair of rectourethral fistulae<br />
R. Sotelo, A.J. Garcia, M. Mariano, G. Trujilo, E. Rodriguez, R. De Andrade, L. Sanchez, C. Andrade,<br />
A. Finelli (Caracas, Venezuela, Porto Alegre, Brazil; Toronto Canada)<br />
130102 First video prize - 22 nd <strong>EAU</strong> <strong>Annual</strong> <strong>Congress</strong>, 21-24 March 2007, Berlin<br />
Pure robot assisted psoas hitch ureteral reimplantation for distal ureteral stenosis<br />
A. Mottrie, G. De Naeyer, P. Van Migem, P. Schatteman, P. Carpentier, E. Fonteyne (Aalst, Belgium)<br />
130103 Second video prize - 22 nd <strong>EAU</strong> <strong>Annual</strong> <strong>Congress</strong>, 21-24 March 2007, Berlin<br />
Tension and energy-free robotic assisted laparoscopic radical prostatectomy with lateral approach<br />
for the interfascial dissection of the neurovascular bundles: Technique description and early results<br />
A. Mattei, R. Naspro, F. Annino, D. Burke, R. Guida, R. Gaston, Clinique Saint Augustin (Bordeaux,<br />
France)<br />
130104 Third video prize - 22 nd <strong>EAU</strong> <strong>Annual</strong> <strong>Congress</strong>, 21-24 March 2007, Berlin<br />
Intraspinal nerve re-routing to reestablish bladder function in spinal cord injured patients<br />
K.D. Sievert, B. Winter, A. Anastasiadis, B. Amend, A. Badke, H. Kaps, M. Tatagiba, A. Stenzl<br />
Volume 12.4 December 2006 06 <strong>EAU</strong> 43<br />
120401 Laparoscopic radical prostatectomy: Technical aspects and pitfalls during the apical dissection<br />
G. Fournier, A. Valeri, A. Rammal, V. Joulin, J. Donohue, L. Cormier, X. Taccoen, C. Deruelle, L. Doucet,<br />
A. Volant (Brest, Nancy, France)<br />
120402 Bladder neck dissection during laparoscopic radical prostatectomy: Difficult cases<br />
G. Fournier, A. Valeri, A. Rammal, V. Joulin, J. Donohue, L. Cormier, X. Taccoen, C. Deruelle, L. Doucet,<br />
A. Volant (Brest, Nancy, France)<br />
120403 Dealing with a difficult urethrovesical anastomisis in laparascopic radical prostatectomy<br />
F. Secin, N. Karanikolas, A.J. Stephenson, F. Bianco, K. Touijer, B. Guillonneau (New York, United<br />
States of America)<br />
120404 Laparoscopic repair of an inferior vena cava injury during a right partial nephrectomy<br />
F. Secin, Z. Dotan, B. shayegan, S. Olgac, B. Guilonneau, K. Touijer (New York, United States of<br />
America)<br />
120405 Technical difficulties in retroperitoneoscopic radical nephrectomy. Is tumour location important?<br />
M. Lucan, V. Lucan, F. Elec, G. Iacob, C. Burghelea, A. Barbos ( Cluj-Napoca, Romania)<br />
120406 Laparoscopic repair of rectourethral fistulae<br />
R. Sotelo, A.J. Garcia, M. Mariano, G. Trujilo, E. Rodriguez, R. De Andrade, L. Sanchez, C. Andrade,<br />
A. Finelli (Caracas, Venezuela, Porto Alegre, Brazil; Toronto, Canada)<br />
The <strong>EAU</strong> Digital Video Library is supported by an unrestricted educational grant from ASTELLAS<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
431
<strong>EAU</strong> Digital Video Library<br />
Volume 12.3 December 2006 06 <strong>EAU</strong> 42<br />
120301 Evolution of seminal sparing cystectomy: From ileocapsuloplasty to endocapsular ileourethral<br />
anastomosis<br />
G. Muto, F. Bardari, L. D’Urso, E. Castelli, A. Formiconi, P. Coppola (Turin, Italy)<br />
120302 The use of albumine gluteraldehyd tissue adhesive (Bio Glue) in nephrone sparing surgery<br />
O. Nativ, A. Kastin, G. Hidas, M. Mullerad, E. Issaq, B. Moskovitz (Haifa, Israel)<br />
120303 Glansectomy and circumcision for penile carcinoma with skin graft on the corporal heads<br />
C. Gangu, G. Plugaru, B. Stefan, V. Zogas, C. Serbanescu, S. Patrasciou, C. Surcel, I. Sinescu<br />
(Bucharest, Romania)<br />
120304 One day stay for robotic pyeloplasty<br />
D. Murphy, S. Khan, B. Challacombe, J. Olsgurgh, P. Dasgupta (London, United Kingdom)<br />
120305 Magnetic resonance image-guided robot for prostate brachytherapy<br />
M. Muntener, H. Bagga, A. Patriciu, D. Mazilu, D. Petrisor, N. Patel, L. Kavoussi, D. Stoianovici<br />
(Baltimore, United States of America)<br />
Volume 12.2 October 2006 06 <strong>EAU</strong> 41<br />
120201 Urachal-sparing laparoscopic radical cystectomy<br />
F. Secin, F. Bianco, N. Karanikolas, K. Touijer, B. Guilloneau (New York, United Stated of America)<br />
120202 Selective dissection of the apex during radical prostatectomy allows better tumour control and<br />
continence<br />
J. Walz, M. Graefen, A. Haese, H. Heinzer, H. Huland (Hamburg, Germany)<br />
120203 Nerve-sparing radical prostatectomy - the surgeons view through the Varioscope M5<br />
R. Goetschl, N. Schmeller (Salzburg, Austria)<br />
120204 The radical perneal prostatectomy with simultaneous extended pelvic lymphadenectomy via the<br />
same incision<br />
J. Beier, H. Keller (Hof, Germany)<br />
120205 Laparoscopic radical prostatectomy. Differences between the inter-fascial and intra-facial technique<br />
L. Martinez-Pineiro, J.R. Cansino, C. Sanchez, A. Tabernero, J. Cisneros, J. De La Pena (Madrid, Spain)<br />
432 Programme Book<br />
The <strong>EAU</strong> Digital Video Library is supported by an unrestricted educational grant from ASTELLAS
Volume 12.1 October 2006 06 <strong>EAU</strong> 40<br />
1<strong>2010</strong>1 Prize for the Best Video published in EUVJ 2005<br />
Laparoscopic radical cystectomy with orthotopic ileal neobladder<br />
A. Hoznek, D. Vordos, G. Matthew, L. Salomon, A. De La Taille, R. Yiou, C-C. Abbou (Creteil, France)<br />
1<strong>2010</strong>2 First Video Prize - 21 st <strong>EAU</strong> annual congress, 5-8 April 2006, Paris<br />
Open retropubic nerve sparing radical prostatectomy - how I do it.<br />
U.E. Studer, F.C. Burkhard, G.N. Thalmann (Berne, Switzerland)<br />
1<strong>2010</strong>3 Second video prize - 21 st <strong>EAU</strong> annual congress, 5-8 April 2006, Paris<br />
Transvesical laparoscopic diverticulectomy<br />
V. Pansodoro, P. Emiliozzi, G. Federico, M. Martini, M. Pozzo, P. Scarpone (Rome, Italy)<br />
1<strong>2010</strong>4 Third video prize - 21 st <strong>EAU</strong> annual congress, 5-8 April 2006, Paris<br />
Video laparoscopic radical cystectomy in female<br />
F. Gaboardi, A. Bozzola, S. Galli, A. Gregori, F. Scieri, S. Stener, B. Rocco (Milan, Italy)<br />
Volume 11.4 December 2005 05 <strong>EAU</strong> 39<br />
110401 Early ligature of the renal artery during laparoscopy radical nephrectomy<br />
F. Porpiglia, C. Terrone, R. Tarabuzzi, C. Fiori, M. Cossu, C. Cracco, C. Scoffone, R. Scarpa (Orbassano,<br />
Italy)<br />
110402 Laparoscopic radical nephrectomy<br />
A. Shoma, E. Ibrahim, H. El Kappany (Mansoura, Egypt)<br />
110403 Laparoscopic partial nephrectomy for renal tumours after renal artery clamping the Quebec City<br />
experience<br />
T. Dujardin, R. Sabbagh, B. Inman (Québec, Canada)<br />
110404 Laparoscopic nephron-sparing sugery techniques of haemostatis<br />
F. Gaboardi, A. Simonata, A. Lissiani, A. Gregori, S. Galli, A. Bozzola (Milan, Italy)<br />
110405 Laparoscopic radical nephrectomy with lymp node dissection for advanced renal cell carcinoma<br />
pT3aN2.<br />
H. Baumert, F. Khan, N. Shah, T. Aho, W. Turner (Paris, France; London, United Kingdom)<br />
The <strong>EAU</strong> Digital Video Library is supported by an unrestricted educational grant from ASTELLAS<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
433
<strong>EAU</strong> Digital Video Library<br />
Volume 11.3 December 2005 05 <strong>EAU</strong> 38<br />
110301 Surgical treatment of total uterine prolapse associated with stress urinary incontinence and<br />
bilateral hydronephrosis<br />
J. Hadzi-Djokic, D. Basic, Z. Dzamic, M. Acimovic, V. Stamenkovic, S. Velikovic (Belgrade, Serbia and<br />
Montenegro)<br />
110302 Female laparoscopic artificial urinary sphincter in women for type III incontinence: Preliminary<br />
results.<br />
B. Nijinou (Le Havre, France)<br />
110303 Treatment of male urinary incontinence with submucosal bulking agents<br />
J. Seibold, A. Merseberger, K. Sievert, A. Stenzl (Tübingen, Germany)<br />
110304 The tunica-albuginea-patch-technique: A new technique of an autologous grafting procedure for<br />
patients with Peyronie’s disease<br />
J.U. Schwarzer, J. Mayerhofer, O. Schukai, B. Mühlen (Freising, Germany)<br />
110305 Treatment of Peyronie’s disease with plaque incision and application of bovine pericardium graft<br />
L. Martinez-Pineiro, S. Alonso, J. Cruz, E. Cuervo, J. De la Pena (Madrid, Spain)<br />
Volume 11.2 December 2005 05 <strong>EAU</strong> 37<br />
110201 Sigma-Rectum pouch, modified technique<br />
J. Hadzi-Djokic, D. Basic, M. Petrovic, D. Jovanovic, Z. Dzamic, N. Prokopiv (Belgrade, Serbia and<br />
Montenegro)<br />
110202 Laparoscopic radical cystectomy with Mainz rectal pouch urinary diversion<br />
A. Loualalen (Toulouse, France)<br />
110203 Genital organ preservation during radical cystectomy and orthotopic bladder substitution in<br />
selected women<br />
B. Ali-El-Dein, A. Mosbah, Y. Osman, M. Abdel-Latiff, I. Eraky, A. Shaaban, M. Ghoneim (Mansoura,<br />
Egypt)<br />
110204 Laparoscopic cystoprostatectomy for bladder cancer, description step by step<br />
C. Vaessen, M. Mouzin, X. Game, N. Berrogain, B. Malavaud, P. Rischmann (Toulouse, France)<br />
110205 Laparoscopic cystoprostatectomy<br />
X. Cathalineau, F. Rozet, S. Lorin, W. Duncan, C. Arroyo, E. Barret (Paris, France)<br />
110206 Laparoscopic radical cystectomy and ileal conduit in women<br />
H. Baumert, F. Khan, R. Morgan, H. Patel, M.Al-Akraa, A. Kaisary (London, United Kingdom)<br />
110207 Laparoscopic radical cystectomy<br />
A. Hoznek, C-C. Abbou (Creteil, France)<br />
434 Programme Book<br />
The <strong>EAU</strong> Digital Video Library is supported by an unrestricted educational grant from ASTELLAS
Volume 11.1 December 2005 05 <strong>EAU</strong> 36<br />
110101 First video prize- 20 th <strong>EAU</strong> annual congress, 16-19 March 2005, Istanbul<br />
One stage primary reconstruction of bladder exstrophy with modified penile disassembly<br />
A.T. Hafez, M.T. El-Sherbiny, M.A. Ghoneim (Mansoura, Egypt)<br />
110102 Educational – laparoscopy video prize<br />
Transobturator tape – perineal hammock<br />
V. Delmas (Paris, France)<br />
110103 Educational – surgery video prize<br />
Endoscopic extraperitoneal radical prostatectomy (EERPE)<br />
U. Stolzenburg, R. Rabenalt, M. Do, M. H. Pfeiffer, M. Truss, W. Dorschner (Hannover, Leipzig,<br />
Germany)<br />
110104 Innovational video prize<br />
Robotic-assisted (da Vinci®) laparoscopic conduit urinary diversion in neurogenic bladder<br />
J. Hubert, J. Beis, B. Feuillu, A. Coissard, P. Mangin, J. Andre (Nancy, France)<br />
110105 Endourologic treatment of renal pelvic and urethral transitional cell carcinoma<br />
P. Geavlete, D. Georgescu, G. Nita, V. Mirciuleascu (Bucharest, Romania)<br />
110106 Pyelocaliceal diverticulum particularities: Experiences on 5 cases<br />
P. Geavlete, D. Georgescu, G. Nita, V. Cauni (Bucharest, Romania)<br />
110107 Endoscopic treatment of superficial transitional cell carcinoma in the intramural ureter<br />
P. Geavlete, D. Georgescu, G. Nita (Bucharest, Romania)<br />
Volume 10.4 September 2004 04 <strong>EAU</strong> 35<br />
100401 Clitoroplasty in intersex repair using disassembly technique<br />
M.L.J. Djordjevic, S.V. Perovic (Belgrade, Serbia and Montenegro)<br />
100402 Complex repair in failed male transsexual surgery<br />
S. Perovic, M.L.J. Djordjevic, A. Kolias (Belgrade, Serbia and Montenegro)<br />
100403 Perugia orthotopic neo-bladder vesicle. Prostate sparing cystectomy: A complete after seminal-<br />
recovery of sexual function and body image<br />
E. Mearini, A. Zucchi, L. Mearini, E. Costantini, M. Porena (Perugia, Italy)<br />
100404 Primary malignant melanoma of the urethra. Reconstructive solution in a rare case<br />
G. Carmignani, P. Traverso, A. Naselli, F. Bertolotto, A. Romagnoli, C. Corbu (Genova, Italy)<br />
The <strong>EAU</strong> Digital Video Library is supported by an unrestricted educational grant from ASTELLAS<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
435
<strong>EAU</strong> Digital Video Library<br />
Volume 10.3 September 2004 04 <strong>EAU</strong> 34<br />
100301 Retroperitoneoscopic nephroureterectomy without a positioning change<br />
Saito Seichi (Sapporo, Japan)<br />
100302 The new lithoclast<br />
P. Van Cangh, A. Feyaerts, B. Tombal, R. Opsomer, F. Wese (Brussels, Belgium)<br />
100303 Bilateral partial obstructive lithiasis on pyeloplasty sutures. Retrograde ureteroscopic treatment<br />
P. Geavlete, V. Mirciulescu, D. Georgescu (Bucharest, Romania)<br />
100304 Endoscopic classification and endourological treatment of incomplete urethral duplication pathology<br />
P. Geavlete, G. Nita, V. Mirciulescu, D. Georgescu (Bucharest, Romania)<br />
100305 Multiple lithiasis on sutures points after orthotropic ileal bladder replacement. Endourological<br />
treatment<br />
P. Geavlete, D. Georgescu, V. Mirciulesc (Bucharest, Romania)<br />
Volume 10.2 January 2004 04 <strong>EAU</strong> 33<br />
100201 Conservative vaginal surgery for total genitourinary prolapse<br />
G. Nicita (Florence, Italy)<br />
100202 ACT: Adjustable continence therapy: A minimally invasive post-operative adjustable therapy for<br />
female stress urinary incontinence.<br />
E. Kocjancic, T. Sauter, D. Minocci, G. Monesi, M. Favro, G. Ceratti, M. Sala, P. Gontero,<br />
S. Guglielmetti, S. Crivellaro, B. Frea (Novara, Italy; Berlin, Germany)<br />
100203 Laparoscopic repair of recurrent prolapse<br />
H. Baumert, H. Widmer, R. Gupta, R. Adorna Rosa, B. Guilloneau, G. Vallencien (Paris, France)<br />
100204 Innovational Video Prize Madrid 2003<br />
Video-assisted nerve and prostate-sparing cystectomy<br />
X. Cathelineau (Paris, France)<br />
100205 Research Video Prize Madrid 2003<br />
Extraperitoneal laparoscopic radical prostatectomy<br />
C-C. Abbou, A. Hoznek, P. Antiphon, L. Salomon, A. De La Taille, R. Katz, D. Borkowski, D. Chopin<br />
(Paris, France)<br />
436 Programme Book<br />
The <strong>EAU</strong> Digital Video Library is supported by an unrestricted educational grant from ASTELLAS
Volume 10.1 January 2004 04 <strong>EAU</strong> 32<br />
100101 Penile duplication with long distance: Joining with successful outcome<br />
S. Perovic, M. Djordevic, R. Brdar, (Belgrade, Serbia and Montenegro)<br />
100102 Re-do end to end urethroplasty in traumatic disruption of the membranous urethra<br />
L. Martínez-Piñeiro, J. Madrid, A.J. Garcia (Madrid, Spain)<br />
100103 Reconstructive phalloplasty after amputation for penile cancer, using dermal-epidermal grafts,<br />
prosthesis implantation and glanduloplasty with oral mucosa<br />
E. Austoni, F. Colombo (Milan, Italy)<br />
100104 Primary malignant melanoma of the urethra: Reconstructive solution in a rare case<br />
G. Carmignani, P. Traverso, A. Naselli, F. Bertolotto, A. Romagnoli, C. Corbu (Genova, Italy)<br />
100105 One stage primary reconstruction of bladder extrophy with modified penile disassembly<br />
A. Hafez, M. Eisherbny, M. Baazed, M. Ghoneim (Mansoura, Egypt)<br />
100106 Management of radiation of rectoprostatic fistulas with skin or buccal graft patch onlay and gracilis<br />
muscle interpretation<br />
A. Sorcini, J. Latini, L. Zinman (Burlington, United States of America)<br />
Volume 9.4 December 2002 02 <strong>EAU</strong> 31<br />
090401 Penile curvature and Peyronie: New problems, new solutions<br />
F. Mantovani, E. Patelli, C. Castelnuovo, E. Pisani (Milan, Italy)<br />
090402 Total urethral reconstruction with S.I.S. (porcine small intestinal sub-mucosa)<br />
D. Mauro (Rome, Italy)<br />
090403 Seminal vesicle sparing sigmoid neobladder reconstruction<br />
G. Nicita, D. Villari, E. Dattolo, V. Li Marzi, M. Paoletti, M. Marzocco (Florence, Italy)<br />
090404 Conversion of a conduit to continent cutaneous diversion<br />
D. Melloni, M. Caramia, C. Magno, V. Serretta, W. Mansson (Messina, Palermo, Italy; Lund, Sweden)<br />
090405 Retroperitonescopic partial nephrectomy<br />
S. Sato (Sapporo, Japan)<br />
The <strong>EAU</strong> Digital Video Library is supported by an unrestricted educational grant from ASTELLAS<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
437
<strong>EAU</strong> Digital Video Library<br />
Volume 9.3 December 2002 02 <strong>EAU</strong> 30<br />
090301 Educational Video Prize 2002 Birmingham<br />
Nerve sparing laparoscopic radical retropubic prostatectomy<br />
C-C. Abbou, A. Hoznek, L. Salomon, R. Quintela, F. Saint, E. Olsson, D. Chopin (Creteil, France)<br />
090302 Innovational Video Prize 2002 Birmingham<br />
Resection of RCC with extended vena caval involvement performed with cardiopulmonary bypass,<br />
hypothermia and cardiac arrest with heartport device<br />
P. Graziotti, M. Maffezzini, G. Giusti, M. Seveso, G. Taverna, D. Lavelli, R. Gallotti, A. Bandera,<br />
A. Benetti (Milan, Italy)<br />
090303 Research Video Prize 2002 Birmingham<br />
The risk of bladder denervation during antireflux surgery: A reliable neurophysiological model<br />
C. Seif, P. Braun, F. Martinez Porillo, B. Herberger, G. Boehler, J. Leissner, K-P. Juenemann,<br />
R. Hohenfellner (Mannheim, Magdeburg, Kiel, Mainz, Germany)<br />
090304 Best Video published in EUVJ in 2001<br />
Inlay-onlay flap urethroplasty in the absence of the urethral plate<br />
R. Kocvara, J. Dvoracek<br />
Volume 9.2 September 2002 02 <strong>EAU</strong> 29<br />
090201 Excision and end-to-end anastomosis for repair of bulbar urethral stricture<br />
L. Martínez-Piñeiro, N. Cruz, F. Torrubia, R. Medina, P. Montañes (Madrid, Sevilla, Spain)<br />
090202 Ventral onlay preputial graft urethroplasty for repair of bulbar urethral stricture<br />
L. Martínez-Piñeiro, F. Torrubia, N. Cruz, J.B. García Ramos, P. Montañes (Madrid, Sevilla, Spain)<br />
090203 Endoscopic ureteral stripping in the treatment of renal pelvis tumours<br />
T. Maghiar, G. Bumbu, V. Coltoiu (Oradea, Romania)<br />
090204 Lithiasis on the vesical-urethral anastomosis after radical prostatectomy<br />
G. Bumbu, V. Coltoiu, T. Maghiar, L. Szilagyi (Oradea, Romania)<br />
090205 Dorsal onlay graft urethroplasty with oral mucosa<br />
J. Martínez-Piñeiro, E. Ríos, J. García Mediero, L. Martínez-Piñeiro (Madrid, Spain)<br />
438 Programme Book<br />
The <strong>EAU</strong> Digital Video Library is supported by an unrestricted educational grant from ASTELLAS
Volume 9.1 July 2002 02 <strong>EAU</strong> 28<br />
090101 V.I.P. (Vescica Ileale Padovana) Ileal neobladder: The evolution<br />
P. Bassi, F. Pagano, W. Battenello, D. Battaglia (Padua, Italy)<br />
090102 Seminal vesicle and prostatic capsule sparing cystectomy<br />
M. Carini, A. Lapini, U. Locuntom, L. Maseiri, S. Serni (Padua, Italy)<br />
090103 Total penectomy with perineal urethrostomy for locally advanced neoplasms of the penis<br />
A. Simonato, A. Gregori, A. Lissiani, S. Galli, A. Bozzola, F. Gaboardi (Milan, Italy)<br />
090104 Radical ilioinguinal node dissection with transposition of the sartorius muscle<br />
A. Simonato, A. Lissiani, A. Gregori, S. Galli, A. Bozzola, F. Gaboardi (Milan, Italy)<br />
090105 News in urosonography<br />
H. Heynemann, M. Zacharias, A. Wicht, K-V. Jenderka, P. Formara (Halle-Wittenberg, Germany)<br />
Volume 8.4 December 2001 01 <strong>EAU</strong> 27<br />
080401 Nerve and seminal vesicle sparing cystectomy with orthotopic urinary diversion for selected bladder<br />
cancer<br />
R. Colombo, R. Bertini, A. Salonia, L. Da Pozzo, M. Roscigno, P. Rigatti (Milan, Italy)<br />
080402 Seminal vesicle sparing cystectomy and ileocapsuloplasty<br />
G. Muto, F. Bardari, L. D’Urso, P. Coppola (Turin, Italy)<br />
080403 The Ghoneim antireflux ureteroileal implantation technique on GIA stapler detubularised ileal neobladder<br />
G. Muto, F. Bardari, L. D’Urso, P. Coppola (Turin, Italy)<br />
080404 Cost effective hand assisted laparoscopic radical nephrectomy (Hungarian technique)<br />
G. Kovacs, E. Holman, B.S. Dénes, J. Kalman, A. Karsza, J. Rozsahegy (Budapest, Hungary)<br />
080405 Local tumour excision in renal cell carcinoma<br />
L. Martinez-Piñeiro, A. Aguilera, D. Rendon, E. Rios, J. De la Peña (Madrid, Spain)<br />
The <strong>EAU</strong> Digital Video Library is supported by an unrestricted educational grant from ASTELLAS<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
439
<strong>EAU</strong> Digital Video Library<br />
Volume 8.3 November 2001 01 <strong>EAU</strong> 26<br />
080301 Use of pedicled flap labia minora for the repair of female urethral strictures<br />
M. Tanello, E. Frego, C. Simeone, S. Cosciani Cunico (Brescia, Italy)<br />
080302 Female urethral sticture and diverticula<br />
V. Pansadoro, F. De Paula, M. Pizzo, P. Emiliozzi, P. Scarpone, G. Federico (Rome, Italy)<br />
080303 Hadera continent reservoir - 5 year follow-up<br />
D. Yachia, N. Erlich (Hadera, Israel)<br />
080304 Retroperitoneal lymph node dissection with caval thrombectomy for advanced nonseminomatous<br />
germ cell tumour of the left testicle<br />
F. Martins, M. Alves, J. Freeman, J. Lencastre, J. Varela (Lisbon, Portugal)<br />
080305 Dorsal onlay preputial graft urethroplasty for repair of distal bulbar urethral stricture<br />
L. Martinez-Piñeiro, J. Cisneros, J. Ramón De Fata, J. De la Peña (Madrid, Spain)<br />
Volume 8.2 October 2001 01 <strong>EAU</strong> 25<br />
080201 First Prize <strong>EAU</strong> 2001 Geneva<br />
Simultaneous flap vaginoplasty and introitoplasty in urogenital sinus malformation<br />
L. Martínez-Piñeiro, J. García-Mediero, P. Cárcamo, M. Gacía-Matres, J. De la Peña (Madrid, Spain)<br />
080202 Second Prize <strong>EAU</strong> 2001 Geneva<br />
Laparoscopic retroperitoneal lymphnode dissection for testicular cancer<br />
R. Peschel, G. Janetschek, D. Strohmeyer, G. Bartsch, A. Hobisch (Innsbruck, Austria)<br />
080203 Third Prize <strong>EAU</strong> 2001 Geneva<br />
Robotically assisted laparoscopic radical prostatectomy<br />
G. Vallancien, G. Pasticier, J. Rietbergen, B. Guillonneau (Paris, France)<br />
080204 Telesurgical laparoscopic radical prostatectomy<br />
J. Rassweiler, T. Frede, O. Seemann, C. Stock, L. Sentker (Heilbronn, Germany)<br />
440 Programme Book
Volume 8.1 May 2001 01 <strong>EAU</strong> 24<br />
080101 Female cystectomy with orthotopic ileal afferent limb reconstruction<br />
R. Mills, U. Studer (Berne, Switzerland)<br />
080102 ‘Y’ neobladder: Preliminary results<br />
D. Fontana, M. Bellina, C. Scoffone, M. Poggio, S. Guercio (Turin, Italy)<br />
080103 Duplex Doppler Ultrasound evaluation in single-system ureteroceles<br />
P. Geavlete, D. Georgescu, G. Nita (Bucharest, Romania)<br />
080104 Nephro-ureterectomy performed by transurethral excision of a bladder cuff and retroperitoneal<br />
laparoscopy<br />
J. Rozenman, J. Shental, D. Almog, G. Chaimovitch (Afula, Israel)<br />
080105 Percutaneous nephrolithotomy of transplanted kidney<br />
F. Francesca, R. Felipetto, F. Mosca, U. Boggi, G. Rizzo, R. Puccini (Pisa, Italy)<br />
080106 Inlay-onlay flap urethroplasty in the absence of the urethral plate<br />
R. Kocvara, J. Dvoracek (Prague, Czech Republic)<br />
080107 Inverted ‘Y’ incision-variant of transurethral incision of the prostate<br />
P. Geavlete (Bucharest, Romania)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
441
<strong>EAU</strong> Digital Video Library<br />
The following videos are a selection of video presentations during the<br />
25 th <strong>EAU</strong> in <strong>Barcelona</strong>, April 16-20, <strong>2010</strong><br />
<strong>2010</strong>-1 Gasless two port access total nephroureterectomy: MIES total nephroureterectomy<br />
K. Saito, K. Kihara, S. Kawakami, Y. Fujii, H. Masuda, F. Koga (Tokyo, Japan)<br />
<strong>2010</strong>-2 Hybrid NOTES transvaginal nephrectomy<br />
R. Sotelo, R. De Andrade, G. Fernandez, R. Garza, D. Ramirez, C. Giedelman, E. Di Grazia,<br />
O. Carmona, D. Canes, M. Aron, M. Desai, I. Gill (Caracas, Venezuela; Burlington, Los Angeles, United<br />
States of America)<br />
<strong>2010</strong>-3 Transvaginal NOTES-assisted laparoscopic living donor nephrectomy<br />
A. Alcaraz, L. Peri, M. Musquera, M. Piqueras, M.J. Ribal (<strong>Barcelona</strong>, Spain)<br />
<strong>2010</strong>-4 Gasless single port access ultrasound-guided clampless partial nephrectomy: MIES partial<br />
nephrectomy<br />
K. Kihara, T. Tsushima, S. Kawakami, Y. Fujii, H. Masuda, F. Koga, K. Saito (Tokyo, Okayama, Japan)<br />
<strong>2010</strong>-5 NOTES hybrid transvaginal upper pole heminephrectomy<br />
R. De Andrade, O. Carmona, D. Ramirez, C. Mejia, C. Giedelman, E. Herrera, D. Canes, M. Aron,<br />
M. Desai, I. Gill, R. Sotelo (Caracas, Venezuela; Burlington, Los Angeles, United States of America)<br />
<strong>2010</strong>-6 Left less partial nephrectomy without ischemia: First experience<br />
G.S. Gidaro, C.L. Cindolo, S.L. Schips (Chieti, Vasto, Italy)<br />
<strong>2010</strong>-7 Less transumbilical radical nephrectomy<br />
A. Alcaraz, L. Peri, M. Musquera, A. Molina, M.J. Ribal (<strong>Barcelona</strong>, Spain)<br />
<strong>2010</strong>-8 LESS adrenalectomy<br />
S. Gidaro, L. Cindolo, L. Schips, F. Neri (Chieti, Vasto, Italy)<br />
<strong>2010</strong>-9 Laparoscopic single port adrenalectomy<br />
W. Massoud, B. Iliescu, M. Fennouri, O. Dumonceau, M. Ceddaha, H. Baumert (Le Kremlin-Bicêtre,<br />
Paris, France)<br />
<strong>2010</strong>-10 Single incision single port transabdominal adrenalectomy: Our preliminary results<br />
I. Yavascaoglu, Y. Kordan (Bursa, Turkey)<br />
<strong>2010</strong>-11 “LESS” radical prostatectomy performed with a personal original technique<br />
F. Gaboardi, A. Salvaggio, A.M. Granata, A.L. Romanò, G.P. Incarbone, F. Scieri, F. Pietrantuono,<br />
A. Gregori (Milan, Italy)<br />
<strong>2010</strong>-12 Extraperitoneal laparo-endoscopic single site radical prostatectomy (LESS)<br />
R. Rabenalt, M. Giessing, C. Arsov, C. Winter, P. Albers (Düsseldorf, Germany)<br />
<strong>2010</strong>-13 Robotic simple prostatectomy<br />
V.D. Matei, M.G. Spinelli, A. Nordio, A. Brescia, N. Crisan, I. Coman (Milan, Italy; Cluj, Romania)<br />
<strong>2010</strong>-14 Robotic assisted laparoscopic radical prostatectomy: Lateral approach to the bladder neck<br />
preservation in case of median lobe<br />
F. Annino, A. Beato, C. De Carne, S. Micali, M.C. Sighinolfi, S. De Stefani, G. Bianchi (Modena, Italy)<br />
442 Programme Book
<strong>2010</strong>-15 Complications during robotic radical prostatectomy<br />
R. Sotelo Noguera, O.C. Carmona, C.M. Mejia, E. Di Grazia, V.P. Patel, K.P. Palmer, D.C. Canes,<br />
R. Abaza, I. Tuerk, A. Moinzadeh, P. Carpentier, A. Mottrie (Caracas, Venezuela; Orlando, Burlington,<br />
Columbus, Boston, United States of America; Aalst, Belgium)<br />
<strong>2010</strong>-16 Repair of rectovesical fistula using the York Mason approach<br />
H. Zecha, G. Hellmich, F. Steinbach (Dresden, Germany)<br />
<strong>2010</strong>-17 Laparoscopic resolution of complications during radical prostatectomy<br />
R. Sanseverino, G. Napodano, O. Intilla, U. Di Mauro, T. Realfonso (Nocera Infedriore, Italy)<br />
<strong>2010</strong>-18 Recognition and management of rectal injury during laparoscopic or robotic radical prostatectomy<br />
O. Carmona, D. Canes, D. Ramirez, E. Herrera, F. Santinelli, V. Patel, K. Palmer, S. Deger, R. Sotelo<br />
(Caracas, Venezuela; Burlington, Orlando, United States of America; Berazategui, Argentina; Berlin,<br />
Germany)<br />
<strong>2010</strong>-19 Laparoscopic resolution of vascular complications in laparoscopic surgery<br />
C. Nuñez Mora, J.M. Garcia Mediero, A. Garcia Tello, P. Cabrera Castillo, J. Angulo Cuesta (Madrid,<br />
Spain)<br />
<strong>2010</strong>-20 Haemostasis during nerve-sparing endoscopic extraperitoneal radical prostatectomy (nsEERPE)<br />
J-U. Stolzenburg (Leipzig, Germany)<br />
<strong>2010</strong>-21 Combined endoscopic and surgical treatment for bladder erosion by prolene mesh<br />
S. Guercio, A. Ambu, F. Mangione, M. Mari, F. Vacca, E. Guercio, M. Bellina (Turin, Italy)<br />
<strong>2010</strong>-22 Supine percutaneous nephrolithotomy<br />
A. Hoznek, S. Esquivel, K. De Laet, A. De La Taille, L. Salomon, C.C. Abbou (Creteil, France; Antwerp,<br />
Belgium)<br />
<strong>2010</strong>-23 Staghorn calculi: Single percutaneous traject (experience on 263 cases)<br />
P.A. Geavlete, V.A. Mirciulescu, V. Cauni, D.A. Georgescu, D.R. Multescu (Bucharest, Romania)<br />
<strong>2010</strong>-24 Combined endoscopic and laparoscopic treatment of bilateral staghorn urolithiasis in a horseshoe<br />
kidney<br />
C.M. Scoffone, C.M. Cracco, M. Poggio, M. Cossu, F. Porpiglia, S. Grande, A. Di Stasio, R.M. Scarpa<br />
(Orbassano, Italy)<br />
<strong>2010</strong>-25 Ureteroscopic “cut to the light”: A new technique<br />
P.A. Geavlete, V.A. Mirciulescu, D.R. Multescu, D.A. Georgescu, B.F. Geavlete (Bucharest, Romania)<br />
<strong>2010</strong>-26 TURis plasma vaporization of the prostate: Experience on 200 cases<br />
P.A. Geavlete, B.F. Geavlete, M. Jecu, D.A. Georgescu, D.R. Multescu, M.D. Dragutescu (Bucharest,<br />
Romania)<br />
<strong>2010</strong>-27 Dr. Son’s arterial bleeding control technique during photoselective vaporization of the prostate<br />
(PVP) of 120W GreenlightTM High Power System<br />
J.H. Park, C.J. Lee, J.B. Bae, S.B. Lee, H. Jeong, H.C. Son (Seoul, South Korea)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
443
<strong>EAU</strong> Digital Video Library<br />
<strong>2010</strong>-28 Surgical management of renal cell cancer with tumour thrombus using liver transplantation<br />
techniques<br />
J. Gonzalez, J.C. Angulo, G. Ciancio (Madrid, Spain; Miami, United States of America)<br />
<strong>2010</strong>-29 Elective vacuum assisted cardiopulmonary bypass in the surgical treatment of renal neoplasms<br />
extending into the right atrium<br />
F. Nigro, P. Ferrarese, E. Scremin, G. Benedetto, P. Magagna, C. Piccin, A. Fabbri, A. Tasca (Vicenza,<br />
Italy)<br />
<strong>2010</strong>-30 The intrafascial nerve sparing radical perineal prostatectomy<br />
J. Beier, H. Keller (Hof, Germany)<br />
<strong>2010</strong>-31 Ileal neobladder with substitution of the urethral mucosa and sphincter preservation in female<br />
multifocal bladder cancer<br />
J. Palou, J. Caffaratti, J.M. Santillana, J.M. Gaya, H. Villavicencio (<strong>Barcelona</strong>, Spain)<br />
<strong>2010</strong>-32 Nerve sparing cystectomy in a male patient<br />
U.E. Studer, F.C. Burkhard, G.N. Thalmann (Berne, Switzerland)<br />
<strong>2010</strong>-33 Pelvic lymph node dissection in a female patient with bladder cancer<br />
U.E. Studer, B. Roth, F.C. Burkhard (Berne, Switzerland)<br />
<strong>2010</strong>-34 Direct access to UPJ in robot-assisted pieloplasty<br />
F. Gaboardi, A. Salvaggio, A.L. Romanò, A.M. Granata, G.P. Incarbone, F. Scieri, F. Pietrantuono,<br />
A. Gregori (Milan, Italy)<br />
<strong>2010</strong>-35 Robot-assisted pyeloplasty with two working trocars: Optimal cosmetic and functional results<br />
G.M. Schoen, N. Harke, S. Plhal, F. Schiefelbein (Würzburg, Germany)<br />
<strong>2010</strong>-36 Transmesololic robot-assisted pyeloplasty<br />
G. Bianchi, G. Pini, F. Annino, S. Micali, M.C. Sighinolfi, S. De Stefani (Modena, Italy)<br />
<strong>2010</strong>-37 Right laparoscopic retroperitoneal lymph node dissection in Leydig-Sertoli testis tumour<br />
A. Alcaraz, Ll. Peri, M. Musquera, A. Bohorquez, M.J. Ribal (<strong>Barcelona</strong>, Spain)<br />
<strong>2010</strong>-38 Post-chemotherapy robot-assisted laparoscopic resection of a residual retroperitoneal tumour in<br />
testicular cancer<br />
G.M. Schoen, N. Harke, T. Egner, F. Schiefelbein (Würzburg, Germany)<br />
<strong>2010</strong>-39 Laparoscopic partial nephroureterectomy in the treatment of hydronephrosis of the upper pole of<br />
duplex kidney with megaureter<br />
P. Wisniewski, P. Jarzemski, S. Listopadzki, R. Kalinowski (Bydgoszcz, Poland)<br />
<strong>2010</strong>-40 Posterior urethroplasty using a combined surgical and endoscopical technique<br />
E. Palminteri, E. Berdondini, M. Poluzzi, A. Molon, G. Franco, V. Gentile (Arezzo, Negrar, Rome, Italy)<br />
<strong>2010</strong>-41 Hypospadias repair - inlay-onlay urethroplasty<br />
A. Oeztuerk, N. Djakovic, B. Hadaschik, J. Nyarangi-Dix, J. Pfitzenmaier, S. Pahernik, A. Haferkamp,<br />
M. Hohenfellner (Heidelberg, Germany)<br />
444 Programme Book
<strong>2010</strong>-42 One sided urethral dissection for full length stricture<br />
S.B. Kulkarni, G.V. Barbagli (Pune, India; Arezzo, Italy)<br />
<strong>2010</strong>-43 Reconstruction of a completely destroyed urethra from the sphincter up to the meatus by bucal<br />
mucosa graft<br />
J. Beier, H. Keller (Hof, Germany)<br />
<strong>2010</strong>-44 GreenLEP, Greenlight laser enucleation of the prostate<br />
F. Gomez Sancha (Madrid, Spain)<br />
<strong>2010</strong>-45 Intraoperative photodynamic evaluation of surgical margins in endoscopic extra peritoneal radical<br />
prostatectomy with the use of 5-aminolevulinic acid<br />
R. Ganzer, A. Blana, S. Denzinger, W.F. Wieland, C. Adam, A. Becker, W. Khoder, S. Walther, C.G. Stief,<br />
D. Zaak, G. Salomon, A. Hartmann, S. Bertz, R. Knuechel, G. Popken (Regensburg, Munich, Hamburg,<br />
Erlangen, Aachen, Berlin, Germany)<br />
<strong>2010</strong>-46 Robotic anterior pelvic exenteration with intracorporeal urinary diversion in the female<br />
G. D’Elia, P. Emiliozzi, G. Ortolani, A. Iannello (Rome, Italy)<br />
The following videos are a selection of video presentations during the<br />
24 th <strong>EAU</strong> in Stockholm, March 17-21, 2009<br />
2009-1 Evolution of the robotic continence preservation technique: An anatomical approach<br />
Jhaveri J., Chhabra P., Tan Y.M., Rao R., Bartsch G., Menon M., Leung A., Yadav A., Te E., Vaughan Jr.<br />
E.D., Tewari K. (New York, Detroit, United States of America; Innsbruck, Austria)<br />
2009-2 Tension- and energy-free robotic assisted laparoscopic radical prostatectomy: Modified technique<br />
for its application during the learning curve<br />
Annino F., Beato A., De Carne C., Micali S., De Stefani S., Bianchi G. (Modena, Italy)<br />
2009-3 Optimization of robotic anatomical radical prostatectomy and preservation of neurovascular<br />
bundles<br />
Villavicencio H., Gausa L., Peña J.A., Rosales A., Palou J. (<strong>Barcelona</strong>, Spain)<br />
2009-4 Duplicating open principles retrograde robotic radical prostatectomy<br />
Sotelo R.J., Carmona O.J., Astigueta J.C., De Andrade R.J., Canes D. (Caracas, Venezuela)<br />
2009-5 Robotic radical female cystectomy with intracorporal Studer-pouch urinary reconstruction<br />
John H., Moeckel C., Horton K., Wiklund P. (Zurich, Switzerland; Stockholm, Sweden)<br />
2009-6 Robot-assisted laparoscopic radical cystoprostatectomy: Totally intracorporeal Studer neobladder<br />
Pardalidis N., Andriopoulos N., Giannakou N., Karagianni E., Kosmaoglou E., Wiklund P.N. (Athens,<br />
Greece; Stockholm, Sweden)<br />
2009-7 Robotic-assisted extrafascial radical cystoprostatectomy and intracorporeal ureteral Wallace technique<br />
anastomosis<br />
Palou J., Gausa L., Rengifo D., Sagristà R., Huguet J., Peña J.A., Villavicencio H. (<strong>Barcelona</strong>, Spain)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
445
<strong>EAU</strong> Digital Video Library<br />
2009-8 Complications after 5.000 ureteroscopies - single-center experience<br />
Georgescu D., Multescu R., Moldoveanu C., Geavlete B., Geavlete P. (Bucharest, Romania)<br />
2009-9 Use and maintenance of laser fibers during flexible uretero-renoscopy<br />
Hoznek A., De Laet K., Paul A., De La Taille A., Salomon L., Yiou R., Vordos D., Abbou C-C. (Creteil,<br />
France)<br />
2009-10 Conservative treatments of upper tract tumours<br />
Simone G., Papalia R., Ferriero M., Leonardo C., Guaglianone S., Gallucci M. (Rome, Italy)<br />
2009-11 Transurethral plasma vaporization of the prostate in saline (TUVis-P) in patients under continuing<br />
oral anticoagulation<br />
Müller A., Bigger K.D.P., Blick N., Suter S. (Zurich, Switzerland)<br />
2009-12 Ejaculation preserving (EP) technique in endourological treatment of BPH - epLaservaporesection<br />
and epTUR of the prostate<br />
Lang C., Eichel R., Alloussi S.H., Alloussi S. (Neunkirchen, Germany)<br />
2009-13 Usefulness of real-time transrectal ultrasound navigation during holmium laser enucleation of the<br />
prostate<br />
Shibata Y., Arai S., Koike H., Hatori M., Ito K., Suzuki K. (Maebashi, Japan)<br />
2009-14 Isobaric laparascopic radical prostatectomy with the “laparo-tenser” system<br />
Granata A.M., Scieri F., Gregori A., Incarbone G.P., Romanò A.L., Salvaggio A., Pietrantuono F.,<br />
Gaboardi F. (Milan, Italy)<br />
2009-15 Extraperitoneoscopic intrafascial nerve sparing prostatectomy<br />
Porpiglia F., Fiori C., Morra I., Grande S., Di Stasio A., Vaccino D., Scarpa R.M. (Orbassano, Italy)<br />
2009-16 Laparoscopic radical prostatectomy after brachytherapy failure<br />
Palou J., Peña J.A., Esquena S., Rodríguez Faba O., Villavicencio H. (<strong>Barcelona</strong>, Spain)<br />
2009-17 Laparoscopic radioisotope-guided sentinel lymph node dissection for prostate cancer<br />
Marchioro M.G., Volpe A., Billia M., Taarabuzzi R., Zaramella S., Maso G., Ranzoni S., Roduni M.,<br />
Inglese E., Terrone C. (Mosso, Novara, Italy)<br />
2009-18 A new approach for optimal exposure during lymph node dissection following radical cystectomy<br />
Ghazi A., Janetschek G. (Linz, Austria)<br />
2009-19 Chicken gizzard. A novel training model for laparoscopic urethro-vesical anastomosis<br />
Sotelo R.J., Astigueta J.C., Carmona O.J., De Andrade R.J., Velasquez A., Canes D. (Caracas,<br />
Venezuela)<br />
2009-20 Hybrid transvaginal radical nephrectomy<br />
Alcaraz A., Peri L., Izquierdo L., Carmona F., Molina A., Ribal M.J. (<strong>Barcelona</strong>, Spain)<br />
2009-21 Transumbilical endoscopic surgery – are special devices strictly necessary?<br />
Branco A.W., Branco Filho A.J., Kondo W., Stunitz L.C., Riella C.V., Aoki Y.S. (Curitiba, Brazil)<br />
446 Programme Book
2009-22 Single port transvesical enucleation of prostate (STEP)<br />
Sotelo R.J., Desai M.M., Carmona O.J., Aron M., Astigueta J.C., De Andrade R.J., Herrera C., Ulchaker<br />
J., Canes D., Khaled F., Desai M., Shoskes D., Gill I.S. (Caracas, Venezuela;<br />
2009-23 Laparoscopic endoscopic single site surgery (LESS): Tumour nephrectomy<br />
Stolzenburg J.U., Hellawell G.O., Do M., Haefner T., Dietel A., Liatsikos E.N. (Leipzig, Germany;<br />
London, United Kingdom; Patras, Greece)<br />
2009-24 Single port transumbilical simple prostatectomy<br />
Sotelo R.J., Carmona O.J., De Andrade R.J., Astigueta J.C., Velasquez A., Canes D., Desai M.M., Kaouk<br />
J., Gill I.S. (Caracas, Venezuela; Ohio, United States of America) Ohio, United States of America;<br />
Nadiad, India)<br />
2009-25 Single incision laparoscopic nephrectomy (SILN). Assessing and overcoming new challenges<br />
Gidaro S., Cindolo L., Mirone V., Tamburro F.R., Schips L. (Vasto, Naples, Italy)<br />
2009-26 Laparoscopic suture techniques for percutaneous endopyeloplasty<br />
Lezrek M., Bazine K., Samir J., Alami M., Kasmaoui E.H., Zaini R., Ouhbi Y., Touiti D., Ameur A.,<br />
Abbar M., Beddouch A. (Meknes, Marrakech, Rabat, Morocco)<br />
2009-27 Tubeless PCNL in supine position<br />
Giusti G., Piccinelli A., Maugeri O., Taverna G., Pasini L., Benetti A., Corinti M., Zandegiacomo S.,<br />
Graziotti P. (Rozzano (Milan), Italy)<br />
2009-28 Percutaneous needle renal displacement technique<br />
Lezrek M., Bazine K., Alami M., Najoui M., Samir J., Kasmaoui E.H., Zaini R., Ouhbi Y., Touiti D.,<br />
Ameur A., Abbar M., Beddouch A. (Meknes, Marrakech, Rabat, Morocco)<br />
2009-29 Laparoscopic transmesocolic pyelolithotomy<br />
Volpe A., Tarabuzzi R., Zaramella S., Varvello F., Marchioro G., Maso G., Ranzoni S., Zacchero M.,<br />
Terrone C. (Novara, Italy)<br />
2009-30 Robotically assisted laparoscopic pyeloplasty-utility of the 4th arm (the pure non touch technique)<br />
Al-Sameraaii A.S., Raman A., Yuen C., Kooner R. (Sydney, Australia)<br />
2009-31 Supine percutaneous nephrolithotripsy (PCNL) in children: Technical aspects<br />
Frattini A., Ferretti S., Dinale F., Salsi P., Granelli P., Cortellini P. (Parma, Italy)<br />
2009-32 Dorsal transverse mini-lumbotomy incision as a minimally invasive approach for pyeloplasty in<br />
children<br />
Önol F.F., Onol S.Y., Akbas A., Kose O., Antar B., Arslan B. (Sakarya, Istanbul, Turkey)<br />
2009-33 The surgical technique of robotic-assisted laparoscopic partial nephrectomy<br />
Ho H.S.S., Harbicher M., Neururer R., Steiner H., Bartsch G., Peschel R. (Innsbruck, Austria)<br />
2009-34 Simplified method of robotic-assisted laparoscopic nephroureterectomy: Adequate position of the<br />
trocars<br />
Palou J., Gausa L., Rengifo D., Peña J., Dominguez A., Villavicencio H. (<strong>Barcelona</strong>, Spain)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
447
<strong>EAU</strong> Digital Video Library<br />
2009-35 Laparoscopic heminephroureterectomy for duplex kidney anomalies in children<br />
Seibold J., Nagele U., Schilling D., Anastasiadis A.G., Sievert K.D., Stenzl A., Corvin S. (Tübingen,<br />
Burgwedel, Eggenfelden, Germany)<br />
2009-36 Laparoscopic management of a renal mass with type I venous thrombus<br />
Rodríguez Faba O., Palou J., Rosales A., Huguet J., Parada R., Villavicencio H. (<strong>Barcelona</strong>, Spain)<br />
2009-37 Gasless single port access radical nephrectomy<br />
Kihara K., Kawakami S., Fujii Y., Masuda H., Koga F., Saito K. (Tokyo, Japan)<br />
2009-38 Vascular repair in laparoscopic nephrectomy<br />
Branco A.W., Branco Filho A.J., Kondo W., Stunitz L.C., Riella C.V., Aoki Y.S. (Curitiba, Brazil)<br />
2009-39 Penile prosthesis implantation and tunica albuginea incisions without grafting in the treatment of<br />
Peyronie’s disease<br />
Djordjevic M.L., Majstorovic M., Bizic M., Kojovic V., Milosevic A., Pandey S. (Belgrade, Serbia;<br />
Mumbai, India)<br />
2009-40 Total phalloplasty using latissimus dorsi flap - indications and technique<br />
Perovic S.V., Djinovic R.P., Milosavljevic M.Z. (Belgrade, Serbia)<br />
2009-41 New refinements in male-to-female sex reassignment surgery<br />
Perovic S.V., Djinovic R.P., Milosavljevic M.Z. (Belgrade, Serbia)<br />
2009-42 Laparoscopic sacrocolpopexy<br />
Curto F., Gaston R., Piechaud T. (Palermo, Italy; Bordeaux, France)<br />
2009-43 Laparoscopic promontofixation: Modification of the posterior mesh positioning<br />
Fournier G.H., Erauso A., Perrouin-Verbe M.A., Papin G., Rousseau B., Joulin V., Deruelle C., Valeri A.<br />
(Brest, France)<br />
2009-44 AdVance male sling TO – the transobturatoric tape to treat mild and moderate urinary stress incontinence<br />
in male patients<br />
Sievert K.D., Amend B., Rehder P., Gakis G., Stenzl A. (Tübingen, Germany; Innsbruck, Austria)<br />
2009-45 Contemporary implant of trans obturatory sling advance and inflatable penile prosthesis AMS CX<br />
700<br />
Conti E., Fasolo P.P., Lacquaniti S., Fiorio M., Puccetti L., Mandras R., Fasolis G. (Alba, Italy) Austria)<br />
The following videos are a selection of video presentations during the<br />
23 rd <strong>EAU</strong> in Milan, March 21-24, 2008<br />
2008-1 Laparoscopic radical nephrectomy with renal vein thrombus<br />
Massoud W., Saheb N., Schlosser J., Dumonceau O., Fennouri M., Iliescu B., Baumert H. (Paris,<br />
France)<br />
2008-2 Laparoscopic partial nephrectomy in a transplanted kidney<br />
Rosales A., Salvador J., Azuero J., Caffaratti J., Montlleo M., Ponce De León J. (<strong>Barcelona</strong>, Spain)<br />
2008-3 Laparoscopic heminephrectomy in horseshoe kidney<br />
Celia A., Zeccolini G., Breda G. (Bassano del Grappa, Italy)<br />
448 Programme Book
2008-4 Transvaginal NOTES nephrectomy with two additional 5mm laparoscopic ports<br />
Branco A.W., Branco A.J., Noda R.W., Camargo A.H.L., Stunitiz L.C., Kondo W., Miranda M.M.L.<br />
(Curitiba, Brazil)<br />
2008-5 Laparoscopic nephroureterectomy for upper tract urothelial cancer: A novel closed system pluck<br />
Pathak S., Lavin V., Watcyn-Jones T., Doyle D., Oakley N. (Sheffield, United Kingdom)<br />
2008-6 Management of complications during laparoscopic nephrectomy<br />
Milfont J.C.A., Dubeux V., Medeiros L., Barcellos E.G. (Rio de Janeiro, Brazil)<br />
2008-7 Laparoscopic extraperitoneal bladder diverticulectomy<br />
Celia A., Zeccolini D., Breda G. (Bassano de Grappa, Italy)<br />
2008-8 Vesico-vaginal fistula laparoscopic repair<br />
Porpiglia F., Morra I., Volpe A., Cracco C., Renard J., Scarpa R.M. (Orbassano (TO), Italy)<br />
2008-9 Vesico-colnic fistula laparoscopic repair<br />
Sanchez C., Kibanov V., Gonzalez M., Mez J.G., Flores J., Elizalde A. (Mexico, Mexico)<br />
2008-10 Laparoscopic ureteral reimplantation in Bricker<br />
Polara A., Aresu L., Maritati F., Occhipinti M., Grosso G. (Peschiera del Garda, Italy)<br />
2008-11 Ureteroscopically assisted laparoscopic segmental ureterectomy with psoas hitch procedure<br />
Nagele U, Sherif H, Merseburger AS, Sturm W, Sievert KD, Kuczyk MA, Stenzl A (Tübingen, Germany;<br />
Benha, Egypt)<br />
2008-12 Laparoscopic repair of retrocaval ureter in a solitary kidney<br />
Sanseverino R., Intilla O., Di Mauro U., Napodano G., Realfonso T., Campitelli A. (Nocera Inferiore,<br />
Italy)<br />
2008-13 E-TURP: Technical evolution of TURP<br />
Breda G., Celia A., Zeccolini G., Eldahashan S. (Bassano del Grappa, Italy)<br />
2008-14 Laparoscopic simple retro pubic prostatectomy: Technique and preliminary series<br />
Stember D.S., Disick G.I.S., Hassen W.A. (New York, United States of America)<br />
2008-15 Green light HPS laser prostatectomy: Recommendations on surgical technique<br />
Gomez Sancha F., Muir G., Bachmann A., Choi B., Collins E., De La Rosette J., Reich O., Tabatabei<br />
S., Woo H. (Madrid, Spain; London, United Kingdom; Basel, Switzerland; New York, San Francisco,<br />
Boston, United States of America; Amsterdam, The Netherlands; Munich, Germany; Sydney,<br />
Australia)<br />
2008-16 Thulium laser enucleation of the prostate<br />
Massoud W., Dumonceau O., Saheb N., Iliescu B., Schlosser J., Guetta T., Fournier F., Fennouri M.,<br />
Baumert H. (Paris, France)<br />
2008-17 Laser vaporization for benign prostate hyperplasia. The initial Romanian experience<br />
Lucan M., Witzsch U., Lucan V., Elec F., Moga S., Iacob G., Barbos A. (Cluj Napoca, Romania;<br />
Frankfurt, Germany)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
449
<strong>EAU</strong> Digital Video Library<br />
2008-18 Intracorporeal pneumatic lithotripsy: Evaluation of the stonebreaker<br />
Querton M., Salvado-Besnier J., Feyaerts A., Opsomer R., Wese F., Tombal B., Van Cangh P. (Brussels,<br />
Belgium)<br />
2008-19 Argus male sling system- surgical technique and results<br />
Hübner W., Gallistl H. (Korneuburg, Austria)<br />
2008-20 Br-sl-as 904: The Brazilian artificial sphincter<br />
Lima V.C., Vilar O., De Araujo P., Lima S., Andrade T. (Recife, Brazil)<br />
2008-21 The use of lingual mucosal graft in adult anterior urethroplasty: Surgical steps and short-term<br />
outcome<br />
Romano G., De Angelis M., Ciabatti P.G., Lazzeri M., Annino F., Barbagli G. (Arezzo, Florence,<br />
Modena, Italy)<br />
2008-22 A new double buccal mucosa graft bulbar urethroplasty<br />
Palminteri E., Manzoni G., Berdondini E., Di Fiore F., Testa G., Poluzzi M., Pastorello M., Molon A.<br />
(Arezzo, Varese, Naples, Negrar, Italy)<br />
2008-23 Surgery of Mb. Peyronie associated with exaggerated ventral penile curvature: Grafting procedure<br />
based on geometrical principle<br />
Perovic V.S., Djinovic P.R., Milosavljevic Z.M., Sansalone S. (Belgrade, Serbia; Rome, Italy)<br />
2008-24 Reconstructive phalloplasty after amputation for penile cancer using dermal epidermal grafts, prosthesis<br />
implant, with oral mucosa glanduloplasty<br />
Austoni E., Guarneri A., Colombo F., Cazzniga A., Ceresoli A., Grasso Macola G., Romano A., Rivolta L.<br />
(Milan, Italy)<br />
2008-25 Memokath stenting in neoplastic extrinsic ureteral stenosis<br />
Geavlete P., Nita Gh., Geavlete B. (Bucharest, Romania)<br />
2008-26 Flexible ureteroscopic approach in pyelocaliceal diverticula lithiasis<br />
Geavlete P., Multescu R., Georgescu D., Mirciulescu V., Geavlete B. (Bucharest, Romania)<br />
2008-27 Retrograde intrarenal surgery (RIRS) in the treatment of renal calculi larger than 2 cm: Myth or reality?<br />
Giusti G., Piccinelli A., Taverna G., Pasini L., Maugeri O., Benetti A., Corinti M., Zandegiacomo S.,<br />
Graziotti P. (Milan, Italy)<br />
2008-28 Endoscopic Combined Intra-Renal Surgery (ECIRS) for the treatment of complex urological pathologies<br />
using Galdakao-modified supine Valdivia position<br />
Scoffone C., Morra I., Cracco C., Ragni F., Poggio M., Cossu M., Vaccino D., Billia M., Grande S.,<br />
Scarpa R.M., Ibarluzea G., Valdivia Uria J.G. (Orbassano, Italy; Bizkaia, Saragozza, Spain)<br />
2008-29 Diagnostic flexible ureteroscopy in upper urinary tract pathology<br />
Geavlete B., Multescu R., Mirciulescu V., Geavlete P. (Bucharest, Romania)<br />
2008-30 Transureteral resection in ureteral tumours– long term follow-up<br />
Geavlete P., Nita G., Multescu R., Mirciulescu V., Geavlete B. (Bucharest, Romania)<br />
450 Programme Book
2008-31 Patterns of management of neurovascular bundle preservation during robotic radical prostatectomy<br />
Martinez-Salamanca J.I., Tewari A., Patel V., Gaston R., Allona A., Gonzalez J., Rao S., Palmer K.,<br />
Platas A., Lopez-Fando L. (Madrid, Spain; New York, Columbus, United States of America; Bordeaux,<br />
France)<br />
2008-32 Early retrograde release of the neurovascular bundle during robotic radical prostatectomy<br />
Dangle P., Samavedi S., Palmer K., Patil N., Coughlin G., Patel V.R. (Columbus, United States of<br />
America)<br />
2008-33 Nerve advancement technique with end-to-end reconstruction during robotic radical prostatectomy:<br />
A new challenge<br />
Martinez-Salamanca J.I., Tewari A., Mulhall J., Carballido J., Rao S., Muller A., Gonzalez J., Takenaka<br />
A., Li P., Ramanathan R. (Madrid, Spain; New York, United States of America)<br />
2008-34 Early continence recovery after robotic prostatectomy with restoration of posterior aspect of the<br />
rhabdosphincter<br />
Rocco B., Matei D.V., Bonghi A., Cedeira F., Pimentel M., De Cobelli O. (Milan, Italy)<br />
2008-35 Laparoscopic robot assisted vesico-vaginal fistula repair with peritoneal flap inlay<br />
Engel N., John H. (Zurich, Switzerland)<br />
2008-36 Robot-assisted laparoscopic partial nephrectomy<br />
Mottrie A., Koliakos N., De Naeyer G., Willemsen P., Carpentier P., Schatteman P., Fonteyne E. (Aalst,<br />
Belgium)<br />
2008-37 The intrafascial nerve-sparing endoscopic extra peritoneal radical prostatectomy (nsEERPE)<br />
Stolzenburg J.U., Rabenalt R., Do M., Schwalenberg T., Neuhaus J., Liatsikos E.N. (Leipzig, Germany;<br />
Leipzig, Greece)<br />
2008-38 Laparoscopic anatomical view of crucial surgical passages in radical prostatectomy<br />
Gaboardi F., Galli S., Scieri F., Pietrantuono F., Gregori A., Kartalas Goumas I., Stener S., Incarbone<br />
G.P. (Milan, Italy)<br />
2008-39 Sutureless vesico-urethral anastomosis: Introduction of a novel device and one year clinical data in<br />
a single patient<br />
Kella N. (San Antonio, United States of America)<br />
2008-40 Laparoscopic radical prostatectomy in a renal allograft recipient: Surgical technique<br />
Fournier G., Erauso A., Rammal A., Moal M.C., Joulin V., Deruelle C., Rousseau B., Valeri A. (Brest,<br />
France)<br />
2008-41 Anatomic robot-assisted radical prostatectomy<br />
Joseph J.V., Capello S.A., Patel H.P. (Rochester, United States of America)<br />
2008-42 Management of difficult anatomy during robotic assisted laparoscopic radical prostatectomy<br />
Palmer K.J., Coughlin G., Samavedi S.S., Patil N.N., Dangle P.P., Patel V.R. (Columbus, United States<br />
of America)<br />
2008-43 Laparoscopic robot assisted radical cystectomy with intracorporal urinary diversion<br />
John H., Fehr J., Fischer B., Engel N., Wiklund P. (Zurich, Switzerland)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
451
<strong>EAU</strong> Digital Video Library<br />
2008-44 The antegrade inter/intra/extrafascial da Vinci prostatectomy after transrectal injection<br />
Recker F., Seiler D., Werthemann P. (Aarau, Switzerland)<br />
The following videos are a selection of video presentations during the<br />
22 nd <strong>EAU</strong> in Berlin, March 21-24, 2007<br />
2007–1 Intraspinal nerve re-routing to reestablish bladder function in spinal cord injured patients<br />
B. Winter, A. Anastasiadis, B. Amend, A. Badke, H.P. Kaps, M. Tatagiba, A. Stenzl, K.D. Sievert<br />
(Tübingen, Germany)<br />
2007-2 High Intensity Focused Ultrasound at 3 MHz (HIFU)<br />
S. Thüroff, C. Chaussy (Munich, Germany)<br />
2007-3 York Mason trans-sphynteric trans-rectal repair of iatrogenic recto-urinary fistula: Case report<br />
R. Sanseverino, O. Intilla, G. Napodano, A. Barela, U. Di Mauro, T. Realfonso (Nocera Inferiore, Italy)<br />
2007-4 Renal cell carcinoma with cavo-atrial thrombosis, partially obstructing the tricuspid valve: Surgical<br />
technique<br />
R. Bertini, N. Suardi, B. Mazzoccoli, M. Roscigno, E. Strada, G. Petralia, L. Da Pozzo, R. Colombo,<br />
A. Bocciardi, S. Moriggia, P. Rigatti (Milan, Italy)<br />
2007-5 Renal neoplasm with hyperdiaphragmatic intracaval thrombus up to the right atrium. Our surgical<br />
technique<br />
A. Grigorakis, P. Dedeilias, P. Papadaniil, V. Androutsopoulou, S. Karakaidos, A. Papadopoulos, S.<br />
Stefanakis, D. Malovrouvas (Athens, Greece)<br />
2007-6 An anusual localisation of hydatid cyst operated retroperitoneoscopically<br />
M. Lucan, V. Lucan, F. Elec, S. Moga, F. Bologa, G. Iacob, A. Barbos (Cluj-Napoca, Romania)<br />
2007-7 Simultaneous implantation of bone anchored sling and inflatable penile prosthesis through a single<br />
peno-scrotal incision<br />
M. Lucan, V. Lucan, F. Elec, S. Moga, F. Bologa, G. Iacob, A. Barbos (Orbassano, Turin, Italy)<br />
2007-8 Implantation of an urethral artificial sphincter in a female patient<br />
K.D. Sievert, B. Amend, A. Anastasiadis, U. Nagele, J. Seibold, A. Stenzl (Tübingen, Germany)<br />
2007-9 Fast implantation of an artificial urethral sphincter through a peno-scrotal approach<br />
K.D. Sievert, B. Amend, S.K. Wilson, A. Anastasiadis, U. Nagele, M. Kuczyk, A. Stenzl (Tübingen,<br />
Germany; Little Rock, United States of America)<br />
2007-10 Transrectal ultrasound-guided implantation of the ProACT system in patients with post-radical<br />
prostatectomy stress urinary incontinence<br />
A. Gregori, I.K. Goumas, S. Galli, S. Zaramella, M. Favro, S. Ranzoni, F. Scieri, S. Stener, A. Deliperi,<br />
C. Terrone, F. Gaboardi, R. Knez (Milan, Novara, Italy)<br />
2007-11 The use of fibrin glue in bulbar urethral reconstruction<br />
G. Barbagli, S. De Stefani, F. Annino, M.C. Sighinolfi, S. Micali, G. Bianchi (Arezzo, Modena, Italy)<br />
2007-12 Endoscopic reconstruction after posttraumatic urethral disruption using a temporary urethral stent<br />
S. Kato, T. Takeuchi, N. Hagiwara, Y. Ban, H. Uno, T. Deguchi (Gifu, Japan)<br />
452 Programme Book
2007-13 Combined endoscopic and surgical technique for repair of posterior traumatic urethral stricture<br />
M. De Angelis, T. Verdacchi, F. Annino, G. Barbagli, G. Romano (Arezzo, Modena, Italy)<br />
2007-14 Hand-assisted laparoscopic approach for T3b radical nephrectomy<br />
D. Murphy, A. Henderson, W. Roberts, J.S. Wolf, A. Rane (London, United Kingdom; Ann Arbor,<br />
Redhill, United Statesof America)<br />
2007-15 Laparoscopic nephron sparing surgery and haemostasis with suture associated to fibrin glue and<br />
collagen fleece<br />
J. Renard, M. Cossu, F. Ragni, C. Cracco, F. Porpiglia, M. Billia, R.M. Scarpa (Orbassano, Italy)<br />
2007-16 Significance of tumor size in retroperitoneoscopic radical nephrectomy for renal cell carcinoma<br />
M. Lucan, V. Lucan, F. Elec, S. Moga, F. Bologa, G. Iacob, A. Barbos (Cluj-Napoca, Romania)<br />
2007–17 Transurethral approach for distal superficial ureteral tumors<br />
P. Geavlete, G. Nita, D. Soroiu, S. Bancu, B. Geavlete (Bucharest, Romania)<br />
2007-18 Endoscopic terminal ureter approaches in one step nephroureterectomy<br />
D. Georgescu, P. Geavlete, S. Bancu, V. Mirciulescu, B. Geavlete (Bucharest, Romania)<br />
2007-19 Maneuvers for completely laparoscopic nephroureterectomy<br />
I. Oyarzabal, J. Estebanez, L. Agirreazaldegi, L. Zubiaurre, E. Artozki, J.P. Sanz Jaka (San Sebastian,<br />
Spain)<br />
2007-20 Extended pelvic lymphadenectomy during laparoscopic radical cystectomy<br />
A. Hoznek, D. Vordos, S. Larré, L. Salomon, A. De La Taille, R. Yiou, C-C. Abbou (Creteil, France)<br />
2007-21 Laparoscopic iliac lymphadenectomy could duplicate the principles of open technique during radical<br />
cystectomy<br />
A. Shoma (Mansoura, Egypt)<br />
2007-22 Laparoscopic nerve sparing cystectomy and orthotopic neobladder in female patients<br />
U. Nagele, A.G. Anastasiadis, K.D. Sievert, M. Kuczyk, J. Seibold, A. Stenzl (Tübingen, Germany)<br />
2007-23 Laparoscopic cystectomy and neo-bladder formation in woman<br />
H. Baumert, N. Rebai, N. Shah, W. Massoud, L. Peyrat, T. Aho, D. Neal (Paris, France; Cambridge,<br />
United Kingdom)<br />
2007-24 Robotic assisted laparoscopic radical cystectomy in the male: A technique illustrated step by step<br />
F. Gaboardi, S. Galli, A. Gregori, I. Goumas Kartalas, F. Sceri, R. Knez, S. Stener (Milan, Italy)<br />
2007–25 Combined potency- and continence preserving radical cystectomy with hemiprostatectomy<br />
H. Wunderlich, M. Wolf, J. Schubert (Jena, Germany)<br />
2007-26 Laparoscopic heminephrectomy in horseshoe kidney<br />
I.A. Aridogan, Y. Bayazit, V. Izol, A. Eken, S. Doran (Adana, Turkey)<br />
2007-27 Is retroperitoneoscopic peripelvic cyst ablation a simple issue?<br />
M. Lucan, V. Lucan, F. Elec, S. Moga, F. Bologa, G. Iacob, A. Barbos (Cluj-Napoca, Romania)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
453
<strong>EAU</strong> Digital Video Library<br />
2007-28 Laparoscopic management of a retro peritoneal ganglionic recurrence after an open radical cystectomy<br />
+ neobladder formation<br />
N. Rebai, W. Massoud, N. Saheb, F. Fournier, O. Dumonceau, H. Baumert (Paris, France)<br />
2007-29 Minimally invasive percutaneous nephrolithotomy (Mini-Perc)<br />
P. Liske, V. Zimmermanns, S. Lahme (Pforzheim, Germany)<br />
2007-30 Mini-invasive approach to pyelogenic cyst<br />
F. Nigro, P. Ferrarese, G. Abatangelo, G. Benedetto, E. Scremin, A. Tasca (Vicenza, Italy)<br />
2007-31 Endourologic treatment of upper urinary stones in pregnant woman<br />
P. Geavlete, G. Nita, D. Georgescu, B. Geavlete (Bucharest, Romania)<br />
2007-32 Left transperitoneal laparoscopic pyeloplasty with direct access to the uretero-pelvic junction<br />
F. Porpiglia, M. Billia, J. Renard, A. Volpe, I. Morra, C. Scoffone, R.M. Scarpa (Orbassano, Italy)<br />
2007-33 Retroperitoneoscopic upper pole heminephrectomy in complete duplication of the ureter:<br />
Management of the distal ureter<br />
M. Lucan, V. Lucan, F. Elec, S. Moga, G. Iacob, A. Barbos, F. Bologa (Cluj-Napoca, Romania)<br />
2007-34 Laparoscopic dismembered pyeloplasty for right retrocaval ureter<br />
F. Porpiglia, J. Renard, M. Billia, I. Morra, C. Cracco, M. Cussotto, G. Biamino, R.M. Scarpa (Orbassano,<br />
Asti, Italy)<br />
2007-35 Pure robot assisted psoas hitch ureteral reimplantation for distal ureteral stenosis<br />
A. Mottrie, G. De Naeyer, P. Van Migem, P. Schatteman, P. Carpentier, E. Fonteyne (Aalst, Belgium)<br />
2007-36 Laparoscopic intraperitonealisation of ureter and usage of tissue adhesion barrier in retroperitoneal<br />
fibrosis<br />
Y. Bayazit, V. Izol, I.A. Aridogan, A. Eken, S. Doran (Adana, Turkey)<br />
2007-37 Laparoscopic pyeloplasy using robotic system<br />
F. Gaboardi, S. Galli, I. Kartalas-Goumas, A. Gregori, R. Knez, F. Scieri, S. Stener (Milan, Italy)<br />
2007-38 Extended laparoscopic pelvic lymph node dissection (LND) for prostate cancer<br />
F.P. Secin, T. Koppie, K. Touijer, B. Guillonneau (New York, United States of America)<br />
2007-39 Nerve sparing laparoscopic radical prostatectomy: The step by step technique<br />
W. Massoud, N. Rebai, N. Saheb, M. Fennouri, O. Dumonceau, H. Baumert (Paris, France)<br />
2007-40 New approach for the ultra-dissection of the neurovascular bundles (NVB) during robot-assisted<br />
laparoscopic radical prostatectomy (RALP) in selected patients with prostate cancer<br />
A. Mattei, R. Naspro, F. Annino, D. Burke, R. Guida, R. Gaston (Bordeaux, France)<br />
2007-41 Periprostatic fascia preservation in da Vinci robotic radical prostatectomy<br />
S. Silvio (Milan, Italy)<br />
2007-42 Total interfascial robot assisted prostatectomy<br />
A. Mottrie, G. De Naeyer, P. Van Migem, P. Schatteman, P. Carpentier, E. Fonteyne (Aalst, Belgium)<br />
454 Programme Book
2007-43 Common problems in laparoscopic radical prostatectomy: How to deal with hernia mesh, median<br />
lobe and previous TURP?<br />
A. Hoznek, L. Salomon, A. De La Taille, D. Vordos, R. Yiou, S. Larré, C-C. Abbou (Creteil, France)<br />
The following videos are a selection of video presentations during the<br />
21 st <strong>EAU</strong> in Paris, April 5-8, 2006<br />
2006-1 Anatomical features and dissection of the accessory pudendal arteries during laparoscopic radical<br />
prostatectomy<br />
G.H. Fournier, A. Valeri, A. Rammal, V. Joulin, J. Donohue, X. Taccoen, C. Deruelle, L. Doucet, A.<br />
Volant, O. Cussenot (Brest, Paris, France)<br />
2006-2 Laparoscopic radical prostatectomy, preservation of accessory pudendal arteries<br />
L. Martínez-Piñeiro, J.R. Cansino, F. Cáceres, A. Tabernero, J. Cisneros, J.J. De La Peña (Madrid, Spain)<br />
2006-3 Anatomy and preservation of accessory pudendal arteries in laparoscopic radical prostatectomy<br />
F. Secin, N. Karanikolas, J.I. Martinez Salamanca, F. Bianco, K. Touijer, B. Guillonneau (New York,<br />
United States of America)<br />
2006-4 Neurovascular bundle dissection: Interfascial, extrafascial and full resection techniques<br />
F. Secin, A.J. Stephenson, N. Karanikolas, Z. Dotan, K. Touijer, B. Guillonneau (New York, United<br />
States of America)<br />
2006-5 Description of the surgical anatomy of the fascias surrounding the prostate during laparoscopic<br />
radical prostatectomy<br />
G.H. Fournier, A. Valeri, A. Rammal, V. Joulin, D. John, X. Taccoen, C. Deruelle, L. Doucet, A. Volant,<br />
O. Cussenot (Brest, Paris, France)<br />
2006-6 How to prevent iatrogenic capsular incision during laparoscopic nerve sparing radical prostatectomy<br />
G.H. Fournier, A. Valeri, A. Rammal, V. Joulin, J. Donohue, C. Deruelle, L. Cormier, X. Taccoen,<br />
L. Doucet, A. Volant (Brest, Nancy, France)<br />
2006-7 Laparoscopic partial cystectomy for bladder müllerianosis<br />
V. Pansadoro, P. Emiliozzi, G. Federico, M. Martini, A. Pansadoro, M. Pizzo, P. Scarpone (Rome, Italy)<br />
2006-8 Laparoscopic radical cystectomy in female<br />
F. Gaboardi, A. Bozzola, S. Galli, A. Gregori, F. Scieri, S. Stener, B. Rocco (Milan, Italy)<br />
2006-9 Laparoscopic radical cystectomy with neobladder acc. to Studer<br />
V. Pansadoro, P. Emiliozzi, G. Federico, M. Martini, A. Pansadoro, M. Pizzo, P. Scarpone (Rome, Italy)<br />
2006-10 Laparoscopic radical cystectomy with bladder replacement<br />
L. Cecchini, A. Orsola, C. Raventos, E. Trilla, J. Planas, C. Salvador, J. Morote (<strong>Barcelona</strong>, Spain)<br />
2006-11 Transvesical laparoscopic diverticulectomy<br />
V. Pansadoro, P. Emiliozzi, G. Federico, M. Martini, A. Pansadoro, M. Pizzo, P. Scarpone (Rome, Italy)<br />
2006-12 Endoscopic lymphadenectomy for penile carcinoma<br />
R. Sotelo, A.J. Garcia, R. Sánchez Salas, O. Carmona, R. Dubois, F. Cornejo, M. Mariano, G. Neiva,<br />
A. Finelli (Caracas, Venezuela; Quito, Ecuador; Porto Alegre, Goiania, Brazil; Toronto, Canada)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
455
<strong>EAU</strong> Digital Video Library<br />
2006-13 Laparoscopic partial nephrectomy with clamping of the renal parenchyma<br />
A. Manunta, K. Bensalah, S. Vincendeau, G. Verhoest, N. Rioux-Leclercq, B. Lobel, F. Guillé,<br />
J.J. Patard (Rennes, France)<br />
2006-14 Laparoscopic partial nephrectomy for RCC in warm ischemia<br />
A. Häcker, K. Leeb, N. Albquami, A. Al Badour, S. Jeschke, G. Janetschek (Mannheim, Germany; Linz,<br />
Austria)<br />
2006-15 Laparoscopic upper pole heminephroureterectomy in complete duplication of the ureter<br />
P. Casale, M. Simone, R. Marzano, C. Casarosa, G. Pomara, F. Francesca (Pisa, Italy)<br />
2006-16 Tachosil® is an effective haemostatic aid during laparoscopic partial nephrectomy in a porcine model<br />
D. Murphy, R. Puri, P. Rimington, A. Rane (London, Bradford, Eastbourne, Redhill, United Kingdom)<br />
2006-17 A refined technique of laparoscopic nephroureterectomy<br />
A. Tsivian, S. Benjamin, A.A. Sidi (Holon, Israel)<br />
2006-18 Laparoscopic removal of local recurrence of renal cell carcinoma (RCC)<br />
A. Tsivian, S. Benjamin, A. Kheifets, A.A. Sidi (Holon, Israel)<br />
2006-19 Urachal sparing laparoscopic radical prostatectomy<br />
F. Secin, F. Bianco, N. Karanikolas, K. Touijer, B. Guillonneau (New York, United States of America)<br />
2006-20 Open retropubic nerve sparing radical prostatectomy? How I do it<br />
U.E. Studer, F.C. Burkhard, G.N. Thalmann (Berne, Switzerland)<br />
2006-21 Selective dissection of the apex during radical prostatectomy allows better tumour control and continence<br />
J. Walz, M. Graefen, A. Haese, H. Heinzer, H. Huland (Hamburg, Germany)<br />
2006-22 Nerve sparing radical prostatectomy - the surgeons view through the varioscope M5<br />
R. Götschl, N. Schmeller (Salzburg, Austria)<br />
2006-23 The radical perineal prostatectomy with simultaneous extended pelvic lymphadenectomy via the<br />
same incision<br />
J. Beier, H. Keller (Hof, Germany)<br />
2006-24 Laparoscopic radical prostatectomy. Differences between the inter-fascial and intra-fascial technique<br />
L. Martínez-Piñeiro, J.R. Cansino, C. Sanchez, A. Tabernero, J. Cisneros, J.J. De La Peña (Madrid, Spain)<br />
2006-25 Combined obturator - pre pubic cystocele and incontinence repair: Rationale & technique<br />
P. Palma, C. Riccetto, M. Dambros, R. De Fraga, N. Rodrigues Netto Jr. (Campinas, Brazil)<br />
2006-26 A new surgical technique for implantation of a permanent electro stimulation system for treatment of<br />
female overactive bladder and interstitial cystitis<br />
I. Nissenkorn, R. De Jong, P. Radziszewski, M. Cervigni, M. Parsons, L. Cardozo, B. Farnsworth,<br />
J. Nordling (Tel- Aviv, Israel; Cape Town, South Africa; Warsaw, Poland; Rome, Italy; London, United<br />
Kingdom; Sydney, Australia; Herley, Denmark)<br />
2006-27 Bulbo-urethral sling with invance device for the treatment of post-prostatectomy incontinence<br />
I. Morra, R. Tarabuzzi, F. Porpiglia, M. Cossu, M. Billia, J. Renard, R. Scarpa (Turin, Italy)<br />
456 Programme Book
2006-28 Laparoscopic sacral colpopexy using a double polyester mesh<br />
J.P. Giolitto (Reims, France)<br />
2006-29 Simultaneous implantation of the artificial urinary sphincter and inflatable penile prosthesis<br />
L. Jones (San Antonio,Texas, United States of America)<br />
2006-30 Dorsal graft urethroplasty for urethral stricture in the female<br />
A. Tsivian, S. Benjamin, A.A. Sidi (Holon, Israel)<br />
2006-31 Ureteroscopic laser approach in recurrent ureteropelvic junction stenosis<br />
V. Mirciulescu, P. Geavlete, G. Nita, D. Georgescu (Bucharest, Romania)<br />
2006-32 One day stay for robotic pyeloplasty<br />
D. Murphy, S. Khan, B. Challacombe, J. Olsgurgh, P. Dasgupta (London, United Kingdom)<br />
2006-33 The thulium laser vaporesection of the prostate<br />
R. Götschl, N. Schmeller (Salzburg, Austria)<br />
2006-34 Magnetic resonance image-guided robot for prostate brachytherapy<br />
M. Muntener, H. Bagga, A. Patriciu, D. Mazilu, D. Petrisor, N. Patel, L. Kavoussi, D. Stoianovici<br />
(Baltimore, United States of America)<br />
2006-35 Retrograde flexible ureteroscopic approach in symptomatic caliceal calculi<br />
D.R. Multescu, P. Geavlete, G. Nita, D. Georgescu (Bucharest, Romania)<br />
2006-36 Extending the application of tubeless percutaneous nephrolithotomy (PNL)<br />
M. Sofer, I. Kaver, J. Ben Chaim, A. Friedman, E. Metlitzky, H. Matzkin (Tel Aviv, Israel)<br />
2006-37 Laparoscopic radical prostatectomy: Technical aspects and pitfalls during the apical dissection<br />
G.H. Fournier, A. Valeri, A. Rammal, V. Joulin, J. Donohue, L. Cormier, X. Taccoen, C. Deruelle, L.<br />
Doucet,<br />
A. Volant (Brest, Nancy, France)<br />
2006-38 Bladder neck dissection during laparoscopic radical prostatectomy: Difficult cases<br />
G.H. Fournier, A. Valeri, A. Rammal, V. Joulin, J. Donohue, L. Cormier, X. Taccoen, C. Deruelle, L.<br />
Doucet,<br />
A. Volant (Brest, Nancy, France)<br />
2006-39 Dealing with a difficult urethrovesical anastomosis in laparoscopic radical prostatectomy<br />
F. Secin, N. Karanikolas, A.J. Stephenson, F. Bianco, K. Touijer, B. Guillonneau (New York, United<br />
States of America)<br />
2006-40 Laparoscopic repair of an inferior vena cava injury during a right partial nephrectomy<br />
F. Secin, Z. Dotan, B. Shayegan, S. Olgac, B. Guillonneau, K. Touijer (New York, United States of<br />
America)<br />
2006-41 Technical difficulties in retroperitoneoscopic radical nephrectomy. Is tumour location important?<br />
M. Lucan, V. Lucan, F. Elec, G. Iacob, C. Burghelea, A. Barbos (Cluj – Napoca, Romania)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
457
<strong>EAU</strong> Digital Video Library<br />
2006-42 Laparoscopic repair of rectourethral fistulae<br />
R. Sotelo, A.J. Garcia, M. Mariano, G. Trujillo, E. Rodriguez, R. De Andrade, L. Sánchez, C. Andrade,<br />
A. Finelli (Caracas, Venezuela; Porto Alegre, Brazil; Toronto, Canada)<br />
The following videos are a selection of video presentations during the<br />
20 th <strong>EAU</strong> in Istanbul, March 16-19, 2005<br />
2005-1 Laparoscopic nerve sparing radical prostatectomy using clips for haemostasis during postero-lateral<br />
dissection: an unusual “point of view” of the surgical anatomy<br />
G. Fournier, A. Valeri, V. Joulin, A. Rammal, X. Taccoen, C. Deruelle, F. Sallusto (Brest, France)<br />
2005-2 Technique of nerve-sparing endoscopic extraperitoneal radical prostatectomy (NSEERPE)<br />
J.U. Stolzenburg, R. Rabenalt, M. Do, K. Ho, J. Mondry, M. Truß (Leipzig, Hannover, Germany)<br />
2005-3 Extraperitoneal laparoscopic radical intrafascial prostatectomy<br />
F. Porpiglia, C. Terrone, R. Rarabuzzi, F. Ragni, C. Fiori, C. Cracco, M. Cossu, C. Scoffone, R. Scarpa<br />
(Orbassano, Italy)<br />
2005-4 Nerve-sparing extraperitoneal laparoscopic radical prostatectomy<br />
V. Poulakis, W. Dillenburg, U. Witzsch, E. Becht (Frankfurt am Main, Germany)<br />
2005-5 Robotic-assisted laparoscopic transperitoneal radical prostatectomy<br />
F. Gaboardi, A. Lissiani, A. Simonato, A. Gregori, S. Galli, A. Bozzola. (Milan, Italy)<br />
2005-6 Robot assisted endoscopic extraperitoneal seminal vesical tip and nerve sparing radical prostatectomy<br />
M. Muentener, D. Schmid, R. Strebel, D. Hauri, H. John (Zürich, Switzerland)<br />
2005-7 Laparoscopic cystectomy for bladder cancer: description step by step<br />
C. Vaessen, M. Mouzin, X. Game, N. Berrogain, B. Malavaud, P. Rischmann (Toulouse, France)<br />
2005-8 Laparoscopic cystoprostatectomy<br />
X. Cathelineau, F. Rozet, S. Lorin, W. Duncan, C. Arroyo, E. Barret (Paris, France)<br />
2005-9 Genital organ preservation during radical cystectomy and orthotopic bladder substitution in selected<br />
women<br />
B. Ali-El-Dein, A. Mosbah, Y. Osman, M. Abdel-Latif, I. Eraky, A. Shaaban, M. Ghoneim (Mansoura,<br />
Egypt)<br />
2005-10 Laparoscopic radical cystectomy + ileal conduit in women<br />
H. Baumert, F. Khan, R. Morgan, H. Patel, M. Al-Akraa, A. Kaisary (Paris, France; London, United<br />
Kingdom)<br />
2005-11 Laparoscopic radical cystectomy with mainz rectal pouch urinary diversion<br />
A. Ioualalen, M. Ziani. (Toulouse, France)<br />
2005-12 Laparoscopic radical cystectomy with orthotopic ileal neobladder<br />
A. Hoznek, D. Vordos, G. Matthew, L. Salomon, A. De la Taille, R. Yiou, C-C. Abbou. (Creteil, France;<br />
Rochester, United States of America)<br />
458 Programme Book
2005-13 Early ligature of the renal artery during laparoscopic radical nephrectomy<br />
F. Porpiglia, C. Terrone, R. Tarabuzzi, C. Fiori, M. Cossu, C. Cracco, C. Scoffone, R. Scarpa (Orbassano,<br />
Italy)<br />
2005-14 Laparoscopic radical nephrectomy could duplicate the open technique<br />
A. Shoma, E. Ibrahim, H. El Kappany (Mansoura, Egypt)<br />
2005-15 Laparoscopic partial nephrectomy for renal tumours after renal artery clamping: the Québec City<br />
experience<br />
T. Dujardin, R. Sabbagh, B. Inman (Québec, Canada)<br />
2005-16 Laparoscopic nephron-sparing surgery: techniques of haemostasis<br />
F. Gaboardi, A. Simonato, A. Lissiani, A. Gregori, S. Galli, A. Bozzola (Milan, Italy)<br />
2005-17 Laparoscopic radical nephrectomy with lymph node dissection for advanced renal cell carcinoma<br />
(pt3a n2)<br />
H. Baumert, F. Khan, N. Shah, T. Aho, W. Turner (Paris, France; Cambridge, United Kingdom)<br />
2005-18 Donor nephrectomy and renal transplantation in horseshoe kidney<br />
J. Palou Redorta, A. Alcaraz, J. Huguet, C. Baez, H. Villavicencio (<strong>Barcelona</strong>, Spain)<br />
2005-19 Total glans resurfacing for pre-invasive carcinoma of the penis: a new approach<br />
P. Hadway, R. Singh, C. Corbishley, N. Watkin (London, United Kingdom)<br />
2005-20 Dorsal dartos flap for fistula prevention in Snodgrass hypospadias repair<br />
M. Djordjevic, S. Perovic (Belgrade, Serbia and Montenegro)<br />
2005-21 Lingual mucosa graft in the management of short anterior urethral strictures<br />
A. Simonato, A. Lissiani, A. Gregori, S. Galli, A. Bozzola, F. Gaboardi (Milan, Italy)<br />
2005-22 Phalloplasty penile prosthesis insertion for transexualism<br />
D. Ralph, N. Christopher, S. Minhas, C. Bettocchi (London, United Kingdom)<br />
2005-23 Treatment of Peyronie´s disease with plaque incision and application of bovine pericardium graft<br />
L. Martínez-Piñeiro, S. Alonso, J. Cruz, E. Cuervo, J. De la Peña (Madrid, Spain)<br />
2005-24 The tunica-albuginea-patch-technique: a new technique of an autologous grafting procedure for<br />
patients with Peyronie`s disease<br />
J.U. Schwarzer, J. Mayerhofer, O. Schukai, B. Mühlen (Freising, Germany)<br />
2005-25 Laparoscopic retroperitoneal lymph node dissection (RPLND) for a large residual mass post chemotherapy<br />
H. Baumert, F. Khan, T. Aho, N. Shah, W. Turner (Paris, France; Cambridge, United Kingdom)<br />
2005-26 Laparoscopic adrenalectomy: an established approach for management of adrenal pheochromocytoma<br />
A. Shoma, I. Eraky, H. El Kappany (Mansoura, Egypt)<br />
2005-27 Endourological treatment of ureteral and bladder pathology after renal transplant<br />
F.J. Burgos, R. Marcen, J. Pascual, D. Garcia Ortells, I. Gomez Garcia, V. Gomez Dosantos, (Madrid,<br />
Spain)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
459
<strong>EAU</strong> Digital Video Library<br />
2005-28 Robot assisted dismembered pyeloplasty: a new approach for management of primary ureteropelvic<br />
junction obstruction with secondary renal stones<br />
A. Shoma, A. Hemal, N. El Tabey (Mansoura, Egypt; Detroit, United States of America)<br />
2005-29 Retroperitoneoscopic dismembered double-V pyeloplasty<br />
M. Kilinç (Konya, Turkey)<br />
2005-30 Transmesocolic approach in laparoscopic pyeloplasty<br />
R. Kocvara, J. Dvorácek, J. Sedlácek, Z. Díte (Prague, Czech Republic)<br />
2005-31 Extra peritoneoscopic millin transcapsular prostatic adenomectomy<br />
F. Porpiglia, C. Terrone, R. Tarabuzzi, F. Vacca, M. Cossu, C. Cracco, C. Scoffone, F. Ragni, R.M. Scarpa<br />
(Orbassano, Italy)<br />
2005-32 Laparoscopic simple prostatectomy without the requirement of post operative irrigation: the technique<br />
H. Baumert, F. Khan, N. Shah, T. Aho, W. Turner (Paris, France; Cambridge, United Kingdom)<br />
2005-33 Laparoscopic transvesical ureteral advancement<br />
P. de Kuyper, W. Oosterlinck (Ghent, Belgium)<br />
2005-34 Laparoscopic Lich Gregoir ureteral implantation<br />
C. Vaessen, M. Mouzin, N. Berrogain, X. Game, P. Rischmann (Toulouse, France)<br />
2005-35 Laparoscopic treatment of urachal diverticulum<br />
A. Tsivian, S. Benjamin, A.A. Sidi (Holon, Israel)<br />
2005-36 Laparoscopic partial cystectomy and en-bloc removal of the urachus for urachal adenocarcinoma<br />
F. Porpiglia, C. Terrone, R. Tarabuzzi, F. Ragni, M. Cossu, C. Cracco, C. Scoffone, R.M. Scarpa<br />
(Orbassano, Italy)<br />
2005-37 Technique for vesico-uretral anastomosis in laparoscopic radical prostatectomy: an educational video<br />
G. Fournier, A. Valeri, V. Joulin, A. Rammal, X. Taccoen, C. Deruelle, F. Sallusto (Brest, France)<br />
2005-38 Bladder neck - urethral anastomosis after laparoscopic extraperitoneal radical prostatectomy: technical<br />
details after 200 procedures<br />
G. Martina, J. Lovisolo, P. Giumelli, S. Scuzzarella, M. Remotti, C. Giacomo (Sondalo, Tradate, Italy)<br />
2005-39 Laparoscopic radical prostatectomy: preservation of a left accessory pudendal artery<br />
G. Fournier, A. Valeri, V. Joulin, A. Rammal, X. Taccoen, C. Deruelle, F. Sallusto (Brest, France)<br />
2005-40 Bladder neck dissection in laparoscopic radical prostatectomy. Technical details after more than 250<br />
cases<br />
L. Martínez-Piñeiro, J. Cisneros, C. Núñez, A. Tabernero, J. Pacios, S. Alonso, J. de la Peña (Madrid,<br />
Spain)<br />
2005-41 Female laparoscopic artificial urinary sphincter in women for type III incontinence: preliminary<br />
results<br />
B.Njinou (Yvoir, Belgium)<br />
2005-42 Bulking agents for the treatment male postoperative stress urinary incontinence<br />
J. Seibold, A. Merseburger, K. Sievert, A. Stenzl (Tübingen, Germany)<br />
460 Programme Book
The following videos are a selection of video presentations during the<br />
19 th <strong>EAU</strong> in Vienna, March 24-27, 2004<br />
2004-1 Animal model for laparoscopic radical prostatectomy<br />
L. Martínez Piñeiro, C. Núñez, S. Alonso, J. Pacios, J. De La Peña (Madrid, Spain)<br />
2004-2 Retrograde extraperitoneal laparoscopic prostatectomy (RELP) the Lyon technique-a 204 cases<br />
experience. Access to and exposure of the operative field<br />
P. Dubernard, S. Benchetrit, P. Chaffange, B. Cuzin, T. Hamza, C. Rochat, C.L.U.B. (Lyon, Fance)<br />
2004-3 Creation of the working space for extraperitoneal laparoscopic radical prostatectomy<br />
L. Ruiz, A. Hoznek, L. Salomon, A. De La Taille, D. Vordos, R. Yiou, P. Antiphon, D. Chopin, C-C. Abbou<br />
(Creteil, France)<br />
2004-4 The role of surgical assistants during extraperitoneal laparoscopic radical prostatectomy<br />
J. Audet, L. Ruiz, V. Destéfano, S. Stener, A. De La Taille, L. Salomon, A. Hoznek, C-C. Abbou (Creteil,<br />
France)<br />
2004-5 Complete solo laparoscopic radical prostatectomy<br />
P. Antiphon, L. Ruiz, J. Audet, R. Yiou, D. Vordos, A. De La Taille, L. Salomon, A. Hoznek, D. Chopin,<br />
C-C. Abbou (Creteil, France)<br />
2004-6 Holmium laser enucleation of prostate combined with mechanical morcellation Italian experience<br />
I. Vavassori, R. Hurle, S. Valenti, A. Manzetti, A. Vismara, O. Fenice (Bergamo, Italy)<br />
2004-7 Laparoscopic transperitoneal left partial nephrectomy: the value of isolated arterial cross-clamping<br />
W. Hassen, E. Trabulsi, A. Toujier, J. Saranchuk, S. Savage, B. Guillonneau (New York, United States<br />
of America)<br />
2004-8 The use of synthetic glue to enhance hemostatic control during laparoscopic partial nephrectomies<br />
H. Baumert, H. Widmer, F. Dugardin, F. Rozet, X. Cathelineau, G. Vallancien (Paris, France)<br />
2004-9 Laparoscopic excision of renal cell carcinoma under intracorporeal vascular control<br />
X. Krah, O. Lux, U. Hanschmann, N. Benken, G. Eschholz, H. Weber (Blankenhain, Bad Berka,<br />
Germany)<br />
2004-10 Hand-assisted laparoscopy with the LAP DISC®<br />
N. Kreutzer, F. Redwig, H. Schulze (Dortmund, Germany)<br />
2004-11 Radical nephrectomy by transperitoneal, extraperitoneal and hand-assisted laparoscopy: comparative<br />
description of surgical steps<br />
J. Audet, L. Ruiz, S. Laurent, F. Desgrandchamps, T. Piechaud, R. Gaston, A. Hoznek, C-C. Abbou<br />
(Creteil, Paris, Bordeaux, France)<br />
2004-12 Laparoscopic robotic-assisted (da Vinci®) live-donor nephrectomy<br />
J. Hubert, B. Feuillu, N. Billaut, L. Frimat, L. Cormier, L. Prevot, D. Hestin, P. Mangin, M. Kesler<br />
(Nancy, France)<br />
2004-13 Retrograde extraperitoneal laparoscopic prostatectomy (RELP): the Lyon technique - a 204 cases<br />
experience<br />
P. Dubernard, S. Benchetrit, P. Chaffange, B. Cuzin, T. Hamza, P. Van Box Som, C.L.U.B. (Lyon, France)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
461
<strong>EAU</strong> Digital Video Library<br />
2004-14 Endoscopic extraperitoneal radical prostatectomy (EERPE)<br />
J-U. Stolzenburg, R. Rabenalt, M. Do, H. Pfeiffer, M. Truss, W. Dorschner (Leipzig, Hannover, Germany)<br />
2004-15 Laparoscopic radical prostatectomy. Preservation of neurovascular bundles with the combined retrograde<br />
and descending technique<br />
L. Martínez Piñeiro, C. Núñez, A. Tabernero, J. Pacios, S. Alonso, J. De la Peña (Madrid, Spain)<br />
2004-16 Laparoscopic cysto-prostatectomy and orthotopic neo-bladder in man<br />
H. Baumert, H. Widmer, F. Dugardin, F. Rozet, X. Cathelineau, G. Vallancien (Paris, France)<br />
2004-17 Laparoscopic radical cystectomy with open construction of an orthotopic ileal neobladder<br />
F. Porpiglia, R. Tarabuzzi, M. Cossu, C. Scoffone, C. Terrone, S. Guercio, R. Scarpa (Orbassano, Italy)<br />
2004-19 Robotic assisted laparoscopic dismembered pyeloplasty<br />
J. Hubert, A. Hoznek, B. Feuillu, A. Lobontiu, C-C. Abbou (Nancy, Creteil, France)<br />
2004-20 Laparoscopic pyeloplasty for uretero-pelvic stenosis treatment failures<br />
H. Baumert, H. Widmer, F. Dugardin, F. Combes, F. Rozet, X. Cathelineau, G. Vallancien (Paris, France)<br />
2004-21 Laparoscopic pyeloplasty for an ureteropelvic junction syndrome on a horseshoe kidney<br />
F. Rozet, H. Widmer, F. Dugardin, F. Combes, X. Cathelineau, H. Baumert, G. Vallancien (Paris, France)<br />
2004-22 Robotic-assisted (da Vinci®) laparoscopic conduit urinary diversion in neurogenic bladder<br />
J. Hubert, J. Beis, B. Feuillu, A. Coissard, P. Mangin, J. Andre (Nancy, France)<br />
2004-23 Retroperitoneal venous hemangioma: laparoscopic approach<br />
J. Estebanez Zarranz, M. Conde Redondo, J. Amon Sesmero, R. Perez Martin, A. Rodriguez Toves,<br />
A. Robles Samaniego, N. Del Valle Gonzalez, F. Castroviejo Royo, J. Martinez Sagarra (Valladolid,<br />
Spain)<br />
2004-24 Sequential trans-urethral resection of prostate and laparoscopic bladder diverticulectomy under US<br />
guidance<br />
F. Porpiglia, M. Cossu, R. Tarabuzzi, C. Terrone, C. Cracco, R. Scarpa (Orbassano, Italy)<br />
2004-25 Transobturator tape - perineal hammock<br />
V. Delmas (Paris, France)<br />
2004-26 Trans-obturator sling procedure for urinary stress incontinence<br />
L. Ruiz, A. Cicco, R. Yiou, D. Vordos, A. De la Taille, L. Salomon, A. Hoznek, D. Chopin, C-C. Abbou<br />
(Creteil, France)<br />
2004-27 Novel surgical technique for the treatment of female stress urinary incontinence: transobturator vaginal<br />
tape inside-out<br />
J. De Leval, P. Bonnet, O. Reul, D. Waltregny (Liege, Belgium)<br />
2004-28 Bulbourethral composite suspension for post-prostatectomy urinary incontinence: step by step<br />
H. John (Zurich, Switzerland)<br />
2004-29 Laparoscopic artificial urinary sphincter insertion<br />
M. Abi Moussa, A. Manunta, Y. Barbé, J. Patard, B. Lobel, F. Guillé (Rennes, France)<br />
462 Programme Book
2004-30 Laparoscopic urethrolysis, treatment of genital prolapse and artificial urinary sphincter insertion<br />
A. Manunta, Y. Barbé, S. Vincendeau, M. Abi Moussa, J. Patard, B. Lobel, F. Guillé (Rennes, France)<br />
2004-31 Renal autotransplantation: an alternative after metallic ureteral stent incrustation<br />
J. Burgos Revilla, P. Perez, F. Arias, R. Rodriguez Patron, I. Gomez, E. Fernandez (Madrid, Spain)<br />
2004-32 Organ-sparing therapy with ureteroscopic and percutaneous approach in upper urinary tract<br />
tumours (UUTT)<br />
A. De Lisa, P. Usai, R. Scarpa, E. Usai (Cagliari, Italy)<br />
2004-33 Dorsal free graft urethroplasty by ventral approach<br />
F. Gomez-Sancha, L.M. Herranz Fernández, M. Jiménez Gálvez, R. Arellano Gañán, I. Pereira Sanz<br />
(Madrid, Spain)<br />
2004-34 Complex epispadias repair: new advances<br />
S. Perovic (Belgrade, Serbia and Montenegro)<br />
2004-35 Distal urethra transposition in female patients with chronic uti associated with sexual intercourse<br />
V. Diakov, D. Pushkar (Moscow, Russia)<br />
2004-36 Sex reassignment surgery for male-to-female transsexuals: an urological job<br />
G. Liguori, C. Trombetta, L. Salamè, S. Bucci, G. Garaffa, E. Belgrano (Trieste, Italy)<br />
2004-37 Difficulties, mishaps and errors encountered during the first laparoscopic radical prostatectomies<br />
A. Messas, D. Bohin, S. Beley, J. Ghossein, B. Lhoest, V. Boublil, S. Dominique, O. Dumonceau, V.<br />
Delmas, V. Ravery, L. Boccon Gibod (Paris, Argenteuil, France)<br />
2004-38 Laparoscopic correction of surgical complications that can occur during laparoscopic radical prostatectomy<br />
H. Baumert, H. Widmer, F. Dugardin, F. Rozet, X. Cathelineau, G. Vallancien (Paris, France)<br />
The following videos are a selection of video presentations during the<br />
18 th <strong>EAU</strong> in Madrid, March 12-15, 2003<br />
2003-1 Laparoscopic training in urology<br />
R. Katz, A. Hoznek, P. Antiphon, L. Salomon (Creteil, France)<br />
2003-2 Using fresh cadavers to teach laparoscopic radical prostatectomy<br />
H. Baumert, H. Widmer, S. Gholami, R. Gupta, J. Adorno Rosa, G. Fournier, X. Cathelineau, B.<br />
Guillonneau, G. Vallancien (Paris, France)<br />
2003-3 Laparoscopic anatomical radical prostatectomy - experience after 350 cases<br />
J. Rassweiler, O. Seemann, M. Hatzinger, L. Sentker, T. Frede (Heilbronn, Germany)<br />
2003-4 Step by step teaching of the assistant’s technique in laparoscopic prostatectomy<br />
H. Baumert, H. Widmer, R. Gupta, V. Cardot, R. Adorno, B. Guillonneau, G. Vallancien (Paris, France)<br />
2003-5 Prostate brachytherapy: a real-time, ultrasound-guided, original technique<br />
L. Nava, A. Losa, A. Cestari, M. Riva, P. Mangili, N. Di Muzio, G. Guazzoni, L. Rigatti (Milan, Italy)<br />
2003-6 Urethral reconstruction with buccal mucosa graft<br />
H. Keller, F. Lamadé (Hof, Offenburg, Germany)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
463
<strong>EAU</strong> Digital Video Library<br />
2003-7 Extraperitoneal laparoscopic radical prostatectomy<br />
C-C. Abbou, A. Hoznek, P. Antiphon, L. Salomon, A. De la Taille, R. Katz, T. Borkowski, D. Chopin<br />
(Creteil, France)<br />
2003-8 Laparoscopic extraperitoneal radical prostatectomy: the Montsouris technique 2<br />
X. Cathelineau, H. Bermudez, S. Gholami, H. Baumert, S. Elard, F. Bruyere, G. Vallancien (Paris,<br />
France)<br />
2003-9 Modifications of laparoscopic radical prostatectomy:extraperitoneal approach and identification of<br />
dissection plane at the bladder neck using simultaneous bi-planar transrectal ultrasonography<br />
M. Komuro, T. Tsuchida, I. Araki, Y. Takihana, K. Matsushita, M. Takeda (Yamanishi, Japan)<br />
2003-10 Laparoscopic salvage prostatectomy compared with normal laparoscopic prostatectomy<br />
B. Guillonneau, H. Baumert, H. Bermudez, S. Gholami, G. Loison, X. Cathelineau, G. Vallancien (Paris,<br />
France)<br />
2003-11 Extraperitoneal laparoscopic robot assisted radical prostatectomy<br />
P. Antiphon, A. Hoznek, M. Gettman, A. De la Taille, L. Salomon, R. Katz, T. Borkowski, C-C. Abbou<br />
(Creteil, France)<br />
2003-12 Radical perineal prostatectomy<br />
H. Villavicencio (<strong>Barcelona</strong>, Spain)<br />
2003-13 The nerve-sparing radical perineal prostatectomy<br />
H. Keller, M. Linder, F. Lamadé (Hof, Offenburg, Germany)<br />
2003-14 Continent vesicostomy after female urethrectomy<br />
B. Frea, E. Kocjancic, P. Gontero, D. Minocci, G. Monesi, M. Sala, S. Crivellaro, M. Favro, S. Baietto<br />
(Novara, Italy)<br />
2003-15 Act: adjustable continence therapy: a minimally invasive post operatively adjustable therapy for<br />
female stress urinary incontinence<br />
E. Kocjancic, T. Sauter, D. Minocci, G. Monesi, M. Favro, G. Ceratti, M. Sala, P. Gontero, S. Guglielmetti,<br />
S. Crivellaro, B. Frea (Novara, Italy; Berlin, Germany)<br />
2003-16 Safyre: a versatile self-anchoring readjustable sling<br />
P. Palma, C. Riccetto, M. Dambros, M. Thiel, R. Fraga, C. Vilas-Boas, N. Netto Jr. (Campinas, Brazil)<br />
2003-17 Intravaginal slingplasty (IVS): building safety in the management of female stress urinary incontinence<br />
P. Palma, C. Riccetto, M. Dambros, M. Thiel, R. Fraga, C. Villas-Boas, N. Netto Jr. (Campinas, Brazil)<br />
2003-18 Laparoscopic repair of recurrent prolapse<br />
H. Baumert, H. Widmer, R. Gupta, R. Adorno, V. Joulin, B. Guilloneau, G. Vallancien (Paris, France)<br />
2003-19 Robot assisted laparoscopic prolapse repair<br />
H. Baumert, H. Widmer, S. Gholami, R. Gupta, R. Adorno, F. Rozet, B. Guillonneau, G. Vallancien (Paris,<br />
France)<br />
2003-20 Redo end to end urethroplasty in traumatic disruption of the membranous urethra<br />
L. Martínez-Piñeiro, J. Madrid, A. García (Madrid, Léon, Spain)<br />
464 Programme Book
2003-21 Penile duplication with long distance: joining with successful outcome<br />
S. Perovic, M. Djordjevic, R. Brdar, S. Ducic (Belgrade, Serbia and Montenegro)<br />
2003-22 Primary malignant melanoma of the urethra: reconstructive solution in a rare case<br />
G. Carmignani, P. Traverso, A. Naselli, F. Bertolotto, A. Romagnoli, C. Corbu (Genoa, Italy)<br />
2003-23 One stage primary reconstruction of bladder exstrophy with modified penile disassembly<br />
A. Hafez, M. Elsherbiny, M. Bazeed, M. Ghoneim (Mansoura, Egypt)<br />
2003-24 Carcinoma of the penis: video-algorithm for inguinal lymphadenectomy<br />
A. Simonato, A. Lissiani, A. Gregori, A. Bozzola, S. Galli, F. Gaboardi (Milan, Italy)<br />
2003-25 Management of radiation recto-prostatic fistula with skin or buccal graft patch onlay and gracilis<br />
muscle interposition<br />
A. Sorcini, J. Latini, L. Zinman (Burlington, United States of America)<br />
2003-26 Laparoscopic retroperitoneal lymphadenectomy in stage I NSGCT<br />
G. Schön (Würzburg, Germany)<br />
2003-27 Bilateral laparoscopic retroperitoneal lymph node dissection (RPLND) in a patient with metachronous<br />
bilateral NSGCTT<br />
C. Trombetta, G. Liguori, S. Bucci, F. Scieri, E. Belgrano (Trieste, Italy)<br />
2003-28 Laparoscopic retroperitoneal lymph node dissection for residual masses<br />
H. Baumert, H. Widmer, S. Gholami, R. Adorno, R. Gupta, B. Guilloneau, G. Vallancien (Paris, France)<br />
2003-29 Technique of laparoscopic adrenalectomy in large adrenal tumours<br />
G. Schön (Würzburg, Germany)<br />
2003-30 Limitation of retroperitoneoscopic surgery for adrenal and retroperitoneal tumours<br />
T. Yagisawa, F. Ito, N. Ishikawa, Y. Hashimoto, N. Goya, H. Toma (Tokyo, Japan)<br />
2003-31 Substitution of inferior vena cava with reimplantation of hepatic and renal veins<br />
A. Sorcini, D. Lewis, R. Jenkins (Burlington, United States of America)<br />
2003-32 Laparoscopic nephro-ureterectomy with endoscopic laser excision of the distal ureter<br />
G. Schön (Würzburg, Germany)<br />
2003-33 Robot assisted kidney transplantation<br />
A. Hoznek, M. Gettman, P. Antiphon, A. De la Taille, L. Salomon, F. Saint, A. Lobontiu, C-C. Abbou<br />
(Creteil, France)<br />
2003-34 Retroperitoneal laparoscopic pyeloplasty<br />
R. Katz, A. Hoznek, P. Antiphon, T. Borkowski, A. De la Taille, L. Salomon, C-C. Abbou (Creteil, France)<br />
2003-35 Retroperitoneal endoscopic nephrectomy: new technique for access and management of vessels<br />
G. Schön (Würzburg, Germany)<br />
2003-36 Hand-assisted retroperitoneoscopic radical nephrectomy<br />
P. Dekuyper, W. Oosterlinck (Gent, Belgium)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
465
<strong>EAU</strong> Digital Video Library<br />
2003-37 Is there still a role for open conservative surgery?<br />
F. Francesca, R. Felipetto, A. Barsali, M. Cosci, P. Casale (Pisa, Italy)<br />
2003-38 Video-assisted nerve and prostate-sparing cystectomy<br />
X. Cathelineau, A. Renda, H. Bermudez, D. Cahill, H. Widmer, G. Loison, B. Guillonneau, H. Baumert,<br />
G. Vallancien (Paris, France)<br />
2003-39 Laparoscopic prostate, nerve and seminal sparing cystectomy and orthotopic ileal neobladder: technical<br />
aspects<br />
A. Cestari, G. Guazzoni, R. Colombo, M. Riva, L. Nava, A. Losa, P. Bellinzoni, P. Rigatti (Milan, Italy)<br />
2003-40 Laparoscopic radical cystectomy with external ileal neobladder: our technique step by step<br />
P. Paulhac, M. Hubert, G. Philippe, C. Pierre (Limoges, France)<br />
2003-41 Minimally invasive laparoscopic neobladder (MILAN)<br />
F. Gaboardi, A. Simonato, A. Lissiani, A. Gregori, S. Galli, A. Bozzola (Milan, Italy)<br />
2003-42 Bipolar transurethral prostate resection (TURP): a new approach with co-blation technology<br />
A. Patel, J. Adshead, M. Swinn (London, United Kingdom)<br />
2003-43 Laparoscopic retropubic adenomectomy<br />
H. Baumert, S. Gholami, H. Bermudez, H. Widmer, X. Cathelineau, G. Vallancien (Paris, France; San<br />
Francisco, UnitedStates of America)<br />
The following videos are a selection of video presentations during the<br />
17 th <strong>EAU</strong> in Birmingham, February 23-26, 2002<br />
2002-1 Laparoscopic nerve-sparing retroperitoneal lymph node dissection: the surgical technique<br />
R. Peschel, M. Gettman, A. Hobisch, R. Neururer, G. Bartsch (Innsbruck, Austria)<br />
2002-2 Laparoscopic left partial nephrectomy for cancer<br />
C. Gerard, H. Bermudez, D. Rey, G. Vallancien, B. Guillonneau (Paris, France)<br />
2002-3 The vascular steps of right lumboscopic nephrectomy for cancer<br />
P. Paulhac, F. Dargent, J. Dumas, P. Colombeau (Limoges, France)<br />
2002-5 Retroperitoneal laparoscopic renal surgery in children without clips<br />
S. Micali, P. Caione, L. Storti, N. Capozza, M. Scarfini, F. Micali (Rome, Italy)<br />
2002-6 Lymphatic-sparing laparoscopic varicocelectomy: a microsurgical repair<br />
R. Kocvara, J. Dvoracek, J. Kriz, Z. Dite, K. Novak (Prague, Czech Republic)<br />
2002-7 Nerve sparing laparoscopic radical retropubic prostatectomy<br />
C-C. Abbou, A. Hoznek, L. Salomon, R. Quintela, F. Saint, E. Olsson, D. Chopin (Creteil, France)<br />
2002-8 Radical prostatectomy by simplified extra peritoneal laparoscopic technique<br />
P. Dubernard, P. Van Box Som, T. Hamza, S. Benchetrit (Lyon, France)<br />
2002-9 Telerobotic laparoscopic radical prostatectomy<br />
C-C. Abbou, A. Hoznek, E. Olsson, D. Samadi, A. Nadu, R. Quintela, L. Salomon (Creteil, France)<br />
466 Programme Book
2002-10 Laparoscopic radical prostatectomy: nerve sparing technique<br />
J. Davis, M. Fabrizio, S. Deger, S. Loening, I. Türk (Norfolk, United States of America; Berlin,<br />
Germany)<br />
2002-11 Cavernous nerve sparing during radical prostatectomy<br />
L. Martínez-Piñeiro, M. García-Matres, J. García Mediero, J. Cruz, J. De la Peña (Madrid, Spain)<br />
2002-12 Prostate brachytherapy technique<br />
F. Aguilo, J. Suarez, N. Serrallach, S. Arbeláez (<strong>Barcelona</strong>, Spain)<br />
2002-13 Resection of RCC with extended vena caval involvement performed with cardiopulmonary by pass,<br />
hypothermia and cardiac arrest with heartport device<br />
P. Graziotti, M. Maffezzini, G. Giusti, M. Seveso, G. Taverna, D. Lavelli, R. Gallotti, A. Bandera, A.<br />
Benetti (Milan, Italy)<br />
2002-15 Is disseminated angiomyolipomatosis a contra-indication to renal transplantation?<br />
M. Lucan, P. Rotariu, G. Iacob, L. Ghervan, M. Neculoiu, V. Lucan, D. Sarb, C. Burghelea (Cluj-Napoca,<br />
Romania)<br />
2002-16 Surgical management of RCC with intrapericardiac IVC extension: diaphragmatic approach to the<br />
intrapericardiac IVC<br />
M. Davydov, V. Matveev, B. Matveev, K. Figurin (Moscow, Russia)<br />
2002-17 Surgical management in the growing teratoma syndrome<br />
R. Miano, T. Christmas, C. Vicentini, A. Tubaro, F. Forte, L. Miano (Rome, L’Aquila, Italy)<br />
2002-18 Tumorectomy for carcinoma in a single kidney. Classic hemostasis procedures<br />
L. Martin, A. Diego, A. Diest, A. Santiberi, J. Sanz, J. Godoy, R. Bermudez (Segovia, Spain)<br />
2002-19 Incisionless suprapubic pubovaginal sling using the porcine small intestine submucosa (SIS): technical<br />
refinements<br />
P. Palma, C. Riccetto, V. Herrmann, M. Dambros, M. Thiel, N. Netto Jr. (Campinas, Brazil)<br />
2002-20 Urethral restoration with simultaneous fascial sling procedure in patients with urethral loss<br />
O. Loran, D. Pushkar (Moscow, Russia)<br />
2002-21 The Sling Plus: a new concept for minimally invasive treatment of female urinary stress incontinence<br />
P. Palma, C. Riccetto, V. Herrmann, M. Dambros, M. Thiel, L. Paz, N. Netto Jr. (Campinas, Americana,<br />
Brazil)<br />
2002-23 Radical cystectomy and orthotopic neobladder in women: rationale and nerve-sparing technique<br />
G. Martorana, S. Concetti, E. Vece, A. Bertaccini (Bologna, Italy)<br />
2002-24 Laparoscopic supratrigonal cystectomy with substitute bladder ileoplasty<br />
H. Bermudez, C. Gerard, D. Rey, J. Adorno Rosa, G. Vallancien, B. Guillonneau (Paris, France)<br />
2002-25 Waterjet technology in penile disassembly for M. Peyronie - the ideal tool for worst cases of<br />
Induratio Penis Plastica (IPP)<br />
F. Basting, N. Perovic (Altötting, Germany)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
467
<strong>EAU</strong> Digital Video Library<br />
2002-26 Clitoroplasty in intersex repair using disassembly technique<br />
S. Perovic, M. Djordjevic, V. Vukadinovic (Belgrade, Yugoslavia)<br />
2002-28 Penile revascularization with epigastric artery by-pass<br />
L. Martínez-Piñeiro, A. Aguilera, J. Cruz, J. De la Peña (Madrid, Spain)<br />
2002-29 Complex repair in failed male transsexual surgery<br />
S. Perovic, M. Djordjevic, A. Kollias (Belgrade, Yugoslavia; Westerstede, Germany)<br />
2002-30 Total penectomy with perineal urethrostomy for carcinoma of the penis<br />
A. Simonato, A. Lissiani, S. Galli, A. Bozzola, A. Gregori, F. Gaboardi (Milan, Italy)<br />
2002-31 The Tyrolean iceman: urethroscopy in a 5200-year old man<br />
A. Pycha, L. Lusuardi, M. Marberger, E. Egarter Vigl (Bolzano, Italy)<br />
2002-32 News in urosonography<br />
M. Zacharias, K. Jenderka, H. Heynemann (Halle/Saal, Germany)<br />
2002-33 Robotic remote laparoscopy (da Vinci®): results in experimental surgery<br />
J. Hubert, B. Feuillu, M. Artis, P. Mangin (Vandoeuvre Les Nancy, France)<br />
2002-34 Percutaneous access to the kidney using PAKY: our experience in telesurgery<br />
S. Micali, D. Stoianovici, A. De Carolis, N. Grassi, A. Patriciu, G. Vespasiani, L. Kavoussi (Rome, Italy;<br />
Baltimore, United States of America)<br />
2002-35 The risk of bladder denervation during antireflux surgery: a reliable neurophysiological model<br />
C. Seif, P. Braun, F. Martinez Porillo, B. Herberger, G. Boehler, J. Leissner, K-P. Juenemann, R.<br />
Hohenfellner (Mannheim, Maddeburg, Mainz, Germany)<br />
2002-36 Adjuvant “Miniperc” in percutaneous nephrolithotomy<br />
A. Frattini, P. Salsi, S. Ferretti, M. Ziveri, P. Cortellini (Parma, Italy)<br />
The following videos are a selection of video presentations during the<br />
16 th <strong>EAU</strong> in Geneva, April 7-10, 2001<br />
2001-1 Laparoscopic radical prostatectomy - the Berlin experience<br />
I. Tuerk, S. Deger, B. Winkelmann, S. Loening (Berlin, Germany)<br />
2001-2 Nerve sparing laparoscopic radical prostatectomy<br />
C-C. Abbou, A. Hoznek, L. Salomon, P. Antiphon, F. Saint, D. Chopin (Creteil, France)<br />
2001-4 Advances in laparoscopic radical prostatectomy: separation of the bladder from the prostate associated<br />
with endoscopic access<br />
J. Cosson, C. Leleu, G. Kouri, Y. Bottine (Perigueux, France)<br />
2001-5 Telesurgical laparoscopic radical prostatectomy<br />
J. Rassweiler, T. Frede, O. Seemann, C. Stock, L. Sentker (Heilbronn, Germany)<br />
2001-7 Initial pitfalls in laparoscopic radical prostatectomy<br />
M. Dubs, M. Largo, F. Recker (Aarau, Switzerland)<br />
468 Programme Book
2001-8 Nerve and seminal-sparing cystectomy with orthotopic urinary diversion for select bladder cancer<br />
R. Colombo, R. Bertini, A. Salonia, L. Da Pozzo, M. Roscigno, P. Rigatti (San Raffaele, Milan, Italy)<br />
2001-9 The Ghoneim antireflux ureteroileal implantation technique on GIA stapler detubularized ileal neobladder<br />
G. Muto, F. Bardari, L. D’Urso, R. Leggero (Turin, Italy)<br />
2001-11 How to minimise urinary incontinence following radical prostatectomy<br />
N. Blick, J. Crew, U. Studer (Berne, Switzerland)<br />
2001-12 The extended radical perineal prostatectomy<br />
G. Jakse (Aachen, Germany)<br />
2001-13 The radical perineal prostatectomy using a self-retaining system<br />
H. Keller, F. Lamadé, R. Horsch (Offenburg, Germany)<br />
2001-14 Percutaneous treatment of a pyelogenic cyst containing stones<br />
A. Tasca, A. Cacciola, E. Scremin (Vicenza, Italy)<br />
2001-15 Laparoscopic renal cryoablation: technical notes<br />
A. Cestari, G. Guazzoni, L. Nava, F. Montorsi, T. Maga, V. Scattoni, A. Addis, P. Rigatti (Milan, Italy)<br />
2001-17 Laparoscopic donor nephrectomy - first experience<br />
I. Tuerk, S. Deger, B. Schoenberger, S. Loening (Berlin, Germany)<br />
2001-18 Retroperitoneal laparoscopic nephrectomy for polycystic kidney disease<br />
A. Hoznek, L. Salomon, F. Saint, A. Cicco, W. Alamé, D. Chopin, C-C. Abbou (Creteil, France)<br />
2001-19 Cost effective hand assisted laparoscopic radical nephrectomy (Hungarian technique)<br />
G. Kovács, E. Holman, B.S. Dénes, J. Kálmán, A. Karsza, J. Rózsahegyi (Budapest, Hungary)<br />
2001-20 Percutaneous nephrolitholapaxy (PCNL) by a new lithoclast plus ultrasonic handpiece combination -<br />
a novel and highly effective technique in the therapy of renal calculi<br />
R. Hofmann, P. Olbert, Z. Varga, S. Wille, A. Heidenreich (Marburg, Germany)<br />
2001-21 Percutaneous nephrolithotomy in the childhood: our experience with 65 children<br />
C. Tóth, A. Nagy, I. Kocsis (Debrecen, Hungary)<br />
2001-22 Ureteroscopic management of lower pole renal calculi<br />
P. Dahm, B. Auge, N. Wu, G. Preminger (Durham, United States of America)<br />
2001-23 Retroperitoneal lymph node dissection with caval thrombectomy for advanced nonsemonimatous<br />
germ cell tumour of the left testicle<br />
F. Martins, J. Alves, J. Freeman, J. Lencastre, J. Varela (Lisboa, Portugal)<br />
2001-25 Laparoscopic approach to large para-aortic lymphocyst after radical nephrectomy and regional<br />
lymphadenectomy<br />
P. Cortellini, N. Sebastio, G. Incarbone, A. Barbieri, M. Simonazzi, C. Pavlidis, L. Sarli (Parma, Italy)<br />
2001-26 Left sided kidney tumour with caval thrombus into right atrium<br />
H. Weber, M. Torka, N. Benken, E. Gey, M. Günnewig, X. Krah, G. Eschholz (Blankenheim, Bad Berka,<br />
Germany)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
469
<strong>EAU</strong> Digital Video Library<br />
2001-27 Retroperitoneoscopic adrenalectomy: lateral approach vs. posterior approach<br />
T. Yagisawa, F. Ito, H. Amano, N. Goya, H. Toma (Tokyo, Japan)<br />
2001-28 Reconstruction of distal urethra with buccal mucosa onlay patch graft<br />
M. Fisch, F. Martins, J. Lencastre, J. Varela, J. Alves (Hamburg, Germany; Lisbon, Portugal)<br />
2001-29 Local tumour excision in renal cell carcinoma<br />
L. Martinez-Piñeiro, A. Aguilera, D. Rendon, E. Rios, J. De la Peña (Madrid, Spain)<br />
2001-30 Tailored laminectomy for neuromodulator implantation<br />
P. Braun, C. Seif, S. Bross, J. Boschert, P. Alken, K-P. Jünemann (Mannheim, Germany)<br />
2001-31 Multi-obstruction of the seminal duct<br />
J. Pomerol, J. Vicente, J. Sarquella, N. Ribé (<strong>Barcelona</strong>, Spain)<br />
2001-33 Tendinous vaginal support (T.V.S.) using the porcine small intenstine submucosa (SIS): a promising<br />
anatomical approach for urinary stress incontinence<br />
P. Palma, C. Riccetto, V. Herrmann, M. Dambrós, R. Mesquita, N. Netto jr. (Campinas, Brazil)<br />
2001-34 Megameatus intact prepuce: a rare hypospadias presentation<br />
A. Mendes Leal, T. Aires (Clipóvoa, Portugal)<br />
2001-35 Genital prolapse repair - pubovaginal sling sacrospinous ligament suspension with cadaveric fascia<br />
M. Kozminski (St. Joseph, United States of America)<br />
2001-36 Complete penile disassembling and tunica albuginea autograft in the treatment of severe penile<br />
deformities due to la Peyronie’s disease<br />
G. Carmignani, C. Corbu, A. De Rose, P. Traverso (Genoa, Italy)<br />
2001-37 Correction of the curvature in Peyronie’s disease by transplantation of saphenous vein patches<br />
F. Boeminghaus, M. Schermesser, J. Witt, M. König (Neuss, Germany)<br />
2001-38 TURP: state of the art<br />
V. Pansadoro (Rome, Italy)<br />
The following videos are a selection of video presentations during the<br />
15 th <strong>EAU</strong> in Brussels, April 12-15, 2000<br />
2000-1 Malignant dysgerminoma in a true hermaphrodite<br />
V. Bucuras, R. Bardan, J. Corcan, P. Dragan (Timisoara, Romania)<br />
2000-7 Surgical treatment of morbus Peyronie using penile disassembly technique accomplished by water<br />
jet device and laser beam<br />
R. Basting, N. Djakovic, P. Widmann, S. Perovic (Belgrade, Yugoslavia; Altoetting, Germany)<br />
2000-8 Tension-free vaginal tape (TVT): rationale, technique & complications<br />
P. Palma, C. Riccetto, G. Ribeiro, A. Das Fo, N. Rodriques Netto Jr. (São Paulo, Brazil)<br />
2000-9 Our experience on tension free vaginal tape for stress urinary incontinence<br />
M. Naudin, D. Pamart, A. Corbusier (Brussels, Mons, Belgium)<br />
470 Programme Book
2000-20 New strategy and minimal access approach for cardiopulmonary bypass (CPB) in renal cell carcinoma<br />
(RCC) with suprahepatic caval thrombi<br />
A. Sorcini, J. Libertino (Burlington, United States of America)<br />
2000-21 Use of the ultrasonic scalpel to facilitate radical prostatectomy<br />
W. Young, J. Pow-Sang, D. Cuthbertson (Tampa, United States of America)<br />
2000-22 Radical perineal prostatectomy, an interesting surgical approach in some selected patients<br />
A. Mendes Leal, T. Aires (Povoa de Varzim, Portugal)<br />
2000-23 Video assisted minilaparotomy for RRP<br />
P. Puppo, G. Conzi, C. Introini, G. Vigliercio (Genova, Italy)<br />
2000-24 Advances in laparoscopic radical prostatectomy: a pure extraperitoneal approach<br />
R. Bollens, M. Vanden Bossche, T. Roumeguere, A. Damoun, A. Zlotta, C. Schulman (Brussels,<br />
Belgium)<br />
2000-25 Vesicourethral reconstruction during laparoscopic radical prostatectomy<br />
C-C. Abbou, A. Hoznek, L. Salomon, P. Antiphon, M. Ben Slama, F. Saint, D. Chopin (Creteil, France)<br />
2000-26 Brachytherapy for prostate cancer: technique of transperineal seed implantation<br />
G. Guazzoni, L. Nava, A. Losa, R. Matteo, A. Cestari, P. Bellinzoni, F. Montorsi, P. Rigatti (Milan, Italy)<br />
2000-27 Laparoscopic radical prostatectomy - the Heilbronn technique<br />
J. Rassweiler, O. Seemann, M. El- Quaran, L. Sentker (Heilbronn, Germany)<br />
2000-28 The anatomical approach to radical cystectomy<br />
M. Gallucci, A. Vincenzoni, M. Mauro, P. Fortunato (Rome, Italy)<br />
2000-29 Continent urinary diversion with parietal stoma of Indiana type<br />
G. Glück (Bucharest, Romania)<br />
2000-30 Acucise RP: an experimental and clinical demonstration<br />
E. Cirillo Marucco, A. Pagliarulo, G. Cardo, V. Pagliarulo, G. Ludovico, G. Giocoli Nacci (Bari, Italy)<br />
2000-31 Systematic processing of radical prostatectomy specimens<br />
H. Schmid, A. Semjonow, A. Terpe, L. Hertle (Münster, Germany)<br />
2000-32 Extra-peritoneal radical cystectomy and sigmoid neo-bladder with tenyomyotomy<br />
K. Krajka, A. Mikszewicz, M. Markuszewski, M. Matuszewski (Gdansk, Poland), Belgium, 12-15<br />
2000-34 Retroperitoneoscopy 2000 - the technique<br />
J. Rassweiler, T. Frede, O. Seemann, M. Hatzinger (Heilbronn, Germany)<br />
2000-35 Single stage retrograde endopyelotomy with the Rite-Cut® electrode<br />
A. Patel, J. Webster (London, United Kingdom)<br />
2000-36 Posterior retroperitoneoscopic adrenalectomy for large adrenal tumour<br />
T. Yagisawa, F. Ito, T. Shimizu, H. Amano, H. Toma (Tokyo, Japan)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
471
<strong>EAU</strong> Digital Video Library<br />
2000-38 Laparoscopic bilateral partial adrenalectomy in a boy with familial pheochromocytoma<br />
G. Janetschek, R. Peschel, C. Radmayr, G. Bartsch, H. Neumann (Innsbruck, Austria; Freiburg,<br />
Germany)<br />
2000-39 Laparoscopic surgery of bilateral multiple renal cysts with the ultracision scalpel<br />
W. Kozak, W. Feil, U. Maier (Vienna, Austria)<br />
2000-40 Retroperitoneoscopy in child: the Visiport technique<br />
S. Micali, P. Bove, R. Miano, G. Maturo, E. Matarazzo, N. Capozza, P. Caione (Rome, Italy)<br />
2000-42 Ileal T pouch with split-cuff ureteral anastomosis<br />
G. Marino, R. Cevoli, G. Del Noce, M. Laudi (Turin, Italy)<br />
The following videos are a selection of video presentations during the<br />
14 th <strong>EAU</strong> in Stockholm, April 7-11, 1999<br />
1999-1 Extraperitoneal laparoscopic partial nephrectomy<br />
Hoznek A., Salomon L., Rahmouni A., Gasman D., Antiphon P.,Chopin D., Abbou C.C. (Créteil, France)<br />
1999-2 Extraperitoneal laparoscopic uncrossing of retro-caval ureter<br />
Hoznek A., Salomon L., Gasman D., Antiphon P., Hafiani M.,Chopin D., Abbou C. (Créteil, France)<br />
1999-3 Laparoscopic lymphocele resection<br />
Fornara P., Doehn C., Jocham D. (Lübeck, Germany)<br />
1999-4 Retroperitoneal laparoscopic adrenalectomy<br />
Abbou C.C., Gasman D., Antiphon P., Salomon L., Hafiani M., Chopin D., Hoznek A. (Créteil, France)<br />
1999-5 Laparoscopic partial ureter resection and appendectomy for simultaneous urinary tract and intestinal<br />
endometriosis, a case report<br />
Fahlbusch M., Fahlbusch B., Stein J., Thon W.F. (Hannover, Germany)<br />
1999-6 Laparoscopic treatment of genito urinary prolapse and stress incontinence<br />
Mugnier C., Piechaud T., Gaston R. (Bordeaux, France)<br />
1999-7 Periurethral self detachable balloon system for urinary stress incontinence<br />
Palma P., Riccetto C., Netto Jr. N.R. (Campinas, Brazil)<br />
1999-8 Laparoscopic sacral colpopexy: Technical aspect<br />
Kovács G., Simon Z., Karsza A. (Budapest, Hungary)<br />
1999-9 One more reason to choose TVT procedure (tension free vaginal tape) in the treatment of female<br />
urinary incontinence<br />
Randone D.F., Carone R., Caccia P. (Turin, Italy)<br />
1999-10 Transvaginal urethrolysis for obstruction following anti-incontinence procedures<br />
Netto Jr. N.R., Riccetto C., Herrmann V., D’Ancona C., Pereira F.,Palma P. (Campinas, Brazil)<br />
1999-12 Laparoscopic radical prostatectomy<br />
Abbou C.C., Hoznek A., Salomon L., Pollux C., Hafiani M., Antiphon P., Gasman D., Chopin D. (Créteil,<br />
France)<br />
472 Programme Book
1999-13 Preservation of pubo-prostatic ligaments and bladder neck for improving continence in R.R.P.<br />
Martorana G., Concetti S., Brunocilla E., Vignoli G.C., Manferrari F.,Bisceglie L. (Bologna, Italy)<br />
1999-14 Radical retropubic prostatectomy (RRP): Improved continence after a modified apical dissection<br />
Patel A., DeKernion J., Franklin J. (Los Angeles, U.S.A.;London, United Kingdom)<br />
1999-16 Transcoccygeal radical prostatectomy: Updated surgical technique<br />
Da Pozzo L., Rigatti P., Colombo R., Montorsi F., Scattoni V.(Milan, Italy)<br />
1999-17 Hadera continent reservoir - The video<br />
Yachia D., Erlich N. (Hadera, Israel)<br />
1999-19 The sigma-rectum pouch (Mainz pouch II) - Our experience in 15 patients<br />
Arvanitakis T., Rempelakos A., Lymberakis C.H., Thanos A. (Athens, Greece)<br />
1999-20 W-shaped ileal bladder with extramural serosal tunnel<br />
Puppo P., Ricciotti G., Canepa G., Introini C. (Genova, Italy)<br />
1999-21 Radical cystectomy and ileal Hautmann neobladder: Extraperitoneal approach<br />
Pagliarulo A., Ludovico G., Giocoli Nacci G., Curatolo C., Cardo G., Cirillo-Marucco E. (Bari, Italy)<br />
1999-22 Orthotopic bladder substitution in women<br />
Conde C., Amón J., Estébanez J., Rodríguez-Toves A.,Martinez-Sagarra J., Camacho J. (Valladolid,<br />
Spain)<br />
1999-23 Laserendopyelotomy - The first cut is the deepest<br />
Rassweiler J., Renner C., Frede T., Seemann O. (Heilbronn, Germany)<br />
1999-24 Ultrasound-guided transurethral injection of implants for treatment of stress incontinence<br />
Stenzl A., Strasser H., Bartsch G. (Innsbruck, Austria)<br />
1999-25 Holmium YAG laser resection of prostate (HoLRP)<br />
Kural A.R., Coskuner E.R., Akpinar H., Adil G. (Istanbul, Turkey)<br />
1999-27 Endoscopic management of bladder tumours<br />
artínez-Piñeiro J.A., Martínez-Piñeiro L., López-Tello J. (Madrid, Spain)<br />
1999-28 Minimized skin sling in patients with severe stress incontinence<br />
Pushkar D.U., Loran O. (Moscow, Russia)<br />
1999-29 A new continent suprapubic vesicostomy technique<br />
Martorana G., Vignoli G., Concetti S., Manferrari F., Bisceglie L.,Brunocilla E. (Bologna, Italy)<br />
1999-30 Augmentation ileocystoplasty with appendicial stoma or Monti procedure (continent augmentation)<br />
Demirkesen O., Çetinel B., Yaycioglu O., Tüfek I., Kural A.R., Solok V. (Istanbul, Turkey)<br />
1999-31 Extravesical ‘detrusor tunneling’ ureterocystoneostomy in the surgical treatment of a megaureter<br />
Perovic S.V., Djordjevic L.M. (Belgrade, Yugoslavia)<br />
1999-32 Inguinal node dissection in penile carcinoma: Surgical techniques<br />
Bouchot O., Bouchot-Hermouet B., Prunet D., Gaschignard N., Buzelin J.M. (Nantes, France)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
473
<strong>EAU</strong> Digital Video Library<br />
1999-33 Upper urinary tract reconstruction<br />
Carmignani G., Simonato A., Traverso P., Romagnoli A., Galli S. (Genova, Italy)<br />
1999-34 Surgery of penile deformations<br />
Yachia D. (Hadera, Israel)<br />
1999-36 Retroperitoneal laparoscopy in urology<br />
Hoznek A., Abbou C.C., Antiphon P., Gasman D., Chopin D. (Créteil, France)<br />
1999-37 Nerve-sparing retroperitoneal lymphadenectomy in patient with teratocarcinoma of left testis, clinical<br />
stage IIA<br />
Solsona E., Iborra I., Mónros J.L., Dumont R., Casanova J.L., Ricós J.V. (Valencia, Spain)<br />
1999-38 Percutaneous nephrolithotripsy with USL-2000 ultrasound lithotripsy by CIRCON ACMI<br />
Gallucci M., Vincenzoni A., Schettini M., Mauro M. (Rome, Italy)<br />
1999-39 De Sy’s flap in hypospadias<br />
Mende Leal A., Aires T. (Póvoa De Varzim, Portugal)<br />
1999-40 Transurethral insertion of ureter-stents using the flexible fibre urethro-cystoscope<br />
Sauter T.W., Müller M., Steiner U., Miller K. (Berlin, Germany)<br />
1999-41 Inlay-onlay flap urethroplasty in the absence of a uretheral segment<br />
Kocvara R., Dvorácek J. (Prague, Czech Republic)<br />
1999-42 The role of microsurgery in the treatment of varicocele<br />
Erdei E., Tritto J., Laki A., Arvis G., Rózsahegyi J., Karsza A., North M.O. (Budapest, Hungary; Paris,<br />
France)<br />
1999-43 Epididymal sperm aspiration for obstructive azoospermia by using a micropuncture technique<br />
Hibi H., Yamamda Y., Honda N., Fukatsu H. (Aichi, Japan)<br />
1999-46 Repair of severe hypospadias using penile disassembly technique<br />
V.S. Perovic, L.M. Djordjevic, G.N. Djakovic (Belgrade, Yugoslavia)<br />
1999-47 Urethroplasty with free graft of buccal mucosa<br />
Martínez-Piñeiro J., Martínez-Piñeiro L., Tabernero A. (Madrid, Spain)<br />
1998-1 Hazards of laparoscopic urology<br />
Weber H.M., Hörmann M., Bader P., Frohneberg D.H. (Blankenhain, Germany)<br />
1998-2 Hand-assisted laparoscopic renal surgery<br />
Moon T.D., Nakada S.Y., Wolf Jr. S. (Madison, U.S.A.)<br />
1998-3 The use of the ultrasonic scalpel for laparoscopic nephrectomy<br />
Keeley F.X., Naeem Akhtar M., Tolley D.A. (Edinburgh,United Kingdom)<br />
1998-4 Retroperitoneoscopy 2000<br />
Rassweiler J., Seemann O., Frede T., Hatzinger M., Grenacher L.(Heilbronn, Germany)<br />
474 Programme Book
1998-5 Laparoscopic bladder neck suspension<br />
Hernández C., Palacio A., Escribano G., Ma Diez Cordero J., Bueno G., Leal F. (Madrid, Spain)<br />
1998-6 Laparoscopic non-dismembered pyeloplasty<br />
Janetschek G., Reschel R., Bartsch G. (Innsbruck, Austria)<br />
1998-7 Laparoscopic bladder neck suspension<br />
Hernández C., Palacio A., Escribano G., Diez Corbero J.M., Bueno G., Leaf F. (Madrid, Spain)<br />
1998-8 Ileal blader with colposacropexy following cystectomy in women<br />
Pisani E., Trichieri A., Zanetti G., Montanari E., Montavani F. (Milano, Italy)<br />
1998-9 Sutureless intestinal anastomosis (BAR, Valtrec, biofragmentable anastomosis ring) in urological surgery<br />
Wronczewski A., Wolski Z., Siekiera J. (Bydgoszcz, Poland)<br />
1998-10 Endourological recanalization of the uretero-neovesical anastomosis in the orthotopic ileal neobladder<br />
Gallucci M., Fortunato P., Schettini M., Vincenzoni A., Mauro M. (Rome, Italy)<br />
The following videos are a selection of videos presentations during the 13 th<br />
<strong>EAU</strong> in <strong>Barcelona</strong>, March 21-25, 1998<br />
1998-12 Seminal sparing cystectomy and ileocapsuloplasty<br />
Moroni M., Muto G., Bardari F., Bozzo R., Leggero R., Manzo M.(Turin, Italy)<br />
1998-14 ‘Bladder neck sparing’ radical retropubic prostatectomy: Why choose it?<br />
Randone D.F., Giacomelli G., Caccia P., Giargia E., Pasquale M., Cavallini A., Neira D. (Turin, Italy)<br />
1998-15 Obesity is not a contra-indication to radical prostatectomy: The perineal approach<br />
Yachia D. (Hadera, Israel)<br />
1998-16 Treatment of prostate cancer with “ablatherm” (trans rectal focused ultrasound)<br />
Gelet A., Chapelon Jy., Bouvier R., Sauchon R., Pangaud C.(Lyon, France)<br />
1998-17 Radical retropubic prostatectomy and early urinary incontinence: What about the bladder neck?<br />
Carmignani G., Simonato A., Galli S., Traverso P., Scotto S., Romagnoli A., Stubinksi R. (Genova, Italy)<br />
1998-18 Prostate laser coagulation can replace TURP and prostatectomy: The perineal approach<br />
Yachia D,. (Hadera, Israel)<br />
1998-19 Transsurethral needle ablation (TUNA) of prostate: An alternative the therapy for BPH: Transrectal ultrasound<br />
findings in TUNA prostate<br />
Vohra A., McNicholas T. (Stevenage, United Kingdom)<br />
1998-20 The progressive perineal route for the repair of traumatic urethral disruptions<br />
Martímez-Piñeiro J.A., Cisneros J., Martínez-Piñeiro L. (Madrid, Spain)<br />
1998-21 Dorsal onlay urethroplasty in very long urethral strictures<br />
Yachia D. (Hadera, Israel)<br />
1998-22 Septum pedicled scrotal skin for partial or complete coverage of penile shaft<br />
Yachia D. (Hadera, Israel)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
475
<strong>EAU</strong> Digital Video Library<br />
1998-23 Use of proximal-based vaginal flap in stricture of the female urethral<br />
Palou J., Caparrós J., Arañó P., Vincente J. (<strong>Barcelona</strong>, Spain)<br />
1998-24 Reconstruction of glans<br />
Bondavalli C., Luciano M., Pegoraro C., Schiavon L., Dall’oglio B., Canclini L., Parma A. (Manua, Italy)<br />
1998-25 Simplified repair of post-pelvic fracture anterior-posterior urethral distraction defect<br />
Martins F., Lopes T., Boyd S. (Lisbon, Portugal)<br />
1998-26 Bladder stone percutaneous lithotripsy approach using Hassons’s laparoscopic trocar<br />
Segarra J., Ponce De León J., Huguet J., Montlleó M., Salvador J.,Vicente J. (<strong>Barcelona</strong>, Spain)<br />
1998-27 A new technique of the percutaneous cystolithotripsy<br />
Antoniewicz A.A., Borówka A., Chlosta P., Kata G. (Warsaw, Poland)<br />
1998-28 Electrokynetic energy in the treatment of urinary stones<br />
Stubinski R., Germinale F., Bottino P., Di Pierro M. (Genoa, Italy)<br />
1998-29 Endourological treatment of upper tract transitional cell carcinoma (TCC)<br />
Stubinski R., Di Pierrro M., Bottino P., Germinale F. (Genoa, Italy)<br />
1998-30 Endourological treatment of upper tract transitional cell carcinoma (TCC)<br />
Montanari E., Del Nero A., Mangiarotti B., Ceresoli A., Trinchieri A., Zanetti G., Paccaduscio A., Pisani<br />
E. (Milan, Italy)<br />
1998-31 Endoscopic technique for treatment of female stress urinary incontinence with macroplastique<br />
implants - a training video<br />
Lewi H., Sheriff M. (Chelmsford, Essex, United Kingdom)<br />
1998-32 Effectiveness of different surgical prodedures in the treatment of primitive varicocele<br />
Ughi G., Gigante L., Romano A., Simone M., Daniele C. (Ferrara, Italy)<br />
1998-33 Surgery for renal cell carcinoma<br />
Mungan U., Çinar T., Kirkali Z. (Inciralti-Izmir, Turkey)<br />
1998-34 Use of splenic vessels in kidney transplantation<br />
Saladie-Roig J.M., Çinar T., Kirkali Z. (Izmir, Turkey)<br />
1998-35 A new transvesical technique for the excision of bladder diverticula<br />
Margaritopoulou A., Giouris S., Sideromenos P. (Athens, Greece)<br />
1998-36 The role of microsurgical vasoepididymostomy in the ICSI ERA<br />
Franco G., Rocchegiani A., Di Marco M., Martini M., Iacobelli M., Aragona C., Laurenti C. (Rome,<br />
Italy)<br />
1998-37 Posterior access recto-prostatic fistula repair<br />
Fanciullacci F., Viganó P., Barana L., Franzini A., Alfano G., Antolini C. (Milan, Italy)<br />
1998-38 Male intersexuality: One stage repair<br />
Perovic S. (Belgrade, Yugoslavia)<br />
476 Programme Book
1998-39 Latissimus dorsi dynamic myoplasty for the treatment of acontractile bladder<br />
Stenzl A. Ninkovic M., Anderl H., Bartsch G. (Innsbruck, Austria)<br />
1998-40 Angiographical treatment of congenital arteriocavernosal fistulae<br />
Saladie Roig J.M., Areal J., Perendreu , Muchart , Blanco, Cecchini L. (<strong>Barcelona</strong>, Spain)<br />
1998-41 Transurethral resection of cystic and non-cystic ejaculatory duct obstructions<br />
Popken G., Wetterauer U., Schultze- Seemann W., Katzenwadel A., Deckart A. (Freiburg, Germany)<br />
1998-42 Transurethral vaporisation of the prostate: Technique, histopathology and urodynamic follow-up<br />
Scarpa R.M., De Lisa A., Campus G., Usai P., Montisci I., Usai E., Porru D. (Cagliari, Italy)<br />
1998-43 Ureteral ectopia into the seminal vesicle<br />
Da Silva Oliveira A., Prisco R., Carvalho L., Pimenta A. (Porto, Portugal)<br />
1998-44 Staged endoscopic management of complete obliteration of posterior urethra<br />
Erlich N., Yachia D. (Hadera, Israel)<br />
1998-45 Endoscopic laser treatment of a fibrous sparing anterolateral transabdominal approach to renal tumors<br />
Gallucci M., Fortunato P., Mauro M., Nesci L. (Rome, Italy)<br />
1998-47 Modified suburethral sling cystourethropexy<br />
Martins F.E., Alves J.M., Lencastre J.C., Lopes T.M. (Lisbon, Portugal)<br />
1998-48 Post traumatic arterial priapism<br />
Prisco R., Oliveira A., Araujo D., Stocker A., Moreira A., Pimenta A.(Maia, Portugal)<br />
1998-49 Endourological anterograde and retrograde “rendez vouz” in a patient with ureteral fistula and complete<br />
detachment of the ureter<br />
Liberti M., Perugia G., Salvatori F.M., Rossi P., Palleschi G., Di Marco M. (Rome, Italy)<br />
1998-50 Technical measures for the prevention of iatrogenic spleen lesions during left radical nefrectomy<br />
Carmignani G., Simonato A., Traverso P., Pizzorno R., Scotto S., Romagnoli A. (Genoa, Italy)<br />
1998-51 Submaximum effort tourniquet technique for pain measurement: A routine clinical investigation prior to<br />
high energy ESWL<br />
Carminagnani G., Simonato A., Traverso P., Pizzorno R., Scotto S., Romagnoli A. (Genoa, Italy)<br />
1998-52 Laparoscopic assisted litholapaxy in horseshoe kidney<br />
Gallucci M., Fortunato P., Schettini M., Mauro M., Vincenzoni A. (Rome, Italy)<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
477
Abstract Authors<br />
478<br />
A Aalders T. 283<br />
Abad C. 419<br />
Abal M. 966<br />
Abascal R. 42<br />
Abaza R. V15<br />
Abbaraju J. 225<br />
Abbas M. 112<br />
Abbou C.C. 63, 691, 768, 840, V22<br />
Abd-Elsalam M. 214<br />
Abdel Raheem A.M.M. 530<br />
Abdel Raouf Morsy H. 342<br />
Abdel-Latif M. 408, 653, 1023<br />
Abdolell M. 291<br />
Abdollah F. 23, 70, 115, 172, 449,<br />
577, 907, 917, 1010<br />
Abdul-Rahman A. 522<br />
Abdullah H. 430<br />
Abdullajanov M. 239<br />
Abe T.A. 407<br />
Abedi A. 749<br />
Abol-Enein H. 408, 653, 1023<br />
Aboseif S.R. 398<br />
Abou Farha M.O. 385<br />
Abou Farha O.M. 385<br />
Abouel Fettouh H.I. 342<br />
Abouel Fettouh I. 342<br />
Abovyan A.A. 461<br />
Abrahamsson K. 660<br />
Abrahamsson P.A. 283<br />
Abrams P. 783<br />
Abu Eid R. 111<br />
Abu-Kischk I. 211<br />
Abu-Ramadan A.R. 803<br />
Acosta K. 607, 1033<br />
Adam C. V45<br />
Adam P. 753<br />
Adamakis I. 867<br />
Adamy A. 438, 943<br />
Adolfsson J. 134, 608, 612, 909<br />
Afoko A.A. 370, 371, 380, 434, 482,<br />
485, 872<br />
Agabo H.M. 342<br />
Agrawal S. 789<br />
Aguilar L. 630<br />
Aguilar Y. 600<br />
Aguilera R. 904<br />
Aguirre F. 339<br />
Ahallal Y.A. 1005<br />
Programme Book<br />
Ahmad M.S. 17<br />
Ahmadi H. 425, 657, 996, 998<br />
Ahmed A. 625<br />
Ahmed A. 863<br />
Ahmed A.S. 345<br />
Ahmed H.U. 69, 108, 156, 712<br />
Ahmed M. 506<br />
Ahn H.J. 107, 324, 439, 719<br />
Ahn H.S. 161, 212<br />
Ahn K. 1052<br />
Ahn S.H. 483, 981<br />
Ahn T.Y. 177<br />
Ahrar K. 762<br />
Ahyai S.A. 132, 413, 684<br />
Aigner F. 150<br />
Aikawa K. 507<br />
Aillet G. 610, 711, 1011<br />
Aizawa N. 1044<br />
Akand M. 303<br />
Akbulut Z. 110<br />
Akdogan B. 832<br />
Akduman B. 376<br />
Akilov F.A. 354<br />
Akincioglu E. 67<br />
Akino H. 127<br />
Akpinar H. 791<br />
Aksit S. 791<br />
Al Najar A. 549<br />
Al-Ali Mohamad B. 787<br />
Albala D.M. 417<br />
Albanese S. 362<br />
Albanesi L. 886<br />
Albers P. 730, V12<br />
Albouy B. 768<br />
Albrecht K. 845<br />
Albrecht S. 473<br />
Alcaraz A. 55, 264, 332, 337, 343,<br />
455, 813, 972, V3, V7, V37<br />
Alekseev B.Y. 901, 1003<br />
Aleksic R.P. 1021<br />
Alexandre L. 131<br />
Alfarone A. 707<br />
Algaba F. 189<br />
Alhoseeny G. 329<br />
Ali-El-Dein B. 1036<br />
Alizad A. 717<br />
Alken P. 478, 545<br />
Alkhateeb S.S. 194, 195, 321, 690<br />
Allard J. 521<br />
Allegro R. 49, 191, 1041<br />
Allen C. 156, 712, 936<br />
Allory Y. 63, 691, 840<br />
Alloussi S.H. 387, 656, 692, 701<br />
Alloussi S. 656, 692, 701<br />
Almasi C.E. 144<br />
Alongi F. 615<br />
Alongi P. 163<br />
Alonso-Dorrego J.M. 188<br />
Alp T.A. 479<br />
Altavilla D. 632<br />
Althof S.E. 314<br />
Altieri V. 1041<br />
Altinkilic B. 487<br />
Altinova S. 67<br />
Altunin D.V. 444, 1040<br />
Altuntas C.Z. 648, 649<br />
Alturas Silva J.F. 642<br />
Aluru P. 357<br />
Alvarez M. 606<br />
Álvarez Múgica M. 817<br />
Alvarez-Vijande Garcia J.R. 337,<br />
343<br />
Alvey C. 274<br />
Alyaev Y.G. 373, 689<br />
Alzahrani A. 646<br />
Amarenco G. 516, 783<br />
Amaruch N. 1037<br />
Ambert V. 7<br />
Ambu A. V21<br />
Amelink A. 276<br />
Amend B. 254, 515, 604, 862, 1055<br />
Ametov R.E. 363<br />
Ameye F. 153, 948<br />
Amin M.B. 815<br />
Amini S. 996, 998<br />
Aminsharifi A.R. 9<br />
Amir S. 855<br />
Amstalden A.N.N. 706<br />
Anai S. 143, 1008<br />
Anastasi G. 163<br />
Anastasiou I. 867<br />
Andergassen U. 868<br />
Anderson P.C.B. 388<br />
Andersson C. 660<br />
Andersson K.E. 182<br />
Andersson S.O. 870<br />
Andolfo A. 973<br />
Andreeva Y. 1003<br />
Numbers refer to abstract numbers
Andreuccetti M. 247<br />
Andrews B. 519, 699<br />
Andriole G.L. 960, 975, 976<br />
Andrén O. 551, 870<br />
Angerer-Shpilenya M. 730<br />
Angiolilli D. 23, 70, 449<br />
Angulo J.C. 202, 325, 489, 492, 493,<br />
955, V28<br />
Angulo Cuesta J. V19<br />
Angusti P. 534<br />
Anjum F.H. 225<br />
Annese P. 2, 1041<br />
Anning J.J. 884<br />
Annino F. V14, V36<br />
Antonelli A. 440<br />
Antoniou N. 142<br />
Aoyagi T.A. 407<br />
Apa D. 18<br />
Apolikhin O.I. 159, 444, 901, 1040<br />
Appelbaum I. 251<br />
Aquilina J. 313, 314<br />
Arafat W.M. 329<br />
Arai A. 919<br />
Arai G. 428<br />
Arai S. 626, 888<br />
Araki I. 119<br />
Arcaniolo D. 229, 526<br />
Arentsen H.C. 931, 932<br />
Argirovic A. 727, 729, 731<br />
Argirovic D. 727, 729, 731<br />
Arianayagam M. 1033<br />
Ariano V. 164<br />
Aricioglu A. 808<br />
Arima K. 447<br />
Arjane P. 769<br />
Armillotta N. 247<br />
Aron M. V2, V5<br />
Arrabal-Martin M. 467<br />
Arrabal-Polo M. 467, 484<br />
Arrighi N. 263, 440<br />
Ars E. 55<br />
Arscott R. 767<br />
Arsov C. V12<br />
Arumainayagam N. 69, 156, 712,<br />
936<br />
Asante-Asamani A.A. 370, 434<br />
Asgari S.A. 309<br />
Ashfaq R. 327, 926<br />
Ashikari D. 206<br />
Ashizawa Y. 428<br />
Asil E. 67<br />
Aslan S. 737<br />
Aslan Y. 310<br />
Assimos D.G. 1<br />
Atak M. 376<br />
Atala A. 933<br />
Atan A. 310<br />
Athanasopoulos P.J. 321<br />
Ather H. 379<br />
Atmaca A.F. 110<br />
Atschekzei F. 567<br />
Attisani F. 886<br />
Atug F. 791<br />
Aubin S.M.J. 871, 975, 976<br />
Augustin H. 787, 979<br />
Auprich M. 24, 680, 787, 970, 977,<br />
979, 980<br />
Aus G. 611, 962, 965<br />
Auskalnis S. 946<br />
Ausmees K. 423<br />
Aussie J. 975, 976<br />
Autenrieth M. 930<br />
Autier P. 147<br />
Autieri D. 524<br />
Autorino R. 3, 105<br />
Autran Gomez A.M. 726<br />
Auvinen A. 68, 784, 965, 971<br />
Avallone R. 633<br />
Avelino A. 85, 118, 629<br />
Aydin O. 310<br />
Aydın A.A. 479<br />
Aydın S.A. 479<br />
Ayres B.E. 552, 556<br />
Azemar M.D. 415, 463<br />
Azzarito G. 105<br />
Azzouzi A.R. 415, 463, 580, 752,<br />
853, 936<br />
B<br />
Baba S. 37, 38, 925<br />
Babenko N.N. 461<br />
Babjuk M. 205, 865<br />
Baccos A. 833<br />
Bachmann A. 460, 891<br />
Bachmann L.M. 772<br />
Bacle J. 402<br />
Badani K.K. 797<br />
Bader M.J. 597<br />
Bader P. 679, 683, 686, 832, 838,<br />
1009, 1013<br />
Badet L. 415, 463<br />
Bae J.B. V27<br />
Bae J.H. 222, 505<br />
Baeurle L. 113<br />
Bagner J. 256<br />
Bahloul A. 411<br />
Bahnasy M. 641<br />
Bahílo P. 592<br />
Baik S. 60<br />
Baird A. 652<br />
Baka-Ostrowska M. 658, 804<br />
Bakhautdin B. 648<br />
Bakhautdin E. 649<br />
Bakke A.M. 599<br />
Balbay M.D. 67, 110, 737<br />
Balci M. 310<br />
Ballarè A. 687<br />
Ballesteros C. 27, 966<br />
Ballesteros E. 419<br />
Balogun-Ojuri B. 171<br />
Balsanu C. 293, 382<br />
Balzer O. 928, 1014<br />
Bancevic V.M. 1021<br />
Bang S.H. 483, 981<br />
Bangma C.H. 51, 52, 195, 611, 969,<br />
1013<br />
Baniel J. 1043<br />
Bantis A. 218<br />
Bapat B. 51, 52<br />
Barakat T.S. 1023, 1036<br />
Barbagli G. 377, 384, V42<br />
Barbanti G. 381<br />
Barber N. 936<br />
Barbet S. 415, 463<br />
Barbieri L. 32, 82, 83, 84, 836<br />
Barentsz J.O. 584, 713<br />
Baretton G. 569<br />
Barillaro F. 988<br />
Barkin J. 990<br />
Barod R. 847<br />
Barratt D. 69<br />
Barret E. 759, 793, 835, 841, 936<br />
Barrio M. 209, 419<br />
Barrou B. 415, 463<br />
Barry N. 714, 716<br />
Barré C. 610, 711<br />
Bartenstein P. 553<br />
Numbers refer to abstract numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
479
Abstract Authors<br />
Bartkuhn M. 424<br />
Bartoletti R. 62, 360, 362, 365, 819<br />
Bartsch G. 150, 736, 750, 985<br />
Barwari K. 299, 764<br />
Baschet F. 580<br />
Basilico F. 973<br />
Bassi B.P.F. 184, 198, 234, 723<br />
Bastian P. 35, 36, 37, 38, 322, 323,<br />
1027<br />
Bastide C. 906<br />
Bastien L. 415, 463<br />
Bataille F.R. 853<br />
Battaglia M. 338<br />
Battermann J.J. 613<br />
Batzill W. 893<br />
Bauer R.M. 240<br />
Bauer S. 967<br />
Baum N.H. 398<br />
Baumann M. 57<br />
Baumann S. 1047<br />
Baumert H. 415, 463, V9<br />
Baumgartner M. 967<br />
Baumunk D. 571, 911<br />
Baxevanis K. 950<br />
Beamud M. 340<br />
Beato A. V14<br />
Beauval J.B. 906<br />
Bechler R. 475<br />
Becker A. 796, 830, V45<br />
Becker F. 457, 572<br />
Beckmann A. 103<br />
Beckmann C.F. 519<br />
Bedair A.S. 232<br />
Bedke J. 254, 515, 572, 604<br />
Bedretdinova D.A. 997, 1040<br />
Beemster P. 764<br />
Beer A.J. 157<br />
Beer T.M. 905<br />
Behr-Roussel D. 128, 130, 131, 268,<br />
269<br />
Beier F. 132<br />
Beier J. 383, V30, V43<br />
Bektic J. 736, 985<br />
Belcher J. 863<br />
Beldì D. 687<br />
Belhiba H. 148<br />
Bell J.C. 574<br />
Bella A.J. 532<br />
Belldegrun A.S. 418, 768<br />
480 Programme Book<br />
Bellec L. 451, 540, 768<br />
Bellina M. 409, V21<br />
Bellmunt J. 13, 94<br />
Belousov I.I. 363, 371<br />
Beltrán S. 340<br />
Ben Rais N. 166<br />
Ben-Chaim J. 598<br />
Benchikh A. 878<br />
Benedetto G. V29<br />
Beneke M. 307<br />
Benetti A. 5, 594<br />
Benjamin S. 546<br />
Bensalah K. 300, 418, 566, 768<br />
Berardelli A. 91<br />
Berardi G. 615<br />
Béraud C. 573<br />
Bercea B.S. 72, 498<br />
Bercea R.M. 72, 498<br />
Berdondini E. 381, V40<br />
Berg W.J. 97<br />
Berg W. 475<br />
Berger I. 501<br />
Bergman A.M. 851<br />
Bergmann L. 96<br />
Bermell L. 340<br />
Bernabé J. 130, 269<br />
Bernardini S. 601<br />
Bernhard B. 899<br />
Bernhard J.C. 300, 418, 768<br />
Bernstein B. 442<br />
Berruti A. 207<br />
Bertaccini A. 829<br />
Bertapelle M.P. 513<br />
Bertini R. 32, 84, 115, 158, 213, 449,<br />
450, 768, 1010<br />
Bertolo R. 534, 538<br />
Bertz S. 43, V45<br />
Berzuk K. 704<br />
Bestard Vallejo J.E. 135<br />
Bettocchi C. 338<br />
Beuvon F. 714, 716<br />
Bex A. 101, 555<br />
Bezerra E.S.B. 706<br />
Bezrukov E.A. 689<br />
Bhatt J.R. 951<br />
Bianchi G. V14, V36<br />
Bianchi M. 83, 213, 609, 836, 1010<br />
Bianco Jr F. 835<br />
Biasoni D. 561, 726<br />
Bielsa O. 42<br />
Biers S.M. 805, 956<br />
Bigot P. 415, 463, 562, 566, 768,<br />
853<br />
Bill-Axelson A. 134, 612<br />
Billia M. 687, 1012<br />
Bindary A. 641<br />
Bini V. 395<br />
Birch M. 595<br />
Birkhaeuser F.D. 1017<br />
Birowo P. 358<br />
Biserte J. 414<br />
Bisogni S.B. 706<br />
Bitker M.O. 57, 752, 812<br />
Bittard H. 601<br />
Bitto A. 632<br />
Bivalacqua T.J. 80<br />
Bizic M. 249, 259<br />
Bizzarri C. 833<br />
Bjartell A. 863, 926, 982<br />
Bjerklund Johansen. T.E. 486<br />
Bjørge T. 945<br />
Bjork T. 982<br />
Black L. 991<br />
Blaheta R.A. 145<br />
Blaivas J.G. 779<br />
Blana A. 941, 942, V45<br />
Blanker M.H. 496, 499, 502<br />
Blas Marín M. 188<br />
Blase A. 975, 976<br />
Blaszyk H. 815<br />
Bläuer M. 635<br />
Blázquez C. 1037<br />
Blick C.G.T. 14, 48<br />
Blok B.F.M. 243<br />
Blute M.L. 133, 620<br />
Bochner B. 1034, 1035<br />
Boddy S. 523, 1057<br />
Bodei S. 263<br />
Boeller G. 261<br />
Boerman O.C. 421, 563<br />
Boermans A. 307<br />
Boerrigter P. 774<br />
Bogaerts K. 153<br />
Böhler G. 86<br />
Bohorquez A. V37<br />
Bolenz C. 36, 327, 915<br />
Bollito E. 207<br />
Bolton D.M. 575, 914<br />
Numbers refer to abstract numbers
Boncher N.A. 1050, 1053<br />
Bonillo M.A. 670<br />
Bonkat G. 460, 891<br />
Bonniaud V. 516<br />
Bono A.V. 189<br />
Bonvini D. 397<br />
Bonvissuto G. 632<br />
Bordenave M. 57<br />
Borgatti F. 833<br />
Borkowski T. 500<br />
Boronat F. 592<br />
Borque A. 675<br />
Borre M. 920<br />
Bosch J.L.H.R. 201, 496, 499, 502,<br />
576, 761<br />
Bosio A. 409, 462<br />
Bostrom P.J. 52, 194, 321, 690, 961<br />
Botelho F. 391, 995<br />
Botto H. 869<br />
Bouchelouche K. 265, 270, 857<br />
Bouchelouche P. 265, 270, 857<br />
Bouchot O. 403, 610, 647, 711, 768<br />
Bourreau A. 853<br />
Bourrelly E. 674<br />
Boutin J.M. 415, 463<br />
Bouzouita A. 148<br />
Bove A. 320<br />
Boy S. 86<br />
Boyes A. 944<br />
Bozkirli I. 808<br />
Bracarda S. 97<br />
Bragina L.E. 370<br />
Brähler E. 179, 367<br />
Brajtbord J.S. 578, 916<br />
Branchereau J. 415, 463<br />
Brandina R. 441<br />
Brandstätter A. 750<br />
Brasso K. 144<br />
Braticevici B. 7<br />
Bratslavsky G. 417<br />
Bratt O. 134, 612<br />
Brauckmann N. 490<br />
Braun G. 744<br />
Braun M. 667, 671, 743<br />
Brausi M. 196, 1025<br />
Brechtel K. 216<br />
Breda A. 1042<br />
Breda G. 535<br />
Brehmer B. 730, 898<br />
Brenner W. 574<br />
Brescia A. V13<br />
Bresette J.F. 398<br />
Brett A.G. 557<br />
Brichart N. 415, 463<br />
Briganti A. 32, 81, 82, 83, 84, 115,<br />
133, 155, 158, 172, 213, 577, 609,<br />
615, 620, 679, 682, 827, 828,<br />
832, 836, 907, 917, 1009, 1010,<br />
1013<br />
Briganti A. 1007<br />
Brock G. 314, 994<br />
Brock M. 151<br />
Broderick G. 313<br />
Broessner C. 831<br />
Brohet R. 733<br />
Bronskill M.J. 944<br />
Broquères-You D. 268<br />
Broseta E. 592<br />
Brown M.D. 280<br />
Brown S.C.W. 941, 942<br />
Bruno R. 395<br />
Brunocilla E. 833<br />
Brunori S. 886<br />
Bruns H. 452<br />
Bruskewitz R.C. 879<br />
Bruyere F. 415, 463<br />
Bryckaert P.E. 402<br />
Bubendorf L. 743<br />
Buchholz N. 8, 228, 230, 349, 595,<br />
602<br />
Büchler M.W. 452<br />
Buchner A. 36, 548, 796, 830<br />
Buchner H. 26<br />
Budäus L. 40, 41 288, 619, 680, 681,<br />
684, 769, 792, 979<br />
Budiharto T. 153<br />
Budía A. 592<br />
Buechner B. 665<br />
Bueno Serrano G. 244<br />
Bueno-Chomon G. 336<br />
Buffi N.M. 32, 81, 204, 542, 763<br />
Bull S. 313, 314<br />
Bullock A.J. 1049<br />
Bultitude M.F. 210, 953<br />
Buonopane R. 229<br />
Burchardt M. 756<br />
Burger H. 738<br />
Burger M. 36, 37, 38, 43, 326<br />
Burgos F.J. 331, 335, 693, 705<br />
Burgu B. 739<br />
Burgues J.P. 1038<br />
Burkhard F.C. 702, 834, 1016, V32,<br />
V33<br />
Burnett A.L. 80<br />
Burset M. 55<br />
Busch C. 189<br />
Busch J. 745<br />
Busetto G.M. 929<br />
Bussolati G. 39<br />
Buttazzoni A. 736<br />
Büttner H. 306<br />
Büttner R. 568<br />
Bycroft J. 101<br />
Byers A. 878<br />
Byrne L.N. 648, 649, 1048<br />
Bystrov S.V. 901<br />
Byun S.S. 60, 104, 107, 239, 673,<br />
823, 825, 866, 912, 1001<br />
C<br />
Cabral Dias Filho A.C.D.F. 217<br />
Cabrera Castillo P. 325, V19<br />
Cáceres F. 325, 492<br />
Cacho J. 489, 492, 493<br />
Cadeddu J.A. 915<br />
Caffaratti J. V31<br />
Cagini R. 644<br />
Cai T. 62, 360, 362, 365, 819<br />
Caisey S. 130, 268<br />
Calais Da Silva F.E. 142, 189, 900<br />
Calais Da Silva Junior F. 142, 900<br />
Calatrava A. 670<br />
Calin C. 7<br />
Caliolo C. 724<br />
Calorini L. 278<br />
Calvet C. 876<br />
Calvo E. 97<br />
Cammann H. 984<br />
Campá J.M. 675<br />
Campanario F. 285<br />
Campara Z. 1021<br />
Camparo P. 869<br />
Campbell J.D. 89<br />
Campillo P.C. 332<br />
Campitelli A. 694<br />
Camps T. 513<br />
Canals F. 966<br />
Numbers refer to abstract numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
481
Abstract Authors<br />
Cancel-Tassin G. 752, 812<br />
Canda A.E. 110<br />
Canes D. V2, V5, V15, V18<br />
Cantiani C.A. 497<br />
Cantor K. 42<br />
Cao Y. 935<br />
Cao Y.L. 260<br />
Capala J. 857<br />
Capelli G. 196<br />
Capewell A. 696<br />
Capitán C. 1037<br />
Capitanio U. 83, 84, 115, 158, 323,<br />
577, 609, 615, 620, 682, 827,<br />
828, 907, 917, 1010<br />
Cappa C.E. 198<br />
Capparelli G. 246<br />
Carballido J. 37<br />
Carbone A. 524<br />
Carchedi M. 409<br />
Cardella C.C. 464<br />
Caremel R. 128, 148<br />
Caretta N. 436<br />
Carini M. 278, 443, 634, 1007<br />
Carlo D. 724<br />
Carlsson S.C. 962, 965<br />
Carlsson S. 786<br />
Carmignani G. 1007<br />
Carmona O. V2, V5, V15, V18<br />
Carneiro L. 574<br />
Carone R. 513<br />
Carpanese L. 448<br />
Carpentier P. 537, V15<br />
Carr B. 811<br />
Carraffiello G. 215<br />
Carrato A. 42<br />
Carrieri G. 2, 164, 409, 1041<br />
Cartwright R. 784<br />
Casado J. 285<br />
Casado J.S.C. 706<br />
Casanova J. 837<br />
Casetta G. 39, 820<br />
Caso J.R. 417<br />
Castela A. 71, 180<br />
Castellano D. 295<br />
Castelli T. 632<br />
Castiglione F. 82, 182, 422, 973<br />
Castillo Cadiz O.A. 725<br />
Castro L. 27<br />
Castro R. 959, 960, 991<br />
482 Programme Book<br />
Catanzaro M. 561, 726<br />
Cathala N. 793, 835<br />
Cathelineau X. 759, 793, 835<br />
Cattarino S. 707<br />
Catto J.W.F. 46, 815, 816<br />
Cauberg E. 299<br />
Cauni V. V23<br />
Cava M. 84<br />
Cavaliere A. 724<br />
Cayan S. 18<br />
Cebrían V. 817<br />
Cecchini M.G. 279, 281, 282<br />
Ceddaha M. V9<br />
Ceder J.A. 283<br />
Cek M. 486<br />
Cekauskas A. 452<br />
Celhay O. 669, 875<br />
Celia A. 535<br />
Centemero A. 204<br />
Cerempei V. 293, 382<br />
Cermák A. 160<br />
Cerruto M.A. 169<br />
Cerundulo V. 767<br />
Cespedes M. 42<br />
Cestari A. 81, 84, 115, 204, 422,<br />
450, 542, 577, 763<br />
Chabannes E. 601<br />
Chabchoub K. 411<br />
Chade D. 199, 438, 926, 943, 1034<br />
Chadwick K. 961<br />
Chakraborty T. 487<br />
Challacombe B.J. 918, 1028<br />
Champetier D. 190<br />
Champion H.C. 80<br />
Chan C.K. 235<br />
Chan J. 759<br />
Chan Y.H. 818<br />
Chancellor M. 92, 117<br />
Chandra A. 625<br />
Chang H.S. 212, 481, 992<br />
Chang I.H. 277, 483, 981<br />
Chang S.G. 636<br />
Chang W.S. 760<br />
Chang Y.S. 627<br />
Chantada-Abal V. 188<br />
Chapelon J.Y. 940<br />
Chapman W. 921<br />
Chapple C.R. 92, 123, 126, 774, 887,<br />
999, 1049<br />
Charlesworth P.J.S. 231<br />
Charrua A. 118, 629<br />
Chartier-Kastler E. 89, 131, 268,<br />
269<br />
Chauhan S. 790<br />
Chautard D. 415, 463<br />
Chauveau P. 610, 711<br />
Chavelmane A.K. 634<br />
Cheetham P.J. 797<br />
Chen J. 64<br />
Chen P.C. 355<br />
Cheng C.W.S. 59, 167<br />
Cheng M.C. 355<br />
Cheon C.J. 508, 582, 1020<br />
Cheon S.H. 177<br />
Chernishev I.V. 444<br />
Chernogubova E.A. 371, 872<br />
Chernyshev I.V. 1040<br />
Chester J. 14<br />
Cheung H.F. 733<br />
Chi B.H. 273, 631<br />
Chiarugi P. 278<br />
Chibelean C. 293, 382<br />
Chibichyan M.B. 872<br />
Chien G. 50<br />
Chin P.T. 879<br />
Chinnaiyan A. 871<br />
Chiong E. 685, 818, 938<br />
Chitarrai R. 362<br />
Chiyomaru T. 44, 821<br />
Chkhotua A.B. 330<br />
Cho D.Y. 582<br />
Cho I.C. 28<br />
Cho I.R. 627<br />
Cho J.S. 107, 227<br />
Cho K.S. 28<br />
Cho M.C. 60, 883<br />
Cho S.T. 227, 271<br />
Cho S.Y. 311<br />
Cho Y.H. 76, 369<br />
Cho Y.S. 137, 477<br />
Choe G. 104<br />
Choi H.Y. 107, 543<br />
Choi H.Y. 603<br />
Choi H. 399<br />
Choi H. 734<br />
Choi J.B. 87, 161, 785<br />
Choi J.D. 543<br />
Choi J.W. 222<br />
Numbers refer to abstract numbers
Choi K.H. 107, 466, 510, 588, 590,<br />
895<br />
Choi M.J. 186, 301<br />
Choi N.G. 227<br />
Choi N.Y. 483, 981<br />
Choi S. 741<br />
Choi Y.D. 65, 107, 319, 588, 590,<br />
760, 895<br />
Chokhonelidze I. 330<br />
Chong K.T. 438<br />
Chopra R. 944<br />
Chopra S. 21, 910<br />
Choudhry H.M.Z. 46<br />
Chowdhury S. 101<br />
Chrisofos M. 203, 993<br />
Christensen I.J. 144<br />
Christine B.S. 532<br />
Christopher A.N. 250, 530<br />
Chromecki T.F. 286, 294, 541<br />
Chun F.K.H. 24, 132, 565, 619, 681,<br />
684, 928, 970, 977, 979, 980,<br />
1014<br />
Chun J.W. 880<br />
Chung B.H. 116<br />
Chung H.S. 28<br />
Chung H.C. 880<br />
Chung J.M. 741<br />
Chung J.S. 28<br />
Chung J.S. 107, 590<br />
Chung J.Y. 168, 212<br />
Chung M.K. 107<br />
Chung S.D. 224<br />
Chung S.K. 709<br />
Chung Y.G. 509<br />
Ciancio G. V28<br />
Cicalese V. 991<br />
Ciccariello C.M. 854<br />
Cicek T. 359<br />
Cimino S. 632<br />
Cindolo L. 418, V6, V8<br />
Citeri M. 514<br />
Ciudin A. 343<br />
Clarke H.S. 939<br />
Clarke N.W. 280<br />
Clavé Civit P. 264<br />
Clezardin P. 674<br />
Climent M.A. 97<br />
Cochetti G. 988<br />
Coelho A. 85<br />
Coelho R.F.C. 790<br />
Cohen M. 192<br />
Cohen N.P. 882<br />
Cojocaru E. 72<br />
Collado A. 837<br />
Colleselli D. 53, 216, 378, 558, 710,<br />
801<br />
Collette S. 189<br />
Collins V.M. 126<br />
Collura Z. 632<br />
Colombel M. 190, 193, 674, 768<br />
Colombo J.R. 544<br />
Colombo R. 115, 158, 917<br />
Colome N. 966<br />
Colquhoun A.J. 664<br />
Coman I. V13<br />
Compagnie S. 268<br />
Comperat E. 269, 812<br />
Concetti S. 833<br />
Conde G. 1038<br />
Connolly D. 963<br />
Conort P. 57, 193<br />
Constantinides C.A. 867<br />
Conti G.N. 941, 942<br />
Conus P.A. 1045<br />
Cookson M.S. 141<br />
Copel L. 211<br />
Coquard C. 573<br />
Coqueret O. 853<br />
Corbishley C.M. 552, 554, 556<br />
Corcoran N.M. 210<br />
Córdoba L. 693<br />
Cormier L. 580, 936<br />
Cormio L. 2, 164<br />
Cornu J-N. 814<br />
Cornud F. 714, 716<br />
Correas J.M. 415, 463<br />
Corvasce T. 164<br />
Cosciani Cunico S. 263, 440<br />
Cosgrove J. 1024<br />
Cossons N. 639<br />
Cossu M. 347, V24<br />
Costa C. 71, 175, 180<br />
Costantini E. 395<br />
Costello A.J. 918<br />
Cottini E. 988<br />
Cowan N.C. 48<br />
Cozzarini C. 133, 615, 620, 682<br />
Cozzoli A. 440<br />
Cracco C.M. 347, V24<br />
Cranston D. 767<br />
Crea G. 163<br />
Cremers R.G.H.M. 622<br />
Crepel M. 300, 418, 768<br />
Crespo L. 606<br />
Cresswell J. 17<br />
Creta M. 229, 526<br />
Crevels A.J. 252, 253<br />
Crew J.P. 14, 48<br />
Crisan N. V13<br />
Cristini C. 929<br />
Crivellaro S. 397, 1012<br />
Crnkovic-Mertens I. 570<br />
Croci T. 302, 633<br />
Cron C. 451<br />
Cronin A. 442, 982, 1034, 1035<br />
Crosby R.D. 776<br />
Crosthwaite A. 914<br />
Crouzet S. 544, 940<br />
Cruz C.D. 85, 118<br />
Cruz F.R. 85, 118, 391, 629, 642, 995<br />
Csizmadia E. 863<br />
Culine S. 13, 566<br />
Cumaoglu A. 808<br />
Cumpanas A. 645<br />
Curtet C. 1011<br />
Cussenot I. 580<br />
Cussenot O. 580, 669, 752, 812,<br />
814, 853<br />
Cuvillier O. 876<br />
Czyzc J. 804<br />
D<br />
Da Pozzo L.F. 133, 158, 213, 449,<br />
450, 615, 620, 917<br />
Daamen W.F. 252, 253<br />
Daanen V. 57<br />
Dababne U. 829<br />
Dacher J.N. 148<br />
D’Addessi A. 184, 234<br />
Daffara F. 207<br />
Dagli S. 737<br />
D’Agostino D.D. 198, 234<br />
Dahl M. 857<br />
Dahlem R. 413, 1014<br />
Dahlin A. 982<br />
Dahlstrand C. 237<br />
Dai Y.T. 255<br />
Numbers refer to abstract numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
483
Abstract Authors<br />
Dalbagni G. 1034, 1035<br />
Dallas N.L. 614<br />
Dambros M.D. 706<br />
Damhougy M. 641<br />
Damiano R. 105<br />
Damm O. 328<br />
Dammann R.H. 746<br />
Daneshgari F. 648, 649, 1048, 1050,<br />
1053<br />
Daneshpajouh A. 996, 998<br />
Daniele C. 246<br />
Daniele G.P. 246<br />
Daniell G. 92<br />
Danø K. 144<br />
Dansranjav T. 746<br />
Darabi Mahboub M.R. 333<br />
Darbouret B. 566<br />
Darekar A. 639<br />
Daricello D. 1041<br />
D’Armiento M. 105<br />
Darnell A. 419<br />
Darte C. 985<br />
Darweesh A.M. 329<br />
Dasgupta P. 88, 625, 1028<br />
Davarcı M. 737<br />
Davidson S.R.H. 937<br />
Davis B. 717<br />
Davis I.D. 575<br />
Davis K. 659<br />
Davis P.G. 210<br />
Davis III R.L. 139<br />
De Andrade R. V2, V5<br />
De Andres A. 339<br />
De Angelis M. 377<br />
De Berardinis E. 929<br />
De Bruin D.M. 299<br />
De Carne C. V14<br />
De Cillis A. 724<br />
De Cobelli O. 1007<br />
De Domenico R. 105<br />
De Dominicis D.C. 497, 854<br />
De Jong B.W.D. 276<br />
De Jong T.P.V.M. 738<br />
De La Fuente V. 455<br />
De La Morena J.M. 1037<br />
De La Orden V. 285<br />
De La Peña E. 1037<br />
De La Rosa F. 295, 339<br />
De La Rosette J.J. 1, 139, 299, 478,<br />
484 Programme Book<br />
764, 887<br />
De La Taille A. 24, 61, 63, 193, 418,<br />
768, 840, 970, 977, 980, V22<br />
De Laet K. V22<br />
De Luca G. 1025<br />
De Maria M. 247<br />
De Naeyer G. 537<br />
De Nunzio C. 381, 497, 724<br />
De Reijke T. 24, 61, 970, 977, 980<br />
De Rienzo G. 114<br />
De Rose F. 1007<br />
De Santo C. 767<br />
De Seze M. 516, 516<br />
De Siati M. 2, 164<br />
De Sio M. 3, 105<br />
De Stefani S. V14, V36<br />
De Torres I. 27<br />
De Vente J. 129<br />
De Vries I.J.M. 564<br />
De Wachter S.G.G. 129<br />
Deacon S. 777, 783<br />
Debruyne F. 307<br />
Decensi A. 1007<br />
Deger S. 984, V18<br />
Dehner L.P. 815<br />
Dehò F. 70<br />
Dekel Y. 192<br />
Dekker H.M. 420<br />
Del Amo J. 675<br />
Del Cañizo-Lopez J.F. 453<br />
Del Zingaro M. 91, 395<br />
Delakas D. 208<br />
D’Elia G. V46<br />
Deligne E. 986<br />
Deliveliotis C. 203, 993<br />
Della Melina A. 822<br />
Dell’Atti L. 246<br />
Delongchamps N.B. 583<br />
Delorenzi M. 279<br />
Delorme G. 601<br />
Demichelis F. 870<br />
Demura T. 708<br />
Dente D. 724<br />
Denys P. 89, 268, 269, 516<br />
Denzinger S. 43, 326, V45<br />
Derakhshani P. 617, 618<br />
Deruelle C. 415, 463, 580<br />
Derweesh I.H. 765<br />
Desai M.R. 1, 215<br />
Desai M. V2, V5<br />
Desar I.M. 563, 564<br />
Descazeaux A. 415, 463<br />
Descotes J.L. 193<br />
Desgrandchamps F. 999<br />
Destefanis P. 409, 820<br />
Devonec M. 190<br />
Di Brina R. 2<br />
Di Capua C. 592<br />
Di Cristofano C. 443<br />
Di Fino G. 2, 164<br />
Di Girolamo V. 32, 213<br />
Di Grazia E. V2, V15<br />
Di Lallo A. 1041<br />
Di Lorenzo G. 105<br />
Di Mauro U. 694, V17<br />
Di Muzio N. 133, 615, 620<br />
Di Paola G. 247<br />
Di Pierro G. 929<br />
Di Silverio F. 929<br />
Di Stasi S.M. 196, 197<br />
Di Stasio A. 347, 534, 538, V24<br />
Di Trapani D. 115, 836, 907<br />
Diaconescu D. 7<br />
Diaz M. 42<br />
Diaz R. 339<br />
Diaz Naranjo S. 331, 693<br />
Diaz Rubio E. 285<br />
Dieker W. 550<br />
Dietel A. 757<br />
Diez-Cordero J.M. 336<br />
Diez Nicolás V. 244, 693<br />
Dikov T. 748<br />
Dillenburg T. 862<br />
Dillioglugil O. 297<br />
Dillis A. 102<br />
Dinis P. 391, 629, 995<br />
Dinney P. 35, 322, 323<br />
Dinter D.J. 149<br />
Díte Z. 809<br />
Ditonno P. 338<br />
Djakovic N. 1004, 1022, V41<br />
Djinovic R.P. 384, 525, 527, 531<br />
Djordjevic M. 249, 259<br />
Dmochowski R. 92<br />
Do M. 757<br />
Dobkowicz L. 383<br />
Dogan B. 110<br />
Dogan R. 359<br />
Numbers refer to abstract numbers
Doggart A.J. 614<br />
Doglioni C. 70, 682<br />
Doherty A. 949<br />
Dohle G. 429<br />
Dolci S. 197<br />
Dolinga R. 372<br />
Doll A. 27, 966<br />
Dominguez M. 295<br />
Domnisor L. 293, 382<br />
Donat S.M. 1034, 1035<br />
Donatucci C. 994<br />
Donmez I. 376<br />
D’Onofrio A. 723<br />
Donohue J.F. 79<br />
Doo S.H. 104, 239, 673, 823, 825,<br />
866, 1001<br />
Doré B. 669, 875<br />
Dormoy V. 573<br />
Dosemeci M. 42<br />
Doucet L. 580<br />
Doumerc N. 317, 876, 906<br />
Dowson C. 88<br />
Doyle P.W. 789<br />
Dragutescu M.D. 885, V26<br />
Drasa K. 491<br />
Drenidis D.G. 203<br />
Drewa T.D. 248<br />
Dridi M. 166<br />
Drnevich M. 795<br />
Drouin S.J. 752, 812<br />
Dryhurst D. 506<br />
Duarte J.M. 295<br />
Dudderidge T.D. 789<br />
Dudziec E. 816<br />
Dugardin F. 415, 463<br />
Dulin E. 453<br />
Dumonceau O. V9<br />
Duran-Merino R. 336<br />
Durand X. 986<br />
Durkan G.C. 1024<br />
Durrant K.L. 99<br />
Dursun M. 359<br />
Dusek P. 865<br />
Dvorácek J. 205, 809<br />
Dvorak V. 774<br />
E<br />
Eardley I. 560<br />
Eastham J.A. 677, 943<br />
Ebbing J. 571<br />
Eberli D. 93, 798<br />
Edeline J. 562<br />
Eden G. 678<br />
Efesoy O. 18<br />
Efstathiou E. 905<br />
Egevad L. 909<br />
Eggert T. 151<br />
Eggink A.J. 252, 253<br />
Egner T. V38<br />
Egydio P.H. 528<br />
Ehlers L. 920<br />
Eiber M. 688<br />
Eichel R. 692, 701<br />
Eichelberg C. 565, 684, 1014<br />
Eimer C. 242, 256, 1051<br />
Ekman M. 275<br />
Ekwueme K.C. 58<br />
El Fayoumy H.M. 232<br />
El Husseiny T. 8, 228, 230, 349,<br />
595, 602<br />
El Refai M. 385<br />
El Shenoufy A. 232, 342<br />
El-Assmy A.M. 345, 346<br />
El-Hakim A. 38<br />
El-Houssiny E.I. 345<br />
El-Kenawy M.R. 345, 346<br />
El-Nahas A.R. 345<br />
El-Tabey N.A.M. 345, 346<br />
El-Zawahry A.M. 939<br />
Eladl M. 10<br />
Eldefrawy A. 607<br />
Elganayny O. 214<br />
Elgh F. 551<br />
Elhage O. 1028<br />
Elhawary A. 214<br />
Elion-Mboussa A. 994<br />
Elkappany H.A. 346<br />
Elkentaoui H. 415, 463<br />
Ellinger J. 568<br />
Elman B. 585<br />
Elnahas A.R. 346<br />
Elneil S. 512<br />
Elsawy M. 458<br />
Elshal A.M. 408, 653, 1023<br />
Emberton M. 69, 108, 156, 712, 936<br />
Emiliozzi P. V46<br />
Emme D. 549<br />
Encabo G. 676<br />
Endo F. 889<br />
Engel O. 799<br />
Engeland A. 945<br />
Engeler D.S. 512, 517, 616, 703<br />
Engelhard K. 718<br />
Engelmann U. 744<br />
English P. 954<br />
Enokida H. 821<br />
Entwistle J. 921<br />
Epplen R. 898<br />
Epstein J.I. 815<br />
Eraky E.I. 345, 346<br />
Erdem S.R. 511<br />
Erdmann K. 747<br />
Eremina L.S. 987<br />
Ergen A. 432<br />
Ergün S. 870<br />
Erkkilä T. 852<br />
Ermilova V.D. 579<br />
Erol B. 376<br />
Eronini N.K. 17<br />
Ersöz G. 303<br />
Ertemi H. 181<br />
Escaf Barmadah S. 284, 672, 817<br />
Escudier B. 94, 97, 415, 463<br />
Eshel G. 211<br />
Eskridge M.R. 939<br />
Esquivel S. V22<br />
Esterbauer B. 305<br />
Esuvaranathan K. 818<br />
Evans A.E. 99, 961<br />
Evans A. 690<br />
Evans R.J. 639<br />
Even Schneider A. 516<br />
Everaert K. 92<br />
Ewald S. 307<br />
F<br />
Fabbri A. V29<br />
Fabbri F. 204, 377, 542<br />
Faber D.J. 299<br />
Fabrizio D. 765<br />
Fahlenkamp D. 480<br />
Fakhfakh H. 411<br />
Fakhfakh S. 411<br />
Falahatkar S. 6<br />
Falke J. 931, 932<br />
Falsaperla M. 1041<br />
Fangerau H. 842<br />
Numbers refer to abstract numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
485
Abstract Authors<br />
Farag F. 781<br />
Farahat A. 641, 803<br />
Fares G. 192<br />
Farina U. 62<br />
Farshid B. 742<br />
Fasolis G. 409<br />
Fasoulakis C. 176, 203<br />
Fasoulis L. 162, 950<br />
Fatemi M. 717<br />
Fateri F. 386<br />
Favaretto R.F. 1005<br />
Favilla V. 632<br />
Fawcett D.P. 951<br />
Fayers P. 406<br />
Fayyazi A. 589<br />
Fehri K. 415, 463<br />
Feil G. 258, 1047<br />
Feitz W.F.J. 252, 253<br />
Felberg K. 658<br />
Felix F. 351<br />
Fend F. 667, 671, 743<br />
Feng G. 289<br />
Fennouri M. V9<br />
Ferazzini M. 302, 633<br />
Fergelot P. 566<br />
Ferlosio A. 525<br />
Fermo I. 973<br />
Fernandes K. 961<br />
Fernandez G. V2<br />
Fernandez J.M. 42<br />
Fernandez L. 606<br />
Fernández M. 55<br />
Fernandez Fernandez E. 244<br />
Fernández Gómez J.M. 188, 284,<br />
672, 817<br />
Fernández-Serra A. 670<br />
Ferrarese P. V29<br />
Ferrari M. 84, 422<br />
Ferrari M. 973<br />
Ferriere J.M. 415, 418, 463, 768<br />
Ferriero M. 320, 536, 1029<br />
Feuillu B. 415, 463<br />
Fibbi B. 634<br />
Ficarra V. 33, 35, 37, 38, 199, 322,<br />
323, 418, 1027<br />
Fidaev N.N. 354<br />
Filippi S. 634<br />
Fine S.W. 815<br />
Finelli A. 99, 194, 464, 715, 961<br />
486 Programme Book<br />
Fiori C. 207, 534, 538<br />
Fiorino C. 615<br />
Fiorito C. 39<br />
Firdaoessaleh F. 358<br />
Firek P. 898<br />
Fisch M. 413, 565, 619, 684, 928,<br />
1014<br />
Fischer M.A. 587<br />
Fitzpatrick J.M. 1000<br />
Flam T. 714, 716<br />
Flamand V. 864<br />
Flaris N. 890<br />
Fleischmann A. 34, 850, 873, 874<br />
Fleshner N.E. 52, 99, 194, 195, 321,<br />
664, 690, 715, 961<br />
Fliser D. 457<br />
Floercken A. 95<br />
Floresco J.F. 175<br />
Foad A. 341<br />
Foda K. 219<br />
Foley R. 989<br />
Foley S.J. 951<br />
Fontana D. 409, 462, 820<br />
Fonteyne E. 537<br />
Forastiere E. 154, 448, 536, 1029<br />
Foresta C. 436<br />
Fornara P. 344, 396, 465, 539<br />
Fornasiari L. 246<br />
Forrest H. 488<br />
Fossati N. 828, 907, 973, 1010<br />
Fourati M. 411<br />
Fournier G. 580<br />
Fowler C.J. 512<br />
Fowler I.L. 960<br />
Fowler S. 913<br />
Fox P.L. 648<br />
Fradet Y. 33, 35, 322, 323, 621, 871<br />
Franceschelli A. 829, 833<br />
Franco G. 381, 497, 724, V40<br />
Franco De Castro A. 264<br />
Frank G.A. 1003<br />
Franken V.C. 420<br />
Franks K. 560<br />
Frånlund M. 237<br />
Franssen G.M. 421<br />
Frauscher F. 150, 262<br />
Frea B. 397, 409, 687, 1012<br />
Frederico G. 900<br />
Freedland S.J. 983<br />
Freeman A. 69, 108, 156, 625, 712<br />
Freschi M. 23, 32, 115, 172, 449, 577,<br />
682, 907<br />
Fresno F. 817<br />
Frias B. 118<br />
Fridman E. 860<br />
Friedersdorff F. 984<br />
Friedman B. 192<br />
Friedrich M.G. 928<br />
Frimodt-Møller P.C. 593<br />
Fritsche H.M. 35, 36, 37, 38, 43, 199,<br />
322, 323, 326, 923, 1027<br />
Fritzer A. 732<br />
Frohme C. 233<br />
Frohneberg D. 679, 683, 686, 832,<br />
838, 1009, 1013<br />
Fromont G. 669, 875<br />
Frühbauer J. 149<br />
Frumenzio E. 395<br />
Fucci G. 197<br />
Fuhllase C. 933<br />
Fujihara A. 697<br />
Fujii Y. 12, 20, 45, 47, 56, 165, 591,<br />
839, 897, 927, 964, V1, V4<br />
Fujimoto K. 143, 1008<br />
Fujimoto N. 859<br />
Fujisaki A. 889<br />
Fujisawa M. 459<br />
Fujita T. 925<br />
Fujiwara J. 697<br />
Fukasawa M. 119, 170, 698<br />
Fukuda M. 858<br />
Fukui I. 16, 20, 56, 106, 165, 591,<br />
839, 964<br />
Fukuma Y. 751<br />
Fukushima H. 927<br />
Furuya Y. 861<br />
Fusco F. 229, 526<br />
Füssel S. 473, 569, 572, 665, 747<br />
Füssle R. 487<br />
Fütterer J.J. 584<br />
G<br />
Gaafar S. 219<br />
Gaboardi F. 236, V11, V34<br />
Gacci M. 634<br />
Gadda G. 81, 82, 542, 828, 836<br />
Gafanov R.A. 901<br />
Gaffory C. 812<br />
Numbers refer to abstract numbers
Gagiu C. 429<br />
Gagnat A. 875<br />
Gagnier P. 990, 991<br />
Gainsburg D.M. 800<br />
Gajewski J.B. 646, 696<br />
Gakis G. 30, 31, 316, 515, 1018, 1056<br />
Galante Romo I. 285, 312<br />
Galeano C. 331<br />
Galeone G. 114<br />
Galì A. 163<br />
Galiano M. 175, 759, 793, 835, 841<br />
Gallien P. 516<br />
Gallina A. 32, 81, 82, 83, 133, 158,<br />
172, 422, 577, 609, 615, 620,<br />
836, 907, 917, 1010<br />
Galliot I. 415, 463<br />
Gallistl H. 245<br />
Gallo A. 105<br />
Gallo D. 863<br />
Gallo L. 105<br />
Galloway N.T. 398<br />
Gallucci M. 154, 320, 448, 536,<br />
1029<br />
Gallè G. 979<br />
Gam S.C. 78, 178<br />
Gamelin E. 853<br />
Gamé X. 317, 521<br />
Gandaglia G. 827, 836<br />
Gandelman K. 274<br />
Gankovskaya L. 361<br />
Gans M. 487<br />
Ganzer R. 941, 942, V45<br />
Gao X. 435<br />
Garaffa G. 250, 530<br />
Garaganis G. 208<br />
García D. 1037<br />
Garcia M. 27, 966<br />
Garcia Mediero J.M. 325, V19<br />
Garcia Navas R. 244<br />
Garcia Tello A. 202, V19<br />
García-Cañas A. 492<br />
García-Casado Z. 670<br />
Garcia-Closas M. 42<br />
Garcia-Closas R. 42<br />
García-Cruz E. 972<br />
Garcia-Diez M. 955<br />
Garcia-Lopez F. 42<br />
Garcia-Rojo D. 42, 209, 419<br />
García-Tello A. 325, 489, 492, 493<br />
Gardi M. 234<br />
Gardner P. 280<br />
Garmo H. 134, 612, 755<br />
Garofalo M. 829, 833<br />
Garza R. V2<br />
Gashignard N. 906<br />
Gasser T.C. 460, 891<br />
Gastol P. 658<br />
Gausa L. 1042<br />
Gavazzi A. 62<br />
Gavin A. 963<br />
Gaya J.M. V31<br />
Gazi E. 280<br />
Gazquez C. 813<br />
Gazzaniga P. 929<br />
Geavlete B.F. 596, 885, V25, V26<br />
Geavlete P.A. 596, 885, V23, V25,<br />
V26<br />
Gebska M.A. 80<br />
Geiges G. 991<br />
Gelabert-Mas A. 42<br />
Gelbke R. 86<br />
Gelet A. 940, 941, 942<br />
Gelikonov V.M. 637<br />
Gencer E. 303<br />
Genin C. 289<br />
Gentil-Perret A. 289<br />
Gentile B.C. 886<br />
Gentile V. 381, 707, V40<br />
Gentilucci A. 707<br />
Georgescu D.A. 596, 885, V23, V25,<br />
V26<br />
Geppetti P. 819<br />
Germann M. 282<br />
Gernone A.G. 896<br />
Gerullis H. 242, 256, 1051<br />
Gerwens N. 199<br />
Geryk B. 298<br />
Geutjes P.J. 252, 253<br />
Ghaly A.M. 653<br />
Ghawidel C. 245<br />
Ghazal G. 540<br />
Ghazi A. 795<br />
Ghoneim M.A. 408, 653<br />
Ghoneim T. 414<br />
Ghorbel J. 166<br />
Ghozzi S. 166<br />
Ghulam N. 757<br />
Giammusso B. 527<br />
Giancane S. 634<br />
Giannantoni A. 91, 644<br />
Giannarini G. 822, 1015<br />
Giannoni E. 278<br />
Gianolli L. 155<br />
Giardiello G. 513<br />
Gidaro S. V6, V8<br />
Giedelman C. V2, V5<br />
Giedl J. 815<br />
Giesinger J. 732<br />
Giessing M. V12<br />
Gigante M. 289, 415, 463<br />
Gil M. 340<br />
Gil Diez De Medina S. 814<br />
Gilbert H.W. 884<br />
Giliberto G.L. 1025<br />
Gilio F. 524<br />
Gill H.S. 879<br />
Gill I. 441, 544, V2, V5<br />
Gillespie J.I. 129<br />
Gillitzer R. 375<br />
Gillo A. 39<br />
Gimlin D. 406<br />
Gingu C. 293, 382<br />
Giocoli Nacci G. 114<br />
Giovacchini G. 155<br />
Giovannozzi S. 91, 644<br />
Girardin S. 574<br />
Girman C.J. 503<br />
Gittelman M. 141<br />
Giugliano F. 3<br />
Giulianelli R. 886<br />
Giuliano F. 128, 130, 131, 268, 269<br />
Giusti G. 5, 535, 594<br />
Gjengstø P. 599<br />
Gleason J. 50<br />
Gleave M.E. 826<br />
Glorioso J. 117<br />
Gnanarajah D. 488<br />
Goble S. 140<br />
Godoy G. 1034<br />
Goh M.H.C. 884<br />
Gohel M.D.I. 223<br />
Goicoechea Maturana I. 264<br />
Goins W. 117<br />
Gökçe A. 737<br />
Gökce M.I. 739<br />
Golan M. 855<br />
Golan S. 1043<br />
Numbers refer to abstract numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
487
Abstract Authors<br />
Gold R. 765<br />
Goldfischer E. 994<br />
Goldin D. 192<br />
Gomez V. 331<br />
Gómez-Ferrer A. 837<br />
Gómez Pérez L. 695<br />
Gomez Sancha F. V44<br />
Gonçalves F.E.C. 142<br />
Gontero P. 24, 39, 61, 679, 683, 686,<br />
820, 832, 838, 970, 980, 1009,<br />
1013<br />
Gonul I.I. 808<br />
Gonzalez J. 202, 489, V28<br />
Gonzalez J.M. 284, 672<br />
Gonzalez L.O. 284, 672<br />
Gonzalez Lopez R. 244<br />
Gonzalez-Reyes S. 284, 672<br />
Gonzalez-Sala J.L. 419<br />
González De Chaves E. 188<br />
González-Torralba A. 492<br />
Goodman C.M. 807<br />
Gopar P. 949<br />
Goretzki P. 1051<br />
Gorgal T. 629, 995<br />
Gorny D. 131, 269<br />
Górski A. 374<br />
Gorur S. 737<br />
Goss J. 117<br />
Gotoda H. 708<br />
Gotoh M. 241, 1002<br />
Gowardhan B. 357<br />
Goyal A. 848, 849<br />
Gozzi C. 240<br />
Graafland N.M. 555, 559<br />
Grabski B. 113<br />
Graefen M. 24, 40, 41, 61, 103, 132,<br />
288, 619, 679, 680, 681, 684,<br />
686, 792, 799, 832, 908, 970,<br />
977, 980, 1009, 1013<br />
Granata A. 236, V11, V34<br />
Grande S. 347, 534, 538, V24<br />
Grasso M. 302<br />
Gratzke C.J. 80, 548, 553, 597<br />
Graziotti P. 5, 594<br />
Greco F. 163, 344, 539<br />
Green J. 90, 101<br />
Greenleaf J. 717<br />
Greenspan M. 587<br />
Greenstein A. 598<br />
488 Programme Book<br />
Gregori A. 236, V11, V34<br />
Grigoriev M. 361<br />
Grima F. 752<br />
Grimm M.O. 109, 569, 747<br />
Grimsley S.J.S. 882<br />
Grise P. 128, 148<br />
Grobholz R. 29, 146<br />
Groen J. 243<br />
Gröschl I. 460<br />
Groskopf J. 871, 975, 976<br />
Gross M.L. 452<br />
Gross O. 893<br />
Grosseti B. 397<br />
Grundy D. 126<br />
Grunenwald E. 451<br />
Grünwald V. 95, 97<br />
Gschwend J.E. 157, 688, 824, 868,<br />
930, 1006<br />
Guaglianone S. 154, 320, 448, 536,<br />
1029<br />
Guagnini F. 302, 633<br />
Guan Z. 779<br />
Guate J.L. 42<br />
Guazzoni G. 32, 81, 83, 204, 422,<br />
450, 542, 577, 609, 615, 682,<br />
763, 827, 828<br />
Gucuk A. 739<br />
Gudima I.A. 370, 482, 485<br />
Guercio E. V21<br />
Guercio S. V21<br />
Guette C. 853<br />
Guidi M. 829<br />
Guillaume G. 601<br />
Guillonneau B. 677, 943, 1005<br />
Guillotreau J. 317, 521<br />
Gulen M.F. 649<br />
Gulino G. 184, 723<br />
Gülpınar O. 303<br />
Gulur D.M. 884<br />
Gunawan B. 572<br />
Guner N.D.G. 479<br />
Gupta A. 37, 38, 915, 1027<br />
Gurgan T. 432<br />
Gurocak S. 808<br />
Gurung P. 108<br />
Gustafsson J.A. 182<br />
Gutiérrez J. 1<br />
Guy L. 415, 463, 752<br />
Guy P. 956<br />
Gyomber D.V. 914<br />
H<br />
Ha M.S. 273, 277, 631<br />
Ha S.B. 60<br />
Ha U.S. 76, 87, 369<br />
Haab F. 783<br />
Haag S. 200<br />
Haag-Molkenteller C. 92<br />
Haas G.P. 583<br />
Haber G.P. 544<br />
Hacek J. 651<br />
Häcker A. 545<br />
Hackett G. 306<br />
Hadaschik B.A. 826, 1004, 1022,<br />
V41<br />
Hadj Slimen M. 411<br />
Haeberle L. 11<br />
Haefner T. 757<br />
Haese A. 24, 61, 103, 619, 680, 681,<br />
684, 792, 799, 908, 970, 977,<br />
980<br />
Haferkamp A. 36, 226, 445, 570,<br />
1004, 1022, V41<br />
Hafez A.T. 653<br />
Hageman M.P. 733<br />
Hagen T. 410<br />
Häggström C. 945<br />
Haider M. 715, 937, 944<br />
Haifler M. 211<br />
Hainagiu L. 7<br />
Haineala B. 429<br />
Hakenberg O.W. 456, 547<br />
Hakulinen T. 969<br />
Hall P. 14<br />
Hallmans G. 945<br />
Hallouin P. 610, 711<br />
Ham W.S. 65, 107, 588, 590, 760<br />
Hamajima H. 782<br />
Hamann M.F. 520, 549<br />
Hamano T. 751<br />
Hambrock T. 584<br />
Hamdy H.A. 345<br />
Hamdy F. 816<br />
Hamid R.A. 358<br />
Hamid R. 522<br />
Hammar N. 755<br />
Hammerschmied C. 572<br />
Hampel C. 200, 375<br />
Numbers refer to abstract numbers
Hamza A. 344, 465<br />
Han B. 859<br />
Han C.H. 87, 212<br />
Han J.H. 168, 471, 483, 981<br />
Han J.Y. 186<br />
Han J.Y. 655, 806<br />
Han K.S. 65, 319, 510, 588, 590,<br />
895<br />
Han S.W. 760<br />
Han W.K. 65, 466, 588, 760<br />
Hanci V. 376<br />
Haneda Y. 119, 170, 698<br />
Hanisch J.U. 75<br />
Hanna S. 194, 690<br />
Hannaoui N. 209, 419<br />
Hannen J. 101<br />
Hansen L. 766<br />
Hanus T. 205, 651<br />
Hara N. 947<br />
Harel M. 779<br />
Harewood L. 914<br />
Harke N. V35, V38<br />
Harnett M.D. 141<br />
Harris C. 863<br />
Hart C.A. 280<br />
Hartmann A. 43, 326, 572, 722, 815,<br />
824, 923, V45<br />
Hartmann W. 568<br />
Harza M. 382, 429<br />
Hasan M.N. 15<br />
Hascicek M. 432<br />
Hasegawa T. 708<br />
Hashimto Y. 720, 858<br />
Hatakeyama S. 720, 858<br />
Hatano T. 287<br />
Hatiboglu G. 226<br />
Hatoupis K. 208<br />
Hattori K. 889<br />
Hattori R. 241, 1002<br />
Hatzichristou D. 304<br />
Hatzimouratidis K. 304<br />
Hauser S. 568<br />
Haustermans K. 153, 948<br />
Hawkes D. 69<br />
Hayward E. 89<br />
Heck M.M. 688, 868, 1006<br />
Hedelin H. 237<br />
Heenan S. 556<br />
Heesakkers J.P.F.A. 120, 500, 781<br />
Hefermehl L.J. 798, 893<br />
Hegele A. 233, 350, 416<br />
Heidenreich A. 238, 728, 730, 744,<br />
898, 899<br />
Heinzelbecker J. 149<br />
Heinzer H. 103, 565, 619, 680, 681,<br />
684, 792, 799, 908, 928<br />
Helczynski L. 863<br />
Helenius G. 551<br />
Hell J. 545<br />
Hellmich G. V16<br />
Helmy S. 342<br />
Helwig J.J. 573<br />
Hemmerich M. 547<br />
Henk H.J. 100, 903<br />
Hennenlotter J. 26, 30, 31, 53, 254,<br />
567, 710, 862, 978<br />
Herkommer K. 688, 868, 1006<br />
Hermanns T. 893<br />
Hernandez A. 441<br />
Hernández E. 493<br />
Hernandez J.E. 202<br />
Hernández V. 1037<br />
Hernandez-Fernandez C. 336, 453<br />
Hernando Arteche A. 285<br />
Herr H. 1034, 1035<br />
Herr I. 452<br />
Herranz-Amo F. 336<br />
Herrera E. V5, V18<br />
Herrmann E. 36<br />
Herrmann J. 473<br />
Herrmann T. 416, 446, 504, 756<br />
Hessels D. 974<br />
Hetzer F. 703<br />
Heuer R. 565<br />
Hickerton B. 652<br />
Hideki E. 44<br />
Higano C. 905<br />
Hijaz A. 1048, 1050, 1053<br />
Hindley R. 936<br />
Hinnen K.A. 613<br />
Hioka T. 708<br />
Hirano D. 206<br />
Hirao Y. 143, 1008<br />
Hirmand M. 905<br />
Hirsch K. 654<br />
Hlasny E. 937<br />
Ho H.S.S. 59, 167<br />
Ho K.F. 314<br />
Ho R. 327, 915<br />
Hocaoglu Y. 240, 597<br />
Hoda M.R. 344, 396, 465, 539<br />
Hodgson D.J. 958<br />
Hoefner K. 887<br />
Hoeks C.M.A. 713<br />
Hoffman M. 392<br />
Hofmann R. 233, 350, 416<br />
Höfner T. 36, 1004, 1022<br />
Hohenfellner M. 36, 226, 445, 570,<br />
1004, 1022, V41<br />
Hohwü L. 920<br />
Holland D. 570<br />
Holmberg E. 608, 909, 965<br />
Holmberg L. 134, 608, 612, 755<br />
Holmström B. 909<br />
Holmäng S. 328<br />
Holz A. 794<br />
Holzner B. 732<br />
Homma T. 638<br />
Homma Y. 638<br />
Honeck P. 351<br />
Hong B. 212<br />
Hong J.H. 177, 324, 439, 719<br />
Hong M. 918<br />
Hong S.H. 76<br />
Hong S.J. 65, 319, 510, 588, 760,<br />
895<br />
Hong S.K. 60, 104, 239, 673, 823,<br />
825, 866, 912, 1001<br />
Honjo H. 782<br />
Honma S. 626<br />
Hoppe-Seyler F. 570<br />
Hoppe-Seyler K. 570<br />
Horenblas S. 101, 555, 559<br />
Horgan A. 99<br />
Hori S. 171<br />
Horn T. 157, 868<br />
Hornberg J. 179<br />
Horninger W. 150, 985<br />
Hosker G.L. 696<br />
Hossain H. 490<br />
Hosseini A. 1026<br />
Hosseini J. 390<br />
Hosseini M.M. 9<br />
Hosseini Niashiran D. 9<br />
Høstmark J.G. 599<br />
Hotakainen K. 926<br />
Hotze T. 915<br />
Numbers refer to abstract numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
489
Abstract Authors<br />
Hou J.C. 1048<br />
Houlgatte A. 986<br />
Høyer-Hansen G.H. 144<br />
Hoznek A. 63, 691, 840, V22<br />
Hricik T.R. 878<br />
Hripko N. 1014<br />
Hruza M. 788<br />
Hsu C.Y. 679, 832, 838, 1009<br />
Hsu R. 523<br />
Hu Y. 69<br />
Huang C.H. 77<br />
Huang H.S. 224, 474<br />
Huang H.X. 435<br />
Huang I.I.L. 574<br />
Huang S.P. 77<br />
Huber A. 967<br />
Huber E. 245<br />
Huber J. 226, 445<br />
Huber S. 53, 216<br />
Hubert J. 415, 463<br />
Hübner W. 245<br />
Hudak L. 145<br />
Huergo F. 42<br />
Hughes D. 815<br />
Hugosson J. 608, 611, 909, 962,<br />
963, 965<br />
Huguet Pérez J. 343, 972<br />
Huisman H.J. 713<br />
Huland H. 132, 619, 680, 681, 684,<br />
792, 799, 928, 1014<br />
Hulsbergen-Van De Kaa C.A. 584,<br />
622, 713, 931, 932<br />
Humphrey P.A. 815<br />
Hung S.F. 224<br />
Hungerhuber E. 548<br />
Hussein A.F. 426<br />
Hussein H.A. 232<br />
Hutterer G.C. 286, 294<br />
Hutton C. 678<br />
Huyghe E. 173, 540<br />
Huynh N.N. 306<br />
Hwang E.G. 627<br />
Hwang S.I. 104, 912<br />
Hyodo Y. 459<br />
Hyun J.S. 78, 178, 222, 273, 277,<br />
483, 981<br />
I<br />
Iacone M. 694<br />
490 Programme Book<br />
Iadevaia M. 1041<br />
Iannello A. V46<br />
Ibishev H.S. 370, 482, 485<br />
Iborra F. 906<br />
Iborra I. 670, 837, 1038<br />
Ibrahiem E.I. 346, 1036<br />
Ichino M. 1058<br />
Ichinose T. 394<br />
Ierardi A. 278<br />
Igarashi T. 206<br />
Igawa Y. 638, 1044, 1058<br />
Iguchi T. 934<br />
Ikeda T. 143, 1008<br />
Ilat S. 6<br />
Iliescu B. V9<br />
Imamura T. 638, 1044<br />
Imanishi K. 720, 858<br />
Imbimbo C. 229, 526<br />
Imkamp F. 756<br />
Impedovo S. 338<br />
Incarbone G.P. 236, V11, V34<br />
Inci K. 432<br />
Inferrera A. 163, 539<br />
Ingelmo-Torres M. 55, 813<br />
Ingelsson E. 134<br />
Inghilleri M. 524<br />
Inglese E. 1012<br />
Inoue M. 934<br />
Inoue T. 143<br />
Intermite I. 114<br />
Intilla O. 694, V17<br />
Inuduka Y. 170<br />
Inuzuka H. 119, 121, 698<br />
Ioakeimidis N. 176<br />
Ioannis I.I. 203<br />
Ippolito C. 246<br />
Irani J. 24, 61, 415, 463, 669, 875,<br />
977, 980<br />
Irrera N. 632<br />
Isahaya E. 947<br />
Isbarn H. 35, 41, 322, 565, 619, 680,<br />
681, 684, 792, 908, 1013<br />
Iselin C. 386<br />
Ishibashi K. 507<br />
Ishida M. 290<br />
Ishii C. 45, 47<br />
Ishikawa Y. 839<br />
Ishimura T. 459<br />
Ishizuka O. 638, 1044<br />
Isidori I.A. 854<br />
Ismail R. 341, 458<br />
Ismail S. 522<br />
Istanbulluoglu M.O. 359<br />
Ito K. 136, 888, 968<br />
Ito M. 16<br />
Itoh N. 771<br />
Ivaz S. 554<br />
Iversen P. 144<br />
Iwabuchi T. 889<br />
Iwamoto Y. 447<br />
Iwamura M. 925<br />
Izawa J.I. 35, 199, 322, 323<br />
Izquierdo L. 337, 813<br />
J Jabbari M. 390<br />
Jacobs J.F.M. 564<br />
Jacobsen S.J. 50, 503<br />
Jacobson D.J. 503<br />
Jacqmin D. 193, 573<br />
Jacques J. 970<br />
Jaeger W. 375<br />
Jäger W. 200<br />
Jagota A. 911<br />
Jahnson S. 328, 922<br />
Janetschek G. 645<br />
Jang H.A. 399<br />
Jang L. 442<br />
Jänisch S. 567<br />
Janjua K.S. 54<br />
Jankevicius F. 452<br />
Jans J.J.M. 576, 761<br />
Jansen C.F.J. 120, 283, 931, 932<br />
Jansen O. 520<br />
Janssen D.A.W. 120<br />
Janssen M.W.W. 457<br />
Jarolim L. 865<br />
Jarzemski P. V39<br />
Jecu M. 885, V26<br />
Jeldres C. 40, 41, 288, 769, 792<br />
Jensen J.B. 318<br />
Jensen K.M. 318<br />
Jentzmik F. 571<br />
Jeon H.G. 466, 895<br />
Jeon S.H. 636<br />
Jeon S.S. 543<br />
Jeong B.C. 472, 543<br />
Jeong C.W. 60, 758<br />
Numbers refer to abstract numbers
Jeong H. 60, 472, 662, V27<br />
Jeong I.G. 324, 439, 719<br />
Jeong S.J. 104, 239, 673, 754, 823,<br />
825, 866, 912, 1001<br />
Jeong T.W. 603<br />
Jeong W.J. 107, 590<br />
Jeschke K. 533, 541<br />
Jewett M.A.S. 51, 52, 99, 194, 195,<br />
321, 715<br />
Jewett M.J. 464<br />
Jiang L.H. 356<br />
Jichlinski P. 1045<br />
Jievaltas M. 19, 946<br />
Jiménez M.A. 331, 693, 705<br />
Jiménez-Cruz J.F. 592<br />
Jimenez-Pacheco A. 467, 484<br />
Jin H.R. 186, 301<br />
Joachimiak R. 248<br />
Joannides A. 171<br />
Jocham D. 478<br />
Joerg T. 26<br />
Johannsen M. 95<br />
Johansen D. 945<br />
Johansen T.E. 766<br />
Johansson J.E. 608, 870, 909<br />
Johns-Putra L. 575<br />
Johnson M.I. 1024<br />
Johnson P. 357<br />
Johnson T.M. 784<br />
Jonas D. 145<br />
Jonas U. 183<br />
Jonasch E. 762<br />
Jonca F. 585<br />
Jones A. 614, 951<br />
Jones J. 375<br />
Jones J.C. 614<br />
Jones L. 397<br />
Jones N. 921<br />
Joniau S. 153, 389, 679, 683, 686,<br />
832, 838, 948, 1009, 1013<br />
Jonsson H. 945<br />
Jonsson N.M. 1026<br />
Jonsson O.K. 660<br />
Joo K.J. 137, 477<br />
Joseph J.V. 795<br />
Joseph W. 778<br />
Jou Y.C. 355, 924<br />
Jouan F. 562<br />
Jouin P. 566<br />
Joulin V. 580<br />
Joung J.Y. 28<br />
Joutsi T. 971<br />
Jovanovic M. 1021<br />
Ju H.J. 590<br />
Juengel E. 145<br />
Jumadilova Z. 274<br />
Junaid I. 8, 230<br />
Jünemann K.P. 86, 261, 520, 549<br />
Jung H. 50<br />
Jung H. 66, 271<br />
Jung H.C. 222, 400, 404, 481, 505,<br />
992<br />
Jung H.U. 593<br />
Jung H.J. 510<br />
Jung J.H. 78, 178<br />
Jung J.L. 631<br />
Jung K. 745, 984<br />
Jung M. 745<br />
Jung S.I. 1020<br />
Jung S.J. 481<br />
Jung T.Y. 107<br />
Jung V. 146, 744<br />
Jung Y.B. 881<br />
Jungner I. 755<br />
Jungwirth A. 75<br />
Junius S. 948<br />
Junker K. 98, 550, 572, 722<br />
Junquera S. 284, 672<br />
Jurgen J.J. 713<br />
Just L. 258<br />
Juszczak K. 122<br />
K<br />
Kaabak M.M. 461<br />
Kaag M. 438, 1035<br />
Kachakova D. 748<br />
Kahl P. 568<br />
Kaiser S. 569<br />
Kajbafzadeh A.M. 657<br />
Kajioka S. 267, 1046<br />
Kakiashvili D.M. 195<br />
Kakies C. 547<br />
Kalinowski R. V39<br />
Kaliska V. 865<br />
Kallidonis P. 757, 890<br />
Kalogirou C. 856<br />
Kalsi J.S. 430, 431<br />
Kalthoff H. 549<br />
Kamal M. 408<br />
Kamat A.M. 323<br />
Kamecki K. 1032<br />
Kamimura N. 720, 858<br />
Kamin B. 704<br />
Kamiyama M. 119, 121, 170, 698<br />
Kampel-Kettner K. 286, 294<br />
Kamradt J. 29, 146<br />
Kanaroglou N. 587<br />
Kancherla K. 560<br />
Kaneta T. 708<br />
Kaneva R. 748<br />
Kang K.M. 709<br />
Kang S.H. 508, 582, 1020<br />
Kang S.G. 1020<br />
Kang W.M. 227<br />
Kaploun A. 192<br />
Kaprin A.D. 901<br />
Kara O. 432<br />
Karakiewicz P.I. 33, 35, 37, 38, 40,<br />
41, 172, 199, 288, 322, 323, 327,<br />
577, 619, 680, 681, 684, 769,<br />
792, 827, 828, 907, 917, 926,<br />
1027<br />
Karam G. 415, 463<br />
Karam J.A. 762<br />
Karami H. 4, 353<br />
Karaolides T. 162, 950<br />
Karavitakis M. 843<br />
Karbalaei M. 275<br />
Karellas E. 442<br />
Karig R. 1051<br />
Karl A. 36, 1039<br />
Karlsson M. 15<br />
Karlsson M.G. 551<br />
Karmasova K. 160<br />
Karnes J. 133, 620<br />
Karthaus H.F. 584<br />
Kashiwagi B. 626<br />
Kasraeian A. 841<br />
Kassouf W. 33, 35, 37, 38, 199, 322,<br />
323, 1027<br />
Kasyan G.R. 185, 637<br />
Kata S.G. 1030<br />
Katie K. 500<br />
Katkoori D. 607, 1033<br />
Kato C. 393<br />
Katsuya K.N. 454<br />
Katz D. 677<br />
Numbers refer to abstract numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
491
Abstract Authors<br />
Kauffels W. 183<br />
Kaura S. 100, 903<br />
Kava B. 607<br />
Kaviani A. 390<br />
Kavran M. 1048, 1053<br />
Kawahara K. 821<br />
Kawakami S. 12, 20, 45, 47, 56, 106,<br />
165, 591, 839, 897, 927, 964,<br />
V1, V4<br />
Kawan F. 539<br />
Kawashima H. 934<br />
Kawauchi A. 697, 782<br />
Kaya Y.S. 737<br />
Kaznica A. 248<br />
Kazutaka K. 20<br />
Ke H.L. 77<br />
Keane T.E. 939<br />
Keck B. 923<br />
Kedia G.T. 623, 628, 1054<br />
Keil C. 350<br />
Keilholz U. 95<br />
Kell A. 565<br />
Keller H. 383, V30, V43<br />
Kempkensteffen C. 95<br />
Kempter J.U. 892<br />
Kennedy A.M. 989<br />
Kenny S. 652<br />
Keren-Paz G. 598<br />
Kerger M. 918<br />
Kerrin Palazzi-Churas K. 765<br />
Kerschbaumer A. 262, 334<br />
Kesavan A. 818<br />
Keshishev N.G. 159, 901<br />
Keskin U. 511<br />
Kessels A.G.H. 772<br />
Kessler T.M. 512, 702, 772, 1015<br />
Ketata H. 411<br />
Khalil S. 10<br />
Khan M.A. 152<br />
Khan M.S. 88<br />
Khan M.S. 1028<br />
Khan S. 1057<br />
Khan S.R. 468<br />
Khedis M. 451, 540<br />
Khoder W. 796, 830, V45<br />
Khoshrang H. 6<br />
Khouni H. 166<br />
Kihara K. 12, 20, 45, 47, 56, 106,<br />
165, 591, 897, 927, 964, V1, V4<br />
492 Programme Book<br />
Kijima T. 16, 56, 897<br />
Kikidakis D. 218<br />
Kikuchi E. 290<br />
Kil P. 24, 61, 970, 977, 980<br />
Kiliçkesmez M. 220<br />
Kiltie A.E. 560<br />
Kim B.S. 709<br />
Kim B.H. 400, 404, 481, 992<br />
Kim C.S. 324, 439, 719<br />
Kim C.I. 481, 992<br />
Kim D.I. 880<br />
Kim D.S. 104, 239, 673, 823, 825,<br />
866, 912, 1001<br />
Kim D.S. 116<br />
Kim D.B. 76, 369<br />
Kim D.Y. 400, 404, 481, 992<br />
Kim E.D. 306<br />
Kim G.N. 400, 404<br />
Kim G.H. 319, 588<br />
Kim H.H. 60, 472, 662, 758, 1020<br />
Kim H.J. 631<br />
Kim H.J. 631<br />
Kim H.J. 785<br />
Kim H.K. 138<br />
Kim H.R. 471<br />
Kim H.S. 543<br />
Kim H.S. 627<br />
Kim H.T. 222, 505<br />
Kim J.C. 87, 785<br />
Kim J.H. 239, 754<br />
Kim J.I. 124<br />
Kim J.J. 73, 174, 508, 582<br />
Kim J.K. 719<br />
Kim J.M. 222, 505<br />
Kim J.S. 277<br />
Kim J.W. 439<br />
Kim K.D. 273<br />
Kim K.H. 66, 271<br />
Kim K.H. 107, 466, 590<br />
Kim K.H. 400, 404<br />
Kim K.K. 227<br />
Kim K.S. 655, 806<br />
Kim M.K. 881<br />
Kim M.S. 273<br />
Kim M.S. 466<br />
Kim S.C. 324<br />
Kim S.D. 76, 369<br />
Kim S.I. 161<br />
Kim S.J. 76<br />
Kim S.J. 138<br />
Kim S.J. 161<br />
Kim S.J. 161<br />
Kim S.O. 1052<br />
Kim S.U. 624, 666<br />
Kim S.W. 76, 369, 881<br />
Kim S.W. 311, 883<br />
Kim T.B. 66, 271<br />
Kim T.H. 709<br />
Kim T.H. 273, 277, 483, 631, 981<br />
Kim T.K. 99<br />
Kim W.J. 186, 301<br />
Kim W.J. 107<br />
Kim W.S. 543<br />
Kim W.Y. 277<br />
Kim Y.S. 161, 785<br />
Kim Y.S. 466<br />
Kimura T. 393<br />
Kincius M. 946<br />
Kinder R.B. 884<br />
King D. 914<br />
Kinnick R. 717<br />
Kinter T. 717<br />
Kiper A.N. 737<br />
Kira S. 119, 121, 170<br />
Kirchner M. 149<br />
Kirillov S.V. 461<br />
Kirkali Z. 189<br />
Kirkeby H.J.K. 405<br />
Kirkham A. 156, 712<br />
Kirrander P. 551<br />
Kirschner-Hermanns R. 238<br />
Kiss B. 702, 1015<br />
Kiss G. 512<br />
Kissel J. 994<br />
Kitakoji K. 782<br />
Kitayama S. 165<br />
Kitsukawa S. 16, 839<br />
Kiyohiko K.H. 454<br />
Kiziloz H. 432<br />
Klak M. 374<br />
Klapsas V. 950<br />
Klatte T. 286, 294, 298, 437, 581,<br />
586<br />
Klein B. 86, 261<br />
Klein B. 211<br />
Kleinclauss F. 415, 463, 601<br />
Klevecka V. 112<br />
Kliment J.K. 142<br />
Numbers refer to abstract numbers
Klingeler R. 665<br />
Klingler H.C. 437<br />
Klippstein E. 545<br />
Klitsch M.C. 831<br />
Klocker H. 750, 985<br />
Klopf C. 911<br />
Klotz L.H. 664, 944<br />
Kneitz B. 683, 686, 753, 832, 838,<br />
856, 1009, 1013<br />
Kneitz S. 686, 856<br />
Knoll T. 351, 478, 480<br />
Knox J.J. 99<br />
Knuechel R. 1039, V45<br />
Ko K.W. 174<br />
Ko Y.H. 508, 582<br />
Kobayashi H. 119, 121<br />
Kobayashi K. 771<br />
Kobayashi M. 626, 968<br />
Kobayashi M. 859<br />
Kobayashi S. 45<br />
Kobayashi T. 507<br />
Kobayashi Y. 1031<br />
Kobori Y. 428<br />
Kobylarz K.A. 79<br />
Koci E. 491<br />
Kocjancic E. 397<br />
Kocot A. 412<br />
Kocvara R. 809<br />
Koga F. 12, 20, 45, 47, 56, 591, 897,<br />
927, 964, V1, V4<br />
Kogan M.I. 363, 370, 371, 380, 434,<br />
482, 485, 872<br />
Kogevinas M. 42<br />
Koh G.Y. 301<br />
Koh J.I. 624, 666<br />
Kohler K. 258<br />
Koie T. 720, 858<br />
Koike H. 136, 751, 861, 888<br />
Kojima S. 44<br />
Kojovic V. 249<br />
Kok D.J. 276<br />
Kok E.T. 201, 496, 499, 502<br />
Kolaric A. 551<br />
Koletsas N. 218<br />
Kolios L. 663<br />
Kollarik B. 298<br />
Kollias S.K. 518<br />
Komai Y. 16, 45, 47, 56, 591<br />
Komatsu T. 1002<br />
Komninos C. 843<br />
Konandreas A. 950<br />
Kondo T. 782<br />
Konemura T. 125<br />
Kong J. 519, 699<br />
Konishi N. 143, 1008<br />
Kono H. 290<br />
Konstantinovsky A. 192<br />
Kontos S. 843, 993<br />
Koo D.H. 883<br />
Kopsaftis T. 21, 910<br />
Koptsis M. 218<br />
Korac G. 249<br />
Körbel C. 146<br />
Kordan Y. V10<br />
Koritsiadis G. 967<br />
Koritsiadis S. 843, 993<br />
Korrovits P. 423<br />
Kortmann B.B.M. 252, 253<br />
Koryakin A.V. 159<br />
Kosaka T. 290<br />
Kosch M. 96<br />
Kosdak S. 511<br />
Kosevic J.B. 1021<br />
Kössler R. 911<br />
Koukounaras J. 210<br />
Koutsiaris E. 950<br />
Kovalchuk L. 361<br />
Kovalyov L.I. 987<br />
Kovalyova M.A. 987<br />
Kowalski M.M. 921<br />
Koyuncu H. 220<br />
Kraemer K. 665, 747<br />
Kramer M.W. 416, 446, 572<br />
Kramer-Marek G. 857<br />
Kranse R. 969<br />
Kraske S. 654<br />
Krasny S. 1019<br />
Krasulin V.V. 380<br />
Krause B.J. 157<br />
Krause F.S. 11<br />
Krause T.M. 1017<br />
Krasnicki K. 1032<br />
Kreiner B. 572<br />
Krekeler G. 96<br />
Kremensky I. 748<br />
Krengli M. 687<br />
Kribus S. 111<br />
Krings T. 893<br />
Krischel M. 842<br />
Kristiansen G. 667, 671, 743, 745<br />
Krivoborodov G.G. 643<br />
Kroepfl D. 112<br />
Kroesen J.M.P. 733<br />
Kroeze S.G.C. 576, 761<br />
Kröger N. 98<br />
Kron M. 1006<br />
Kruck S. 254, 515, 604, 862<br />
Krug J. 258<br />
Kruijssen L.J.W. 761<br />
Krupinov G.E. 689<br />
Krupskaya Y. 665<br />
Ku J.H. 60, 472, 662, 734, 758, 883<br />
Kübler H. 157, 688<br />
Kubo Y. 16, 106, 165<br />
Kucharcyzk W. 937<br />
Kuczyk M.A. 183, 416, 446, 504,<br />
567, 572, 623, 628, 663, 756,<br />
845, 1054<br />
Kudo S. 720, 858<br />
Kudo S. 119, 121, 698<br />
Kuefer R. 671<br />
Kuehs U. 26, 30, 31, 53, 862<br />
Kugler M. 756<br />
Kühn R. 718<br />
Kuhtz-Buschbeck J.P. 520<br />
Kuijuclu V.N. 689<br />
Kujala P. 68, 852<br />
Kulkarni S.B. V42<br />
Kumar P. 488<br />
Kumar P.V.S. 231, 951<br />
Kumon H. 1031<br />
Kumsar S. 511<br />
Kuncova J. 822<br />
Kural A.R. 791<br />
Kuratsukuri K. 934<br />
Kurosch M. 226<br />
Kurrer M. 967<br />
Kus E. 297<br />
Kushida N. 507<br />
Kuwayama T. 777, 783<br />
Kuznetsov R.A. 444<br />
Kwak C. 60, 472, 662, 758<br />
Kwak K.W. 471, 483, 981<br />
Kwiatkowski M. 967<br />
Kwon C.H. 137, 477<br />
Kwon D.D. 1052<br />
Kwon G.Y. 471<br />
Numbers refer to abstract numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
493
Abstract Authors<br />
Kwon J.B. 400, 404<br />
Kwon S.W. 510<br />
Kwon T. 806<br />
Kwon T.G. 400, 404, 709, 1020<br />
Kwon Y.W. 273, 277<br />
Kyan A. 720<br />
Kyriakides A. 773<br />
Kyriazis I. 890<br />
L<br />
La Framboise D. 512<br />
Labanaris A.P. 718<br />
Labat J.J. 403, 647<br />
Labus L. 259<br />
Lacave R. 814<br />
Lacombe L. 621<br />
Lacoste J. 1011<br />
Ladurner Rennau M. 750<br />
Laguna-Pes M.P. 299, 478, 725, 764<br />
Lähdesmäki H. 852<br />
Lahme S. 589, 600<br />
Lahoz-Garcia C. 467, 484<br />
Laihia J.K. 931<br />
Lam N.Y. 223<br />
Lam T. 54, 882<br />
Lam W. 552, 554, 556<br />
Lamb B.W. 90<br />
Lambe M. 134, 612, 755<br />
Lammers B.J. 256<br />
Lamrani D. 228<br />
Lamy P.J. 566<br />
Lanciotti M. 278<br />
Lang C. 692, 701<br />
Lang E. 211<br />
Lang H. 415, 463, 573<br />
Langenhuijsen J.F. 420<br />
Lantoine-Adam F. 630<br />
Lanzat P. 312<br />
Lapini A. 278, 443<br />
Larbi H. 166<br />
Larrinaga J. 675<br />
Larue S. 906<br />
Lasaponara F. 462<br />
Lask D. 1043<br />
Latil A. 630<br />
Lau D.H.W. 181<br />
Laube N. 475<br />
Laurila M. 68<br />
Laverman P. 421<br />
494 Programme Book<br />
Lavery H.J. 578, 800, 916<br />
Lavrus M.A. 380<br />
Lawler M. 989<br />
Lawrentschuk N. 575, 690, 715<br />
Lawson K. 123<br />
Lazzara A. 632<br />
Lazzeri M. 81, 377, 395, 542, 763<br />
Le Coguic G. 1011<br />
Leandri P. 585<br />
Lebdai S. 853<br />
Lebret T. 415, 463, 869<br />
Lebwohl D. 97<br />
Lecea Lopez B. 264<br />
Lecouvet F. 894<br />
Lee C.J. 239, 662, V27<br />
Lee D.H. 87<br />
Lee D.K. 124<br />
Lee E. 472, 662<br />
Lee E.S. 107, 673, 754, 823, 825<br />
Lee F. 523, 1057<br />
Lee H.J. 104, 912<br />
Lee H.J. 624, 666<br />
Lee H.M. 543<br />
Lee H.R. 76, 369<br />
Lee J.B. 212<br />
Lee J.G. 399, 508, 582, 785<br />
Lee J.H. 124<br />
Lee J.K. 60<br />
Lee J.S. 590<br />
Lee K.H. 28<br />
Lee K.Y. 66, 271<br />
Lee M.S. 66<br />
Lee M.Y. 277<br />
Lee S.B. 60, 472, 662, V27<br />
Lee S.E. 60, 104, 107, 239, 673, 823,<br />
825, 866, 912, 1001<br />
Lee S.H. 858<br />
Lee S.H. 116, 509<br />
Lee S.H. 161<br />
Lee S.H. 212<br />
Lee S.J. 124, 227<br />
Lee S.W. 603<br />
Lee S.W. 754<br />
Lee S.Y. 273, 631<br />
Lee T. 271<br />
Lee W.K. 104, 239, 673, 823, 825,<br />
866, 1001<br />
Lee Y.C. 77<br />
Lee Y.G. 227, 1020<br />
Lee Y.H. 510<br />
Lee Y.H. 65, 319, 588, 895<br />
Lee Y.S. 107, 590<br />
Lee Y.T. 981<br />
Lehmann J. 923<br />
Lehmann K. 967<br />
Lehmusvaara S. 852<br />
Leichtle U. 254<br />
Lein M. 745, 984<br />
Leino L. 931<br />
Lemaitre L. 414<br />
Lemberger R.J. 38<br />
Lenero E. 306<br />
Lenherr O. 589<br />
Lenzi L.A. 854<br />
Leon Rueda M.E. 285<br />
Leonardo L.C. 497, 724, 854<br />
Leoni L.M. 932<br />
Leprini G. 196, 197<br />
Lerner S.P. 199, 322, 323<br />
Leroy X. 414<br />
Lerut E. 153<br />
Leslie T.A. 767<br />
L’Esperance J. 765<br />
Letkiewicz S. 374<br />
Leuschner I. 549<br />
Leusmann D.B. 480<br />
Leventis L.A. 203<br />
Leveridge M.L. 464<br />
Levi Y. 251<br />
Levy B. 313<br />
L’Her J. 580<br />
Li D.L. 59<br />
Li F.J. 435<br />
Li G. 289<br />
Li H. 356<br />
Li M.L. 235<br />
Li W. 77, 435<br />
Li X. 274, 649<br />
Li X.M. 435<br />
Li Z.J. 435<br />
Liatsikos E. 757, 890<br />
Liberale F. 462<br />
Liberatore M. 714, 716<br />
Liberman D. 40, 41, 288, 769, 792<br />
Lichy M.P. 710<br />
Lidawi G. 64<br />
Lieber M.M. 503<br />
Liedberg F. 328, 478<br />
Numbers refer to abstract numbers
Lifeng Y. 661<br />
Lilja H. 878, 974, 982<br />
Lim E. 59<br />
Lim J.S. 627<br />
Lim K.T. 603<br />
Lim L. 101<br />
Lin C.T. 355<br />
Lin Y. 1048<br />
Lindner A. 211<br />
Lindner U. 937<br />
Lindner V. 573<br />
Lingeman J.E. 1<br />
Linse C. 103<br />
Lisi D. 707<br />
Lisitskaya K.V. 987<br />
Liske P. 589, 600<br />
Listopadzki S. V39<br />
Liu C.C. 77<br />
Liu G. 1048, 1050<br />
Liu L. 51, 52<br />
Liu M. 877<br />
Liu W. 260<br />
Livne P.M. 1043<br />
Ljungberg B. 328<br />
Llanes L. 606<br />
Llarena R. 675<br />
Lledo-Garcia E. 336, 453<br />
Llorente C. 1037<br />
Lo A. 223<br />
Lobik L. 494<br />
Loch A.C. 113<br />
Loch T. 113<br />
Lockhart J. 392<br />
Lockwood G.A. 961<br />
Lodde M. 621<br />
Loehrer D. 772<br />
Loeschmann P.A. 96<br />
Loeser A. 412<br />
Loftus B. 989<br />
Lohn M. 302<br />
Lokshin K.L. 373<br />
Long J.A. 415, 463, 906<br />
Long N. 685, 938<br />
Longo N. 229, 526<br />
Loo R. 50<br />
Loock P.Y. 601<br />
Lopes T.A. 642<br />
Lopez M.N. 904<br />
López-Guerrero J.A. 670<br />
Lopez Farre A.J. 312<br />
López-Fando Lavalle L. 693, 705<br />
López López A. 695<br />
Lopez-Luque A. 484<br />
Löppenberg B. 794<br />
Loran O.B. 987<br />
Lorusso A. 114<br />
Lorusso F. 2, 164<br />
Losa A. 763, 836<br />
Lotan Y. 33, 199, 322, 323, 327, 915,<br />
926<br />
Lotzkat U. 473<br />
Lovász S. 650<br />
Lowrance W.T. 438, 442<br />
Löyttyniemi E. 141<br />
Lu J.P. 860<br />
Lu M.J. 260<br />
Lucarelli G. 338<br />
Lucas C. 13<br />
Lucas M. 500<br />
Lucente A. 263<br />
Luciani L.G. 535<br />
Luger F. 979<br />
Lughezzani G. 40, 41, 115, 172, 288,<br />
542, 577, 619, 681, 763, 769, 792<br />
Luján Marco S. 592<br />
Lund L. 766<br />
Luo G. 435<br />
Luque De Pablos A. 336<br />
Lux M. 795<br />
Luyckx F. 403, 610, 647, 711<br />
Lycklama À Nijeholt A.A.B. 704<br />
Lynch T.H. 989<br />
M<br />
Ma M.C. 474<br />
Maan Z. 230, 602<br />
Maarouf A.M. 10, 221<br />
Maartinez V. 295<br />
Maass N. 238<br />
Määttänen L. 971<br />
Mabjeesh N. 64, 855<br />
Mabjeesh N.J. 598<br />
Mac Neil S. 1049<br />
Macaya C. 312<br />
Maccagnano C. 23, 70<br />
MacDonald G. 921<br />
Macek P. 205<br />
Macher-Goeppinger S. 570<br />
Machiels J.P. 894<br />
Madaan S. 225<br />
Madden F. 417<br />
Madero-Jarabo R. 188<br />
Madersbacher H. 656<br />
Madersbacher S. 292, 305, 501,<br />
533, 541, 787<br />
Madonia M. 632<br />
Maegawa M. 127<br />
Maestro De Las Casas M. 285<br />
Maffezzini M. 409, 1007<br />
Maga T. 204<br />
Magagna P. V29<br />
Magagnotti C. 973<br />
Maggi M. 75, 634<br />
Maglakelidze N. 330<br />
Magno C. 163<br />
Magri V. 364, 366<br />
Magrill D. 552, 557<br />
Mah S.Y. 509<br />
Mahdavi Zafarghandi M. 333<br />
Mahdavi Zafarghandi R. 333<br />
Mahendran R. 818<br />
Mahillo E. 312<br />
Maini C.L. 154<br />
Maj R. 932<br />
Majstorovic M. 249<br />
Malaguti S. 514<br />
Malats N. 42<br />
Malavaud B. 317, 521, 585, 876<br />
Malcolm J.B. 765<br />
Malentacchi F. 822<br />
Malet A. 419<br />
Malet J. 42<br />
Malhotra B. 274<br />
Mallick S. 752<br />
Malmström P.U. 328<br />
Malone P.R. 614, 951<br />
Malone P.S. 805<br />
Malossini G. 535<br />
Mamoulakis C. 764<br />
Managadze L. 330<br />
Manassero F. 247<br />
Mandron E. 402<br />
Manea I. 429<br />
Manferrari F. 829, 833<br />
Mangera A. 1049<br />
Mangiapia F. 229, 526<br />
Mangin P. 580, 752<br />
Numbers refer to abstract numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
495
Abstract Authors<br />
Mangione F. V21<br />
Manikas M. 452<br />
Manjer J. 945, 982<br />
Mannson W. 478<br />
Mannweiler S. 286, 294, 979<br />
Manoharan M. 607, 1033<br />
Månsson W. 328<br />
Manu M.A. 293, 382<br />
Manzi C. 3<br />
Marangi F. 184, 234<br />
Marberger M.J. 24, 296, 298, 323,<br />
437, 581, 586, 959, 977, 980<br />
Marcen R. 331<br />
Marcheix B. 451<br />
Marchioro G. 679, 683, 686, 687,<br />
832, 838, 1009, 1012, 1013<br />
Mareckova N. 160<br />
Mari M. 409, V21<br />
Maria M. 783<br />
Marignol L. 989<br />
Marini Bettolo C. 524<br />
Mario M. 935<br />
Marits P. 15<br />
Marketakis A. 162<br />
Maroto J.P. 94<br />
Marsh H. 225<br />
Marsh R. 357<br />
Marshall T. 776<br />
Marszalek M. 292, 533, 541<br />
Martens F.M.J. 781<br />
Martignoni G. 38<br />
Martin B. 562<br />
Martín J. 419<br />
Martin K. 456<br />
Martin L. 415, 463<br />
Martín M.D. 1037<br />
Martin X. 190, 674, 940<br />
Martin Morales A. 306<br />
Martínez A. 675<br />
Martinez M. 955<br />
Martinez-Piñeiro J.A. 188<br />
Martínez-Salamanca J.I. 38, 1027<br />
Martinez-Torres J. 484<br />
Martins Da Silva C.P. 642<br />
Martorana G. 829, 833<br />
Martos R. 419<br />
Maru S.M. 407<br />
Maruschke M. 456<br />
Maruyama O. 428<br />
496 Programme Book<br />
Maruyama S.M. 407<br />
Maruyama T. 125<br />
Marzook E. 219<br />
Marín-Aguilera M. 55<br />
Masahiko I. 44<br />
Masayuki N. 44<br />
Mascha M. 802<br />
Masenio P. 164<br />
Masieri L. 278<br />
Masiliunas J. 19<br />
Maso G. 687, 1012<br />
Mason R.J. 291<br />
Masood J. 8, 228, 230, 349, 595,<br />
602<br />
Massenio P. 2<br />
Massfelder T. 573<br />
Massoner P. 750<br />
Massoud R. 197<br />
Massoud W. V9<br />
Masters J.R. 625<br />
Masuda H. 839<br />
Masuda H. 12, 45, 47, 897, V1, V4<br />
Masuda T. 777, 783<br />
Masumori N. 771<br />
Matcaev A.B. 637<br />
Matcionis A.E. 363<br />
Matei D.V. V13<br />
Matei M. 429<br />
Mateo E. 492<br />
Mateos A. 42<br />
Mateos Caceres P.J. 312<br />
Mathias S.D. 776<br />
Mathieu R. 415, 463<br />
Matikainen M.P. 878<br />
Matin S.F. 762<br />
Matjosaitis A. 946<br />
Matsui H. 136, 751, 861<br />
Matsui Y. 826<br />
Matsukawa Y. 241, 1002<br />
Matsumoto E. 587<br />
Matsumoto K. 37, 38, 925, 1027<br />
Matsumoto T. 859<br />
Matsumura Y. 1008<br />
Mattelaer J. 957<br />
Mattern A. 75<br />
Matullo G. 820<br />
Matveev V.B. 579<br />
Matzkin H. 64, 598<br />
Maugeri O. 5, 535, 594<br />
Maul T. 30, 31<br />
Maurer S. 258<br />
Maurer T. 688, 868<br />
Mavilla L. 886<br />
May T. 192<br />
Mayer E.K. 789<br />
Mayer M.E. 240<br />
Mayer N. 152<br />
Mayor J. 705<br />
Mazerolles C. 876<br />
Mazloomfard M.M. 353, 390<br />
Mazzoli S. 360, 362, 365<br />
Mc Kay N.G. 123, 126<br />
Mc Nicholas T.A. 879<br />
McAndrew H.F. 652<br />
McCabe J.E. 913<br />
McGree M.E. 503<br />
McLoughlin J. 171<br />
McMahon S. 88<br />
Meacci F. 360, 362, 365<br />
Mearini E. 91, 988<br />
Mearini L. 395<br />
Mecz Y. 192<br />
Mege Lechevallier F. 674<br />
Mehmet M.D. 479<br />
Mehnert U. 518<br />
Mehrazin R. 765<br />
Mehrsai A.R. 996, 998<br />
Mehrsai A. 749<br />
Mehta D. 878<br />
Meier-Drioli S. 245<br />
Meijer R.P. 201<br />
Meinhardt W. 101, 555<br />
Meixl H. 533, 541<br />
Mejean A. 415, 463<br />
Mejia C. V5, V15<br />
Melchior D. 261<br />
Melides P. 208<br />
Melloni D. 49, 191, 1041<br />
Melone F. 62<br />
Menard J. 102, 529<br />
Menard S. 102<br />
Menger M.D. 146<br />
Mengual L. 55, 813<br />
Mercimek M.N. 810<br />
Merks B.T. 738<br />
Merseburger A.S. 416, 446, 567,<br />
572, 756<br />
Mertens C. 568<br />
Numbers refer to abstract numbers
Messa C. 155<br />
Meyer D. 517, 703<br />
Meyer H.A. 984<br />
Meyer M. 183<br />
Mhiri M.N. 411<br />
Miah S. 816<br />
Micali S. V14, V36<br />
Michel M.C. 778<br />
Michel M.S. 36, 149, 351, 545<br />
Michels L.M. 518<br />
Mickisch G.H. 94<br />
Miclea F. 645<br />
Midori M.M. 454<br />
Mielnik A. 427<br />
Miglioranza M.E. 198<br />
Mihaescu T. 72, 498<br />
Mijan-Ortiz J.L. 467<br />
Mikami S. 290<br />
Mikhailidis D.P. 181<br />
Miki T. 697, 782<br />
Mikolajczak W. 1032<br />
Milakovic S. 1022<br />
Milani A. 561, 726<br />
Militello A. 163<br />
Miller D. 424<br />
Miller K. 95, 140, 571, 745, 911, 984<br />
Mills I. 639<br />
Milonas D. 19, 946<br />
Milosavljevic M.Z. 384, 531<br />
Milosevic R. 1021<br />
Milovic N. 1021<br />
Min K. 308<br />
Minagawa S. 889<br />
Minagawa T. 1044<br />
Minder C. 772<br />
Minervini A. 278, 443<br />
Mingat N. 521<br />
Minhas S. 430, 431<br />
Minich A. 1019<br />
Minisola F. 929<br />
Minner S. 565, 928<br />
Minutoli L. 632<br />
Mir M.C. 27, 966<br />
Mirabella G. 263<br />
Miranda O. 284, 672<br />
Miranda Serrano B. 455<br />
Mirciulescu V.A. V23, V25<br />
Mirkin Y.B. 997<br />
Mirone V. 229, 526, 1007<br />
Mirtti T. 321<br />
Mishriki S.F. 54, 882<br />
Mitev V. 748<br />
Mitin A.A. 579<br />
Mitkova A. 748<br />
Mitri F. 717<br />
Mitropoulos D. 867<br />
Mitterberger M. 150, 262, 334, 736<br />
Mitusov V.V. 380<br />
Miwa Y. 127<br />
Miyajima A. 290<br />
Miyake H. 459<br />
Miyake M. 143, 1008<br />
Miyakubo M. 968<br />
Miyamoto S. 771<br />
Miyamoto T. 119, 121, 170, 698<br />
Miyashiro Y. 626<br />
Miyazato M. 117<br />
Miedzybrodzki R. 374<br />
Moch H. 565<br />
Mochida J. 206, 394<br />
Mochizuki T. 121<br />
Mochtar A. 358<br />
Mocovic D. 1021<br />
Mogorovich A. 247<br />
Mohamad Al Ali B. 541<br />
Mohammed A.A. 848, 849<br />
Mohan P. 59<br />
Möhle R. 1047<br />
Mohr E. 452<br />
Mohrbach J. 457<br />
Moineau M.P. 580<br />
Moinzadeh A. V15<br />
Moldrup U. 766<br />
Molducci S. 829, 833<br />
Moldwin R.M. 639<br />
Molina A. 332, V7<br />
Molina Cabeza A. 264<br />
Molinié V. 869<br />
Moll F.H. 842<br />
Mollenkopf H.J. 745<br />
Molokwu C.N. 54, 807, 882<br />
Molon A. V40<br />
Mombet A. 793, 835<br />
Mondaini N. 62, 819<br />
Monrós J.L. 837<br />
Montaser-Kouhsari L. 425, 657<br />
Montesino-Semper M. 188<br />
Montlleo Gonzalez M. 991<br />
Montmany S. 209<br />
Montorsi F. 23, 32, 35, 40, 41, 70,<br />
81, 82, 83, 84, 115, 133, 155, 158,<br />
172, 204, 213, 288, 306, 422,<br />
449, 450, 542, 577, 609, 615,<br />
620, 679, 682, 763, 768, 769,<br />
827, 828, 832, 836, 907, 917,<br />
973, 983, 990, 999, 1009, 1010,<br />
1013<br />
Moon D.G. 73, 174, 508, 582, 740<br />
Moon H.S. 603<br />
Moon K.H. 78, 178, 222, 505<br />
Moon Y.T. 471<br />
Moonen L.M.F. 559<br />
Moore C. 156, 712, 936<br />
Moraitis K. 8, 228, 230, 349, 595,<br />
602<br />
Moralejo-Garate M. 336<br />
Morales San Jose D. 336<br />
Moratalla L.M. 340<br />
Moreira D.M. 417<br />
Morelli A. 634<br />
Morgia G. 409, 632, 1041<br />
Morikawa Y. 861<br />
Morill B. 990<br />
Morote Robles J. 27, 135, 675, 676,<br />
966<br />
Morrill B. 991<br />
Morrow J.D. 778<br />
Mosbah A.O. 408, 653, 1023<br />
Moskovitz B. 215<br />
Mosquera J. 42<br />
Moss S.M. 965<br />
Motawae O. 219, 341<br />
Mottaghy F. 153<br />
Mottaz A. 61<br />
Mottier S. 562<br />
Mottrie A. 537, V15<br />
Motzer R.J. 97<br />
Moulière A. 853<br />
Mouly P. 585<br />
Mouraviev V. 417<br />
Mozer P. 57<br />
Mpisias S. 162, 950<br />
Mrachkovskiy V.V. 721<br />
Muacevic A. 770<br />
Mucciardi G. 163<br />
Muir G. 936<br />
Mukai M. 290<br />
Numbers refer to abstract numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
497
Abstract Authors<br />
Mukhtarov S.T. 354<br />
Mulders P.F.A. 420, 421, 563, 564<br />
Mulhall J.P. 79<br />
Müller A. 79<br />
Müller O. 254<br />
Müller S. 36, 568<br />
Mullerad M. 79<br />
Multescu D.R. 596, 885, V23, V25,<br />
V26<br />
Mumtaz F.H. 181<br />
Mundhenk J. 378, 801<br />
Mundy A.R. 1045<br />
Muneer A. 430, 431, 530<br />
Mungan N.A. 376<br />
Muñoz H. 295<br />
Muñoz J. 419<br />
Muntañola-Armora P.L. 42, 188<br />
Muraishi O. 889<br />
Muraoka S. 708<br />
Murat F.J. 940, 941, 942<br />
Muriel A. 335<br />
Murone C. 575<br />
Murphy D. 918<br />
Murphy T.M. 989<br />
Murtola T. 635<br />
Mürtz G.E. 656<br />
Muscariello R. 105<br />
Musch M. 112<br />
Musitelli S. 952<br />
Musquera M. 51, 332, 464, V3, V7,<br />
V37<br />
Musquera Felip M. 343<br />
Mynderse L. 717<br />
Myung S.C. 277, 483, 631, 981<br />
N<br />
Na Y.G. 627<br />
Nabeeh A. 1036<br />
Naber K. 486<br />
Nabi G. 882<br />
Nabizada-Pace F. 578, 916<br />
Naboka Y.L. 370, 482, 485<br />
Nagane Y. 394<br />
Naganuma T. 934<br />
Nagase K. 127<br />
Nagata H. 290<br />
Nagele U.N. 558, 756<br />
Naghibi M. 333<br />
Naijjari L. 238<br />
498 Programme Book<br />
Nair R. 844<br />
Naito S. 267, 859, 1046<br />
Nakagawa K. 290<br />
Nakagawa M. 821<br />
Nakagomi H. 119, 121, 170<br />
Nakano Y. 459<br />
Nakao N. 782<br />
Nakashima J. 287<br />
Nakata S. 751<br />
Nakatani T. 934<br />
Nakayama S. 1046<br />
Namdari F. 996<br />
Namiki S. 919<br />
Naohiko S. 44<br />
Naohiko N.S. 454<br />
Napodano G. 694, V17<br />
Nargund V. 101<br />
Narita S. 826<br />
Naseh H. 6<br />
Nash S.D. 398<br />
Nasu Y. 1031<br />
Nativ O. 215<br />
Naumann C.M. 549<br />
Nava L.D. 23, 763<br />
Navarra P. 197<br />
Navarro S. 209<br />
Nawar N. 10<br />
Nawroth R. 824, 868<br />
Nazemian F. 333<br />
Nazir S. 48<br />
N’Dow J. 406<br />
Necchi A. 561, 726<br />
Negro C. 409<br />
Neilsen S. 544<br />
Neiroomand H. 309<br />
Neri F. V8<br />
Nesbitt I. 1024<br />
Nesi G. 819<br />
Neubauer S. 617, 618<br />
Neuhaus J. 272<br />
Neuzillet Y. 415, 463, 869<br />
Neves D. 74<br />
Ng C.F. 223<br />
Ng L.G. 167<br />
Ng W.S. 59<br />
Nguyen T. 630<br />
Nguyen Huu Y. 601<br />
Nicita G. 1007<br />
Nickkholgh A. 452<br />
Nicolai N. 561, 726<br />
Nicolazzo C. 929<br />
Nielsen J.S. 270<br />
Nielsen T. 405<br />
Niforos D. 921<br />
Nigro F. V29<br />
Nikoobakht M.R. 996, 998<br />
Nilsson A.E. 786, 1026<br />
Nilsson P.M. 982<br />
Ninkovic M. 1056<br />
Nishikawa M. 934<br />
Nishino S. 708<br />
Nishiyama K. 44, 821<br />
Nishiyama T. 947<br />
Nishizawa O. 117, 638, 1044, 1058<br />
Nissenkorn I. 494<br />
Nistal Alonso J. 135<br />
Nitta Y. 934<br />
Nitti V. 92, 778<br />
Noble J.G. 519, 699<br />
Noeldge-Schomburg G. 456<br />
Nogueras Ocaña M. 484<br />
Noh C.H. 168<br />
Nohra J. 540<br />
Noldus J. 151, 794<br />
Nomiya M. 507<br />
Nonomura K.N. 407<br />
Noordzij M.A. 733<br />
Nørby B. 593<br />
Nordhaus C. 770<br />
Nordio A. V13<br />
Nordling J. 265, 270, 857<br />
Nørgaard N. 147<br />
Nosirov F.R. 354<br />
Novak K. 205<br />
Novara G. 33, 35, 37, 38, 199, 322,<br />
323, 418, 1027<br />
Novella G. 169<br />
Nowroozi M.R. 425<br />
Nuhn P. 35, 770<br />
Nuijten M. 94<br />
Numao N. 20, 47, 56, 106, 165, 591,<br />
839, 964<br />
Nuñez Mora C. 202, 325, V19<br />
Nunzi E. 644<br />
Nützel R. 718<br />
Nyamwaro H. 123<br />
Nyarangi-Dix J. V41<br />
Numbers refer to abstract numbers
O<br />
Ober P. 600<br />
Obinata D. 394<br />
O’Brien M. 442<br />
O’Brien T. 101<br />
Odensky E. 173<br />
Oderda M. 39<br />
O’Donaghue J.P. 519, 699<br />
Oehlschläger S. 473, 476<br />
Oelke M. 504<br />
Oeztuerk A. V41<br />
Ogawa T. 638, 1058<br />
Oger S. 128, 130, 131, 268, 269<br />
Oh C.Y. 227<br />
Oh C.K. 65, 588<br />
Oh M.M. 73, 174, 399, 740<br />
Oh M.A. 757<br />
Oh S.Y. 471, 734, 981<br />
Oh Y.T. 466<br />
Ohh M. 574<br />
Ohlmann C.H. 744<br />
Ohno Y. 287<br />
Ohori M. 287<br />
Ohtake A. 266<br />
Ohtake N. 751<br />
Ohyama C. 720, 858<br />
Ojea-Calvo A. 188<br />
Okada H. 125<br />
Okada H. 428<br />
Okada Y. 290<br />
Okada Y. 897<br />
Okajima E. 1008<br />
Okamoto A. 720, 858<br />
Okamoto T. 720, 858<br />
Okeke A.A. 884<br />
Okhrits V.E. 987<br />
Okihara K. 697<br />
Okubo Y. 16<br />
Olarra J. 606<br />
Olbert P. 233, 350<br />
Olesen T.K. 139<br />
Oliveira P.D. 642<br />
Oliver T. 142, 900<br />
Olivier Gomez C. 285, 312<br />
Olsson H. 922<br />
Omorphos S. 488<br />
Omrani M.D. 742<br />
Oosterlinck W. 189<br />
Oosterwijk E. 252, 253, 421, 563,<br />
931, 932<br />
Ordoño F. 1038<br />
Ordorica R. 392<br />
Orlandi A. 525<br />
Orlando C. 822<br />
Ortiz Gorraiz M.A. 695<br />
Ortolani G. V46<br />
Orvieto M. 790<br />
Osanto S. 97<br />
Osawa T.O. 407<br />
Osca J.M. 340<br />
Oshepkov B.N. 159<br />
Oshepkov V.N. 901<br />
Osmonov D. 261<br />
Osther P.J.S. 470, 593, 605<br />
Osther S.S. 605<br />
Østraat O. 766<br />
Oswald J. 334, 736<br />
Ott O. 11<br />
Otterbein L. 863<br />
Otto T. 242, 256, 1051<br />
Otto W. 37, 43, 326<br />
Oudard S. 97<br />
Owen H.C. 815<br />
Own H. 46<br />
Oya M. 290<br />
Oyama N. 127<br />
Oyen R. 153<br />
Oyen W.J.G. 421, 563<br />
Özdemir B. 279<br />
Özden E. 810<br />
Özdiler E. 303<br />
Ozkan L. 297<br />
Ozkan T.A. 297<br />
Özkardes H. 511<br />
Özkaya O. 810<br />
Ozturk B. 359<br />
P<br />
Pacchioni D. 39<br />
Pacheco Bru J.J. 695<br />
Pacik D. 160<br />
Paduch D.A. 79, 427<br />
Paez Borda A. 606<br />
Page T. 954<br />
Pagliarulo A.P. 114, 896<br />
Pagliarulo V.P. 114, 896<br />
Pahernik S. 226, 445, 1004, 1022,<br />
V41<br />
Pahnke J.M. 112<br />
Paick J.S. 311, 883<br />
Paick S.H. 673, 823, 825<br />
Palao Yago F. 467, 484<br />
Palazzo S. 338<br />
Palego P.F. 436<br />
Palermo G. 723<br />
Palisaar R.J. 794<br />
Pallardó L. 340<br />
Pallardy A. 1011<br />
Palleschi G. 524<br />
Pallwein L. 150<br />
Palmer K. 790, V15, V18<br />
Palmer M. 848, 849<br />
Palmieri A. 229, 526<br />
Palminteri E. 381, 724, V40<br />
Palou Redorta J. 135, 489, 493,<br />
1042, V31<br />
Pamplona M. 339<br />
Panah A. 228<br />
Pandey A. 383<br />
Panebianco V. 707<br />
Pannek J. 512<br />
Pantel K. 928<br />
Pantsulaia T. 330<br />
Pantuck A.J. 418, 500, 768<br />
Papadopoulou G. 208<br />
Papaioannou P. 773<br />
Papalia R. 154, 320, 448, 536, 1029<br />
Paparel P. 415, 463, 521<br />
Papatsoris A. 402, 993<br />
Papazoglou J. 176<br />
Paperini D. 247<br />
Papin G. 580<br />
Pappas A. 162, 950<br />
Pappot H. 144<br />
Parada R. 1042<br />
Paradowska A. 424, 746<br />
Paredes Zapata D. 455<br />
Parente U. 707<br />
Park C.H. 138<br />
Park C.H. 400, 404, 481, 992<br />
Park C.M. 138<br />
Park H. 104, 239, 673, 823, 825,<br />
866, 912, 1001<br />
Park H.J. 137, 477<br />
Park H.J. 212, 308<br />
Park H.K. 66<br />
Park H.S. 73, 508, 582<br />
Numbers refer to abstract numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
499
Abstract Authors<br />
Park J. 324<br />
Park J.H. 662, 758<br />
Park J.H. V27<br />
Park J.K. 308, 881<br />
Park J.Y. 399<br />
Park J.S. 222, 505<br />
Park J.S. 603<br />
Park J.Y. 138<br />
Park K. 308, 1052<br />
Park K.J. 311, 734, 754<br />
Park K.K. 116, 509<br />
Park M.C. 439, 655, 806<br />
Park M.G. 73, 174, 740<br />
Park M.J. 673, 823, 825, 825<br />
Park N.C. 212, 308<br />
Park S. 177<br />
Park S.C. 212, 1020<br />
Park S.U. 116, 509<br />
Park S.W. 483, 981<br />
Park S.Y. 603<br />
Park T.C. 222, 505<br />
Park W.H. 87<br />
Park W.S. 28<br />
Park Y.H. 60, 472, 662, 734, 758<br />
Park Y.I. 168<br />
Park Y.K. 709<br />
Parma P. 535<br />
Parr N.J. 58<br />
Parratte B. 516<br />
Paschalidis K. 218<br />
Pascual J. 335<br />
Pasquale G. 462<br />
Passalacqua D. 49<br />
Passariello R. 707<br />
Passaro P.G. 198<br />
Passas J. 339<br />
Passoni N. 213, 827, 973, 1010<br />
Pasticier G. 940, 941, 942<br />
Pastidis S. 142<br />
Pastor T. 340<br />
Pastore A.L. 524<br />
Patard J.J. 300, 415, 418, 463, 562,<br />
566, 768, 906<br />
Patel A. 506<br />
Patel D. 8, 230<br />
Patel H. 50<br />
Patel H. 625<br />
Patel H. 795<br />
Patel V. 790, V15, V18<br />
500 Programme Book<br />
Patel V.D. 89<br />
Pati M.A. 436<br />
Patki P. 90<br />
Patrascoiu S. 293, 382<br />
Patschan O. 926<br />
Paul R. 688<br />
Paul S. 289<br />
Paul U. 113<br />
Pavel C. 429<br />
Pavlakis K. 867<br />
Payne H. 156<br />
Pchejetski D. 876<br />
Pecoraro S. 527<br />
Pedersen K.V. 605<br />
Pedersen K.V. 920<br />
Peehl D.M. 864<br />
Pei Y.P. 464<br />
Pelger R.C.M. 704<br />
Pellucchi F. 827, 828<br />
Pelz H. 96<br />
Pelzer A.E. 149<br />
Penabella Y. 871<br />
Pennanen P. 635<br />
Pentimone S. 2<br />
Peracchia G. 1025<br />
Perdona S. 105<br />
Pereda C. 904<br />
Perez S. 950<br />
Pérez Márquez M. 972<br />
Peri Cusi L. 264, 332, 337, 343, 455,<br />
V3, V7, V37<br />
Perletti G. 364, 366<br />
Perner S. 667, 671, 743, 1018<br />
Pernetti R. 829, 833<br />
Peroni A. 263<br />
Perovic S.V. 384, 525, 527, 528, 531<br />
Perrin P. 190<br />
Perrone A. 2<br />
Perrotte P. 40, 41, 288, 769<br />
Perry A.S. 989<br />
Perry M.J.A. 552, 554, 556, 557<br />
Persson B.E. 139, 140<br />
Persson J. 863<br />
Perucchini D. 93<br />
Perucchini L. 440<br />
Peschechera R. 5, 594<br />
Pesic V. 531<br />
Peskircioglu L. 511<br />
Petca R.C. 7<br />
Peters J. 101<br />
Peters J. 918<br />
Petersen K. 667, 671, 743<br />
Petit J. 415, 463<br />
Petracca A. 929<br />
Petralia G. 449, 450, 827<br />
Petrus A. 1032<br />
Pettaway C. 959<br />
Pettersson S. 660<br />
Peyromaure M. 906<br />
Pfister C. 193, 415, 463, 768, 906<br />
Pfister D. 728, 730, 898, 899<br />
Pfitzenmaier J. 226, 445, 1004,<br />
1022, V41<br />
Pfost B. 930<br />
Piao S. 186, 301<br />
Picard A. 190<br />
Picchio M. 155<br />
Piccin C. V29<br />
Piccinelli A. 5, 535, 594<br />
Pichler M. 979<br />
Pichler R. 262, 334<br />
Pierconti F. 723<br />
Pierotti P.S. 854<br />
Pierre Mozer 57<br />
Pierrevelcin J. 529<br />
Pietrantuono F. 236, V11, V34<br />
Pilatz A. 490<br />
Pilcher J. 554, 556<br />
Pilchowski R. 550, 722<br />
Pillai P.L. 1024<br />
Pini G. V36<br />
Pinnock C. 21, 910<br />
Pinthus J.H. 587, 860<br />
Pinto F. 184, 234<br />
Pinto R. 629, 642, 995<br />
Pinton P. 306<br />
Piqueras M. 332, 337, V3<br />
Piqueras Bartolomé M. 972<br />
Pirozhok I. 775<br />
Pirès C. 875<br />
Pisanti F. 886<br />
Piselli M. 644<br />
Pisters L.L. 685, 938<br />
Pistilli A. 988<br />
Pistolesi D. 247<br />
Pitson S. 876<br />
Pitzler C. 533<br />
Piussan J. 402<br />
Numbers refer to abstract numbers
Piva L. 561, 726<br />
Pizzi G. 448<br />
Pizzuti M. 3, 105<br />
Placer J. 27, 676<br />
Planas J. 27, 675, 676<br />
Planas N. 335<br />
Planas Morin J. 135<br />
Plante M.K. 879<br />
Plante P. 540<br />
Plasswilm L. 616<br />
Plettenburg O. 302<br />
Plhal S. V35<br />
Ploumides A. 208<br />
Ploussard G. 63, 691, 840<br />
Podio V. 534<br />
Poetsch M. 547<br />
Poggio M. 347, V24<br />
Poissonnier L. 415, 463, 940<br />
Pokrywczynska M. 248<br />
Polascik T.J. 417<br />
Politis V. 843<br />
Polito F. 632<br />
Pollak M. 664<br />
Poluzzi M. V40<br />
Polyakov S. 1019<br />
Pommerville P. 398, 994<br />
Ponholzer A. 305, 501, 787<br />
Poon A.M.T. 575<br />
Popeneciu V. 226<br />
Popert R. 625<br />
Popken G. V45<br />
Popov E.P. 748<br />
Porena M. 395, 933<br />
Porpiglia F. 207, 534, 535, 538, V24<br />
Porst H. 306<br />
Porta C. 94, 97<br />
Portalez D. 585<br />
Portillo-Martín J.A. 188<br />
Possner M. 856<br />
Poubel V.J.P. 217<br />
Pourmand G. 749, 996, 998<br />
Pourreza F. 309<br />
Povilaitite P.E. 363<br />
Powles T. 101<br />
Prapotnich D. 793, 835<br />
Prats J. 42, 209, 419<br />
Prats Galino A. 135<br />
Preda A. 429<br />
Prelevic R. 1021<br />
Prera A. 419<br />
Primus G. 401<br />
Pritsch M. 570<br />
Proietti S. 91, 644<br />
Protheroe A. 14<br />
Protzel C. 456, 547<br />
Pryambodho P. 358<br />
Pryor J. 430<br />
Pshikhachev A.M. 368<br />
Puchwein E. 401<br />
Puertas M. 1038<br />
Puig J. 419<br />
Pummer K. 286, 294, 401, 541, 787,<br />
979<br />
Punab M. 423<br />
Pürstner P. 979<br />
Pushkar D.Y. 185, 637<br />
Putora P. 616<br />
Putter H. 704<br />
Pwint T. 14<br />
Pycha A. 586<br />
Pylkkänen L. 931<br />
Q<br />
Qiang F. 257<br />
Qin J. 649<br />
Quartesan R. 644<br />
Quarto G. 105<br />
Quast S. 242<br />
Queimadelos A.M. 142<br />
R<br />
Rabadan M. 188<br />
Rabadi A. 1004<br />
Rabbani F.R. 1005<br />
Rabenalt R. V12<br />
Raber M. 23, 70, 115, 172<br />
Rabinovitch E.Z. 159<br />
Racioppi R.M. 184, 198<br />
Rack B.K. 868<br />
Rack T. 663<br />
Radmayr C. 216, 378, 736, 801, 804<br />
Radosevic-Jelic L. 731<br />
Radwan M.H. 385<br />
Radziszewski P. 500, 774<br />
Rafii S. 870<br />
Ragab M.M. 385<br />
Ragavan N. 652<br />
Rahardjo D. 183, 358<br />
Rahardjo H.E. 183, 358<br />
Rahbek M. 270<br />
Raheem O.A. 989<br />
Rahnama’i M.S. 129<br />
Raibaut P. 516<br />
Ralph D.J. 250, 530<br />
Rambotti M.G. 988<br />
Ramirez D. V2, V5, V18<br />
Ramirez J. 986<br />
Ramon A. 256, 1051<br />
Ramón De Fata F. 325<br />
Ramos-Barcelo E. 725<br />
Ranghino A. 462<br />
Ranzoni S. 397<br />
Rapp K. 945<br />
Rasheed M. 803<br />
Raspollini M.R. 443<br />
Raßler J. 892<br />
Rassweiler J.R. 478, 788<br />
Rasyid N. 358<br />
Ratovitski E. 927<br />
Rauchenwald M. 292, 501, 533<br />
Ravaud A. 97, 418<br />
Raventos C.X. 27, 675, 676<br />
Raynaud J.P. 869<br />
Raz O. 211, 937<br />
Real F. 42<br />
Realfonso T. 694, V17<br />
Rebai N. 411<br />
Rebelakos R.A. 203<br />
Recker F. 967<br />
Redondo E. 606<br />
Rehder P. 262, 334<br />
Reich O. 33, 199, 322, 553, 597, 796,<br />
870<br />
Reichelt O. 344, 465<br />
Reichelt U. 571<br />
Reid J. 975, 976<br />
Reimer B. 688<br />
Reischl M. 743<br />
Reiß C. 753<br />
Reissigl A. 586<br />
Rempelakos A. 176<br />
Remzi M. 286, 294, 296, 298, 437,<br />
581, 586<br />
Rende M. 988<br />
Rendon D. 606<br />
Rendon R.A. 291<br />
Renninger M. 316<br />
Numbers refer to abstract numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
501
Abstract Authors<br />
Rentsch C.A. 460, 891<br />
Rentschler A. 476<br />
Resel Folkersma L. 285<br />
Rettkowski A. 504<br />
Retz M. 688, 824, 868<br />
Reuter V. 677, 943, 1005<br />
Reventós J. 27, 966<br />
Reyes D. 904<br />
Reynard J.R. 519, 699<br />
Rezaei I. 353<br />
Rezaeidanesh M. 749, 996, 998<br />
Rha K.H. 65, 588, 760, 1020<br />
Riant T. 403, 647<br />
Ribal Caparrós M.J. 55, 332, 972,<br />
V3, V7, V37<br />
Ricceri F. 39, 820<br />
Ricci E. 674<br />
Richter S. 728<br />
Ricós J.V. 837<br />
Ricotta G. 163<br />
Riedler I. 478<br />
Riedmiller H. 412, 753, 856<br />
Rieken M. 460, 891<br />
Riethdorf S. 928<br />
Rigatti P. 23, 32, 70, 81, 82, 83, 84,<br />
115, 133, 155, 158, 172, 204, 213,<br />
422, 449, 450, 542, 577, 609,<br />
615, 620, 682, 763, 827, 828,<br />
836, 907, 917, 973, 1010<br />
Rigau M. 27, 966<br />
Rigaud J. 403, 415, 463, 610, 647,<br />
711, 768, 906<br />
Rigopoulos C. 890<br />
Rimington P. 1028<br />
Rink M. 565, 928, 1014<br />
Rioja L.A. 675<br />
Rioja Zuazu J.P. 725<br />
Rioux-Leclercq N. 415, 463, 562,<br />
566<br />
Ripert T. 102, 529<br />
Ripoli A. 524<br />
Rischmann P. 317, 415, 451, 463,<br />
521, 768, 876<br />
Ritchie R.W. 767<br />
Rittenhouse H. 871, 975, 976<br />
Rittmaster R.S. 975, 976, 983<br />
Rivas M. 42<br />
Riviere J. 759<br />
Rix D. 735<br />
502 Programme Book<br />
Robert R. 403, 647<br />
Roberts A.M. 574<br />
Robertson C.N. 941, 942<br />
Robinette M.R. 464<br />
Robinson K. 811<br />
Rocchini L. 82, 83, 84, 422, 682,<br />
828, 973<br />
Rocco F. 478<br />
Rocha C. 850, 873, 874<br />
Rocha F. 71, 180<br />
Rocha Jr J.E. 759<br />
Roche J.B. 317, 521<br />
Rode F. 270<br />
Rodjani A. 358<br />
Rodrigo V. 340<br />
Rodriguez A. 392<br />
Rodriguez A. 339<br />
Rodriguez D. 453<br />
Rodriguez N. 202<br />
Rodríguez O. 1042<br />
Rodriguez P. 312<br />
Rodríguez De Vera J. 42<br />
Roehrborn C.G. 879, 915, 990<br />
Roelofs L.A.J. 252, 253<br />
Rogenhofer S. 568<br />
Rogers A. 954<br />
Rogers P.B. 614<br />
Roggenbuck U. 112<br />
Rogler A. 923<br />
Roigas J. 96<br />
Rokkas K. 176<br />
Rolevich A. 1019<br />
Rollin G. 585<br />
Romanenko A.M. 721<br />
Romano A.L. 236, V11, V34<br />
Romano G. 377<br />
Romero C. 762<br />
Romero I. 202<br />
Romero Maroto J. 695<br />
Romics I. 550, 846<br />
Ronn L.B.C. 270<br />
Roobol M.J. 25, 583, 611, 963, 965,<br />
969, 974<br />
Roos F.C. 574<br />
Roosen A. 240<br />
Rosario D. 816<br />
Roscigno M. 23, 70, 172, 213, 422,<br />
449, 450<br />
Rosen R.C. 314, 1000<br />
Roser F. 1055<br />
Rosier P.F.W.M. 696<br />
Rößler W. 43<br />
Roth B. 1016, 1017, V33<br />
Rothman M. 314<br />
Rothman N. 42<br />
Rouanne M. 714, 716<br />
Roumiguie M. 317<br />
Rouprêt M. 415, 463, 752, 812, 814,<br />
906<br />
Rouse P. 678<br />
Rousseau C. 1011<br />
Rousseau T. 1011<br />
Rouviere O. 940<br />
Rowland D.L. 314<br />
Roy-Guggenbuehl S. 93, 780<br />
Royce P.L. 210<br />
Rozet F. 759, 793, 835, 841<br />
Rubin M.A. 671, 743, 870<br />
Rubio L. 670<br />
Rubio Aurioles E. 306<br />
Rubio-Briones J. 670, 837<br />
Rudoni M. 1012<br />
Ruffion A. 521, 752<br />
Ruggiero G. 1041<br />
Ruggirello A. 49, 191, 1041<br />
Ruiz A. 455<br />
Ruiz C. 743<br />
Ruljancich P. 914<br />
Rusakov I.G. 901, 1003<br />
Russano De Paiva Silva G. 876<br />
Rüssel C. 140<br />
Russo A. 182, 682, 828, 973<br />
Russo M. 632<br />
Russo P. 438, 442<br />
Rutkowski M. 245<br />
Ruutu M. 640, 971<br />
Ryu D.S. 481, 992<br />
Ryu H.S. 65, 319, 588, 895<br />
Ryu J.K. 186, 301<br />
S<br />
Saar M. 29, 146<br />
Sabir E. 328<br />
Saccà A. 70, 82, 83, 84, 422<br />
Sacco S.E. 184, 198, 234, 723<br />
Sacerdote C. 820<br />
Saenz J. 606<br />
Safarik L. 205<br />
Numbers refer to abstract numbers
Safarinejad M.R. 187, 315, 433<br />
Safwat S. 214<br />
Sagalowsky A.I. 33, 199, 322, 323<br />
Sagalowsky A.I. 327<br />
Sahai A. 88, 225<br />
Sahdev A. 101<br />
Sahm M. 112<br />
Saika T. 1031<br />
Saint F. 415, 463<br />
Sairanen J. 640<br />
Saito K. 12, 16, 45, 47, 56, 165, 591,<br />
897, 964, V1, V4<br />
Sakai S. 771<br />
Sakai W. 708<br />
Sakai Y. 897<br />
Sakalar C. 648, 649<br />
Sakalo A.V. 721<br />
Sakalo V.S. 721<br />
Sakamoto K. 871<br />
Sakelariou P. 176<br />
Sakuma T. 394<br />
Sakura M. 964<br />
Saladie J.M. 42<br />
Salagierski M. 668<br />
Salari Lak S. 742<br />
Salazar-Onfray F. 904<br />
Salazzari S. 513<br />
Salchli F. 1045<br />
Salciccia S. 707<br />
Salem E. 10<br />
Salem S. 749<br />
Salhi Y. 13<br />
Sallahedin Y. 7<br />
Salloum A. 540<br />
Sallusto F. 415, 463, 521<br />
Salomon G. 103, 619, 680, 680, 681,<br />
684, 792, 799, V45<br />
Salomon L. 63, 415, 418, 463, 691,<br />
768, 840, 906, V22<br />
Salonia A. 32, 82, 83, 84, 172, 422,<br />
449, 450, 609, 682, 827, 836<br />
Salpigidis G. 304<br />
Salvaggio A. 236, V11, V34<br />
Salvioni R. 561, 726, 1007<br />
Salvitti S.M. 854<br />
Salzer A. 200<br />
Samadi D.B. 578, 800, 916<br />
Samadzadeh S. 742<br />
Sameh W.M. 329<br />
Samsonov Y.V. 444<br />
San Jose Manso L. 285, 312<br />
Sánchez A. 695<br />
Sánchez-Carbayo Martín M. 817<br />
Sánchez-Chapado M. 489, 493<br />
Sanchez-Salas R. 759, 793, 835<br />
Sand P.K. 696<br />
Sandner P. 130, 634<br />
Sangalli M.N. 537, 542<br />
Sansalone S. 384, 525, 527, 528<br />
Sanseverino R. 694, V17<br />
Santillana J.M. V31<br />
Santinelli F. V18<br />
Santos A.R. 142<br />
Santos E.M. 215<br />
Santos Oliveira R. 391<br />
Santti H. 971<br />
Sanz Casla M.T. 285<br />
Sanz Mayayo E. 244<br />
Sarafian V. 248<br />
Sarchielli E. 634<br />
Sarhan O. 653<br />
Sari R. 359<br />
Sarica K. 220<br />
Sarkissian G. 566<br />
Sarma A.V. 503<br />
Sarno M.J. 975, 976<br />
Sarıkaya S. 810<br />
Sasamata M. 266<br />
Sato K. 206, 394<br />
Sato R. 428<br />
Sato S. 266<br />
Satoh T. 925<br />
Satoh Y. 925<br />
Satoshi A. 638<br />
Saunders C. 652<br />
Saunders P. 349<br />
Sauter G. 132, 565, 619, 873, 874,<br />
908<br />
Savage C. 677, 1034<br />
Savas N. 737<br />
Sawada N. 119, 170<br />
Sawada S. 121<br />
Sayedahmed K.A.M. 413<br />
Sazawa A.S. 407<br />
Scanziani E. 633<br />
Scapaticci E. 81, 542, 763<br />
Scardino P.T. 79, 677, 878, 943, 982,<br />
1005<br />
Scarpa R.M. 1, 207, 347, 534, 535,<br />
538, V24<br />
Scattoni V. 23, 70, 115, 155, 158, 172,<br />
450, 973, 1010<br />
Schachtner L. 732<br />
Schaefer G. 985<br />
Schäfer A. 745<br />
Schäfer G. 750<br />
Schäfer J. 1047<br />
Schäfer R. 1047<br />
Schäfers S. 911<br />
Schafhauser W. 111<br />
Schagdarsurengin U. 746<br />
Schalken J.A. 120, 283, 668, 974<br />
Schatteman P. 537<br />
Scheble V.J. 667, 671, 743<br />
Scheepe J.R. 276<br />
Scheeren T.W.L. 456<br />
Scheiner D. 93<br />
Scheller F. 183, 623<br />
Schemmer P. 452<br />
Schenner M. 831<br />
Scher H.I. 878, 905<br />
Schiavina R. 829, 833<br />
Schiefelbein F. V35, V38<br />
Schiefer H. 616<br />
Schilling D. 26, 30, 31, 53, 216, 316,<br />
378, 558, 667, 710, 801, 804,<br />
978, 1018<br />
Schipilliti M. 436<br />
Schips L. V6, V8<br />
Schirmacher P. 570<br />
Schlegel P.N. 141, 427<br />
Schlemmer H.P. 710<br />
Schlenck B. 736<br />
Schlenker B. 548, 553, 597<br />
Schlomm T. 103, 565, 619, 680, 681,<br />
684, 799<br />
Schmeller N. 305<br />
Schmid D.M. 93, 93, 780<br />
Schmid H.P. 517, 616, 703<br />
Schmidbauer J.R. 296<br />
Schmidt M. 865<br />
Schneede P. 553<br />
Schneider C. 710<br />
Schneider H. 179, 367<br />
Schneider S.O. 366<br />
Schobinger S. 850<br />
Schoen G.M. V35, V38<br />
Numbers refer to abstract numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
503
Abstract Authors<br />
Schoenberg M. 199, 322, 323<br />
Scholfield D. 639<br />
Scholz C.J. 856<br />
Schönberg S. 149<br />
Schönfeld D.J. 628<br />
Schöppler G.M. 545<br />
Schostak M. 571, 911<br />
Schott G.E. 654<br />
Schover L. 173<br />
Schrader A.J. 350, 416<br />
Schrader M. 984<br />
Schramek P. 831<br />
Schröder A. 410, 659, 802<br />
Schröder F.H. 25, 583, 611, 963,<br />
965, 969, 974, 1013<br />
Schroeder C. 113<br />
Schubert B. 480<br />
Schubert G. 480<br />
Schuessler B. 93<br />
Schüller G. 298, 437<br />
Schulze M. 788<br />
Schumacher M.C. 786, 1026<br />
Schumacher S. 424<br />
Schurch B. 93, 512, 518, 780<br />
Schwander B. 94<br />
Schwaninger R. 279, 281<br />
Schwarz H. 893<br />
Schwentner C. 53, 216, 378, 558,<br />
710, 801, 804, 978<br />
Sciarra A. 707, 929<br />
Scieri F. 236, V11, V34<br />
Scigalla F. 272<br />
Sciuto R. 154<br />
Scoffone C.M. 347, V24<br />
Scott A.M. 575<br />
Scremin E. V29<br />
Scuto F. 49, 191<br />
Searle P.F. 949<br />
Sebe P. 752<br />
Sebesta I. 469<br />
Secin F.P. 835<br />
Secondini C. 279, 281<br />
Seculic N. 873, 874<br />
Sedigh O. 462<br />
Sedlácek J. 809<br />
Seelentag W.W. 616<br />
Segoloni G.P. 462<br />
Sehmisch S. 663<br />
Seibel J.M. 145<br />
504 Programme Book<br />
Seibold J. 316, 378, 387, 656, 801,<br />
804<br />
Seidl C. 930<br />
Seidler M. 628, 1054<br />
Seif C. 86<br />
Seifart C. 750<br />
Seifert H.H. 893<br />
Seiler D. 967<br />
Seiler R. 34, 850<br />
Seitz C. 37, 38, 586, 1027<br />
Seitz G. 667<br />
Seitz M. 553, 796<br />
Seki N. 821<br />
Seki N. 267, 1046<br />
Seki S. 638<br />
Sekine Y. 751, 861<br />
Sellers D.J. 123, 126<br />
Selli C. 247, 822<br />
Selvaggi F.P. 338, 1041<br />
Selvaggio O. 2, 164<br />
Senaratne S. 578, 916<br />
Senekowitsch-Schmidtke R. 930<br />
Sengupta A. 171<br />
Seo H.K. 28<br />
Seo J.H. 222, 400, 404, 481, 505,<br />
992<br />
Seo J.T. 785<br />
Seo S.I. 107, 543<br />
Seo Y.J. 400, 404<br />
Seong D.H. 186, 301<br />
Serafetinides E. 208<br />
Serefoglu E.C. 67, 110<br />
Serferaz G. 663<br />
Sergon M. 747<br />
Serni S. 278, 443<br />
Serra C. 42<br />
Serrano M. 1042<br />
Serretta V. 49, 191, 1041<br />
Serth J. 567, 572<br />
Serva M.R. 988<br />
Sester M.L. 457<br />
Sester U. 457<br />
Seth A.K. 272<br />
Sethugavalar B. 560<br />
Seveso M. 5, 594<br />
Sezgin T. 310<br />
Shaaban A.M. 385<br />
Shabsigh R. 313<br />
Shady S.A.S. 345<br />
Shah P.J.R. 90, 522<br />
Shah Z. 951<br />
Shahab N. 267, 1046<br />
Shahaf Y. 192<br />
Shahrokh S.F. 769<br />
Shaikh T. 8<br />
Shakeri S. 9<br />
Shakiba M. 6<br />
Shangichev A.V. 363, 371<br />
Shariat S.F. 33, 35, 37, 38, 40, 41,<br />
199, 288, 322, 323, 327, 438,<br />
792, 870, 926, 1027, 1034<br />
Sharifipoor F. 333<br />
Shayegan B. 587<br />
Shelly B. 704<br />
Shen C.H. 355<br />
Shenfeld O.Z. 251<br />
Shergill I.S. 848, 849<br />
Sherif A.M. 15<br />
Shestani T. 886<br />
Shestiperov P.A. 689<br />
Shi Y.J. 435<br />
Shiau A.L. 924<br />
Shibata Y. 136, 626, 861, 888<br />
Shiga S. 889<br />
Shigeto S. 919<br />
Shilo Y. 211<br />
Shim K.S. 400, 404<br />
Shimada K. 1008<br />
Shin J.H. 627<br />
Shin S.H. 186, 301<br />
Shinohara N.S. 407<br />
Shiota M. 859<br />
Shishido K. 507<br />
Shishkin S.S. 987<br />
Shokeir A.A. 346<br />
Shoma A.M.S. 345, 346<br />
Shore N.D. 141<br />
Shoskes D.A. 372<br />
Shumilo D.V. 643<br />
Sibony M. 812<br />
Siddiqui J. 871<br />
Siddiqui K. 944<br />
Sidi A.A. 546<br />
Siegel J. 216, 978<br />
Siegert S. 553<br />
Siekiera J. 1032<br />
Siemer S. 29, 457, 478<br />
Siemßen K. 984<br />
Numbers refer to abstract numbers
Siena G. 443<br />
Sievert K.D. 53, 254, 258, 316, 378,<br />
387, 512, 515, 558, 604, 801,<br />
862, 1018, 1047, 1055, 1056<br />
Sigala S. 263<br />
Sighinolfi M.C. V14, V36<br />
Silberstein J. 871<br />
Silimi-Moyano A. 188<br />
Sillén U. 660<br />
Silva A.S. 642<br />
Silva C.M.P.M. 391, 995<br />
Silva J.F.A. 629, 995<br />
Silva P. 391, 995<br />
Silvani M. 527<br />
Silverman D. 42<br />
Silvestri L. 524<br />
Silvestrini E. 634<br />
Simaioforidis V.P. 843, 993<br />
Simeone C. 263, 440<br />
Simmons M.N. 441, 544<br />
Simón L. 675<br />
Simon R. 565<br />
Simonato A. 1007<br />
Simone G. 154, 320, 448, 536, 1029<br />
Simone O. 3<br />
Sinescu I. 293, 382, 429<br />
Singer B.B. 870<br />
Singh P.B. 108<br />
Sipela H. 211<br />
Sivkov A.V. 159, 444, 901<br />
Siziakin D.V. 434<br />
Sizonov V.V. 434<br />
Skinner E. 33, 35, 199, 322, 323<br />
Skobejko-Wlodarska L. 658<br />
Skradski V. 985<br />
Slavov C.K. 748<br />
Slezak J. 50<br />
Slobek I. 873<br />
Slutsky J.N. 398<br />
Smiszek R. 718<br />
Smit F.P. 668<br />
Snowden C. 1024<br />
So A.I. 826<br />
So B.K. 543<br />
So S. 428<br />
Soares R. 71<br />
Sofer M. 598<br />
Soga N. 447<br />
Sohaib A. 712<br />
Sohn D.W. 76, 369<br />
Soker S. 933<br />
Soler R. 933<br />
Soloway C. 607<br />
Soloway M.S. 607, 1033<br />
Solsona E. 670, 837<br />
Solsona-Narbón E. 188<br />
Solvig J. 766<br />
Somani B.K. 406, 807, 1030<br />
Somerville M.C. 983<br />
Someya A. 266<br />
Somford D.M. 584, 713<br />
Sommerer F. 151<br />
Son H.C. V27<br />
Song C. 107, 324, 439, 719<br />
Song H.R. 107<br />
Song J.M. 880<br />
Song J.S. 301<br />
Song K.H. 212, 627<br />
Song P.H. 222, 505<br />
Song S.H. 1052<br />
Song Y.S. 624, 666<br />
Sonnenberg J.E. 623, 1054<br />
Soomro N. 735<br />
Sorrentino D. 3<br />
Sotelo Noguera R. V2, V5, V15, V18<br />
Sotlar K. 30, 31<br />
Soukup V. 651<br />
Soulié M. 415, 451, 463, 540, 768,<br />
906<br />
Sountoulides P. 218<br />
Soygur T. 739<br />
Sozzi F. 449, 450, 828<br />
Spahn M. 412, 679, 683, 686, 753,<br />
832, 838, 856, 1009, 1013<br />
Spana G. 1053<br />
Spano P.F. 263<br />
Sperling H. 307<br />
Speroni Di Fenizio P. 272<br />
Sperveslage J. 549<br />
Spethmann J. 103, 680, 681, 908<br />
Spinelli M.G. V13<br />
Spinelli M. 514<br />
Spira G. 617, 618<br />
Spisani L. 246<br />
Spivak L.G. 373<br />
Squadrito F. 632<br />
Squintone L. 513<br />
Sridhar S. 99<br />
Sriprasad S. 225, 844, 847<br />
St. Sauver J.L. 503<br />
Stabile A.M. 988<br />
Stadler T. 1039<br />
Staehler M. 770<br />
Staerman F. 102, 415, 463, 529<br />
Stagni S. 561, 726<br />
Stainier A. 894<br />
Stakhovsky O. 759<br />
Stamenkovic D. 1021<br />
Stanic V. 727, 729<br />
Stanislaus P. 1039<br />
Stanojevic D. 249, 259<br />
Stanojevic N. 531<br />
Staskin D. 778<br />
Stattin P.E. 134, 608, 612, 909, 945<br />
Stavrou A. 773<br />
Stefaina D. 524<br />
Stefanadis C. 176<br />
Steffenhagen V. 623<br />
Steger K. 424, 746<br />
Steidle C. 313<br />
Stein A. 192<br />
Stein R. 410, 659, 802<br />
Steinbach F. V16<br />
Steineck G. 786<br />
Steiner E. 985<br />
Steiner H. 732<br />
Steiner T. 96, 98<br />
Stellwagen F. 824<br />
Stenman U.H. 926<br />
Stenzl A. 24, 26, 30, 31, 53, 111, 216,<br />
254, 258, 316, 378, 387, 515,<br />
558, 604, 656, 692, 701, 710,<br />
801, 804, 862, 977, 978, 980,<br />
1018, 1047, 1055, 1056<br />
Stephan C. 745, 984<br />
Stephen R.L. 196, 197<br />
Steuber T. 103, 132, 619, 680, 681,<br />
684, 792, 799, 908<br />
Stevens D. 108<br />
Steyerberg E.W. 583, 611<br />
Stiburkova B. 469<br />
Stiedl A.C. 667, 671, 743<br />
Stief C.G. 33, 36, 80, 199, 240, 322,<br />
548, 553, 597, 770, 796, 830,<br />
870, 1039, V45<br />
Stiggelbout A.M. 704<br />
Stijn S.W.T.P.J. 713<br />
Numbers refer to abstract numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
505
Abstract Authors<br />
Stillebroer A. 421, 563, 564<br />
Stocks T. 945<br />
Stoehr R. 815, 923<br />
Stoerkel S. 112<br />
Stoilov S.V. 368<br />
Stojanovic B. 249<br />
Stolzenburg J.U. 272, 757, 789, V20<br />
Strada E. 449, 450<br />
Stravodimos K.G. 867<br />
Strebel D.D. 893<br />
Stöckle M. 29, 146, 457, 744<br />
Stöhr B. 732<br />
Stöhr R. 722, 824<br />
Stroebel P. 149, 753, 856<br />
Strom K.H. 765<br />
Strong T.D. 80<br />
Stroup S.P. 765<br />
Strugala G. 656<br />
Strupas K. 452<br />
Stuckey B. 306<br />
Studer U.E. 34, 282, 834, 1015, 1016,<br />
1017, V32, V33<br />
Stuermer E.K. 663<br />
Stuermer K.M. 663<br />
Sturtz G. 1056<br />
Suardi N. 32, 81, 133, 158, 172, 213,<br />
422, 449, 577, 609, 615, 620,<br />
682, 836, 907, 917, 1010<br />
Suarez A. 284, 672<br />
Subira-Rios D. 336, 453<br />
Subramanian V.S. 544<br />
Sugar L. 944<br />
Sugimura T. 889<br />
Sugimura Y. 447<br />
Sugiyama N. 720, 858<br />
Suh J.K. 186, 301<br />
Sui D. 173<br />
Suillvan L. 989<br />
Sukegawa G. 16<br />
Sukonko O. 1019<br />
Sul C.K. 627<br />
Sullivan S.D. 89<br />
Sulser T. 93, 780, 798, 893<br />
Sumerova N.M. 185<br />
Summerer M. 750<br />
Sun M. 40, 41, 288, 619, 681, 769,<br />
792<br />
Sun Z.Y. 255<br />
Sung K.T. 1020<br />
506 Programme Book<br />
Sung L.H. 168<br />
Surange R.S. 652<br />
Surcel C. 293, 382<br />
Surenkov D. 361<br />
Susilo C. 358<br />
Sutherland P. 21, 910<br />
Sutherland S.E. 398<br />
Suyama T. 16<br />
Suzuki K. 136, 626, 751, 861, 888,<br />
968<br />
Suzuki M. 266<br />
Suzuki Y. 720, 858<br />
Svatek R. 33, 35, 199, 322, 323<br />
Svensson M.A. 870<br />
Swallow T.W. 554, 1057<br />
Swärd K. 275<br />
Sweeney C. 54<br />
Sylvester R.J. 189<br />
Syvälä H. 635<br />
Szábo L. 696<br />
Szendroi A. 550<br />
Szendroi A. 846<br />
T Tabares J. 336<br />
Tabata K. 925<br />
Tachibana M.O. 287<br />
Tack I. 521<br />
Tadayyon A.R. 9<br />
Tae Seo J. 87<br />
Taghavi R. 333<br />
Taghipour Bazargani S. 742<br />
Taha Rasheed M. 641<br />
Taher A. 183, 358<br />
Tähtinen R.M. 784<br />
Takahashi K. 947<br />
Takahashi R. 267, 1046<br />
Takahashi S. 206, 394<br />
Takahashi-Yanaga F. 1046<br />
Takazawa R. 165<br />
Takeda M. 459<br />
Takeda M. 119, 121, 170, 698<br />
Takenaka A. 459<br />
Takeshita H. 56<br />
Takeyama M. 393<br />
Tal R. 79<br />
Talbot D. 735<br />
Talimi S. 893<br />
Tamblyn D. 21, 910<br />
Tammela T.L.J. 68, 635, 640, 784,<br />
852, 959, 960, 963, 965, 971,<br />
983<br />
Tampuori J.B. 380, 434<br />
Tan T.M.C. 818<br />
Tanaka A. 287<br />
Tanaka H. 45, 47<br />
Tanaka H. 968<br />
Tanaka I. 127<br />
Tanaka T.K. 459<br />
Tanaka N. 143, 1008<br />
Tandogdu Z. 486<br />
Tannir N. 762<br />
Tao M. 1048, 1050, 1053<br />
Taño J. 42<br />
Taplin M. 905<br />
Tarabuzzi R. 687<br />
Tarantola J. 514<br />
Tardon A. 42<br />
Tarek T.M. 345<br />
Tartaglia T.N. 497, 854<br />
Tasca A. V29<br />
Tatagiba M. 1055<br />
Tatarano S. 821<br />
Tatawy H. 641<br />
Tatokoro M. 56<br />
Taubert H. 572<br />
Taverna G. 5, 594<br />
Taylor A. 665<br />
Taylor J.A. 789<br />
Teber D. 788<br />
Tefekli A. 1<br />
Tejedor D. 675<br />
Tejedor-Jorge A. 453<br />
Tejido A. 295<br />
Teloken C. 959, 960, 983<br />
Temml C. 501<br />
Tenke P. 486, 650<br />
Terai K. 428<br />
Terracciano L. 565<br />
Terrier J.E. 415, 463<br />
Terrier N. 415, 463<br />
Terrone C. 409, 687, 1012<br />
Terry S. 691<br />
Terzolo M. 207<br />
Tesfaye F. 313, 314<br />
Tews V. 53<br />
Tezval H. 504, 567, 663<br />
Tezval M. 663<br />
Numbers refer to abstract numbers
Thalgott M.K. 157, 688, 868<br />
Thalmann G.N. 34, 279, 281, 282,<br />
834, 850, 873, 874, 1015, 1017,<br />
V32<br />
Thanos A. 162, 950<br />
Theodosiou A. 218<br />
Theuerkauf I. 256<br />
Thévenaz P. 1045<br />
Theveniaud P.E. 415, 463<br />
Thibault F. 57<br />
Thomae C. 747<br />
Thomas C. 200, 375<br />
Thomas L. 573<br />
Thomas T. 713<br />
Thompson C.R. 92<br />
Thompson C.S. 181<br />
Thompson P.M. 958<br />
Thomson R.C. 953<br />
Thor P.J. 122<br />
Thörn M. 15<br />
Thorpe A.C. 17, 1024<br />
Thorstenson A. 1026<br />
Thoulouzan M. 451, 540, 906<br />
Thüer D. 728, 898, 899<br />
Thum M.Y. 430<br />
Thuret R. 566, 769<br />
Thüroff J.W. 200, 375, 410, 574,<br />
659, 802<br />
Thüroff S. 941, 942<br />
Tica D. 293, 382<br />
Tiemann A. 36<br />
Tiemessen T.M. 252, 253<br />
Tienforti D. 184, 234<br />
Tikkinen K.A.O. 784<br />
Tiling R. 553<br />
Tilki D. 33, 35, 36, 199, 322, 323,<br />
548, 553, 870<br />
Till H. 757<br />
Tillou X. 415, 463<br />
Timberg G. 423<br />
Timoney A.G. 884<br />
Timsit M.O. 415, 463<br />
Tindall D.J. 959, 983<br />
Tisserand B. 415, 463<br />
Tizzani A. 39, 679, 686, 820, 832,<br />
838, 1009, 1013<br />
Tochigi T. 919<br />
Toi A. 961<br />
Tokgoz H. 376<br />
Toma M.I. 569<br />
Tomada I. 74<br />
Tomada N. 74<br />
Tomaru Y. 626, 968<br />
Tomasetti S. 747<br />
Tombal B. 102, 679, 686, 832, 838,<br />
894, 1009, 1013<br />
Tomioka A. 143<br />
Tomioka T. 1008<br />
Tomisaki I. 859<br />
Tomlins S.A. 871<br />
Tomovic S. 384, 531<br />
Torelli F. 197<br />
Torelli T. 561, 726<br />
Torino M. 436<br />
Torkelsen T.K. 599<br />
Torres G. 492<br />
Tostain J. 289, 300, 415, 418, 463,<br />
768<br />
Touijer K. 677, 943, 1005<br />
Toutziaris C. 304<br />
Townell N. 1030<br />
Tozzi P. 1045<br />
Tracey I. 519, 699<br />
Trachtenberg J. 936, 937<br />
Tran S. 386<br />
Trassierra M. 837<br />
Traxer O. 814<br />
Treiber U. 688, 930<br />
Trinchieri A. 364<br />
Trink B. 927<br />
Tritschler S. 37, 1039<br />
Troccaz J. 57<br />
Troccoli G.T. 896<br />
Trojan L. 36, 545<br />
Trottier G. 690, 961<br />
Trottmann M. 830<br />
Truesdale M.J. 797<br />
Trumbeckas D. 946<br />
Tsai H.T. 924<br />
Tsai Y.S. 22, 355, 924<br />
Tsang W.C. 519, 699<br />
Tsivian A. 546<br />
Tsivian M. 417, 546<br />
Tsuchida T. 119, 698<br />
Tsujii T. 165<br />
Tsukamoto T. 771<br />
Tsushima T. V4<br />
Tu L.M. 398<br />
Tubaro A. 497, 887, 990<br />
Tuccio A. 443<br />
Tuerk I. V15<br />
Tufek I. 791<br />
Tumurbaatar M. 186, 301<br />
Tuncel A. 310<br />
Tuohy V.K. 648, 649<br />
Tur E.I. 643<br />
Turksoy O. 376<br />
Turney B.W. 48<br />
Tutolo M. 82, 155, 158, 213, 609,<br />
1010<br />
Tuvshintur B. 186, 301<br />
Tyritzis S. 867<br />
Tzai T.S. 22, 924<br />
U Uchida J. 934<br />
Ückert S. 183, 623, 628, 845, 1054<br />
Uddin M.M. 167<br />
Uehara S. 1031<br />
Ueshima K. 266<br />
Ueyama J. 782<br />
Ughi G. 246<br />
Ugras N.S. 67<br />
Ukai M. 266<br />
Ukimura O. 544, 697, 782<br />
Ulbrich E. 307<br />
Ulhøi B.P. 318<br />
Ulmer H. 945<br />
Ulmert D. 945, 982<br />
Ulvik N.M. 599<br />
Ulvik O. 599<br />
Umbas R. 358<br />
Umbehr M. 772<br />
Unda-Urzaiz M. 188<br />
Unger D. 533<br />
Unteregger G. 146<br />
Uragami S. 165<br />
Urakami S. 16, 839<br />
Urbauer D. 685, 938<br />
Urdaneta G. 1042<br />
Ure I. 808<br />
Usera G. 295<br />
Useros E. 285<br />
Ushijima S. 697<br />
Uvelius B. 275<br />
Numbers refer to abstract numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
507
Abstract Authors<br />
V Vacca F. V21<br />
Vacherot F. 691<br />
Vacirca F. 1041<br />
Vagnoni V. 829, 833<br />
Vaiciunas K. 946<br />
Vaishampayan U. 97<br />
Vajpeyi R. 194<br />
Valdés Olmos R.A. 555<br />
Valeri A. 415, 463, 580, 752<br />
Valerio M. 1045<br />
Validire P. 131<br />
Vallancien G. 759, 793, 835, 841<br />
Vallasciani S.A. 377<br />
Van Agt S. 906<br />
Van Audenhove C. 948<br />
Van Basten J.P. 584<br />
Van Boven H.H. 555, 559<br />
Van Cangh P. 679, 832, 1009<br />
Van Den Bergh L. 153<br />
Van Den Bergh R.C.N. 25, 611, 974<br />
Van Der Aa M.N.M. 52, 195<br />
Van Der Graaf W.T.A. 564<br />
Van Der Horst C. 520, 549<br />
Van Der Horst E.J.H. 733<br />
Van Der Kwast T. 51, 52, 195, 321,<br />
690<br />
Van Der Ploeg T. 733<br />
Van Der Poel H.G. 555, 851<br />
Van Diest P.J. 761<br />
Van Doorn B. 496, 499, 502<br />
Van Hemelrijck M.J.J. 134, 755<br />
Van Herpen C.M.L. 564<br />
Van Kerrebroeck P.E.V. 129, 774<br />
Van Koeveringe G.A. 129<br />
Van Kuppevelt T.H. 252, 253<br />
Van Leeuwen P. 25, 611, 963, 969,<br />
974<br />
Van Leeuwen T.G. 299<br />
Van Lin E.N.J.T. 622<br />
Van Onna I.E.W. 201<br />
Van Oort I.M. 584, 622, 713<br />
Van Poppel H. 24, 153, 679, 683,<br />
686, 832, 838, 948, 977, 1009,<br />
1013<br />
Van Rhijn B.W. 51, 52, 194, 195,<br />
321, 690<br />
Van Roermund J.G.H. 613<br />
Van Vugt H.A. 25<br />
508 Programme Book<br />
Van Vulpen M. 613<br />
Van Werkhoven E. 559<br />
Van Zevenhoven J. 851<br />
Vanden Berg B. 894<br />
Vander Eeckt K. 389, 679, 832, 838,<br />
1009<br />
Vannelli G. 634<br />
Varca V. 1007<br />
Varkarakis V.I. 203<br />
Varshavskij V.A. 368<br />
Vasdev N. 735<br />
Vasilev A.V. 643<br />
Vasilyeva L.I. 485<br />
Vattovani V. 535<br />
Vaucher L. 427<br />
Vavallo A. 338<br />
Vázquez J.J. 705<br />
Vedulas S. 944<br />
Veliev E.I. 987<br />
Vendeira P. 71, 180<br />
Venier N.A. 664<br />
Venkateswaran V. 664<br />
Venzi G. 386<br />
Vercellotti G. 863<br />
Vereshagin G.V. 901<br />
Vergunst H. 713<br />
Verhoest G. 300, 418, 768<br />
Verri C. 196, 197<br />
Verrini G. 1025<br />
Verze P. 229, 526<br />
Vesely S. 865<br />
Vesey S.G. 913<br />
Vespasiani G. 525, 527<br />
Vianello A. 933<br />
Vianello F. 169<br />
Vicente E. 419<br />
Vickers A.J. 974, 982<br />
Vidal-Mora I. 725<br />
Vidali M. 687, 1012<br />
Vidaurreta M. 285<br />
Vigneau C. 562<br />
Vignozzi L. 634<br />
Vikram R. 762<br />
Viktrup L. 994<br />
Villa L. 23, 213, 609, 827, 836, 1010<br />
Villacampa F. 295, 339<br />
Villard E. 521<br />
Villari D. 822<br />
Villavicencio H. 55, 489, 493, 887,<br />
1042, V31<br />
Villers A. 414, 415, 418, 463, 768,<br />
936<br />
Vinarov A.Z. 368, 373<br />
Vincendeau S. 752, 906, 986<br />
Vincent S. 777, 783<br />
Vincenti G. 886<br />
Vinci S. 822<br />
Vineis P. 820<br />
Viney R.P.C. 949<br />
Viola M. 1025<br />
Virag R. 175, 180<br />
Viryasov A. 361<br />
Vis A.N. 51<br />
Visakorpi T. 852<br />
Viso M.J. 675<br />
Vittori V. 443, 634<br />
Vivacqua C. 988<br />
Vizoso F. 284, 672<br />
Vlachopoulos C. 176<br />
Vlahova A. 748<br />
Vogel U. 710<br />
Voigt S. 109<br />
Voinea S. 429<br />
Volkmer B.G. 323<br />
Volkov A. 1019<br />
Volkova M.I. 579<br />
Volpe A. 687, 1012<br />
Volpe V.A. 198, 234<br />
Von Bodman C. 442, 878<br />
Von Eggeling F. 98, 722<br />
Von Gunten M. 34<br />
Von Ruecker A. 568<br />
Von Weyhern C.H. 26<br />
Voorham-Van der Zalm P.J. 704<br />
Vora K. 1035<br />
Vordos D. 63, 691, 840<br />
Vorobyev N.V. 1003<br />
Vos P. 713<br />
Vottero M. 513<br />
Vozianov S.A. 721<br />
Vricella G.J. 1050<br />
Vuorela A. 141<br />
W<br />
Waalkes S. 416, 446, 567, 572<br />
Wach S. 923<br />
Wael W. 341<br />
Wagener N. 570, 1004, 1022<br />
Numbers refer to abstract numbers
Wagenlehner F.M.E. 366, 367, 487,<br />
490, 746<br />
Wagner S. 396, 539<br />
Wagner V. 978<br />
Wahyudi I. 358<br />
Wake R. 765<br />
Walcher U. 756<br />
Waldert M. 437, 581, 586<br />
Waliszewski P. 111<br />
Walldius G. 755<br />
Wallerand H. 415, 463<br />
Walter B. 572<br />
Walter M. 98, 550<br />
Walther S. 597, V45<br />
Walton T. 37, 38, 1027<br />
Walz J. 132, 679, 686, 832, 1009<br />
Walzer S. 94<br />
Wang C. 261<br />
Wang C.J. 77<br />
Wang G. 352<br />
Wang J. 779<br />
Wang J.Y. 877<br />
Wang K.J. 348, 356<br />
Wang L. 348, 356<br />
Wang S.M. 224<br />
Wang Z. 260<br />
Wangpeng W. 935<br />
Ward J.F. 941<br />
Warneke C.L. 685, 938<br />
Watanabe M. 266<br />
Watanabe N. 127<br />
Watanabe T. 1031<br />
Watd J.F. 942<br />
Watkin N. 552, 554, 556, 557<br />
Watson I.R. 574<br />
Watson J. 759<br />
Wazait H. 349, 595<br />
Webb D.R. 914<br />
Weber T. 569<br />
Weber Dsbrowska B. 374<br />
Wedel S.A. 145<br />
Weder L. 549<br />
Wefer B. 113<br />
Wegener G. 416, 446<br />
Wegiel B. 863<br />
Wehrberger C. 292, 501, 787<br />
Weibl P. 298, 437<br />
Weidner W. 179, 366, 367, 424, 487,<br />
490, 746<br />
Weikert E. 654<br />
Weikert S. 95, 571, 911<br />
Weise C. 617, 618<br />
Weiss C. 545<br />
Weiss J.P. 779<br />
Wendt-Nordahl G. 351, 478<br />
Wenske S. 878<br />
Werner W. 150<br />
Werther M. 387<br />
Westermann J. 95<br />
Weston R. 918<br />
Westphal J. 893<br />
Wetterwald A. 279, 281, 282<br />
Wharton I.P. 388<br />
Whelan K. 860<br />
Whelan P. 142, 560<br />
Whiteway J.E. 17<br />
Widmer A.F. 460<br />
Widmer H. 769<br />
Wieczorek D. 487<br />
Wieland M. 1045<br />
Wieland W.F. 36, 43, 326, V45<br />
Wiener H. 296<br />
Wiesner C. 200<br />
Wijkstra H. 299, 764<br />
Wijkström H. 328<br />
Wijnen R.M.H. 252, 253<br />
Wiklund N.P. 786, 1026<br />
Wilbertz T. 667, 671, 743<br />
Wilbraham D. 777<br />
Wilbrandt K. 367<br />
Wild J.B. 152<br />
Wild P.J. 815<br />
Williams K. 933<br />
Williams S.T. 488<br />
Wilson S.K. 532<br />
Wilson T.H. 959, 960, 983, 990<br />
Wilson T. 717<br />
Windahl T. 551<br />
Winkler C. 1006<br />
Winkler M.H. 789<br />
Winqvist O. 15<br />
Winter A. 911<br />
Winter C. 730, V12<br />
Wirbatz A. 179<br />
Wirth M.P. 109, 473, 476, 569, 665,<br />
747<br />
Wissmeyer M.P. 1017<br />
Witjes J.A. 584, 622, 713, 931, 932<br />
Wiunig C. 586<br />
Wisniewski P. V39<br />
Wolff S. 520<br />
Wolffenbuttel K.P. 276<br />
Wolters T. 25, 611, 974<br />
Won Y.Y. 161, 785<br />
Wong C.W. 765<br />
Wong K.K. 223<br />
Woo H.H. 879<br />
Wood C.G. 762<br />
Wood D.N. 811<br />
Wood S. 90<br />
Woodhouse C.R.J. 811<br />
Wowra B. 770<br />
Wronczewski A. 1032<br />
Wu C.L. 924<br />
Wu C.Y. 22<br />
Wu P. 348<br />
Wu P.H. 235<br />
Wu W.J. 77<br />
Wuethrich P.Y. 702, 834<br />
Wülfing C. 36<br />
Wullich B. 11, 654, 923<br />
Wunderlich H. 98, 475, 550, 572,<br />
722<br />
Wuttig D. 569<br />
Wyczólkowski M. 122<br />
Wyler S. 460, 891<br />
Wyndaele J.J. 774<br />
X Xavier X. 841<br />
Xiao X. 765<br />
Xiao N. 1053<br />
Xie H. 257<br />
Xylinas E. 63<br />
Y Yacoub M. 669<br />
Yadav A. 519, 699<br />
Yagi H. 428<br />
Yakar D. 713<br />
Yakovlev P.G. 721<br />
Yakupoglu Y.K. 810<br />
Yalçınkaya F.R. 737<br />
Yamada Y. 697<br />
Yamaguchi A. 393<br />
Yamaguchi K. 394<br />
Yamaguchi O. 507<br />
Numbers refer to abstract numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
509
Abstract Authors<br />
Yamamoto H. 720, 858<br />
Yamamoto H. 625<br />
Yamamoto S. 16, 56, 106, 165, 591,<br />
839, 964<br />
Yamamoto T. 968<br />
Yamamoto T. 241, 1002<br />
Yaman O. 303<br />
Yamanaka H. 968<br />
Yamanaka Y. 206<br />
Yanagida T. 507<br />
Yanai H. 266<br />
Yang B. 255<br />
Yang S.C. 65, 319, 466, 588, 895<br />
Yang W.J. 624, 666<br />
Yano A. 897<br />
Yashi M. 889<br />
Yavascaoglu I. V10<br />
Yazdannejad H. 742<br />
Yee D.S. 438, 943<br />
Yeh H.C. 77<br />
Yencilek F. 220<br />
Yi J.S. 883<br />
Yildiz K. 297<br />
Yim S.H. 76, 369<br />
Yin G.N. 186<br />
Yip S.K.H. 235<br />
Ylikomi T. 635<br />
Yokomizo A. 859<br />
Yokoyama H. 117<br />
Yokoyama M. 20, 165<br />
Yokoyama O. 127<br />
Yonese J. 16, 20, 106, 165, 591, 839,<br />
964<br />
Yoneyama T. 720, 858<br />
Yoo C. 227<br />
Yoo E.S. 400, 404, 709<br />
Yoo J.J. 933<br />
Yoo K.H. 636<br />
Yoo T.K. 603<br />
Yoon C.Y. 104, 239, 673, 823, 825,<br />
866, 912, 1001<br />
Yoon D.K. 73, 174, 508, 582<br />
Yoon S.J. 66, 271<br />
Yoon S.M. 186, 271, 301<br />
Yoshida K. 925<br />
Yoshida S. 12, 45, 47, 927<br />
Yoshimura N. 117<br />
Yoshiyama M. 119<br />
Yoshiyasu T. 507<br />
510 Programme Book<br />
Yossepowitch O. 1043<br />
You D. 177, 324, 439, 719<br />
Youcheng Y. 935<br />
Youn D.K. 740<br />
Yu H.J. 224, 474<br />
Yu H.S. 107, 510, 590, 760<br />
Yu J.H. 168<br />
Yudovskiy S.O. 637<br />
Yue-Min X. 257<br />
Yuen J.S.P. 59<br />
Yuichi Y. 20<br />
Yun J.C. 66, 271<br />
Yunoki T. 267<br />
Yunusov D.S. 354<br />
Z Zaak D. 1039, V45<br />
Zabarskas A. 19<br />
Zacchero M. 687<br />
Zacharakis E. 431, 530<br />
Zaggia B. 207<br />
Zahariou A. 773<br />
Zahran A.R. 219<br />
Zaitcev A. 637<br />
Zaiton F. 10, 221<br />
Zakhour H.D. 58<br />
Zakohji H. 119, 698<br />
Zamecnik J. 651<br />
Zamecnik L. 651<br />
Zamora J. 335<br />
Zampa G. 196<br />
Zandegiacomo S. 5, 594<br />
Zangerl F. 732<br />
Zani D. 263, 440<br />
Zanni G. 827<br />
Zanollo L. 514<br />
Zanoni M. 81<br />
Zanotelli T. 440<br />
Zarkovski M. 423<br />
Zattoni F. 169<br />
Zaytsev V. 775<br />
Zecha H. V16<br />
Zehnder P. 1017<br />
Zehri A.A. 379<br />
Zempleni M.Z. 518<br />
Zerrouki S. 562<br />
Zhang X.C. 352<br />
Zhao A. 289<br />
Zhao C. 881<br />
Zhao H. 864<br />
Zheng J.H. 255<br />
Zheng Y.Q. 435<br />
Zhou G.D. 260<br />
Zhou J. 92<br />
Zhou L.H. 255<br />
Zhou L.Q. 352<br />
Zhu L. 877<br />
Ziegler M. 692<br />
Zigeuner R. 286, 294, 450, 478, 541<br />
Zikman J. 587<br />
Zimmermann K. 95<br />
Zimmermann R.P. 645<br />
Zimmermanns V. 600<br />
Zini L. 414, 415, 418, 463, 768<br />
Zisman A. 211<br />
Zitella A. 820<br />
Zitzmann M. 75<br />
Zlobec I. 874<br />
Zlotta A.R. 51, 52, 99, 194, 195, 321,<br />
690<br />
Zogas V. 382<br />
Zokoev A.K. 461<br />
Zorn M. 452<br />
Zucchi A. 395, 527<br />
Zuluaga Gomez A. 467, 484<br />
Zwarthoff E.C. 51, 52<br />
Numbers refer to abstract numbers
Abstracts sorted by Topic<br />
Adrenals<br />
V8, V9, V10, 203, 204, 205, 206, 207<br />
BPH<br />
Basic research<br />
500, 501, 502, 623, 624, 625, 626, 627, 628, 629, 630,<br />
631, 632, 633, 634, 635, 636<br />
Evaluation<br />
496, 497, 498, 499, 503, 504, 505, 506, 507, 508, 509,<br />
510<br />
Medical therapy<br />
990, 991, 992, 995, 996, 999, 1000, 1001, 1002<br />
Intervention therapy<br />
V13, V26, V27, V44, 879, 880, 881, 882, 883, 884, 885,<br />
886, 887, 888, 889, 890, 891, 892, 893, 993, 994, 997,<br />
998<br />
Female urology<br />
Basic research<br />
649, 704, 1045, 1048, 1049, 1050, 1052<br />
Diagnosis and treatment<br />
V21, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400,<br />
401, 402, 403, 404, 637, 638, 639, 641, 693, 694, 695,<br />
703, 705, 784, 785<br />
History of urology<br />
842, 843, 844, 845, 846, 847, 848, 849, 951, 952, 953,<br />
954, 955, 956, 957, 958<br />
Infectious diseases<br />
V5, 171, 360, 361, 362, 363, 364, 365, 366, 367, 368,<br />
369, 370, 371, 372, 373, 374, 482, 483, 484, 485, 486,<br />
487, 488, 489, 490, 491, 492, 493, 494<br />
Infertility<br />
422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432,<br />
433, 434, 435, 436<br />
Kidney transplantation<br />
Basic research<br />
V3, 452, 453, 454, 457<br />
Clinical<br />
330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340,<br />
341, 342, 343, 344, 455, 456, 458, 459, 460, 461, 462,<br />
463, 464, 465, 466<br />
Kidney tumours<br />
Basic research<br />
96, 563, 564, 565, 566, 568, 569, 570, 571, 572, 573,<br />
574, 575, 576, 757<br />
Diagnosis<br />
286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296,<br />
297, 298, 299, 414, 415, 416, 419, 420, 421, 567<br />
Surgical treatment<br />
V4, V28, V29, 101, 437, 438, 439, 440, 441, 442, 443,<br />
444, 445, 446, 448, 449, 450, 451, 533, 534, 535, 536,<br />
537, 538, 539, 540, 541, 542, 756, 769<br />
Minimally invasive treatment<br />
V2, V6, V7, V39, 417, 447, 543, 545, 546, 758, 759, 760,<br />
761, 762, 763, 764, 765, 766, 767, 768, 770<br />
Medical Treatment<br />
94, 95, 97, 98, 99, 100, 300, 418, 544, 562<br />
Neuro-urology<br />
Basic research<br />
85, 86, 87, 117, 118, 119, 124, 125, 126, 127, 130, 263, 264,<br />
265, 268, 269, 270, 271, 272, 275, 518, 520, 524, 1054<br />
Diagnosis and treatment<br />
89, 90, 91, 405, 511, 512, 513, 514, 515, 516, 517, 521,<br />
522, 523, 643, 645, 646, 647, 650, 697, 702, 771, 1055,<br />
1056, 1057, 1058<br />
Non-neurogenic voiding dysfunction<br />
Basic research<br />
88, 120, 121, 122, 123, 128, 129, 131, 237, 238, 266, 267,<br />
273, 276, 277, 519, 648, 651, 783, 1044, 1046, 1047, 1051,<br />
1053<br />
Diagnosis and treatment<br />
92, 93, 233, 234, 235, 236, 239, 240, 241, 242, 243, 244,<br />
245, 246, 247, 274, 640, 642, 644, 692, 696, 698, 699,<br />
701, 706, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781,<br />
782<br />
Paediatrics<br />
V41, 652, 653, 654, 655, 656, 657, 658, 659, 733, 734,<br />
735, 736, 737, 738, 739, 740, 801, 802, 803, 804, 805,<br />
806, 807, 808, 809, 810, 811<br />
Penis/testis<br />
Testis tumours<br />
V37, V38, 553, 720, 721, 723, 724, 725, 726, 727, 728,<br />
729, 730, 731, 732<br />
Penile disorders (excluding urethra)<br />
525, 526, 527, 528, 529, 530, 531, 547, 548, 549, 550,<br />
551, 552, 554, 555, 556, 557, 558, 559, 560, 561<br />
Numbers refer to abstract numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
511
Abstracts sorted by Topic<br />
Prostate cancer<br />
Basic research<br />
146, 278, 279, 280, 281, 282, 283, 284, 285, 661, 662,<br />
664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674,<br />
741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751,<br />
752, 753, 754, 755, 850, 851, 852, 853, 854, 855, 856,<br />
857, 858, 859, 860, 861, 862, 863, 864, 876, 877, 904,<br />
946, 949, 950, 987, 988<br />
Screening/diagnosis<br />
24, 25, 61, 68, 102, 103, 104, 105, 106, 107, 116, 169, 580,<br />
583, 584, 587, 588, 589, 590, 959, 960, 961, 962, 963,<br />
964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974<br />
Pathology and biopsies<br />
18, 19, 20, 21, 22, 23, 28, 29, 30, 31, 32, 56, 57, 58, 59,<br />
60, 62, 63, 64, 65, 66, 67, 69, 70, 108, 109, 110, 111, 112,<br />
113, 114, 115, 160, 161, 162, 163, 164, 165, 166, 167, 168,<br />
170, 172, 577, 578, 579, 581, 582, 585, 586, 591<br />
PSA and markers<br />
26, 27, 140, 865, 866, 867, 868, 869, 870, 871, 872, 873,<br />
874, 875, 878, 975, 976, 977, 978, 979, 980, 981, 982,<br />
983, 984, 985, 986, 989<br />
Imaging and new techniques<br />
V45, 147, 149, 150, 151, 153, 154, 155, 156, 159, 676, 707,<br />
708, 709, 710, 711, 712, 713, 714, 715, 717, 718, 719, 1012<br />
Staging<br />
152, 675, 716, 1003, 1004, 1005, 1006, 1007, 1009, 1011,<br />
1013<br />
Surgical management of localised tumours<br />
V11, V12, V14, V15, V17, V18, V20, V30, 148, 616, 677, 678,<br />
679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689,<br />
690, 691, 786, 787, 788, 789, 790, 791, 792, 793, 794,<br />
795, 796, 797, 798, 799, 800, 827, 828, 829, 830, 831,<br />
832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 906,<br />
907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918,<br />
9<br />
Non-surgical management of localised tumours<br />
607, 608, 609, 610, 611, 612, 613, 614, 615, 617, 618, 619,<br />
620, 621, 622, 663, 898, 940, 941, 942, 943, 944, 945,<br />
947, 948<br />
Management of metastatic disease<br />
132, 133, 134, 135, 136, 137, 138, 139, 141, 142, 143, 144,<br />
145, 157, 158, 894, 895, 896, 897, 899, 900, 901, 903,<br />
905, 939, 1010<br />
Sexual dysfunction<br />
Basic research<br />
71, 72, 73, 74, 76, 77, 79, 80, 174, 176, 177, 180, 181, 182,<br />
183, 184, 302, 311, 312<br />
512 Programme Book<br />
Diagnosis and treatment<br />
75, 78, 81, 82, 83, 84, 173, 175, 178, 179, 185, 186, 187,<br />
301, 303, 304, 305, 306, 307, 308, 309, 310, 313, 314,<br />
315, 532<br />
Stones<br />
Medical/research<br />
218, 231, 467, 468, 469, 470, 471, 472, 473, 474, 475,<br />
476, 477, 478, 479, 480, 481<br />
ESWL<br />
219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229<br />
Open and percutaneous<br />
V22, V23, V24, 1, 2, 3, 4, 5, 6, 7, 8, 9, 345, 346, 347, 348,<br />
349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359<br />
Ureteroscopy<br />
232, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601,<br />
602, 603, 604, 605, 606<br />
Upper tract benign disease<br />
V25, 230<br />
Trauma<br />
V19, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217<br />
Uro-genital reconstruction/urethral<br />
strictures<br />
V16, V34, V35, V36, V40, V42, V43, 248, 249, 250, 251,<br />
252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262,<br />
375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385,<br />
386, 387, 388, 389, 390, 406, 407, 408, 409, 410, 411,<br />
412, 413, 660<br />
Urothelial tumours<br />
Basic research<br />
722, 812, 813, 815, 816, 817, 819, 820, 821, 822, 823, 824,<br />
825, 826, 922, 923, 924, 925, 926, 927, 928, 929, 930,<br />
931, 932, 933, 934, 935<br />
Diagnosis and staging<br />
V33, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46,<br />
47, 48, 49, 50, 51, 52, 53, 54, 55<br />
Management of superficial tumours<br />
188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199,<br />
200, 201, 202, 814, 818, 921, 1029, 1030, 1031, 1032,<br />
1033, 1034, 1035, 1036, 1037, 1038, 1039, 1040, 1041,<br />
1042, 1043<br />
Management of infiltrative/advanced tumours<br />
V1, V31, V32, V46, 10, 11, 12, 13, 14, 15, 16, 17, 316, 317,<br />
318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328,<br />
329, 1014, 1015, 1016, 1017, 1018, 1019, 1020, 1021, 1022,<br />
1023, 1024, 1025, 1026, 1027, 1028<br />
Numbers refer to abstract numbers
Sessions sorted by Topic<br />
Andrology<br />
39, 42, 106, 167, 239, 240, 241, 257, 278, 304, 310, 355<br />
Benign prostatic hyperplasia<br />
44, 47, 259, 283, 306, 328, 330, 333, 339, 344, 351<br />
Bladder cancer<br />
40, 44, 105, 264, 274, 308, 320, 323, 345, 356<br />
Bladder overactivity<br />
47, 239, 327, 332, 338<br />
Infections<br />
43, 106, 260, 320, 350<br />
Female urology<br />
111, 243, 254, 273, 318, 350<br />
Laparoscopy<br />
241, 263, 281, 284, 286, 289, 297, 299, 300, 301, 354<br />
Miscellaneous<br />
52, 108, 168, 186, 188, 251, 270, 271, 303, 334, 335<br />
Miscellaneous- oncology<br />
47, 239, 294, 288, 308, 342<br />
Molecular medicine<br />
Neuro-urology<br />
239, 296<br />
(New) technologies<br />
108, 169, 184, 186, 306, 314, 346, 349, 354, 357<br />
Paediatric urology<br />
50, 182, 183, 239, 256<br />
Penis cancer<br />
43, 357<br />
Prostate cancer/Prostate disease<br />
39, 40, 41, 42, 44, 45, 47, 91, 186, 167, 188, 239, 240,<br />
246, 253, 266, 268, 276, 293, 306, 324, 325, 329, 331,<br />
337, 340, 344, 346, 348, 349, 350, 357<br />
Reconstruction<br />
42, 44, 167, 181, 239, 243, 273, 310, 314<br />
Renal cancer<br />
40, 44, 45, 47, 51, 56, 58, 249, 279, 309, 326, 342, 343,<br />
349, 353<br />
Robotic surgery<br />
58, 168, 241, 247, 269, 286, 306, 318, 347<br />
Testis cancer<br />
291, 308<br />
Transplantation<br />
50, 109, 167, 183, 239, 262, 312<br />
Trauma<br />
239, 292<br />
(Urinary) incontinence<br />
39, 41, 43, 44, 239, 240, 295, 327, 336, 345<br />
Urolithiasis/Stone disease<br />
239, 245, 316<br />
Numbers refer to <strong>page</strong> numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
513
List of Speakers (not abstracts)<br />
514<br />
A<br />
Abbou C., 68, 130, 168, 174, 195,<br />
198, 204, 221, 237, 306, 359<br />
Abenhaim L., 346<br />
Abol-Enein H., 170, 231, 311, 320<br />
Abrahamsson P-A., 53, 55, 92, 240,<br />
346, 359, 364<br />
Abrams P., 197, 259<br />
Aghajanyan G., 48<br />
Akduman B., 48, 126<br />
Akilov F.A., 49, 122<br />
Al Awadi K., 45<br />
Al Dayel A., 45<br />
Al Zahrani H., 46<br />
Albaugh J., 377<br />
Albers P., 72, 148, 180, 291, 343<br />
Albertsen P.C., 91, 340<br />
Alcaraz A., 59, 67, 103, 120, 138, 167,<br />
190, 201, 224, 264, 307, 344, 359<br />
Alchinbayev M.K., 48<br />
Algaba F., 51, 93, 303, 306<br />
Alivizatos G.J., 211, 306<br />
Alken P., 48, 122, 140, 151<br />
Alkhudair W., 45<br />
Allen C., 84, 177, 219<br />
Alothman K., 46<br />
Andrich D.E., 310<br />
Andriole G., 91, 225<br />
Anson K.M., 227, 283<br />
Apolikhin O., 48<br />
Arce J., 306<br />
Aref M., 48<br />
Arlandis Guzman S., 319, 332<br />
Artibani W., 41, 239, 286<br />
Assimos D.G., 60<br />
Aulitzky W., 278<br />
Aus G., 160, 223<br />
Austoni E., 310<br />
Ayati M., 42<br />
Ayubov B., 49<br />
Azzouzi R., 132, 139, 156, 193, 207,<br />
219, 346<br />
B<br />
Babjuk M., 95, 201, 209, 274<br />
Bachmann A., 138, 212, 330<br />
Bamias A., 326<br />
Bangma C.H., 66, 93, 160, 224, 230<br />
Barbagli G., 42, 101, 126, 254<br />
Programme Book<br />
Bardan R.T., 297<br />
Barentsz J., 186<br />
Barkin J., 227, 328<br />
Barret E., 59, 194, 198, 203, 219,<br />
346<br />
Bartoletti R., 68, 124, 201, 217, 320<br />
Bartsch G., 83, 191, 226<br />
Bassi P., 88, 99<br />
Bassi P.F., 94, 179, 308<br />
Batista Miranda J.E., 351<br />
Baumert H., 72, 132, 139, 297<br />
Belgrano E., 310<br />
Bellmunt J., 51, 56, 61, 75, 308, 342<br />
Bettocchi C., 120, 304<br />
Bex A., 56, 76, 152, 309<br />
Bjartell A., 208, 217, 225, 308<br />
Bjerklund Johansen T.E., 142, 283,<br />
320, 349<br />
Blana A., 169, 205, 219, 348<br />
Bliwise D., 327<br />
Boccon-Gibod L., 254, 309, 340<br />
Bogaert G.A., 183, 239, 256, 318<br />
Bolla M., 329<br />
Bonfils-Rasmussen B., 373<br />
Borre M., 216, 368, 378<br />
Bosch J.L.H.R., 94, 144, 155, 194<br />
Bossi A., 324<br />
Botto H., 209, 320<br />
Boustedt G., 306<br />
Bracarda S., 75<br />
Brausi M., 94, 118, 169, 232, 308,<br />
356<br />
Breda A., 234, 299, 307, 335, 349<br />
Breda G., 150, 297, 306<br />
Brehmer M., 359<br />
Brewster S., 215, 308<br />
Brock G., 117, 227<br />
Bruun P., 378<br />
Buchholz N.P., 97, 122, 158, 316, 369<br />
Bucholz N.P., 299<br />
Bucuras V., 299, 307<br />
Burchardt M., 194<br />
Burgos Revilla F.J., 120, 262, 312,<br />
328<br />
Burkhard F.C., 148, 176, 203, 231,<br />
243<br />
Buvat J., 341<br />
C<br />
Carballido J., 64, 343<br />
Castillo O., 44<br />
Cathelineau X., 194, 198, 203, 229,<br />
239, 263<br />
Catto J.W.F., 66, 201<br />
Cavelier L.E., 44<br />
Cecchini L., 44<br />
Çek H.M., 124, 321<br />
Cestari A., 70, 78, 95, 132, 137, 150,<br />
156, 194, 297<br />
Chapple C.R., 43, 47, 73, 79, 111, 211,<br />
228, 235, 237, 254, 333, 359<br />
Chartier-Kastler E., 73, 80, 103, 146,<br />
239, 295, 319, 333<br />
Chatterton K., 369, 371<br />
Chiu A., 56<br />
Chkhotua A.B., 120, 312<br />
Chlosta P., 167<br />
Choo M.S., 39<br />
Christiansen T., 367, 369<br />
Chung M.K., 39, 77<br />
Clarke N.W., 91, 113, 291, 325<br />
Coelho M.F., 314<br />
Colecchia M., 303<br />
Colombel M., 93, 172, 195, 219, 337,<br />
356<br />
Compérat E., 303<br />
Constantinou C., 318<br />
Costa P., 39<br />
Costantini E., 91, 128, 318<br />
Cowan N., 186<br />
Cranston D., 109, 195<br />
Cruz F.R., 45, 73, 79, 111, 162, 164,<br />
167, 239, 296, 333<br />
Cussenot O., 156, 171, 193, 201, 207<br />
D<br />
Dasgupta P., 73, 162, 232, 286, 369<br />
De Blok W.M., 368, 370<br />
De La Rosette J., 60, 81, 140, 211,<br />
279, 303, 306<br />
De La Taille A., 62, 68, 93, 130, 132,<br />
195, 204, 221, 224, 307, 344, 347<br />
De Reijke T.M., 160, 308<br />
De Ridder D.J.M.K., 273, 336<br />
De Wachter S.G.G., 80, 167, 196<br />
Debruyne F.M.J., 41, 53, 339, 346<br />
Deger S., 112, 226, 310<br />
Numbers refer to <strong>page</strong> numbers
Demirkesen O., 311<br />
Denis L., 53, 92, 368<br />
Deprest J., 243<br />
Derchi L.E., 187<br />
Desai M.M., 185<br />
Desgrandchamps F., 228, 331<br />
Di Tonno P., 312<br />
Dickens N., 369<br />
Diemer T., 305<br />
Dietel A., 194, 307<br />
Dinis Oliveira P., 73, 319<br />
Dinis P., 73, 111, 128, 162, 319<br />
Ditonno P., 120<br />
Djakovic N., 189, 205, 229, 231<br />
Djavan B., 42, 276, 309<br />
Dohle G.R., 305<br />
Dreikorn K., 262<br />
Drudge-Coates L., 363, 368<br />
E<br />
Eardley I., 153, 239, 257, 305<br />
Egawa S., 47<br />
Elf V., 369<br />
Emberton M., 45, 69, 77, 84, 156,<br />
169, 177, 219, 306, 344, 346<br />
Erdogru T., 297<br />
Esen T., 144, 359<br />
F<br />
Faithfull S., 368<br />
Feitz W.F.J., 101, 182<br />
Ferrero C.F., 378<br />
Ficarra V., 43, 64, 94, 118, 136, 232,<br />
270<br />
Figarov I., 48<br />
Figueiredo A.J., 109, 138, 312<br />
Fillingham S.P., 362<br />
Fisch M.M., 200, 295, 310<br />
Fitzgerald M.P., 327<br />
Fitzpatrick J.M., 45, 228, 351<br />
Fitzpatrick K., 369, 379<br />
Fizazi K., 308<br />
Fornara P., 121, 128, 139, 150, 281<br />
Fowler C.J., 79, 146, 318<br />
Frauscher F., 83, 102<br />
Fredriksen A., 369<br />
Fusco F., 98, 149, 304<br />
Fütterer J., 156<br />
G<br />
Gaboardi F., 49, 72, 99, 190, 297<br />
Garofalo M., 203, 359<br />
Gausa L., 234, 306<br />
Gaybullaev A., 49<br />
Gea-Sánches M., 364<br />
Geavlete B., 211, 330<br />
Geavlete P.A., 130, 158, 177, 211, 314<br />
Gelet A., 219<br />
Geng V., 378<br />
Ghoneim M.A., 131, 170<br />
Giannarini G., 64, 202, 231, 270<br />
Giessing M., 50, 59, 72, 312<br />
Giuliano F., 80, 103<br />
Gleave M., 325<br />
Gomez Sancha F., 205<br />
Gontero P., 62, 64, 68, 173, 201, 203,<br />
224, 229, 279<br />
Govorov A., 309<br />
Grabe M., 122, 320, 350<br />
Grainger E., 373<br />
Gratzke C.J., 70, 240, 271, 345<br />
Grenabo L.J.G., 251<br />
Grimm M.O., 64, 77, 154, 192<br />
Gronberg H., 91<br />
Gross A.J., 299<br />
Gruenwald I., 87<br />
Gruschy L., 369<br />
Gschwend J.E., 61, 84, 174, 202,<br />
209, 217, 229, 280, 353<br />
Guazzoni G., 63, 70, 95, 134, 137,<br />
150, 156, 160, 173, 194, 203, 269,<br />
306<br />
Guillonneau B., 173, 219<br />
Guisti G., 299<br />
Gözen A.S.,297, 306, 359<br />
H<br />
Haas G.P., 156, 359<br />
Haas H., 251<br />
Haase U.L.M., 378<br />
Haese A., 62, 68, 77, 91, 161, 173,<br />
198, 215, 224<br />
Hakenberg O.W., 138, 152, 246<br />
Hamdy F.C., 91, 201, 240, 253<br />
Hammerer P., 198, 293, 328<br />
Hanus M., 251, 339<br />
Hargreave T.B., 106<br />
Hartmann A., 65, 119, 155, 179, 201,<br />
205, 217<br />
Hashim H., 175<br />
Heesakkers J.P.F.A., 49, 79, 128, 144,<br />
197, 240, 318<br />
Heidenreich A., 40, 47, 99, 179, 189,<br />
192, 213, 288, 308, 329, 357<br />
Hendrickx J., 371<br />
Hernández C., 307<br />
Heynemann H., 314<br />
Hieronymi S., 361<br />
Hilborn J., 181<br />
Hjuler A., 378<br />
Hoefner K., 211, 259<br />
Hoepffner J.L., 318<br />
Holmberg L., 81, 91, 160, 193<br />
Horenblas S., 76, 152<br />
Hosseini J., 42, 126<br />
Hoznek A., 68, 130, 174, 190, 204,<br />
221<br />
Hubert J., 132, 139, 269<br />
I<br />
Imamverdiyev B., 48<br />
J<br />
Jacqmin D., 42, 93, 114, 155, 279,<br />
343<br />
James N., 324<br />
Janetschek G., 56, 164, 168, 184,<br />
281, 306<br />
Jannini E.A., 341<br />
Jansen W.C., 378<br />
Jaureguizar Monereo E., 374<br />
Javad-zada S., 48<br />
Jensen B.T., 363, 373, 377<br />
Jonas U., 53, 87<br />
Jones J., 126, 312<br />
Joniau S.G., 324<br />
Jordan G.H., 167<br />
Joyce A.D., 263, 307<br />
Jungwirth A., 70<br />
Jünemann K.P., 73, 102, 146, 152<br />
K<br />
Kadioglu A., 48, 149, 304<br />
Kamoto T., 47<br />
Karakiewicz P., 51, 156, 173, 203,<br />
215, 326<br />
Numbers refer to <strong>page</strong> numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
515
List of Speakers (not abstracts)<br />
Karam G., 109, 132, 139, 312<br />
Kawakami S., 47, 59, 61, 66, 68, 77,<br />
85, 157, 204, 213, 217, 221<br />
Keeley F., 60, 297<br />
Khauli R., 45<br />
Kiesbye B., 362<br />
Kimura T., 47, 128<br />
Kinsella J., 369<br />
Kinsella J.E., 369<br />
Kirkali Z., 51, 56, 93, 136, 249, 303,<br />
309, 326<br />
Klein J., 297<br />
Klingler H.C., 136, 297<br />
Klocker H., 192, 226<br />
Knoll T., 122, 140, 299, 316<br />
Kuczyk M.A., 87, 132, 136, 144, 154,<br />
162, 171, 194, 235,249, 308, 326<br />
Kulkarni J.N., 43<br />
Kuntz R.M., 283<br />
L<br />
Laguna M.P., 115, 169, 194, 245, 303,<br />
306, 349<br />
Lahme S., 157, 316<br />
Lamm D.L., 356<br />
Larré S., 209, 237<br />
Lauridsen S.V., 364<br />
Lechevallier E., 120<br />
Lee K.S., 39<br />
Lerner S.P., 94, 118<br />
Lester M.E., 369<br />
Li M., 41, 70, 135<br />
Liatsikos E., 194, 212, 297, 306, 354<br />
Lima E., 184<br />
Lledo-garcia E., 120, 138, 312<br />
Llorente C.L.L., 44, 333<br />
Lobel B., 53<br />
Loch T., 78, 83, 306, 314<br />
Lopez Pereira P., 183<br />
Lopez-Beltran A., 303<br />
M<br />
MacNeil S., 181<br />
Machtens S., 266, 314<br />
Madersbacher S., 114, 116, 144, 150,<br />
198, 227, 259, 270, 328<br />
Mahmadyor K.M., 48<br />
Malavaud B., 118, 146, 156, 192, 210,<br />
264, 307<br />
516 Programme Book<br />
Mammedov R., 48<br />
Mammen K., 43<br />
Managadze L., 48, 120<br />
Manassero F., 100, 110<br />
Marberger M., 45, 62, 115, 136, 156,<br />
169, 223, 225, 239, 245, 345<br />
Marin M., 378<br />
Markarov D.V., 352<br />
Martin-Morales A., 70<br />
Martínez-Piñeiro L., 95, 184, 292,<br />
329, 359<br />
Masumori N., 47, 196<br />
McCormack A., 376<br />
McDougall E., 168<br />
Mejean A., 132, 139<br />
Merseburger A.S., 108, 132, 136,<br />
154, 194<br />
Meryn S., 305<br />
Messas A., 300<br />
Messelink E.J., 112, 243<br />
Meuleman E.J.H., 134, 304<br />
Michel M.S., 49, 83, 122, 151, 251,<br />
299, 306<br />
Micic S., 134, 339<br />
Mickisch G., 132, 294, 309<br />
Mikuz G., 303<br />
Miller K., 75, 81, 155, 192, 213, 215,<br />
226, 268, 337<br />
Millán-Rodríguez F., 299<br />
Minhas S., 43, 134, 366<br />
Miranda B., 138<br />
Mirone V., 39, 98, 106, 149, 229,<br />
304, 345<br />
Mitterberger M., 120, 191<br />
Mochtar C.A., 40<br />
Moncada I., 109, 116, 341<br />
Monolov N., 48<br />
Monsalve C., 313<br />
Montironi R., 303<br />
Montorsi F., 47, 62, 69, 78, 81, 83,<br />
86, 95, 114, 116, 134, 137, 150, 156,<br />
160, 173, 194, 203, 215, 224, 227,<br />
270, 324<br />
Moore C., 84, 177, 346<br />
Morgentaler A., 355<br />
Morgia G., 95, 131, 162, 234, 266<br />
Morkved S., 243<br />
Morote Robles J., 81, 188, 213<br />
Mottrie A., 112, 150, 168, 269, 307<br />
Muir G., 219<br />
Mukhtarov S.T., 49, 122<br />
Mulders P.F.A., 47, 51, 56, 75, 132,<br />
154, 325<br />
Mundy A.R., 235, 240, 310<br />
Muradyan A., 48<br />
Murat F.J., 219, 348<br />
Muschter R., 299, 307<br />
Månsson W., 119, 292, 311<br />
Müller S., 64, 168<br />
N<br />
Naber K.G., 320<br />
Naito S., 47, 103, 207, 235<br />
Nappi R., 304<br />
Neal D.E., 91<br />
Nelson J.B., 325<br />
Newman D., 365<br />
Nicita G., 229<br />
Nickel J.C., 260<br />
Nicolai N., 153, 179, 303<br />
Nijman J.M., 41, 183, 191, 256<br />
Nonomura N., 47<br />
Nordling J., 103, 164, 207, 260, 318<br />
Novara G., 64, 94, 99, 118, 132, 232,<br />
271, 338<br />
Nusratulloev I., 48<br />
Nyirády P.J., 68, 297, 366<br />
N’Dow J.M.O., 131, 167<br />
O<br />
O`Brien T., 76, 307, 323, 369<br />
Oelke M., 144, 327<br />
Olsburgh J.O., 312<br />
Oosterlinck W., 93, 233<br />
Orntoft T., 308<br />
Osanto S., 75, 308<br />
Osther P.J., 158, 299, 378<br />
Osther S.S., 159, 316<br />
Ostri P., 307<br />
Oudard S., 75, 342, 357<br />
Ozbas A.O., 378<br />
Özen H., 177, 240, 309<br />
P<br />
Paick J.S., 39, 117, 211<br />
Palma P., 44, 111<br />
Palminteri E., 126, 179, 205, 310<br />
Numbers refer to <strong>page</strong> numbers
Palou J., 81, 142, 148, 234, 274, 306,<br />
309, 320, 331<br />
Pannek J., 146<br />
Pansadoro V., 284, 310<br />
Park K.S., 39<br />
Parsons K.F., 52, 108, 189<br />
Pascual J., 120, 313<br />
Patard J-J., 51, 56, 75, 154, 353<br />
Patel A., 39, 144, 158, 237, 245<br />
Pelzer A., 306<br />
Peri L., 59, 103, 121, 138, 312<br />
Perovic S., 126, 149, 310<br />
Persad R., 356<br />
Peña J.A., 347<br />
Piechaud P.T., 286<br />
Piechaud T., 286, 306<br />
Pieters R., 365, 373<br />
Popert R., 162, 369<br />
Porpiglia F., 95, 130, 150, 281, 354<br />
Porst H., 39, 116, 341<br />
Porta C., 75, 353<br />
Pourmand G.R., 42<br />
Powles T., 76, 343<br />
Pummer K., 114, 128, 150, 198, 225,<br />
268<br />
Pushkar D., 48, 101, 273, 359<br />
Pytel A., 359<br />
Q<br />
Quintanilla Sanz A., 364<br />
R<br />
Rabah D., 45<br />
Radmayr C., 96, 126, 191, 200<br />
Radziszewski P., 196, 239, 339<br />
Ralph D., 149, 257, 304<br />
Rao P.N., 316<br />
Rassweiler J., 150, 168, 198, 241,<br />
297, 306, 316<br />
Ravery V., 308<br />
Redmond K., 368<br />
Reich O., 64, 94, 118, 152, 158, 199,<br />
209, 211, 330<br />
Reichelt O., 121, 139, 297, 354<br />
Reis dos Santos J.M., 316<br />
Renninger M., 118, 181<br />
Ribal Caparros M.J., 61, 91, 184,<br />
344<br />
Ribeiro-Filho L., 44<br />
Riccabona M., 183<br />
Riedmiller H., 131, 193, 207, 310<br />
Rischmann P., 118, 132, 137, 139, 146,<br />
195, 210, 330<br />
Roehrborn C.G., 211, 215, 227<br />
Roigas J., 75<br />
Romics I., 53, 152, 206, 253<br />
Roobol M.J., 62, 156, 160, 223, 352<br />
Rosen R.C., 117, 228, 327<br />
Rouprêt M., 201<br />
Rozet F., 194, 198, 203, 225, 300<br />
Rubin M.A., 209<br />
Rubio Aurioles E., 116<br />
S<br />
Saad F., 342<br />
Sadighi M.A., 42<br />
Safarinejad M.R., 304<br />
Sahl W.A.K., 373<br />
Salonia A., 63, 71, 86, 134, 137, 160,<br />
173, 203, 304, 355<br />
Sanchez-Salas R., 44, 198, 330<br />
Sarica K., 97, 316<br />
Savaser S.S., 378<br />
Scarpa R.M., 49, 60, 95, 122, 130,<br />
150, 316, 334<br />
Scarpelli M., 303<br />
Scattoni V., 62, 69, 78, 83, 86, 137,<br />
224, 229, 293<br />
Schalken J.A., 79, 113, 171, 181, 224,<br />
237<br />
Scherz A., 346<br />
Schlegel P.N., 81, 107, 134<br />
Schneider G., 314<br />
Schneider T., 332<br />
Schröder F.H., 62, 91, 156, 160, 223<br />
Schulman C.C., 304<br />
Schultz A., 311<br />
Scoffone C., 334<br />
Seki N., 47, 103, 201, 235<br />
Selli C., 44, 100, 202, 239<br />
Selvaggi F.P., 120, 234, 313<br />
Semjonow A., 352<br />
Shafir A., 378<br />
Shah J.R., 147, 318<br />
Shariat S.F., 64, 94, 114, 118, 136,<br />
198, 209, 217, 232, 271<br />
Shenfeld O.Z., 101, 310<br />
Shore N., 331, 376<br />
Sibony M., 201<br />
Sievert K.D., 66, 101, 118, 126, 146,<br />
159, 200, 208, 231, 235, 310, 338<br />
Sillén U., 170, 183<br />
Singh P.B., 43, 77<br />
Slawin K.M., 352<br />
Smit - Van Den Hof D., 373<br />
Soebadi D.M., 40<br />
Sofikitis N., 305<br />
Sohn M., 310<br />
Soloway M.S., 105, 160, 233<br />
Solsona E., 43, 105, 171, 204<br />
Sommerhuber A., 371<br />
Sotelo Noguera R., 112<br />
Speakman M.J., 351<br />
Spinelli M., 146, 296<br />
Srinivas V., 43<br />
Stanley N., 351<br />
Stenzelius K., 373<br />
Stenzl A., 62, 66, 77, 96, 101, 118,<br />
126, 146, 159, 170, 175, 177, 181,<br />
200, 208, 225, 231, 235, 239, 280<br />
Sternberg C.N., 294, 337, 357<br />
Stief C., 233, 240, 257<br />
Stolzenburg J-U., 112, 184, 194, 289,<br />
307, 330, 354<br />
Studer U.E., 40, 64, 113, 148, 203,<br />
229, 231, 280<br />
Stöckle M., 63, 83, 138, 192, 247<br />
Sugandi S., 40<br />
Sulser T., 74, 196, 199, 212<br />
Sylvester R.J., 93, 189, 270<br />
T Tailly G., 299<br />
Takahashi M., 47<br />
Tchanturaia Z., 48, 50<br />
Teber D., 198, 297<br />
Tekgül S., 170, 189, 256<br />
Tenke P., 124, 142, 165, 321<br />
Terkelsen R., 369<br />
Thalmann G.N., 64, 91, 113, 148,<br />
203, 207, 209, 231, 309<br />
Thulin H., 375<br />
Thüroff J.W., 94, 105, 126, 131, 155,<br />
170, 200<br />
Thüroff S., 219, 266, 348<br />
Timorlan K., 48<br />
Tiselius H-G., 140, 316<br />
Numbers refer to <strong>page</strong> numbers<br />
<strong>EAU</strong> <strong>Barcelona</strong> <strong>2010</strong><br />
517
List of Speakers (not abstracts)<br />
Tolley D., 307<br />
Tomada N., 70, 167<br />
Tombal B., 44, 56, 77, 156, 173, 188,<br />
203, 213, 229, 288, 308, 331<br />
Tomita Y., 47<br />
Torres A., 44<br />
Tostain J., 114, 132, 139, 195, 355<br />
Touijer K., 173, 219, 289<br />
Trachtenberg J., 219, 346<br />
Traxer O., 91, 130, 201, 299, 307,<br />
316, 335<br />
Trombetta C., 310, 314<br />
Truss M., 306<br />
Tubaro A., 144, 211, 223, 227, 342,<br />
363<br />
Tuerk I., 112<br />
Turmanidze N., 48<br />
Törnberg S., 92<br />
Türkeri L.N., 188, 223<br />
U Uemura H., 47, 207<br />
Umbas R., 40, 123<br />
Usupbaev A.Ch., 48<br />
V Valdivia J., 307<br />
Vallancien G., 194, 198, 203<br />
Van Cangh P., 173, 203, 229<br />
Van Cleynenbreugel B.S.E.P., 247,<br />
359<br />
Van Der Aa F., 79, 318<br />
Van Der Kwast T., 174<br />
Van Der Poel H.G., 152, 171, 207,<br />
247, 300, 348<br />
Van Kerrebroeck P.E., 327<br />
Van Moorselaar J., 300<br />
Van Muilekom H.A.M., 367, 373<br />
Van Poppel H., 40, 42, 45, 51, 56,<br />
62, 83, 173, 203, 220, 225, 229,<br />
246, 303, 340, 359<br />
Van Velthoven R.F., 241, 306<br />
Vaze A., 43<br />
Vela Navarrete R., 206<br />
Verze P., 98, 149, 304<br />
Vickers A.J., 91, 224<br />
Villavicencio H., 67, 142, 148, 211,<br />
234, 347<br />
Vinarov A.Z., 124, 339<br />
518 Programme Book<br />
Volpe A., 94, 99, 174, 230<br />
Vu Minh Arnell M., 374<br />
W<br />
Wagenlehner F.M.E., 124, 142, 320,<br />
350<br />
Wagstaff J., 353<br />
Walz J., 81, 173, 203, 229, 314<br />
Wang J.Y., 210<br />
Watkin N., 152<br />
Watson R.W.G., 113<br />
Weidner W., 87, 106, 124, 134, 142,<br />
192, 278, 305, 320, 350<br />
Wespes E., 116, 304<br />
Wiegel T., 276<br />
Wijkstra H., 115, 194, 314<br />
Wiklund P., 168, 198, 232, 241<br />
Wirth M., 47, 55<br />
Witjes J.A., 105, 156, 161, 218, 274,<br />
323<br />
Witzsch U., 361<br />
Wyndaele J.J., 196, 260, 318, 338<br />
X<br />
Xhani M., 313<br />
Xie L.P., 41<br />
Z<br />
Zaak D., 205, 233, 307<br />
Zaffaroni N., 308<br />
Zatura F., 306<br />
Zitzmann M., 70, 355<br />
Zivi A., 188<br />
Zlotta A.R., 44, 66, 93, 118, 174,<br />
271, 344<br />
Zóber T.G., 359<br />
Numbers refer to <strong>page</strong> numbers
Change language